<?xml version="1.0" encoding="UTF-8" ?>
<rss version="2.0"
	xmlns:excerpt="http://wordpress.org/export/1.2/excerpt/"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:wp="http://wordpress.org/export/1.2/"
>

<channel> 
	<title>Compass</title>
	<link>http://localhost/wordpress</link>
	<description>Blah blah</description>
	<pubDate>Sun, 07 Feb 2016 14:06:19 +0000</pubDate>
	<language>en-US</language>
	<wp:wxr_version>1.2</wp:wxr_version>
	<wp:base_site_url>http://localhost/wordpress</wp:base_site_url>
	<wp:base_blog_url>http://localhost/wordpress</wp:base_blog_url>

	<wp:author>
		<wp:author_id>5</wp:author_id>
		<wp:author_login><![CDATA[spoon]]></wp:author_login>
		<wp:author_email><![CDATA[georges.guigui@spoonconsulting.com]]></wp:author_email>
		<wp:author_display_name><![CDATA[spoon]]></wp:author_display_name>
		<wp:author_first_name><![CDATA[]]></wp:author_first_name>
		<wp:author_last_name><![CDATA[]]></wp:author_last_name>
	</wp:author>

	
			<item>

	<title>Daewoong/Evolus Drug DWP450/Nabota Have Now Completed Multiple Trials For Glabellar Lines In The US</title>
	<pubDate>2015-12-30T16:43:51+01:00</pubDate>
	<wp:post_id>6604</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20151231&edate=20150901&rec=8282">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-12-30T16:43:51+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-12-30T16:43:51+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Teva and Takeda Establish a JV to Meet the Growing Importance of Generic Medicines Use in Japan</title>
	<pubDate>2015-12-30T09:46:36+01:00</pubDate>
	<wp:post_id>6605</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Teva and Takeda Establish a JV to Meet the Growing Importance of Generic Medicines Use in Japan</span>&nbsp;<br><span style="font-size: 12px;">Comment: The new business venture, which will operate as an independent company, is expected to start in April 2016.<wbr> It will create a company ideally positioned to lead the high growth in the generic market in Japan, and will be aligned with the Japanese government objectives to reach 80% generic penetration by the end of fiscal year 2020.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20151231&edate=20150901&rec=11324">...</a><br></div><div>Comment: Takeda has made a follow-up announcement regarding to the new business venture with Teva that was announced on Nov 30.<wbr> Takeda will split off its off-patented and data exclusivity expired products business ("long listed products business") via an absorption-type split, and subsequently the business will be succeeded by the Japanese subsidiaries of Teva Pharmaceutical Industries Ltd.<wbr> of Israel.<wbr> The details of establishing these companies by an absorption-type company split are outlined in a separate release issued by Takeda to file to the Tokyo Stock Exchange: <a href="http://ci.beaufour-ipsen.com/traction?type=rchron&proj=*&sdate=20151231&edate=Week&rsin=/link%20week%20%27(Link)%27%20((c(news)%20AND%20c(2015))%20AND%20(c(20151228)%20AND%20(c(7258)%20AND%20c(html%20))))&find=(AND%20(AND%20(c%20news)%20(c%202015))%20(AND%20(c%2020151228)%20(AND%20(c%207258)%20(c%20html))))&title=(Link)&wassearch=true" class="defaultlink">(Link)</a>.<wbr>The new business venture, to be owned 51% by Teva and 49% by Takeda, will consist of Teva Takeda Pharma and Teva Takeda Yakuhin.<wbr> The major long listed products of Takeda to be transferred to the new business venture in FY2016 are BLOPRESS, TAKEPRON and BASEN.<wbr> LEUPLIN still remains at Takeda, as a product of Takeda Oncology.<wbr> (Source: Takeda Press Release 28 Dec 2015) </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20151231&edate=20150901&rec=10840">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld11324">View thread  PharmaWorld11324: Teva and Takeda Establish a JV to Meet the Growing Importance of Generic Medicines Use in Japan</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-12-30T09:46:36+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-12-30T09:46:36+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Revance Has Commenced pII Study For RT001/RT1150 For Axillary Hyperhidrosis</title>
	<pubDate>2015-12-24T18:55:13+01:00</pubDate>
	<wp:post_id>6606</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Revance Has Commenced pII Study For RT001/<wbr>RT1150 For Axillary Hyperhidrosis</span>&nbsp;<br><span style="font-size: 12px;">Comment: The study investigating Revance RT001 (now referred to as RTT150) a BoNT A topical gel, has commenced.<wbr> The methodology will be a pII randomized double-blinded, placebo-controlled study designed to evaluate the safety and efficacy in the treatment of primary axillary hyperhidrosis</span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20151231&edate=20150901&rec=8175">...</a><br></div><div style="margin-bottom: 10px;"><SPAN style="font-size: small; font-family: arial,helvetica,sans-serif;">Revance today announced interim efficacy and safety results from its Phase II trial of RT001 topical botulinum toxin type A for the treatment of axilarry hyperhidrosis (excessive underarm sweating).<wbr> The trial was designed to evaluate two doses of RT001 applied on a single day of treatment.<wbr> </SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-size: small; font-family: arial,helvetica,sans-serif;">Revance announced that the data was positive using 'quantitative gravimetric measurements' (the trial sample size was not chosen to meet statistical significance), showing that a single treatment of RT001 topical gel achieved clinically meaningful efficacy at Week 4.<wbr> Using the qualitative Hyperhidrosis Disease Severity Scale (HDSS), RT-001 showed a positive efficacy trend for both 1-point and 2-point improvement.<wbr> Both doses appear to be safe and well tolerated.<wbr> </SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-size: small; font-family: arial,helvetica,sans-serif;">In the details below, however, its is interesting to note that at week 4, using the primary qualitative efficacy assessment of 2-point improvement, though the trend is positive in absolute, the RT001 improvement in relatively inferior to placebo (14.<wbr>3% to 13.<wbr>3% for RT001 vs 29.<wbr>4% for placebo)</SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-size: small; font-family: arial,helvetica,sans-serif;">Revance announced plans to advance RT001 to a larger hyperhidrosis Phase 2 study in 2016, to be designed to confirm a final dose.<wbr> Following the larger Phase 2 trial, Revance plans to meet the FDA to take RT001 into Phase 3 studies.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-size: small; font-family: arial,helvetica,sans-serif;">Key interim results are as below:</SPAN> </div><div><UL><LI><SPAN style="font-size: small; font-family: arial,helvetica,sans-serif;">On the primary quantitative assessment of average reduction from baseline in gravimetrically-measured sweat production, the results ranged from 214.<wbr>2 mg to 165.<wbr>7 mg (p=0.<wbr>003 for the higher dose) per five minutes for RT001, compared to 66.<wbr>3 mg per five minutes in patients who received placebo.<wbr> These ranges corresponded to 81.<wbr>1% to 79.<wbr>6% change for RT001, compared to 54.<wbr>6% for placebo.<wbr>  </SPAN>
</LI>
<LI><SPAN style="font-size: small; font-family: arial,helvetica,sans-serif;"> On the primary qualitative efficacy assessment of a 2-point or greater responders from baseline using the HDSS, at Weeks 1 and 2 the results ranged from a 23.<wbr>8% to 13.<wbr>3 % improvement for RT001 compared to a range of 17.<wbr>6% to 11.<wbr>8% improvement for placebo.<wbr>  By Week 4, there was a 14.<wbr>3% to 13.<wbr>3% improvement for RT001, compared to a 29.<wbr>4% improvement in patients who received placebo.<wbr></SPAN>
</LI>
<LI><SPAN style="font-size: small; font-family: arial,helvetica,sans-serif;">RT001 appears to be safe and well tolerated at both doses.<wbr>  Adverse events were generally mild, localized and transient.<wbr> There were no serious adverse events or evidence of any systemic exposure for either of the two doses evaluated.<wbr> The most common treatment-related adverse events reported were application site erythema (redness), folliculitis (razor bumps) and application site pain.<wbr></SPAN>
</LI>
</UL> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20151231&edate=20150901&rec=8280">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology8175">View thread  Neurology8175: Revance Has Commenced pII Study For RT001/<wbr>RT1150 For Axillary Hyperhidrosis</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-12-24T18:55:13+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-12-24T18:55:13+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Merz PURE Data To Be Published</title>
	<pubDate>2015-12-24T18:30:56+01:00</pubDate>
	<wp:post_id>6607</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Merz PURE Data To Be Published</span>&nbsp;<br><span style="font-size: 12px;">Comment: Merz Neurosciences has announced today that data from its Phase III PURE: Post-stroke Spasticity Upper Limb Study to investigate the efficacy and safety of NT 201 clinical trial for incobotulinumtoxinA has been accepted for publication by the medical journal &ldquo;Muscle &amp; Nerve&rdquo;.<wbr> Merz also confirmed that it has submitted an sBLA to the FDA to seek approval for the use of incobotulinumtoxinA in the treatment of post-stroke upper limb spasticity and anticipates FDA action prior to the end of this calendar year.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20151231&edate=20150901&rec=8157">...</a><br></div><div style="margin-bottom: 10px;">Merz announced today that Xeomin (incobotulinumtoxinA) has received US FDA approval for the treatment of Upper Limb Spasticity (ULS) in adult patients.<wbr> Glenn Bloc, VP and Head of US Neurosciences for Merz North America stated "We know that each patient has unique needs , and this new indication for Xeomin (incobotulinumtoxinA) is a result of our long-term committment to serving individuals with movement disorders and spasticity.<wbr> We look forward to supporting the launch of Xeomin for adult upper-limb spasticity with forward thinking strategies in product support, clinical education, and patient advocacy and engagement" </div><div>The safety and efficacy of Xeomin was evaluated in phIII studies involving more than 400 adult patients.<wbr>  These trials were placebo-controlled in which subjects experienced statistically significant improvements in two co-primary outcome measures: muscle tone (Ashworth Scale score) and the Investigator&rsquo;s Global Impression of Change of the Primary Target Clinical Pattern (PTCP) at week 4.<wbr> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20151231&edate=20150901&rec=8278">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology8157">View thread  Neurology8157: Merz PURE Data To Be Published</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-12-24T18:30:56+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-12-24T18:30:56+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Prophylactic Loperamide Reduces Neratinib-Related Diarrhea in HER2+ Breast Cancer</title>
	<pubDate>2015-12-23T17:35:22+01:00</pubDate>
	<wp:post_id>6608</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Puma Biotech has released Phase 2 data on the use of loperamide prophylaxis to treat diarrhea in breast cancer patients.<wbr> According to management, " .<wbr>.<wbr>.<wbr> high-dose loperamide prophylaxis appears to be working.<wbr> Nonetheless, today's  dataset is the first to demonstrate that loperamide is also capable of lowering diarrhea rates in the extended adjuvant setting, neratinib's first targeted indication; it appears that loperamide prophylaxis is having a very meaningful impact on reducing diarrhea rates".<wbr> </div><div style="margin-bottom: 10px;">Source: <A href="http://global.onclive.com/web-exclusives/prophylactic-loperamide-reduces-neratinib-related-diarrhea-in-her2-breast-cancer">http:/<wbr>/<wbr>global.<wbr>onclive.<wbr>com/<wbr>web-exclusives/<wbr>prophylactic-loperamide-reduces-neratinib-related-diarrhea-in-her2-breast-cancer</A> </div><div><STRONG>Puma Biotechnology</STRONG> is a biopharmaceutical company with a focus on the acquisition, development and commercialization of innovative products to enhance cancer care.<wbr> The Company aims to acquire proprietary rights to these products, by license or otherwise, fund their research and development and bring the products to market.<wbr> The Company is initially focused on the development of PB272 (oral neratinib), a potent irreversible tyrosine kinase inhibitor, for the treatment of patients with HER2-positive breast cancer and patients with non-small cell lung cancer, breast cancer and other solid tumors that have a HER2 mutation.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20151231&edate=20150901&rec=11345">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-12-23T17:35:22+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-12-23T17:35:22+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Recent Publication Outlines Effects of Bacillus subtilis CU1 on the Immune System</title>
	<pubDate>2015-12-23T09:29:08+01:00</pubDate>
	<wp:post_id>6609</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Recent Publication Outlines Effects of Bacillus subtilis CU1 on the Immune System</span>&nbsp;<br><span style="font-size: 12px;">Comment: Led by Marie Lefevre from Lesaffre Human Care, the study recruited approx 100 people (aged btw 60 and 74) in a randomized, double-blinded, placebo-controlled, parallel-arms study.<wbr> The results suggest that daily B.<wbr>subtilis CU1 supplementation during the winter months may be a safe effective way to stimulate systemic ans mucosal immune response of the elderly.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20151231&edate=20150901&rec=2726">...</a><br></div><div>As usual for probiotic studies relatively small sample size and negative results on the clinical primary end point (decrease of the mean number of days of reported Common Infectious Disease symptoms over the 4-month).<wbr> Interesting trend of  increased fecal and salivary secretory IgA concentrations in a subgroup of subjects.<wbr> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20151231&edate=20150901&rec=2730">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2726">View thread  GastroEnterology2726: Recent Publication Outlines Effects of Bacillus subtilis CU1 on the Immune System</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-12-23T09:29:08+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-12-23T09:29:08+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Pfizer's Anti-PD1 Is Being Evaluated As A 1L Maintenance Treatment In Bladder Cancer</title>
	<pubDate>2015-12-22T15:54:37+01:00</pubDate>
	<wp:post_id>6610</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Pfizer's Anti-PD1 Is Being Evaluated As A 1L Maintenance Treatment In Bladder Cancer</span>&nbsp;<br><span style="font-size: 12px;">Comment: As bladder cancer is becoming a very competitive market for immuno-oncology agents, especially with both Roche and MSD are both running pivotal trial, Pfizer has planned a Ph3 trial to evaluate its anti-PD1, Avelumab, with a differentiating positioning from Roche and MSD.<wbr> Avelumab is being evaluated as a 1L maintenance treatment after completion of platinum containing therapy for locally advanced or metastatic urothelial cancer patients.<wbr> The study has yet opened for recruitment.<wbr> OS for up to 40 months is the primary objective and trial completion is estimated to be in Q2 2019.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20151231&edate=20150901&rec=10794">...</a><br></div><div>Comment: During a joint press release made by Merck KGaA and Pfizer, it was confirmed that this study has been approved by FDA and the first site is expected to open shortly.<wbr> JAVELIN Bladder 100 is expected to enroll 668 patients across more than 200 sites in 38 countries.<wbr> PD-L1 expression status will be determined by retrospective analysis of mandatory tumour samples collected from patients enrolled in the trial.<wbr> (Source: company press release) </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20151231&edate=20150901&rec=10839">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10794">View thread  Oncology10794: Pfizer's Anti-PD1 Is Being Evaluated As A 1L Maintenance Treatment In Bladder Cancer</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-12-22T15:54:37+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-12-22T15:54:37+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Recent Publication Outlines Effects of Bacillus subtilis CU1 on the Immune System</title>
	<pubDate>2015-12-22T11:16:18+01:00</pubDate>
	<wp:post_id>6611</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Led by Marie Lefevre from Lesaffre Human Care, the study recruited approx 100 people (aged btw 60 and 74) in a randomized, double-blinded, placebo-controlled, parallel-arms study.<wbr> The results suggest that daily B.<wbr>subtilis CU1 supplementation during the winter months may be a safe effective way to stimulate systemic ans mucosal immune response of the elderly.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><A href="http://www.immunityageing.com/content/12/1/24"><EM>Immunity &amp; Ageing</EM> </A>2015,12:24, doi:10.<wbr>1186/<wbr>s12979-015-0051-y </div><div>"Probiotic strain Bacillus subtilis CU1 stimulates immune system of elderly during common infectious disease period: a randomized, double-blind placebo-controlled study - M.<wbr> Lefevre et al.<wbr> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="GastroEnterology2730c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div>As usual for probiotic studies relatively small sample size and negative results on the clinical primary end point (decrease of the mean number of days of reported Common Infectious Disease symptoms over the 4-month).<wbr> Interesting trend of  increased fecal and salivary secretory IgA concentrations in a subgroup of subjects.<wbr> </div></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20151231&edate=20150901&rec=2726">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-12-22T11:16:18+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-12-22T11:16:18+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Positive Ph2 Results for Brickel Biotech's BBI-4000 in Patients with Axillary Hyperhidrosis</title>
	<pubDate>2015-12-22T10:21:22+01:00</pubDate>
	<wp:post_id>6612</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: On Dec 17, Brickell Biotech announced success in the BBI-4000 (sofpironium bromide) Ph2b trial in hyperhidrosis (189 patients, 3 concentrations + placebo), using the drug as a topical treatment.<wbr> Statistically significant efficacy for the primary endpoint (HDSM-Ax score) was achieved, and no major safety issues arose.<wbr> The company intends to move into Ph3.<wbr> The drug is in Ph2a development for palmar hyperhidrosis.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Originator</STRONG> </div><div style="margin-bottom: 10px;">Sofpironium bromide was originally developed at Bodor Laboratories, Inc.<wbr> by Dr.<wbr> Nicholas Bodor, an internationally recognized leader in retrometabolic drug design approaches.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Partnerships</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_8275_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;">Kaken will conduct a small-scale domestic trial in 2016, and then join Brickell in the Ph3 trials.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Trial Details</STRONG> </div><div style="margin-bottom: 10px;">Please see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20151231&edate=20150901&rec=7886" class="defaultlink">Neurology7886: Topical BBI-4000 to Enter POC Trial for Primary Axillary Hyperhidrosis</a> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_8275_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;">Sofpironium bromide, a new molecular entity, belongs to a class of drugs called ‘anticholinergics,’ </div><div style="margin-bottom: 10px;">Soft-anticholinergics, such as sofpironium bromide, exert their action topically and are rapidly metabolized into a considerably less active metabolite when they reach the blood system, thus potentially allowing for effective doses to be used while reducing the limiting systemic side effects associated with other drugs in this class.<wbr> </div><div>Source: <A href="http://brickellbiotech.businesscatalyst.com/12172015_BrickellBiotech.html">http:/<wbr>/<wbr>brickellbiotech.<wbr>businesscatalyst.<wbr>com/<wbr>12172015_BrickellBiotech.<wbr>html</A> </div><!-- Comment details --><a name="neurology8275attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_8275_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(86,5 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_8275_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(67,9 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20151231&edate=20150901&rec=8275">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-12-22T10:21:22+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-12-22T10:21:22+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Update on Proellex® Endometriosis Program</title>
	<pubDate>2015-12-22T09:29:37+01:00</pubDate>
	<wp:post_id>6613</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Proellex<SUP>®</SUP> is a new chemical entity that acts as a selective blocker of the progesterone receptor.<wbr> Repros has reported that the initial assessment from Ph2 endometriosis study shows substantial reduction of pain and use of analgesics in women with severe endometriosis.<wbr> Based on the initial assessment, enrollment for the Phase 2 endometriosis study is scheduled to conclude by end of January 2016, with topline results for the first four months of treatment expected by end of Q3'16.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10837_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;">Previous studies with Proellex® at doses of 25 and 50 mg in women with severe endometriosis showed substantial reductions in both the associated pain and resulting analgesic usage.<wbr> </div><div style="margin-bottom: 10px;">To date, Repros has enrolled 41 subjects in a low dose trial of both 6 and 12 mg Proellex® in women with severe endometriosis (Biberoglu Berman Symptom Survey Score &gt; 7) and who require analgesics to control the associated pelvic abdominal pain.<wbr> </div><div style="margin-bottom: 10px;">Based on results from an interim analysis of the data, women treated with placebo exhibited pain scores at the end of treatment that were 83% of baseline but showed no reduction in analgesic usage (100% of baseline).<wbr> Women in the two active treatment groups exhibited clinically relevant reductions in both pain scores and analgesic usage.<wbr> In this group, pain scores were 39% of baseline and analgesic usage was reduced to 23% of baseline.<wbr> Both of these assessments achieved statistically significant reduction compared to baseline and achieved or approached significance compared to placebo.<wbr> </div><div style="margin-bottom: 10px;">Based on this assessment Repros has decided to end enrollment of the endometriosis study, as it believes the study will provide sufficient data to design a Ph3 study based on the 40-45 subjects expected to be randomized.<wbr> Topline results from this study should be available by the end of the 3rd quarter of 2016.<wbr> </div><div style="margin-bottom: 10px;">The Company plans to request meetings with the FDA at the appropriate time to determine the Ph3 programs that will be required for NDAs for the endometriosis and uterine fibroids indications.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Standard of Care</STRONG> </div><div style="margin-bottom: 10px;">The current standards of care for uterine fibroids and endometriosis consist of surgery or short-term treatment with GnRH agonists drugs.<wbr> GnRH agonists induce a low estrogen, menopausal-like state and promote bone loss and are not recommended for use for more than six months.<wbr> </div><div>Source: Repros </div><!-- Comment details --><a name="oncology10837attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10837_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(28,5 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20151231&edate=20150901&rec=10837">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-12-22T09:29:37+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-12-22T09:29:37+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>First Edition of the Therapy Area Landscape on Acute/Chronic Diarrhea and IBS Symptoms</title>
	<pubDate>2015-12-21T17:12:40+01:00</pubDate>
	<wp:post_id>6614</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: You will find attached the first edition of the Smecta RTU /<wbr> Probiotics competitive landscape, with the strategy of the key players, and a detailed profile of their product candidates.<wbr> The focus of this document has been on drugs.<wbr> Over-the-Counter (OTC) and Food Supplement (FS) products are not included.<wbr> However Medical Device (MD) products have been covered in the first part thanks to an ad-hoc external project on liquid smectite.<wbr> We welcome any contribution to our Key Intelligence Questions (KIQs) to ensure the utility of the tool.<wbr><WBR> A special thank you to the Primary Care team for their contribution to this edition.<wbr></WBR> </div><div style="margin-bottom: 10px;">Full document attached.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Key Intelligence Questions</STRONG> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2720_4_ScreenCapture3.jpg"> </div><!-- Comment details --><a name="gastroenterology2720attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2720_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(119,2 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2720_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(237,4 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2720_4_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(140,5 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2720_5_Therapy%20Area%20Landscape%255fSmecta%255fDec2015%255f1.pdf">Therapy Area Landscape_Smecta_Dec2015_1.pdf</a>&nbsp;&nbsp;(1,8 MB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20151231&edate=20150901&rec=2720">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-12-21T17:12:40+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-12-21T17:12:40+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>EUSA Pharma Gets EU Rights to AVEO's Tivozanib for Advanced RCC</title>
	<pubDate>2015-12-21T13:52:13+01:00</pubDate>
	<wp:post_id>6615</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The agreement includes a number of additional countries such as South Africa and South America.<wbr> EUSA Pharma will pay an upfront of $2.<wbr>5M and up to $394M in potential payments and milestones.<wbr> According to the PR, MAA submission (1st-L treatment for advanced RCC) is planned in Q1:16.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><H1></H1> </div><div style="margin-bottom: 10px;">In August of 2014, AVEO regained all rights to tivozanib.<wbr> In November 2014, AVEO entered into an option agreement with Ophthotech to investigate tivozanib for the potential treatment of non-oncologic diseases of the eye.<wbr> In August 2015, AVEO entered into an exclusive license agreement with Pharmstandard OJSC for the development, manufacturing and commercialization of tivozanib in the territories of Russia, Ukraine and the Commonwealth of Independent States (CIS), for all indications excluding ocular conditions.<wbr> The Company is actively pursuing partnerships in Europe to advance the development and commercialization of tivozanib in solid tumors.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Antitumor Activity and Safety of Tivozanib (AV-951) in a Phase II Randomized Discontinuation Trial in Patients With Renal Cell Carcinoma<BR>Authors: Nosov D, Esteves B, Lipatov O, Lyulko A, Anischenko A, Chacko R, Doval D, Strahs A, Slichenmyer W, and Bhargava P JCO May 10, 2012:1678-1685; DOI:10.<wbr>1200/<wbr>JCO.<wbr>2011.<wbr>35.<wbr>3524 </div><div>Source: <A href="http://investor.aveooncology.com/phoenix.zhtml?c=219651&amp;p=irol-newsArticle&amp;ID=2124270">http:/<wbr>/<wbr>investor.<wbr>aveooncology.<wbr>com/<wbr>phoenix.<wbr>zhtml?c=219651&amp;p=irol-newsArticle&amp;ID=2124270</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20151231&edate=20150901&rec=10835">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-12-21T13:52:13+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-12-21T13:52:13+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: MAA for AZ' Gout Treatment Accepted by EMA</title>
	<pubDate>2015-12-21T10:08:51+01:00</pubDate>
	<wp:post_id>6616</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">MAA for AZ' Gout Treatment Accepted by EMA</span>&nbsp;<br><span style="font-size: 12px;">Comment: The Agency has accepted the Marketing Authorisation Application for lesinurad 200mg tablets, setting it up for a possible approval later this year.<wbr> Lesinurad is a selective uric acid reabsorption inhibitor (SURI) developed for the chronic treatment of hyperuricaemia in combination with xanthine oxidase (XO) inhibitors allopurinol or febuxostat in gout patients when additional therapy is warranted.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20151231&edate=20150901&rec=2204">...</a><br></div><div style="margin-bottom: 10px;">The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the marketing authorisation of lesinurad 200mg tablets.<wbr> Lesinurad, in combination with a xanthine oxidase inhibitor (XOI), is recommended for the adjunctive treatment of hyperuricaemia in adult gout patients (with or without tophi) who have not achieved target serum uric acid levels (sUA) with an adequate dose of a XOI alone.<wbr> </div><div style="margin-bottom: 10px;">The CHMP&rsquo;s positive opinion on lesinurad will now be reviewed by the European Commission (EC), which has the authority to approve medicines for the European Union (EU).<wbr> The final decision will be applicable to all 28 EU member countries plus Iceland, Norway and Liechtenstein.<wbr> AstraZeneca anticipates a final decision by the EC in the first quarter of 2016.<wbr> If approved, lesinurad will be the first selective uric acid reabsorption inhibitor (SURI) to treat patients with inadequately controlled gout in Europe.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>US Situation</STRONG> </div><div>Lesinurad is also under review in the United States.<wbr> On 23 October 2015, the US Food and Drug Administration&rsquo;s Arthritis Advisory Committee recommended the approval of lesinurad 200mg tablets for the treatment of hyperuricemia associated with gout, in combination with an XOI.<wbr> The Prescription Drug User Fee Act (PDUFA) target goal date is 29 December 2015.<wbr> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20151231&edate=20150901&rec=2718">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2204">View thread  GastroEnterology2204: MAA for AZ' Gout Treatment Accepted by EMA</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-12-21T10:08:51+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-12-21T10:08:51+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Sulfatininb Two New PhIII NET Trials To Be Initiated In China</title>
	<pubDate>2015-12-18T18:54:34+01:00</pubDate>
	<wp:post_id>6617</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Hutchison China MediTech Limited announced today that its R&amp;D subsidiary, Hutchison MediPharma Limited, has initiated SANET-ep, a phase III registration trial in patients with extra-pancreatic neuroendocrine tumors (NETs), which are all non-pancreatic NETs, including NETs originating in the lymph, lung and across the gastrointestinal tract.<wbr> In addition to its NET studies, HMP also plans to initiate a Phase Ib study in China to evaluate the safety, pharmacokinetics and efficacy of sulfatinib in patients with both medullary and differentiated thyroid cancer by the end of 2015.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Sanet-ep Design</STRONG> </div><div style="margin-bottom: 10px;">According to its press release, SANET-ep is a randomized, double-blind, placebo-controlled, multi-center phase III registration study of sulfatinib to treat pathologically low or intermediate grade NET patients whose disease has progressed, locally advanced or distant metastasized and for whom there is no effective therapy.<wbr> </div><div style="margin-bottom: 10px;">The primary objective of the study is to evaluate the progression-free survival of sulfatinib compared to that of placebo, with secondary endpoints including objective response rate, disease control rate, time to response, duration of response, overall survival, safety and tolerability.<wbr> Approximately 270 patients will be enrolled in the SANET-ep study from more than 20 centers across China, with top-line results expected in 2018.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Sanet-p To Be Initiated Soon</STRONG> </div><div style="margin-bottom: 10px;">Additionally of note, the second phase III sulfatinib registration trial, SANET-p, in pancreatic NET patients, is expected to be initiated imminently in China.<wbr> SANET-p employs a similar treatment regimen and has primary and secondary endpoints similar to those for SANET-ep trial.<wbr> Approximately 195 patients will be enrolled in SANET-p which is expected to start by the end of 2015, with top-line results expected in 2017.<wbr> </div><div style="margin-bottom: 10px;">Published on behalf of Giorgia Vicentini </div><div>Source: <A href="http://www.chi-med.com/news/">http:/<wbr>/<wbr>www.<wbr>chi-med.<wbr>com/<wbr>news/<wbr></A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20151231&edate=20150901&rec=8313">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-12-18T18:54:34+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-12-18T18:54:34+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>New Therapeutic Toxin Area Landscape</title>
	<pubDate>2015-12-18T16:01:16+01:00</pubDate>
	<wp:post_id>6618</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div>Comment: You will find attached an updated competitive landscape for Toxins.<wbr> This slide deck provides a disease overview including key market analysis, competitor landscape and timelines.<wbr> The focus is on spasticity, however, NDO and sialorrhoea are also discussed.<wbr> The new competitors incorporated into this version include Medytox and Revance.<wbr> While the new sections include the patient journey and landscape, the patent setting, liquid toxin environment and the marketing material.<wbr> We welcome any contribution to our Key Intelligence Questions (KIQs) to ensure the utility of the tool.<wbr> A special thank you to the Neurology franchise and IP team for their contribution to this edition.<wbr> </div><!-- Comment details --><a name="neurology8271attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_8271_2_Toxin%20Therapeutic%20Landscape.18.12ppt.pdf">Toxin Therapeutic Landscape.18.12ppt.pdf</a>&nbsp;&nbsp;(2,5 MB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20151231&edate=20150901&rec=8271">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-12-18T16:01:16+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-12-18T16:01:16+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Amgen to Reacquire Rights to Three Drugs from GSK</title>
	<pubDate>2015-12-17T14:42:58+01:00</pubDate>
	<wp:post_id>6619</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Amgen has reached an agreement with GSK to reacquire the sales rights to the osteoporosis treatment drugs <EM>Prolia</EM> (denosumab), <EM>XG</EM><EM>eva</EM> (denosumab), and advanced colorectal cancer drug <EM>Vectibix</EM> (panitumumab) in Australia, Asia, South America and Europe.<wbr> </div><div style="margin-bottom: 10px;">GSK reported $111M in combined sales in 2014 from the licensing of three drugs, according to Amgen.<wbr> </div><div style="margin-bottom: 10px;"><U>Under of the agreement</U>, Amgen will make undisclosed milestone payments to GSK upon signing and the successful transition of the products back to Amgen.<wbr> </div><div style="margin-bottom: 10px;">The transition is expected to be completed in the majority of these emerging markets within a 12-month period.<wbr> </div><div>Source: BMI Research </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20151231&edate=20150901&rec=11342">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-12-17T14:42:58+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-12-17T14:42:58+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>J&J Invests To Protect Its Current Prostate Cancer Protfolio</title>
	<pubDate>2015-12-17T11:32:41+01:00</pubDate>
	<wp:post_id>6620</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Acceptance of ADU-741 IND application by FDA triggered a milestone payment from J&amp;J to Aduro Biotech.<wbr> J&amp;J plans to initiate a multicenter Ph1 to eavluate the safety and immunogenicity of intravenous administration of ADU-741 (JNJ-64041809 ).<wbr> The trial has now been listed on clinicaltrial.<wbr>gov.<wbr> Under the agreement, Aduro received an upfront payment with milestone payments up to a potential total of $345.<wbr>5 miliion plus royalties on net sales upon launch and commercialisation.<wbr> </div><div style="margin-bottom: 10px;">This is a first-in-human (FIH), Phase 1, open-label, multicenter and 2-part study.<wbr> The Part 1 of study will be Dose Escalation phase to determine the recommended Phase 2 dose (RP2D) based on safety and pharmacodynamic assessments and Part 2 will be Dose Expansion Phase to evaluate 2 expansion cohorts (Cohort 2A and 2B) after the RP2D for JNJ-64041809 is determined in Part 1.<wbr> The study will consist of a Screening Period (from signing of informed consent until immediately before the first dose), an open-label Treatment Period (from the first dose of study drug until the End-of-Treatment Visit); and a Post treatment Follow-up Period (after the End-of Treatment Visit until study discontinuation).<wbr> Participants will be primarily evaluated for RP2D.<wbr> </div><div style="margin-bottom: 10px;">ClinicalTrials.<wbr>gov ID: NCT02625857 </div><div style="margin-bottom: 10px;">Experimental: Dose Cohort 1A and 1B <BR>JNJ-64041809 will be administered intravenously (IV) once every 21 days.<wbr><BR>JNJ-64041809 will be administered IV at a lower dose in Cohort 1A and at a higher dose in Cohort 1B.<wbr> </div><div style="margin-bottom: 10px;">Experimental: Dose Cohort 2A and 2B <BR>JNJ-64041809 will be administered intravenously (IV) once every 21 days.<wbr><BR>JNJ-64041809 will be administered intravenously (IV) once every 21 days at the recommended dose as determined in Cohort 1A or 1B.<wbr> </div><div style="margin-bottom: 10px;">About ADU-741 </div><div style="margin-bottom: 10px;">ADU-741 is a LADD immunotherapy product candidate for the treatment of prostate cancer.<wbr> LADD is Aduro's platform technology designed to enable the safe administration of <EM>Listeria</EM> by deleting two genes critical to the bacterium&rsquo;s natural virulence &ndash; <EM>internalin B</EM> and <EM>act A</EM>, which control infection of hepatocytes and spread of bacterial DNA.<wbr> </div><div style="margin-bottom: 10px;">LADD-based therapies have several attractive characteristics: </div><div style="margin-bottom: 10px;"><UL><LI><EM>Listeria</EM> is well understood and characterized after more than 50 years as a research tool in immunology
</LI>
<LI>The double attenuated methodology has a well-characterized safety profile in multiple clinical trials
</LI>
<LI>Unlike therapeutic virus vectors, LADD-engineered bacteria are not neutralized by antibodies and can be administered repeatedly
</LI>
<LI>LADD-based agents have potential therapeutic effect both as a monotherapy and in combination with other conventional and emerging therapies, including GVAX*, chemotherapy, radiotherapy and checkpoint inhibitors.<wbr>
</LI>
</UL> </div><div style="margin-bottom: 10px;">The LADD technology has been applied to several novel compounds in clinical and preclinical testing including CRS-207 (pancreatic cancer, mesothelioma and ovarian/<wbr>fallopian/<wbr>peritoneal cancer (collaboration with Incyte Corporation to be tested in combination with epacadostat)), ADU-623 (brain cancer), ADU-214 (lung cancer, licensed to Janssen Biotech, Inc.<wbr>) and ADU-741 (prostate cancer, licensed to Janssen Biotech, Inc.<wbr>).<wbr> </div><div>Source: AduroBiotech Press Release, clinicaltrials.<wbr>gov </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20151231&edate=20150901&rec=10832">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-12-17T11:32:41+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-12-17T11:32:41+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>AZ To Invest Up To $4m in Acerta Pharmaceuticals For Best-In-Class BTK-Inhibitor</title>
	<pubDate>2015-12-17T10:34:56+01:00</pubDate>
	<wp:post_id>6621</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: AstraZeneca has entered into a significant agreement to invest in a majority 55% equity stake in Acerta Pharma, a privately-owned biopharmaceutical company based in the Netherlands and US.<wbr> The transaction provides AstraZeneca with a potential best-in-class irreversible oral Bruton's tyrosine kinase (BTK) inhibitor, acalabrutinib (ACP-196)<STRONG>,</STRONG> currently in Phase III development for B-cell blood cancers and in Phase I/<wbr>II clinical trials in multiple solid tumours including bladder cancer.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Strategic Rational</STRONG> </div><div style="margin-bottom: 10px;">Commenting on the transaction Pascal Soriot, Chief Executive Officer of AstraZeneca, said: &ldquo;The investment is consistent with our focus on long-term growth and reflects the role targeted business development plays in our business model.<wbr> We are boosting a key area in our comprehensive oncology portfolio with a late-stage, potential best-in-class medicine that could transform treatment for patients across a range of blood cancers.<wbr> &ldquo;Acalabrutinib provides us with a small molecule presence in blood cancers to complement our existing immunotherapy approach, in collaboration with Celgene in haematological malignancies.<wbr> Furthermore, we look forward to working closely with the Acerta team and benefiting from the considerable clinical expertise they bring in this complex area of medicine.<wbr>&rdquo; </div><div style="margin-bottom: 10px;">Deal Terms </div><div style="margin-bottom: 10px;">AstraZeneca will acquire 55% of the entire issued share capital of Acerta for an upfront payment of $2.<wbr>5 billion.<wbr> A further unconditional payment of $1.<wbr>5 billion will be paid either on receipt of the first regulatory approval for acalabrutinib for any indication in the US, or the end of 2018, depending on which is first.<wbr> The agreement also includes options which, if exercised, provide the opportunity for Acerta shareholders to sell, and AstraZeneca to buy, the remaining 45% of shares in Acerta.<wbr> The options can be exercised at various points in time, conditional on the first approval of acalabrutinib in both the US and Europe and when the extent of the commercial opportunity has been fully established, at a price of approximately $3 billion net of certain costs and payments incurred by AstraZeneca and net of agreed future adjusting items, using a pre-agreed pricing mechanism.<wbr> </div><div style="margin-bottom: 10px;">Acerta will initially be a majority owned subsidiary of AstraZeneca; if AstraZeneca acquires the remaining shares of the company in the future, Acerta would become a wholly-owned subsidiary.<wbr> <A name="_cp_text_1_38"></A>The transaction will be accounted for as a business combination and is expected to complete by the end of the first quarter of 2016, subject to customary closing conditions.<wbr> The initial acquisition payment of $2.<wbr>5 billion will be funded from cash and debt.<wbr> The agreement is expected to be moderately dilutive to AstraZeneca&rsquo;s core earnings in the near term.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Development Programme</STRONG> </div><div style="margin-bottom: 10px;">An extensive development programme is underway for acalabrutinib with the opportunity for initial regulatory submissions in the second half of 2016 for the treatment of patients with specific types of haematological malignancies.<wbr> Expanding further into B-cell cancers, acalabrutinib is estimated to reach potential peak-year sales in excess of $5 billion globally.<wbr> </div><div style="margin-bottom: 10px;">AstraZeneca will also benefit from the substantial expertise in haematological cancers offered by Acerta&rsquo;s approximately 150 employees.<wbr> </div><div style="margin-bottom: 10px;">The BTK inhibitor class is transforming the treatment of B-cell blood cancers, allowing a potentially more effective treatment option with limited side effects, replacing current chemotherapy and antibody-containing regimens.<wbr> Acalabrutinib is a highly selective, irreversible, next-generation small molecule oral BTK inhibitor supported by strong clinical evidence, with approximately 1,000 patients treated to date, of whom more than 600 were on the potential medicine as monotherapy.<wbr> Data indicate that acalabrutinib offers enhanced BTK inhibition.<wbr> Phase I/<wbr>II data presented at the recent American Society of Haematology Annual Meeting 2015 showed a 95% response rate in patients with relapsed chronic lymphocytic leukaemia, the most prevalent form of adult leukaemia, and a 100% overall response rate in the difficult-to-treat 17p deletion patients<SUP>1</SUP>.<wbr> </div><div style="margin-bottom: 10px;">John C.<wbr> Byrd MD, Professor and Director, Division of Haematology, Department of Medicine, at The Ohio State University School of Medicine, said: &ldquo;The BTK inhibitor class has been transformational in the management of B-cell cancers but a portion of patients treated with ibrutinib (the first generation BTK inhibitor), can&rsquo;t tolerate the side effects and sadly discontinue their treatment.<wbr> The acalabrutinib data are highly encouraging as they show that high selectivity, a short half-life and an optimised dosing schedule result in very high efficacy and a significantly better tolerability profile with very low discontinuation rates.<wbr> Acalabrutinib may potentially offer improved long-term benefit over other options available for these patients.<wbr>&rdquo; </div><div style="margin-bottom: 10px;">In addition to blood cancers, acalabrutinib is currently being explored in Phase I/<wbr>II studies in combination with immunotherapy or chemotherapies in a range of solid tumours.<wbr> Pre-clinical data show that acalabrutinib has an immune-modulatory effect that, as monotherapy and alongside PD-1/<wbr>PD-L1 antibodies, has the potential to enhance anti-tumour activity.<wbr> </div><div>, <img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10830_2_Acerta%20Development%20Pipeline.PNG"> </div><!-- Comment details --><a name="oncology10830attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10830_1_UK%20INETS%20Intelligence%20Review.docx">UK INETS Intelligence Review.docx</a>&nbsp;&nbsp;(5,3 MB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10830_2_Acerta%20Development%20Pipeline.PNG">Acerta Development Pipeline.PNG</a>&nbsp;&nbsp;(45,1 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20151231&edate=20150901&rec=10830">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-12-17T10:34:56+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-12-17T10:34:56+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Roche Bags A Preclinical Next Generation Prostate Cancer Programme</title>
	<pubDate>2015-12-16T18:22:50+01:00</pubDate>
	<wp:post_id>6622</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Roches has in-licensed the preclinical work of two Canadian investigators whose reseach expertise focuses on drug discovery from inhibition all forms of the androgen receptor.<wbr> Roche paid an undisclosed upfront and committing up to $141.<wbr>7 million on milestones payment.<wbr> </div><div style="margin-bottom: 10px;">Paul Rennie and Artem Cherkasov have been focusing on the DNA bining domain of the androgen receptor, which turns on genes invovled in the growth of cancer and is prone to mutation.<wbr> Last year Paul Rennie was in a group of investigators who won a $2.<wbr>8m award from the DOD for their work on prostate cancer.<wbr> </div><div>Source: Fierce Biotech </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20151231&edate=20150901&rec=10828">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-12-16T18:22:50+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-12-16T18:22:50+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>UKINETS Meeting December 7th - Key Takeaways</title>
	<pubDate>2015-12-16T18:03:20+01:00</pubDate>
	<wp:post_id>6623</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Whilst this year&rsquo;s UKINET meeting was not as international as previously, the headline focus was PRRT.<wbr> The aim of the meeting was more educational but it also demonstrated the UK experience with PRRT to date.<wbr> Whilst PRRT therapy is no longer funded by the UK&rsquo;s Cancer Drug Fund, once Lutathera is approved (est 2H16) clinicians are hopeful that this will lead to an early NICE review.<wbr> In addition to its PRRT focus, a nurses session highlighted some interesting trends with regard to short and long-acting SSA therapy and the symposium closed with its usual round-up of clinical trial developments.<wbr> A full report with pictures is attached.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>PRRT Session</STRONG> </div><div style="margin-bottom: 10px;">Peter Mancharzu from Manchester&rsquo;s Christie hospital began the presentation with a focus on imaging noting that the majority of NET centres should now be using or moving towards the use of Gallium PET as the gold standard imaging agent of today and the technology of the future.<wbr> Hybrid imaging in the form of SPECT/<wbr>MDCT or PET/<wbr>MDCT is now where most NETdepartments stand.<wbr> London, Liverpool, Manchester and Southampton are all utilising Gallium PET, Newcastle and Cardiff are coming on board whilst the rest of the country is still utilising octreoscan for diagnostic purposes, Gallium PET sensitivity being in the region of 90% compared to 50-60% for Octreoscan.<wbr> </div><div style="margin-bottom: 10px;">Peter noted that since Gallium PET has been adopted at the Christie hospital, 70% of their NET patients are now eligible for PRRT therapy and that with Gallium PET taking 90 minutes to perform vs.<wbr> 24 hours for SPECT there is a not inconsiderable cost saving that has arisen from adoption of the new technology plus lower radiation exposure.<wbr> </div><div style="margin-bottom: 10px;">Valerie Lewington (Kings College Longon) continued with a focus more on the detailed eligibility and exclusion criteria of the NETTER-1 trial.<wbr> Her synopsis of When Why and What PRRT treatments should be used highlighted a number of key points:- </div><div style="margin-bottom: 10px;"><STRONG>When To Consider</STRONG> </div><div style="margin-bottom: 10px;">Progressive inoperable disease when biochemical markers and symptoms are increasing depsite maximal medical intervention and where a comprehensice medical imaging review is supportive of approach.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Why PRRT?</STRONG> </div><div style="margin-bottom: 10px;">PRRT is a systemic therapy the tumour specificity of which mitigates against toxicity and results in a reduced side-effect profile associated with some other systemic NET therapies.<wbr> The radiation cross fire from adjacent cells also means that not every cell needs to be targeted.<wbr> This can be advantageous in the contect of with cancers being dynamic ecosystems where metastases can often have very different characteristics to primary tumours.<wbr> There is also potential for theranostic probes that can give real-time information on tumour behaviour, something that biopsies are unable to do.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>What Should Be Used?</STRONG> </div><div style="margin-bottom: 10px;">The merits of ytrium vs lutiteum were highlighted in terms of short-half life longer particle range versus longer half life shorter particle range.<wbr> Val Lewington also refererenced results from the largest historical cohort treated in Basle of 1109 patients treated with Ytrium where an ORR of 34% was seen and the similar response rates seen with Lutiteum.<wbr> She noted that results from the NETTER-1 study the first randomised rigorous evaluation of PRRT whilst lower than previously seen (ORR 19%) are still impressive and that safety has been in keeping with previous observations </div><div style="margin-bottom: 10px;">Highlighting some key points to consider from a therapy administration perspective she noted that patients should be treated with the same peptide for both diagnosis and therapy, their Hb&gt;10g/<wbr>l and renal GFR&gt;40ml/<wbr>min and LFTs &lt; 3x ULN.<wbr> Patients are administered prophylactic amino acids for renal protection, anti-emetics and steroids, the latter to dampen any radiation effects.<wbr> Post treatment patients at Kings are kept in overnight and then imaged again the following day.<wbr> However, in terms of response the maximal response to treatment is often delayed.<wbr> </div><div style="margin-bottom: 10px;">In terms of the future landscape for PRRT, Val Lewington noted the recent paper by Esther van Vliet on potential neoadjuvant usage of PRRT for pre-surgery cytoreduction which shows some promise and the possibility that patients who progress through beta therapy radiation can continue with treatment with alpha nuclide therapy .<wbr> PRRT she suggested should also be slightly further down the list of treatment options for pNET than for mid-gut.<wbr> "We need" , she claimed "to find out how to use these treatments appropriately as there is no robustly agreed dosimetry method at the present time.<wbr> We are" she acknowleged" miles away from the planned dose to tumour knowledge that exists today for external beam radiation therapy.<wbr>" </div><div style="margin-bottom: 10px;">Whilst there exists a philosophy of utilising lutiteum rather than Ytrium for small vs.<wbr> bulky disease Val advocated that there is an enormous sense in using combination therapy but no rigorous data to support any evidence based approach or whether treatment should be in sequence as the tumour burden decreases in size.<wbr> Finally, it was acknowledge that FDG-PET imaging is often negative in NET patients because of the slow mitotic activity seen in neuroendocrine tumours.<wbr> </div><div style="margin-bottom: 10px;"><EM><STRONG>Interactive PRRT Cases </STRONG></EM> </div><div style="margin-bottom: 10px;">The presentation that followed by Mairead McNamara (Christie Hospital Manchester), highlighted through an interactive case session how some of the treatment considerations flagged by Val Lewington can impact clinical practice and influence patient selection criteria.<wbr> Amongst the three patient cases presented PRRT was not recommend for Case 1 because updated imaging showed extensive disease ( &gt;75% liver involvement) plus bone metastases with the fomer likely to have resulted in liver failure during treatment.<wbr> Case 2 PRRT was recommended albeit at a lower dose because of extensive liver disease and and peritoneal carcinomatosis.<wbr> Whilst Case 3 was more typical of a conventional patient suitable for standard PRRT therapy.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Surgical Session</STRONG> </div><div style="margin-bottom: 10px;">Andrea Frilling (Imperial College London) in a surgical session noted how much we have now moved into an era of cytoreductive therapy based on bespoke pathways and combination therapies rather than as existed in the past oncologists vs.<wbr> surgeons vs.<wbr> nucleur medicine specialists all having more individualised recommendations for sub-sets of patients.<wbr> Essentially surgery is now embedded in a multimodal treatment pathway.<wbr> She presented three key slides one illustrating how many patients are metasatatic at presentation, another summarising the case for surgery in different settings and the third recent data from a neoadjuvant trial undertaken in non-functioning pNET patients illustrating how PRRT may be successfully used to down-stage tumours for subsequent surgery (the 2nd reference to this during the meeting).<wbr> </div><div style="margin-bottom: 10px;"><STRONG>UK PRRT Experience</STRONG> </div><div style="margin-bottom: 10px;">As an interesting comparison with the NETTER-1 data Deborah Pencherez presented data on the early experience with Lutathera from a UK Tertiary Referral Centre, with the subsequent comment by a member of the audience that we now need a prospective registry for PRRT therapy in the UK.<wbr> Deborah acknowledged that a National registry would be great but also how difficult in terms of her evaluation it proved to record all data and how challenging it may be to obtain adequate data from different centres.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Clinical Trials Update</STRONG> </div><div style="margin-bottom: 10px;">As is commonplace at the UKINETS meeting, Professor Juan Valle (Professor of Medical Oncology at the Institute of Cancer Studies University of Manchester) gave his annual update on clinical trial developments introducing the talk by noting that 2015 had been a &ldquo;Grand Cru Year&rdquo; in terms of new NET data.<wbr> He noted the UK&rsquo;s involvement in all 3 trials namely RADIANT-4, NETTER-1 and the TELESTAR trials.<wbr> </div><div style="margin-bottom: 10px;">Professor Juan&rsquo;s slides, other than those focusing on the above studies, are included in the written attachment.<wbr> The National Cancer Fund&rsquo;s delisting of everolimus delayed the opening of the SEQTOR trial in the UK but it finally opened last week in Scotland where the product remains available.<wbr> </div><div style="margin-bottom: 10px;">With regard to the TALENT study which is poised to open with lenvatinib, this trial is being led by the Spanish Neuroendocrine Group GETNE.<wbr> The protocol is just about to go to ethics committee in the US with the trial scheduled to open early next year.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Nurse Dosing Survey</STRONG> </div><div style="margin-bottom: 10px;">Finally the afternoon Nurse Session was also of notable interest in terms of some audit data that was highlighted by Mike Tadman (Royal Free) recorded between 2012 and November 2015.<wbr> Mike suggested that in a couple of years from the initial dosing chart will probably look quite different as more recently patients have been starting on higher doses.<wbr> The true value of a test dose is also beginning to be questioned with the belief that it is safe to administer long-acting SSAs withouth a test dose.<wbr> Whilst the data presented is from one centre the UKNETS nursing group is looking to conduct a national survey and potentially extend this to Europe.<wbr> </div><div>For a full review of the various key slides presented, please open the attachment below or request a copy from Jacquelyne Cantle </div><!-- Comment details --><a name="endocrinology8308attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8308_2_UKINETS%20Meeting%20Review%20Dec%207th%202015.pdf">UKINETS Meeting Review Dec 7th 2015.pdf</a>&nbsp;&nbsp;(1,2 MB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20151231&edate=20150901&rec=8308">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-12-16T18:03:20+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-12-16T18:03:20+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>December 2015 NET Therapy Area Landscape</title>
	<pubDate>2015-12-16T16:16:20+01:00</pubDate>
	<wp:post_id>6624</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div>Comment: Last week, Juan Valle defined 2015 as one of the most remarkable years for NET treatment options, a year that will make NET history (UKINETS , London).<wbr> We indeed witnessed the release of key new clinical data in the second part of the year (RADIANT-4, NETTER-1 and TELESTAR, plus the latest PR on TELECAST) and are currently evaluating the impact of these and the new comers to the market for Ipsen NET business.<wbr> Here enclosed the updated NET TAL: while the introduction section does not different from the August published version, we have mainly updated the key clinical results and the strategic implications for our business.<wbr> Also we have redrawn the always evolving competitor landscape and timelines.<wbr> This December NET TAL is a good 2015 NET activities wrap-up document and a useful tool for looking ahead to the 2016 NET challenges.<wbr> </div><!-- Comment details --><a name="endocrinology8307attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8307_1_Corporate%255fBusiness%255fIntelligence%255fNET%255fTAL%255fDecember%255f2015.pdf">Corporate_Business_Intelligence_NET_TAL_December_2015.pdf</a>&nbsp;&nbsp;(1,8 MB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20151231&edate=20150901&rec=8307">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-12-16T16:16:20+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-12-16T16:16:20+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Key Messages from Valeant Investor Day</title>
	<pubDate>2015-12-16T14:49:00+01:00</pubDate>
	<wp:post_id>6625</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11340_11_ScreenCapture11.jpg"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG>
<STRONG></STRONG> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11340_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;"><STRONG>Relistor Oral Next Step</STRONG> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11340_8_ScreenCapture8.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11340_7_ScreenCapture7.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11340_6_ScreenCapture6.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11340_5_ScreenCapture5.jpg"> </div><div>Source: Valeant Presentation </div><!-- Comment details --><a name="pharmaworld11340attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11340_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(54,4 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11340_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(631 B)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11340_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(90,9 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11340_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(42,7 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11340_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(69,1 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11340_6_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(118,6 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11340_7_ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(156,7 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11340_8_ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(11,3 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11340_9_ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(24,3 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11340_10_ScreenCapture10.jpg">ScreenCapture10.jpg</a>&nbsp;&nbsp;(36,6 KB)<br>&nbsp;&nbsp;11.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11340_11_ScreenCapture11.jpg">ScreenCapture11.jpg</a>&nbsp;&nbsp;(32 KB)<br>&nbsp;&nbsp;12.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11340_12_ScreenCapture12.jpg">ScreenCapture12.jpg</a>&nbsp;&nbsp;(28,6 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20151231&edate=20150901&rec=11340">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-12-16T14:49:00+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-12-16T14:49:00+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>New Product Format for Probi Digestis® Launched in South Korea</title>
	<pubDate>2015-12-16T13:29:23+01:00</pubDate>
	<wp:post_id>6626</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Probi’s partner, Sanofi, is launching Cenovis Kids Superbiotics in South Korea.<wbr> Cenovis Kids Superbiotics, based on Probi Digestis is launched as a new product application.<wbr> The new format, a powder stick, is a convenient solution targeting a new market segment, the kids segment.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20151231&edate=20150901&rec=1966" class="defaultlink">GastroEnterology1966: Sanofi Korea to Launch Probi Digestis® for IBS</a> </div><div style="margin-bottom: 10px;">Probi and Sanofi established partnership in 2014, with a distribution and supply agreement under which the Consumer Healthcare division of Sanofi South Korea sells Probi’s gut health product, Probi Digestis®.<wbr> In South Korea, the product is marketed under the brand name Cenovis Superbiotics.<wbr> Cenovis Kids is a line extension of this product and is aimed for children in the ages between 4-10 years old.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><STRONG><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2715_1_ScreenCapture1.jpg"></STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>Stick-pack product</LI>
<LI>Fast-melt powder that can be poured straight into the mouth, without the need of mixing it with water.<wbr> </LI>
<LI>The product is convenient and easy for kids to consume, and comes in a nice strawberry flavor.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Sanofi is launching an extensive nationwide campaign for the new kids product in South Korea.<wbr> </div><div style="margin-bottom: 10px;">The product is being sold in department stores, duty free and on-line, reaching out to potential customers through a mix of advertising, PR, retail promotion, sampling and on-line marketing.<wbr> </div><div>Source: <A href="http://probi.se/en/press/new-product-format-probi-digestisr-targeting-kids-segment">http:/<wbr>/<wbr>probi.<wbr>se/<wbr>en/<wbr>press/<wbr>new-product-format-probi-digestisr-targeting-kids-segment</A> </div><!-- Comment details --><a name="gastroenterology2715attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2715_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(66,3 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20151231&edate=20150901&rec=2715">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-12-16T13:29:23+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-12-16T13:29:23+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>AstraZeneca Continues Strategic Investment in China</title>
	<pubDate>2015-12-16T11:09:29+01:00</pubDate>
	<wp:post_id>6627</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: AstraZeneca <AZN.L>aims to build up its already strong position in China by making and developing more medicines locally, and will invest more than $800M in the country over the next 10 years.<wbr> These investments and dedicated R&amp;D capabilities are aimed at accelerating Chinese patients’ access to innovative medicines to address significant unmet need in AstraZeneca’s main therapy areas - respiratory, inflammation and autoimmunity; cardiovascular and metabolic diseases; and oncology.<wbr></AZN.L> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>A strategic alliance with <STRONG>WuXi AppTec</STRONG>, a leading Chinese biologics manufacturer and CRO, <STRONG>to produce innovative biologics locally in China</STRONG>.<wbr> Under the agreement, AstraZeneca has the option to acquire WuXi AppTec’s biologics manufacturing capacity in Wuxi City in the next few years through an overall investment approximating $100 million.<wbr> Prior to that, Wuxi AppTec remains the company’s exclusive partner for R&amp;D manufacturing for innovative biologics in China.<wbr> The alliance builds on the existing joint venture between MedImmune and WuXi AppTec to develop and commercialise MEDI5117, a novel biologic for autoimmune and inflammatory diseases, in China.<wbr></LI>
<LI>An investment of <STRONG>$50 million to build an additional development and launch facility</STRONG> alongside our existing manufacturing site in Wuxi City to support the development and manufacture of innovative small molecules discovered in China and our global R&amp;D sites.<wbr></LI>
<LI>Additional investments include the <STRONG>creation of a new global hub for Pharmaceutical Development</STRONG> – alongside those in the UK and Sweden - with up to 50 scientists based in Shanghai and Wuxi City, to support both China and global needs.<wbr> AstraZeneca is also establishing an integrated China medicines development organisation, bringing together early and late-stage medicines development across small molecules and biologics.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><B>About WuXi AppTec</B> </div><div style="margin-bottom: 10px;"><A href="http://www.wuxiapptec.com">http:/<wbr>/<wbr>www.<wbr>wuxiapptec.<wbr>com</A> </div><div style="margin-bottom: 10px;">Etablished in 2000 </div><div style="margin-bottom: 10px;">WuXi AppTec, an operating subsidiary of WuXi PharmaTech, is a leading open-access R&amp;D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, with operations in China and the US.<wbr> As a research-driven and customer-focused company, WuXi PharmaTech provides pharmaceutical, biotechnology, and medical device companies with a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&amp;D process.<wbr> WuXi is also building a platform to provide clinical diagnostic services directly to physicians and their patients globally.<wbr> WuXi PharmaTech’s services are designed to help its global partners in shortening the cycle and lowering the cost of drug and medical device R&amp;D.<wbr> </div><div>Source <A href="https://www.astrazeneca.com/our-company/media-centre/press-releases/2015/AstraZeneca-continues-strategic-investment-in-China-to-accelerate-delivery-of-innovative-biologics-and-targeted-medicines-16122015.html">https:/<wbr>/<wbr>www.<wbr>astrazeneca.<wbr>com/<wbr>our-company/<wbr>media-centre/<wbr>press-releases/<wbr>2015/<wbr>AstraZeneca-continues-strategic-investment-in-China-to-accelerate-delivery-of-innovative-biologics-and-targeted-medicines-16122015.<wbr>html</A>#! </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20151231&edate=20150901&rec=11335">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-12-16T11:09:29+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-12-16T11:09:29+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Valeant and Walgreens Enter 20-year Deal in the US</title>
	<pubDate>2015-12-16T10:13:40+01:00</pubDate>
	<wp:post_id>6628</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Valeant announced new fulfillment agreements with <ORG>Walgreens</ORG> while indicating it intends to extend this distribution model to additional participating independent retail pharmacies.<wbr> Starting in 1Q16, Walgreens will distribute Valeant's branded prescription dermatology and ophthalmology products in exchange for a 10% discount.<wbr> In 2H16, Walgreens also will distribute Valeant's off-patent branded dermatology, ophthalmology, gastrointestinal and neurology products at generic prices, which the partners expect will result in an average price reduction of more than 50%.<wbr> This agreement also covers Valeant's OTC product portfolio.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Valeant's dermatology products – including, most notably, Jublia®, Luzu™, Solodyn®, Retin-A Micro® Gel 0.<wbr>08%, Onexton™ and Acanya® Gel – and ophthalmology products – including Besivance®, Lotemax®, Alrex®, Prolensa ®, Bepreve® and Zylet®.<wbr> </div><div style="margin-bottom: 10px;">Valeant's branded products, where generics are available such as Aldara®, Tiazac®, and Glumetza®.<wbr> </div><div style="margin-bottom: 10px;">Valeant estimates that the price decreases across both programs are expected to provide the healthcare system up to <MONEY>$600 million</MONEY> in annual savings.<wbr> </div><div style="margin-bottom: 10px;"><B>ABOUT <ORG>WALGREENS</ORG> </B> </div><div style="margin-bottom: 10px;"><ORG>Walgreens</ORG> is included in the <ORG>Retail Pharmacy USA Division of Walgreens Boots Alliance</ORG><ORG>, Inc.<wbr></ORG> (Nasdaq: <ORG value="SL/wbxa">WBA</ORG>), the first global pharmacy-led, health and wellbeing enterprise.<wbr> </div><div style="margin-bottom: 10px;">More than 8 million customers interact with <ORG>Walgreens</ORG> each day in communities across America, using the most convenient, multichannel access to consumer goods and services and trusted, cost-effective pharmacy, health and wellness services and advice.<wbr> </div><div style="margin-bottom: 10px;"><ORG>Walgreens</ORG> operates 8,173 drugstores with a presence in all 50 states, the <LOCATION value="LS/us.dc">District of Columbia</LOCATION>, <LOCATION value="LC/pr;LB/car">Puerto Rico</LOCATION> and the <LOCATION value="LC/vi;LB/car">U.<wbr>S.<wbr> Virgin Islands</LOCATION>.<wbr> <ORG>Walgreens</ORG> digital business includes Walgreens.<wbr>com, drugstore.<wbr>com, Beauty.<wbr>com, SkinStore.<wbr>com and VisionDirect.<wbr>com.<wbr> <ORG>Walgreens</ORG> also manages more than 400 <ORG>Healthcare Clinic</ORG> and provider practice locations around the country.<wbr> </div><div>Source: <A href="http://ir.valeant.com/investor-relations/news-releases/news-release-details/2015/Valeant-Announces-New-US-Fulfillment-Agreements-With-Walgreens-Plans-To-Further-Extend-Distribution-To-Independent-Pharmacies/default.aspx">http:/<wbr>/<wbr>ir.<wbr>valeant.<wbr>com/<wbr>investor-relations/<wbr>news-releases/<wbr>news-release-details/<wbr>2015/<wbr>Valeant-Announces-New-US-Fulfillment-Agreements-With-Walgreens-Plans-To-Further-Extend-Distribution-To-Independent-Pharmacies/<wbr>default.<wbr>aspx</A> </div><!-- Comment details --><a name="pharmaworld11334attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11334_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(102,1 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11334_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(45,3 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20151231&edate=20150901&rec=11334">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-12-16T10:13:40+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-12-16T10:13:40+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Takeda's 24-Week 22.5mg Leuplin® PRO Approved For Prostate And Premenopausal Breast Cancer In Japan</title>
	<pubDate>2015-12-15T19:04:43+01:00</pubDate>
	<wp:post_id>6629</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Takeda's 24-Week 22.<wbr>5mg Leuplin® PRO Approved For Prostate And Premenopausal Breast Cancer In Japan</span>&nbsp;<br><span style="font-size: 12px;">Comment: Takeda submitted New Drug Application for 6 month formulation of its leuprorelin on Sept 2014.<wbr> On 28th Sept 2015, Takeda announced that its Leuplin&reg; PRO for injection kit 22.<wbr>5mg (s.<wbr>c) is approved in Japan for prostate and premenopausal breast cancer.<wbr> This is its 6 month formulation of leuprorelin acetate.<wbr> This is the first approval of 24 week depot leuprorelin for the treatment of premenopausal breast cancer.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20151231&edate=20150901&rec=10683">...</a><br></div><div style="margin-bottom: 10px;">Comment: Takeda announced that its Leuplin PRO for injection kit 22.<wbr>5mg is launched in Japan for Prostate and Premenopausal breast cancer with a price of &yen; 105,039.<wbr> </div><div style="margin-bottom: 10px;"><P style="white-space: normal; word-spacing: 0px; text-transform: none; color: #000000; font: 14px/21px Arial, 'Hiragino Kaku Gothic Pro', sans-serif, Helvetica, Geneva; margin: 0px 0px 15px; widows: 1; letter-spacing: normal; text-indent: 0px; -webkit-text-stroke-width: 0px; padding: 0px;"><STRONG style="font-size: 14px; font-weight: bold; line-height: 1.3;">Overview of the 24-week depot formulation </STRONG></P> </div><div style="margin-bottom: 10px;"><TABLE border="1" style="margin-bottom: 20px; border-top: #e6e6e6 1px solid; width: 693px; white-space: normal; word-spacing: 0px; text-transform: none; color: #000000; font: 14px/21px Arial, 'Hiragino Kaku Gothic Pro', sans-serif, Helvetica, Geneva; border-spacing: 0px; border-left: #e6e6e6 1px solid; widows: 1; letter-spacing: normal; text-indent: 0px; -webkit-text-stroke-width: 0px;"><TBODY><TR><TD style="border-right: #e6e6e6 1px solid; border-bottom: #e6e6e6 1px solid; margin: 0px; padding: 10px;">Brand name</TD>
<TD style="border-right: #e6e6e6 1px solid; border-bottom: #e6e6e6 1px solid; margin: 0px; padding: 10px;">Leuplin<SUP>&reg;</SUP><STRONG style="font-weight: bold;"> </STRONG>PRO for Injection Kit 22.<wbr>5 mg</TD>
</TR>
<TR><TD style="border-right: #e6e6e6 1px solid; border-bottom: #e6e6e6 1px solid; margin: 0px; padding: 10px;">Generic name</TD>
<TD style="border-right: #e6e6e6 1px solid; border-bottom: #e6e6e6 1px solid; margin: 0px; padding: 10px;">Leuprorelin acetate</TD>
</TR>
<TR><TD style="border-right: #e6e6e6 1px solid; border-bottom: #e6e6e6 1px solid; margin: 0px; padding: 10px;">Indications     </TD>
<TD style="border-right: #e6e6e6 1px solid; border-bottom: #e6e6e6 1px solid; margin: 0px; padding: 10px;">Prostate cancer<BR>Premenopausal breast cancer</TD>
</TR>
<TR><TD style="border-right: #e6e6e6 1px solid; border-bottom: #e6e6e6 1px solid; margin: 0px; padding: 10px;">Dosage and administration</TD>
<TD style="border-right: #e6e6e6 1px solid; border-bottom: #e6e6e6 1px solid; margin: 0px; padding: 10px;">Usually, for adults, 22.<wbr>5 mg of Leuprorelin Acetate is subcutaneously administered once every 24 weeks.<wbr><BR>When using Leuplin<SUP>&reg;</SUP> PRO, it should be used after suspending it completely by transferring the whole quantity of the vehicle into the powder part, by pressing the plunger rod, with the injection needle held upward, with caution against foaming.<wbr></TD>
</TR>
<TR><TD style="border-right: #e6e6e6 1px solid; border-bottom: #e6e6e6 1px solid; margin: 0px; padding: 10px;">Drug price</TD>
<TD style="border-right: #e6e6e6 1px solid; border-bottom: #e6e6e6 1px solid; margin: 0px; padding: 10px;">&yen; 105,039</TD>
</TR>
</TBODY>
</TABLE> </div><div>Source Takeda Press Release 15 Dec 2015 </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20151231&edate=20150901&rec=10827">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10683">View thread  Oncology10683: Takeda's 24-Week 22.<wbr>5mg Leuplin® PRO Approved For Prostate And Premenopausal Breast Cancer In Japan</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-12-15T19:04:43+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-12-15T19:04:43+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Midatech Signs Supply Agreement With Centurion Pharma For Q-Octreotide</title>
	<pubDate>2015-12-15T15:17:26+01:00</pubDate>
	<wp:post_id>6630</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Midatech Pharma has announced the entering into a supply agreement for Q-octreotide, a sustained release version of octreotide under development for the treatment of carcinoid and acromegaly, to Centurion Pharma for the Turkish market.<wbr> As part of the agreement, Midatech will receive up front, milestone and royalty payments but financial terms of the agreement have not been disclosed.<wbr> Midatech&rsquo;s Q-Octreotide is aimed at offering patients and physicians an alternative therapy for carcinoid and acromegaly with distinct advantages including ease of reconstitution and administration.<wbr> Midatech was planning to finalize the product optimization /<wbr>pre-clinical work by end of 2015 and moving Q-octreotide into clinical development in 2016.<wbr> No further updates on development have been disclosed/<wbr>confirmed.<wbr> </div><div style="margin-bottom: 10px;">Commenting on the announcement, Dr.<wbr> Jim Phillips, CEO of Midatech Pharma, said: &ldquo;This is the first deal of this type for Q-Octreotide and another step towards proving the international and commercial focus of Midatech.<wbr> Following on closely from the successful completion of the DARA Biosciences acquisition earlier this month, Midatech is now very well placed to commercialise products in the US and, in other territories, we will continue to partner with companies such as Centurion, where they can maximise the value of products in their specialist markets.<wbr>&rdquo; </div><div>Source: Midatech </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20151231&edate=20150901&rec=8302">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-12-15T15:17:26+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-12-15T15:17:26+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>ENEA Workshop On Acromegaly: Key Highlights</title>
	<pubDate>2015-12-15T14:17:49+01:00</pubDate>
	<wp:post_id>6631</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The ENEA Worskshop held in Marseille (10-12 December 2015) gathered around 200 acromegaly experts and was a very insightful forum for discussing this disease key issues both from a clinical and a biological perspective.<wbr> The treatment aims of acromegaly clearly still remain to relieve symptoms, to reduce the tumor volume, to avoid relapse and improve long-term morbidity and mortality.<wbr> Early diagnosis still poses one of the greatest challenges, while surgery and SSA remains key first treatment options respectively.<wbr> The greatest unmet medical need is represented by patients who are partially or totally resistant to SSA where the development of robust predictive biomarkers should help in the choice of the more appropriate treatment to ensure more &lsquo;personalized&rsquo; medicine.<wbr> All these different aspects were strongly addressed in NVS and Pfizer (and Ipsen) symposia as well as by many different key note speakers that also discussed the future treatment options for acromegaly.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><U>NVS Symposium</U></STRONG>: &lsquo;Case by case: an individualized approach to the treatment of acromegaly&rsquo; [Diego Ferone, Maria Fleseriu and Ilan Shiman] </div><div style="margin-bottom: 10px;">The symposium presented some real life cases and highlighted the main challenges of acromegaly and in particular: </div><div style="margin-bottom: 10px;"><UL><LI>Challenge of diagnosis which is often delayed and lead to late initiation of treatments
</LI>
<LI>Multiple factors should be considered when choosing the most appropriate treatment option for the patients, including: disease severity, tumor size/<wbr>invasiveness and histology, co-morbidities and patient preference
</LI>
<LI>Vigilant monitoring and appropriate adjustment of treatment are vital in order to achieve the best possible outcomes for acromegaly patients.<wbr>
</LI>
<LI>Achievement of biochemical control is a key treatment goal for acromegaly as it can reduce morbidity and restore life expectancy and QoL
<UL><LI>Many patients remain uncontrolled during treatment with the current first generation SSA (octreotide LAR and lanreotide) &ndash; pasireotide was presented as a good alternative.<wbr>
</LI>
</UL>

</LI>
<LI>Other goals of treatment include control of tumor mass, attenuation of symptoms and maintenance of pituitary function.<wbr>
</LI>
</UL> </div><div style="margin-bottom: 10px;"><U>Case 1- Diagnosis, Initial treatment and monitoring</U> : Patient initially underwent transsphenoidal surgery because of compression of the optic chiasm and visual disturbances.<wbr> Medical treatment was subsequently initiated with octreotide LAR with the goal of controlling acromegaly and reduce tumor volume (octreotide was administered first at 30mg/<wbr>28 days for 6 months and then increased to 40 mg/<wbr>28 days) </div><div style="margin-bottom: 10px;"><U>Case 2: Patient with inadequately controlled acromegaly: </U>Patient underwent debulking surgery and proactively switched medical therapy to achieve biochemical control and reduce tumor size: started on 20 mg/<wbr>28 days octreotide, went to 30mg/<wbr>28 days, switched to pasireotide LAR 40mg and then stabilized on pasireotide LAR 20mg.<wbr> Hyperglycaemia associated to pasireotide was managed with 850mg/<wbr>day metformin.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8300_1_IMG%255f3372.JPG"> <img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8300_2_IMG%255f3386.JPG"> <img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8300_3_IMG%255f3387.JPG"> <img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8300_4_IMG%255f3403.JPG"> <img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8300_6_IMG%255f3431.JPG"> <img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8300_7_IMG%255f3481.JPG"> </div><div style="margin-bottom: 10px;"><STRONG><U>Pfizer symposium: </U></STRONG>Towards disease control in acromegaly: comorbidities and key considerations [S.<wbr> Neggers, K.<wbr>Ho, A.<wbr>Barkan] </div><div style="margin-bottom: 10px;">Pfizer symposium focused on the long-term complications for the patients where there is an often lengthy delay in diagnosis, and in particular: </div><div style="margin-bottom: 10px;"><UL><LI><U>Hypersinulism and diabetes</U> [S.<wbr>Neggers]: the prevalence of type 2 diabetes with concurrent acromegaly is approximately 20-50% ad although current guidelines suggest that control of GH hypersecretion is crucial for the improvement of glucose metabolism, there is clinical concern regarding the potentially negative effects of certain treatments on glucose homeostasis, especially in patients with baseline glucose intolerance or type 2 diabetes mellitus.<wbr> Hyperinsulinism, insulin resistance and diabetes are all well-known cardiovascular risk factors and might contribute to the increased cardiac morbidity and mortality of acromegaly patients.<wbr>
</LI>
<LI><U>Sleep apnoea</U> [K.<wbr> Ho]: Sleep apnoea affects up to 70% of patients with acromegaly and can cause significant morbidity and mortality.<wbr> It is predominantly obstructive in type from tongue enlargement and pharyngeal soft tissue swelling which restricts airflow.<wbr> Sleep apnoea may not resolve in patients whom GH secretion is normalized.<wbr>
</LI>
<LI><U>Musculoskeletal problems</U> [ A.<wbr>Barkan]: Acromegalic arthopathy is one of the most frequent and disabling complications of acromegaly and affects up to 75% of patients.<wbr> This is linked to the IGF-I mediate cartilage growth and altered joint geometry and can affect both spine and peripheral joints, especially hips and knees.<wbr> The treatment of this arthopathy is still highly unsatisfactory and the only hope is to diagnose the disease prior to development of major structural damage.<wbr> Non-specific treatment with NSAID is purely symptomatic and only partially effective and most patients eventually require spinal surgeries and joint replacement.<wbr>
</LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG><U>Other presentations of note</U></STRONG>: </div><div style="margin-bottom: 10px;">Peter Trainer gave a very extensive presentation of GH receptor antagonists and key take away: </div><div style="margin-bottom: 10px;"><UL><LI>Pegvisomant 15 years of treatment highlights:
<UL><LI>Effective drug
</LI>
<LI>Safe drug (tumor growth, liver enzyme disturbance and lipodystrophy are side effects)
</LI>
<LI>Problems: Prohibitively expensive; There is a major lack of patient friendly preparation (dosing and formulation); Drug is daily dose in label but weekly dosing interval have never been adequately explored
</LI>
</UL>

</LI>
<LI>The ATL1103 antisense new pipeline drug &ndash; no updates from previously released data at ENDO, March 2015, but the drug is now part of Strongbridge Biopharma portfolio.<wbr>
</LI>
<LI>A new antagonist fusion with GH binding protein under development by Richard Ross - the MRC has currently granted &pound;2.<wbr>4M for the development of the GH antagonist fused to GH binding protein that potentially will generate a potent long acting antagonist to a phase I study.<wbr> The site 2 mutant antagonist seems more potent than pegvisomant in vivo.<wbr>
</LI>
</UL> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8300_8_IMG%255f3541.JPG"> <img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8300_9_IMG%255f3545.JPG"> </div><div style="margin-bottom: 10px;"><STRONG>Raul Luque</STRONG> (Spain) &ndash; the role of somatostatin receptor 5 isoforms in SA resistance: </div><div style="margin-bottom: 10px;"><UL><LI>Identification of novel sst5-variants in humans with 5 and 4 trans- membrane domains (TMD) which display unique molecular/<wbr>functional features and can alter the normal function of full-length sst2 and sst5.<wbr> Specifically sst5TMD5 is rarely expressed in normal or tumoural pituitary tissues, whereas sst5TDM4 is frequently expressed in pituitary tumours, particularly in somatotropinomas.<wbr> Sst5TMD4 might be a useful tool to refine diagnosis, predict outcome of clinical response to SA-therapy and develop new therapeutic targets in somatotroprinomas and other endocrine related tumours (also mentioned pNETs and MTC)
</LI>
<LI>The presence of sst4TMD4 blocks the response to octreotide in acromegaly but not pasireotide: could be pasireotide instead of octreotide a good option in patients with a specific expression profile of ssts (ie.<wbr> High sst5 AND sst4TMD4)?
</LI>
</UL> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8300_10_IMG%255f3653.JPG"> <img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8300_11_IMG%255f3656.JPG"> <img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8300_13_IMG%255f3658.JPG"> </div><div style="margin-bottom: 10px;"><STRONG>Monica Gadelha</STRONG>, discussed how to manage resistance, as only 30% patients achieve disease control during treatment with first-generation SSA.<wbr> Current treatment options for people who are not controlled with first-generation SSA are: debulking surgery, combination treatment with cabergoline, pegvisomant, next-generation SSA pasireotide and radiotherapy.<wbr> Of the approximately 7-0% of the acromegaly patients that are not fully controlled with first-generation SSA, the vast majority exhibits partial resistance with only around 10% being totally resistant.<wbr> The treatment of the SSA-resistant patients should be individualized taking into consideration many factors as efficacy, safety, posology, availability in the health system, tumor volume and GH and IGF-1 levels.<wbr> New and reliable biomarkers are necessary to guide in the choice of treatment.<wbr> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8300_14_IMG%255f3676.JPG"> </div><!-- Comment details --><a name="endocrinology8300attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8300_1_IMG%255f3372.JPG">IMG_3372.JPG</a>&nbsp;&nbsp;(978,8 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8300_2_IMG%255f3386.JPG">IMG_3386.JPG</a>&nbsp;&nbsp;(931 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8300_3_IMG%255f3387.JPG">IMG_3387.JPG</a>&nbsp;&nbsp;(1 MB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8300_4_IMG%255f3403.JPG">IMG_3403.JPG</a>&nbsp;&nbsp;(1,1 MB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8300_5_IMG%255f3347.JPG">IMG_3347.JPG</a>&nbsp;&nbsp;(1,1 MB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8300_6_IMG%255f3431.JPG">IMG_3431.JPG</a>&nbsp;&nbsp;(1 020,4 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8300_7_IMG%255f3481.JPG">IMG_3481.JPG</a>&nbsp;&nbsp;(987,7 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8300_8_IMG%255f3541.JPG">IMG_3541.JPG</a>&nbsp;&nbsp;(721,8 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8300_9_IMG%255f3545.JPG">IMG_3545.JPG</a>&nbsp;&nbsp;(915,6 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8300_10_IMG%255f3653.JPG">IMG_3653.JPG</a>&nbsp;&nbsp;(1,2 MB)<br>&nbsp;&nbsp;11.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8300_11_IMG%255f3656.JPG">IMG_3656.JPG</a>&nbsp;&nbsp;(1,2 MB)<br>&nbsp;&nbsp;12.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8300_12_IMG%255f3658.JPG">IMG_3658.JPG</a>&nbsp;&nbsp;(998,7 KB)<br>&nbsp;&nbsp;13.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8300_13_IMG%255f3658.JPG">IMG_3658.JPG</a>&nbsp;&nbsp;(998,7 KB)<br>&nbsp;&nbsp;14.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8300_14_IMG%255f3676.JPG">IMG_3676.JPG</a>&nbsp;&nbsp;(1 MB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20151231&edate=20150901&rec=8300">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-12-15T14:17:49+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-12-15T14:17:49+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Revance Appoints New COO With Toxin Experience</title>
	<pubDate>2015-12-15T14:05:30+01:00</pubDate>
	<wp:post_id>6632</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Revance has announced the appointment of Abhay Joshi as Chief Operating Officer with immediate effect.<wbr> Dr Joshi is a seasoned industry executive with extensive global experience in global biologics including oversight of botulinum toxin research, development and operations during an 18-year tenure with Allergan earlier in his career.<wbr> </div><div style="margin-bottom: 10px;">He joins Revance from Alvine Pharmaceuticala, a private, clinical-stage company focused on the development of biologics targeting autoimmune and inflammatory diseases, where he was President, Chief Executive Officer, and Director.<wbr> Prior to this, he was Chief Technical Officer and Executive Vice President at CoTherix, Inc.<wbr> (acquired by Actelion Pharmaceuticals Ltd.<wbr>).<wbr> Dr.<wbr> Joshi began his career at Allergan, where during 18 years he had increasing management responsibilities in pharmaceutical development, manufacturing, and global operations, rising to Vice President, Specialty Pharmaceuticals Operations, where he managed global biologics operations for the BOTOX&reg; product lines, and also managed Allergan's Latin America and Asia Pacific pharmaceutical operations </div><div style="margin-bottom: 10px;">Commenting on this development CEO Dan Brown stated "Abhay joins us at an important time following positive results from our BELMONT Phase 2 study and as we advance our pipeline and scale up of commercial manufacturing for our two unique botulinum toxin drug product candidates, which we intend to commercialize globally.<wbr>" </div><div style="margin-bottom: 10px;">Revance also announced the promotion of Lauren Silvernail to Chief Financial Officer and Chief Business Officer.<wbr> Mrs.<wbr> Silvernail joined the company in March of 2013 as Chief Financial Officer and Executive Vice President of Corporate Development.<wbr> She has since helped take the company public, raise more than $400 million in equity and debt and attain a market capitalization of approximately $1 billion.<wbr> </div><div><A href="http://www.revance.com/">www.<wbr>revance.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20151231&edate=20150901&rec=8266">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-12-15T14:05:30+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-12-15T14:05:30+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>With Boehringer Ingelheim Negotiations Sanofi Would Become a Global Leader in Consumer Healthcare</title>
	<pubDate>2015-12-15T10:46:36+01:00</pubDate>
	<wp:post_id>6633</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Both companies have entered into exclusive negotiations to swap businesses.<wbr> The proposed transaction would consist of an exchange of Sanofi animal health business (“Merial”) with an enterprise value of €11.<wbr>4 bn and Boehringer Ingelheim consumer healthcare (CHC) business with an enterprise value of €6.<wbr>7 bn.<wbr> Boehringer Ingelheim CHC business in China would be excluded from the transaction.<wbr> The transaction would also include a gross cash payment from Boehringer Ingelheim to Sanofi of €4.<wbr>7 bn.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Sanofi would gain access to iconic brands in Antispasmodics, Gastrointestinal, VMS and Analgesics, and attain critical mass in Cough &amp; Cold.<wbr> </div><div style="margin-bottom: 10px;">Sanofi CHC business in the US, Europe, Latin America and Eurasia would also expand significantly, giving it multiple leadership postions in key countries and/<wbr>or on key product categories.<wbr> </div><div style="margin-bottom: 10px;">Germany would become a key center of Sanofi CHC business, including in particular for Gastro-Intestinal and Cough &amp; Cold categories that will benefit from the strong capabilities of Boehringer Ingelheim teams.<wbr> </div><div style="margin-bottom: 10px;">The execution of definitive agreements is expected in the coming months following consultations with the relevant social bodies.<wbr> Boehringer Ingelheim and Sanofi’s goal currently is to close the potential transaction in Q4 2016, subject to appropriate regulatory approvals.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2712_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Boehringer Ingelheim Consumer Healthcare is the 8th largest Consumer Healthcare business in the world.<wbr> </div><div style="margin-bottom: 10px;">Sales of Boehringer Ingelheim’s CHC business were €1.<wbr>4 bn in 2014, contributing 11% to Boehringer Ingelheim’s net sales.<wbr> </div><div style="margin-bottom: 10px;">The leading brands of Boehringer Ingelheim’s CHC business are the antispasmodic Buscopan® (2014 sales of €219 million; mainly sold in Europe and Latin America), </div><div style="margin-bottom: 10px;"><UL><LI>the laxative Dulcolax® (2014 sales of €204 million; sold in more than 40 countries with a strong presence in the U.<wbr>S.<wbr>), </LI>
<LI>the multivitamins Pharmaton® (2014 sales of €133 million, with majority of sales in Latin America), </LI>
<LI>the cough treatments Mucosolvan® (2014 sales of €165 million, mainly in China, Germany and Russia) and </LI>
<LI>Bisolvon® (2014 sales of €101 million with a fragmented worldwide presence with largest countries being Spain and Italy) and </LI>
<LI>the cold treatment Mucoangin®/<wbr>Lysopaine® (2014 sales of €48 million).<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Sales of Sanofi CHC business were €3.<wbr>3 bn in 2014.<wbr> In 2014, 52.<wbr>6% of CHC sales were generated in emerging markets, 21.<wbr>2% in the U.<wbr>S.<wbr> and 20.<wbr>3% in Western Europe </div><div style="margin-bottom: 10px;">The leading brands of Sanofi’s CHC business are </div><div style="margin-bottom: 10px;"><UL><LI>the allergy products Allegra® (2014 sales of €350 million) and Nasacort® (2014 sales of €114 million), </LI>
<LI>the pain killers Doliprane® (2014 sales of €310 million), </LI>
<LI>No-Spa® (2014 sales of €109 million) and </LI>
<LI>Dorflex® (2014 sales of €90 million), </LI>
<LI>the digestive products Essentiale® (2014 sales of €235 million), </LI>
<LI>Enterogermina® (2014 sales of €156 million) and </LI>
<LI>Maalox® (2014 sales of €98 million), </LI>
<LI>the feminine care product Lactacyd® (2014 sales of €104 million) and </LI>
<LI>the vitamins, minerals and supplements Magné B6® (2014 sales of €88 million).<wbr></LI>
</UL> </div><div>Source: BI; Sanofi </div><!-- Comment details --><a name="gastroenterology2712attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2712_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(38,6 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20151231&edate=20150901&rec=2712">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-12-15T10:46:36+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-12-15T10:46:36+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Management Reports that Boehringer Ingelheim Consumer Health Care Could Double in Size Over the Next Decade</title>
	<pubDate>2015-12-14T18:11:11+01:00</pubDate>
	<wp:post_id>6634</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;"><P class="newsItemSubHeader">Comment: According to WW head of the business, Boehringer Ingelheim Consumer Health Care has carried out a large-scale evaluation of the consumer healthcare market and is now open to a broader range of business possibilities.<wbr> Management aims to create a new OTC stand-alone BU in 2018.<wbr> Management believes it can address a major health problem through a combination of an active pharmaceutical ingredient, diagnostics and support services, citing WeightWatchers as a successful example of this sort of holistic approach in the health and wellbeing sector.<wbr></P> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The aim is to launch the initiative in 2018 in developed regions of the world such as the US and Europe, adding that China and some other emerging markets might also be targeted at this initial stage.<wbr> </div><div style="margin-bottom: 10px;">The German company still wants to develop the business in emerging markets, it still wants to gain a stronger presence in China and the US, and it still wants to launch a robust pipeline of new products including switches </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">A major reorganisation means Consumer Health Care is now a stand-alone business unit within Boehringer Ingelheim, and the large-scale evaluation means the business is open to a broader range of business possibilities.<wbr> </div><div style="margin-bottom: 10px;">In the emerging markets, for example, Boehringer Ingelheim Consumer Health Care has carried out a “huge evaluation exercise” over the past 18 months.<wbr> The end result is a “very robust strategy” focusing on a small number of priority growth markets.<wbr> </div><div style="margin-bottom: 10px;">China remains at the top of the list, and India is still regarded as an important opportunity.<wbr> The Consumer Health Care is now targeting core countries in Africa, as well as some in the Middle East and South-East Asia.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The Boehringer Ingelheim Consumer Health Care business contributes 11% to Boehringer Ingelheim's total net sales.<wbr> In 2014, the self-medication business achieved net sales of nearly 1.<wbr>4 billion euros.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2710_1_ScreenCapture1.jpg"> </div><div>Source: OTC ToolBox </div><!-- Comment details --><a name="gastroenterology2710attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2710_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(22,6 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20151231&edate=20150901&rec=2710">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-12-14T18:11:11+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-12-14T18:11:11+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Publication of Preliminary Clinical Data on Check Cap's Preparation-Free Colon Screening Capsule</title>
	<pubDate>2015-12-14T18:00:20+01:00</pubDate>
	<wp:post_id>6635</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Check-Cap has announced that data related to its clinical studies have been published in <I>Gut</I>.<wbr> The article, entitled "A Novel Prepless X-ray Imaging Capsule for Colon Cancer Screening," includes safety and motility data collected in Europe and Israel on passage of the capsule through the GI tract, as well as a preliminary analysis of the first participants evaluated in the Company's ongoing multi-center clinical feasibility study, which aims to establish the safety, functionality and preliminary efficacy of the Check-Cap system.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Preliminary analysis of the ongoing clinical feasibility study evaluated data from participants who swallowed Check-Cap's scanning capsule, tracking the entire passage of the capsule through the alimentary tract using radio frequency telemetry and Check-Cap's proprietary capsule position tracking system.<wbr> </div><div style="margin-bottom: 10px;">Pedunculated and sessile polyps were clearly seen and validated by subsequent colonoscopy, and the total radiation exposure was found to be ultra-low (0.<wbr>03±0.<wbr>007 mSv, or the equivalent exposure of one chest x-ray).<wbr> </div><div style="margin-bottom: 10px;">Capsules were excreted naturally in all 48 volunteers who completed the study (one asymptomatic volunteer withdrew prior to completion and the capsule was retrieved endoscopically from the colon).<wbr> </div><div style="margin-bottom: 10px;">Initial data show the system to be safe, as well as able to produce 3D reconstructions of the colonic wall and lumen, including identifying polyps.<wbr> </div><div style="margin-bottom: 10px;">Publication <A href="http://gut.bmj.com/content/early/2015/12/01/gutjnl-2015-310893.short?g=w_gut_ahead_tab">http:/<wbr>/<wbr>gut.<wbr>bmj.<wbr>com/<wbr>content/<wbr>early/<wbr>2015/<wbr>12/<wbr>01/<wbr>gutjnl-2015-310893.<wbr>short?g=w_gut_ahead_tab</A> </div><div>Source: Check-Cap </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20151231&edate=20150901&rec=2709">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-12-14T18:00:20+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-12-14T18:00:20+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>MSD Initiated A Ph2 Trial (KEYNOTE-057) To Study Pembrolizumab In High Risk NMIBC</title>
	<pubDate>2015-12-14T17:23:22+01:00</pubDate>
	<wp:post_id>6636</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: MSD listed a ph2 trial to evaluate its anti-PD1, pembrolizumab, in high risk non muscle invasive bladder cancer pateints who are unresponsive to BCG and are considered ineligible for or have refused to undergo radical cystectomy.<wbr> An estimatd enrollment of 260 patinets.<wbr> The study is expected to start in January 2016 and has not yet opened for recruitment.<wbr> </div><div style="margin-bottom: 10px;"><DIV class="info-title">ClinicalTrials.<wbr>gov Identifier: NCT02625961</DIV> </div><div style="margin-bottom: 10px;">Estimated Primary completion Date January 2019 </div><div style="margin-bottom: 10px;">Primary Oucome measures: complete response rate up to 3 years, DFS up to 3 years </div><div style="margin-bottom: 10px;">Secondary Outcome measures: Duration of response up to 3 years </div><div style="margin-bottom: 10px;"><P style="margin-bottom: 1ex; margin-top: 1ex;">Inclusion Criteria:</P> </div><div style="margin-bottom: 10px;"><UL style="margin-bottom: 1ex; margin-top: 1ex;"><LI class="color-bullet" style="margin-top: 0.7ex;">Histologically-confirmed diagnosis of high risk non-muscle-invasive (T1, high grade Ta and /<wbr> or carcinoma in situ) transitional cell carcinoma of the bladder (mixed histology tumors allowed if transitional cell histology is predominant histology)
</LI>
<LI class="color-bullet" style="margin-top: 0.7ex;">Absence of resectable disease after at least 2 cystoscopy /<wbr>transurethral resection (TURBT) procedures (residual CIS acceptable)
</LI>
<LI class="color-bullet" style="margin-top: 0.7ex;">BCG-unresponsive high risk non-muscle-invasive bladder cancer after treatment with adequate BCG therapy
</LI>
<LI class="color-bullet" style="margin-top: 0.7ex;">Ineligible for radical cystectomy or refusal of radical cystectomy
</LI>
<LI class="color-bullet" style="margin-top: 0.7ex;">Available tissue from a newly obtained core biopsy of a tumor lesion not previously irradiated
</LI>
<LI class="color-bullet" style="margin-top: 0.7ex;">Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2
</LI>
<LI class="color-bullet" style="margin-top: 0.7ex;">Adequate organ function
</LI>
<LI class="color-bullet" style="margin-top: 0.7ex;">Female participants of childbearing potential have a negative urine or serum pregnancy test and must be willing to use an adequate method of contraception
</LI>
<LI class="color-bullet" style="margin-top: 0.7ex;">Male participants must be willing to use an adequate method of contraception
</LI>
</UL> </div><div style="margin-bottom: 10px;"><P style="margin-bottom: 1ex; margin-top: 0ex;">Exclusion criteria:</P> </div><div style="margin-bottom: 10px;"><UL style="margin-bottom: 1ex; margin-top: 1ex;"><LI class="color-bullet" style="margin-top: 0.7ex;">Muscle-invasive, locally advanced nonresectable, or metastatic urothelial carcinoma (i.<wbr>e.<wbr>, T2, T3, T4, and /<wbr> or stage IV)
</LI>
<LI class="color-bullet" style="margin-top: 0.7ex;">Concurrent extra-vesical (i.<wbr>e.<wbr>, urethra, ureter, or renal pelvis) non-muscle invasive transitional cell carcinoma of the urothelium
</LI>
<LI class="color-bullet" style="margin-top: 0.7ex;">Currently participating or has participated in a study of an investigational agent and received study therapy or received investigational device within 4 weeks prior to the first dose of study treatment
</LI>
<LI class="color-bullet" style="margin-top: 0.7ex;">Received intervening intravesical chemotherapy or immunotherapy from the time of most recent cystoscopy /<wbr> TURBT to starting study treatment
</LI>
<LI class="color-bullet" style="margin-top: 0.7ex;">Received prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to starting study treatment or not recovered from adverse events due to a previously administered agent
</LI>
<LI class="color-bullet" style="margin-top: 0.7ex;">Known additional malignancy that is progressing or requires active treatment excepting basal cell carcinoma of the skin, squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer.<wbr> A history of prostate cancer that was treated with definitive intent (surgically or through radiation therapy) is acceptable
</LI>
<LI class="color-bullet" style="margin-top: 0.7ex;">Active autoimmune disease that has required systemic treatment in the past 2 years
</LI>
<LI class="color-bullet" style="margin-top: 0.7ex;">Evidence of interstitial lung disease or active non-infectious pneumonitis
</LI>
<LI class="color-bullet" style="margin-top: 0.7ex;">Active infection requiring systemic therapy
</LI>
<LI class="color-bullet" style="margin-top: 0.7ex;">Pregnant or breastfeeding, or expecting to conceive within the projected duration of the trial through 120 days after the last dose of study treatment
</LI>
<LI class="color-bullet" style="margin-top: 0.7ex;">Prior therapy with an anti-programmed cell death 1 (PD-1), anti-PD-ligand 2 (L2) agent, or with an agent directed to another co-inhibitory T-cell receptor
</LI>
<LI class="color-bullet" style="margin-top: 0.7ex;">Known human immunodeficiency virus (HIV)
</LI>
<LI class="color-bullet" style="margin-top: 0.7ex;">Known active Hepatitis B or C infection
</LI>
<LI class="color-bullet" style="margin-top: 0.7ex;">Received a live virus vaccine within 30 days of planned start of study treatment
</LI>
</UL> </div><div>Source: clinicaltrials.<wbr>gov </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20151231&edate=20150901&rec=10825">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-12-14T17:23:22+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-12-14T17:23:22+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Viralytics Raised $28M With A Goal To Strengthen Clinical Evidences to Support CAVATAK's Potential In Melanoma, Bladder, And Prostate Cancer</title>
	<pubDate>2015-12-14T16:22:27+01:00</pubDate>
	<wp:post_id>6637</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Viralytics announced that it has completed a placement of 46,118,270 shares at an issue price of $0.<wbr>614 per share to raise $28 millions.<wbr> Viralytics' CAVATAK&trade; is currently being studied in Phase 1 and 2 clinical trials for the treatment of melanoma, as well as prostate, bladder and lung cancers.<wbr> The funds from this capital raise will enable acceleration of the collaborative study with MSD's anti-PD1 in metastatic bladder and lung cancer (STORM trial) - commencing in 2016 - and completion of the Ph1 CANON trial in non muscle invasive bladder cancer with potential extension into Ph2 trial.<wbr> </div><div style="margin-bottom: 10px;">Viralytics is based in Sydney Australia, the company is listed on the Australian Securities Exchange (ASX: VLA) while Viralytics' ADRs also trade under VRACY on the US OTCQX International market.<wbr> Viralytics has completed a $28M placement.<wbr> As a result of the placement, OrbiMed Advisors, a New York headquartered specialist global healthcare fund, becomes a substantial shareholder in Viralytics.<wbr> Existing shareholders who participated in the placement included the Biotechnology Value Fund, L.<wbr>P.<wbr> and other affiliates of BVF Partners L.<wbr>P.<wbr> Bell Potter Securities Limited was the Lead Manager with Roth Capital Partners acting as the Sole US Placement Agent.<wbr> </div><div style="margin-bottom: 10px;">Funds will also be applied to manufacture of CAVATAK for use in clinical trials and general working capital.<wbr>  The proceeds will be used as follows: </div><div style="margin-bottom: 10px;"><OL type="1"><LI>Completion of Part A of the STORM trial and accelerated recruitment into Part B assessing CAVATAK&trade; in combination with KEYTRUDA&reg; in approximately 80 metastatic bladder and lung cancer patients
</LI>
<LI>Completion of the CANON clinical trial in patients with non-muscle invasive bladder cancer with potential extension into a phase 2 trial
</LI>
<LI>Completion of the CAPRA and MITCI clinical trials in late stage melanoma patients
</LI>
<LI>Initiation of a clinical trial to assess intravenously delivered CAVATAK&trade; in combination with a checkpoint inhibitor in late stage melanoma patients
</LI>
<LI>New CAVATAK&trade; studies in indications /<wbr> immunotherapy combinations to be determined following scientific and commercial review
</LI>
<LI>Manufacture of CAVATAK&trade; for use in clinical trials
</LI>
<LI>General Working Capital and strengthening of the balance sheet ahead of commercial negotiations
</LI>
</OL> </div><div style="margin-bottom: 10px;"><STRONG>About CAVATAK</STRONG> </div><div style="margin-bottom: 10px;">CAVATAK is a proprietary formulation of the common cold Coxsackievirus Type A21 (CVA21) that preferentially binds to specific 'receptor' proteins highly expressed on multiple cancer types.<wbr> CAVATAK acts to kill both local and metastatic cancer cells through cell lysis and the potential generation of an immune response against the cancer cells -- a two-pronged mechanism of action known as oncolytic immunotherapy.<wbr> </div><div>Source: Viralytics Press Release 14 Dec 2015 </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20151231&edate=20150901&rec=10824">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-12-14T16:22:27+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-12-14T16:22:27+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Ferring Gets the Rights to CORTIMENT® MMX® for Japan</title>
	<pubDate>2015-12-14T14:23:32+01:00</pubDate>
	<wp:post_id>6638</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Cosmo has signed a licensing agreement with Ferring.<wbr> If approved, CORTIMENT<SUP>®</SUP> MMX<SUP>®</SUP> will offer a treatment with a novel formulation for active, mild-to-moderate Ulcerative Colitis.<wbr> This will mark Ferring Japan’s second entry in the gastroenterology field (First entry is the submission of PICOPREP<SUP>®</SUP> for cleansing of the colon as a preparation for colonoscopy in adults).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Ferring will conduct, at its expense, the necessary clinical trials which are required for the submission of the registration in Japan.<wbr> </div><div style="margin-bottom: 10px;">Ferring has entered into an obligation to pay a signing fee of EUR 8 million and double digit royalties upon first sale of the product.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>About CORTIMENT<SUP>®</SUP> MMX<SUP>®</SUP></STRONG> </div><div style="margin-bottom: 10px;">CORTIMENT<SUP>®</SUP> is a locally acting corticosteroid in a novel, patented, oral tablet formulation, which utilizes MMX<SUP>®</SUP> multi-matrix technology and is designed to result in the prolonged release and distribution of budesonide throughout the length of the colon.<wbr> </div><div style="margin-bottom: 10px;">Budesonide has mainly topical anti-inflammatory activity and due to its high first pass metabolism, it has low system bioavailability.<wbr> Budesonide using MMX<SUP>®</SUP> technology may be marketed under another name in some countries.<wbr> </div><div>Source: Cosmo pharm.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20151231&edate=20150901&rec=2708">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-12-14T14:23:32+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-12-14T14:23:32+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>AAA Q3 Takeaways</title>
	<pubDate>2015-12-11T16:22:19+01:00</pubDate>
	<wp:post_id>6639</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: AAA's Q3 earnings release highlighted how the third quarter was a pivotal time for the company with the release of the NETTER-1 data and the successful execution of the group's IPO.<wbr> The company confirmed that EU/<wbr>US regulatory submissions for Lutathera will now take place by the end of Q116.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Financial performance</STRONG> </div><div style="margin-bottom: 10px;">Total sales for the first nine months of 2015 were &euro;66.<wbr>138 million, a 31.<wbr>8% year-over-year increase vs.<wbr> 2014.<wbr> </div><div style="margin-bottom: 10px;">For the first nine months of 2015, the group's operating loss was &euro;4.<wbr>162 million, compared to &euro;1.<wbr>281 million in 2014.<wbr> Whilst its net loos was &euro;10.<wbr>281 million.<wbr> </div><div style="margin-bottom: 10px;">Adjusted EBITDA remained positive despite increasing R&amp;D expenses and significant costs for the preparation of the commercial launch of Lutathera.<wbr> </div><div style="margin-bottom: 10px;">R&amp;D expenditures for the first nine months of 2015 were &euro;10.<wbr>710 million compared to &euro;7.<wbr>393 million the first nine months of 2014 and as of September 30, 2015 the Company had cash and cash equivalents of &euro;52.<wbr>291 million </div><div style="margin-bottom: 10px;"><STRONG>Latest NETTER-1 findings</STRONG> </div><div style="margin-bottom: 10px;">Within the current evaluable patient dataset for tumor responses (n=201), 19 patients (19%) reported complete and partial responses (CR+PR) in the Lutathera group versus 3 (3%) in the Octreotide LAR 60 mg group (p&lt;0.<wbr>0004).<wbr> Although the overall survival ("OS") data is not mature enough for a definitive analysis, the number of deaths was 13 in the Lutathera group and 22 in the Octreotide LAR 60 mg group (p=0.<wbr>0186 at interim analysis), which initially suggests an improvement in OS.<wbr> </div><div style="margin-bottom: 10px;">The development of Lutathera's companion PET diagnostic candidate Somakit -TATE, is also advancing well with the U.<wbr>S.<wbr> Food and Drug Administration ("FDA") granting Priority Review to AAA's NDA for SomaKit-TATE.<wbr> The company also submitted a MAA for SomaKit-TOC with the EMA on 8 October 2015.<wbr> </div><div style="margin-bottom: 10px;">source: <CITE class="_Rm"><a href="http://www.adacap.com" class="defaultlink" title="www.adacap.com">adacap.com</a></CITE> </div><div>Source: www, </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20151231&edate=20150901&rec=8297">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-12-11T16:22:19+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-12-11T16:22:19+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Merz In Vitro Assay Is Now Approved In Europe</title>
	<pubDate>2015-12-11T14:44:08+01:00</pubDate>
	<wp:post_id>6640</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Germany&rsquo;s drug regulatory authority The Bundesinstitut f&uuml;r Arzneimittel und Medizinprodukte (BfArM) and other European Union regulatory aurthorities have now approved the cell culture-based alternative test method, for establishing the potency and stability of Botulinum toxin found in Xeomin and Bocouture.<wbr> </div><div style="margin-bottom: 10px;">The FDA approved this alternative test method in February of this year, with the recent approval granted in November </div><div style="margin-bottom: 10px;">Dr.<wbr> Torsten Wagner, the Merz Pharma Board&rsquo;s Vice President Global Technical Operations discussed &ldquo;<EM>We are extremely pleased with the regulatory authorities&rsquo; decision.<wbr> It represents an important milestone for our products, which are both of such strategic significance to us,&rdquo;</EM> </div><div style="margin-bottom: 10px;">Merz has been reported at being confident that it can stop using the LD50 assay for the release of botulinum neurotoxin type A entirely within a few years.<wbr> Once the requisite approval has been obtained in all the other countries, all the potency measurements can then be performed using the cell culture-based alternative test method.<wbr> </div><div>Source: Merz </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20151231&edate=20150901&rec=8264">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-12-11T14:44:08+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-12-11T14:44:08+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Raptor Expects Important Milestone for its Huntington Drug by YE2015</title>
	<pubDate>2015-12-11T12:22:24+01:00</pubDate>
	<wp:post_id>6641</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Raptor Expects Important Milestone for its Huntington Drug by YE2015</span>&nbsp;<br><span style="font-size: 12px;">Comment: Alongside financial results for the second quarter of 2015, management indicated that in Q4:15 it will be reporting 36-month data of RP103 Ph2/<wbr>3 CYST-HD study, and a regulatory guidance update regarding the regulatory pathway.<wbr> Of note, 18 month data for RP103 in the Ph 2/<wbr>3 HD study showed RP103 missed its primary endpoint, although did demonstrate a stat sig improvement vs.<wbr> placebo in patients not receiving concurrent tetrabenazine.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20151231&edate=20150901&rec=8150">...</a><br></div><div style="margin-bottom: 10px;">Raptor Pharmaceutical Corp announced 36-month efficacy results from the pII/<wbr>III CYST-HD trial evaluating RP103 for the potential treatment of Huntington's disease.<wbr> Data from the study revealed that there was a slowing in the rate of change in the Total Motor Score (TMS) of the Unified Huntington's Disease Rating Scale (UHDRS) at 36 months of treatment.<wbr>  It also favoured earlier RP103 treatment.<wbr> There was only a 25% treatment effect, while not statistically significant, the results are still viewed as clinically meaningful.<wbr> </div><div style="margin-bottom: 10px;">Dominique Bonneau, M.<wbr>D.<wbr>, Professor of Medical Genetics at the CHU reported <EM>"The 36-month efficacy results from the CYST-HD study are clinically meaningful and suggest that RP103 may play an important role in the treatment of Huntington's disease.<wbr>  These data warrant further assessment as there remains a clear need for new, safe and tolerable therapies to treat this disease.<wbr>"</EM> </div><div style="margin-bottom: 10px;">Raptor has been in regulatory discussions with the FDA and the EMA, with the outcomes revealing an additional study required before approval.<wbr> Raptor intends to update both regulatory agencies with the 36-month data and to discuss a trial design that would support marketing authorization.<wbr> </div><div>Source: Streetinsider </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20151231&edate=20150901&rec=8263">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology8150">View thread  Neurology8150: Raptor Expects Important Milestone for its Huntington Drug by YE2015</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-12-11T12:22:24+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-12-11T12:22:24+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: MAA for AZ' Gout Treatment Accepted by EMA</title>
	<pubDate>2015-12-11T09:42:36+01:00</pubDate>
	<wp:post_id>6642</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">MAA for AZ' Gout Treatment Accepted by EMA</span>&nbsp;<br><span style="font-size: 12px;">Comment: The Agency has accepted the Marketing Authorisation Application for lesinurad 200mg tablets, setting it up for a possible approval later this year.<wbr> Lesinurad is a selective uric acid reabsorption inhibitor (SURI) developed for the chronic treatment of hyperuricaemia in combination with xanthine oxidase (XO) inhibitors allopurinol or febuxostat in gout patients when additional therapy is warranted.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20151231&edate=20150901&rec=2204">...</a><br></div><div style="margin-bottom: 10px;">In a letter sent to the US FDA, Public Citizen has asked the agency to reject the advice of its advisory commitee and not approve lesinurad.<wbr> </div><div style="margin-bottom: 10px;">Public Citizen maintains that multiple FDA-approved gout medications already are on the market and lesinurad does not offer any major benefits compared to these approved therapies.<wbr> Clinical trials of lesinurad showed that it provides at best meager benefits, but is associated with very troubling safety concerns, the most significant being compelling evidence of kidney toxicity and serious cardiac adverse events.<wbr> </div><div>“FDA approval of lesinurad — even with reliance on warnings in the product labeling, a risk evaluation and mitigation strategy, and postmarket safety studies — would be a reckless approach and would not be in the interests of public health,” said Dr.<wbr> Michael Carome, director of Public Citizen’s Health Research Group.<wbr> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20151231&edate=20150901&rec=2706">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2204">View thread  GastroEnterology2204: MAA for AZ' Gout Treatment Accepted by EMA</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-12-11T09:42:36+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-12-11T09:42:36+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Astellas and Bellicum Ink Agreement to Advance CAR-T cell Technology</title>
	<pubDate>2015-12-11T09:34:21+01:00</pubDate>
	<wp:post_id>6643</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Agensys, an affiliate of Astellas  </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><STRONG>Bellicum Pipeline</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10822_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><STRONG>Bellicum Technology</STRONG> </div><div style="margin-bottom: 10px;"><A href="http://www.bellicum.com/technology/gocart/">http:/<wbr>/<wbr>www.<wbr>bellicum.<wbr>com/<wbr>technology/<wbr>gocart/<wbr></A> </div><div>Source: Astellas </div><!-- Comment details --><a name="oncology10822attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10822_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(82 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20151231&edate=20150901&rec=10822">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-12-11T09:34:21+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-12-11T09:34:21+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Oncology Pricing Divergence Across The US & Europe</title>
	<pubDate>2015-12-10T18:14:04+01:00</pubDate>
	<wp:post_id>6644</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: A recent article in Lancet Oncology has highlighted the divergence in oncology product pricing not only between Europe and the US but also within Europe.<wbr> The report is based on a W/<wbr>W survey undertaken by Wim van Harten and colleagues from the Netherlands Cancer Insitute, Insitute Gustave Roussey and The Cambridge Cancer Centre.<wbr> </div><div style="margin-bottom: 10px;">The researchers surveyed the prices for several cancer drugs in European countries through the membership of the European Organization of Cancer Institutes (OECI) and Cancer Core Europe.<wbr> A word-based survey was emailed to all full members of the OECI (n=51), both European Union (EU) members and non-EU members, and to the non-OECI member of Cancer Core Europe.<wbr> The survey was sent to the board of the centre; for most centres the leading pharmacist responded, together with an oncologist.<wbr> </div><div style="margin-bottom: 10px;">Centres were asked to provide list or official and actual prices, corrected for VAT differences, and asked for information about central or government coordinated purchasing.<wbr> </div><div style="margin-bottom: 10px;"><UL><LI>The actual price was defined as the net price&mdash;ie, as price per one dose (eg, one 100 mg vial or one capsule of 12&middot;5 mg) to allow for a comparison in case of different pack sizes.<wbr>
</LI>
<LI>Any type of discount was taken into account because centres were asked to provide the price they actually paid.<wbr>
</LI>
</UL> </div><div style="margin-bottom: 10px;">Responses were received from 21 centres based in 15 countries with most responses received in June and July 2015.<wbr> </div><div style="margin-bottom: 10px;">It was noted that official or list prices differ substantially between countries (up to 92% lower than the highest), and actual prices also differ between countries (up to 58% lower).<wbr> Additionally, reductions on list prices were very different between countries.<wbr> The table below illustrates  a selection of prominent examples: Lithuania to show the unavailability of drugs in certain countries; Spain to highlight the high discounts some countries get by contrast with others (eg, France); and the Netherlands as an example of a high-income country.<wbr> <img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10821_1_Pricing%201.PNG"> </div><div style="margin-bottom: 10px;"><P align="left">The authors calls for joint action by countries and medical societies with the pharmaceutical industry, since fast and equitable access to promising new drugs is important to improving treatment results.<wbr> The societal challenge is seen as combining the development and availability of promising new drugs with the sustainability of the healthcare system.<wbr> </P> </div><div style="margin-bottom: 10px;"><P align="left">Access to the full article can be obtained by downloading the PDF and supplementary appendix on the link page.<wbr> The latter includes reference to Xtandi pricing for prostate cancer.<wbr></P> </div><div>.<wbr>Source: <A href="http://www.sciencedirect.com/science/article/pii/S1470204515004866">http:/<wbr>/<wbr>www.<wbr>sciencedirect.<wbr>com/<wbr>science/<wbr>article/<wbr>pii/<wbr>S1470204515004866</A> </div><!-- Comment details --><a name="oncology10821attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10821_1_Pricing%201.PNG">Pricing 1.PNG</a>&nbsp;&nbsp;(38,5 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20151231&edate=20150901&rec=10821">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-12-10T18:14:04+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-12-10T18:14:04+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Apatorsen Ph2 Trial in Metastatic Bladder Cancer Continues Following The Pre-Specified Futility Analysis</title>
	<pubDate>2015-12-10T14:31:43+01:00</pubDate>
	<wp:post_id>6645</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: OncoGenex annouced that the independent data saafety monitoring board at Dana-Farber/<wbr>Harvard cancer center has recommended that the Ph2 Borealis-2 trial continue as planned after completing the pre-specified futility analysis.<wbr> In addition to Borealis-2, OncoGenex expects to announce progression-free survival results for the Phase 2 Spruce&trade; trial in the first quarter of 2016 with continued overall survival follow up.<wbr> </div><div style="margin-bottom: 10px;">Borealis-2 is evaluating apatorsen in combination with docetaxel treatment in patients with metastatic bladder cancer.<wbr> It is the third clinical trial assessing the ability of apatorsen to improve outcomes for patients in this tumor type.<wbr> Borealis-2 is an investigator-sponsored, randomized Phase 2 trial evaluating a survival benefit with apatorsen in combination with docetaxel treatment compared to docetaxel treatment alone in approximately 200 patients with metastatic bladder cancer who have disease progression following first-line platinum-based chemotherapy.<wbr> The trial is being coordinated by the Hoosier Cancer Research Network at 27 sites across the United States.<wbr> </div><div style="margin-bottom: 10px;">Previously, encouraging results were observed in the Borealis-1&trade; trial evaluating apatorsen in combination with standard of care chemotherapy in metastatic bladder cancer, as well as a trial evaluating apatorsen as monotherapy in patients with non-muscle invasive (superficial) disease.<wbr> </div><div style="margin-bottom: 10px;">Investigators have concluded in the bladder cancer trials conducted to date that 600mg apatorsen administered intravenously and all apatorsen doses administered intravesically have been well tolerated.<wbr> Clinical trials of apatorsen across four tumor types involving over 700 patients have been conducted or are currently ongoing with patient safety monitored throughout the course of these trials.<wbr> The final results are expected in 2016.<wbr> </div><div>Source: Oncogenex Press Release 9 Dec 2015 </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20151231&edate=20150901&rec=10818">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-12-10T14:31:43+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-12-10T14:31:43+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Takeda Inks Deal with Cour Pharm. for Celiac and Other GI Diseases</title>
	<pubDate>2015-12-10T12:16:22+01:00</pubDate>
	<wp:post_id>6646</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The partnership will focus on using nanotechnologies based on Cour's Tolerizing Immune Modifying nanoParticle (TIMP) platform, which can be extended to certain autoimmune and allergic conditions.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Financial: not disclosed </div><div style="margin-bottom: 10px;">Terms:  </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The TIMPs, developed in cooperation with Northwestern University researchers, consist of a proprietary polymer and antigenic proteins, which are fully encapsulated for safety and administered intravenously.<wbr> </div><div style="margin-bottom: 10px;">The TIMP compounds target the underlying cause of celiac disease by systemically targeting and controlling, gluten-reactive T-cells in patients, as opposed to broad immunosuppression.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Takeda GI Pipelines</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2703_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;">Source: Takeda </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Astellas Pharma</STRONG> entered into an agreement with <STRONG>Anokion</STRONG> in the summer of 2015 to collaborate in the fields of Type I diabetes and coeliac disease.<wbr> Under the terms of the agreement, a new company, <STRONG>Kanyos Bio</STRONG>, was created to develop clinical candidates in the two selected indications, with an option for Astellas to add a third autoimmune indication as part of the collaboration.<wbr> </div><div style="margin-bottom: 10px;">In February 2014, <STRONG>Alba Therapeutics</STRONG> reported the positive results of its Phase IIb trial evaluating its investigational product, larazotide acetate, intended for the treatment of patients with coeliac disease.<wbr> This was the seventh study in a broad clinical trial programme for larazotide that had at that point included 828 patients with coeliac disease.<wbr> Larazotide has been granted fast track designation by the FDA.<wbr> Alba has a funding agreement in place with <STRONG>Cephalon</STRONG> (<STRONG>Teva Pharmaceutical Industries</STRONG>), entered into in February 2011.<wbr> The agreement provides Cephalon with an option to purchase all of Alba's assets relating to larazotide.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>BioLineRx</STRONG> is developing BL-7010, a novel co-polymer for the treatment of coeliac disease.<wbr> A Phase I/<wbr>II study with BL-7010 was successfully completed in 2014.<wbr> BioLineRx expects to commence a randomised, placebo-controlled efficacy study towards the end of 2015 or the beginning of 2016, contingent on finalising a regulatory pathway classification process of BL-7010 as a medical device in the EU.<wbr> </div><div style="margin-bottom: 10px;">In February 2015, <STRONG>Celimmune</STRONG> was created.<wbr> The firm is a clinical development-stage immunotherapy company targeting autoimmunity and inflammation.<wbr> Celimmune's initial efforts are focusing on diet non-responsive coeliac disease and refractory coeliac disease (coeliac disease-triggered T-cell lymphoma).<wbr> In March, Celimmune licensed a Phase II-stage, anti-IL-15 monoclonal antibody (AMG 714) from <STRONG>Amgen</STRONG>.<wbr> Celimmune plans to initiate Phase II studies of AMG 714 for the treatment of diet non-responsive coeliac disease and refractory coeliac disease.<wbr> </div><div>In September 2015, <STRONG>Glenmark Pharmaceuticals</STRONG>' novel monoclonal antibody, GBR 830, completed Phase I dosing.<wbr> GBR 830 is an antagonist of OX40, a co-stimulatory receptor expressed on T-cells mediating T-cell activation and survival.<wbr> The firm commented that preparations for initiating Phase II studies in both atopic dermatitis and coeliac disease in the US and Europe are well advanced.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20151231&edate=20150901&rec=2703">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-12-10T12:16:22+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-12-10T12:16:22+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>2014 Pharmaceutical Price Regulation Scheme (PPRS)</title>
	<pubDate>2015-12-09T20:07:13+01:00</pubDate>
	<wp:post_id>6647</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: At the EPPR Conference in London, David Watson, Director for P&amp;R at the Association of the British Pharmaceutical Industry (ABPI), discussed the backdrop, major changes, latest data analyses and projections for the PPRS </div><div style="margin-bottom: 10px;"><U>UK Healthcare Environment</U> </div><div style="margin-bottom: 10px;">As a backdrop to the Department of Health viewpoints on the context of the 2014 PPRS, David outlined the key dynamics of the UK Healthcare environment that have an impact on, and are impacted by the PPRS 2014-2019 </div><div style="margin-bottom: 10px;">First the UK government commitment to £8bn extra funding by 2020 will still require the NHS to make £22bn in efficiency savings </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11333_1_copiedImage%5b0%5d.png"> </div><div style="margin-bottom: 10px;">Second, the complexity of the new NHS system, as evidenced by the schematic (below) and the ABPI estimate of between 6000-10,000 Medicines Management stakeholders in the NHS </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11333_2_copiedImage%5b2%5d.png"> </div><div style="margin-bottom: 10px;">Third, the mechanisms of drug pricing &amp; reimbursement in the UK, with pricing a reserve (UK) power, and reimbursement a devolved power….<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11333_3_copiedImage%5b4%5d.png"> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-SIZE: 11pt; FONT-FAMILY: 'Calibri','sans-serif'; LINE-HEIGHT: 115%; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-fareast-language: EN-US; mso-ansi-language: EN-GB; mso-bidi-language: AR-SA">…this being a contributing factor to the slow uptake of new drugs in the UK relative to the rest of the EU (per an OHE analysis for 2015)</SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-SIZE: 11pt; FONT-FAMILY: 'Calibri','sans-serif'; LINE-HEIGHT: 115%; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-fareast-language: EN-US; mso-ansi-language: EN-GB; mso-bidi-language: AR-SA"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11333_4_copiedImage%5b6%5d.png"></SPAN>
<U>2014 PPRS Mechanism</U> </div><div style="margin-bottom: 10px;">David pointed out that at the time of negotiation of the PPRS, both sides (DH &amp; Industry), recognized the challenges (outlined above).<wbr>  He further outlined the starting point of the negotiations, and where the agreement was reached </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11333_5_copiedImage%5b8%5d.png"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11333_6_copiedImage%5b10%5d.png"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11333_7_copiedImage%5b12%5d.png"> </div><div style="margin-bottom: 10px;"><U>Recent ABPI Payment Calculations and Projections</U> </div><div style="margin-bottom: 10px;">Performing a comparative analysis of IMS data, which measures spend in ‘list prices’, vs PPRS data, shows an average ~38% discount offered on branded medicines to the NHS in 2014 .<wbr> Note: The analysis covers 152 companies; representing ~93% of the UK branded sales market.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11333_8_copiedImage%5b14%5d.png"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11333_9_copiedImage%5b16%5d.png"> </div><div style="margin-bottom: 10px;">The ABPI calculated a 10% to 12% payment range for 2016, based on a 2015 full year growth estimate of 2.<wbr>88% </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11333_10_copiedImage%5b18%5d.png"> </div><div style="margin-bottom: 10px;"><U>Cancer Drugs Fund and PPRS</U> </div><div style="margin-bottom: 10px;">Prior to 2014, overspending through the CDF has been returned to the DH as part of the PPRS.<wbr> In December 2014, the ABPI took a dispute to the PPRS Dispute Resolution Panel, the outcome of which was that a cap was placed each year on the amount of CDF, to be included in total spending calculations for the PPRS.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11333_11_copiedImage%5b20%5d.png"> </div><div style="margin-bottom: 10px;">In conclusion, David outlined the ABPI focus for 2016: </div><div><UL><LI>Accelerated Access Review — input and (potential implementation review</LI>
<LI>Delivery of commitments in PPRS to improve access and uptake, through formal reviews with DH and working with OLS/<wbr>NHS</LI>
<LI>Phase 2 of the PPRS  and Medicines Optimisation programme </LI>
<LI>Medium term solutions for the CDF</LI>
<LI>Working with The Ministerial Industry Strategy Group (MISG), a short life working group with the mandate to develop recommendations to unlock barriers in the NHS for non-NICE, non-specialised </LI>
</UL> </div><!-- Comment details --><a name="pharmaworld11333attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11333_1_copiedImage%5b0%5d.png">copiedImage[0].png</a>&nbsp;&nbsp;(48,8 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11333_2_copiedImage%5b2%5d.png">copiedImage[2].png</a>&nbsp;&nbsp;(77,4 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11333_3_copiedImage%5b4%5d.png">copiedImage[4].png</a>&nbsp;&nbsp;(68 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11333_4_copiedImage%5b6%5d.png">copiedImage[6].png</a>&nbsp;&nbsp;(40,1 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11333_5_copiedImage%5b8%5d.png">copiedImage[8].png</a>&nbsp;&nbsp;(82,2 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11333_6_copiedImage%5b10%5d.png">copiedImage[10].png</a>&nbsp;&nbsp;(79,2 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11333_7_copiedImage%5b12%5d.png">copiedImage[12].png</a>&nbsp;&nbsp;(39,6 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11333_8_copiedImage%5b14%5d.png">copiedImage[14].png</a>&nbsp;&nbsp;(78,8 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11333_9_copiedImage%5b16%5d.png">copiedImage[16].png</a>&nbsp;&nbsp;(64,7 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11333_10_copiedImage%5b18%5d.png">copiedImage[18].png</a>&nbsp;&nbsp;(64,5 KB)<br>&nbsp;&nbsp;11.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11333_11_copiedImage%5b20%5d.png">copiedImage[20].png</a>&nbsp;&nbsp;(47,6 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20151231&edate=20150901&rec=11333">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-12-09T20:07:13+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-12-09T20:07:13+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Galderma and ZELTIQ Announce Nationwide Collaboration in Aesthetics</title>
	<pubDate>2015-12-09T17:01:07+01:00</pubDate>
	<wp:post_id>6648</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Companies have announced that the creation of this US collaboration will provide healthcare professionals and consumers with greater access to a robust range of technologically-advanced and scientifically-proven beauty solutions for facial rejuvenation and non-invasive fat reduction.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Galderma and ZELTIQ plan to initiate a joint educational effort, as well as market growth strategies to benefit both healthcare providers and consumers.<wbr> </div><div style="margin-bottom: 10px;">The two companies will create connections between the Galderma portfolio of aesthetic brands and ZELTIQ's CoolSculpting procedure for healthcare professionals and consumers through their respective industry-leading loyalty programs: </div><div style="margin-bottom: 10px;">ASPIRE Galderma Rewards loyalty program (<A href="http://www.aspirerewards.com/">www.<wbr>aspirerewards.<wbr>com</A>) and </div><div>Crystal Rewards (<A href="http://www.coolsculpting.com/">www.<wbr>coolsculpting.<wbr>com</A>) </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20151231&edate=20150901&rec=8261">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-12-09T17:01:07+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-12-09T17:01:07+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Eisai Paired with Ajinimoto to Build a Specialist Company in the Field of Gastrointestinal Pharmaceuticals</title>
	<pubDate>2015-12-09T16:15:08+01:00</pubDate>
	<wp:post_id>6649</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Last month Eisai and Ajinomoto annonced the creation of "EA Pharma".<wbr> The JV will begin operations in April 2016.<wbr> It will have a product line-up that "comprehensively covers the upper and lower digestive tract, as well as the liver and pancreas", according to documents explaining the rationale for the merger.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><U>HQ:</U> Japan </div><div style="margin-bottom: 10px;"><U>Structure</U>: Jointly owned by Eisai and Ajinimoto (60:40 split) </div><div style="margin-bottom: 10px;"><U>Management</U> </div><div style="margin-bottom: 10px;">Ajinomoto Pharma's chief executive Takashi Nagamachi will serve as chairman and Eisai's corporate officer Hajime Shimizu will be taking on the role of president.<wbr> </div><div style="margin-bottom: 10px;"><U>Objective</U>: to become the leading GI company in Japan </div><div style="margin-bottom: 10px;"><U>Pipeline</U> </div><div style="margin-bottom: 10px;">E3810, a new formulation of rabeprazole for reflux oesophagitis, oral alpha 4 integrin antagonist AJM300 for ulcerative colitis and IBAT inhibitor AJG533 for chronic constipation.<wbr> </div><div style="margin-bottom: 10px;">In addition, a new Crohn's disease candidate E6011 (an anti-fractalkine antibody) coming through phase II testing </div><div style="margin-bottom: 10px;"><U>Portfolio</U> </div><div>Eisai's GI unit - <STRONG>Pariet</STRONG> (rabeprazole) and <STRONG>Selbex</STRONG> (teprenone) - will be combined with Ajinomoto's pharmaceutical subsidiary, which has developed drugs such as alcoholic liver disease therapy <STRONG>Livact/<wbr>Livamin</STRONG> (leucine, isoleucine and valine) and also focuses on contract manufacturing as well as researching new GI therapies.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20151231&edate=20150901&rec=2700">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-12-09T16:15:08+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-12-09T16:15:08+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>New Models for European Reimbusrement</title>
	<pubDate>2015-12-08T19:37:26+01:00</pubDate>
	<wp:post_id>6650</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: At the EPPR Conference in London, Nick Bosanquet, Emeritus Professor for Health Policy, Imperial College London, discussed the opportunities presented to Pharma in the face of national health authority cost containment and disease management responses </div><div style="margin-bottom: 10px;"><U>Budget concerns have led to a number of cost containment &amp; disease management responses </U> </div><div style="margin-bottom: 10px;">A combination of reduced spending growth in healthcare and aging populations have led to many cost containment &amp; disease management responses by funders across EU and North America </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11332_1_copiedImage%5b0%5d.png"> </div><div style="margin-bottom: 10px;"><U>Funders responses are increasingly in line with Porter’s principles of value based competition</U> </div><div style="margin-bottom: 10px;">Professor Bosanquet then stated that he believes that funder responses have increasingly shifted from cost containment towards Michael Porter’s Value-Based competition principles, the fundamental principle of which is that competition in healthcare should not be a zero-sum game but rather increase value for patients </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11332_2_copiedImage%5b2%5d.png"> </div><div style="margin-bottom: 10px;">The NHS five year forward view was cited as an example of funders moving towards value-based competition </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11332_3_copiedImage%5b4%5d.png"># </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11332_4_copiedImage%5b6%5d.png"> </div><div style="margin-bottom: 10px;"><U>Opportunities for Pharma require an alignment of goals</U> </div><div style="margin-bottom: 10px;">Professor Bosanquet cited the Finland COPD programme (1993-2004), which saw a ~40% reductions in hospital admissions go hand-in-hand with a ~56% increase in patients receiving reimbursement for COPD medications (and an overall reduction in annual costs per patient by 10-20%), as a case example of how Pharma can contribute to the key goals of funders.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11332_5_copiedImage%5b8%5d.png"> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11332_6_copiedImage%5b10%5d.png"> </div><!-- Comment details --><a name="pharmaworld11332attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11332_1_copiedImage%5b0%5d.png">copiedImage[0].png</a>&nbsp;&nbsp;(91,3 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11332_2_copiedImage%5b2%5d.png">copiedImage[2].png</a>&nbsp;&nbsp;(91,2 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11332_3_copiedImage%5b4%5d.png">copiedImage[4].png</a>&nbsp;&nbsp;(110 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11332_4_copiedImage%5b6%5d.png">copiedImage[6].png</a>&nbsp;&nbsp;(78,5 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11332_5_copiedImage%5b8%5d.png">copiedImage[8].png</a>&nbsp;&nbsp;(45,6 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11332_6_copiedImage%5b10%5d.png">copiedImage[10].png</a>&nbsp;&nbsp;(64 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20151231&edate=20150901&rec=11332">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-12-08T19:37:26+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-12-08T19:37:26+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Astellas Presented Its Ph1 Data Enzalutamide With Fulvestrant In Breast Cancer</title>
	<pubDate>2015-12-08T18:25:03+01:00</pubDate>
	<wp:post_id>6651</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Results of a multicenter phase 1 clinical trial presented at the 2015 San Antonio Breast Cancer Symposium show that the anti-androgen agent enzalutamide is active and well-tolerated alone and with fulvestrant in patients with advanced breast cancer.<wbr> The study takes another important step toward larger clinical trials targeting androgen receptors in breast cancer.<wbr> These early data would warrant a further larger trial.<wbr> </div><div style="margin-bottom: 10px;">The goal of the current study was to explore the bioavailability and safety of the anti-androgen agent enzalutamide alone and in combination with the existing agent fulvestrant (FDA approved for use in metastatic hormone-receptor positive breast cancer).<wbr> The small, phase 1 trial enrolled 11 patients and found that side-effects were similar in this population as previously reported in larger trials of enzalutamide against prostate cancer.<wbr> There were no unexpected interactions between enzalutamide and fulvestrant.<wbr> Concentrations of both drugs reached target levels in tumor tissues.<wbr> </div><div style="margin-bottom: 10px;">This human data follows extremely promising preclinical data (much of which was reported at the previous year's San Antonio Breast Cancer Symposium) supporting the androgen receptor as a target in breast cancer.<wbr> Enzalutamide is also being evaluated in a phase 2 clinical trial in combination with the aromatase inhibitor exemestane (NCT02007512) and demonstrated promising results in another phase 2 trial against estrogen-receptor-negative advanced disease (NCT01889238).<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10815_1_ScreenCapture1.jpg"> </div><div>Source: SABCS 2015 </div><!-- Comment details --><a name="oncology10815attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10815_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(328,2 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20151231&edate=20150901&rec=10815">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-12-08T18:25:03+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-12-08T18:25:03+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Celldex And Roche Are Investigating Combination Approach In RCC And Bladder Cancer</title>
	<pubDate>2015-12-08T18:16:47+01:00</pubDate>
	<wp:post_id>6652</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Celldex Therapeutics initiates a Ph1/<wbr>2 study with Roche to invesitigate combination immuno-oncology doublet (varlilumab + atezolizumab) approach.<wbr> The Ph1 portion will enroll patinets with melanoma, RCC, bladder cancer, triple negative breast cancer, H&amp;N cancer or NSCLC.<wbr> The Ph2 portion will enroll patients with RCC to assess the preliminary efficacy for this combination approach.<wbr> Up to 10 sites in the US are expected open for enrollment of a total of 60 patients.<wbr> </div><div style="margin-bottom: 10px;">Varlilumab is a fully human monoclonal agonist antibody that binds and activates CD27, a critical co-stimulatory molecule in the immune activation cascade.<wbr> CD27 can be effectively manipulated with activating antibodies to induce potent anti-tumor responses and may result in fewer toxicities due to its restricted expression and regulation.<wbr> Varlilumab is a potent anti-CD27 agonist that induces activation and proliferation of human T cells when combined with T cell receptor stimulation.<wbr> Preclinical tumour models suggest the possible synergistic anti-tumour immune response from the combination approach with anti-PDL1.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Study Design</STRONG> </div><div style="margin-bottom: 10px;">Phase 1 study portion </div><div style="margin-bottom: 10px;">The Phase 1, dose-escalation portion of the study will assess the safety and tolerability of varlilumab at 0.<wbr>3, 1.<wbr>0 and 3.<wbr>0 mg/<wbr>kg combined with atezolizumab at 1200 mg in order to identify a recommended dose for the Phase 2 portion of the study.<wbr> The Phase 1 portion will enroll patients with unresectable stage III or IV melanoma, RCC, triple negative breast cancer, bladder cancer, head and neck cancer or non-small cell lung cancer (NSCLC).<wbr> </div><div style="margin-bottom: 10px;">Phase 2 study portion </div><div style="margin-bottom: 10px;">The Phase 2 portion of the study will enroll patients with RCC.<wbr> The primary objective of this portion of the study is to assess the preliminary anti-tumor efficacy of the varlilumab/<wbr>atezolizumab combination measured by objective response rate (ORR).<wbr> Secondary objectives include safety and tolerability, pharmacokinetics, immunogenicity and further assessment of anti-tumor activity across a broad range of endpoints.<wbr> </div><div>In total, the Phase 1/<wbr>2 study is anticipated to include up to 10 sites in the United States and enroll approximately 60 patients.<wbr> In each 12-week cycle for both phases of the trial, varlilumab and atezolizumab will be administered once every three weeks (four doses).<wbr> Patients will be treated with varlilumab until intolerance, disease progression or completion of up to 4 cycles.<wbr> There is no limit on the duration of treatment with atezolizumab.<wbr> <BR>Source: Celldex Press Release </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20151231&edate=20150901&rec=10813">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-12-08T18:16:47+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-12-08T18:16:47+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Synthetic Biologics Expects to Initiate Ph3 of SYN-010 (IBS-C) Next Year</title>
	<pubDate>2015-12-08T16:41:33+01:00</pubDate>
	<wp:post_id>6653</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Positive topline results from the 4-week Ph2 trial of SYN-010, a proprietary modified-release formulation of lovastatin lactone, show that the drug lowered breath methane and improved stool frequency in patients with IBS-C.<wbr> Results from the second 8-week Ph2 are expected Q1:16.<wbr> Mark Pimentel, MD, FRCP(C), Director, GI Motility Program, Professor of Medicine, Cedars-Sinai, Los Angeles, CA and Marianela de la Portilla, MD, Principal Investigator, Genoma Research Group, Miami, FL will be presenting additonal results on Dec.<wbr>10 during the company clinical program seminar.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">In the four week Ph2 study, 63 patients with IBS-C and a breath methane value &gt; 10 parts per million at screening were randomly assigned to receive placebo, a 21 mg SYN-010 dose or a 42 mg SYN-010 dose orally once daily for 28 days.<wbr> </div><div style="margin-bottom: 10px;">The primary endpoint was the change from baseline in the area under the curve (AUC) of breath methane production at day 7, based on a 180-minute lactulose breath test (LBT).<wbr> </div><div style="margin-bottom: 10px;">Secondary efficacy assessments included change in methane AUC at day 28, stool frequency and consistency, abdominal pain, and safety data.<wbr> </div><div style="margin-bottom: 10px;">A necessary normalization of the severely left-skewed breath test data, not prespecified in the statistical analysis plan, was accomplished by square root transformation; paired t-tests were performed allowing each subject to serve as their own control.<wbr> The analyses of the clinical outcomes were performed with untransformed raw data.<wbr> While this study was considered exploratory in nature and no formal hypothesis testing was prespecified, p-values of less than 0.<wbr>10 are generally considered 'significant' in Phase 2 proof-of-concept studies.<wbr> </div><div style="margin-bottom: 10px;">SYN-010 effects on breath methane were evaluated in a within group analysis by comparing the methane area under the curve (AUC) on a lactulose breath test at Day 7 vs.<wbr> baseline Day 1 or Day 28 vs.<wbr> baseline Day 1.<wbr> <STRONG>After 7 days reductions in breath methane levels were seen in the 42 mg dose group (p=0.<wbr>02) but not the 21 mg dose group (p=0.<wbr>64).<wbr> In contrast, after 28 days both the 21 mg (p=0.<wbr>03) and 42 mg (p=0.<wbr>01) dose groups showed reductions in breath methane levels.<wbr></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2698_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;">Preliminary analysis of secondary efficacy assessment data indicates that an<STRONG> improvement in the stool frequency response for the 21 mg dose group (p=0.<wbr>02) was apparent, while the 42 mg dose group (p=0.<wbr>54) was numerically better demonstrating a positive trend.<wbr> Additionally, an improvement in weekly abdominal pain intensity for the 42 mg dose group (p=0.<wbr>08) was seen, while the 21 mg dose group (p=0.<wbr>26) was numerically better demonstrating a positive trend.<wbr></STRONG> </div><div style="margin-bottom: 10px;">The definitions of these outcomes are consistent with the U.<wbr>S.<wbr> Food and Drug Administration (FDA) IBS guidance.<wbr> There were no serious adverse events observed.<wbr> </div><div style="margin-bottom: 10px;"><DIV class="item_name"><STRONG>SYN Microbiome Clinical Program Seminar</STRONG></DIV> </div><div style="margin-bottom: 10px;"><DIV class="item_date"></DIV> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><P style="MARGIN-LEFT: 0.25in"></P> </div><div style="margin-bottom: 10px;"><P style="MARGIN-LEFT: 0.5in"></P> </div><div style="margin-bottom: 10px;"><P style="MARGIN-LEFT: 0.5in"></P> </div><div style="margin-bottom: 10px;"><UL><LI></LI>
<LI></LI>
</UL> </div><div style="margin-bottom: 10px;"><P style="MARGIN-LEFT: 0.25in"></P> </div><div style="margin-bottom: 10px;"><P style="MARGIN-LEFT: 0.5in"></P> </div><div style="margin-bottom: 10px;"><P style="MARGIN-LEFT: 0.5in"></P> </div><div><UL><LI></LI>
<LI></LI>
</UL> </div><!-- Comment details --><a name="gastroenterology2698attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2698_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(21,6 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20151231&edate=20150901&rec=2698">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-12-08T16:41:33+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-12-08T16:41:33+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Sunesis Pharmaceuticals: Positive Results in AML Presented At ASH</title>
	<pubDate>2015-12-07T19:01:46+01:00</pubDate>
	<wp:post_id>6654</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment:QINPREZO&trade; (vosaroxin) is an anti-cancer quinolone derivative (AQD), a class of compounds that has not been used previously for the treatment of cancer.<wbr> An analysis of Sunesis' Ph3 VALOR trial of vosaroxin and cytarabine in RR AML and positive results from its MD Anderson Sponsored Ph1b/<wbr>2 Trial was presented at ASH.<wbr> These results demonstratethat vosaroxin could become a new backbone of treatment and in combination with other important therapeutic candidates can increase the rates of complete response, translating to promising overall survival.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>About QINPREZO&trade; (vosaroxin)</STRONG> </div><div style="margin-bottom: 10px;">QINPREZO&trade; (vosaroxin) is an anti-cancer quinolone derivative (AQD), a class of compounds that has not been used previously for the treatment of cancer.<wbr> Preclinical data demonstrate that vosaroxin both intercalates DNA and inhibits topoisomerase II, resulting in replication-dependent, site-selective DNA damage, G2 arrest and apoptosis.<wbr> Both the U.<wbr>S.<wbr> Food and Drug Administration (FDA) and European Commission have granted orphan drug designation to vosaroxin for the treatment of AML.<wbr> Additionally, vosaroxin has been granted fast track designation by the FDA for the potential treatment of relapsed or refractory AML in combination with cytarabine.<wbr> Vosaroxin is an investigational drug that has not been approved for use in any jurisdiction.<wbr> </div><div style="margin-bottom: 10px;">An ongoing Phase 1b/<wbr>2 University of Texas MD Anderson cancer Center-sponsored trial of vosaroxin in combination with decitabine in older patients with previously untreated acute myeloid leukemia (AML) and high-risk myelodyplastic syndrome (MDS).<wbr> The results are being presented today at 8:00 AM in an oral session titled "Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: New Epigenetic Approaches" taking place from 7:00 AM to 8:30 AM ET at the 56th American Society of Hematology Annual Meeting in Orlando, Florida.<wbr> The presentation (abstract 461, Orange County Convention Center, W109), titled "Phase I/<wbr>II Study of Vosaroxin and Decitabine in Newly Diagnosed Older Patients (pts) with Acute Myeloid Leukemia (AML) and High Risk Myelodyplastic Syndrome (MDS) </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10802_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;">Baseline Predictors of Mortality in Patients with Relapsed or Refractory Acute Myeloid Leukemia Treated with Vosaroxin Plus Cytarabine or Placebo Plus Cytarabine in the Phase 3 VALOR Study </div><div style="margin-bottom: 10px;">Atotal of 705 patients from VALOR were included in the safety population (355 treated with vosaroxin/<wbr>cytarabine and 350 treated with placebo/<wbr>cytarabine).<wbr> Rates of 30-day (7.<wbr>9% vs 6.<wbr>6%, respectively) and 60-day (19.<wbr>7% vs 19.<wbr>4%, respectively) mortality in VALOR were comparable between vosaroxin plus cytarabine and placebo plus cytarabine arms.<wbr> Several individual baseline factors independently predicted risk of early mortality, including ECOG performance status, hemoglobin, bilirubin and albumin levels, intermediate or high bone marrow blasts, and prior myelodysplastic syndrome.<wbr> The previously validated TRM score for predicting early mortality in newly diagnosed AML was also predictive of mortality in this relapsed/<wbr>refractory population.<wbr> Vosaroxin/<wbr>cytarabine treatment and age were not significant predictors of early mortality.<wbr> </div><div>Source: Sunesis Press Release </div><!-- Comment details --><a name="oncology10802attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10802_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(52,1 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20151231&edate=20150901&rec=10802">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-12-07T19:01:46+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-12-07T19:01:46+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Spectrum and Onxeo Reported Positive Results At ASH</title>
	<pubDate>2015-12-07T18:43:23+01:00</pubDate>
	<wp:post_id>6655</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Spectrum Pharmaceuticals and Onxeo Announce Complete Response in 67% of Patients with Peripheral T-Cell Lymphoma in Combination of Belinostat (Beleodaq&reg;) and Standard CHOP.<wbr> Data was Highlighted in an Oral Presentation of a Phase 1 Study at the 57th Annual Meeting of the American Society of Hematology (ASH)Study Shows 86% Objective Response Rate with 67% Complete Responses in Newly Diagnosed Patients with Peripheral T-cell Lymphoma (PTCL) At Full Dose Intensity the Belinostat-CHOP Combination was well tolerated.<wbr> </div><div style="margin-bottom: 10px;">The results were presented in an oral presentation at the <A href="http://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.hematology.org%2FAnnual-Meeting%2F&amp;esheet=51237837&amp;newsitemid=20151206005022&amp;lan=en-US&amp;anchor=57th+American+Society+of+Hematology+%28ASH%29+Annual+Meeting+%26+Exposition&amp;index=1&amp;md5=9c31d527e1d4d882b6d40a7b6df414d4" id="yui_3_18_1_1_1449509968640_2038" rel="nofollow">57<SUP>th</SUP> American Society of Hematology (ASH) Annual Meeting &amp; Exposition</A> by Dr.<wbr> Patrick Johnston, MD, PhD, Assistant Professor of Medicine at the Mayo Clinic, Rochester, MN, USA.<wbr> </div><div style="margin-bottom: 10px;">This open-label, two-part trial enrolled a total of 23 patients.<wbr> Eleven were enrolled in Part A, the dose-escalation phase, to determine the study&rsquo;s primary endpoint, the maximum tolerated dose (MTD).<wbr> Part B of the study, the Expansion Phase, enrolled 12 additional patients at this dose level.<wbr> The MTD of belinostat was established at 1,000 mg/<wbr>m<SUP>2</SUP> IV infusion on Days 1-5 (the recommended single agent dose) when combined with the CHOP regimen, with each component given at its full recommended dose.<wbr> Secondary endpoints included safety, tolerability, Objective Response Rate (ORR: Complete Response + Partial Response), and pharmacokinetics.<wbr> </div><div style="margin-bottom: 10px;">Results outlined in the oral presentation showed an ORR of 86% with the belinostat and CHOP combination, based on 21 evaluable patients (18/<wbr>21), with the vast majority, 67%, achieving a Complete Response (14/<wbr>21), and 19% achieving a Partial Response (4/<wbr>21).<wbr> In addition, the belinostat and CHOP combination was shown to have an acceptable safety profile with no new or unexpected toxicities.<wbr> The most common (&gt;10%) Grade 3-4 hematologic adverse events (AEs) reported with Bel-CHOP were as expected: neutrophil count decreased (30%), anemia (22%), neutropenia (22%), white blood cell (WBC) count decreased (22%), febrile neutropenia (17%) and lymphocyte count decreased (17%).<wbr> No Grade 3-4 non-hematologic AEs &gt;10% were reported.<wbr> No patient discontinued therapy due to AEs.<wbr> One patient died as a result of disease progression during the study.<wbr> </div><div>Source: Spectrum Press Release </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20151231&edate=20150901&rec=10800">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-12-07T18:43:23+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-12-07T18:43:23+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Novartis' Afinitor Gains Reimbursement Approval for pNET in Norway</title>
	<pubDate>2015-12-07T17:48:31+01:00</pubDate>
	<wp:post_id>6656</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The Norwegian Medicines Agency (NOMA) has granted reimbursement approval of Novartis (Switzerland)&rsquo;s Afinitor (everolimus) for the treatment of &ldquo;inoperable or metastatic, well /<wbr> moderately differentiated pancreatic neuroendocrine tumours in adults with progressive disease&rdquo;.<wbr> Patients may only receive reimbursement for treatment with Afinitor for this indication subject to treatment being prescribed by a specialist or specialist clinic; one month&rsquo;s supply being dispensed; and undergoing a treatment review within three months and two to three months thereafter.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Significance</STRONG> </div><div style="margin-bottom: 10px;">In granting reimbursement approval, NOMA compared the cost of treatment with Afinitor to the cost of treatment with Pfizer (US)'S Sutent (sunitinib malate).<wbr> </div><div style="margin-bottom: 10px;">The agency considers treatment with Afinitor to be 12% lower in cost than that with Sutent, based on &ldquo;current drug prices&rdquo;.<wbr> Afinitor has already received reimbursement approval in Norway for the treatment of some forms of breast cancer.<wbr> </div><div><EM>Source: IHS GlobalInsight</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20151231&edate=20150901&rec=10799">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-12-07T17:48:31+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-12-07T17:48:31+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Merck/Threshold's TH302 Won Fast Track For Its Pancreatic Cancer Indication</title>
	<pubDate>2015-12-07T17:33:54+01:00</pubDate>
	<wp:post_id>6657</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Merck/<wbr>Threshold's TH302 Won Fast Track For Its Pancreatic Cancer Indication</span>&nbsp;<br><span style="font-size: 12px;">Comment: Germany's Merck KGaA said that experimental cancer drug evofosfamide (TH-302), which it is jointly developing with Threshold Pharmaceuticals, won fast track status for the treatment of advanced pancreatic cancer from the U.<wbr>S.<wbr> FDA.<wbr> Evofosfamide is currently being evaluated in a Ph3 trial and already received orphan drug status in EU and US.<wbr> The topline OS data is expected in 2016.<wbr> Under current licensing agreement, Threshold retains the rigth to co-commercialize Evosafamidein the US.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20151231&edate=20150901&rec=10469">...</a><br></div><div style="margin-bottom: 10px;">Despite signs of activity in local advanced and metastatic pancreatic cancer, Merck has announced that the 2 Ph3 studies did not meet pre-specified PEs.<wbr> The company will therefore not pursue development further for both applications.<wbr> </div><div style="margin-bottom: 10px;">Merck reported it will now be deploying its reources into high-profile future drugs, such as <STRONG>avelumab</STRONG>, and all other priority programs in oncology, I-O and immunology.<wbr> </div><div>Merck will host its analyst day on Thursday (Dec 10).<wbr> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20151231&edate=20150901&rec=10797">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10469">View thread  Oncology10469: Merck/<wbr>Threshold's TH302 Won Fast Track For Its Pancreatic Cancer Indication</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-12-07T17:33:54+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-12-07T17:33:54+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Unilab Launches Pamorelin® in the Philippines</title>
	<pubDate>2015-12-07T17:27:53+01:00</pubDate>
	<wp:post_id>6658</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Unilab has signed an exclusive agreement for the distribution and commercialization of Pamorelin® 1, 3, and 6-month formulations for locally advanced and metastatic hormone-dependent prostate cancer and as adjuvant to radiotherapy in high-risk localized and locally advanced prostate cancer, and for the treatment of endometriosis.<wbr> The company has a market share of &gt;20%.<wbr> Its portfolio includes some of the biggest prescription, consumer healthcare (i;e loperamide) and personal care brands in the country.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Availability</STRONG> </div><div style="margin-bottom: 10px;">Urologists, oncologists and gynecologists </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div><A href="http://www.unilab.com.ph/">http:/<wbr>/<wbr>www.<wbr>unilab.<wbr>com.<wbr>ph/<wbr></A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20151231&edate=20150901&rec=10796">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-12-07T17:27:53+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-12-07T17:27:53+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>New Research Outlines Variation of Price for Cancer Drugs in 16 EU Countries Australia and New Zealand</title>
	<pubDate>2015-12-04T09:55:24+01:00</pubDate>
	<wp:post_id>6659</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: According to a new research published online on December 3rd in the <EM>Lancet Oncology, </EM>the price of new cancer drugs varies widely (from 28% to 388%) between high-income countries in Europe, Australia, and New Zealand.<wbr> The authors note that information on real drug prices is scarce.<wbr> The cancer drug prices they surveyed did not include confidential discounts such as agreed in managed-entry arrangements that are increasingly used in countries such as Australia, Italy, the UK and the Netherlands.<wbr> </div><div style="margin-bottom: 10px;"><H3 class="sectionTitle">Methods</H3> </div><div style="margin-bottom: 10px;">Based on comparability in terms of the economic situation and of the pharmaceutical system, authors surveyed official list prices per unit at ex-factory price level of 31 originator cancer drugs in 16 European countries, Australia, and New Zealand as of June, 2013.<wbr> </div><div style="margin-bottom: 10px;">Drug price data for the European countries were provided by the Pharma Price Information (PPI) service; Australian and New Zealand drug price data were retrieved from the respective pharmaceutical schedules.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Key Findings</STRONG> </div><div style="margin-bottom: 10px;">In Austria, Denmark, Finland, Germany, Italy, Norway, Sweden, and the UK, price information was available for all or all but one drug surveyed whereas the availability of price data was restricted for some drugs in other countries, especially in New Zealand and Portugal.<wbr> </div><div style="margin-bottom: 10px;">The difference of a drug price between the highest priced country and the lowest priced country varied between 28% and 388%.<wbr> A few drugs had lower outliers, especially Greek and UK prices, and upper outliers (particularly prices in Switzerland, Germany, and Sweden).<wbr> </div><div style="margin-bottom: 10px;">Overall, Greek prices ranked at a low level, whereas Sweden, Switzerland, and Germany showed price data in similarly high ranges.<wbr>.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Reference</STRONG> </div><div style="margin-bottom: 10px;">Cancer drugs in 16 European countries, Australia, and New Zealand: a cross-country price comparison study - S Vogler and al </div><div>Published Online: 03 December 2015 <A href="http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00449-0/abstract">http:/<wbr>/<wbr>www.<wbr>thelancet.<wbr>com/<wbr>journals/<wbr>lanonc/<wbr>article/<wbr>PIIS1470-2045(15)00449-0/<wbr>abstract</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20151231&edate=20150901&rec=10795">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-12-04T09:55:24+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-12-04T09:55:24+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Teva May Plan to Divest $1bn of Assets</title>
	<pubDate>2015-12-04T09:20:42+01:00</pubDate>
	<wp:post_id>6660</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: While the assets have not ben disclosed yet, it is reported that the drugs span the US, EU and the Middel East.<wbr>.<wbr> They will be sold in a series of provcesses that are expected to be completed early next year.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Rationale</STRONG> </div><div style="margin-bottom: 10px;">to ease antitrust concerns regarding Teva deal to purchase Allergan's generic business.<wbr> </div><div><EM>source: Globe</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20151231&edate=20150901&rec=11331">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-12-04T09:20:42+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-12-04T09:20:42+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Clostridium Butyricum to be Assessed in China for IBS</title>
	<pubDate>2015-12-03T18:21:48+01:00</pubDate>
	<wp:post_id>6661</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Sponsored by the Shandong U.<wbr> and in collaboration with Qingdao Eastsea Pharmacetical, the randomized, double-blinded, placebo-controlled multicenter study will assess if Clostridium Butyricum might be effective for IBS.<wbr> PE will measure the changes of Irritable Bowel Syndrome-Severity Scoring System.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">ID: <A href="https://clinicaltrials.gov/ct2/show/NCT02614963?recr=Open&amp;phase=01234&amp;fund=2&amp;rcv_s=11%2F03%2F2015&amp;rank=281">NCT02614963</A> - 2015SDU-QILU-G13 </div><div style="margin-bottom: 10px;">Recruitment: approx 300 </div><div style="margin-bottom: 10px;"><P style="MARGIN-BOTTOM: 1ex; MARGIN-TOP: 1ex">Inclusion Criteria:</P> </div><div style="margin-bottom: 10px;"><UL style="MARGIN-BOTTOM: 1ex; MARGIN-TOP: 1ex"><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">the presence of Rome III criteria for IBS ;</LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Aged between 18 and 65 years old</LI>
</UL> </div><div style="margin-bottom: 10px;">Timelines from Dec 2015 to June /<wbr> July 2016 </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div><A href="http://www.45215.tradebig.com/">http:/<wbr>/<wbr>www.<wbr>45215.<wbr>tradebig.<wbr>com/<wbr></A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20151231&edate=20150901&rec=2696">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-12-03T18:21:48+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-12-03T18:21:48+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Novo to Start Global POC With its Once-Weekly hGH Drug</title>
	<pubDate>2015-12-03T18:07:01+01:00</pubDate>
	<wp:post_id>6662</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Newly listed in clinicaltrials.<wbr>gov, the Ph2 will investigate efficacy and safety of once-weekly NNC0195-0092 treatment compared to daily growth hormone treatment (Norditropin&reg; FlexPro&reg;) in growth hormone treatment na&iuml;ve pre-pubertal children with growth hormone deficiency.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">ID: <A href="https://clinicaltrials.gov/ct2/show/NCT02616562?recr=Open&amp;phase=01234&amp;fund=2&amp;rcv_s=11%2F03%2F2015&amp;rank=84">NCT02616562</A> </div><div style="margin-bottom: 10px;">Recruitment: approx 68 (2 years to 10 years) </div><div style="margin-bottom: 10px;">Timelines </div><div style="margin-bottom: 10px;">Stuy is reported to start in May 2016 with completion June 2017 /<wbr> Dec 2017 </div><div>Locations: Austria; Brazil; Germany; Israel; Slovenia; Turkey: Ukraine </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20151231&edate=20150901&rec=8295">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-12-03T18:07:01+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-12-03T18:07:01+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Pfizer's Anti-PD1 Is Being Evaluated As A 1L Maintenance Treatment In Bladder Cancer</title>
	<pubDate>2015-12-03T17:12:56+01:00</pubDate>
	<wp:post_id>6663</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: As bladder cancer is becoming a very competitive market for immuno-oncology agents, especially with both Roche and MSD are both running pivotal trial, Pfizer has planned a Ph3 trial to evaluate its anti-PD1, Avelumab, with a differentiating positioning from Roche and MSD.<wbr> Avelumab is being evaluated as a 1L maintenance treatment after completion of platinum containing therapy for locally advanced or metastatic urothelial cancer patients.<wbr> The study has yet opened for recruitment.<wbr> OS for up to 40 months is the primary objective and trial completion is estimated to be in Q2 2019.<wbr> </div><div style="margin-bottom: 10px;">ClinicalTrials.<wbr>gov Identifier: <a href="https://clinicaltrials.gov/ct2/show/NCT02603432?cond=Bladder+cancer&lup_s=10%2F30%2F2015&lup_d=14&show_rss=Y&sel_rss=mod14" class="defaultlink">NCT02603432</a> </div><div><DIV class="info-title">
<TABLE border="0" cellpadding="0" cellspacing="0" class="layout_table" style="margin-bottom: 3ex;" summary="Layout table for enrollment information"><TBODY><TR valign="top"><TD headers="enrollmentInfoTitle" nowrap="nowrap">Estimated Enrollment:</TD>
<TD headers="enrollmentInfoData" style="padding-left: 1em;">668</TD>
</TR>
<TR valign="top"><TD headers="enrollmentInfoTitle" nowrap="nowrap">Study Start Date:</TD>
<TD headers="enrollmentInfoData" style="padding-left: 1em;">December 2015</TD>
</TR>
<TR valign="top"><TD headers="enrollmentInfoTitle" nowrap="nowrap">Estimated Study Completion Date:</TD>
<TD headers="enrollmentInfoData" style="padding-left: 1em;">May 2019</TD>
</TR>
<TR valign="top"><TD headers="enrollmentInfoTitle" nowrap="nowrap">Estimated Primary Completion Date:</TD>
<TD headers="enrollmentInfoData" style="padding-left: 1em;">May 2019 (Final data collection date for primary outcome measure)</TD>
</TR>
</TBODY>
</TABLE>
<P>Ph3 Trial Design:</P>
<P>Arm A: Avelumab + Best Supportive Care 1 hour intravenous infusion every 2 weeks (Q2W) in 4 week cycles</P>
<P>Arm B: Best supportive Care</P>
<P>Source: ClinicalTrials.<wbr>gov</P>
</DIV> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Oncology10839c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div>Comment: During a joint press release made by Merck KGaA and Pfizer, it was confirmed that this study has been approved by FDA and the first site is expected to open shortly.<wbr> JAVELIN Bladder 100 is expected to enroll 668 patients across more than 200 sites in 38 countries.<wbr> PD-L1 expression status will be determined by retrospective analysis of mandatory tumour samples collected from patients enrolled in the trial.<wbr> (Source: company press release) </div></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20151231&edate=20150901&rec=10794">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-12-03T17:12:56+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-12-03T17:12:56+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Key Messages from AstraZeneca's Pipeline Conference</title>
	<pubDate>2015-12-03T15:34:23+01:00</pubDate>
	<wp:post_id>6664</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: AZ outlined numerous pipeline catalysts in 2016, with Ph3 read outs for Brilinta (stroke and PAD), benralizumab (severe asthma) and lynparza (various tumor types and 3 new launches (Tagrisso (lung cancer), PT003 (COPD), ZS9 (Hyperkalemia).<wbr> AZ' plans are to stay focused on 1/<wbr>Respiratory, Inflammation &amp; Autoimmunity 2/<wbr> Cardiovascular &amp; Metabolic Disease and 3/<wbr> Oncology.<wbr> This implies that all assets outside this core TA are candidates for externalisation revenue ((ie anti infectives, neuroscience, gastro intestinal).<wbr> Management outlined that ' .<wbr>.<wbr>.<wbr> the externalization revenue will remain important in 2016'.<wbr> The company's Immuno-Oncology (I-O) strategy is to focus on combinations and first-mover indications.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2694_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">1/<wbr> <STRONG>Tagrisso </STRONG>in EGFR/<wbr>T790 mutated lung cancer (ongoing) </div><div style="margin-bottom: 10px;">2/<wbr> <STRONG>PT003</STRONG> in COPD (1H 16) </div><div style="margin-bottom: 10px;">3/<wbr><STRONG> ZS9</STRONG> in hyperkalemia (US/<wbr>26 May 2016, EU/<wbr>4Q 2016) </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Focus on combination and first-mover indications.<wbr> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2694_2_ScreenCapture2.jpg"> </div><!-- Comment details --><a name="gastroenterology2694attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2694_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(66,6 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2694_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(45,2 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20151231&edate=20150901&rec=2694">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-12-03T15:34:23+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-12-03T15:34:23+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>TxCell Reacquires Full Ovasave® Rights from Ferring and Looks to Re-partner the Drug</title>
	<pubDate>2015-12-03T14:27:02+01:00</pubDate>
	<wp:post_id>6665</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Ovasave<SUP>®</SUP> is TxCell lead product candidate derived from its proprietary platform.<wbr> It is classified as Advanced Therapy Medicinal Product (ATMP) by the European Medicines Agency.<wbr> Last March, Ferring acquired an option for the exclusive WW license of Ovasave® for IBD (Ph2 currently underwy for CD).<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Following this reacquisition</STRONG>, TxCell now proposes to amend the CATS29 phase IIb trial for Ovasave<SUP>®</SUP>, currently underway in refractory Crohn's disease patients.<wbr> The primary endpoint of the trial (1 million cell dose vs placebo) is intended to be maintained.<wbr> The dose exploring arms are however expected to be omitted.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Following the amendments</STRONG> to the CATS29 trial, TxCell intends to recommence the trial in Q2 2016, with the drug product manufactured by MaSTherCell, a contract manufacturing organization.<wbr> </div><div style="margin-bottom: 10px;"><U>Milestones</U>: TxCell expects to complete recruitment in CATS29 at the end of 2017 and announce topline data by Q4 2017 or Q1 2018.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Background</STRONG> </div><div>Collaboration Deal : Please see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20151231&edate=20150901&rec=1943" class="defaultlink">GastroEnterology1943: Ferring Reinforces Committment in the Gastro Field</a>.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20151231&edate=20150901&rec=2693">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-12-03T14:27:02+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-12-03T14:27:02+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Boehringer Ingelheim and U. of Texas MD Anderson Cancer Center to Develop Innovative Medicines for Pancreatic Ductal Adenocarcinoma (PDAC)</title>
	<pubDate>2015-12-02T17:33:58+01:00</pubDate>
	<wp:post_id>6666</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Pancreatic ductal adenocarcinoma is one of the most lethal of cancers with no effective treatments available.<wbr> The collaboration will focus on identifying and developing therapeutic concepts in novel target areas as well as identification of biomarkers that can accurately identify patients who would respond to potential new therapies.<wbr> </div><div style="margin-bottom: 10px;">The PR indicates that: </div><div style="margin-bottom: 10px;">Pancreatic cancer accounts for 4% of cancer deaths worldwide (330,000 people) and is the seventh most common cause of death from cancer.<wbr> </div><div style="margin-bottom: 10px;">Pancreatic cancer is anticipated to become the second leading cause of cancer-related death in the United States before 2030.<wbr> </div><div style="margin-bottom: 10px;">Newly diagnosed patients have a median survival of less than one year, and a 5-year survival rate of only 3 to 5 percent.<wbr> </div><div>PDAC is one of the most lethal of cancers due to its late detection and resistance to available standard-of-care therapy.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20151231&edate=20150901&rec=10793">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-12-02T17:33:58+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-12-02T17:33:58+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Oncogenex's Curtisen Ph3 Trial Remains Ongoing Following Interim Analyses</title>
	<pubDate>2015-12-02T14:26:40+01:00</pubDate>
	<wp:post_id>6667</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Oncogenex annouced Ph3 Affinity trial is to continue following interim analyses by an independent data monitoring committee.<wbr> No safey issues were identified.<wbr> The final analyses are expected in the 2H 2016, but it will depend on the timing of the event driven final analysis.<wbr> The final AFFINITY efficacy analysis is designed to show a survival benefit with 85 percent power based on a hypothesized hazard ratio of 0.<wbr>75.<wbr> In addition, OncoGenex will pursue the evaluation of the subpopulation who had multiple poor prognostic risk factors, independent of the ITT, in order to obtain an expedited approval for these patients with more aggressive disease.<wbr> Other than Curtisen, Oncogenex is also expecting to report results from its Ph2 trial in metastatic bladder cancer for apatorsen.<wbr> </div><div style="margin-bottom: 10px;">Scott Cormack, CEO of OncoGenex commented: </div><div style="margin-bottom: 10px;">"<EM>The overall survival endpoint of the entire AFFINITY trial remains clinically meaningful and its target hazard ratio of 0.<wbr>75 is attainable with sufficient power to demonstrate a benefit from custirsen for men who are battling advanced prostate cancer.<wbr> We designed the AFFINITY trial so that the final analysis of the ITT population could stand alone as a Phase 3 submission to regulatory agencies regardless of the outcome of the smaller subgroup</EM>.<wbr>" </div><div style="margin-bottom: 10px;">The company also expects several additional clinical trial milestones in 2016 with its other lead product candidate apatorsen, which include: </div><div style="margin-bottom: 10px;">Announcing results for the primary progression-free survival endpoint of the Phase 2 Spruce&trade; trial in advanced NSCLC<BR>Announcing results of the Phase 2 Borealis-2&trade; trial in patients with metastatic bladder cancer<BR>Completing enrollment in the Phase 2 Pacific&trade; trial in metastatic CRPC </div><div>Source: Oncogenex Press release </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20151231&edate=20150901&rec=10792">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-12-02T14:26:40+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-12-02T14:26:40+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Positive Topline Results from First Ph2a Trial of SYN-004 for the Prevention of C. difficile Infection</title>
	<pubDate>2015-12-01T18:21:04+01:00</pubDate>
	<wp:post_id>6668</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Topline results from the ten ileostomized participants who completed the Ph2a open-label study demonstrated that SYN-004 successfully degraded residual IV ceftriaxone in the chyme (digestive fluid in the small intestine) without affecting the intended level of ceftriaxone in the bloodstream.<wbr> The second Ph2a is currently ongoing to assess the GI antibiotic-degrading effects and the safety of SYN-004 in the presence of the proton pump inhibitor (PPI), esomeprazole, in participants with functioning ileostomies (topline results expected H1:16).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Evaluation of the chyme from the ileostomized participants indicates that both dosage strengths of SYN-004 (75 mg and 150 mg) degrade residual IV ceftriaxone present in the chyme, supporting the mechanism of action of SYN-004.<wbr> In addition, both dosage strengths of SYN-004 appear to be well tolerated by the participants in the study.<wbr> </div><div style="margin-bottom: 10px;">Overall, the topline data support the hypothesis that SYN-004 has the capacity to degrade residual IV ceftriaxone in the GI tract, thereby preserving the balance of the gut microbiome for the prevention of CDI, AAD and emergence of antibiotic-resistant organisms, without affecting the antibiotic level in the bloodstream intended for treatment of a primary infection.<wbr> </div><div>Source: <A href="http://www.syntheticbiologics.com/2015-12-01-Synthetic-Biologics-Announces-Positive-Topline-Results-from-First-Phase-2a-Clinical-Trial-of-SYN-004-the-Companys-Candidate-for-the-Prevention-of-C-difficile-Infection">http:/<wbr>/<wbr>www.<wbr>syntheticbiologics.<wbr>com/<wbr>2015-12-01-Synthetic-Biologics-Announces-Positive-Topline-Results-from-First-Phase-2a-Clinical-Trial-of-SYN-004-the-Companys-Candidate-for-the-Prevention-of-C-difficile-Infection</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20151231&edate=20150901&rec=2692">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-12-01T18:21:04+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-12-01T18:21:04+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: BioGaia Invests in MetaboGen</title>
	<pubDate>2015-12-01T18:12:37+01:00</pubDate>
	<wp:post_id>6669</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">BioGaia Invests in MetaboGen</span>&nbsp;<br><span style="font-size: 12px;">Comment: The metagenomic field is growing rapidly as the role of the gut microbiota in metabolic disease becomes more and more evident.<wbr> The aim of the collaboration is to develop new treatments and products (for different metabolic and other microbial associated diseases by influencing large parts of the microbiota), as well as next generation of probiotic products.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20151231&edate=20150901&rec=2140">...</a><br></div><div style="margin-bottom: 10px;">In December 2014 BioGaia reported its decision to invest SEK 12 million in MetaboGen AB, Gothenburg, Sweden.<wbr> The first investment of SEK 4 million took place in December 2014 and as MetaboGen has reached the agreed milestones the second investment of SEK 4 million was made on December 1 2015.<wbr> </div><div>BioGaia thereafter owns 27% of the share capital of MetaboGen, and if further milestones will be reached, the last investment of SEK 4 million will take place at the end of 2016.<wbr> BioGaia's share of the company will then be 35%.<wbr> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20151231&edate=20150901&rec=2691">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2140">View thread  GastroEnterology2140: BioGaia Invests in MetaboGen</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-12-01T18:12:37+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-12-01T18:12:37+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Newly Released Results of an Online Survey on Probiotics</title>
	<pubDate>2015-12-01T11:47:31+01:00</pubDate>
	<wp:post_id>6670</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The survey was conducted in the US by Harris Poll, on behalf of VSL#3 (developed by Sigma-Tau Pharm).<wbr> Results show that taking probiotics has grown in popularity based on the proliferation of probiotic supplements now on store shelves.<wbr> However, this survey showed that more than half of adults (55%) do not know what to look for when choosing a probiotic, and a similar proportion, 54%, say they are confused by the array of probiotics available on store shelves.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><U>Survey Duration</U>: The survey was administered online within the United States between April 1 - 7, 2015.<wbr> </div><div style="margin-bottom: 10px;"><U>Surveyed Population</U>: 607 adults ages 18+ diagnosed with a gastrointestinal disease or condition, such as IBS, UC and ileal pouch.<wbr> </div><div style="margin-bottom: 10px;"><UL><LI>From this population, 98% have made attempts to manage their symptoms through a variety of strategies: self-made dietary changes (61%), consultations with their healthcare practitioner (HCP; 58%) and/<wbr>or taking a probiotic product (49%).<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>HCPs not educating patients</STRONG> </div><div style="margin-bottom: 10px;">The survey suggests that HCPs are in part responsible for the lack of education regarding probiotic products.<wbr> </div><div style="margin-bottom: 10px;"><UL><LI>71% of the polled patients reported they have discussed probiotics with their HCP, but only 10% stated that the HCP educated them on which probiotic would be more suitable given their specific condition.<wbr> </LI>
<LI>13% of the patients reported that their HCPs clarified that some probiotics may not help in certain gastrointestinal conditions, </LI>
<LI>10% claimed that their HCP suggested a specific strain or brand of probiotics.<wbr> </LI>
</UL> </div><div style="margin-bottom: 10px;">In total, 24% of the HCPs recommended a dietary or lifestyle changes, and 22% the ingestion of yogurt with live bacteria to help on symptom management.<wbr> </div><div style="margin-bottom: 10px;"><B>Knowledge about Probiotics</B> </div><div style="margin-bottom: 10px;"><UL style="LIST-STYLE-TYPE: disc" type="disc"><LI>Nearly half of IBS, UC, ileal pouch/<wbr> sufferers (46%) believe all probiotics are pretty much the same.<wbr> 
</LI>
<LI>Roughly 2 in 5 IBS, UC, ileal pouch/<wbr> sufferers (41%) don't understand which strain of probiotics is best to help treat their symptoms.<wbr> 
</LI>
<LI>Nearly half of IBS, UC, ileal pouch/<wbr> sufferers (49%) are not at all knowledgeable about the differences between a "medical food" and a "dietary supplement.<wbr>" </LI>
</UL> </div><div style="margin-bottom: 10px;"><B>Taking Control of their Symptoms</B> </div><div style="margin-bottom: 10px;"><UL style="LIST-STYLE-TYPE: disc" type="disc"><LI>Slightly less than one quarter of sufferers (24%) say they regularly take probiotics to control their symptoms.<wbr> 
</LI>
<LI>Nearly 7 in 10 of those who have used probiotics (69%) say probiotics have helped change their life for the better.<wbr> 
</LI>
<LI>Only about a third of sufferers (35%) feel they are at least somewhat knowledgeable about the benefits of a low-FODMAP diet.<wbr> </LI>
</UL> </div><div style="margin-bottom: 10px;"><B>Who's Buying Probiotics?</B> </div><div style="margin-bottom: 10px;"><UL style="LIST-STYLE-TYPE: disc" type="disc"><LI>Nearly half of IBS, UC, ileal pouch/<wbr> sufferers (48%) have looked for reviews of particular probiotic brands before heading to the store shelves.<wbr> 
</LI>
<LI>Only 12% of IBS, UC, ileal pouch/<wbr> sufferers say when choosing a probiotic they look for the certain strain that will help best with their condition.<wbr> 
</LI>
<LI>Only 21% say that their insurance plan pays for part of the cost of their probiotic prescriptions.<wbr> </LI>
</UL> </div><div>Source: <A href="http://www.prnewswire.com/news-releases/knowing-the-difference-between-probiotics-is-more-than-a-gut-feeling-300182825.html">http:/<wbr>/<wbr>www.<wbr>prnewswire.<wbr>com/<wbr>news-releases/<wbr>knowing-the-difference-between-probiotics-is-more-than-a-gut-feeling-300182825.<wbr>html</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20151231&edate=20150901&rec=2690">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-12-01T11:47:31+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-12-01T11:47:31+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Valneva's C.difficile Vaccine to Enter POC Trial</title>
	<pubDate>2015-12-01T09:00:09+01:00</pubDate>
	<wp:post_id>6671</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Valneva's C.<wbr>difficile Vaccine to Enter POC Trial</span>&nbsp;<br><span style="font-size: 12px;">Comment: Valneva, formed in 2013 through the merger of Intercell AG and Vivalis SA, is a biotech company developing, manufacturing and commercializing vaccines.<wbr> Its vaccine candidate for C.<wbr>difficile is a recombinant protein vaccine consisting of two truncated toxins A and B from C.<wbr>difficile.<wbr>The trial will take place in the US and Germany, and recruit approx 500 subjects.<wbr> PE will measure seroconversion rate (SCR) on D56.<wbr> GSK has got opt-in rights if Ph2 successful.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20151231&edate=20150901&rec=11041">...</a><br></div><div style="margin-bottom: 10px;">Valneva SE has reported that its VLA84 vaccine met the primary endpoint in a Ph2 study to prevent <EM>Clostridium difficile</EM> infection.<wbr> The study included 500 healthy volunteers who received a 75 &micro;g intramuscular vaccine dose without an alum adjuvant, a 200 &micro;g dose with or without the adjuvant, or placebo, administered at days 0, 7 and 28.<wbr> Valneva said the vaccine induced immune responses to both <EM><EM>C.<wbr> difficile</EM></EM>toxins A and B at all doses, and said the 200 &micro;g dose without alum led to the highest seroconversion rate against both toxins A and B on day 56.<wbr> Next development steps to be announced after final study close-out in Q2 2016 and consultations with regulators and Partner.<wbr> </div><div style="margin-bottom: 10px;"><EM></EM> </div><div style="margin-bottom: 10px;">Valneva&acute;s vaccine candidate is targeting the prevention of primary symptomatic <EM></EM> </div><div><EM></EM> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20151231&edate=20150901&rec=11329">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld11041">View thread  PharmaWorld11041: Valneva's C.<wbr>difficile Vaccine to Enter POC Trial</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-12-01T09:00:09+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-12-01T09:00:09+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Ironwood / Astellas Report Positive Top-Line Data from Ph3 IBS-C Trial in Japan</title>
	<pubDate>2015-12-01T08:51:20+01:00</pubDate>
	<wp:post_id>6672</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Astellas expects to submit a new drug application to the ministry of health, labor and welfare in Japan in 2016.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Linaclotide-treated patients showed statistically significant improvement compared to placebo-treated patients for both of the two co-primary endpoints.<wbr> </div><div style="margin-bottom: 10px;">Regarding the first primary endpoint, 34% of linaclotide-treated patients were Global Assessment of Relief of IBS Symptoms Responders, compared to 18% of placebo-treated patients (p&lt;0.<wbr>001).<wbr> </div><div style="margin-bottom: 10px;">Regarding the second primary endpoint, 35% of linaclotide-treated patients were <ORG>Complete Spontaneous Bowel Movement</ORG> (CSBM) Overall Responders, compared to 19% of placebo-treated patients (p&lt;0.<wbr>001).<wbr> </div><div style="margin-bottom: 10px;">Additionally, improvements were achieved in pre-specified secondary endpoints in this trial covering<STRONG>.<wbr> </STRONG>Diarrhea rates in this trial were 9.<wbr>6% for linaclotide vs.<wbr> 0.<wbr>4% for placebo; all cases were characterized as mild or moderate in severity.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>IBS-C in Japan</STRONG> </div><div style="margin-bottom: 10px;">Ironwood mentionned in its PR that 2.<wbr>9% of adults in <LOCATION value="LC/jp;LB/eas">Japan</LOCATION> suffer from IBS-C, and there are no prescription products currently approved in <LOCATION value="LC/jp;LB/eas">Japan</LOCATION> for the treatment of this condition.<wbr> </div><div><EM>Source: Ironwood</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20151231&edate=20150901&rec=2689">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-12-01T08:51:20+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-12-01T08:51:20+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Kura Oncology's Tipifarnib: A New Agent Targeting HRAS Mutant Metastatic Urothelial Cancer</title>
	<pubDate>2015-12-01T08:46:31+01:00</pubDate>
	<wp:post_id>6673</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Kura Oncology announces first patient dosed in an Investigator-Sponsored Phase 2 Trial of Tipifarnib in Patients With HRAS Mutant Urothelial Cancer.<wbr>The study is being conducted under the direction of Se Hoon Park, M.<wbr>D.<wbr>, Ph.<wbr>D.<wbr> in the Division of Hematology-Oncology at the Samsung Medical Center in Seoul, South Korea.<wbr> Although the development is yet early stage, the likley target position for tipifarnib is in the metastatic 2L setting.<wbr> </div><div style="margin-bottom: 10px;">The primary objective of the Phase 2 study is to investigate the antitumor activity, in terms of objective response rate, of tipifarnib in patients with locally advanced, unresectable or metastatic, relapsed and/<wbr>or refractory urothelial cancer tumors that carry HRAS mutations.<wbr> Secondary objectives include evaluation of progression-free survival, duration of response and safety.<wbr> It is planned that the study will enroll up to 18 patients </div><div style="margin-bottom: 10px;">Farnesyl transferase inhibitors (FTIs), such as tipifarnib, work to prevent the aberrant growth and proliferation of cells that are dependent on these signaling pathways by switching HRAS off.<wbr> The HRAS protein is a GTPase involved in regulating cell division in response to growth factor stimulation.<wbr> Growth factors act by binding cell surface receptors that span the cell's plasma membrane.<wbr> Once activated, receptors stimulate signal transduction events in the cytoplasm, a process by which proteins and second messengers relay signals from outside the cell to the cell nucleus and instruct the cell to grow or divide.<wbr> HRAS is an early player in many signal transduction pathways.<wbr> </div><div style="margin-bottom: 10px;"><SPAN style="text-decoration: underline;"><STRONG>Kura Oncology Pipeline</STRONG></SPAN> </div><div style="margin-bottom: 10px;">In addition to the currently ongoing Phase 2 clinical trial of tipifarnib in patients with tumors characterized by HRAS mutations, the company initiated a Phase 2 clinical trial in patients with peripheral T-cell lymphomas in the third quarter of 2015.<wbr> Kura Oncology holds an exclusive license to develop and commercialize tipifarnib in the field of oncology, under an agreement with Janssen Pharmaceutica NV.<wbr> The company plans to initiate a third Phase 2 clinical study in patients with lower risk myelodysplastic syndromes in the first half of 2016.<wbr> Kura's preclinical pipeline includes KO-947, an ERK inhibitor, and a menin-MLL inhibitor program.<wbr> </div><div>Source: Kura Oncology Press Release </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20151231&edate=20150901&rec=10791">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-12-01T08:46:31+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-12-01T08:46:31+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Ironwood / Allergan's Linaclotide Meets PE for OIC</title>
	<pubDate>2015-12-01T08:43:17+01:00</pubDate>
	<wp:post_id>6674</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The Ph2 included 254 patients with chronic, non-cancer pain who had been receiving a stable dose of an opioid analgesic and had fewer than three spontaneous bowel movements (SBMs) per week.<wbr> Once-daily 145 μg and 290 μg doses of linaclotide met the primary endpoint of a greater frequency of SBM over eight weeks vs.<wbr> placebo.<wbr> The companies expect data from the linaclotide colonic release Ph2b trial in H2:16.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Ironwood and Allergan intend to determine next steps in the OIC development program after reviewing data expected in 2H16 from a Phase IIb trial of a colonic-release formulation of linaclotide in adults with IBS-C.<wbr> </div><div><EM>Source: Ironwood</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20151231&edate=20150901&rec=2688">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-12-01T08:43:17+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-12-01T08:43:17+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Xeomin to present at the 1st MENA headache conference</title>
	<pubDate>2015-11-30T16:10:11+01:00</pubDate>
	<wp:post_id>6675</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: On twitter Lunatus, a marketing and consulting company who manage Cefaly; a migraine medical device, reported that they were honoured to be the sponsor of the upcoming Headache conference in Dubai and will present Xeomin.<wbr> </div><div style="margin-bottom: 10px;">The pain indication for Xeomin is a new area and further highlights Merz focus on developing the product in multiple therapeutic indications.<wbr>  Merz is currently investigating Trigeminal Neuralgia NCT NCT02088632 </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_8260_2_ScreenCapture2.jpg"> </div><div>Source: Lunatus </div><!-- Comment details --><a name="neurology8260attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_8260_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(675 B)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_8260_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(34,9 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20151231&edate=20150901&rec=8260">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-11-30T16:10:11+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-11-30T16:10:11+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Teva and Takeda Establish a JV to Meet the Growing Importance of Generic Medicines Use in Japan</title>
	<pubDate>2015-11-30T09:49:06+01:00</pubDate>
	<wp:post_id>6676</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The new business venture, which will operate as an independent company, is expected to start in April 2016.<wbr> It will create a company ideally positioned to lead the high growth in the generic market in Japan, and will be aligned with the Japanese government objectives to reach 80% generic penetration by the end of fiscal year 2020.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">To be established in Apr 2016 for an undisclosed amount of time (purchase terms unclear).<wbr> </div><div style="margin-bottom: 10px;">Teva will have a 51% stake in the new company and Takeda will have 49%.<wbr> </div><div style="margin-bottom: 10px;">The new business venture will combine Teva's strong generics platform, portfolio and quality across the value chain with Takeda's leading brand presence and distribution capabilities in Japan.<wbr> Given a domestic patent expiry ratio of 45% (worth ¥200bn+ in sales), Takeda is to transfer some of the relevant products to the JV (how these will be selected is unclear).<wbr> </div><div><EM>Source: Businesswire; MorganStanley Nov 30 2015</EM> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Oncology10840c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div>Comment: Takeda has made a follow-up announcement regarding to the new business venture with Teva that was announced on Nov 30.<wbr> Takeda will split off its off-patented and data exclusivity expired products business ("long listed products business") via an absorption-type split, and subsequently the business will be succeeded by the Japanese subsidiaries of Teva Pharmaceutical Industries Ltd.<wbr> of Israel.<wbr> The details of establishing these companies by an absorption-type company split are outlined in a separate release issued by Takeda to file to the Tokyo Stock Exchange: <a href="http://ci.beaufour-ipsen.com/traction?type=rchron&proj=*&sdate=20151231&edate=Week&rsin=/link%20week%20%27(Link)%27%20((c(news)%20AND%20c(2015))%20AND%20(c(20151228)%20AND%20(c(7258)%20AND%20c(html%20))))&find=(AND%20(AND%20(c%20news)%20(c%202015))%20(AND%20(c%2020151228)%20(AND%20(c%207258)%20(c%20html))))&title=(Link)&wassearch=true" class="defaultlink">(Link)</a>.<wbr>The new business venture, to be owned 51% by Teva and 49% by Takeda, will consist of Teva Takeda Pharma and Teva Takeda Yakuhin.<wbr> The major long listed products of Takeda to be transferred to the new business venture in FY2016 are BLOPRESS, TAKEPRON and BASEN.<wbr> LEUPLIN still remains at Takeda, as a product of Takeda Oncology.<wbr> (Source: Takeda Press Release 28 Dec 2015) </div></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20151231&edate=20150901&rec=11324">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-11-30T09:49:06+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-11-30T09:49:06+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Servier Plans to Cut 610 Jobs Mainly in France</title>
	<pubDate>2015-11-27T15:40:25+01:00</pubDate>
	<wp:post_id>6677</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Servier has reported it had been penalised by patent losses, a rapid growth in generic drugs, regulated prices and delays in obtaining market clearance for its drugs.<wbr> As such, a new organisation, which will be implemented in H2:16 will result in a net loss of 610 jobs (the bulk of the job losses would occur among the commercial operations within France).<wbr> </div><div style="margin-bottom: 10px;">The company has 21,000 employees worldwide, including 5,000 in France, and had revenues of €4bn ($4.<wbr>2bn) last year.<wbr> </div><div style="margin-bottom: 10px;">The cuts represent 12% of its French workforce.<wbr> </div><div style="margin-bottom: 10px;">Servier's sales within France have been cut in half in the last five years to less than €250m, and most of the layoffs involve its domestic salesforce.<wbr> </div><div><EM>Source: pmlive</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20151231&edate=20150901&rec=11321">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-11-27T15:40:25+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-11-27T15:40:25+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Sinclair IS Pharma Has Disposed Of Its Non-Aesthetic Business To Alliance Pharma In Wake Of Its Financial Loss</title>
	<pubDate>2015-11-27T13:09:55+01:00</pubDate>
	<wp:post_id>6678</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Sinclair IS Pharma has reported a finical loss for 2015 in addition to the strategic disposal of its non-aesthetic business to Alliance Pharma plc.<wbr>  The aesthetic business has been viewed as a viable portfolio, gaining attention from a number of international pharmaceutical companies </div><div style="margin-bottom: 10px;">Sinclair IS Pharma Plc.<wbr> reported its fiscal 2015 loss before tax as £8.<wbr>15 million, wider than last year's loss of £4.<wbr>44 million.<wbr> Revenues increased 19.<wbr>4% to £75.<wbr>9 million and on a like-for-like basis, revenues grew 7.<wbr>7%.<wbr> </div><div style="margin-bottom: 10px;">Sinclair is currently in an offer period under the framework provided by a formal sales process under the Takeover Code.<wbr>  They continue to receive attention for the remaining aesthetics business from a number of international companies </div><div style="margin-bottom: 10px;">In addition, Sinclair recently announced the strategic disposal of its non-aesthetics business to Alliance Pharma plc for a total upfront cash consideration of 132 million pounds as well as sales-related royalty payments relating to Flammacerium US.<wbr>  The transaction is expected to complete in December of this year and the company will be re-named Sinclair Pharma plc.<wbr> </div><div>Source: Nasdaq </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20151231&edate=20150901&rec=8259">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-11-27T13:09:55+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-11-27T13:09:55+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Cocrystal Pharma to Initiate FIM Trial Against Norovirus in 2016</title>
	<pubDate>2015-11-27T10:54:15+01:00</pubDate>
	<wp:post_id>6679</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Cocrystal Pharma, Inc.<wbr> is a U.<wbr>S- based private pharmaceutical company, with a mission to discover novel antiviral therapeutics as treatments for serious and/<wbr>or chronic viral diseases.<wbr> The company employs unique technologies and Nobel Prize winning expertise.<wbr> CC-1845, its lead plaform, is a novel anti-norovirus Nuc prodrug, intended to be used as prophylaxis and for acute/<wbr>chronic norovirus infections, especially in immunocompromised patients.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2685_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2685_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Important milestone for the company was the merger in November 2014 with RFS Pharma to create an advanced antiviral development organization.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2685_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><STRONG>Scientific Leadership</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2685_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;"><STRONG>Technology Platform</STRONG> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2685_5_ScreenCapture5.jpg"> </div><!-- Comment details --><a name="gastroenterology2685attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2685_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(55,1 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2685_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(24,9 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2685_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(73,3 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2685_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(40,9 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2685_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(63 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20151231&edate=20150901&rec=2685">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-11-27T10:54:15+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-11-27T10:54:15+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Pfizer Perspective Of The Allergan Merger Is On The Standpoint Of Enhancing Pfizer Pipeline As Well As Opening Up To New Opportunities</title>
	<pubDate>2015-11-26T17:55:18+01:00</pubDate>
	<wp:post_id>6680</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comments: Over the last 3 days, post the announcement of the Pfizer and Allergan merger, infographics have been released by Pfizer (via twitter)highlighting the companies perspective of the merger and how it will complement each company’s strategic direction </div><div style="margin-bottom: 10px;">Ian Read, Chairman and CEO of Pfizer, via a video link, highlighted how the merger will bring together two great companies as each complement each other in terms of pipeline and timing on the market.<wbr> The merger, as most people have discussed, offers costs synergies (outside of tax inversion) and the ability for Pfizer to use their capital more globally for this transaction.<wbr> Ian Read made specific comments at the announcement of the merger about the importance of the enhancement Pfizer gain to the neurology portfolio “<I>In neuroscience, Allergan has a promising pipeline of assets across a number of disease areas, including a novel treatment in development from major depression.<wbr> We can also benefit from Allergan’s work in building an extensive pipeline around Botox for multiple new indications of other disease areas as well as other aesthetic indications”</I> </div><div style="margin-bottom: 10px;">Key info graphics are presented below </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_8256_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_8256_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_8256_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_8256_4_ScreenCapture4.jpg"> </div><div>Source: Premierbiopharmaleader Pfizer Allergan </div><!-- Comment details --><a name="neurology8256attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_8256_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(74,3 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_8256_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(67,3 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_8256_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(70,5 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_8256_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(75,3 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20151231&edate=20150901&rec=8256">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-11-26T17:55:18+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-11-26T17:55:18+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Would Reckitt Benckiser be a Prime Candidate to Acquire Pfizer's Consumer Healthcare Business ?</title>
	<pubDate>2015-11-26T15:04:58+01:00</pubDate>
	<wp:post_id>6681</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Exane BNP Paribas thinks Reckitt Benckiser (RB) will be well positioned to acquire Pfizer's CHC business (transaction expected around 2018).<wbr> The CHC brands in the combined Pfizer-Allergan will have annual sales of $3.<wbr>9 billion (about 6% of the combined company’s estimated annual revenue), however according to the investors it will be a drag on the innovative business that Pfizer intends to create.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2683_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div>- vitamin brand Centrum, calcium supplement Caltrate, analgesic Advil, lip care brand ChapStick and ThermaCare heat wraps for muscle pain </div><!-- Comment details --><a name="gastroenterology2683attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2683_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(66 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20151231&edate=20150901&rec=2683">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-11-26T15:04:58+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-11-26T15:04:58+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Allergan has partnered with RugenTo Develop Novel First-in-Class Small Molecules To Treat Major Unmet Needs In Neurology And Psychiatry</title>
	<pubDate>2015-11-26T14:37:01+01:00</pubDate>
	<wp:post_id>6682</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Allergan and Rugen Therapeutics; a start-up Biotech company, have joined forces to develop novel treatments in CNS.<wbr> Funded by F-Prime Biomedical Research Initiative (FBRI), this collaboration includes novel therapies for Autism Spectrum Disorders (ASD) and Obsessive Compulsive disorders (OCD).<wbr> </div><div style="margin-bottom: 10px;">This collaboration is being positioned as as a way of showing Allergan's commitment to its Open Science model by partnering with smaller firms to help develop and commercialize products.<wbr> Brent Saunders (CEO of Allergan) is known to be pessimistic about early research and believes investment and collaboration into firms that can conduct this for them is the best way forward.<wbr> </div><div style="margin-bottom: 10px;">Under the terms of the agreement, Rugen will receive an upfront initiation fee at the outset of the collaboration, and is entitled to development stage initiation and success-based milestone payments for advancing compounds in development.<wbr> Allergan will have the exclusive option to acquire all rights, including the worldwide intellectual property rights and other assets, related to the compounds following clinical proof of concept studies.<wbr> </div><div style="margin-bottom: 10px;">David Nicholson, Executive VP, Global Brands Research and Development at Allergan was reported as saying "Allergan is committed to finding breakthrough therapies in areas where there are limited treatment options.<wbr> Autism Spectrum Disorders and OCD are areas of medicine where there continues to be a substantial amount of unmet need in identifying and developing treatments for the underlying mechanisms of disease.<wbr> The compounds we are working to develop with Rugen are in preclinical development, but we are excited by the possibilities that these novel molecules may provide to physicians, patients and caregivers facing these disorders.<wbr>" </div><div style="margin-bottom: 10px;">Stacie Weninger, Executive Director of F-Prime Biomedical Research Initiative (FBRI) stated "Rugen was founded on the belief that recent advances in our fundamental understanding of psychiatric illnesses, led by genetic discoveries, will allow us to develop breakthrough therapeutics for devastating illnesses.<wbr> We are thrilled that Allergan, a global leader in the development and commercialization of treatments for CNS diseases, recognizes our scientific capabilities in neuroscience and the promise of the series of new molecules we discovered and developed at Rugen.<wbr> We have a highly committed and experienced partner in Allergan and look forward to working together to develop multiple new breakthrough medicines over the coming years," </div><div style="margin-bottom: 10px;">This collaboration works well with the recent merger with Pfizer, in which the Neurology franchise is positioned as a key therapeutic area for both companies </div><div>Source: Allergan </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20151231&edate=20150901&rec=8254">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-11-26T14:37:01+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-11-26T14:37:01+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Medy-Tox Acquires 25% Stake In Singapore Based Endocrinology Company</title>
	<pubDate>2015-11-26T14:11:04+01:00</pubDate>
	<wp:post_id>6683</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div><STRONG>Source: Reuters</STRONG> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20151231&edate=20150901&rec=8253">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-11-26T14:11:04+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-11-26T14:11:04+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Lallemand Raises its Presence in China</title>
	<pubDate>2015-11-26T13:58:59+01:00</pubDate>
	<wp:post_id>6684</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Lallemand participated to 2 major events in China (see below), with the objectives to netwok and explore business opportunities in Asia.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><A href="http://www.hncexpo.com/en/">Healthplex &amp; Nutraceutical China 2015</A>, one of the largest and most valuable event in the Asia-Pacific Region.<wbr> </div><div style="margin-bottom: 10px;"><A href="http://uschinahpa.org/2015/05/china-international-probiotic-and-omega-3-industry-summit-2015/">China International PROBIOTICS and Omega 3 Summit</A>, an event organized by the US-China Health Products Association.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Euromonitor Data</STRONG> </div><div style="margin-bottom: 10px;">In its PR, Lallemand indicated that: </div><div style="margin-bottom: 10px;"><UL><LI>China offers a great untapped potential for probiotic dietary supplements.<wbr> The probiotic market represents around 5.<wbr>4Bn USD, with a 156% growth between 2009-2014.<wbr> However, dietary food supplements were estimated to represent only 1% of this market.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG>Products</STRONG> </div><div style="margin-bottom: 10px;">Lallemand Health Solutions offers a full line of ready-to-market probiotic formula’s such as ; LACIDOFIL®, PROBIOKID®, PROBIO’STICK®,  PROTECFLOR® </div><div style="margin-bottom: 10px;">Lallemand Health Solutions can also design, develop and produce custom formulations based on the documented ROSELL, LAFTI® or HARMONIUM® strains.<wbr> </div><div>Source: Lallemand </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20151231&edate=20150901&rec=2682">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-11-26T13:58:59+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-11-26T13:58:59+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Insights into GSK's Patient-Focused Selling Model</title>
	<pubDate>2015-11-25T18:42:24+01:00</pubDate>
	<wp:post_id>6685</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: In a discussion with Eyeforpharma, Victoria Williams, GSK&rsquo;s (France) VP and Sales Director, shared insights from the transformation of GSK to a patient-focused selling model, specifically on the implementation.<wbr> Salient points are summarized below: </div><div style="margin-bottom: 10px;"><U>Changes to Sales Manager Roles</U> </div><div style="margin-bottom: 10px;">The main day-to-day change the transformation has brought about is in the way sales teams operate under the new GSK sales model (implemented in 2015), specifically in how much time Sales Managers spend on the field.<wbr> Per Victoria Williams, &ldquo;Sixty percent of a Sales Manager's time is spent on field visits.<wbr>&rdquo; Moreover, the goal of the Sales Manager is now to train the medical representatives through on the field observations and coaching.<wbr> </div><div style="margin-bottom: 10px;"><U>Measuring the non-target based sales incentive scheme</U> </div><div style="margin-bottom: 10px;">In 2014, GSK was the first pharmaceutical company to announce that it would no longer incentivize its Sales reps around the number of prescriptions written by doctors with whom they interact.<wbr> A new sales incentive plan was implemented in early 2015, with no link to sales targets and based entirely on the sales rep&rsquo;s technical knowledge, quality of service and overall business performance.<wbr> </div><div style="margin-bottom: 10px;">Victoria Williams offered a few insights on how the different parameters are being measured.<wbr> Sales Managers are: </div><div style="margin-bottom: 10px;"><UL><LI>Observing and rating the reps on the quality of their communications with customers.<wbr> Specifically, quality is being measured in terms of transparency and patient-centricity, which essentially translates into how well the Reps are understanding and meeting HCP needs
</LI>
<LI>Reviewing and rating business plans and execution against plans.<wbr>
</LI>
<LI>Utilizing summative assessments to review and rate technical skills and/<wbr>or scientific knowledge.<wbr>
</LI>
</UL> </div><div style="margin-bottom: 10px;"><U>Success factors</U> </div><div style="margin-bottom: 10px;">In the discussion, Victoria alludes to two factors that were instrumental to the success of the transformation to a patient-focused-selling model: </div><div><UL><LI>Broad cultural change across the company that was aligned with the tenets of the sales transformation.<wbr>
</LI>
<LI>The sales incentive plan not being linked to targets, helping the sales reps to better value and believe in a patient-centered environment.<wbr>
</LI>
</UL> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20151231&edate=20150901&rec=11320">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-11-25T18:42:24+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-11-25T18:42:24+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Sun Pharma Eyes Expansion in the Consumer Healthcare Space</title>
	<pubDate>2015-11-25T17:32:20+01:00</pubDate>
	<wp:post_id>6686</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Sun Pharma is looking to expand its business in the global consumer healthcare space and is not averse to acquiring new brands.<wbr> Consumer Healthcare is a separate business division engaged in developing and marketing OTC products in India.<wbr> This division offers 5 key brands and many products, including two of the top 10 OTC brands – Revital and Volini.<wbr> The CHC division is among India’s top 10 consumer healthcare businesses.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">bring in more formats, newer extensions, newer programmes </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2681_1_ScreenCapture1.jpg"> </div><!-- Comment details --><a name="gastroenterology2681attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2681_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(58 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20151231&edate=20150901&rec=2681">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-11-25T17:32:20+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-11-25T17:32:20+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Johnson & Johnson Leads $24M Financing into Maker of OTC Liquid 'Shots'</title>
	<pubDate>2015-11-25T16:38:30+01:00</pubDate>
	<wp:post_id>6687</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: First Aid Shot Therapy®, the makers of F.<wbr>A.<wbr>S.<wbr>T.<wbr> single dose liquid "shot" (40ml /<wbr> 1.<wbr>35oz.<wbr>) for pain, heart burn hangovers and common cold, has completed a $24M Series C financing round, led by the inovation arm of J&amp;J.<wbr> FAst plans to use the funding to both expand its portfolio of products, and to bring those products to more stores across the U.<wbr>S.<wbr>.<wbr> J&amp;J's knowledge of consumer healthcare will give an important access to research, and consumer behavior trends.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Founded in 2010 </div><div style="margin-bottom: 10px;">Headquartered in Burlingame, California </div><div style="margin-bottom: 10px;">Privately held </div><div style="margin-bottom: 10px;">The F.<wbr>A.<wbr>S.<wbr>T.<wbr> team is comprised of consumer product executives that have been responsible for the launch and commercial success of products such as vitaminwater, Pretzel Crisps, Krave Jerky and FlatOut.<wbr> </div><div style="margin-bottom: 10px;">F.<wbr>A.<wbr>S.<wbr>T.<wbr> was co-founded by Professor Jay Pasricha, M.<wbr>D.<wbr>, Professor of Medicine at Johns Hopkins Medicine.<wbr> </div><div style="margin-bottom: 10px;">In addition, F.<wbr>A.<wbr>S.<wbr>T.<wbr> has assembled an Advisory Board comprising some of the leading regulatory advisors and consumer marketing executives in the world including Mary Minnick, Partner at Lion Capital and former Chief Marketing, Strategy and Innovation Officer at The Coca-Cola Company and Peter Barton Hutt, former General Counsel of the Food and Drug Administration.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2675_2_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;">According to Fast managment: </div><div style="margin-bottom: 10px;">" .<wbr>.<wbr>.<wbr> F.<wbr>A.<wbr>S.<wbr>T.<wbr>’s liquid shots are the right format for consumers looking for<STRONG> relief on-the-go</STRONG>".<wbr> .<wbr>.<wbr>.<wbr> we have seen that the on-the-go occasion is growing in many consumer categories".<wbr> "F.<wbr>A.<wbr>S.<wbr>T.<wbr> says its medications are faster acting because they do not need to be broken down before being absorbed into the bloodstream, as is the case with tablets like aspirin.<wbr> </div><div style="margin-bottom: 10px;">" .<wbr>.<wbr>.<wbr> the "liquid shots" are FDA-compliant, meaning they consist of ingredients that do not require its permission prior to use because the agency recognizes them as safe and effective.<wbr>" </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2675_3_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><H2></H2> </div><div>F.<wbr>A.<wbr>S.<wbr>T.<wbr>'s products have been formulated by the Company's proprietary research and development organization, F.<wbr>A.<wbr>S.<wbr>T.<wbr> Labs ™.<wbr> F.<wbr>A.<wbr>S.<wbr>T.<wbr> Labs ™ operate under the guidance of our Scientific Advisory Board, which is led by F.<wbr>A.<wbr>S.<wbr>T co-founder, <STRONG>Professor Jay Pasricha</STRONG>.<wbr> </div><!-- Comment details --><a name="gastroenterology2675attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2675_2_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(32,9 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2675_3_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(138,4 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20151231&edate=20150901&rec=2675">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-11-25T16:38:30+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-11-25T16:38:30+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Changes In Merz North America With New Leadership And Partnerships Announced</title>
	<pubDate>2015-11-25T11:51:40+01:00</pubDate>
	<wp:post_id>6688</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Changes In Merz North America With New Leadership And Partnerships Announced</span>&nbsp;<br><span style="font-size: 12px;">Comment: Merz North America has restructured the North American leadership team, making announcements of a number of new employees.<wbr>   This new team is structured to improve the performance in North America and fuel global growth.<wbr>  Merz has also partnered with Empire Medical Training to support this growth</span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20151231&edate=20150901&rec=8251">...</a><br></div><div>Merz North America announced today the appointment of Philippe Adams as Vice President, Managed Markets.<wbr> In this role, Adams will primarily be responsible for developing Merz's North American market access and reimbursement strategy </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20151231&edate=20150901&rec=8252">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology8251">View thread  Neurology8251: Changes In Merz North America With New Leadership And Partnerships Announced</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-11-25T11:51:40+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-11-25T11:51:40+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>BMS Receives FDA Approval For Nivolumab Usage In Advanced Renal Cancer (RCC)</title>
	<pubDate>2015-11-24T15:10:57+01:00</pubDate>
	<wp:post_id>6689</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: BMS late yesterday received its fifth approval for OPDIVO<SUP>®</SUP> (nivolumab) in 12 months for advanced RCC patients who have received prior anti-angiogenic therapy.<wbr> This marks the third distinct tumour type to be approved.<wbr> </div><div style="margin-bottom: 10px;">On September 16, 2015, the FDA granted Breakthrough Therapy Designation to <I>Opdivo </I>for advanced RCC patients  reinforcing the unmet need that exists in the treatment of RCC.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Basis For Approval</STRONG> </div><div style="margin-bottom: 10px;">The U.<wbr>S.<wbr> approval was based on data from CheckMate -025, an open-label, randomized Phase 3 study (data from which was presented at ECC 2015 in September).<wbr> The trial demonstrated a median OS benefit of 25 months (95% CI: 21.<wbr>7-NE) compared with 19.<wbr>6 months (95% CI: 17.<wbr>6-23.<wbr>1) for everolimus (HR: 0.<wbr>73; [95% CI: 0.<wbr>60-0.<wbr>89; p=0.<wbr>0018]).<wbr> This is the first time an immune checkpoint inhibitor has delivered a significant survival benefit in this patient population.<wbr> </div><div style="margin-bottom: 10px;">The safety profile of OPDIVO<SUP>®</SUP> in CheckMate -025 was consistent with prior studies.<wbr><SUP>2</SUP> Serious adverse events occurred in 47% of patients receiving OPDIVO<SUP>®.<wbr></SUP> The most frequent serious adverse reactions reported in at least 2% of patients receiving <I>Opdivo</I> were acute kidney injury, pleural effusion, pneumonia, diarrhea, and hypercalcemia.<wbr><SUP> </SUP>In the study, the most common adverse reactions (≥20%) reported in patients receiving OPDIVO<SUP>®</SUP> versus everolimus were asthenic conditions (56% vs.<wbr> 57%), cough (34% vs.<wbr> 38%), nausea (28% vs.<wbr> 29%), rash (28% vs.<wbr> 36%), dyspnea (27% vs.<wbr> 31%), diarrhea (25% vs.<wbr> 32%), constipation (23% vs.<wbr> 18%), decreased appetite (23% vs.<wbr> 30%), back pain (21% vs.<wbr> 16%), and arthralgia (20% vs.<wbr> 14%).<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Current Status of OPDIVO<SUP>®</SUP></STRONG> </div><div style="margin-bottom: 10px;">Bristol-Myers Squibb has a broad, global development program to study OPDIVO<SUP>®</SUP> in multiple tumor types consisting of more than 50 trials – as a monotherapy or in combination with other therapies – in which more than 8,000 patients have been enrolled worldwide.<wbr> </div><div style="margin-bottom: 10px;">The other indications for which OPDIVO<SUP>®</SUP> is already approved in the US are as follows:- </div><div style="margin-bottom: 10px;">OPDIVO<SUP>®</SUP> as a single agent is indicated for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor.<wbr> This indication is approved under accelerated approval based on tumor response rate and durability of response.<wbr> Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.<wbr> </div><div style="margin-bottom: 10px;">OPDIVO<SUP>®</SUP>, in combination with ipilimumab, is indicated for the treatment of patients with BRAF V600 wild-type, unresectable or metastatic melanoma.<wbr> This indication is approved under accelerated approval based on tumor response rate and durability of response.<wbr> Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.<wbr> </div><div style="margin-bottom: 10px;">OPDIVO<SUP>®</SUP> is indicated for the treatment of patients with metastatic non small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy.<wbr> Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving OPDIVO<SUP>®</SUP>.<wbr> </div><div>From <A href="http://news.bms.com/">http:/<wbr>/<wbr>news.<wbr>bms.<wbr>com</A>, see <A href="http://news.bms.com/press-release/bristol-myers-squibb-receives-fda-approval-opdivo-nivolumab-only-treatment-deliver-sig">original source</A>.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20151231&edate=20150901&rec=10789">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-11-24T15:10:57+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-11-24T15:10:57+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>First Key U.S. Patent Directly Covering SYN-010 for IBS-C</title>
	<pubDate>2015-11-24T13:30:55+01:00</pubDate>
	<wp:post_id>6690</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: U.<wbr>S.<wbr> Patent No.<wbr> 9,192,618, issued on November 24, 2015, includes claims that cover Synthetic Biologics' clinical SYN-010 IBS-C program.<wbr> This patent, which is exclusively licensed from Cedars-Sinai Medical Center (CSMC), is the result of research directed by Mark Pimentel, M.<wbr>D.<wbr>, FRCP©, Director of CSMC's GI Motility Program and Laboratory and Chairman of Synthetic Biologics' IBS-C Clinical.<wbr> This is the company's first issued U.<wbr>S.<wbr> patent directly pertaining to SYN-010.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">This new U.<wbr>S.<wbr> patent enlarges Synthetic Biologics' SYN-010-related patent estate; patents from the same family have been granted in Europe, Canada and Australia.<wbr> </div><div>Additional worldwide patent filings, co-owned by CSMC and Synthetic Biologics and licensed to the Company, include composition of matter claims that <STRONG>could extend patent protection of SYN-010 to 2035.<wbr></STRONG> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20151231&edate=20150901&rec=2673">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-11-24T13:30:55+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-11-24T13:30:55+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Changes In Merz North America With New Leadership And Partnerships Announced</title>
	<pubDate>2015-11-24T12:25:11+01:00</pubDate>
	<wp:post_id>6691</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Merz North America has restructured the North American leadership team, making announcements of a number of new employees.<wbr>   This new team is structured to improve the performance in North America and fuel global growth.<wbr>  Merz has also partnered with Empire Medical Training to support this growth </div><div style="margin-bottom: 10px;">Merz North America today announced that Jim Hartman has been appointed to Vice President of the U.<wbr>S.<wbr> Aesthetics (Merz Aesthetics, Inc.<wbr>), Liz Newman will continue in her role as Director of Marketing and Jessica Wright, Associate Director of OTC Franchise.<wbr> </div><div style="margin-bottom: 10px;">Bill Humphries, president and chief executive officer - north america stated “Jim was the natural choice to lead this business, he is a proven leader, accomplished marketer, and cultivates excellent relationships with customers,” </div><div style="margin-bottom: 10px;">In addition to this announmeneted Merz North America also announced a new partnership with Empire Medical Training.<wbr>  The partnership is a facilitated agreement to introduce the newest aesthetic products and technologies to Empire participants.<wbr> </div><div style="margin-bottom: 10px;">Dr.<wbr> Stephen Cosentino, DO, President and Founder of Empire Medical training stated, “Our teaching organization and faculty are excited to work with a company of this stature and believe this will give Empire an opportunity to showcase more of the newest aesthetic products within our programs for physicians to learn on first hand.<wbr>” </div><div>Source: Thomson Reuters and Empire Medical Training </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Neurology8252c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div>Merz North America announced today the appointment of Philippe Adams as Vice President, Managed Markets.<wbr> In this role, Adams will primarily be responsible for developing Merz's North American market access and reimbursement strategy </div></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20151231&edate=20150901&rec=8251">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-11-24T12:25:11+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-11-24T12:25:11+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: AZ Divests US Entocort® Rights to Perrigo for $380M</title>
	<pubDate>2015-11-24T11:41:54+01:00</pubDate>
	<wp:post_id>6692</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">AZ Divests US Entocort® Rights to Perrigo for $380M</span>&nbsp;<br><span style="font-size: 12px;">Comment: The agreement with Perrigo completes the global divestment of Entocort® (for mild to moderate CD).<wbr> Last July, AZ divested the drug to Tillots for $215M.<wbr> The progressive divestment of AZ in the GI area may potentially impact the development behind linaclotide in China (CFDA approval planned Q1:16).<wbr> Last month, Allergan acquired the EU rights of linaclotide, but with its recently announced merger with Pfizer it is not known wether it will divest the drug or buy its Chinese rights to AZ.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20151231&edate=20150901&rec=2670">...</a><br></div><div style="margin-bottom: 10px;">Under a WW collaboration signed in 2009 with Nektar, AstraZeneca has been responsible for all S&amp;M activities for MOVANTIK, the first once-daily, oral peripherally-acting mu-opioid receptor antagonist (PAMORA) medication for the treatment of opioid-induced constipation (OIC) in adult patients with chronic, non-cancer pain.<wbr> Given the recent divestment of Entocort, it is likely that AZ may consider a new positioning of the drug in its strategy.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Situation In the US</STRONG> </div><div style="margin-bottom: 10px;">Last March, AZ announced a $825M co-commercialisation agreement with Daiichi Sankyo for MOVANTIK™ in the US (launched in Spring 2015).<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Situation In EU</STRONG> </div><div style="margin-bottom: 10px;">In Q4:14 MOVENTIG® was granted Marketing Authorisation by the European Commission (EC).<wbr> See <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20151231&edate=20150901&rec=2153" class="defaultlink">GastroEnterology2153: AstraZeneca's Opioid-Induced Constipation Drug Cleared in EU</a>.<wbr> </div><div>On Nov 5 2015, alongside its financial results for Q3:15 AZ reported additional 2015 launches of MOVANTIK™ in Nordic countries, UK, Ireland, Germany, Canada.<wbr> The product already is launched in France; Italy and Spain.<wbr> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20151231&edate=20150901&rec=2672">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2670">View thread  GastroEnterology2670: AZ Divests US Entocort® Rights to Perrigo for $380M</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-11-24T11:41:54+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-11-24T11:41:54+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Galerma S.A Has Announced The Opening Of Its Branch Office In Dubai Healthcare City</title>
	<pubDate>2015-11-24T11:00:28+01:00</pubDate>
	<wp:post_id>6693</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Dubai will now be the regional Galderma HQ for the Middle East and Africa (MEA) led by Hesham AbdAllah, Regional Director.<wbr>  The purpose of this hub will be to establish closer links to customers as well as provide a gateway into Africa </div><div style="margin-bottom: 10px;">Galderma will now reach over 100 countries with 35 affiliates, 5 state-of-the-art R&amp;D centers and 6 manufacturing facilities </div><div style="margin-bottom: 10px;">Stuart Raetzman, CEO of Galderma S.<wbr>A, reported; “Ever since our inception we have been determined to arm the dermatology community with excellent products and trainings that can in turn help in treating patients with dermatological needs.<wbr> With an in depth understanding of skin issues pertinent to geographic, demographic and hereditary conditions; we aim to strengthen our portfolio and services to serve our patients and physicians even better in the Middle East and Africa region.<wbr> We also look forward to rapidly advancing and extending our services to mark our footprint in the Middle East and Africa.<wbr>” </div><div style="margin-bottom: 10px;">Can Ongen Regional Vice President Europe, Middle East and Africa, added “We see our Management Center in Dubai as a door opener for not only the Middle East but also Africa.<wbr> We will soon be opening more offices in the region which are planned steps towards Galderma’s vision of holistic healthcare and our long-term strategy, to enhance quality of life by delivering science-based solutions for the health of skin, hair and nails over the course of people’s lives.<wbr> </div><div>Source: Business wire </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20151231&edate=20150901&rec=8250">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-11-24T11:00:28+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-11-24T11:00:28+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Allergan And Pfizer Have Officially Announced A Merger Plan To Close 2H 2016</title>
	<pubDate>2015-11-23T16:12:29+01:00</pubDate>
	<wp:post_id>6694</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Both Allergan and Pfizer have issued a joint press release announcing the execution of an agreed Merger plan after the board of directors unanimously approved the agreement.<wbr> The merger comprises of a stock transaction currently valued at $363.<wbr>63 per Allergan share for a total enterprise value of approximately $160 billion.<wbr> Under the deal, Allergan shareholders will receive 11.<wbr>3 shares of the combined company for each of their shares, while Pfizer stockholders will receive one share of the combined company for each of their shares </div><div style="margin-bottom: 10px;">This combined company is positioned as a new global biopharmaceutical leader with over 100 mid-to-late stage programs in development.<wbr> Key outcomes of the deal include </div><div style="margin-bottom: 10px;">· The transaction is expected to close 2H 2016 with more than $2 billion in cost savings over the first three years </div><div style="margin-bottom: 10px;">· Thought to be neutral to Pfizer’s Adjusted Diluted EPS in 2017, accretive beginning in calendar year 2018 and more than 10% accretive in 2019 with high-teens percentage accretion in 2020 </div><div style="margin-bottom: 10px;">· Expect combined Operating Cash Flow in excess of $25 Billion beginning in 2018 </div><div style="margin-bottom: 10px;">· Increased financial flexibility facilitates continued investment in the United States </div><div style="margin-bottom: 10px;">· Pfizer anticipates that the combined company will have a pro forma Adjusted Effective Tax Rate<SUP> </SUP>of approximately 17%-18% by the first full year after the closing of the transaction </div><div style="margin-bottom: 10px;">· Following the transaction, and assuming that all $12 billion of cash is paid in the merger, it is expected that former Pfizer stockholders will hold approximately 56% of the combined company and Allergan shareholders will own approximately 44% of the combined company on a fully diluted basis.<wbr> </div><div style="margin-bottom: 10px;">Ian Read CEO of Pfizer announced <I>“The proposed combination of Pfizer and Allergan will create a leading global pharmaceutical company with the strength to research, discover and deliver more medicines and therapies to more people around the world.<wbr> Allergan’s businesses align with and enhance Pfizer’s businesses, creating best-in-class, sustainable, innovative and established businesses that are poised for growth.<wbr> Through this combination, Pfizer will have greater financial flexibility that will facilitate our continued discovery and development of new innovative medicines for patients, direct return of capital to shareholders, and continued investment in the United States, while also enabling our pursuit of business development opportunities on a more competitive footing within our industry.<wbr>” </I> </div><div style="margin-bottom: 10px;">Brent Saunders CEO of Allergan reported “<I>The combination of Allergan and Pfizer is a highly strategic, value-enhancing transaction that brings together two biopharma powerhouses to change lives for the better.<wbr> This bold action is the next chapter in the successful transformation of Allergan allowing us to operate with greater resources at a much bigger scale.<wbr> Joining forces with Pfizer matches our leading products in seven high growth therapeutic areas and our robust R&amp;D pipeline with Pfizer’s leading innovative and established businesses, vast global footprint and strength in discovery and development research to create a new biopharma leader.<wbr>” </I> </div><div style="margin-bottom: 10px;">The combined company will be renamed “Pfizer plc” and is expected to maintain Allergan’s Irish legal domicile while Pfizer plc will have its global operational headquarters in New York and its principal executive offices in Ireland.<wbr> Pfizer plc’s board is expected to have 15 directors, consisting of all of Pfizer’s 11 current directors and 4 current directors of Allergan; Paul Bisaro, Executive Chairman, Brent Saunders CEO, and two other directors from Allergan to be selected at a later date.<wbr> Ian Read, Pfizer’s Chairman and CEO, will serve as Chairman and CEO of the combined company.<wbr> Brent Saunders will serve as President and Chief Operating Officer of the combined company and will be responsible for the oversight of all Pfizer and Allergan’s combined commercial businesses, manufacturing and strategy functions.<wbr> </div><div style="margin-bottom: 10px;">Pfizer’s businesses will be significantly enhanced by the addition of Allergan’s revenue stream from therapeutic areas such as Aesthetics and Dermatology, Eye Care, Gastrointestinal, Neuroscience and Urology.<wbr> In addition Allergan’s Women’s Health and Anti-Infectives portfolio will add to Pfizer’s established business.<wbr> Allergan also brings topical formulation, manufacturing and its Anda distribution capabilities to the combined company.<wbr> </div><div style="margin-bottom: 10px;">The completion of the transaction, is subject to certain conditions, including: </div><div style="margin-bottom: 10px;">· Receipt of regulatory approval in certain jurisdictions, including the United States and European Union, </div><div style="margin-bottom: 10px;">· The receipt of necessary approvals from both Pfizer and Allergan shareholders; and </div><div style="margin-bottom: 10px;">· The completion of Allergan’s pending divestiture of its generics business to Teva Pharmaceuticals Ltd.<wbr>, which Allergan expects will close in the first quarter of 2016.<wbr> </div><div style="margin-bottom: 10px;">Pfizer is expected to make a decision about a potential separation of the combined company’s innovative and established businesses by no later than the end of 2018.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11315_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11315_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11315_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11315_1_ScreenCapture1.jpg"> </div><div>Source: Allergan and Thomson Reuters </div><!-- Comment details --><a name="pharmaworld11315attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11315_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(57,3 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11315_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(110,4 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11315_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(102,5 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11315_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(120,4 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20151231&edate=20150901&rec=11315">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-11-23T16:12:29+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-11-23T16:12:29+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>AZ Divests US Entocort® Rights to Perrigo for $380M</title>
	<pubDate>2015-11-23T16:08:46+01:00</pubDate>
	<wp:post_id>6695</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The agreement with Perrigo completes the global divestment of Entocort® (for mild to moderate CD).<wbr> Last July, AZ divested the drug to Tillots for $215M.<wbr> The progressive divestment of AZ in the GI area may potentially impact the development behind linaclotide in China (CFDA approval planned Q1:16).<wbr> Last month, Allergan acquired the EU rights of linaclotide, but with its recently announced merger with Pfizer it is not known wether it will divest the drug or buy its Chinese rights to AZ.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Strategic focus of the company on 3 main TAs </div><div style="margin-bottom: 10px;">Simplification of the supply chain </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Expands Perrigo's Rx extended topicals portfolio to include well-established gastrointestinal product and brand </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">US sales were $89M in the YTD (at nine months 2015) </div><div style="margin-bottom: 10px;">- formulated as delayed, extended release capsules and route of administration.<wbr> </div><div style="margin-bottom: 10px;">- also formulated as dispersible tablet administered through the rectal route in the form of suspension and indicated for ulcerative colitis involving rectal and recto-sigmoid disease </div><div>- indicated for the treatment of Crohn's Disease.<wbr> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="GastroEnterology2672c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">Under a WW collaboration signed in 2009 with Nektar, AstraZeneca has been responsible for all S&amp;M activities for MOVANTIK, the first once-daily, oral peripherally-acting mu-opioid receptor antagonist (PAMORA) medication for the treatment of opioid-induced constipation (OIC) in adult patients with chronic, non-cancer pain.<wbr> Given the recent divestment of Entocort, it is likely that AZ may consider a new positioning of the drug in its strategy.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Situation In the US</STRONG> </div><div style="margin-bottom: 10px;">Last March, AZ announced a $825M co-commercialisation agreement with Daiichi Sankyo for MOVANTIK™ in the US (launched in Spring 2015).<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Situation In EU</STRONG> </div><div style="margin-bottom: 10px;">In Q4:14 MOVENTIG® was granted Marketing Authorisation by the European Commission (EC).<wbr> See <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20151231&edate=20150901&rec=2153" class="defaultlink">GastroEnterology2153: AstraZeneca's Opioid-Induced Constipation Drug Cleared in EU</a>.<wbr> </div><div>On Nov 5 2015, alongside its financial results for Q3:15 AZ reported additional 2015 launches of MOVANTIK™ in Nordic countries, UK, Ireland, Germany, Canada.<wbr> The product already is launched in France; Italy and Spain.<wbr> </div></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20151231&edate=20150901&rec=2670">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-11-23T16:08:46+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-11-23T16:08:46+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Merck to Grow Consumer Health in Africa</title>
	<pubDate>2015-11-23T10:02:04+01:00</pubDate>
	<wp:post_id>6696</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Expanding the Consumer Health business in Africa is part of a broader strategy to more than double Merck's annual sales in the continent to about €500M ($535M) by 2020.<wbr> Management has reported that its Consumer Health business would invest in "selected countries in Africa" during 2016 to spread brands such as Seven Seas, Femibion and Neurobion.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Merck currently has approx 400 employees across 10 African countries and aims to increase this number to around 1,000 by 2020.<wbr> </div><div style="margin-bottom: 10px;"><U>Current Presence</U> </div><div style="margin-bottom: 10px;">The business offers a range of products in South Africa, including strategic brands such as the Iliadin nasal decongestant – known as Nasivin in other markets – and local brands such as the Slow-Mag slow-acting magnesium supplement.<wbr> </div><div>The Neurobion vitamin B brand, which is Merck Consumer Health's biggest brand worldwide, is available in a number of African countries including Angola, Ethiopia, Ghana, Kenya, Nigeria and South Africa.<wbr> And Seven Seas is available in Kenya.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20151231&edate=20150901&rec=2669">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-11-23T10:02:04+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-11-23T10:02:04+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Sanofi and AZ Ink Innovative Agreement</title>
	<pubDate>2015-11-20T17:14:42+01:00</pubDate>
	<wp:post_id>6697</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: AstraZeneca and Sanofi will exchange 210,000 compounds in order to boost their libraries and help launch more drug discovery programmes.<wbr> The deal has been reported to be the first of its kind for two major pharma companies.<wbr> No payment was associated with the compound exchange.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><P style="FONT-FAMILY: HelveticaNeue; COLOR: rgb(0,0,0)">Each company will receive sufficient quantities to enable high throughput screening for several years to determine whether they are active against specific biological targets AZ and Sanofi will also share chemical structures and synthetic procedures to facilitate the use of the compounds.<wbr></P> </div><div style="margin-bottom: 10px;"><P style="FONT-FAMILY: HelveticaNeue; COLOR: rgb(0,0,0)">Each company can investigate the compounds it receives without restrictions on disease areas.<wbr></P> </div><div><P style="FONT-FAMILY: HelveticaNeue; COLOR: rgb(0,0,0)">Source: WSJ</P> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20151231&edate=20150901&rec=11312">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-11-20T17:14:42+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-11-20T17:14:42+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>ObsEva SA Granted Exclusive Rights to Kissei's GnRH Antagonist for Endometriosis</title>
	<pubDate>2015-11-20T12:31:39+01:00</pubDate>
	<wp:post_id>6698</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: <A href="http://www.obseva.com/">ObsEva</A> (CEO: Ernest Loumaye) will develop and commercialize KLH-2109 (OBE2109) worldwide (excl.<wbr> Asia).<wbr> The investigational drug has completed three Ph2a in Japan in approx.<wbr> 140 patients with endometriosis.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">A Phase 2b study of OBE2109 versus Placebo in endometriosis is scheduled to start mid-2016.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">New chemical entity discovered by Kissei R&amp;D.<wbr> </div><div style="margin-bottom: 10px;">Phase 2a studies in Japan indicate that KLH-2109 induces a dose-dependent reduction in serum LH and estradiol, resulting in a reduction of endometriosis-associated pain and bleeding days.<wbr> </div><div>Source: Kissei; ObsEva </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20151231&edate=20150901&rec=10788">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-11-20T12:31:39+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-11-20T12:31:39+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Survey Results Indicate IBgard® is the #1 Gastroenterologist-Recommended Peppermint Oil for IBS</title>
	<pubDate>2015-11-20T12:11:21+01:00</pubDate>
	<wp:post_id>6699</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The survey also outlined that 83% of physicians are now recommending peppermint oil for their IBS patients, and that  IBgard® is by far the market leader with 64% of physician recommendations.<wbr> <A href="http://www.ibgard.com/">IBgard</A> has been provided by IM HealthScience in the U.<wbr>S (June 2015).<wbr> In August, the company appointed David Swenson to the newly created position of Vice President, Marketing and Operations to develop the commercial strategies and action plans for IBgard®.<wbr> Expanding its geo footprint to the Canadian market, the company announced last month the appointment of Stéphane Langevin (ex Sanofi Consumer Health) to the newly created position of General Manager.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">- privately held company based in Boca Raton, Florida (USA) </div><div style="margin-bottom: 10px;">- founded in 2010 by a team of highly experienced pharmaceutical research and development and management executives.<wbr> </div><div style="margin-bottom: 10px;">- focus: dedicated to developing products to address gastrointestinal issues where there is a high, unmet need, including Irritable Bowel Syndrome (IBS), Functional Dyspepsia, Ulcerative Colitis, and Crohn's Disease.<wbr> </div><div style="margin-bottom: 10px;">The IM HealthScience<SUP>® </SUP>advantage comes from developing products based on its patented, targeted-delivery technologies called Site Specific Targeting (SST<SUP>®</SUP>) </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The survey was conducted among 202 U.<wbr>S.<wbr> gastroenterologists by AlphaImpactRx using its ProVoice survey methodology </div><div style="margin-bottom: 10px;"><UL><LI>AlphaImpactRx is the leading provider of primary research-based insights, analytics and solutions to biopharmaceutical, consumer health and medical device companies.<wbr></LI>
<LI>ProVoice has the largest sample size of any professional healthcare survey in the U.<wbr>S.<wbr>, with nearly 60,000 respondents across physicians, nurse practitioners, physician assistants, optometrists, dentists and hygienists, measuring recommendations across more than 120 over-the-counter categories.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG>About  IBgard®</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2667_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20151231&edate=20150901&rec=2594" class="defaultlink">GastroEnterology2594: New Clinical Data on IBgard® Presented @ ACG</a> </div><div><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20151231&edate=20150901&rec=2362" class="defaultlink">GastroEnterology2362: OTC Product for IBS-D to be Launched Next Month in the U.<wbr>S</a> </div><!-- Comment details --><a name="gastroenterology2667attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2667_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(49,8 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20151231&edate=20150901&rec=2667">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-11-20T12:11:21+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-11-20T12:11:21+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Camurus Plans IPO To Raise $258m</title>
	<pubDate>2015-11-19T19:44:31+01:00</pubDate>
	<wp:post_id>6700</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Reuters confirms today the planned IPO of Swedish company Camurus on the Stockholm Bourse.<wbr> The listing of the shares is planned for December 3rd.<wbr> The prospectus issued with the listing includes positive statements by Camurus regarding the postive attributes of CAM2029 and notes that phIII trials to be undertaken by Novartis in acromegaly and NET are in planning.<wbr> Another pipeline product highlighted in the prospectus is CAM2038 a long-acting fluid cyrstal formulation for treating opiod additiction, partnered with Braeburn.<wbr> This product received fast-track designation from the US last week.<wbr> Specific quotes from the prospectus noting timelines, formulation specifics and device features are shown below.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Key Quotes </STRONG> </div><div style="margin-bottom: 10px;">"Camurus's partner Novartis Pharma AG ("Novartis") has prepared phIII trials of CAM2029 for the treatment of acromegaly and neuroendocrine tumours, which are scheduled to commence subject to Novartis successful completion of manufacturing and confirmation of stability of the final prefilled syringe product format.<wbr> Camurus's assessment is that the phIII programs for ACRO &amp; NET will be completed within 3.<wbr>5 years from study start" estimated Q1/<wbr>Q2 2016 (source external intelligence).<wbr> </div><div style="margin-bottom: 10px;">"Camurus also notes that the development of CAM2029 is delayed in comparison with the indicative development plan from when the parties entered into the collaboration, option and license agreement in December 2011.<wbr> The delay is primarily related to the transition to Novartis's final product format for CAM2029 with confirmed stability and there is always the risk that develompent activities are delayed further which if materialised would result in a materially adverse effect on Camurus's operations, financial position and earnings.<wbr>" </div><div style="margin-bottom: 10px;">"In the US, part of the strategy for obtaining market approval for the company's products including CAM2029 and CAM2038 is to apply to the US FDA for approval via a simplified drug approval pathway know as 505(b)2 which is based on utilising existing and available data for the safety and efficacy of the active substance established for a reference product.<wbr> This may entail that the scope of preclinical and clinical registration programme could be reduced since reference may be made to pre-existing data.<wbr>" </div><div style="margin-bottom: 10px;">"CAM 2029 has demonstrated around 500% higher octreotide bioavailability compared to Sandostatin LAR which might enhance treatment efficacy in patients who do not respond satisfactorily to Sandostatin LA.<wbr> CAM2029 also demonstrates considerably faster absorption of octreotide and thus a more rapid initial suppression of high IGF-1 levels.<wbr> Therefore, this leads to a faster therapeutic effect compared with Sandostatin LAR where treatment efficacy is not achieved for one-two weeks due to the delay in octreotide absorption.<wbr>" </div><div style="margin-bottom: 10px;"><STRONG>Camurus Pipeline </STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8282_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8282_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;">A full copy of the IPO prospectus is attached.<wbr> </div><div>Source: <A href="http://www.camurus.com">www.<wbr>camurus.<wbr>com</A> </div><!-- Comment details --><a name="endocrinology8282attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8282_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(109,6 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8282_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(113,6 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8282_3_Prospectus%255fCamurus%255fIPO.pdf">Prospectus_Camurus_IPO.pdf</a>&nbsp;&nbsp;(2,5 MB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20151231&edate=20150901&rec=8282">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-11-19T19:44:31+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-11-19T19:44:31+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>StemCells Inc Claims Spinal Injury Therapy Shows Promising Improvement In Motor Function In PhII Study</title>
	<pubDate>2015-11-19T15:00:01+01:00</pubDate>
	<wp:post_id>6701</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: StemCells Inc has announced that interim six-month results from the first cohort treated in its ongoing Phase II Pathway™ Study in cervical spinal cord injury (SCI) showed upper limb motor improvements in both strength and function.<wbr> </div><div style="margin-bottom: 10px;"><P align="justify"><STRONG>Background</STRONG></P> </div><div style="margin-bottom: 10px;"><P align="justify">Patients eligible for the study have complete loss of motor control below the level of injury, the most severe degree of SCI as defined by the American Spinal Injury Association Impairment Scale (AIS).<wbr> Clinicians used both ISNCSCI (International Standards for Neurological Classification of Spinal Cord Injury) and GRASSP (Graded Assessment of Strength Sensibility and Prehension) measures to establish a pre-transplant baseline for each patient and to assess post-transplant progress.<wbr></P> </div><div style="margin-bottom: 10px;"><P align="justify">This first cohort of the Pathway Study was designed to assess the safety, and preliminary signs of efficacy, of cell administration into the cervical cord and select the dose level for the 40-patient second cohort, a randomized, controlled and single-blinded arm of the trial, which is already underway.<wbr></P> </div><div style="margin-bottom: 10px;"><P align="justify"><STRONG>Key Outcomes</STRONG></P> </div><div style="margin-bottom: 10px;"><P align="justify">Based on six-month follow-up, for the first cohort, an overall pattern of motor improvement was detected in four of the six patients as measured by gains in both strength and function on the collective ISNCSCI and GRASSP outcomes</P> </div><div style="margin-bottom: 10px;"><UL><LI>Muscle strength was improved in five of the six patients.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI>Four of the five patients with gains in muscle strength also demonstrated improved performance on functional tasks assessing dexterity and fine motor skills.<wbr> </LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI>Four of the six patients had improvement in the spinal level of injury as defined by the ISNCSCI assessment; three upgraded one level and one upgraded two levels.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI>Based on a Patient Global Impression of Change (PGIC) assessment, four of the six patients reported that their condition had improved post-transplant.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI>Changes in muscle strength and function were observed around three months post-transplant, consistent with the onset of sensory improvements seen in the Company's Phase I/<wbr>II thoracic study.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI>No adverse events were attributed to the cells.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI>The timing of the transplants ranged from ten to 23 months post-injury.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG>Key Investigator &amp; Company Remarks</STRONG> </div><div style="margin-bottom: 10px;"><P align="justify">Armin Curt, MD, the principal investigator at the <ORG>University of Zurich</ORG> for the Company’s previous Phase I/<wbr>II thoracic spinal cord injury study has noted that.<wbr> “These findings are even more compelling given that all the patients are between one and two years post injury.<wbr>”</P> </div><div style="margin-bottom: 10px;"><P align="justify">“We do not expect to see spontaneous recovery in spinal cord injury patients more than a year after their injury,” added StemCells’ CMO and Vice President, Clinical Research, <PERSON>Stephen Huhn</PERSON>, M.<wbr>D.<wbr>, FACS, FAAP.<wbr> “The improvements in upper extremity muscle strength and function can be seen in specific tasks such as opening a jar, picking up coins or grasping and turning a key.<wbr>"</P> </div><div><P align="justify"> From <A href="http://investor.stemcellsinc.com/">http:/<wbr>/<wbr>investor.<wbr>stemcellsinc.<wbr>com</A>, see <A href="http://investor.stemcellsinc.com/phoenix.zhtml?c=86230&amp;p=RssLanding&amp;cat=news&amp;id=2113751">original source</A>.<wbr></P> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20151231&edate=20150901&rec=8249">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-11-19T15:00:01+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-11-19T15:00:01+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Europe Was the Main Driver of Merck Consumer Health's 5.6% Organic Sales Growth in Q3</title>
	<pubDate>2015-11-19T13:49:10+01:00</pubDate>
	<wp:post_id>6702</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Consumer Health accounted for 11.<wbr>7% of Merck's Healthcare sales in Q3:15, which were up by 1.<wbr>4% to €1.<wbr>71 billion.<wbr> The company has reported that Europe generated 51% of Consumer Health's sales in the quarter, up from 46% in the same period a year earlier.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2666_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Neurobion and Dolo-Neurobion</STRONG> had been the main drivers of organic sales growth.<wbr> <STRONG>The Neurobion vitamin B</STRONG> brand achieved organic sales growth of 10.<wbr>2% in the third quarter, but sales were flat at €64 million (US$69 million) once the effect of currency translations was included.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Worldwide sales at the business fell by 2.<wbr>3% to €200 million, after a negative currency effect of 7.<wbr>9% was taken into account.<wbr> Merck said the currency effect was "especially caused by the translation of the Venezuelan bolivar".<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div>Merck said organic sales growth in the nine months had mainly been generated in Latin America, where the increase was 14.<wbr>1%.<wbr> The company noted that new marketing approaches had fuelled demand, especially for <STRONG>Neurobion in Latin America</STRONG>.<wbr> </div><!-- Comment details --><a name="gastroenterology2666attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2666_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(65,3 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20151231&edate=20150901&rec=2666">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-11-19T13:49:10+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-11-19T13:49:10+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Pfizer & Merck KgaA Trump Other IO Companies With Breakthrough Designation In Merkel Cell Carcinoma</title>
	<pubDate>2015-11-18T19:17:41+01:00</pubDate>
	<wp:post_id>6703</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment:Merck KGaA and Pfizer have announced that the US FDA has granted avelumab, a fully human anti-PD-L1 IgG1 monoclonal antibody, Breakthrough Therapy designation for the treatment of patients with metastatic Merkel cell carcinoma (MCC) who have progressed after at least one previous chemotherapy regimen.<wbr> The homing in on this indication has given Merck KGaA and Pfizer an opportunity to leapfrog rivals, at least in a small corner of the PD-L1 market.<wbr> Merck KGaA believes avelumab can also claim a spot among the first immunotherapies to win approval for the treatment of ovarian, gastric, bladder and renal cancers.<wbr> </div><div style="margin-bottom: 10px;">Basis For Breakthrough Designation </div><div style="margin-bottom: 10px;">The two companies are conducting phII study named JAVELIN.<wbr> It is a multicenter, single-arm, open-label Phase II study with a primary objective of overall response rate.<wbr> Secondary endpoints include duration of response, progression-free survival, overall survival and safety.<wbr> The study, which has enrolled 88 patients, is being conducted in sites across Asia Pacific, Australia, Europe and North America.<wbr> </div><div style="margin-bottom: 10px;">The regulator gained the impression that avelumab may be able to help such patients after getting an early look at data from an 88-person Phase II clinical trial, the full readout from which is due for publication next year.<wbr> </div><div style="margin-bottom: 10px;">In less than two months, the alliance between Merck KGaA, Darmstadt, Germany, and Pfizer has achieved its third regulatory milestone for avelumab, including Orphan Drug designation and Fast Track designation granted in September and October.<wbr> </div><div>Source: <A href="http://www.pfizer.com">www.<wbr>pfizer.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20151231&edate=20150901&rec=8274">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-11-18T19:17:41+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-11-18T19:17:41+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>IMS Health Study Forecasts Global Spending On Medicines To Rise By 30% By 2018 To $1.3 Trillion</title>
	<pubDate>2015-11-18T18:59:11+01:00</pubDate>
	<wp:post_id>6704</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: A newly published study by IMS titled "The Global Outlook For Medicine Through 2018" has forecast that global spending is forecast to grow at 4-7% CAGR over the next five years with most countries experiencing an increase in drug expenditure per capita.<wbr> More specialty drug innovation, greater patient access to medicines and reduced impact from patent expiries will be the primary drivers of an increase in global medicine spending.<wbr> </div><div style="margin-bottom: 10px;">The increase in annual spending will spike this year when absolute growth will be about $70 billion, up from $44 billion in 2013 and $26 billion in 2012.<wbr> Spending is measured at the ex-manufacturer level before adjusting for rebates, discounts, taxes and other adjustments that affect net sales received by manufacturers.<wbr> The impact of these factors is estimated to reduce growth by $60-80 billion, or approximately 25 percent of the growth forecast over the next five years.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Key Highlights Of The Report</STRONG> </div><div style="margin-bottom: 10px;"><UL><LI><B>Growth in spending in developed markets will spike in 2014-15.<wbr></B> The greater contribution to growth from developed countries through 2018 is being led by the U.<wbr>S.<wbr> and Japan, with France, Germany, Spain, U.<wbr>K.<wbr> and Italy maintaining relatively low growth levels.<wbr> While these markets will moderate as cost-containment measures further limit price levels, rising volumes will continue to contribute to overall market growth.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI><B>Spending on medicines in pharmerging markets will rise more than 50 percent over the next five years.<wbr></B> The 21 pharmerging countries that now account for 25 percent of global spending on medicines will continue to broaden access to treatments as their economies expand and governments advance efforts to provide universal health coverage.<wbr> More than 80 percent of the forecasted growth in drug spending will be for non-branded medicines, including greater use of biologic therapies.<wbr> China, already the world’s second largest pharmaceutical market, will reach spending levels of $155-185 billion in 2018.<wbr> Implementation of health reforms is increasing demand for medicines, while pricing regulations are being used more frequently to manage overall growth levels.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI><B>Specialty medicines will contribute a projected 40 percent of total global spending growth through 2018.<wbr></B> Higher spending on specialty medicines is expected over the next five years, particularly in developed markets.<wbr> Much of this growth is from medicines bringing new treatment options to patients, including breakthrough therapies or even cures that often reduce complications or hospitalizations while improving outcomes.<wbr> Advances will be particularly notable in the oncology, autoimmune, respiratory, anti-virals and immunosuppressants therapy areas.<wbr> The surge in cancer drug innovation in recent years will continue and contribute to global spending on all oncology drugs—reaching about $100 billion in 2018, up from $65 billion last year.<wbr> The introduction and uptake of potent new medicines for treating Hepatitis C are expected to result in about $100 billion in total spending over the five-year period ending 2018.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI><B>Nearly 200 new drugs are forecast to be launched in the next five years.<wbr></B> A high number of new molecular entities (NMEs) are expected to be launched annually, continuing a second wave of innovation similar to levels seen in the mid-2000s.<wbr> More than 2,000 products are currently in late-stage clinical development, of which oncology therapies make up fully one-fourth of that total.<wbr> The growing number of medicines receiving the U.<wbr>S.<wbr> Food &amp; Drug Administration’s Breakthrough Therapy Designation is contributing to an acceleration of approvals.<wbr> The availability of new medicines to patients around the world, however, varies significantly by country and disease: on average, fewer than half of the medicines initially launched over the prior five years are available across the major developed markets.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;">The full report, including a detailed description of the methodology, is available at <A href="http://www.theimsinstitute.org/">www.<wbr>theimsinstitute.<wbr>org</A>.<wbr> It can also be downloaded as an app via iTunes at <A href="https://itunes.apple.com/app/ims-institute/id625347542" target="_blank">https:/<wbr>/<wbr>itunes.<wbr>apple.<wbr>com/<wbr>app/<wbr>ims-institute/<wbr>id625347542</A>.<wbr> The study was produced independently as a public service, without industry or government funding.<wbr> </div><div>From <A href="https://customerportal.imshealth.com/">https:/<wbr>/<wbr>customerportal.<wbr>imshealth.<wbr>com</A>, see <A href="https://customerportal.imshealth.com/portal/site/imsportal/menuitem.ed898ffec3ce21e8902eb452a418c22a/?vgnextoid=8269f454d4ac9410VgnVCM10000076192ca2RCRD&amp;vgnextchannel=cef40db9e2e97110VgnVCM10000071812ca2RCRD&amp;vgnextfmt=defaulten">original source</A>.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20151231&edate=20150901&rec=11311">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-11-18T18:59:11+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-11-18T18:59:11+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Microbiota Suspension Drug Has Entered Ph2b Trial for Recurrent CDI Infection</title>
	<pubDate>2015-11-18T16:07:33+01:00</pubDate>
	<wp:post_id>6705</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Microbiota Suspension Drug Has Entered Ph2b Trial for Recurrent CDI Infection</span>&nbsp;<br><span style="font-size: 12px;">Comment: Fecal transplantation is gaining increasing acceptance as an effective method of treating recurrent Clostridium difficile infection (CDI).<wbr> However, there are many unknowns about the therapy including questions about administration.<wbr> Administration via colonoscopy, nasogastric or nasoduodenal tube, and enema have been reported in the literature.<wbr> Definitive superiority has not been established for any one method.<wbr> <SPAN style="FONT-FAMILY: arial, helvetica, sans-serif"></SPAN></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20151231&edate=20150901&rec=2142">...</a><br></div><div style="margin-bottom: 10px;">Rebiotix has announced the completion for enrollment of the Ph2b.<wbr>  A total of 117 patients recruited at more than 20 sites in the U.<wbr>S.<wbr> and Canada were enrolled in the study, which is the largest randomized controlled study of a Microbiota Restoration Therapy (MRT) for recurrent <EM>C.<wbr> diff.<wbr></EM> to date.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>New Timelines</STRONG> </div><div style="margin-bottom: 10px;">As a consequence of the delay in the recruitment, new timelines have been postponed to three months.<wbr> </div><div><TABLE border="0" cellpadding="0" cellspacing="0" class="layout_table" style="margin-bottom: 3ex;" summary="Layout table for enrollment information"><TBODY><TR valign="top"><TD headers="enrollmentInfoTitle" nowrap="nowrap">Estimated Study Completion Date:</TD>
<TD headers="enrollmentInfoData" style="padding-left: 1em;">October 2017</TD>
</TR>
<TR valign="top"><TD headers="enrollmentInfoTitle" nowrap="nowrap">Estimated Primary Completion Date:</TD>
<TD headers="enrollmentInfoData" style="padding-left: 1em;">October 2015 (Final data collection date for primary outcome measure)</TD>
</TR>
</TBODY>
</TABLE> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20151231&edate=20150901&rec=2665">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2142">View thread  GastroEnterology2142: Microbiota Suspension Drug Has Entered Ph2b Trial for Recurrent CDI Infection</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-11-18T16:07:33+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-11-18T16:07:33+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Preliminary Evidence That Merkel Cell Carcinoma May Respond To PRRT</title>
	<pubDate>2015-11-17T14:52:59+01:00</pubDate>
	<wp:post_id>6706</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: An anecdotal report of Metastatic Merkel Cell Carcinoma responding favourably to PRRT with 177Lu-Dotatate is reported in the latest issue of the Journal of Nuclear Medicine Technology.<wbr> The authors suggest that PRRT could evolve into a useful earlier line of therapy for patients with SSA receptor avidity.<wbr> </div><div style="margin-bottom: 10px;">The patient concerned demonstrated systemic disease progression following second surgery and adjuvant radiotherapy to head and neck and chemotherapy and hence was considered for PRRT.<wbr> The metastatic lesions demonstrated both SSTR &amp; FDG avidity in the pre-treatment diagnostic study.<wbr> Scan evidence indicated a partial response at 3 months prior to the patient being worked up for a second cycle of PRRT.<wbr> </div><div>Source:Sandip Basu &amp; Rohit Ranade J.<wbr> Nucl.<wbr> Med.<wbr> Technol October 15th 2015 115.<wbr>163527 </div><!-- Comment details --><a name="endocrinology8273attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8273_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(34,2 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20151231&edate=20150901&rec=8273">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-11-17T14:52:59+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-11-17T14:52:59+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: BMS Has Initatied EU Approval Submission Process For Nivolumab In RCC</title>
	<pubDate>2015-11-17T12:10:30+01:00</pubDate>
	<wp:post_id>6707</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">BMS Has Initatied EU Approval Submission Process For Nivolumab In RCC</span>&nbsp;<br><span style="font-size: 12px;">Comment: BMS annouced the EMA validated a type II variation application, which seeks to extend the current indication for Opdivo to include the RCC indication.<wbr> The submission is complete and the EMA's centralized revciew process has now begun.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20151231&edate=20150901&rec=10779">...</a><br></div><div style="margin-bottom: 10px;">The FDA has granted a priority review designation to nivolumab for patients with advanced RCC following prior antiangiogenic therapy, based on an extension in OS in the CheckMate-025 trial.<wbr> The final decision date appears to be March 2016.<wbr> </div><div>Source: OncLive </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20151231&edate=20150901&rec=10785">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10779">View thread  Oncology10779: BMS Has Initatied EU Approval Submission Process For Nivolumab In RCC</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-11-17T12:10:30+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-11-17T12:10:30+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Synergy Pharm. Appoints New CFO</title>
	<pubDate>2015-11-16T17:51:41+01:00</pubDate>
	<wp:post_id>6708</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Gary Sender has joined as Executive VP and CFO.<wbr> The company is approaching regulatory filing next year of plecanatide, with a launch planned for early 2017.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Gary Sender has over 25 years of financial leadership experience in the pharmaceutical and biopharmaceutical industries, most recently at Shire plc.<wbr> </div><div style="margin-bottom: 10px;">From 2009-2015, Mr.<wbr> Sender served as Senior Vice President, Finance supporting its Specialty Pharmaceuticals business and subsequently its Global Commercial businesses.<wbr> </div><div style="margin-bottom: 10px;">He was responsible for financial management and support of all commercial areas of Shire’s $6 billion Specialty Pharmaceutical and Rare Disease businesses, including the Gastroenterology Business Unit, with an emphasis on resource allocation, financial forecasting, business cases and M&amp;A.<wbr> Prior to joining Shire, he was the founding CFO of Tengion – a biotechnology company in the field of Regenerative Medicine.<wbr> Mr.<wbr> Sender spent 15 years in a number of leadership roles within Merck, including Investor Relations, M&amp;A Finance, Treasury and Divisional Financial Management.<wbr> Mr.<wbr> Sender holds a bachelor’s degree in Finance and Information Systems from Boston University and a master’s degree in Industrial Administration (MBA) with a concentration in Finance from Carnegie-Mellon University </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><U>MOA</U>: uroguanylin analog </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2663_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><U>Dev Program</U>: currently in late-stage clinical development for the treatment of chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C).<wbr> </div><div style="margin-bottom: 10px;"><U>Reg Timelines</U> </div><div><UL><LI>first plecanatide NDA for CIC and intend to file with the FDA in January 2016.<wbr></LI>
<LI>second plecanatide NDA for IBS-C and iintend to file with the FDA by year-end 2016.<wbr></LI>
</UL> </div><!-- Comment details --><a name="gastroenterology2663attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2663_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(41 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20151231&edate=20150901&rec=2663">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-11-16T17:51:41+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-11-16T17:51:41+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Probi Expands the Scope of its Probiotic Platform</title>
	<pubDate>2015-11-16T11:19:49+01:00</pubDate>
	<wp:post_id>6709</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Probi is now launching a new probiotic iron absorption product, <A href="http://probiferrosorb.com/">Probi FerroSorb</A>®, a supplement for preventive use targeting women of childbearing age at risk of iron deficiency.<wbr> The product will be available through partners WW, and the first market launch is planned for the beginning of 2016.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Probi FerroSorb® formulated into a capsule is a combination of the clinically documented lactic acid bacteria LP299V®, vitamin C, folic acid and a carefully balanced amount of iron.<wbr> </div><div style="margin-bottom: 10px;">One capsule daily with the main meal will help to meet iron requirements, while leaving a minimal amount of unabsorbed iron in the intestines.<wbr> Probi FerroSorb® solves iron deficiency in a completely new way, by increasing the uptake – not only the intake.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Advantage</STRONG> </div><div style="margin-bottom: 10px;">Manageemnt reports in the PR that - FerroSorb® reduced risk of side effects normally seen with traditional iron supplement.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div>Probi FerroSorb®has also been nominated to the Food Ingredients Europe Innovation Awards 2015, in the category ‘Best Functional Innovation’.<wbr> The winner will be announced at the FiE event in Paris in December 2015.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20151231&edate=20150901&rec=2661">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-11-16T11:19:49+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-11-16T11:19:49+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Chiasma Q3 2015 Results and Mycapssa Plans for US and EU</title>
	<pubDate>2015-11-13T12:59:50+01:00</pubDate>
	<wp:post_id>6710</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Chiasma discussed the Q3 2015 results focusing on the patients advantages for taking oral Mycapssa over somatostatin injections.<wbr> Chiasma also confirmed that two weeks ago the EMA has accepted the design for the Phase 3 trial to be carried out in EU, US and other locations that will support the EU approval in acromegaly.<wbr> The trial is to be initiated by early in the second quarter of 2016 (later than what initially planned Chiasma commented), approx.<wbr> 150 patients to be enrolled.<wbr> Chiasma is committed to apply the TPE technology to NET and other indications.<wbr> On the US approval, Chiasma commented to be heavily involved in discussion with the FDA and has clearly stated that Mycapssa will not require to go under advisory committee review.<wbr> The FDA has not raised any safety issue.<wbr> Therefore the April 2016 approval seems very likely.<wbr> On the financial side, Chiasma is expecting to end 2015 with $145 million to $150 million in cash, cash equivalents &amp; marketable securities.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8270_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8270_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8270_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8270_5_ScreenCapture5.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8270_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;">· Approx 150 patients to be enrolled </div><div style="margin-bottom: 10px;">· Patients can be on either octreotide LAR or lanreotide </div><div style="margin-bottom: 10px;">· EMA did not specify the geographic % spread — study run mainly in EU, US and other countries (not specified) </div><div style="margin-bottom: 10px;">· This is a double arm study versus the previous Phase III study </div><div style="margin-bottom: 10px;">· EMA wanted 9 month randomized controlled phase versus the proposed 6 months </div><div style="margin-bottom: 10px;">· 6 months run-in phase starting from 40mg up to 80 mg/<wbr>day </div><div style="margin-bottom: 10px;">· EMA wanted multiple primary endpoints and checks along the way (did not want to comment during the Q&amp;A session) </div><div style="margin-bottom: 10px;">· EMA accepted the same IGF-1 level cut off as the previous Phase III </div><div style="margin-bottom: 10px;">· All patients are eligible to extend the treatment if responsive </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">· Chiasma has clearly stated the intention to target mainly nurses as very close to patients </div><div style="margin-bottom: 10px;">· Chiasma has highlighted how patients are at the centre of their marketing campaign (mentioned also acromegaly.<wbr>care launch and supported by Chiasma) </div><div style="margin-bottom: 10px;">· Chiasma wants to have patient support services putting in place a trained and compassionate team for personal cure — services mapped to current unmet needs to follow the symptoms and the management of disease </div><div style="margin-bottom: 10px;">· Patents issued and pending protect Mycapssa through 2029 </div><div style="margin-bottom: 10px;"><EM>Source: Chiasma Q3 2015 webcast — posted on behalf of Giorgia Vicentini</EM> </div><div><STRONG></STRONG> </div><!-- Comment details --><a name="endocrinology8270attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8270_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(106,8 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8270_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(104,2 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8270_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(79,8 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8270_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(46,9 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8270_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(113,2 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8270_6_Chiasma%255fQ3%202015.pdf">Chiasma_Q3 2015.pdf</a>&nbsp;&nbsp;(546,7 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20151231&edate=20150901&rec=8270">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-11-13T12:59:50+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-11-13T12:59:50+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Merz Releases Positive Fiscal 2014/2015 Results Supported By Expansion Into Emerging Markets</title>
	<pubDate>2015-11-13T12:19:02+01:00</pubDate>
	<wp:post_id>6711</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Merz, a privately held company has reported record sales in the fiscal 2014/<wbr>2015 year with a 16.<wbr>4% increase from last year </div><div style="margin-bottom: 10px;">Key financial figures are as follows </div><div style="margin-bottom: 10px;">· EBIT increased to €255.<wbr>6M, 3.<wbr>4% above last year </div><div style="margin-bottom: 10px;">· Record sales of €1,157.<wbr>0M, rise of 16.<wbr>4% from last year </div><div style="margin-bottom: 10px;">· Group revenue <B>€</B>1,157.<wbr>0M up 16.<wbr>4% from last year (€94.<wbr>0M) </div><div style="margin-bottom: 10px;">· The Consumer Care segment sales of €69.<wbr>9M, an increase of €2.<wbr>1M </div><div style="margin-bottom: 10px;">· Group-wide research and development spend was €148.<wbr>8M, €1.<wbr>9M higher than last year </div><div style="margin-bottom: 10px;">· Over 50% of product sales came from core areas aesthetics and special neurology </div><div style="margin-bottom: 10px;">The key drivers for growth were attributed to the new realigned strategy of a focussed outlook on aesthetics and speciality neurology which was reported to account for more than half of the group’s revenue.<wbr> Multiple recent acquisitions, mainly in the aesthetic field, have contributed to this position including Ulthera which was considered one of the large growth drivers with <B>€</B>100M </div><div style="margin-bottom: 10px;">Philip Burchard, CEO stated <I>“Fiscal year 2014/<wbr>15 marks a strategic milestone for Merz, our revenues and EBIT have far exceeded our forecasts.<wbr> We have succeeded in generating more than half our product sales from our core business areas.<wbr> At the same time, our attractive product pipeline made exceptional progress.<wbr> As a result of new product launches in particular, we are ideally positioned in many markets to continue our growth strategy into the future as well.<wbr> Merz has set its sights high but, backed by our well-stocked product pipeline and our expansion into new countries, we are well-equipped for the future.<wbr> We are very confident that, with our focus on the core business areas of aesthetics and special neurology, we are pursuing the right strategy for the company.<wbr>”</I> </div><div style="margin-bottom: 10px;">The overall spend for R&amp;D for the group increased from last year with continued development in neurotoxins Xeomin/<wbr>Bocouture.<wbr> In addition, there remains to be multiple development products in the aesthetic market.<wbr> </div><div style="margin-bottom: 10px;">Strong expansion in emerging markets with €391.<wbr>4M sales from EMEA region, €325.<wbr>2M from North America, €61.<wbr>9M from the Asia-Pacific region and €47.<wbr>2M from Latin America.<wbr> Merz has continued to expand with new subsidiaries in Malaysia, the Philippines, India, Thailand, Indonesia and Vietnam with 64% of headcount outside of Germany.<wbr> In particular, expansion into LATAM has seen the likes of Xeomin previously marketed by Phoenix, now being commercialized by Merz with all other Merz products continuing to go through this distributer.<wbr> The expansion includes operations in Colombia, Ecuador, El Salvador, Guatemala, Panama, Peru and Venezuela.<wbr> The company predicts USD 2.<wbr>5M in sales during its first year of recently started operations in Colombia.<wbr> The company invested USD 2M to promote its products amongst neurologists and other specialized doctors.<wbr> </div><div style="margin-bottom: 10px;">In regards to future growth, Merz plans to invest up to EUR 25M by way of corporate venture capital in start-up companies or research projects in an early development stage within the aesthetics sector.<wbr> Merz is further supported by a syndicated loan that it secured in May of this year which comprises of €200M borrowing facility that can be increased up to €500M should Merz need to access capital quickly.<wbr> In addition, Merz GmbH &amp; Co.<wbr> KGaA, the parent of the Merz Pharma Group, has a high equity ratio of 71.<wbr>7%.<wbr> </div><div style="margin-bottom: 10px;">This outlook places Merz in a strong position to not only support growth through development but also to have a greater global reach </div><div>Source: Merz and GBI </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20151231&edate=20150901&rec=8245">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-11-13T12:19:02+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-11-13T12:19:02+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Enterome Has Inked Cancer Microbiome Deal with Institut Gustave Roussy (IGR)</title>
	<pubDate>2015-11-13T09:00:58+01:00</pubDate>
	<wp:post_id>6712</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Enterome Bioscience S.<wbr>A.<wbr> (Paris, France) and Institut Gustave Roussy (Villejuif, France) will develop immuno-oncology therapies.<wbr> The partners would seek to develop vaccines and diagnostics derived from bacterial components of the gut microbiome that appear to mimic tumoral antigens.<wbr> Researchers at Gustave Roussy published a paper in <I><I>Science</I></I> last week suggesting that the efficacy of <A href="https://www.sciencemag.org/content/early/2015/11/04/science.aad1329.short?cited-by=yes&amp;legid=sci;science.aad1329v1">CTLA-4</A> blockade in a mouse cancer model is dependent on the presence of <I><I><I>Bacteroides fragilis</I></I></I>.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Enterome retains commercialization rights to all drug candidates in the partnership, which are preclinical.<wbr> </div><div style="margin-bottom: 10px;">Specific drug candidates and targets were not disclosed, as well as the financial details.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><U>Reference</U></STRONG> </div><div style="margin-bottom: 10px;">Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota (<A href="https://www.sciencemag.org/content/early/2015/11/04/science.aad1329.short?cited-by=yes&amp;legid=sci;science.aad1329v1">https:/<wbr>/<wbr>www.<wbr>sciencemag.<wbr>org/<wbr>content/<wbr>early/<wbr>2015/<wbr>11/<wbr>04/<wbr>science.<wbr>aad1329.<wbr>short?cited-by=yes&amp;legid=sci;science.<wbr>aad1329v1</A>).<wbr> </div><div><U>Abstract </U>Antibodies targeting CTLA-4 have been successfully used as cancer immunotherapy.<wbr> We find that the antitumor effects of CTLA-4 blockade depend on distinct <EM>Bacteroides</EM> species.<wbr> In mice and patients, T cell responses specific for <EM>B.<wbr> thetaiotaomicron</EM> or <EM>B.<wbr> fragilis</EM> were associated with the efficacy of CTLA-4 blockade.<wbr> Tumors in antibiotic-treated or germ-free mice did not respond to CTLA blockade.<wbr> This defect was overcome by gavage with <EM>B.<wbr> fragilis</EM>, or by immunization with <EM>B.<wbr> fragilis</EM> polysaccharides, or by adoptive transfer of <EM>B.<wbr> fragilis</EM>-specific T cells.<wbr> Fecal microbial transplantation from humans to mice confirmed that anti–CTLA-4 treatment of melanoma patients favored the outgrowth of <EM>B.<wbr> fragilis</EM> with anticancer properties.<wbr> This study reveals a key role for <EM>Bacteroidales</EM> in the immunostimulatory effects of CTLA-4 blockade.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20151231&edate=20150901&rec=2660">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-11-13T09:00:58+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-11-13T09:00:58+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Biosyent Now Has The Commercialisation Right In Canada For Cystview From Photocure</title>
	<pubDate>2015-11-12T17:55:38+01:00</pubDate>
	<wp:post_id>6713</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Biosyent Inc (a niche Canadian pharmceutical company) annouced during its Q3 earning presentation that the company signed an exclusive license agreement to sell Cysview® in Canada.<wbr> The marketing authorisation was transferred to BioSyent Pharma and launch is expected in Q4.<wbr> The expected peak penetration revenues is said to be between $4-6 M annually.<wbr> </div><div style="margin-bottom: 10px;">BioSyent Inc.<wbr> is a specialty pharmaceutical company.<wbr> The company has a market cap of $97.<wbr>76 million.<wbr> The Company, through its subsidiary, BioSyent Pharma Inc.<wbr>, sources, acquires or in-licenses pharmaceutical products and markets these products in Canada.<wbr> It has 28.<wbr>11 P/<wbr>E ratio.<wbr> Through its subsidiary, Hedley Technologies Ltd.<wbr>, the Company also operates legacy business marketing bio and non-chemical insecticides.<wbr>Cysview® is synergistic with the company's existing product portfolio and represents a significant investment in our Hospital Business Unit.<wbr> The marketing authorization for Cysview® was recently successfully transferred to BioSyent Pharma from our partner, Photocure ASA.<wbr> The Company is now in final preparations for the launch of Cysview® to the Canadian market.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10784_2_ScreenCapture2.jpg"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10784_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10784_1_ScreenCapture1.jpg"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10784_4_ScreenCapture4.jpg"> </div><div>Source: Biosyent Q3 2015 Earning Presentation </div><!-- Comment details --><a name="oncology10784attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10784_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(100,6 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10784_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(165 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10784_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(94,5 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10784_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(152,8 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20151231&edate=20150901&rec=10784">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-11-12T17:55:38+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-11-12T17:55:38+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>AAA Lists In The US & Opens 50% Higher Than Its IPO Price</title>
	<pubDate>2015-11-12T17:12:29+01:00</pubDate>
	<wp:post_id>6714</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: AAA's American depositary shares opened yesterday 50% higher than its IPO price and ended a 2-month period of biotech IPO's pricing below the range.<wbr> The issue has raised $75m for the company and places it well positioned to commercialise its drug Lutathera both in the US and Europe and to build a new manufacturing plant in the US.<wbr> The company's prospectus issued alongside the listing contains  significant information on AAA's manufacturing and commercialisation plans and confirms both a US and EU filing for Lutathera by Q12016.<wbr> A EU filing for Somakit-TATE is planned for 1H18 and aparently AAA also plans to submit a NDA for Somakit-TOC to the FDA by the end of 2015 and submitted a MAA to the EMA in October 2015.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Manufacturing</STRONG> </div><div style="margin-bottom: 10px;">AAA has formulated Lutathera with a three-day shelf life, which it believes will enable it to efficiently produce and distribute it in the European Union and initially in the US.<wbr> In the US, it has begun construction of a production facility for Lutathera in New Jersey that will provide the U.<wbr>S.<wbr> supply of Lutathera by Q12017.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Commercialisation</STRONG> </div><div style="margin-bottom: 10px;">AAA will sell its product through a sales and marketing network, of over 360 employees throughout Europe, North America and Israel.<wbr> The group currently has a direct sales and marketing presence in eight countries and generate sales in 19 countries.<wbr> </div><div style="margin-bottom: 10px;">It intends to commercialize Lutathera with its own sales force in the United States, as well as France, Germany, Italy, Spain, and the United Kingdom.<wbr> </div><div style="margin-bottom: 10px;">AAA has identified approximately 50 nuclear medicine centers in the United States that it believes treat over 80% of midgut NET patients in the US.<wbr> Similarly, it has identified approximately 80 nuclear medicine centers in the EU5 that it believes treat over 80% of midgut NET patients in the EU5.<wbr> It believes it can efficiently target these nuclear medicine centers with a specialty sales force of approximately 13 sales representatives and three field-based market access specialists in the US and approximately 30 sales representatives in the EU5.<wbr> I </div><div style="margin-bottom: 10px;">It claims that its commercial leadership team is already in place and that it is currently in the early stages of establishing a commercial infrastructure, including sales representatives, medical affairs, marketing, market access, market research, sales force effectiveness and strategic planning.<wbr> It anticipates commencing marketing for Lutathera in these geographic areas soon after FDA and/<wbr>or EMA approval.<wbr> Outside of the US and EU5 it intends to contract with select partners to commercialize Lutathera.<wbr> </div><div style="margin-bottom: 10px;">At August 31, 2013 AAA had 368 employees, 118 in Italy, 106 in Italy, 106 in France, 41 in Spain, 19 in the UK, 16 in Portugal, 15 in Israel, 17 in the US, 12 in Germany, 11 in Poland, 12 in Switzerland and one in Canada.<wbr> Since that date is has continued to expand the number of employees supporting production, marketing and sales infrastructure.<wbr> </div><div style="margin-bottom: 10px;">MEDraysintell an independent authority on the radiopharmaceutical market estimates that the global molucular nucleur medicine market was worth $4.<wbr>3bn as of December 2014.<wbr> Whilst currently dominated by diagnostics (92% of sales) MEDraysintell estimates that the therpaeutic segments represents a fast-growing field that may constitute up to $13bn of total MNM sales of $24bn by 2030, representing a CAGR of 30%.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Usage Of Lutathera To Date</STRONG> </div><div style="margin-bottom: 10px;">As of June 30, 2015, Lutathera has been administered to over 3,000 NET patients in various studies and has received approval for use in compassionate use and named patient programs in ten countries in Europe for progressive midgut NETs and pNETs.<wbr> Also as of June 30, 2015, Lutathera has been administered to over 800 patients in 48 centers across Europe under such programs, for which AAA has delivered, through third parties, over 2,100 doses of Lutathera.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>AAA's  Strategic Advantage</STRONG> </div><div style="margin-bottom: 10px;">AAA states that it believes its leading position in European MNM is underpinned by (i) its pan-European presence, (ii) proximity to our more than 200 principal customers through its PET production facilities, a key advantage given the short half-life of PET and other MNM products, (iii) scalable and modular manufacturing, (iv) extensive scientific know-how and (v) ongoing interaction with the healthcare field through hospitals, universities and research centers.<wbr> </div><div style="margin-bottom: 10px;">It has R&amp;D teams based in seven of its production facilities (in addition to our dedicated R&amp;D facility in Nantes, France), which allows them to link practical manufacturing know-how to pipeline product candidate development to maximize the opportunity for commercial success.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Profitability of Lutathera May Be Limited By A No Of Agreements</STRONG> </div><div style="margin-bottom: 10px;">AAA is party to agreements, including an acquisition agreement with BioSynthema, that impose royalty, milestone and earn-out payment obligations on the group, in connection with its achievement of specific clinical, regulatory and commercial milestones with respect to Lutathera.<wbr> It is also party to a related license agreement with Mallinckrodt, Inc that requires it to pay a royalty payment to Mallinckrodt at percentage in the low teens of our net sales of Lutathera for each quarter until the first quarter of 2020, a letter of agreement with Erasmus Medical Center, or Erasmus, that requires AAA to pay Erasmus a low single-digit percentage royalty on net sales of Lutathera, which is capped based on the number of clinical trials required by the FDA, with a current maximum of  €2.<wbr>0 million (US$2.<wbr>2 million), and a license and royalty agreement for rights relating to a somatostatin analogue that requires us to pay a low single-digit percentage royalty on net sales of Lutathera.<wbr> </div><div>From <A href="http://www.sec.gov/">http:/<wbr>/<wbr>www.<wbr>sec.<wbr>gov</A>, see <A href="http://www.sec.gov/Archives/edgar/data/1611787/000157104915009106/t1502530-424b1.htm">original source</A>.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20151231&edate=20150901&rec=8268">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-11-12T17:12:29+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-11-12T17:12:29+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Ph3 Program of Ardelyx' Tenapanor for IBS-C is Progressing Ahead of Plans</title>
	<pubDate>2015-11-12T16:52:42+01:00</pubDate>
	<wp:post_id>6715</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Tenapanor is a non-systemic, small-molecule inhibitor of NHE3, which acts locally in the gut to reduce sodium absorption.<wbr> Last June, Ardelyx regained all rights for the drug from AstraZeneca.<wbr> It is not said if the company will develop the drug independently or seek a new partner.<wbr> Alongside fiancial results for Q3:15, the company reported it commenced the first Ph3 in October, and it expects to start the second Ph3 in December (rather than in Q1:16).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Total revenue is comprised of licensing revenue and collaborative development revenue, which were both related to the Company's license agreement with AstraZeneca.<wbr> Total revenues decreased to zero in the third quarter of 2015 from $7.<wbr>6 million in the third quarter of 2014 because of the termination of the AstraZeneca agreement in June 2015.<wbr> </div><div style="margin-bottom: 10px;"><U>Research and development expense</U> in the third quarter of 2015 increased to $14.<wbr>7 million from $5.<wbr>7 million in the third quarter of 2014.<wbr> The change was primarily due the $7.<wbr>3 million in expenses incurred for the clinical trial material from AstraZeneca as well as an increase of $1.<wbr>7 million for clinical development activities associated with tenapanor and RDX022, and process development for RDX022.<wbr> </div><div style="margin-bottom: 10px;"><U>General and administrative expense</U> was $3.<wbr>4 million in the third quarter of 2015 as compared to $1.<wbr>8 million in the third quarter of 2014.<wbr> The increase was primarily due to an increase in personnel expense and professional service fees.<wbr> </div><div style="margin-bottom: 10px;">Cash and cash equivalents were $129.<wbr>0 million as of September 30, 2015 as compared to $107.<wbr>3 million as of December 31, 2014.<wbr> </div><div>Source: Ardelyx </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="GastroEnterology2738c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div>Ardelyx has commenced an underwritten public offering.<wbr> Management will use its existing cash and cash equivalents ($129M as of Sept.<wbr> 0, 2015) and the net proceeds of the offering to support its clinical programs, among which the 2 Ph3 studies of tenapanor for IBS-C initiated 4Q15.<wbr> The company recently assessed the drug development cost (including CMC) to be $65-$80M through NDA filing (2018).<wbr> Tenapanor is likely to reach the EU market in 2019.<wbr> </div></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20151231&edate=20150901&rec=2659">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-11-12T16:52:42+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-11-12T16:52:42+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Focus on Q3 Sales of Sanofi Consumer Healthcare Products</title>
	<pubDate>2015-11-12T16:31:36+01:00</pubDate>
	<wp:post_id>6716</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Focus on Q3 Sales of Sanofi Consumer Healthcare Products</span>&nbsp;<br><span style="font-size: 12px;">Comment: Third-quarter sales of Consumer Healthcare products were €814m, an increase of 3.<wbr>2% driven by Allegra<SUP class="hugin" style="FONT-SIZE: 0.8em; VERTICAL-ALIGN: text-top">®</SUP>, Lactacyd<SUP class="hugin" style="FONT-SIZE: 0.8em; VERTICAL-ALIGN: text-top">®</SUP>, and Dorflex<SUP class="hugin" style="FONT-SIZE: 0.8em; VERTICAL-ALIGN: text-top">®</SUP>.<wbr> To be noted, sales of Enterogermina<SUP>®</SUP> decreased by 25%.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20151231&edate=20150901&rec=2620">...</a><br></div><div style="margin-bottom: 10px;">Brandicourt has reported it is exploring strategic options, including divestment, for its Merial animal health business and European generics operation to achieve "leadership" in consumer healthcare.<wbr> He said that Sanofi Consumer Healthcare aimed to "maximise the value of existing brands" by managing them with "speed, agility and consumer focus".<wbr> However Sanofi would "remain diversified, with a portfolio refocused on areas "where we can win, and innovation driven to improve the lives of millions of people".<wbr> The diversified company would be present in Pharmaceuticals, Vaccines and Consumer Healthcare, he added, and would seek "external opportunities to enhance its growth profile".<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Reasons for Staying in Consumer Healthcare</STRONG> </div><div style="margin-bottom: 10px;">Brandicourt outlined three reasons </div><div style="margin-bottom: 10px;">1/<wbr> consumer healthcare is a highly-fragmented market that is ripe for consolidation, </div><div style="margin-bottom: 10px;">2/<wbr> the market offers consistent growth with different dynamics to the branded prescription market, and </div><div style="margin-bottom: 10px;">3/<wbr> it is a good portfolio fit where Sanofi can capture real synergies.<wbr> </div><div>Building a competitive position for Sanofi's Consumer Healthcare business is part of a new strategic roadmap for the overall company over the next five years.<wbr> This long-term strategy rested on four pillars, said Brandicourt, adding that these were reshaping the portfolio, delivering outstanding launches, sustaining innovation in research and development, and simplifying the organisation.<wbr> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20151231&edate=20150901&rec=2658">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2620">View thread  GastroEnterology2620: Focus on Q3 Sales of Sanofi Consumer Healthcare Products</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-11-12T16:31:36+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-11-12T16:31:36+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Medicinova's Bedoradrine (selective beta2-adrenergic receptor agonist) Receives IBS Patent in Japan</title>
	<pubDate>2015-11-12T15:50:42+01:00</pubDate>
	<wp:post_id>6717</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The allowed claims cover a compound, pharmaceutical composition and a method of treating irritable bowel syndrome.<wbr> Bedoradrine belongs to Medicinova's core programs.<wbr> It is currently in Ph2 for respiratory diseases.<wbr> This new indication may be pursued independently or in collaboration.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">MediciNova's current strategy is to focus on MN-166 (ibudilast) for neurological disorders, MN-221 for the treatment of acute exacerbations of asthma, and MN-001 for NASH.<wbr> </div><div style="margin-bottom: 10px;">MediciNova may pursue development independently or establish a strategic collaboration to support further development of its programs.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">MN-221 (bedoradrine) is a novel, highly selective beta<SUB id="yui_3_18_1_1_1447339164432_1561">2</SUB>-adrenergic receptor agonist.<wbr> </div><div style="margin-bottom: 10px;">MediciNova acquired a sublicensable license to MN-221 from Kissei Pharmaceutical Co.<wbr>, Ltd.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Once issued, the patent maturing from this allowed patent application is expected to expire no earlier than April 2031.<wbr> </div><div>Source: Medicinova </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20151231&edate=20150901&rec=2657">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-11-12T15:50:42+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-11-12T15:50:42+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Outcome Based Pricing "An Elusive Dream"</title>
	<pubDate>2015-11-12T15:22:12+01:00</pubDate>
	<wp:post_id>6718</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: This is the conclusion of Novartis's CEO Joe Jiminez and Roche's CEO Severin Schwan.<wbr> According to Reuters, both CEO's after conducting pilot projects with new drugs have stated that the basic infrastructure in terms of electonic medical records is going to have to impove significantly before outcomes can be adequately tracked to introduce the type of risk-sharing pricing agreement that the pharmaceutical industry is starting to advocate.<wbr> </div><div style="margin-bottom: 10px;">Both CEO's in interviews with Reuters conclude that insurance companies, particularly in the US are not yet ready for "outcome-based" pricing models.<wbr> </div><div style="margin-bottom: 10px;">Both companies have experimented with the concept, Novartis with its multiple sclerosis drug Gilenya and Roche with its Oncology portfolio in Italy.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Limitations Towards Moving To Risk Sharing Pricing Agreements</STRONG> </div><div style="margin-bottom: 10px;">The Rueters articles suggests that the type of barriers that will impede a broader roll-out include, privacy concerns, resistance by doctors who fear more bureaucracy and the sheer scale of the IT infracture needed for outcome-based pricing to work.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Novartis - A Pioneer In The Field</STRONG> </div><div style="margin-bottom: 10px;">Novartis had been hoping to introduce a new risk-sharing model with its recently approved heart drug Entresto with a new analysis having demonstrated that 44% fewer heart patients taking Entresto were re-admitted to hospital within a month of discharge when compared with patients on other drugs.<wbr> Unfortunately Jimenez was advised that his plan was too complicated and so Novartis will have to continue with a more traditional pricing model.<wbr> </div><div style="margin-bottom: 10px;">Roche's Schwan believes cost concerns will eventually prompt change but that it is not going to happen any time soon.<wbr> </div><div>Source: Reuters </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20151231&edate=20150901&rec=11310">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-11-12T15:22:12+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-11-12T15:22:12+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>UEGW 2015 (Part 4): Alfa Wassermann Insights</title>
	<pubDate>2015-11-12T11:59:38+01:00</pubDate>
	<wp:post_id>6719</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Alongside the key aspects of gut microbiota which were reviewed and discussed by four reknown KOLs during the satellite symposium, A Gasbarrini (Div of Internal Medicine and Gastroenterology, A Gemelli Hospital, Italy) outlined the "Eubiotic effect" of rifaximin, and its potential to modulate intestinal homeostasis.<wbr> Importantly, M Pimentel (Gastrointestinal Motility Program, Cedars-Sinai Medical Center, Los Angeles, USA) highlighted that IBS is autoimmune, leading to the validation of a diagnosis test.<wbr> IBSCheck has been launched in the US by Commonwealth Lab to reliably diagnose IBS.<wbr> He also outlined that Rifaximin is one of the first microbiome therapies and the only drug approved in the US that treats a mechanism cause of IBS-D.<wbr> This is clearly a competite advantage over Allergan's Viberzi (elaxudoline), likely to reach next year the US market for IBS-D.<wbr> Pimentel's presentation is highlighted below.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><U>Title </U>Gut Microbiota: modulate its compexity to restore the balance </div><div style="margin-bottom: 10px;"><STRONG>NEW EVIDENCE IN IBS- THE ROLE OF GUT MICROBIOTA</STRONG> </div><div style="margin-bottom: 10px;"><U><STRONG>For M Pimentel</STRONG></U>, it is now known that acute gastroenteritis (AGE) produces a lasting alteration of the intestinal motor function (and stasis) leading to a microbial change.<wbr> He proposed that many patients with IBS, during previous episodes of gastroenteritis, developed antibodies to cdtB, which cross-reacted with vinculin in the intestine to cause IBS.<wbr> Cytolethal distending toxin B (CdtB) is produced by bacteria that cause acute gastroenteritis, and a post-infectious animal model demonstrates that host antibodies to CdtB cross-react with vinculin in the host gut, producing an IBS-like phenotype.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2654_1_copiedImage%5b0%5d.png"> </div><div style="margin-bottom: 10px;">This mechanism has led to a new serum<STRONG> diagnostic test for IBS, suggesting that IBS is autoimmune (</STRONG><A href="http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0126438">Development and Validation of a Biomarker for Diarrhea-Predominant Irritable Bowel Syndrome in Human Subjects</A> - Published: May 13, 2015 DOI: 10.<wbr>1371/<wbr>journal.<wbr>pone.<wbr>0126438).<wbr> </div><div style="margin-bottom: 10px;">Being caused by infection, and on the basis of the new microbial hypothesis in IBS, Pimentel discussed the importance in the selection of antibiotic to mitigate risk.<wbr> Rifaximin, in now 5 RCTs has demonstrated effectiveness in improving IBS symptoms.<wbr> </div><div style="margin-bottom: 10px;">In the TARGET- and 2 trials, the drug demonstrated efficacy over placebo in IBS, with improvement in global outcomes: abdominal pain, bloating and stool consistency.<wbr> Through these trials it was clear that <STRONG>rifaximin was treating a causative factor in IBS since subjects remained well even after 12 weeks after treatment</STRONG>.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2654_2_copiedImage%5b2%5d.png"> </div><div style="margin-bottom: 10px;">In the recently completed TARGET-3 trial (retreatment trial) rifaximin had proven efficacy in up to 3 treatments.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>M Pimentel's conclusion stressed important characteristics of rifaximin:</STRONG> </div><div><UL><LI>safety: rifaximin was identical to placebo in terms of side effects in all the TARGET trials</LI>
<LI>rifaximin did not produce any stable resistance and no evidence of <EM>C.<wbr>difficile</EM></LI>
<LI>98% of stool flora seen before rifaxilin were still present after rifaximin, suggesting little of no effect on the colonic microbiome.<wbr></LI>
</UL> </div><!-- Comment details --><a name="gastroenterology2654attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2654_1_copiedImage%5b0%5d.png">copiedImage[0].png</a>&nbsp;&nbsp;(83,8 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2654_2_copiedImage%5b2%5d.png">copiedImage[2].png</a>&nbsp;&nbsp;(55,8 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20151231&edate=20150901&rec=2654">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-11-12T11:59:38+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-11-12T11:59:38+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Corcept's Earnings & R&D Update</title>
	<pubDate>2015-11-12T10:08:59+01:00</pubDate>
	<wp:post_id>6720</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;"><P align="left">Comment: Corcept's net revenue in the third quarter was $13.<wbr>3 million compared to $7.<wbr>3 million in the third quarter of 2014, an 82% increase, reflecting in the main increased sales of its Cushing's drug Korlym.<wbr> The company reiterated its 2015 full-year revenue guidance of $49 million to $53 million.<wbr> PhII development of the group's new Cushing's Drug CORT125134 will commence in Q116.<wbr></P> </div><div style="margin-bottom: 10px;"><P align="left"><STRONG>Korlym's Commercialisation Progress<BR></STRONG></P> </div><div style="margin-bottom: 10px;"><P align="left">Joseph Belanoff Corcept's CEO noted that the company added both new prescribers and new Cushing's syndrome patients in the third quarter but the vast majority of the 10,000 or more patients who could benefit from Korlym still have yet to use the drug.<wbr> </P> </div><div style="margin-bottom: 10px;"><P align="left">Earlier this year the company hired some clinical specialists who have begun their work of educating physicians about Korlym and the benefits of cortisol modulation.<wbr> Belanoff noted that prompting a doctor's first Korlym prescription often requires a clinical specialist to make five or more visits to the doctor's office.<wbr> Hence, the group, he claimed, is just beginning to see the contributions of its new sales representatives as they take physicians from an initial introduction to a first Korlym prescription.<wbr></P> </div><div style="margin-bottom: 10px;"><P align="left"><STRONG>Korlym's Safety Issues</STRONG></P> </div><div style="margin-bottom: 10px;"><P align="left">Interestingly for all of its power as a treatment for Cushing's syndrome Belanof did admit that Korlym has certain drawbacks, the main one being that it blocks the progesterone receptor and terminates pregnancy and in some nonpregnant women progesterone receptor blockade has prompted  endometrial thickening and irregular vaginal bleeding.<wbr> Non-life-threatening, manageable side effects but ones that patients and their physicians would clearly prefer to avoid.<wbr><BR><BR>However, he noted that 300 compounds in Corcept's portfolio of next-generation molecules do not cause these problems.<wbr> They all bind to the glucocorticoid receptor and therefore share Korlym's ability to modulate cortisol but they are not active at the progesterone receptor, so do not terminate pregnancy or cause endometrial thickening.<wbr><BR></P> </div><div style="margin-bottom: 10px;"><P align="left"><STRONG>Status of Next Generation Molecule</STRONG></P> </div><div style="margin-bottom: 10px;"><P align="left">Corcept plans to advance its lead next-generation molecule, CORT125134, into Phase 2 as a treatment for Cushing's syndrome and an oncology indication in the first quarter of 2016.<wbr> Its Phase 1 data apparently shows that CORT125134 shares Korlym's ability to potently reverse the effects of excess cortisol activity and is more potent than mifepristone.<wbr> </P> </div><div style="margin-bottom: 10px;"><P align="left">Alongside its Cushing's activities, Corcepts overall oncology program also continues to advance.<wbr> At the San Antonio breast Cancer symposium on December 10 the group will present initial efficacy results on its 1/<wbr>2 trial of Korlym to treat metastatic triple negative breast cancer.<wbr></P> </div><div><P align="left">Source: <A href="http://www.corcept.com">www.<wbr>corcept.<wbr>com</A></P> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20151231&edate=20150901&rec=8267">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-11-12T10:08:59+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-11-12T10:08:59+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>UEGW 2015 (Part 3): New Pharmacological and Non-Pharmacological Treatment Alternatives for IBS - B.longum NCC3001</title>
	<pubDate>2015-11-12T10:01:27+01:00</pubDate>
	<wp:post_id>6721</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The free paper session was chaired by A Lembo (Ass.<wbr> Prof.<wbr> of Medicine Beth Israel Deaconess Medical Center Harvard Medical School Boston, USA).<wbr> B.<wbr>longum NCC3001 was the only probiotic presented in this session.<wbr> Supported by a grant from Nestlé the oral presentation showed the effect of the probiotic on reducing brain emotional reactivity in patients with IBS, in a small RCT of 44 patients.<wbr> M.<wbr> I.<wbr> Pinto-Sanchez from Department of Medicine highlighted that this was associated with changes in the brain activation patterns in the amygdala and fronto-limbic regions, suggesting that the reduction in limbic reactivity may underline the beneficial effect of this probiotic.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>A Limbo introduced the session by the recent recommendations for IBS-D</STRONG> (<EM><A href="http://gi.org/wp-content/uploads/2014/08/IBS_CIC_Monograph_AJG_Aug_2014.pdf">American College of Gastroenterology Monograph on the Management of Irritable Bowel Syndrome and Chronic Idiopathic Constipation Alexander C.<wbr> Fordfor the Task Force on the Management of Functional Bowel Disorders</A></EM>) <EM>Am J Gastroenterol 2014; 109:S2 – S26; doi: 10.<wbr>1038/<wbr>ajg.<wbr>2014.<wbr>187</EM> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2648_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><U>Additional potential therapies sometimes used in practice</U>: bile acide binders, cromlyn sodium, 5HT-3 antagonist ondansetron, gabapentin and pregabalin, serum bovine immunoglobulin (such as Enteragam).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> IMPROVES DEPRESSION AND REDUCES BRAIN EMOTIONAL REACTIVITY IN PATIENTS WITH IRRITABLE BOWEL SYNDROME (IBS): A RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED TRIAL </div><div style="margin-bottom: 10px;"><STRONG>The probiotic previously shown that it normalizes anxiety-like behaviour and hippocampal neurotrophin levels in murine models of low-grade gut inflammation.<wbr></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>M.<wbr> I.<wbr> Pinto-Sanchez</STRONG> from Department of Medicine presented the results of a double-blind placebo-controlled RCT in patients PE: reduction in anxiety oand/<wbr>or depression of &gt;2 points on the Hospital anxiety and depression scale (HAD) at 6 weeks.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2648_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;"><STRONG>Outcomes</STRONG> </div><div style="margin-bottom: 10px;">At six weeks, depression scores improved in patients treated with B.<wbr> longum compared with placebo (RR 2.<wbr>94, 95% CI 1.<wbr>05-8.<wbr>23, p=0.<wbr>01) and this was maintained at follow-up.<wbr> More patients treated with B.<wbr> longum than placebo reported adequate relief of overall IBS symptoms (RR 2.<wbr>1, 95% CI 1.<wbr>15-3.<wbr>83, p=0.<wbr>02) <U>but no statistically significant changes were found in the IBS Birmingham scores</U>.<wbr> The physical subdomain of quality of life improved in B.<wbr> longum treated group compared with placebo (p=0.<wbr>03, Mann–Whitney U=228.<wbr>5), with trends for improvement in the mental subdomains of vitality and emotional role functioning.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2648_8_ScreenCapture8.jpg"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2648_9_ScreenCapture9.jpg"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2648_10_ScreenCapture10.jpg"> </div><div style="margin-bottom: 10px;">Functional MRI revealed significant reductions from baseline in response to negative emotional stimuli in multiple brain areas involved in emotion processing, including amygdala, frontal and temporal brain regions (p50.<wbr>001), in B.<wbr> longum treated patients compared with placebo.<wbr> No statistically significant differences were observed in anxiety, cognitive function, inflammatory markers, serum BDNF levels or gut microbiota profiles in B.<wbr> longum-treated patients compared to placebo.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2648_5_ScreenCapture5.jpg"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2648_6_ScreenCapture6.jpg"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2648_7_ScreenCapture7.jpg"> </div><div style="margin-bottom: 10px;"><STRONG>She concluded </STRONG>that six-week treatment with B.<wbr> longum NCC3001 improves comorbid depression, overall gastrointestinal symptoms and quality of life in patients with IBS.<wbr> This is associated with changes in the brain activation patterns in the amygdala and fronto–limbic regions, suggesting that reduction in limbic reactivity may underlie the beneficial effect of this probiotic.<wbr> </div><div><STRONG>Limitaton of this study</STRONG>: need to be vlidated by larger trials </div><!-- Comment details --><a name="gastroenterology2648attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2648_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(31,1 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2648_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(58,9 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20151231&edate=20150901&rec=2648">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-11-12T10:01:27+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-11-12T10:01:27+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Revance Has Released Its Q3 Financial Results Exceeding In Expenses Compared To 2014 With Multiple Trials In Development</title>
	<pubDate>2015-11-11T18:19:43+01:00</pubDate>
	<wp:post_id>6722</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Continued investment into clinical development has resulted in increased operational expenses and overall net loss.<wbr> Equity financing has helped lift this with a year-end cash balance to exceed $245 million.<wbr> </div><div style="margin-bottom: 10px;">The results highlighted </div><div style="margin-bottom: 10px;"><UL><LI>Positive top line interim data from BELMONT Phase 2 Active Comparator Trial of RT002 injectable for the treatment of glabellar (frown) lines</LI>
<LI>Three new trials in the U.<wbr>S.<wbr> for aesthetic and therapeutic indications:</LI>
</UL> </div><div style="margin-bottom: 10px;"><BLOCKQUOTE dir="ltr" style="MARGIN-RIGHT: 0px">
<BLOCKQUOTE dir="ltr" style="MARGIN-RIGHT: 0px">
<P>RT001 topical: pIII pivotal study, REALISE 1, lateral canthal lines (crow's feet).<wbr> Interim results in the first half of 2016</P>
<P>RT002 injectable: pII treatment of primary axillary hyperhidrosis.<wbr> Interim results December 2015.<wbr> A pII moderate-to-severe isolated cervical dystonia.<wbr> Interim results in 2016.<wbr></P></BLOCKQUOTE></BLOCKQUOTE> </div><div style="margin-bottom: 10px;"><UL><LI>Raised $134.<wbr>6 million in gross proceeds from a successful November 2015 public stock offering.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;">Financials for the 3 and 9 months ended September 30, 2015 </div><div style="margin-bottom: 10px;"><UL><LI><STRONG>Research and development expenses</STRONG> were $13.<wbr>0 million and $32.<wbr>6 million, respectively, compared to $8.<wbr>6 million and $24.<wbr>3 million for the same periods in 2014, respectively.<wbr> </LI>
<LI><STRONG>General and administrative expenses</STRONG> were $5.<wbr>8 million and $18.<wbr>2 million, respectively, compared to $5.<wbr>3 million and $14.<wbr>3 million for the same periods in 2014, respectively.<wbr> </LI>
<LI><STRONG>Total operating expenses</STRONG> were $18.<wbr>8 million and $50.<wbr>8 million, respectively, compared to $13.<wbr>9 million and $38.<wbr>5 million for the same periods in 2014, respectively.<wbr> Stock-based compensation for the three and nine months ended September 30, 2015 was $2.<wbr>6 million and $7.<wbr>3 million, respectively.<wbr> When excluding depreciation and stock-based compensation, total operating expenses for the three and nine months ended September 30, 2015 were $15.<wbr>7 million and $41.<wbr>9 million, respectively.<wbr></LI>
<LI><STRONG>Net loss</STRONG> was $19.<wbr>2 million and $51.<wbr>4 million, respectively, compared to $14.<wbr>0 million and $48.<wbr>7 million for the same periods in 2014, respectively.<wbr> Upon completion of the IPO in February 2014, Revance recorded non-cash interest expense, including loss on debt extinguishment, of $9.<wbr>6 million in connection with the settlement of previously outstanding convertible notes.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI>As a result of the equity financings, the company expects its year-end cash balance to exceed $245 million.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;">Dan Browne CEO remarked <EM>"Our third quarter results demonstrate the significant progress we are making in bringing our investigational drug product candidates, RT001 topical and RT002 injectable, closer to commercialization.<wbr> I am proud of the progress we have already made this year.<wbr> We've strengthened the balance sheet and have four important clinical trials underway, enabling us to build a broad product portfolio in the market for botulinum toxins"</EM> </div><div>Source: Globalnews wire </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20151231&edate=20150901&rec=8242">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-11-11T18:19:43+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-11-11T18:19:43+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Galderma Has Partnered With ImaBiotech To Bring A More Innovative Approach To Drug Development</title>
	<pubDate>2015-11-11T16:32:38+01:00</pubDate>
	<wp:post_id>6723</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Galderma has partnered with ImaBiotech using its innovative service Multimaging™  to support drug development </div><div style="margin-bottom: 10px;">The Multimaging™ services is thought to accelerate and combine pharmacokinetic, pharmacology, toxicology and formulation phases through combination of imaging techniques (Quantitative MALDI imaging, staining, immune-staining) associated with dedicated software.<wbr>   This platform has the capability to jointly study quantitatively the distribution of analytes, at a cellular level </div><div style="margin-bottom: 10px;">Dr Laurent Hennequin, Director of Research and Dr Philippe Andres, Director of Global Evaluation, Galderma R&amp;D “<I>We consider ImaBiotech as a key partner to help us to visualise our compounds in skin through imaging.<wbr> Knowing the challenge which is the quantification and the localization of analytes, including biomarkers, in skin, we consider that ImaBiotech technologies can lead us quicker to better and safer products</I>.<wbr>” </div><div style="margin-bottom: 10px;">Dr Jonathan Stauber, CEO of ImaBiotech adds <I>”We are more than proud to become a partner of Galderma, world-known as a major pharmaceutical company.<wbr> This new partnership is a proof that our company and its Multimaging™ technology have become key players in the Molecular imaging field in less than a year.<wbr>”</I> </div><div>Source Galderma </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20151231&edate=20150901&rec=8241">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-11-11T16:32:38+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-11-11T16:32:38+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>PART 3: The American Academy Of Physical Medicine And Rehabilitation (AAPM&R): Pediatric landscape</title>
	<pubDate>2015-11-11T16:19:01+01:00</pubDate>
	<wp:post_id>6724</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment:AAPM&amp;R had a symposium dedicated to the ‘Top papers in Paediatric rehabilitation’.<wbr>  This discussion was on the most influential papers in paediatric rehabilitation over the past year.<wbr>  It was conducted on Friday 2<SUP>nd</SUP>   and lead by Molly Fuentes, Amy J Houtrow and Matthew Mclaughlin </div><div style="margin-bottom: 10px;">Key study presented included one on BoNT use in CP.<wbr>  The results showed that BoNT works well as an adjunctive therapy in meeting therapy goals.<wbr>  There remains to be moderate/<wbr>severe adverse events, though this occurred in both the placebo and intervention groups.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11309_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11309_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11309_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;">The last poster was by Stacy Stibb <I>et al.<wbr> </I>Children with CP experience minimal pain two days following BoNT injection.<wbr>  The purpose of this study was to investigate pain severity and interference with daily living activities.<wbr>  The results have showed that the pain intensity scores did not vary significantly from baseline (no injection).<wbr>  Therefore concerns about lingering pain following BoNT injections should not deter the use in spasticity </div><div>Source: AAPM&amp;R presence </div><!-- Comment details --><a name="pharmaworld11309attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11309_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(43,8 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11309_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(37,2 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11309_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(50,6 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20151231&edate=20150901&rec=11309">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-11-11T16:19:01+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-11-11T16:19:01+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Tokai Pharmaceuticals Inc Reports Third Quarter 2015 Financial Results</title>
	<pubDate>2015-11-10T19:12:58+01:00</pubDate>
	<wp:post_id>6725</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Tokai reported its Q3 results today.<wbr> Jodie Morrison (CEO, Tokai) highlighted the Ph3 ARMOR3 SV is underway and topline results expected by the end of 2016.<wbr> Lisa Taylor (an ex-member in Medivation's Xtandi launching team) will undertake the leadership with its go-to-market strategy for galeterone.<wbr> Notably the substantial increase in R&amp;D spending reflects the start-up costs for ARV7 clinical trial assay and manufacturing activities.<wbr> Its current cash position and investment should sustain all TOKAI's activities beyond when the topline results are reported.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Pivotal ARMOR3-SV Trial Underway</STRONG>: </div><div style="margin-bottom: 10px;">During the quarter, Tokai began screening patients for participation in ARMOR3-SV, the company&rsquo;s pivotal Phase 3 clinical trial of galeterone, the first Androgen Receptor Degrader in clinical testing.<wbr> ARMOR3-SV, the first pivotal trial in prostate cancer employing a precision medicine approach for patient selection, is evaluating whether administration of galeterone results in a statistically significant increase in radiographic progression-free survival as compared to Xtandi<SUP>&reg;</SUP> (enzalutamide) in 148 treatment-na&iuml;ve metastatic castration-resistant prostate cancer (mCRPC) patients whose prostate tumor cells express the androgen receptor splice variant-7 (AR-V7).<wbr> AR-V7 is a truncated form of the androgen receptor that has been associated with non-response to commonly used oral therapies for mCRPC.<wbr> The design of ARMOR3-SV is aligned with feedback obtained from the U.<wbr>S.<wbr> Food and Drug Administration (FDA) and the European Medicines Agency, and top-line data for the trial are expected by the end of 2016.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10781_1_ScreenCapture1.jpg"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10781_2_ScreenCapture2.jpg"> </div><div>Source: TOKAI Press Release </div><!-- Comment details --><a name="oncology10781attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10781_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(76,4 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10781_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(26,3 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20151231&edate=20150901&rec=10781">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-11-10T19:12:58+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-11-10T19:12:58+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Combo PD-1 and VEFGR Inhibitor Are Active in Advanced RCC</title>
	<pubDate>2015-11-10T17:55:35+01:00</pubDate>
	<wp:post_id>6726</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Prelimnary results of a Ph1 Axitinib and Pembrolizumab study in advanced RCC were presented by Dr Choueiri at the 14th International Kidney Cancer Symposium (IKCS) on 7th Nov.<wbr> Early indications of efficacy from the combination were reported although it should be cautioned that these are yet preliminary as there are signs of possible toxicity and longer follow up is required.<wbr> </div><div style="margin-bottom: 10px;">" <EM>The data is quite interesting.<wbr>.<wbr>.<wbr>The drugs are already approved and available, and axitinib is approved for renal cancer.<wbr>.<wbr>.<wbr>That makes it very translatable into the clinical setting.<wbr>.<wbr>.<wbr>.<wbr>.<wbr>However, these are very early data, there was toxicity, and follow-up is very early.<wbr> "There are all of the caveats that go with very early studies.<wbr> We will have to wait for the updated results to have a better idea</EM>.<wbr>" Sabina Signoretti, MD, an associate professor of pathology at Harvard Medical School in Boston, Massachusetts </div><div style="margin-bottom: 10px;">The current trial is an ongoing, open-label, multicenter phase 1b study, with the main objective of assessing the safety and tolerability of this combination and estimating the maximum tolerated dose (MTD).<wbr> </div><div style="margin-bottom: 10px;">As of September 11, 2015, 11 patients (8 men; mean age, 61 years) were enrolled in the study.<wbr> </div><div style="margin-bottom: 10px;">Enrollment criteria including having clear-cell advanced RCC, primary tumor resection, a measurable lesion, Eastern Cooperative Oncology Group Performance Status score 0/<wbr>1, no uncontrolled hypertension, and no prior systemic therapy.<wbr> Axitinib was administered orally at a starting dose of 5 mg twice daily, beginning on day 7.<wbr> Pembrolizumab 2 mg/<wbr>kg was administered intravenously on day 1 of 3-week cycles.<wbr> The MTD was estimated by the modified toxicity probability interval method, and tumors were assessed per Response Evaluation Criteria In Solid Tumors (RECIST) v1.<wbr>1.<wbr> </div><div style="margin-bottom: 10px;">Dose-limiting toxicity was defined as any of the following that occurred during the first 6 weeks: grade 4 neutropenia or thrombocytopenia, grade 3 or higher neutropenia infection, thrombocytopenia with bleeding, febrile neutropenia, nonhematologic toxicities that were grade 3 or higher toxicity, or not being able to complete 75% or more of axitinib dosing or 2 infusions of pembrolizumab during the treatment-related toxicity phas </div><div style="margin-bottom: 10px;"><STRONG>Key results: </STRONG> </div><div style="margin-bottom: 10px;">Efficacy was not the primary endpoint of the study, but six of the 11 patients had confirmed partial response, and the rest had stable disease.<wbr> After 7.<wbr>4 months, nine patients continue receiving treatment without progression, with two patients ending treatment because of toxicity.<wbr> </div><div style="margin-bottom: 10px;">Common all-grade adverse events were diarrhea and hypothyroidism (n = 6 each) and arthralgia, fatigue, and headache (n = 4 each).<wbr> In addition, two patients had increased alanine aminotransferase and aspartate aminotransferase.<wbr> </div><div style="margin-bottom: 10px;">Grade 3/<wbr>4 adverse events included headache, increased alanine aminotransferase and aspartate aminotransferase, hyperuricemia, and acute cholecystitis.<wbr> </div><div>Source: Medscape </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20151231&edate=20150901&rec=10780">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-11-10T17:55:35+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-11-10T17:55:35+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Key Messages from Seres' Q3 Results and Pipeline Update</title>
	<pubDate>2015-11-10T16:31:28+01:00</pubDate>
	<wp:post_id>6727</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Seres' Ecobiotic<SUP>®</SUP> therapeutics include SER-109 for recurrent CDI (currently moving forward in a Ph2 study), and SER-262 for the prevention of the primary recurrence of CDI (intended to be in the clinic in mid-2016).<wbr> Ph1b for SER-187 (for UC) is expected to start by the end of 2015.<wbr> The company's Research is ongoing on microbiome drugs to adress certain rare genetic disease and to treat colitis induced by immuno-oncology therapies.<wbr> Management reported Seres had cash, cash equivalents and investments of <MONEY>$219.<wbr>3 million</MONEY> as of <CHRON>September 30, 2015</CHRON>, compared to <MONEY>$91.<wbr>8 million</MONEY> as of <CHRON>June 30, 2015</CHRON>.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><B><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2647_1_ScreenCapture1.jpg"></B> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">For the third quarter of 2015, Seres reported a net loss of <MONEY>$(14.<wbr>6) million</MONEY>, or <MONEY>$(0.<wbr>38)</MONEY> per share, compared to a net loss of <MONEY>$(4.<wbr>6) million</MONEY>, or <MONEY>$(0.<wbr>68)</MONEY> per share for the same period in 2014.<wbr> </div><div style="margin-bottom: 10px;"><UL><LI class="bwlistitemmargb"><B>Research and Development</B>: R&amp;D expenses for the third quarter of 2015 were <MONEY>$9.<wbr>9 million</MONEY>, compared to <MONEY>$2.<wbr>5 million</MONEY> for the same period in 2014.<wbr> The increase was largely due to expenditures in connection with Seres’ microbiome therapeutic platform and clinical development of SER-109.<wbr> </LI>
<LI class="bwlistitemmargb"><B>General and Administrative Expenses</B>: G&amp;A expenses for the third quarter of 2015 were <MONEY>$4.<wbr>7 million</MONEY>, compared with <MONEY>$1.<wbr>1 million</MONEY> for the same period in 2014.<wbr> The increase was primarily due to Seres’ continued investment in business personnel, facility expansion to support the company’s overall growth, and increased professional fees and other costs associated with operating as a public company.<wbr></LI>
</UL> </div><div><P class="bwlistitemmargb">Source: Seres</P> </div><!-- Comment details --><a name="gastroenterology2647attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2647_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(45,2 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20151231&edate=20150901&rec=2647">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-11-10T16:31:28+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-11-10T16:31:28+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>BMS Has Initatied EU Approval Submission Process For Nivolumab In RCC</title>
	<pubDate>2015-11-10T12:54:14+01:00</pubDate>
	<wp:post_id>6728</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: BMS annouced the EMA validated a type II variation application, which seeks to extend the current indication for Opdivo to include the RCC indication.<wbr> The submission is complete and the EMA's centralized revciew process has now begun.<wbr> </div><div style="margin-bottom: 10px;">The type II variation submitted is based on data from CheckMate -025, a Phase 3 study that evaluated, as the primary endpoint, the overall survival of Opdivo versus everolimus, a current standard of care, in advanced or metastatic clear-cell RCC after prior anti-angiogenic treatment.<wbr> Results from CheckMate -025 were recently presented at the 2015 European Cancer Congress, and published in The New England Journal of Medicine.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Type II Variaitons</STRONG> </div><div style="margin-bottom: 10px;">Commission Regulation (EC) No 1234/<wbr>2008 (the Variations Regulation) defines a major variation of type II as a variation that is not an extension and that may have a significant impact on the quality, safety or efficacy of a medicinal product.<wbr> Assessment of type II variations following a 60 day timetable may, depending on whether they need to follow the CHMP plenary meeting periodicity or not, either start on a weekly basis or on specific monthly dates.<wbr> Type II variation procedures following a 30-day timetable (e.<wbr>g.<wbr> urgent safety issues) or a 90-day timetable (i.<wbr>e.<wbr> new indication or amendment of an existing one) will always follow the monthly-start timetable.<wbr> </div><div style="margin-bottom: 10px;">The type II vairation applications can be sumbitted weekly folowing weekly start timetables being introduced as of March 2015, except the following circumstatnces, monthly schedule needs to be followed </div><div style="margin-bottom: 10px;"><UL><LI><UL><LI>extensions of indication</LI>
<LI>variations involving PRAC, CAT in addition to the CHMP</LI>
<LI>other variations requiring amendment of the Commission Decision granting the Marketing Authorisation within two months from CHMP opinion </LI>
</UL></LI>
</UL> </div><div style="margin-bottom: 10px;">For variations following the weekly-start timetable, should the need for discussion at plenary meeting or for immediate EC decision arise during the procedure, the Agency will accommodate the need for committee discussion and/<wbr>or adoption of the Opinion at the CHMP plenary.<wbr> </div><div>Source: EMA ( <a href="http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/q_and_a/q_and_a_detail_000026.jsp&amp;mid=WC0b01ac0580023b14" class="defaultlink" title="http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/q_and_a/q_and_a_detail_000026.jsp&amp;amp;mid=WC0b01ac0580023b14">ema.europa.eu/<wbr>ema&hellip;</a>) BMS Press Release </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Oncology10785c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">The FDA has granted a priority review designation to nivolumab for patients with advanced RCC following prior antiangiogenic therapy, based on an extension in OS in the CheckMate-025 trial.<wbr> The final decision date appears to be March 2016.<wbr> </div><div>Source: OncLive </div></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20151231&edate=20150901&rec=10779">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-11-10T12:54:14+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-11-10T12:54:14+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Allergan R&D Day - Key Takeaways</title>
	<pubDate>2015-11-10T08:47:14+01:00</pubDate>
	<wp:post_id>6729</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Allergan R&D Day - Key Takeaways</span>&nbsp;<br><span style="font-size: 12px;">Comment: The Allergan R&amp;D day was conducted in Irvine California, highlighting a new operational model of an open science strategy, supported with over 70 Mid-to-Late Stage Development Programs.<wbr> The key therapeutic areas of focus were; Gastroenterology: CNS, Medical Aesthetics &amp; Dermatology, Women's Health, Urology, Anti-Invectives&rsquo; and Eye care.<wbr> Botox was highlighted in three TAs, CNS, Aesthetics &amp; Biosimilars albeit with little detail disclosed on anything potentially competitvely sensitive other than a brief reference to MT10109L (Medytox) in Ph2 for facial lines and Botox X in PhI for spasticity.<wbr> An outlook of $1B in sales, however, was suggested for new indications.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20151231&edate=20150901&rec=8235">...</a><br></div><div style="margin-bottom: 10px;">For those of us wanting to understand the progress of the senrebotase molecule, the final paragraph here is useful ("<EM><EM>The targeted toxin, we have this project called senrebotase, which is basically sort of a link between Botox and ORL1.<wbr> The goal of this was to selectively target sensory neurons to be effective in postherpetic neuralgia.<wbr> Now there's two issues here.<wbr> One is whether or not this approach was going to work as an individual molecule and the other is what it could teach us about targeting with Botox.<wbr> We are presently evaluating the data from the study and we need to make some decisions what that means for the concept of targeting </EM></EM><EM>with Botox, and we are still working our way through that&rdquo;</EM> Our understanding of the situation was that development into this area had been scaled back with the last trial on clinicaltrials.<wbr>gov in pIII recently terminated).<wbr> </div><div>Firstly, I don't recall AGN providing any information on the targeting ligand previously.<wbr>  Secondly, there is a comment about whether the molecule would work in combination, and thirdly a recognition that there are decisions to be made about the concept of BoNT fragment retargeting.<wbr>  Also, please note it was a PhII trial that was terminated rather than a PhIII one.<wbr> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20151231&edate=20150901&rec=8240">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology8235">View thread  Neurology8235: Allergan R&D Day - Key Takeaways</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-11-10T08:47:14+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-11-10T08:47:14+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Just-Published Nestlé Nutrition and Health Research on Heat-Treated Probiotics</title>
	<pubDate>2015-11-09T17:44:02+01:00</pubDate>
	<wp:post_id>6730</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The study, published in the <EM>Journal of Allergy and Clinical Immunology</EM>, has found the probiotic strain Lactobacillus paracasei NCC2461 can deliver immnunity benefits when heat treated.<wbr> Dr Carine Blanchard has outlined that this is strain dependent, as some strains don't change at all.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">increased shelf-life </div><div style="margin-bottom: 10px;">act more efficiently via an epigenetic mechanism to produce more of the imune ystem regulating protein, IL-10 </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2641_1_ScreenCapture1.jpg"> </div><div>Nestlé uses L.<wbr>paracasei NCC2461 in infant formula, nutrition beverages like and fermented drinks.<wbr> </div><!-- Comment details --><a name="gastroenterology2641attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2641_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(86,3 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20151231&edate=20150901&rec=2641">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-11-09T17:44:02+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-11-09T17:44:02+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: RedHill Updates the BEKINDA Development Programs</title>
	<pubDate>2015-11-09T17:32:47+01:00</pubDate>
	<wp:post_id>6731</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">RedHill Updates the BEKINDA Development Programs</span>&nbsp;<br><span style="font-size: 12px;">Comment: RedHill has provided an update on the development programs with BEKINDA<SUP>™</SUP> (RHB-102), a proprietary, extended-release, once-daily oral pill formulation of ondansetron.<wbr> The company expects 1/<wbr>to receive top-line results from the Ph3 GUARD study (gastroenteritis &amp; gastritis) in mid-late 2016, and 2/<wbr>plans to start a Ph2 for IBS-D in Q4:15/<wbr>Q1:16.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20151231&edate=20150901&rec=2590">...</a><br></div><div style="margin-bottom: 10px;">Alongside theQ3 financial results, RedHill has reported a strong cash position of approximately $64 million at the end of Sepember 2015.<wbr> The company continues to advance the ongoing Ph3 studies with RHB-104 for Crohn's disease and with BEKINDA&trade; for acute gastroenteritis.<wbr> BEKINDA<STRONG>&trade;</STRONG> is currently the only once-daily oral formulation of ondansetron, and is likely to be the first to reach the U.<wbr>S.<wbr> and European market.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Upcoming milestones</STRONG> </div><div><UL><LI>the planned initiation of Phase II studies with BEKINDA&trade; for IBS-D
</LI>
</UL> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20151231&edate=20150901&rec=2640">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2590">View thread  GastroEnterology2590: RedHill Updates the BEKINDA Development Programs</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-11-09T17:32:47+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-11-09T17:32:47+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>HS-410 Phase 1 Bladder Cancer Trial Results Reported at the Society for Immunotherapy of Cancer (SITC) Annual Meeting</title>
	<pubDate>2015-11-09T16:49:46+01:00</pubDate>
	<wp:post_id>6732</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Heat Biologics presented its Ph1 study in high risk patients (Post-BCG) at the Society for Immunotherapy of Cancer (SITC) Annual Meeting.<wbr> HS-410 had a positive safety profile and was well tolerated with no patients discontinuing the trial due to adverse events.<wbr> Seven out of ten patients had no documented recurrence more than 1 year after surgery.<wbr> Significantly, 3 out of 4 patients with carcinoma in situ did not recur.<wbr> For its ongoing Phase 2 trial, Heat Biologics recently announced that it has completed enrollment of the full 75 patients in the three blinded, randomized, placebo-controlled arms evaluating HS-410 in combination with BCG (<A href="traction/permalink/Oncology10705" title="Permanent Link to Oncology10705"></A>).<wbr> Heat Biologics remains focused on enrolling the additional 25 patients for the one unblinded, open-label monotherapy arm.<wbr> Topline efficacy, immune-response and safety data are expected in the Q4 2016.<wbr> </div><div style="margin-bottom: 10px;">HS-410 elicited a broad-based (polyclonal) expansion of patient T cells and a high level of CD8+ tumor-infiltrating lymphocytes (TILs); CD8+ TILs are essential to an effective anti-tumor response.<wbr> Additionally, HS-410 shared 15 or more tumor antigens in common with those expressed on the patients' cancer cells, indicating HS-410's ability to target a broad range of tumor antigens for all patients treated to date.<wbr> These data confirm previous clinical findings regarding the unique mechanism of action for HS-410 and for our <EM>ImPACT</EM> and <EM>ComPACT</EM> platform technologies.<wbr> </div><div style="margin-bottom: 10px;"><UL><LI>third-party analysis of blinded samples demonstrated a strong correlation between baseline characteristics of TILs by T cell receptor (TCR) sequencing and clinical outcome.<wbr>
</LI>
<LI>7 patients who remain disease free exhibited the greatest clonal expansion of intratumoral T cells (p-value 0.<wbr>0126).<wbr>
</LI>
<LI>An immune response within tumors that is consistent with the HS-410 mechanism of action and which correlates with clinical outcome.<wbr>
</LI>
<LI>HS-410 has a high degree of overlap with patient tumor antigens, stimulates polyclonal T cell proliferation and leads to a distinct immune signature in responding to patient tumors
</LI>
<LI>HS-410 has been demonstrated to be well-tolerated by these patients, with no patients discontinuing treatment due to adverse events.<wbr> This trend is in contrast to intravesical agents like BCG where the discontinuation rate is significant (approximately 25%)
</LI>
</UL> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10776_7_ScreenCapture7.jpg"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10776_2_ScreenCapture2.jpg"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10776_3_ScreenCapture3.jpg"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10776_4_ScreenCapture4.jpg"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10776_5_ScreenCapture5.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10776_6_ScreenCapture6.jpg"> </div><div>Source: Heat Biologics Press Release </div><!-- Comment details --><a name="oncology10776attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10776_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(199,6 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10776_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(78,1 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10776_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(93,5 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10776_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(57 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10776_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(119,6 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10776_6_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(78,3 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10776_7_ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(479,3 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20151231&edate=20150901&rec=10776">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-11-09T16:49:46+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-11-09T16:49:46+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Viralytics And MSD Colloboration To Investigate Immunotherapy Combination in Bladder Cancer</title>
	<pubDate>2015-11-09T16:25:20+01:00</pubDate>
	<wp:post_id>6733</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Viralytics and MSD has entered a collaboration agreement to evaluate the combination of CAVATAK and Keytruda (Pembrolizumab) in patients with either advanced NSCLC or metastatic bladder cancer.<wbr> This is a Ph1b study and expected to begin in 2016.<wbr> This will be the second phase of Viralytics' ongoing STORM clinical trial.<wbr> Viralytics will provide CAVATAK and sponsor the study; MSD will provide KEYTRUDA and conduct biomarker analysis.<wbr> The agreement includes a provision where the parties may extend the collaboration to include a potential Phase 3 clinical trial.<wbr> Additional details of the collaboration were not disclosed.<wbr> </div><div style="margin-bottom: 10px;">The phase 1b combination trial will be the second stage of Viralytics' ongoing STORM clinical trial.<wbr> The first stage of this study is focusing on assessing the intravenous administration of CAVATAK as a monotherapy in late-stage solid cancer patients.<wbr> Initial results indicate that multiple intravenous infusions of CAVATAK have been well tolerated and have produced potential tumour viral replication in some advanced cancer patients, with anti-tumour activity seen in some individual lesions.<wbr> </div><div style="margin-bottom: 10px;">The second stage of the STORM trial has been re-designed to assess the intravenous delivery of CAVATAK in combination with KEYTRUDA in patients with advanced NSCLC or metastatic bladder cancer.<wbr> The trial will be an open-label, multi-centre study with dose escalation of CAVATAK in combination with fixed doses of KEYTRUDA, followed by an expansion cohort phase.<wbr> The final cohort will contain approximately 80 patients, across both indications.<wbr> The aim of the study is to establish a recommended dose regimen for the CAVATAK/<wbr>KEYTRUDA combination and to evaluate anti-cancer activity and patient tolerability.<wbr> Patient biopsies will be assessed for changes in the tumour microenvironment that may provide a further signal of activity.<wbr> </div><div style="margin-bottom: 10px;">About Viralytics </div><div style="margin-bottom: 10px;">Viralytics is focused on the development and commercialisation of oncolytic immunotherapies that harness the power of certain viruses to preferentially infect and kill cancer cells.<wbr> Our lead product candidate is CAVATAKTM, a proprietary formulation of the common cold Coxsackievirus Type A21 (CVA21).<wbr> <A href="http://www.viralytics.com/our-pipeline/cavatak/cavataktm/" target="_blank" title="About CAVATAKTM">CAVATAK<SUP>TM</SUP></A> is a naturally occurring, genetically unaltered virus with potential activity in a range of cancer types and through both intra-tumoural and intravenous treatment.<wbr> </div><div style="margin-bottom: 10px;">CAVATAK has important potential advantages over current chemotherapy and radiation treatments including:<BR>&bull; Targeted mechanism of action towards external receptors overexpressed specifically on cancer cells<BR>&bull; Potential application across a range of cancer types, including prostate, lung, melanoma and bladder cancers<BR>&bull; Low toxicity with quality-of-life benefits for patients<BR>&bull; Synergies with existing cancer therapies &ndash; there is pre- clinical evidence that CAVATAK used in combination with existing and next-generation products increases the effectiveness of the treatment regimen<BR>&bull; The virus is not genetically modified<BR>&bull; CAVATAK&rsquo;s small molecule size (25nm) enables it to disseminate more widely in the body than larger oncolytic viruses<BR>&bull; Fast replication cycle (6 hours) resulting in a potentially more rapid response </div><div>Source: Vuralytics Press release </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20151231&edate=20150901&rec=10774">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-11-09T16:25:20+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-11-09T16:25:20+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Korean Drugmakers Eye Halal Market</title>
	<pubDate>2015-11-09T14:54:50+01:00</pubDate>
	<wp:post_id>6734</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: South Korean drugmakers are seeking halal certification for their drugs in a bid to tap the growing market as well as diversify and boost their market share.<wbr> Industry experts cite the need to prepare early for the forthcoming policy changes and adhere to consumer preferences in the Islamic world, which takes up around 23% of the world’s population.<wbr> Ildong Pharmaceutical became the first Korean pharma company to receive halal certification from the Korea Muslim Federation (KMF) last September for its lactobacillus supplement Biovita.<wbr> Ildong is now prepared to export not only its finished probiotic drugs but independent base materials to the Muslim community.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Established in 1941 </div><div style="margin-bottom: 10px;"><U>Milestones of Interest</U> </div><div style="margin-bottom: 10px;"><P>2012.<wbr> 04 <!--generated--></P> </div><div style="margin-bottom: 10px;"><TD>Development of ‘Lactobacillus Acidophilus IDCC3302’ and the first domestic registration of DMF(Drug Master File) for each item as raw materials of lactobacillus.<wbr></TD> </div><div style="margin-bottom: 10px;"><STRONG>Biovita</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2639_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2639_2_ScreenCapture2.jpg">  <img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2639_3_ScreenCapture3.jpg"> </div><div>Source: BMI; Korean Herald </div><!-- Comment details --><a name="gastroenterology2639attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2639_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(47,2 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2639_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(46,7 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2639_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(28,3 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20151231&edate=20150901&rec=2639">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-11-09T14:54:50+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-11-09T14:54:50+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Sanofi Sets Up Strategic Roadmap For Long Term Growth</title>
	<pubDate>2015-11-09T14:27:09+01:00</pubDate>
	<wp:post_id>6735</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Sanofi organised a Meet Management Seminar on 6th Nov and Olivier Brandicourt - the new CEO who has joined Sanofisince April 2015 - provided a business update and presented its 2020 roadmap.<wbr> He insisted Sanofi remained &ldquo;strongly committed&rdquo; to reviving its diabetes business, citing two multibillion-dollar licensing deals announced last week with Lexicon Pharmaceuticals of the US and Hanmi of South Korea to develop new treatments for the disease.<wbr>To reach its 2020 vision, a renewed attemp was also promised to crack oncology market to become a "participant" in the immuno-oncology field.<wbr> Further investment and possilby acquistions can be expected in oncology.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11307_1_slide%2011.JPG"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11307_12_slide%2040.JPG"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11307_13_slide%2054.JPG"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11307_2_slide%2012.JPG"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11307_11_slide%2035.JPG"> </div><div style="margin-bottom: 10px;"><STRONG>Strong Cash position for future M&amp;A deals</STRONG> </div><div style="margin-bottom: 10px;"><STRONG><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11307_14_slide%2055.JPG"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11307_15_slide%2056.JPG"></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Reshaping its current protofolio</STRONG> </div><div style="margin-bottom: 10px;"><OL><LI>Strengtheningits Committment in Diabetes,
</LI>
<LI>Sustain leadership in Rare Disease
</LI>
<LI>Focus on BRIC countries such as China, Brazil, Russia and India
</LI>
</OL> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11307_3_slide%2013.JPG"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11307_4_slide%2016.JPG"> </div><div style="margin-bottom: 10px;"><STRONG>Build Competitive positions in Multiple sclerosis, oncology, immunology and consumer healthcare: </STRONG>Mr Brandicourt lamented how Sanofi had &ldquo;made a series of mis-steps&rdquo; that left it absent from an important new category of cancer drugs called immuno-oncology, led by MSD, BMS, Roche and AZ.<wbr> He took the first step towards making up lost ground in July through a deal with Regeneron ($2.<wbr>2B) to jointly develop cancer immunotherapies.<wbr> <BR><EM>&ldquo;We are not saying we will become leader&thinsp;.<wbr>&thinsp;.<wbr>&thinsp;.<wbr>&thinsp;but it means participating in a meaningful way.<wbr> We think we can leapfrog and catch up very quickly&thinsp;.<wbr>&thinsp;.<wbr>&thinsp;.<wbr>&thinsp;I know people are doubtful but we will make sure we prove them wrong.<wbr>&rdquo; </EM> </div><div style="margin-bottom: 10px;"><STRONG><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11307_5_slide%2018.JPG"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11307_6_slide%2019.JPG"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11307_7_slide%2020.JPG"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11307_8_slide%2021.JPG"></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Future Stretegic options: Animal Helath and Generics in Europe.<wbr> A &euro;1.<wbr>5bn cost-saving programme will unlock further capital for growth areas to lift investment in research and development by a fifth to &euro;6bn by 2020.<wbr></STRONG> </div><div style="margin-bottom: 10px;"><STRONG><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11307_9_slide%2023.JPG"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11307_10_slide%2033.JPG"></STRONG> </div><div>Source: Sanofi Investors </div><!-- Comment details --><a name="pharmaworld11307attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11307_1_slide%2011.JPG">slide 11.JPG</a>&nbsp;&nbsp;(101 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11307_2_slide%2012.JPG">slide 12.JPG</a>&nbsp;&nbsp;(121,5 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11307_3_slide%2013.JPG">slide 13.JPG</a>&nbsp;&nbsp;(142,2 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11307_4_slide%2016.JPG">slide 16.JPG</a>&nbsp;&nbsp;(154,8 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11307_5_slide%2018.JPG">slide 18.JPG</a>&nbsp;&nbsp;(120 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11307_6_slide%2019.JPG">slide 19.JPG</a>&nbsp;&nbsp;(110,6 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11307_7_slide%2020.JPG">slide 20.JPG</a>&nbsp;&nbsp;(155,4 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11307_8_slide%2021.JPG">slide 21.JPG</a>&nbsp;&nbsp;(110,1 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11307_9_slide%2023.JPG">slide 23.JPG</a>&nbsp;&nbsp;(133,9 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11307_10_slide%2033.JPG">slide 33.JPG</a>&nbsp;&nbsp;(219,6 KB)<br>&nbsp;&nbsp;11.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11307_11_slide%2035.JPG">slide 35.JPG</a>&nbsp;&nbsp;(142,4 KB)<br>&nbsp;&nbsp;12.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11307_12_slide%2040.JPG">slide 40.JPG</a>&nbsp;&nbsp;(147,7 KB)<br>&nbsp;&nbsp;13.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11307_13_slide%2054.JPG">slide 54.JPG</a>&nbsp;&nbsp;(109,7 KB)<br>&nbsp;&nbsp;14.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11307_14_slide%2055.JPG">slide 55.JPG</a>&nbsp;&nbsp;(109,2 KB)<br>&nbsp;&nbsp;15.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11307_15_slide%2056.JPG">slide 56.JPG</a>&nbsp;&nbsp;(144,5 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20151231&edate=20150901&rec=11307">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-11-09T14:27:09+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-11-09T14:27:09+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Medivation Q3 2015 Financial Results Key Takeaway</title>
	<pubDate>2015-11-09T10:43:23+01:00</pubDate>
	<wp:post_id>6736</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Medivation, Inc.<wbr> reported its financial results for the third quarter ended September 30, 2015.<wbr> U.<wbr>S.<wbr> net sales of XTANDI (enzalutamide) capsules, as reported by Astellas Pharma Inc, were $313.<wbr>0 million for the quarter (+73% vs.<wbr> prior year).<wbr> Third quarter 2015 U.<wbr>S.<wbr> net sales increased by approximately 5% compared with second quarter 2015 net sales of $298.<wbr>4 million.<wbr> Ex-US net sales were $205m for Q3 (+71% vs prior year).<wbr> David Hung (CEO, Medivation) commented on the long term growth is driven by Xtandi beyond prostate cancer (priority focus will be in triple negative breast cancer), pidilizumab, and talazoparib.<wbr> Talazoparib is an oral PARP inhbitor of which Medivation completed the acqusition in Oct 2015.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Xtandi's Perfomance:</STRONG> </div><div style="margin-bottom: 10px;">The sequential quarter increase in net sales was primarily due to an increase in underlying demand (mid-single digit percent growth, compared with June 2015 quarter) and a lower gross-to-net rate recorded by Astellas in the third quarter, which was offset by changes in channel partner inventory levels during the quarters.<wbr><BR><BR>Ex-U.<wbr>S.<wbr> net sales of XTANDI, as reported by Astellas, were approximately $205 million for the quarter (+71% vs.<wbr> prior year).<wbr> Third quarter ex-U.<wbr>S.<wbr> net sales increased by 9% compared with second quarter 2015 net sales of approximately $188 million.<wbr> </div><div style="margin-bottom: 10px;"><UL><LI>Medivation's collaboration revenue related to U.<wbr>S.<wbr> net sales of XTANDI for the third quarter 2015 was $156.<wbr>5 million compared with $90.<wbr>7 million for the same period in 2014 (+73% vs.<wbr> prior year).<wbr>
</LI>
<LI>Medivation's collaboration revenue related to ex-U.<wbr>S.<wbr> net sales of XTANDI for the third quarter 2015 was $33.<wbr>6 million compared with $15.<wbr>5 million for the same period in 2014 (+116% vs.<wbr> prior year).<wbr>
</LI>
<LI>Medivation's collaboration revenue related to upfront and milestone payments for the third quarter 2015 was $70.<wbr>6 million compared with $94.<wbr>2 million for the same period in 2014 (-25% vs.<wbr> prior year).<wbr>
</LI>
</UL> </div><div style="margin-bottom: 10px;">Medivation reported GAAP net income of $79.<wbr>5 million, or $0.<wbr>47 per diluted share, for the quarter ended September 30, 2015, compared with GAAP net income of $78.<wbr>0 million, or $0.<wbr>48 per diluted share, for the same period in 2014.<wbr> Non-GAAP net income for the third quarter of 2015 was $58.<wbr>4 million, or $0.<wbr>35 per diluted share, compared with non-GAAP net income of $16.<wbr>3 million, or $0.<wbr>10 per diluted share, for the same period in 2014.<wbr> </div><div style="margin-bottom: 10px;">Medivation's collaboration revenue for the third quarter of 2015 was $260.<wbr>7 million on a GAAP basis compared with $200.<wbr>5 million for the same period in 2014 (+30% vs.<wbr> prior year).<wbr> Non-GAAP collaboration revenue, which excludes collaboration revenue related to upfront and milestone payments, was $190.<wbr>1 million for the third quarter compared with $106.<wbr>2 million for the same period in 2014 (+79% vs.<wbr> prior year).<wbr> <BR><BR>Medivation's collaboration revenue consists of three components: collaboration revenue related to U.<wbr>S.<wbr> XTANDI net sales, collaboration revenue related to ex-U.<wbr>S.<wbr> XTANDI net sales, and collaboration revenue related to upfront and milestone payments.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><SPAN style="text-decoration: underline;">Enzalutamide Development Program </SPAN></STRONG><BR>Reported updated data in September 2015 from a Phase 2 trial evaluating the investigational use of enzalutamide as a single agent for the treatment of advanced androgen receptor positive, triple-negative breast cancer at the 2015 European Cancer Congress.<wbr> </div><div style="margin-bottom: 10px;"><BR><STRONG><SPAN style="text-decoration: underline;">Medivation Financial:</SPAN> </STRONG> </div><div style="margin-bottom: 10px;"><BR>Operating expenses were $121.<wbr>7 million for the quarter ended September 30, 2015 on a GAAP basis compared with $108.<wbr>6 million for the same period in 2014.<wbr> Non-GAAP operating expenses were $98.<wbr>8 million for the quarter ended September 30, 2015 compared with $79.<wbr>3 million for the same period in 2014.<wbr> <BR><BR>Selling, general and administrative (SG&amp;A) expenses for the third quarter of 2015 were $75.<wbr>8 million on a GAAP basis compared with $63.<wbr>2 million for the same period in 2014.<wbr> Non-GAAP SG&amp;A expenses for the third quarter of 2015 were $58.<wbr>8 million, compared with $47.<wbr>5 million for the same period in 2014.<wbr> The increase in non-GAAP SG&amp;A expenses primarily relates to higher sales, marketing, administrative expenses, higher royalties to UCLA and higher personnel-related costs (excluding stock-based compensation).<wbr> <BR><BR>Research and development (R&amp;D) expenses for the third quarter of 2015 were $45.<wbr>9 million on a GAAP basis compared with $45.<wbr>4 million for the same period in 2014.<wbr> Non-GAAP R&amp;D expenses for the third quarter of 2015 were $40.<wbr>0 million, compared with $31.<wbr>8 million for the same period in 2014.<wbr> The increase in non-GAAP R&amp;D expenses primarily relates to higher pidilizumab (MDV9300) costs, higher facilities and information technology costs and higher personnel-related costs (excluding stock-based compensation).<wbr> <BR><BR>At September 30, 2015, cash and cash equivalents were $488.<wbr>9 million, compared with $502.<wbr>7 million at December 31, 2014.<wbr> During the third quarter, we completed the redemption of the 2017 Convertible Notes, utilizing $167.<wbr>8 million of cash.<wbr> In October 2015, we utilized $410.<wbr>0 million in cash to fund an upfront payment to BioMarin Pharmaceutical Inc.<wbr>, for the acquisition of talazoparib (MDV3800).<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Recent Corporate Developments</STRONG> <BR><BR>Closed the acquisition on October 6, 2015, for all worldwide rights to talazoparib, an orally-available poly ADP ribose polymerase (PARP) inhibitor.<wbr> In connection with the closing, Medivation made an up-front payment of $410.<wbr>0 million to BioMarin in the fourth quarter of 2015.<wbr> All other amounts to be paid to BioMarin in connection with this transaction will be subject to the successful achievement of certain regulatory and sales-based milestones and royalties relating to talazoparib.<wbr> <BR><BR>Effected a two-for-one stock split in the form of a stock dividend on Medivation's common stock, pursuant to which stockholders of record on August 13, 2015, received an additional share of common stock for each share they held as of the record date.<wbr> Approximately 81.<wbr>7 million common shares were issued as a result of the stock dividend in mid-September.<wbr> Medivation's common stock began trading on a post-dividend basis on the NASDAQ Global Select Market at the opening of trading on September 16, 2015.<wbr> <BR><BR>Entered into a Credit Agreement with JPMorgan Chase Bank, N.<wbr>A.<wbr>, as administrative agent, and the lenders, providing for a one-year $75.<wbr>0 million revolving loan facility.<wbr> On September 17, 2015, Medivation executed a borrowing of $75.<wbr>0 million under the Revolving Credit Facility, which was scheduled to mature on March 17, 2016.<wbr> On October 23, 2015, Medivation entered into an amendment and restatement of the credit agreement providing for a five-year $300.<wbr>0 million revolving loan facility and an uncommitted accordion facility subject to the satisfaction of certain conditions.<wbr> On October 23, 2015, Medivation borrowed $75.<wbr>0 million under the amended revolving credit facility, which was used to repay the $75.<wbr>0 million outstanding under the original credit agreement.<wbr> </div><div>Source: Medivation Press Release </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20151231&edate=20150901&rec=10755">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-11-09T10:43:23+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-11-09T10:43:23+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>AstraZeneca Q3 Results - Opportunity for Growth in Emerging Markets</title>
	<pubDate>2015-11-09T09:58:29+01:00</pubDate>
	<wp:post_id>6737</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Management reported that emerging markets grew by 10%.<wbr> There was an uptick in Q3 growth in China to 11% YOY (CER) and USD 622 million, from 10% in Q2, and equating to 17% YOY growth over the first 9 months of the year to USD 1.<wbr>931 billion.<wbr> The country represents an opportunity for both asthma and COPD (Pulmicort was up 47% and remains AZ' lead product by sales).<wbr> For Oncology, Iressa (gefitinib) sales were up 8% YOY to USD 119 million, Zoladex (goserelin) grew by 35% to USD 91 million, and recently launched Faslodex (fulvestrant) reached USD 7 million, up 50%.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10752_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10752_2_ScreenCapture2.jpg"> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10752_1_ScreenCapture1.jpg"> </div><!-- Comment details --><a name="oncology10752attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10752_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(62,4 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10752_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(67,8 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10752_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(34,9 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20151231&edate=20150901&rec=10752">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-11-09T09:58:29+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-11-09T09:58:29+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Allergan R&D Day - Key Takeaways</title>
	<pubDate>2015-11-06T23:28:38+01:00</pubDate>
	<wp:post_id>6738</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The Allergan R&amp;D day was conducted in Irvine California, highlighting a new operational model of an open science strategy, supported with over 70 Mid-to-Late Stage Development Programs.<wbr> The key therapeutic areas of focus were; Gastroenterology: CNS, Medical Aesthetics &amp; Dermatology, Women's Health, Urology, Anti-Invectives&rsquo; and Eye care.<wbr> Botox was highlighted in three TAs, CNS, Aesthetics &amp; Biosimilars albeit with little detail disclosed on anything potentially competitvely sensitive other than a brief reference to MT10109L (Medytox) in Ph2 for facial lines and Botox X in PhI for spasticity.<wbr> An outlook of $1B in sales, however, was suggested for new indications.<wbr> </div><div style="margin-bottom: 10px;">Allergan positions themselves as having an Open Science R&amp;D model that will drive area leadership and the company's long-term growth.<wbr> The initial assumptions of Brenton Saunders (CEO) holding back on clinical development, as he was viewed in other companies he had worked for, was not the impression this day elicited.<wbr> The change in direction is thought to be due to a dramatic change in the pharmaceutical industry <EM>"Over the past 15 years, the pharmaceutical innovation ecosystem has shifted.<wbr> Where global pharma companies had previously driven the lion's share of new product revenue, now the driving source of innovation is coming from smaller biotechnology and specialty pharma companies, as well as academia.<wbr> We bring these programs into our best-in-class product development and commercialization platform to build a sustainable R&amp;D portfolio that enables Allergan to continue to be a leader in Growth Pharma,"</EM> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_8235_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_8235_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;">Updates by therapeutic are includes: </div><div style="margin-bottom: 10px;"><STRONG>Gastroenterology:</STRONG> Building on IBS Leadership and Addressing Unmet Needs </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_8235_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;">&bull;5 mid-to-late stage Gastroenterology (GI) development programs </div><div style="margin-bottom: 10px;">&bull;VIBERZI&trade; receives Drug Enforcement Agency (DEA) schedule IV recommendation </div><div style="margin-bottom: 10px;">&bull;Phase 2b study of Relamorelin for diabetic gastroparesis currently enrolling; top-line data expected Q2 2016 </div><div style="margin-bottom: 10px;"><STRONG>CNS</STRONG>: Focused Development in Undertreated Areas of Mental Health </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_8235_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_8235_5_ScreenCapture5.jpg"> </div><div style="margin-bottom: 10px;">&bull;9 mid-to-late stage CNS development programs </div><div style="margin-bottom: 10px;">&bull;Ubrogepant Phase 2 study showed achievement of acute pain relief and migraine freedom at two hours, and a favourable adverse event profile; Phase 3 study planned.<wbr> </div><div style="margin-bottom: 10px;">&bull;Rapastinel demonstrated rapid response and sustained effect after a single-dose in Phase 2a study in Major Depressive Disorder; Phase 3 ready compound </div><div style="margin-bottom: 10px;">&bull;VRAYLAR&trade; (cariprazine) being investigated for treatment of bipolar depression and as adjunctive MDD therapy in adults.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Women's Health &amp; Urology</STRONG>: Expanding Therapeutic Area Scope </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_8235_6_ScreenCapture6.jpg"> </div><div style="margin-bottom: 10px;">&bull;8 mid-to-late stage Women's Health, Urology development programs </div><div style="margin-bottom: 10px;">&bull;Two pivotal studies for Esmya in uterine fibroids on-going in U.<wbr>S.<wbr>; Allergan expects NDA submission in 2017 </div><div style="margin-bottom: 10px;">&bull;SER-120 Phase 3 studies for nocturia completed; Allergan expects NDA submission in 2016 </div><div style="margin-bottom: 10px;"><STRONG>Anti-Invectives&rsquo;</STRONG>: Meeting the Critical Need for Innovation in Antibiotic Resistance </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_8235_8_ScreenCapture8.jpg"> </div><div style="margin-bottom: 10px;">&bull;5 mid-to-late stage Anti-Infective development programs </div><div style="margin-bottom: 10px;">&bull;AVYCAZ&reg; Phase 3 studies completed; Allergan expects to file sNDA for complicated intra-abdominal infections (cIAI) by end of 2015; sNDA for complicated urinary tract infections (cUTI) TI in Q3 2016 </div><div style="margin-bottom: 10px;">&bull;DALVANCE&reg; Phase 3 study shows safety and efficacy of single-dose regimen compared to two-dose regimen in adults with acute bacterial skin and skin structure infections (ABSSSI); Data submitted to FDA and EMA to support single-dose indication for ABSSSI.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Medical Aesthetics &amp; Dermatology</STRONG>: Leveraging Industry Leading Aesthetic Position to Drive Innovation </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_8235_9_ScreenCapture9.jpg"> </div><div style="margin-bottom: 10px;">&bull;21 mid-to-late stage Medical Aesthetics and Dermatology development programs </div><div style="margin-bottom: 10px;">&bull;Allergan studying KYBELLA&reg; as a potential treatment for additional medical and aesthetic conditions, including the reduction of discrete, localized subcutaneous fat, and potential extension into therapeutic applications.<wbr> </div><div style="margin-bottom: 10px;">&bull;KYTH-105 for hair growth IND filed with FDA earlier this year; Allergan planning Phase 2 proof of concept study </div><div style="margin-bottom: 10px;">&bull;Bimatoprost for hair growth shows favourable safety profile in proof-of-concept study; Allergan planning Phase 1 pharmacokinetic and Phase 2b studies planned for Q1 2016 </div><div style="margin-bottom: 10px;">&bull;AGN-199201 (Oxymetazoline) Phase 3 study in rosacea completed; NDA submission expected in Q1 2016 </div><div style="margin-bottom: 10px;">&bull;Sarecycline currently in Phase 3 study; potential treatment for acne vulgaris </div><div style="margin-bottom: 10px;">&bull;Aczone&reg; 7.<wbr>5% NDA submitted in 2015; approval anticipated in 2016 </div><div style="margin-bottom: 10px;"><STRONG>Neuromodulators</STRONG>: Building on a World-Class Pipeline in a Product </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_8235_10_ScreenCapture10.jpg"> </div><div style="margin-bottom: 10px;">&bull;12 new Botox&reg; indications in development; an additional 6 potential indications under consideration </div><div style="margin-bottom: 10px;">&bull;3 new Neuromodulator toxins in development </div><div style="margin-bottom: 10px;">&bull;Botox&reg; Cosmetic indications in development include forehead lines (FHL), Glabellar Lines (GL), Crow's Feet Lines (CFL) </div><div style="margin-bottom: 10px;">&bull;Therapeutic indications for Botox in development includes Juvenile Cerebral Palsy </div><div style="margin-bottom: 10px;">&bull;Potential indications include atrial fibrillation, platysma </div><div style="margin-bottom: 10px;"><STRONG>Eye Care:</STRONG> Owning the Eye through Continued Innovation </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_8235_11_ScreenCapture11.jpg"> </div><div style="margin-bottom: 10px;">&bull;17 mid-to-late stage eye care development programs </div><div style="margin-bottom: 10px;">&bull;Restasis&reg; Multi-Dose Preservative-Free (MDPF) U.<wbr>S.<wbr> Prior Approval Supplement submitted in 2015; awaiting approval and launch </div><div style="margin-bottom: 10px;">&bull;Oculeve, first dry eye ophthalmic electroceutical; pivotal trials on track </div><div style="margin-bottom: 10px;">&bull;Bimatoprost SR Phase 2 study for glaucoma completed; results to be presented at American Academy of Ophthalmology (AAO) Meeting November 15, 2015 </div><div style="margin-bottom: 10px;">&bull;Ozurdex&reg; Protocol I study in diabetic macular edema (DME) to be presented at AAO </div><div style="margin-bottom: 10px;">&bull;DARPin&reg; initial top line results from 50998-004 PALM study supports 12 weeks duration of treatment with safety comparable to AMD studies, two Phase 3 studies in AMD initiated in Q2 2015, with recruitment in progress.<wbr> </div><div style="margin-bottom: 10px;">The key topics of focus for Ipsen are within the Aesthetic market, Botox current indications and future indications.<wbr> Amongst these topics, the question and answer question provided the most insight.<wbr> </div><div style="margin-bottom: 10px;"><EM>Aesthetic market: </EM> </div><div style="margin-bottom: 10px;">Steve Dayan, Medical Director, Principal Investigator &amp; Founder of DeNova Research, highlighted the change in expectations of aesthetic medicine from just trying to look beautiful to feeling beautiful.<wbr> Allergan wants to help drive this customer centric refocus &ldquo;<EM>It&rsquo;s an opportunity to take the lead if we look at aesthetics differently.<wbr> If you understand those concepts, then you understand where aesthetics is going, because today we have double-blind, placebo-randomized, controlled trials.<wbr>.<wbr>.<wbr>Do we only make people more beautiful? This is what we thought of; this is the primitive component to aesthetic medicine.<wbr> Or do we make them more attractive? There's a difference&rdquo;</EM> The basis is that aesthetics is more than just form and function it&rsquo;s also the ability to improve mind and mood.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_8235_12_ScreenCapture12.jpg"> </div><div style="margin-bottom: 10px;">The Botox franchise shows continued development and growth.<wbr> Investment into new indications in addition to supporting current indications in development shows a strong LCM strategy.<wbr> </div><div style="margin-bottom: 10px;"><SPAN style="font-size: 11pt; font-family: 'Calibri','sans-serif'; line-height: 115%; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-fareast-language: EN-US; mso-ansi-language: EN-GB; mso-bidi-language: AR-SA;">As David <SPAN style="font-size: 11pt; font-family: 'Calibri','sans-serif'; line-height: 115%; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-fareast-language: EN-US; mso-bidi-font-weight: bold; mso-ansi-language: EN-GB; mso-bidi-language: AR-SA; mso-bidi-font-size: 12.0pt;">Nicholson EVP, Brand R&amp;D highlighted </SPAN></SPAN><EM>&ldquo;The point that we want to make here is that we haven't finished identifying the novel indications for Botox.<wbr> We will be initiating studies for Platysma and we are going to start evaluating Botox for postoperative atrial fibrillation&rdquo; </EM>This new indication was on the back of an investigator initiated trial showing the positive effects of Botox to reduce postsurgical AF.<wbr> Allergan will be evaluating themselves within its own clinical trials in the coming years </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_8235_13_ScreenCapture13.jpg"> </div><div style="margin-bottom: 10px;">In terms of early development, Brent and Daniel only briefly touched on the new novel toxins coming from both Allergan clinical labs and its partnership with Medytox <EM>&ldquo;We are looking at novel toxins coming out of our own laboratory and novel toxins coming out of our collaboration with Medytox.<wbr> And we will be seeing to what extent we can distinguish these novel toxins from Botox and evaluating whether there is any need to come up with novel formulations or not&rdquo;</EM> Allergan wants to ensure Botox is positioned alongside any new neurotoxins to avoid cannibalization and provide customers a portfolio of neurotoxin options </div><div style="margin-bottom: 10px;">The pII indications were still in development, so were not discussed.<wbr> For the pIII trials, Brent only mentioned the work in pediatric OAB and NDO and forehead lines.<wbr> </div><div style="margin-bottom: 10px;">Overall David emphasized the potential revenue generation from further expansion of the Botox franchise <EM>&ldquo;So, I think that underlines the point that we still continue to develop Botox, we will continue to develop it and we do believe that these new indications are going to generate in excess of $1 billion in additional revenues&rdquo;</EM> </div><div style="margin-bottom: 10px;"><EM><EM>&ldquo;</EM><EM>The targeted toxin, we have this project called senrebotase, which is basically sort of a link between Botox and ORL1.<wbr> The goal of this was to selectively target sensory neurons to be effective in postherpetic neuralgia.<wbr> Now there's two issues here.<wbr> One is whether or not this approach was going to work as an individual molecule and the other is what it could teach us about targeting with Botox.<wbr> We are presently evaluating the data from the study and we need to make some decisions what that means for the concept of targeting </EM></EM><EM>with Botox, and we are still working our way through that&rdquo;</EM> Our understanding of the situation was that development into this area had been scaled back with the last trial on clinicaltrials.<wbr>gov in pIII recently terminated </div><div>Source: Allergan </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Neurology8240c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">For those of us wanting to understand the progress of the senrebotase molecule, the final paragraph here is useful ("<EM><EM>The targeted toxin, we have this project called senrebotase, which is basically sort of a link between Botox and ORL1.<wbr> The goal of this was to selectively target sensory neurons to be effective in postherpetic neuralgia.<wbr> Now there's two issues here.<wbr> One is whether or not this approach was going to work as an individual molecule and the other is what it could teach us about targeting with Botox.<wbr> We are presently evaluating the data from the study and we need to make some decisions what that means for the concept of targeting </EM></EM><EM>with Botox, and we are still working our way through that&rdquo;</EM> Our understanding of the situation was that development into this area had been scaled back with the last trial on clinicaltrials.<wbr>gov in pIII recently terminated).<wbr> </div><div>Firstly, I don't recall AGN providing any information on the targeting ligand previously.<wbr>  Secondly, there is a comment about whether the molecule would work in combination, and thirdly a recognition that there are decisions to be made about the concept of BoNT fragment retargeting.<wbr>  Also, please note it was a PhII trial that was terminated rather than a PhIII one.<wbr> </div></div><a name="neurology8235attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_8235_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(33 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_8235_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(40,2 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_8235_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(6,6 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_8235_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(17,4 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_8235_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(47 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_8235_6_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(15,6 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_8235_7_ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(27 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_8235_8_ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(26,7 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_8235_9_ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(48,9 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_8235_10_ScreenCapture10.jpg">ScreenCapture10.jpg</a>&nbsp;&nbsp;(24 KB)<br>&nbsp;&nbsp;11.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_8235_11_ScreenCapture11.jpg">ScreenCapture11.jpg</a>&nbsp;&nbsp;(35 KB)<br>&nbsp;&nbsp;12.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_8235_12_ScreenCapture12.jpg">ScreenCapture12.jpg</a>&nbsp;&nbsp;(27,8 KB)<br>&nbsp;&nbsp;13.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_8235_13_ScreenCapture13.jpg">ScreenCapture13.jpg</a>&nbsp;&nbsp;(55,7 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20151231&edate=20150901&rec=8235">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-11-06T23:28:38+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-11-06T23:28:38+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Lexicon Signs Sanofi Collaboration For Sotagliflozin in Diabetes And Releases Q3 2015 Results</title>
	<pubDate>2015-11-06T17:55:23+01:00</pubDate>
	<wp:post_id>6739</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Lexicon, together with the Q3 2015 results, announced today the collaboration and worldwide licence agreement with Sanofi for the development and commercialization of sotaglifozin, a new dual inhibitor of sodium-glucose cotransporter 1 and 2 (SGLT-1 and SGLT-2), a potential oral treatment option for people with diabetes.<wbr> Under the terms of the agreement, Lexicon will receive an upfront payment of $300 million and is eligible to receive development, regulatory and sales milestone payments of up to $1.<wbr>4 billion.<wbr> <SPAN style="line-height: 1.5em;">Sotagliflozin is currently being studied in two pivotal Phase 3 trials in type 1 diabetes, which are expected to report top-line results during the second half of 2016.<wbr> Phase 3 trials in type 2 diabetes are expected to begin in 2016 and Lexicon commented on ' the need to discuss the timelines with Sanofi, while the protocol is ready to go'.<wbr> </SPAN> </div><div style="margin-bottom: 10px;">Lexicon will continue to be responsible for all clinical development activities relating to type 1 diabetes and will retain an exclusive option to co-promote and have a significant role, in collaboration with Sanofi, in the commercialization of sotagliflozin for the treatment of type 1 diabetes in the United States.<wbr> Sanofi will be responsible for all clinical development and commercialization activities of sotagliflozin for the treatment of type 2 diabetes worldwide and will be solely responsible for the commercialization of sotagliflozin for the treatment of type 1 diabetes outside the United States.<wbr> Lexicon will share in the funding of a portion of the planned type 2 diabetes development costs over the next three years, up to an aggregate of $100 million.<wbr> </div><div style="margin-bottom: 10px;">On the Q3 2015 results, Lexicon&rsquo;s revenues for the three months ended September 30, 2015 increased to $0.<wbr>6 million from $0.<wbr>4 million for the corresponding period in 2014, and for the nine months ended September 30, 2015 increased to $2.<wbr>7 million from $1.<wbr>4 million for the corresponding period in 2014.<wbr> The Q3 2015 results did not reflect any impact on Sanofi collaboration.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8265_1_1.JPG"> <img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8265_2_2.JPG"> <img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8265_3_3.JPG"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8265_4_5.JPG">  <img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8265_5_6.JPG"> </div><div style="margin-bottom: 10px;">Also enclosed here (in power point format - please see the attachments) the info Lexicon shared on Sotaglifozin at Wedbush Healthcare conference back in August 2015, with details on market potential and product profile.<wbr> </div><div>Source: Lexcion PR and Wedbush Healthcare </div><!-- Comment details --><a name="endocrinology8265attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8265_1_1.JPG">1.JPG</a>&nbsp;&nbsp;(83,9 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8265_2_2.JPG">2.JPG</a>&nbsp;&nbsp;(77,9 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8265_3_3.JPG">3.JPG</a>&nbsp;&nbsp;(69,9 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8265_4_5.JPG">5.JPG</a>&nbsp;&nbsp;(66,7 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8265_5_6.JPG">6.JPG</a>&nbsp;&nbsp;(46,4 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8265_6_Sotaglifozin%255fWedbush%255fLexicon%255fAugust%255f2015.pptx">Sotaglifozin_Wedbush_Lexicon_August_2015.pptx</a>&nbsp;&nbsp;(3,3 MB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20151231&edate=20150901&rec=8265">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-11-06T17:55:23+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-11-06T17:55:23+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>China's Tarrex and Finland's Aranda to Co-develop Aranda’s AR Antagonist for CRPC in China</title>
	<pubDate>2015-11-06T10:25:51+01:00</pubDate>
	<wp:post_id>6740</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Aranda is a privately owned drug discovery company focused on novel small molecules to combat prostate cancer and neurodegenerative diseases.<wbr> The company acquired its lead asset, the androgen receptor antagonist for advanced prostate cancer, from Medeia Therapeutics, also of Finland.<wbr> Aranda’s AR antagonist has demonstrated efficacy in cellular and animal models of prostate cancer that are resistant to current treatment options.<wbr> It in late-stage preclinical development.<wbr> The PR reports that it "will soon begin regulatory safety pharmacology and toxicology studies".<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Start up discovery company </div><div style="margin-bottom: 10px;">Located in Xiamen, a southern coastal city of China </div><div style="margin-bottom: 10px;">Develops novel anti-cancer through in-licensing or collaborations with universities, research institutions or other small biotech firms.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10749_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Founded in 2006 </div><div style="margin-bottom: 10px;">Private biotechnology company dedicated to discover and develop completely new therapeutic approaches for diseases with high unmet medical needs.<wbr> </div><div style="margin-bottom: 10px;">Medeia’s focus areas include the discovery, preclinical research and early development of novel therapeutics.<wbr> Our R&amp;D programs aim at developing small molecules for life-threatening conditions of the elderly, focusing especially on serious neurological diseases such as Alzheimer’s disease, Parkinson’s disease, Amyotrophic lateral sclerosis and other degenerative diseases.<wbr> </div><div>Medeia operates under a semi-virtual business model- we outsource all non-core business functions while retaining seamless control over key technology assets, strategic partnerships and financial management with a small core group of highly experienced employees.<wbr> </div><!-- Comment details --><a name="oncology10749attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10749_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(102,8 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20151231&edate=20150901&rec=10749">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-11-06T10:25:51+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-11-06T10:25:51+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Allergan Q3 Financial Results Showed Strong Sales And An Execution Plan For Long-Term Sustainable Growth</title>
	<pubDate>2015-11-05T20:02:16+01:00</pubDate>
	<wp:post_id>6741</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Allergan Q3 finance update revealed a 90% strong revenue growth, new acquisitions and an intact plan for the divestiture of its generics portfolio to Teva.<wbr>  The recent Revance results was downplayed by Brenton Saunders </div><div style="margin-bottom: 10px;">Allergan sales surged 90.<wbr>1% year-over-year to $4.<wbr>1 billion with net income reaching $5.<wbr>3 billion, up from a loss of about $1 billion in the year-ago period.<wbr>  CEO Brent Saunders remarked " The company experienced volume-driven year-over-year growth in our US brands, medical aesthetics, international brands and Anda distribution segments.<wbr>" </div><div style="margin-bottom: 10px;">In the recent quarter, US branded revenue rose 50% to $2.<wbr>4B while its medical aesthetics business amassed $457M in sales.<wbr>  Botox reached $605M in sales with continued strong growth in both therapeutic and aesthetic indications totalling 13% excluding foreign exchange.<wbr>  These figures occurred despite the $178M revenue decline in Namenda® IR as a result of generic entry </div><div style="margin-bottom: 10px;">Brent noted that Allergan remains on track to complete its previously announced divestment of its global generics drug business to Teva for $40.<wbr>5 billion.<wbr> </div><div style="margin-bottom: 10px;">Some of the key slides from the presentations are below </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_8233_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_8233_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;">At the Q&amp;A section William J Meury (VP and President of Branded Pharma) discussed the main therapeutic growth drivers for Botox as overactive bladder and migraine “Both indications are growing at a high double digit rate.<wbr> The core indications, the original indications are relatively stable.<wbr> Listen, in both those conditions, it's a highly effective product and it's also very economical.<wbr>  I expect that both indications can continue to grow for the next several years” </div><div style="margin-bottom: 10px;">Brent, briefly touched on the new toxins outside of Botox positioning it as a future portfolio offering “Second, we continue to think about therapeutic BOTOX as with new toxins for the future, but that's a longer-term strategy” </div><div style="margin-bottom: 10px;">In light of the Revance interim BELMONT study results which investigated RT002 H-2-H with Botox in Glabellar Lines, Allergan took a strong stance playing down the duration of action and the possible impact it could have when compared to Botox and everything it offers.<wbr>  The study showed that a double dose (40U) of RT002 was required to show a sustained difference to Botox.<wbr>  Brent remarks “(There are)competitive toxins already in the market, if you talk to customers, very few care about having an extra few weeks or a month of duration or effect for BOTOX or toxins.<wbr> And in fact, what they mostly complain about is price.<wbr> And in our competitors' price, their toxin's at a much lower rate than we price BOTOX, and yet BOTOX continues to be a strong market leader.<wbr> And so I would just urge you to keep perspective.<wbr> We have 2 million members in Brilliant Distinctions, a full range of facial aesthetics and the largest field force.<wbr> BOTOX is the number one branded pharmaceutical brand in the world.<wbr> And so, this is a very strong franchise with very good staying power.<wbr> And so, sometimes there's a hammer looking for a nail, duration may be just that” </div><div style="margin-bottom: 10px;">David Nicholson (VP and Brand and Research &amp; Development) joined in on the discussion “BOTOX of course is a pipeline in a product.<wbr> We remain committed to continuing to build the pipeline.<wbr> We will be launching new indications for BOTOX around the world.<wbr> And we will be developing BOTOX in a new therapeutic application.<wbr> I would point out, if we're talking about duration, that BOTOX in some indications has a duration for up to nine months.<wbr> So if you're talking about hyperhidrosis for instance, BOTOX works for up to nine months.<wbr> And so the duration of BOTOX depends on the use and the dose that we administer” </div><div>Source: Allergan </div><!-- Comment details --><a name="neurology8233attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_8233_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(66,9 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_8233_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(49,4 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20151231&edate=20150901&rec=8233">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-11-05T20:02:16+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-11-05T20:02:16+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Roche's R&D Update Highlights Immunotherapy Focus</title>
	<pubDate>2015-11-05T19:06:47+01:00</pubDate>
	<wp:post_id>6742</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Roche focused the immunotherapy section of its R&amp;D day on the manner in which the IO approach will change the face of cancer treatment.<wbr>The scale of the investment by Roche and other companies is immense with 400 studies now ongoing involving 20 companies and $4bn in R&amp;D.<wbr> That said the complexity of what is trying to be achieved should not be underestimated.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10747_2_ScreenCapture2.jpg"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10747_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10747_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10747_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;">Many combination approaches are beginning to be evaluated including combination of IO with chemotherapy, Avastin, targeted agents and new immunotherapy doublets </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10747_5_ScreenCapture5.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10747_6_ScreenCapture6.jpg"> </div><div style="margin-bottom: 10px;">Roche is slightly unique in being able to leverage two of its businesses i.<wbr>e.<wbr> pharma and diagnostics with the latter developing tools to characterise DNA &amp; RNA sequencing, protein expression, cell free tumour DNA and immuno imaging.<wbr> </div><div style="margin-bottom: 10px;">Two slides shown by Cathi Ahearn | Lifecycle Leader Atezolizumab, Lung and GU Genentech/<wbr>Roche illustrate the speed with which development is occurring.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10747_7_ScreenCapture7.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10747_8_ScreenCapture8.jpg"> </div><div style="margin-bottom: 10px;">In terms of bladder cancer per se the treatment algorithm that is the main focus of Roche's activities is shown below with the timelines for individual trials targeting various sub-segments of the metasatic BC treatment algorithm also highlighted.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10747_9_ScreenCapture9.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10747_10_ScreenCapture10.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10747_11_ScreenCapture11.jpg"> </div><div style="margin-bottom: 10px;">Beyond Immunotherapy Roche also presented exciting data on its new multiple sclerosis treatment ocrelizumab which has demonstrataed remarkable results in the ORATORIO study providing the first positive efficacy outcomes seen in patients with primary progressive multiple sclerosis.<wbr> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10747_12_ScreenCapture12.jpg"> </div><!-- Comment details --><a name="oncology10747attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10747_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(191,4 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10747_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(151,1 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10747_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(165,5 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10747_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(224,5 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10747_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(194,4 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10747_6_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(194 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10747_7_ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(168,8 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10747_8_ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(298,9 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10747_9_ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(120,1 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10747_10_ScreenCapture10.jpg">ScreenCapture10.jpg</a>&nbsp;&nbsp;(136,8 KB)<br>&nbsp;&nbsp;11.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10747_11_ScreenCapture11.jpg">ScreenCapture11.jpg</a>&nbsp;&nbsp;(113,1 KB)<br>&nbsp;&nbsp;12.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10747_12_ScreenCapture12.jpg">ScreenCapture12.jpg</a>&nbsp;&nbsp;(105,6 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20151231&edate=20150901&rec=10747">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-11-05T19:06:47+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-11-05T19:06:47+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Singapore GIC Invests $85m Into Bloomage Bio Technology, Part Of The Joint BoNT A Venture With Medytox</title>
	<pubDate>2015-11-05T18:23:02+01:00</pubDate>
	<wp:post_id>6743</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Sovereign wealth fund Singapore GIC has invested $85M (HK$659M) into Bloomage Technology.<wbr>  Bloomage is a Korean aesthetics company that set up a joint venture with Medytox in July of this year to develop and promote BoNT in China </div><div style="margin-bottom: 10px;">Bloomage is known for its modified hyaluronic acid sodium gel, hyaluronic acid filler, 'BioHyalux' as well as manufacturing medical skin care products.<wbr>  It’s a leading medical cosmetics and services firm in China.<wbr>  It’s thought that Bloomage will use these funds to invest in organic growth and external acquisitions to support its growth strategy as stated by a Bloomage reprehensive “Inject vitality into the aesthetic medical ecosystem in China and drive the Group’s domestic and global expansion,” </div><div>Source: Bloomberg business </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20151231&edate=20150901&rec=8232">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-11-05T18:23:02+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-11-05T18:23:02+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Allergan Plans an Aggressive U.S Launch of Viberzi (eluxadoline) for IBS-D</title>
	<pubDate>2015-11-05T17:02:25+01:00</pubDate>
	<wp:post_id>6744</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: At R&amp;D day management indicated that the company would initiate an aggressive DTC program, and a" big investment" to activate patient awareness approx.<wbr> 3 months post launch of Viberzi (expected in few weeks).<wbr> The EU launch is expected in 2017.<wbr> Bill Meury highlighted it is the perfect complement to Linzess (for IBS-C), and having now both products, one for IBS-constipation and one for IBS-diarrhea represents a 'real competitive advantage'.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Q3 sales of Linzess</STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>Another quarter of double-digit growth as conversion of OTC users continues and awareness among consumers created by DCT campaign is much higher.<wbr>
</LI>
<LI>Total prescription volume was up 38% as a result of consumer advertising and long-term care launch compared to the same quarter prior year
</LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG>Promotion and Launch of Viberzi</STRONG> </div><div style="margin-bottom: 10px;">Management outlined that: </div><div style="margin-bottom: 10px;">" .<wbr>.<wbr>.<wbr> this will be one of the largest launches in the industry, from an investment standpoint, and I'm pretty sure it's going to be the largest launch in gastroenterology.<wbr> It's going to be very noisy.<wbr> </div><div style="margin-bottom: 10px;">We know how to do this.<wbr> We did it with Ironwood during the launch of Linzess.<wbr> The DTC advertising will start not one year after approval, but only three months.<wbr> And the promotional effort, unlike other companies in the area, will capture not only gastroenterologists but primary care physicians.<wbr> And there's an interplay in almost every category between primary care and specialty that we can navigate that other companies can't.<wbr> And I would expect that this drug should do as well as Linzess does on the other side of the market, and could ultimately almost double the size of our GI business over the next five years".<wbr> </div><div><STRONG>Co-Promotion of Linzess: </STRONG>See <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20151231&edate=20150901&rec=2495" class="defaultlink">GastroEnterology2495: Ironwood and Allergan to Co-Promote VIBERZI (eluxadoline) for IBS-D in the U.<wbr>S</a> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20151231&edate=20150901&rec=2633">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-11-05T17:02:25+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-11-05T17:02:25+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Takeda Vaccines Takes a Stake in Univercells to Supply Low-Cost Vaccines</title>
	<pubDate>2015-11-05T11:51:15+01:00</pubDate>
	<wp:post_id>6745</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Univercells' platform will be used for Takeda's viral vaccines.<wbr> Univercells uses process intensification and single-use solutions to reduce infrastructure investment and allow local, flexible production; it claims it can reduce the price of biologics by 75% to 90%.<wbr> Takeda has the most advanced norovirus vaccine candidate in the world: TAK-214 in Ph2b.<wbr> (expected to enter global Ph3 in fiscal years 2015-16).<wbr> </div><div style="margin-bottom: 10px;"><STRONG>About TAK-214</STRONG> </div><div style="margin-bottom: 10px;">In Sept 2015, Takeda completed the Ph2 trial in Norovirus infections (In adolescents, In adults, Prevention) in Belgium (NCT02038907: Safety and Immunogenicity of Norovirus GI.<wbr>1/<wbr>GII.<wbr>4 Bivalent VLP Vaccine (NOR-107).<wbr> </div><div style="margin-bottom: 10px;">The vaccine candidate is administered through intranasal and intramuscular route.<wbr> </div><div style="margin-bottom: 10px;">It is a norovirus GI.<wbr>1/<wbr>GII 4 bivalent virus-like particle (VLP) vaccine adjuvanted with monophosphoryl lipid A (MPL) and aluminum hydroxide (AlOH).<wbr> MPL increases the vaccine&rsquo;s immunogenic effect.<wbr> </div><div style="margin-bottom: 10px;">TAK-214 is based on virus-like particle (VLP) antigens, which are highly purified protein products </div><div><STRONG>Univercells <A href="http://univercells.com/">http:/<wbr>/<wbr>univercells.<wbr>com/<wbr></A></STRONG> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20151231&edate=20150901&rec=2628">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-11-05T11:51:15+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-11-05T11:51:15+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Dr Reddy's to Market Biocodex Products in Romania</title>
	<pubDate>2015-11-05T09:42:48+01:00</pubDate>
	<wp:post_id>6746</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Dr Reddy's has been given the complete rights for promotion and distribution of the Biocodex products, including its flagship ENTEROL (Saccharomyces boulardii).<wbr> Earlier, Akacia was in partnership with Biocodex for similar distribution agreement.<wbr> </div><div style="margin-bottom: 10px;"><P class="abs"><a href="http://www.akacia.eu/about-us" class="defaultlink">Akacia A.G</a>.<wbr> is privately-owned Swiss pharmaceutical company founded in 2006.<wbr> As an independent pharmaceutical corporation which is presented through its affiliates and contractual partners in the countries of Central and Eastern Europe.<wbr></P> </div><div><P class="abs">ENTEROL in Romania <A href="http://www.paginafarmacistilor.ro/medicamente/prospect-enterol-250-645/#atc">http:/<wbr>/<wbr>www.<wbr>paginafarmacistilor.<wbr>ro/<wbr>medicamente/<wbr>prospect-enterol-250-645/<wbr>#atc</A></P> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20151231&edate=20150901&rec=2627">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-11-05T09:42:48+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-11-05T09:42:48+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>PART 2 The American Academy Of Physical Medicine And Rehabilitation (AAPM&R): Independent Spasticity Workshop</title>
	<pubDate>2015-11-04T18:43:11+01:00</pubDate>
	<wp:post_id>6747</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The AAPM&amp;R conducted a spasticity live self-assessment workshop that discussed 
 </div><div style="margin-bottom: 10px;"><UL type="disc"><LI>Aetiology and pathophysiology of spasticity and other movement disorder</LI>
<LI>Examine assessment tools for spasticity</LI>
<LI>Summarize current guidelines for the treatment of spasticity</LI>
<LI>Outline new treatments and techniques to manage spasticity and other movement disorders</LI>
</UL> </div><div style="margin-bottom: 10px;">The presenters continued to correct themselves from referring to BoNT A as Botox.<wbr>  This is part 2 of 3 write ups </div><div style="margin-bottom: 10px;">Though not sponsored by any company, corrections had to be made many times during the lecturer when Botox or onobotulinum toxin A was used instead of botulinum toxin A.<wbr>  They admitted since it was the first product on the market with an extensive history, only now have they had to keep it platonic since other competitors have now entered the market.<wbr> </div><div style="margin-bottom: 10px;">Key slides are as follows </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11306_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11306_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11306_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><I>Example self-assessment questions </I> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11306_5_ScreenCapture5.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11306_6_ScreenCapture6.jpg"> </div><div>Source: Attendance at AAPM&amp;R </div><!-- Comment details --><a name="pharmaworld11306attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11306_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(99,3 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11306_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(60,1 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11306_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(102,6 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11306_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(68,2 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11306_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(67,3 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11306_6_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(99,3 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20151231&edate=20150901&rec=11306">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-11-04T18:43:11+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-11-04T18:43:11+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Sucampo Q3 Results Highlight Strong Performance of Amitiza (lubiprostone) in the U.S and Japan</title>
	<pubDate>2015-11-04T18:03:37+01:00</pubDate>
	<wp:post_id>6748</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Sucampo reported year-over-year growth of 6% to <MONEY>$33.<wbr>4M total revenue.<wbr> Ph3 studies for CIC are expected to begin in H1:2016 (Russia; Mexico: South Korea).<wbr> In China, CFDA accepted IND for CIC.<wbr> LCM programs for Amitiza includes ped functional constipation, and 'alternate formulations.<wbr></MONEY> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2626_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2626_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><U>In the U.<wbr>S</U> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2626_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><U>In Japan</U> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2626_2_ScreenCapture2.jpg"> </div><!-- Comment details --><a name="gastroenterology2626attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2626_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(39,3 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2626_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(19,8 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2626_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(31,8 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2626_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(44,2 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20151231&edate=20150901&rec=2626">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-11-04T18:03:37+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-11-04T18:03:37+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Key Messages from Ironwood Q3 Financial Results</title>
	<pubDate>2015-11-04T17:15:57+01:00</pubDate>
	<wp:post_id>6749</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Ironwood is looking to establish the company as an emerging leader in GI and primary care.<wbr> In the U.<wbr>S, the company has been focused on bringing multiple products to the maket.<wbr> In Europe, management believes Constella (linaclotide) will benefit from Allergan's strong commercial expertise, and broad footprint across EU countries.<wbr> It was outlined that IDL filing for linaclotide in China is expected in Q1:2016 with AstraZeneca.<wbr> In Japan linaclotide continues to progress 'nicely' (Ph3 data for IBS-C expected late 2015; complete Ph2 trial for CC in 2016).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">In addition to Linzess and Cologuard, the innovative colorectal cancer screening test that it is co-promoting with Exact Sciences, Ironwood is preparing to co-promote Viberzi (for IBS-D) with Allergan.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2625_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><STRONG><EM></EM></STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>sNDA expected in H1:2016</LI>
<LI>plan to bring this dose to market in H1:2017</LI>
</UL> </div><div style="margin-bottom: 10px;"><U>Competition</U>: Synergy Pharm's plecanatide: NDA submission expected in January 2016, with an FDA approval in 2017.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><EM></EM></STRONG> </div><div style="margin-bottom: 10px;">2 formulations in this dose ranging study: </div><div style="margin-bottom: 10px;">The first formulation is designed to enhance abdominal pain relief in IBSC patients.<wbr> The second formulation is being evaluated on whether it can enhance abdominal pain relief, while having little to no impact on bowel function.<wbr> </div><div style="margin-bottom: 10px;"><UL><LI>Data expected in the second half of 2016.<wbr> </LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG><EM></EM></STRONG> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div><U><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2625_2_ScreenCapture2.jpg"></U> </div><!-- Comment details --><a name="gastroenterology2625attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2625_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(38 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2625_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(60,9 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20151231&edate=20150901&rec=2625">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-11-04T17:15:57+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-11-04T17:15:57+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>J&J's Subsidiary in China Plans to Launch 10 Drugs by 2020</title>
	<pubDate>2015-11-04T10:24:25+01:00</pubDate>
	<wp:post_id>6750</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: In a PR published in China Daily, Kris Sterkens, chairman of the company, has reported that products will be spread around 4 TAs, such as oncology, mental health, infectious and metabolic diseases.<wbr> He also indicated that Zytiga (for mCRPC) will be launched "soon".<wbr> <A href="http://xian-janssen.com.cn/en/news/454">The drug was approved last May by the CFDA.<wbr></A> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><SPAN style="LINE-HEIGHT: 1.6">The number of new patients with prostate cancer per year has jumped from 5.<wbr>53 per 100,000 in 2001 to 16.<wbr>62 per 100,000 in 2010 in Beijing (2)</SPAN><SPAN style="LINE-HEIGHT: 1.6">, while in Tianjin the incidence of prostate cancer has increased approximately 4 fold over the past 20 years(3).<wbr></SPAN>
 </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">in Q2:14 The Beijing Urological Association (BUA) of the Chinese Medical Association (CMA), the Tianjin Urological Association (TUA) and Xian Janssen Pharmaceutical Ltd.<wbr> held a symposium today on prostate cancer incidence and advanced treatment, under the theme “Benefiting Life, Creating Possibilities”.<wbr> </div><div style="margin-bottom: 10px;">The symposium was designed to raise awareness and call attention to the increasing incidence of prostate cancer in China.<wbr> <STRONG>Some of China’s top urologists</STRONG> were present at the meeting where they discussed innovative treatment options for advanced-stage prostate cancer.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Xi'an Janssen has launched 14 major new products in the past five years aimed at treating conditions like human immunodeficiency virus, cancer and mental illness.<wbr> </div><div style="margin-bottom: 10px;">Established 30 years ago, it has been a regular investor in China since its launch.<wbr> </div><div style="margin-bottom: 10px;">A new $290 million plant in Xi'an will be in operation from 2018, said Cesar Rodriguez, the company's chief.<wbr> </div><div style="margin-bottom: 10px;">The new site will have an annual capacity of 280 million medicine packages, which will be sold around the world, said Rodriguez.<wbr> </div><div style="margin-bottom: 10px;"><U>OTC Strategy</U> </div><div style="margin-bottom: 10px;">Xi'an Janssen is well known in China for over-the-counter drugs such as Domperidone and Daktarin.<wbr> </div><div style="margin-bottom: 10px;">Johnson &amp; Johnson combined its OTC business in China last year with Xi'an Janssen, a controversial move at the time with some industry commentators fearing the integration might hurt sales.<wbr> </div><div style="margin-bottom: 10px;">Rodriguez insisted the integration, named <STRONG>One China OTC</STRONG>, has achieved strong results, although he refused to detail exact numbers.<wbr> </div><div><EM>Source; GBI; Co website</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20151231&edate=20150901&rec=10746">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-11-04T10:24:25+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-11-04T10:24:25+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Stronbridge Biopharma Presents Phase 2 Data Analysis For COR-004 In Acromegaly</title>
	<pubDate>2015-11-03T17:13:27+01:00</pubDate>
	<wp:post_id>6751</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Strongbridge Biopharma has presented today a poster with the secondary efficacy analysis of the completed Phase II trial for COR-004 in patients with acromegaly (previously known as ATL1103 by Antisense Therapeutics) at the Society for Endocrinology BES 2015 conference.<wbr> The trial met its key efficacy endpoint demonstrating a statistically significant average reduction in the serum insulin-like growth factor 1 (IGF-1) levels from baseline in the higher dose group.<wbr> COR-004 was safe and well tolerated.<wbr> The main adverse event was mild to moderate injection site reactions in the majority of patients.<wbr> </div><div style="margin-bottom: 10px;">The Phase 2 clinical trial was a randomized, open-label, parallel group clinical trial of the safety, tolerability, pharmacokinetics and efficacy of two subcutaneous administration regimens of COR-004 in 26 adult patients with acromegaly treated over 13 weeks.<wbr> </div><div style="margin-bottom: 10px;">As one of the secondary endpoints, the level of growth hormone (GH)-binding protein (GHBP) as a marker of growth hormone receptor (GHR) expression was evaluated.<wbr> With the larger dose, a continuous decrease in GHBP was found that reached statistical significance at the end of the study, coinciding with a significant reduction in IGF-1.<wbr> These data provide further evidence for the efficacy of COR-004 and its ability to inhibit growth hormone receptor (GHR) expression.<wbr> Data from future clinical trials will help to evaluate the relationship between COR-004 dose, GH levels, GHBP levels and the change in IGF-1 with treatment.<wbr> </div><div>Source: Strongbridge PR </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20151231&edate=20150901&rec=8264">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-11-03T17:13:27+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-11-03T17:13:27+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Chiasma Starts Planning The Phase III for Oral Octreotide In Europe</title>
	<pubDate>2015-11-03T15:19:39+01:00</pubDate>
	<wp:post_id>6752</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Chiasma Starts Planning The Phase III for Oral Octreotide In Europe</span>&nbsp;<br><span style="font-size: 12px;">Comment: We have gained some primary intelligence that confirms the Chiasma plans for conducting a Phase III study for oral octreotide in Europe for acromegaly.<wbr> The study is not yet in the public domain and the intended start date is January 2016, which potentially could meet the estimated MAA planning submission to the EMA in late 2017 or early 2018.<wbr> The details are listed below.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20151231&edate=20150901&rec=8198">...</a><br></div><div style="margin-bottom: 10px;">Further to the primary intelligence, Chiasma has released a preliminary design of the planned Phase III b trial to support EMA approval (see picture).<wbr> Chiasma is due to present the Q3 2015 results next week where we might learn more.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8262_1_Phase3%2dEU%2dChiasma.JPG"> </div><div>Source: Chiasma IR September 2015 </div><!-- Comment details --><br><a name="endocrinology8262attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8262_1_Phase3%2dEU%2dChiasma.JPG">Phase3-EU-Chiasma.JPG</a>&nbsp;&nbsp;(109,3 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20151231&edate=20150901&rec=8262">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology8198">View thread  Endocrinology8198: Chiasma Starts Planning The Phase III for Oral Octreotide In Europe</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-11-03T15:19:39+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-11-03T15:19:39+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Bavarian Nordic Q3 2015 Results Webcast Key Takeaway: Focusing On Prostvac And CV301</title>
	<pubDate>2015-11-03T14:47:03+01:00</pubDate>
	<wp:post_id>6753</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Bavarian Nordic hosted a webcast to present its Q3 results and announced its financial expectations for the full year are maintained.<wbr> Notebly, its Ph3 PROSTVAC trial in chemo naive mCRPC setting remains on track and topline data are expected in 2017.<wbr> Further, additional trials will be initiated to explore combination with BMS' immune checkpoint protein inhibitors (Ipilimumab and Nivolumab).<wbr> Paul Chaplin, President &amp; Chief Executive Officer of Bavarian Nordic also highlighted additional pipeline in the near term include CV-301 immunotherapy, beginning with lung cancer and in bladder cancer and CRC thereafter.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Financial </STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>Revenue for the period was DKK 703 million (2014: DKK 676 million), the income before interest and tax (EBIT) was DKK 2 million (2014: DKK 121 million loss) and the net profit was DKK 57 million (2014: DKK 72 million loss).<wbr> Financial expectations for the full year are maintained.<wbr>
</LI>
<LI>The cash preparedness at year end is expected to be in the level of DKK 1,450 million and includes the loan facility of EUR 50 million from the European Investment Bank.<wbr>
</LI>
</UL> </div><div style="margin-bottom: 10px;">.<wbr><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10742_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;">Significant events in the third quarter of 2015 and up to the reporting date </div><div style="margin-bottom: 10px;"><UL type="disc"><LI>In July, Bavarian Nordic received a new order from the U.<wbr>S.<wbr> Government (BARDA) for bulk supply of IMVAMUNE smallpox vaccine valued at USD 133 million.<wbr> This bulk material could be converted into freeze-dried IMVAMUNE at a later date.<wbr>
</LI>
<LI>In July, an NCI-sponsored Phase 2 study of PROSTVAC in up to 150 patients with localized prostate cancer was initiated.<wbr>
</LI>
<LI>In August, the first-in-human Phase 1 study investigating a new MVA-BN based vaccine against Respiratory Syncytial Virus (RSV) was initiated.<wbr> The 63 patient study is now fully enrolled.<wbr>
</LI>
<LI>In September, Bavarian Nordic was awarded a subcontract valued up to USD 33 million from Janssen as part of a contract awarded by BARDA to support the advanced development and manufacturing of the MVA-BN&reg;/<wbr>AdVac&reg; prime-boost Ebola vaccine regimen.<wbr>
</LI>
<LI>In October, a safety and immunogenicity study of the prime-boost Ebola vaccine regimen was initiated in Sierra Leone.<wbr> This first study of the vaccine regimen in an outbreak country is conducted in parallel with multiple ongoing Phase 1 and 2 studies, as part of the accelerated development towards licensure of the vaccine.<wbr>
</LI>
<LI>In October, Bavarian Nordic received a new order from Canada for IMVAMUNE valued at USD 6.<wbr>4 million.<wbr> Additional contract options with Canadian authorities remain exercisable over the next years.<wbr>
</LI>
</UL> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10742_4_ScreenCapture4.jpg"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10742_11_ScreenCapture11.jpg"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10742_10_ScreenCapture10.jpg"> </div><div style="margin-bottom: 10px;"><STRONG>Focusing on PROSTVAC</STRONG> </div><div style="margin-bottom: 10px;"><UL type="disc"><LI>Top-line data from the PROSTVAC Phase 3 clinical trial anticipated in 2017.<wbr> Pre-specified, event-driven interim analyses will occur prior to that
</LI>
<LI>Initiate Phase 2 combination study of PROSTVAC and ipilimumab (Yervoy&reg;) in collaboration with Bristol-Myers Squibb
</LI>
<LI>Initiate NCI-sponsored Phase 2 combination study of PROSTVAC, ipilimumab and nivolumab (Opdivo&reg;)
</LI>
<LI>Report data from ongoing NCI-sponsored Phase 2 trials
</LI>
<LI>Initiation of new NCI-sponsored combination trials in various prostate cancer stages
</LI>
</UL> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10742_5_ScreenCapture5.jpg"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10742_6_ScreenCapture6.jpg"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10742_7_ScreenCapture7.jpg"> </div><div style="margin-bottom: 10px;"><STRONG>CV-301- Development Strategy focus is NSCLC, bladder and colorectal cancer</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10742_8_ScreenCapture8.jpg"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10742_9_ScreenCapture9.jpg"> </div><div>Source: Bavarian Nordic Q3 2015 Webcast 3 Nov 2015 </div><!-- Comment details --><a name="oncology10742attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10742_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(21,8 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10742_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(275,1 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10742_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(164 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10742_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(95,1 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10742_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(69,4 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10742_6_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(99,6 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10742_7_ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(66 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10742_8_ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(61,9 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10742_9_ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(56,3 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10742_10_ScreenCapture10.jpg">ScreenCapture10.jpg</a>&nbsp;&nbsp;(89,6 KB)<br>&nbsp;&nbsp;11.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10742_11_ScreenCapture11.jpg">ScreenCapture11.jpg</a>&nbsp;&nbsp;(107,6 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20151231&edate=20150901&rec=10742">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-11-03T14:47:03+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-11-03T14:47:03+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>PART 1 The American Academy Of Physical Medicine And Rehabilitation (AAPM&R) Congress: Merz And Allergan Showed A Strong Presence</title>
	<pubDate>2015-11-03T12:48:32+01:00</pubDate>
	<wp:post_id>6754</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The AAPM&amp;R annual assembly and Technical exhibition was held in Boston of October this year.<wbr>   The main topic was ‘Success in a changing health care environment’.<wbr>  This year showed a shift in Allergan's promotional focus from only spasticity to including migraine.<wbr>  This is part 1 of 3 write-ups </div><div style="margin-bottom: 10px;">Dysport and Xeomin have been available in the US for many years; however, Allergan remains to the market leader.<wbr>  Dysport will expand its indications in 2015 to include AUL followed by Xeomin in early ≈ 2016, while Allergan has included this indication from April of this year.<wbr>  With this change in dynamic, it was evident that many physicians at the congress were getting use to this market change to 3 prominent brands, occasionally referring to botulinum toxin A as Botox.<wbr> </div><div style="margin-bottom: 10px;"><U>Allergan</U> </div><div style="margin-bottom: 10px;">As an adjustment to the now stronger competition in the US, Allergan was seen to have changed its position in the market by now efficiently promoting a portfolio of products relevant to the one speciality.<wbr>  In this case, neurologists that manage pain and movement disorders </div><div style="margin-bottom: 10px;"><I>The stand </I> </div><div style="margin-bottom: 10px;">Allergan had a key position at the front of the first entry point to the exhibition hall.<wbr>  Promotion on the stand was a mix of AUL, CD and the new indication of Migraine </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11302_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;">Of surprising note, Allergan held a different position at this congress to previous years; by focussing on Migraine more than on spasticity as evident in the Allergan sponsored Product Theatre (held on the Thursday).<wbr>   The sponsored Product Forum also had a unique topic focussing on ‘<I>Understanding FDA Regulations and the Distinct Roles of Sales, Marketing and Medical Affair’.<wbr>  </I>The only sponsorship that was spasticity focussed was the educational grant provided to HME for the Satellite event held on Saturday night ‘Striving for Better Outcomes and Improved Quality of Life for patients” </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11302_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;">This symposium took the form of a digitally interactive format (projector as well as individual iPad’s for all attendees) beginning with a video of a spastic patient followed by a Jeopardy style Q&amp;A section.<wbr>  All the answers from the Q&amp;A section were then discussed by the following topics </div><div style="margin-bottom: 10px;">·         Evaluating spasticity and setting treatment goals </div><div style="margin-bottom: 10px;">·         Management strategies: rehabilitation, oral and intrathecal options </div><div style="margin-bottom: 10px;">·         Assessing the evidence for chemodenervation </div><div style="margin-bottom: 10px;">Some example key slides are as follows </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11302_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;">Interestingly, it was highlighted that Dysport and Botox were recommended for ALL and that Botox was reported to have a boxed warning </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11302_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;"><I>The posters</I> </div><div style="margin-bottom: 10px;">There were two key Allergan posters that were presented at the congress.<wbr>  The first by Alerberto Esquenazi <I>et al </I>On Botox in the treatment of Post-stroke ALL: Results from a double-blind, Placebo-Controlled pIII clinical trial.<wbr>  The multicentre pIII 12 week double-blind phase, followed by an open-label &lt;/<wbr> 3 cycle extension.<wbr>  To meet the primary endpoints, the average of weeks 4 and 6 were taken vs.<wbr> baseline for MAS.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11302_5_ScreenCapture5.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11302_6_ScreenCapture6.jpg"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11302_7_ScreenCapture7.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11302_8_ScreenCapture8.jpg"> </div><div style="margin-bottom: 10px;">The study showed that as early as week 2, results showed reduced post-stroke spasticity.<wbr>  Only at specific time points was improvement in muscle tone clinically meaningful with significant improvements measured by CGI and GAS.<wbr> </div><div style="margin-bottom: 10px;">The second poster by Carlos Singer <I>et al.<wbr> </I>was on the treatment outcomes following Botox use in patient switch, CD Naïve to BoNT treatments (PROBE).<wbr>  The study had previously been presented at </div><div style="margin-bottom: 10px;"><SPAN style="FONT-SIZE: 11pt; FONT-FAMILY: 'Calibri','sans-serif'; LINE-HEIGHT: 115%; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-fareast-language: EN-US; mso-ansi-language: EN-GB; mso-bidi-language: AR-SA">Toxins in January of this year.<wbr>  The multicentre observatory registry was designed to capture real-world practices</SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-SIZE: 11pt; FONT-FAMILY: 'Calibri','sans-serif'; LINE-HEIGHT: 115%; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-fareast-language: EN-US; mso-ansi-language: EN-GB; mso-bidi-language: AR-SA"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11302_9_ScreenCapture9.jpg"></SPAN><SPAN style="FONT-SIZE: 11pt; FONT-FAMILY: 'Calibri','sans-serif'; LINE-HEIGHT: 115%; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-fareast-language: EN-US; mso-ansi-language: EN-GB; mso-bidi-language: AR-SA"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11302_10_ScreenCapture10.jpg"></SPAN><SPAN style="FONT-SIZE: 11pt; FONT-FAMILY: 'Calibri','sans-serif'; LINE-HEIGHT: 115%; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-fareast-language: EN-US; mso-ansi-language: EN-GB; mso-bidi-language: AR-SA"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11302_12_ScreenCapture12.jpg"></SPAN>
<B><I><U>Merz</U></I></B> </div><div style="margin-bottom: 10px;"><I>The Stand</I> </div><div style="margin-bottom: 10px;">Merz didn’t sponsor any events; instead Merz maintained a very strong presence with a booth next door to Ipsen as well as very prominent brand name reminders through sponsoring some of the </div><div style="margin-bottom: 10px;">hotel keys and having very visible digital posters with the Merz logo placed at key areas such as the entrance to the congress.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11302_13_ScreenCapture13.jpg"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11302_14_ScreenCapture14.jpg"> </div><div style="margin-bottom: 10px;"><I>The posters</I> </div><div style="margin-bottom: 10px;">The key highlight for Merz was the first presentation of the open-label extension study of the pivotal pIII clinical trial in AUL.<wbr>  Merz has already submitted a sBLA to the FDA to seek approval for the use of Xeomin for AUL.<wbr>  The poster was labelled "Efficacy and safety of repeated incobotulinumtoxinA injections for upper-limb post-stroke spasticity" led by Dr.<wbr> Michael Munin </div><div style="margin-bottom: 10px;">PURE OLEX (<B>P</B>ost-stroke Spasticity <B>U</B>ppe<B>r</B> Limb Study to Investigate <B>E</B>fficacy and Safety of NT 201 clinical trial for incobotulinumtoxinA) was a prospective, 36-week open-label extension of a randomized, double-blind, placebo-controlled pIII trial (NCT01392300).<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11302_15_ScreenCapture15.jpg"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11302_16_ScreenCapture16.jpg"> </div><div style="margin-bottom: 10px;">The second poster presented was Switching BoNT brands from Botox to Xeomin, a cost-effectiveness study.<wbr>  From a cost-savings perspective, this UK based study showed that using a 1:1 dose ratio did not affect the dose requirement or treatment intervals indicating that both products are equally efficacious and tolerable.<wbr>  There was, however, no efficacy data presented to support this assessment and dosing intervals were fixed and not specific to toxin duration of action.<wbr>  Interestingly the lead research Prabal K, discussed that a similar study was to take place with Dysport 300U compared to 100U Xeomin with results available in 2017.<wbr>  The reason for this study is due to the current discount of 300U of Dysport which now has a similar price to Xeomin in the UK.<wbr>  There will be a further study of Botox vs.<wbr> Xeomin for ALL but results will not be published until approval </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11302_17_ScreenCapture17.jpg"> </div><div>Source: Attendance at AAPM&amp;R congress </div><!-- Comment details --><a name="pharmaworld11302attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11302_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(37,5 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11302_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(38,5 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11302_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(55,2 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11302_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(72,4 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11302_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(53,3 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11302_6_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(46,5 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11302_7_ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(34,7 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11302_8_ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(20,3 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11302_9_ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(60,5 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11302_10_ScreenCapture10.jpg">ScreenCapture10.jpg</a>&nbsp;&nbsp;(44,4 KB)<br>&nbsp;&nbsp;11.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11302_11_ScreenCapture11.jpg">ScreenCapture11.jpg</a>&nbsp;&nbsp;(635 B)<br>&nbsp;&nbsp;12.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11302_12_ScreenCapture12.jpg">ScreenCapture12.jpg</a>&nbsp;&nbsp;(50,8 KB)<br>&nbsp;&nbsp;13.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11302_13_ScreenCapture13.jpg">ScreenCapture13.jpg</a>&nbsp;&nbsp;(29,5 KB)<br>&nbsp;&nbsp;14.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11302_14_ScreenCapture14.jpg">ScreenCapture14.jpg</a>&nbsp;&nbsp;(38,1 KB)<br>&nbsp;&nbsp;15.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11302_15_ScreenCapture15.jpg">ScreenCapture15.jpg</a>&nbsp;&nbsp;(41,6 KB)<br>&nbsp;&nbsp;16.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11302_16_ScreenCapture16.jpg">ScreenCapture16.jpg</a>&nbsp;&nbsp;(42 KB)<br>&nbsp;&nbsp;17.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11302_17_ScreenCapture17.jpg">ScreenCapture17.jpg</a>&nbsp;&nbsp;(48,3 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20151231&edate=20150901&rec=11302">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-11-03T12:48:32+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-11-03T12:48:32+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: MidaTech to Merge with Dara BioSciences</title>
	<pubDate>2015-11-03T12:10:51+01:00</pubDate>
	<wp:post_id>6755</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">re: MidaTech to Merge with Dara BioSciences</span>&nbsp;<br><span style="font-size: 12px;"><SPAN style="color: #000000;"><A href="http://www.rmclasslaw.com/cases/dara" target="_new"><SPAN style="color: #000000;">Ryan &amp; Maniskas, a national shareholder litigation firm,</SPAN></A> is investigating potential claims against the board of directors of Dara BioSciences, </SPAN>concerning possible breaches of fiduciary duty and other violations of law related to the Company's efforts to sell the Company to Midatech Pharma.<wbr> This might possibly delay the transaction.<wbr></span>&nbsp;<br></div><div>Dara Biosciences, while announcing the Q3 2015 results, commented on the merger agreement with Midatech Pharma that is expected to close by the end of 2015.<wbr> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20151231&edate=20150901&rec=8261">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology8088">View thread  Endocrinology8088: MidaTech to Merge with Dara BioSciences</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-11-03T12:10:51+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-11-03T12:10:51+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>First-In-Class Oncolytic Viral Therapy Approved By The FDA</title>
	<pubDate>2015-11-03T11:41:36+01:00</pubDate>
	<wp:post_id>6756</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The FDA has approved a BLA for IMLYGIC™ (talimogene laherparepvec), a genetically modified oncolytic viral therapy indicated for the local treatment of unresectable cutaneous, subcutaneous and nodal lesions in patients with melanoma recurrent after initial surgery.<wbr> IMLYGIC is the first oncolytic viral therapy to be approved.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>What is IMLYGIC?</STRONG> </div><div style="margin-bottom: 10px;">IMLYGIC is a genetically modified herpes simplex virus type 1 designed to replicate within tumors and produce an immunostimulatory protein called granulocyte-macrophage colony-stimulating factor (GM-CSF).<wbr> IMLYGIC causes cell lysis, or death, which ruptures tumors, releasing tumor-derived antigens, which along with GM-CSF, may promote an anti-tumor immune response.<wbr> However, the exact mechanism of action is unknown.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Addressing Unmet Need In Melanoma</STRONG> </div><div style="margin-bottom: 10px;">Commenting on the approval Sean E Harper EVP R&amp;D at Amgen stated "IMLYGIC is the first clinical and regulatory validation of an oncolytic virus as a therapy, which <ORG value="NASDAQ-NMS:AMGN">Amgen</ORG> is proud to bring to patients with a serious form of skin cancer.<wbr> Not all melanoma patients currently benefit from available therapies, and IMLYGIC represents an important new option that can provide meaningful durable responses for patients with this aggressive and complex disease.<wbr> Immunotherapy is an exciting area for cancer research, and we are currently studying IMLYGIC in combination with other immunotherapies in advanced melanoma and other solid tumors.<wbr>" </div><div style="margin-bottom: 10px;"><STRONG>Cost of Therapy</STRONG> </div><div style="margin-bottom: 10px;">Amgen intends to make IMLYGIC available to patients in the U.<wbr>S.<wbr> within a week.<wbr> <ORG value="NASDAQ-NMS:AMGN">Amgen</ORG> anticipates the average cost of IMLYGIC therapy to be approximately <MONEY>$65,000</MONEY>.<wbr>  Given that IMLYGIC represents a novel and first-in-class oncolytic viral therapy, <ORG value="NASDAQ-NMS:AMGN">Amgen</ORG> expects variability of IMLYGIC dosing from patient to patient.<wbr> Therefore, <ORG value="NASDAQ-NMS:AMGN">Amgen</ORG> intends to work with the healthcare community to implement a program that helps limit the average cost of IMLYGIC therapy to <MONEY>$65,000</MONEY> for eligible participating institutions.<wbr> </div><div>From <A href="http://investors.amgen.com/">http:/<wbr>/<wbr>investors.<wbr>amgen.<wbr>com</A>, see <A href="http://investors.amgen.com/phoenix.zhtml?c=61656&amp;p=RssLanding&amp;cat=news&amp;id=2103128">original source</A>.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20151231&edate=20150901&rec=10740">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-11-03T11:41:36+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-11-03T11:41:36+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Focus on Q3 Sales of Sanofi Consumer Healthcare Products</title>
	<pubDate>2015-11-03T09:56:35+01:00</pubDate>
	<wp:post_id>6757</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Third-quarter sales of Consumer Healthcare products were €814m, an increase of 3.<wbr>2% driven by Allegra<SUP class="hugin" style="FONT-SIZE: 0.8em; VERTICAL-ALIGN: text-top">®</SUP>, Lactacyd<SUP class="hugin" style="FONT-SIZE: 0.8em; VERTICAL-ALIGN: text-top">®</SUP>, and Dorflex<SUP class="hugin" style="FONT-SIZE: 0.8em; VERTICAL-ALIGN: text-top">®</SUP>.<wbr> To be noted, sales of Enterogermina<SUP>®</SUP> decreased by 25%.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2620_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><U>In the U.<wbr>S</U>.<wbr>, sales grew 10.<wbr>8% to €209 million.<wbr> </div><div style="margin-bottom: 10px;"><U>In Emerging markets</U>, sales were up 2.<wbr>0% to €393 million driven by a low basis for comparison in Brazil and partially offset by lower sales in China.<wbr> </div><div style="margin-bottom: 10px;"><U>In Western Europe</U>, sales decreased 7.<wbr>6% to €146 million impacted by lower sales of Doliprane<SUP class="hugin" style="FONT-SIZE: 0.8em; VERTICAL-ALIGN: text-top">®</SUP> in France where price decreased in January 2015.<wbr> </div><div><U>In the Rest of the World</U>, sales grew 20.<wbr>7% to €66 million, reflecting good performance in Australia.<wbr> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="GastroEnterology2658c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">Brandicourt has reported it is exploring strategic options, including divestment, for its Merial animal health business and European generics operation to achieve "leadership" in consumer healthcare.<wbr> He said that Sanofi Consumer Healthcare aimed to "maximise the value of existing brands" by managing them with "speed, agility and consumer focus".<wbr> However Sanofi would "remain diversified, with a portfolio refocused on areas "where we can win, and innovation driven to improve the lives of millions of people".<wbr> The diversified company would be present in Pharmaceuticals, Vaccines and Consumer Healthcare, he added, and would seek "external opportunities to enhance its growth profile".<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Reasons for Staying in Consumer Healthcare</STRONG> </div><div style="margin-bottom: 10px;">Brandicourt outlined three reasons </div><div style="margin-bottom: 10px;">1/<wbr> consumer healthcare is a highly-fragmented market that is ripe for consolidation, </div><div style="margin-bottom: 10px;">2/<wbr> the market offers consistent growth with different dynamics to the branded prescription market, and </div><div style="margin-bottom: 10px;">3/<wbr> it is a good portfolio fit where Sanofi can capture real synergies.<wbr> </div><div>Building a competitive position for Sanofi's Consumer Healthcare business is part of a new strategic roadmap for the overall company over the next five years.<wbr> This long-term strategy rested on four pillars, said Brandicourt, adding that these were reshaping the portfolio, delivering outstanding launches, sustaining innovation in research and development, and simplifying the organisation.<wbr> </div></div><a name="gastroenterology2620attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2620_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(49,7 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20151231&edate=20150901&rec=2620">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-11-03T09:56:35+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-11-03T09:56:35+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>UEGW 2015 (Part 2): Shire Insights</title>
	<pubDate>2015-11-03T09:27:20+01:00</pubDate>
	<wp:post_id>6758</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Shire symposium was chaired by Prof.<wbr> Jan Track, who received the UEG research Prize 2015 for his pioneering work in functional and motility disorders and the search to find novel pathways to treat these conditions.<wbr> This report will focus on Prof.<wbr> V Stanghellini's talk who explored if approaches to treatment should be tailored based on gender.<wbr> Evaluation of Resolor (prucalopride), polyethylene glycol and lubiprostone in men and women were presented.<wbr> Findings suggest that treatment approaches for CC do not require tailoring by gender.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Prof.<wbr> Y Yiannakou</STRONG> (consultant Neurogastroenterologist at County Durham and Darlington NHS Foundation Trust and an Honorary Consultant at Newcastle Tyne Hospitals) introduced the first part of the symposium.<wbr> His talk focused on the 'emerging evidence base for gender-related burden and symptom patterns'.<wbr> He presented an interim analysis of a prospective study of approx.<wbr> a thousand consecutive referrals to a secondary care, all of which have been studied in detail with regard to presentation, symptom patterns, transit sudies and proctography.<wbr> His conclusion stressed the following: </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2619_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><STRONG>Prof.<wbr> Stanghellini</STRONG> (Professor of Internal Medicine, Chair of International Medicine and Chief of the Functional Gastrointestinal Disorders Laboratory at the U.<wbr> Hospital St.<wbr> Orsola-Malpighi, Bologna, Italy) introduced his presentation with WW prevalence on chronic constipation (CC).<wbr> In a meta-analysis (<EM>Suares NC and Ford AC Am J Gstroenterol 2011;106(9):1582-91</EM>) CC was shown to affect approx.<wbr> twice as many women as men, although this difference varied between the individual studies : </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2619_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;">He then presented data regarding the effect of CC treatments in women vs men for prucalporide, polyethylene glycol and lubiprostone.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2619_5_ScreenCapture5.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2619_6_ScreenCapture6.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2619_7_ScreenCapture7.jpg"> </div><div style="margin-bottom: 10px;">His conclusion outlined that: </div><div style="margin-bottom: 10px;">- most studies do not provide details on gender effects and included few males </div><div style="margin-bottom: 10px;">- if differences in treatment responses exist, they are clincically negligible.<wbr> </div><div><STRONG>Julie Storrie</STRONG> (registered nurse, working at U.<wbr> College Hospital, London in the Gastrointestinal Physiology Unit) closed the session with a presentation showing that from the perspective of a clincial nurse specialist, effective care in CC hinges on good communication between the healthcare team and the patient, and this can be achieved in the same way with men as with women.<wbr> Good communication faciliates an accurate diagnosis, development and implementation of a tailored treatment plan, and enables ongoing assessment of treatment efficacy durin LT FU.<wbr> </div><!-- Comment details --><a name="gastroenterology2619attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2619_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(56,4 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2619_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(36,3 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2619_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(32,4 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2619_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(53,7 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2619_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(57,6 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2619_6_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(57,7 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2619_7_ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(52,8 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20151231&edate=20150901&rec=2619">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-11-03T09:27:20+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-11-03T09:27:20+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>The Impact of Biosimilars in the EU Market</title>
	<pubDate>2015-11-02T19:49:36+01:00</pubDate>
	<wp:post_id>6759</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: At the EPPR Conference in London, Alexander Roediger, Director for EU Affairs at MSD Europe, analysed the effects of biosimilar competition so far, and discussed regulatory differences between generic and biosimilar markets that impact pricing, reimbursement and uptake </div><div style="margin-bottom: 10px;"><U></U> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11301_1_copiedImage%5b0%5d.png"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11301_2_copiedImage%5b2%5d.png"> </div><div style="margin-bottom: 10px;"><U></U> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11301_3_copiedImage%5b4%5d.png"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11301_4_copiedImage%5b6%5d.png"> </div><div style="margin-bottom: 10px;"><U></U> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11301_5_copiedImage%5b8%5d.png"> </div><div style="margin-bottom: 10px;"> </div><div><OL><LI>
</LI>
<LI>
</LI>
<LI>
</LI>
<LI>
</LI>
</OL> </div><!-- Comment details --><a name="pharmaworld11301attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11301_1_copiedImage%5b0%5d.png">copiedImage[0].png</a>&nbsp;&nbsp;(59,5 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11301_2_copiedImage%5b2%5d.png">copiedImage[2].png</a>&nbsp;&nbsp;(64,7 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11301_3_copiedImage%5b4%5d.png">copiedImage[4].png</a>&nbsp;&nbsp;(92,6 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11301_4_copiedImage%5b6%5d.png">copiedImage[6].png</a>&nbsp;&nbsp;(108,7 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11301_5_copiedImage%5b8%5d.png">copiedImage[8].png</a>&nbsp;&nbsp;(89,8 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20151231&edate=20150901&rec=11301">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-11-02T19:49:36+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-11-02T19:49:36+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Revance Therapeutics Announces Proposed Public Offering of Common Stock</title>
	<pubDate>2015-11-02T19:14:32+01:00</pubDate>
	<wp:post_id>6760</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Revance therapeutics has announced a proposed underwritten public offering of 3,250,000 shares of its common stock.<wbr> </div><div style="margin-bottom: 10px;">Revance hopes to grant the underwriters a 30-day option to acquire an additional 487,500 shares.<wbr> This comes to light post the positive interim results of BELMONT pII study.<wbr> Since the results were reported, Revance shares rose by 48.<wbr>43% in the past week and 21.<wbr>76% for the last 4 weeks.<wbr> </div><div>Source: Revance press release </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20151231&edate=20150901&rec=8228">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-11-02T19:14:32+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-11-02T19:14:32+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Canbex Therapeutics Starts pII Trial Of VSN16R in Spasticity</title>
	<pubDate>2015-11-02T19:09:20+01:00</pubDate>
	<wp:post_id>6761</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Canbex Therapeutics has initiated the pII trial of its novel oral VSN16R for the treatment of spasticity in MS patients.<wbr> </div><div style="margin-bottom: 10px;">This Proof of Concept (PoC), Double-Blind, Randomised, Placebo-controlled Study will investigate the efficacy, safety, and pharmacokinetics of VSN16R for the treatment of spasticity in subjects with multiple sclerosis.<wbr>  The trial is being carried out in the UK with a approximately 160 subjects hoped to be enrolled.<wbr>  Estimated primary completion date of July 2016 with a study completion date of October 2016 </div><div style="margin-bottom: 10px;">Dr Jesse Schulman, Canbex’s CEO reported “The Canbex team is very pleased that VSN16R has reached this important milestone.<wbr>  This brings us a step closer to potentially bringing patients a much needed new treatment for this debilitating and disabling condition,” </div><div style="margin-bottom: 10px;">Ipsen entered into agreement with Canbex for an option for acquisition post pII results.<wbr> </div><div>Source: Canbex press-release </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20151231&edate=20150901&rec=8227">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-11-02T19:09:20+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-11-02T19:09:20+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Crinetics Completes $40 Million Financing To Push SSA Development to POC For Acromegaly</title>
	<pubDate>2015-11-02T17:51:36+01:00</pubDate>
	<wp:post_id>6762</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Crinetics is developing a nonpeptide biased SSTR2A receptor for the treatment of acromegaly with the goal of improving efficacy and tolerability in the form of once-a-day pill.<wbr> The program is still in a discovery stage and Crinetics has today confirmed the completion of a $40 million financing to push the development program to proof-of-concept.<wbr> </div><div style="margin-bottom: 10px;">Concurrent with the financing, Wendell Wierenga, Ph.<wbr>D.<wbr> has been appointed as chairman of Crinetics&rsquo; board of directors.<wbr> In addition, Mason Freeman, M.<wbr>D.<wbr> representing 5AM Ventures, Steve Kaldor, Ph.<wbr>D.<wbr> representing Versant Ventures, and Mahendra Shah, Ph.<wbr>D.<wbr> representing Vivo Capital have joined Crinetics&rsquo; board of directors.<wbr> Drs.<wbr> Wierenga, Kaldor, and Shah are all highly successful serial entrepreneurs with extensive CEO and senior management experience in the biopharmaceutical industry.<wbr> In addition to his role as Venture Partner at 5AM Ventures, Dr.<wbr> Freeman is an endocrinologist and professor of medicine at Massachusetts General Hospital, Harvard Medical School.<wbr> </div><div>Source: Crinetics PR </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20151231&edate=20150901&rec=8257">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-11-02T17:51:36+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-11-02T17:51:36+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Functional Constipation with BioGaia's Lactobacillus gasseri DSM 27123</title>
	<pubDate>2015-11-02T17:34:29+01:00</pubDate>
	<wp:post_id>6763</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: clinicaltrials.<wbr>gov is listing a new POC study, which aims to determine the change in frequency of complete SBMs after 4 weeks of ora supplementation with the probiotics in helthy adult women with functional constipation (also known as chronic idiopathic constipation).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><U>Official title</U>: A Double Blind Placebo-Controlled Study on the Effect of the Probiotic Lactobacillus Gasseri DSM 27123 on Functional Constipation in Healthy Women - Proof of Concept </div><div style="margin-bottom: 10px;">REF: <A href="https://clinicaltrials.gov/ct2/show/NCT02592200?recr=Open&amp;no_unk=Y&amp;fund=2&amp;rcv_s=10%2F02%2F2015&amp;rank=57">NCT02592200</A> </div><div style="margin-bottom: 10px;"><P><U>Recruitment</U>: approx 40
<!--generated--></P> </div><div style="margin-bottom: 10px;"><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Women aged 18-49 years at Visit 1</LI> </div><div style="margin-bottom: 10px;"><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">BMI ≥18 and ≤29 at Visit 1</LI> </div><div style="margin-bottom: 10px;"><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Suffering of functional constipation as defined by the Rome III criteria for functional constipation</LI> </div><div style="margin-bottom: 10px;"><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Comply with the requirement not to use any other probiotic products from Visit 1 and throughout the study period</LI> </div><div style="margin-bottom: 10px;"><P><U>Timelines</U>
<!--generated--></P> </div><div style="margin-bottom: 10px;"><P>POC was designed to start in October 2015, and complete March /<wbr> April 2016
<!--generated--></P> </div><div style="margin-bottom: 10px;"><P><U>Location</U>: Sweden
<!--generated--></P> </div><div style="margin-bottom: 10px;"><P>PI: Per Hellström, MD, PhD<!--generated--></P> </div><div><TD headers="affiliation" nowrap="" style="PADDING-BOTTOM: 0px; PADDING-TOP: 1ex; PADDING-LEFT: 0px; PADDING-RIGHT: 1em">Uppsala University</TD> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20151231&edate=20150901&rec=2618">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-11-02T17:34:29+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-11-02T17:34:29+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>UEGW 2015 (Part 1): Norgine Insights</title>
	<pubDate>2015-11-02T17:10:59+01:00</pubDate>
	<wp:post_id>6764</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Norgine has been supporting since 2013 an EU initiative, called the European Colonoscopy Quality Investigation (ECQI) group, which aims is to improve standards in colonoscopy through a practice level audit tool.<wbr> Quality of colonoscopy was the central theme of all the company's initiatives at the UEGW congress, both during its symposia titled 'Assessment in colonoscopy: from preparation to procedure", and the free paper session.<wbr> The scene is set for the upcoming MORA and DAYB results next year (last October, positive top-line results from the NOC studywere reported).<wbr><SPAN lang="EN-US" style="FONT-SIZE: 11pt; FONT-FAMILY: 'Calibri','sans-serif'; LINE-HEIGHT: 115%; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 11pt; FONT-FAMILY: 'Calibri','sans-serif'; LINE-HEIGHT: 115%; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"></SPAN> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><UL><LI></LI>
<LI></LI>
<LI></LI>
<LI></LI>
</UL> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2617_5_ScreenCapture5.jpg"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><UL><LI></LI>
<LI></LI>
<LI></LI>
<LI></LI>
<LI></LI>
</UL> </div><div> </div><!-- Comment details --><a name="gastroenterology2617attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2617_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(45,5 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2617_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(45,1 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2617_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(42,9 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2617_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(27,9 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2617_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(43,2 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2617_6_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(47,3 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2617_7_ECQI%255fP0160.pdf">ECQI_P0160.pdf</a>&nbsp;&nbsp;(156,2 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20151231&edate=20150901&rec=2617">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-11-02T17:10:59+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-11-02T17:10:59+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>PathMaker Neurosystems Inc. Received Expedited Access Pathway Granted By The FDA For MyoRegulator™ PM-2200 System For The Treatment Of Patients With Neuromotor Disorders</title>
	<pubDate>2015-10-30T23:13:14+01:00</pubDate>
	<wp:post_id>6765</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: PathMaker Neurosystems Inc.<wbr> a neuromodulation company has been granted an Expedited Access Pathway from the FDA for MyoRegulator™ PM-2200 system, a non-invasive neurotherapy system used to treat spasticity.<wbr> </div><div style="margin-bottom: 10px;">MyoRegulator is PathMaker’s first product, and is being developed for the treatment of muscle spasticity found in patients with stroke, cerebral palsy, multiple sclerosis, spinal cord injury, traumatic brain injury and other neurological conditions.<wbr>  It’s been developed based on a proprietary DoubleStim™ technology, providing simultaneous non-invasive stimulation at spinal and peripheral locations.<wbr> </div><div style="margin-bottom: 10px;">The Expedited Access Pathway is a new FDA program established in April 2015 to facilitate patients gaining more rapid access to critical medical devices by expediting their development, assessment and review.<wbr>  As discussed by Sheila Hemeon-Heyer, J.<wbr>D.<wbr>, Vice President of Regulatory and Clinical Affairs at PathMaker Neurosystems “We are excited to be working with the FDA through the EAP program to rapidly bring to patients this important new technology for treating spasticity.<wbr>” Pathmaker Neurosystems is one of the first companies selected into this program </div><div>Source: PathMaker Neurosystems press release </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20151231&edate=20150901&rec=8226">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-10-30T23:13:14+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-10-30T23:13:14+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Chiasma Launches New Acromegaly Online Resource For Patients And Caregivers</title>
	<pubDate>2015-10-30T17:15:15+01:00</pubDate>
	<wp:post_id>6766</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Coinciding with 'Acromegaly Awareness Day' on November 1, 2015, Chiasma announced today a new online resource to support people with the disease.<wbr> Acromegaly.<wbr>care is an educational website due to provide practical information and tools for acromegaly patients and their caregivers and was created with the input of many patients whose stories are told in emotional videos, photos and written notes.<wbr> The website is divided in different tabs giving info on what is the disease, treatment options as well as offering support.<wbr> SSAs are mentioned as a 'common' type of medication, given by injection every 28 days.<wbr> Of interest some quotes given by patients on their experience of 'planning their lives around monthly injections'.<wbr> </div><div style="margin-bottom: 10px;">Also SSAs medications are described as: 'injected using large needles into muscle or deep into the tissue underlying the skin.<wbr> The needles may cause injection site pain and reactions, such as hardness, nodules, swelling, bruising and inflammation.<wbr>' </div><div style="margin-bottom: 10px;"><SPAN style="line-height: 1.5em;">The website can be reached through this link: </SPAN><a href="http://acromegaly.care/" class="defaultlink">acromegaly.care</a> </div><div>Source: Chiasma website </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20151231&edate=20150901&rec=8255">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-10-30T17:15:15+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-10-30T17:15:15+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Hutchison China MediTech Gets China FDA Clearance For Two Sulfatinib Phase III Trials In NET</title>
	<pubDate>2015-10-30T16:26:58+01:00</pubDate>
	<wp:post_id>6767</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Following the positive results of the Phase Ib data of sulfatinib in treating advanced NET, Hutchison China MediTech (HCM) has obtained clearance from the China FDA to start two pivotal Phase III registration studies in China, one in pNET and a second one in advanced carcinoids patients (non-pancreatic NET).<wbr> The two trials are now listed on ct.<wbr>gov and are planning to start in November 2015 with estimated completion date in September 2018 and June 2019 respectively.<wbr> Keep in mind that the pivotal phase III trials are planned for China, but HCM has cleared the US IND application in early 2015 and is currently recruiting patients for a bridging Phase I Caucasians dose confirmation study that will enable the company to start a Phase II NET study in US in early 2016.<wbr> HCM believes that sulfatinib has best-in-class potential and, due to the quantum of superiority in efficacy over existing products on the market (everolimus and sunitinib) could possibly be considered for breakthrough therapy designation.<wbr> </div><div style="margin-bottom: 10px;">The listed Phase III studies can be found on ct.<wbr>gov: </div><div style="margin-bottom: 10px;"><UL><LI><SPAN style="text-decoration: underline;">Phase III of sulfatinib in treating advanced pancreatic NET (<a href="https://clinicaltrials.gov/ct2/show/NCT02589821?recr=Open&no_unk=Y&fund=2&rcv_s=09%2F30%2F2015&rank=43" class="defaultlink">NCT02589821</a>) </SPAN>
<UL><LI>Assess efficacy of 300mg once a day
</LI>
<LI>Primary Endpoint: PFS
</LI>
<LI>Secondary Endpoint: ORR
</LI>
<LI>N=195
</LI>
<LI>Start date: November 2015
</LI>
<LI>Estimated Completion: September 2018 (primary completion March 2018)
</LI>
</UL>

</LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI><SPAN style="text-decoration: underline;">Phase III of sulfatinib in treating advanced extrapancreatic NET (<a href="https://clinicaltrials.gov/ct2/show/NCT02588170?recr=Open&no_unk=Y&fund=2&rcv_s=09%2F30%2F2015&rank=68" class="defaultlink">NCT02588170</a>)</SPAN>
<UL><LI>Assess efficacy of 300mg once a day
</LI>
<LI>Primary Endpoint: PFS
</LI>
<LI>Secondary Endpoint: ORR
</LI>
<LI>N=273
</LI>
<LI>Start date: November 2015
</LI>
<LI>Estimated Completion: June 2019 (primary completion December 2018)
</LI>
</UL>

</LI>
</UL> </div><div style="margin-bottom: 10px;">The Phase I bridging study can be found on ct.<wbr>gov: </div><div style="margin-bottom: 10px;"><UL><LI><U>A multi-center open-label study of sulfatinib in patients with advanced solid tumors (<a href="https://clinicaltrials.gov/ct2/show/NCT02549937?term=sulfatinib&rank=5" class="defaultlink">NCT02549937</a>)</U>
<UL><LI>Assess maximum tolerated dose
</LI>
<LI>Primary Endpoint: adverse events
</LI>
<LI>Secondary Endpoint: maximum plasma concentration
</LI>
<LI>N=36
</LI>
<LI>Start date: October 2015
</LI>
<LI>Estimated Completion: December 2017 (primary completion March 2017)
</LI>
</UL>

</LI>
</UL> </div><div style="margin-bottom: 10px;">HCM will present clinical data from its Phase I trial in China (<a href="https://clinicaltrials.gov/ct2/show/NCT02267967?term=NCT02267967&rank=1" class="defaultlink">NCT02267967</a>) at the 2015 AACR NCI EORTC Molecular Targets and Cancer Therapeutics conference which will be held in Boston, MA from 5-9 November 2015.<wbr> In this study, sulfatinib's objective response rate among the 18 efficacy-valuable NET patients was 44.<wbr>4% and disease control rate was 100%.<wbr> By comparison sunitinib and everolimus achieve ORR of less than 10% in their pivotal clinical trials.<wbr> Furthermore, NET responses to sulfatinib have been observed to improve gradually with time.<wbr> The poster of the data will be available on HCM website after the conference.<wbr> </div><div style="margin-bottom: 10px;">Below the abstract from the company website: </div><div style="margin-bottom: 10px;"><STRONG>Title:</STRONG> <EM>First-in-human phase I study of a selective VEGFR/<wbr>FGFR dual inhibitor sulfatinib in patients with advanced solid tumours</EM> </div><div style="margin-bottom: 10px;"><P style="padding-left: 30px;"><STRONG>Authors:</STRONG> Jian-Ming Xu, Lin Shen, Yan Wang, Yu-ling Chen, Ru Jia, Jian Wang, Ke Li, Yang Sai, Jing Li, Chuan Qi, Hua Ye, Su Weiguo</P> </div><div style="margin-bottom: 10px;"><P style="padding-left: 30px;"><STRONG>Background:</STRONG> Sulfatinib is a highly selective oral small molecule inhibitor targeting both vascular endothelial growth factor receptors (VEGFR) and fibroblast growth factor receptors (FGFR).<wbr> A phase I dose-escalation study was carried out to determine sulfatinib maximum tolerated dose (MTD) and/<wbr>or recommended phase 2 dose (RP2D), pharmacokinetic (PK) profiles, and preliminary antitumor activity in patients with advanced solid tumours.<wbr></P> </div><div style="margin-bottom: 10px;"><P style="padding-left: 30px;"><STRONG>Methods:</STRONG> Sulfatinib was administered orally in 28-day treatment cycles until disease progression or unacceptable toxicity.<wbr> The study utilized 3+3 dose escalation method, with ascending dose cohorts from 50mg to 350mg daily.<wbr> During the study, a milled formulation was developed to reduce the inter-patient PK variations and optimize drug absorption.<wbr> The milled formulation was used in 200mg once daily (QD) to 350mg QD dose cohorts.<wbr></P> </div><div style="margin-bottom: 10px;"><P style="padding-left: 30px;"><STRONG>Results:</STRONG> As of July 6, 2015, a total of 77 patients had been enrolled.<wbr> Forty three of the 77 patients received original formulation in dose cohorts from 50mg to 300mg daily.<wbr> The data of patients treated with original formulation dosing from 50 to 300mg once daily, or 125mg and 150mg twice daily were reported in ASCO 2012(#3040).<wbr> Thirty-four of the 77 patients received milled formulation.<wbr> Among the 34 patients, 23 were enrolled in the dose-escalation phase, receiving sulfatinib 200mg to 350mg QD whereas 11 patients were enrolled in the dose-expansion phase receiving sulfatinib 300mg or 350 mg QD.<wbr> Among the 34 patients, there were 24 male patients (70.<wbr>6%) and 10 female patients (29.<wbr>4%).<wbr> The median age was 55.<wbr>97 (23.<wbr>35-73.<wbr>17) years.<wbr> The most common adverse events of 34 patients were hypertension, proteinuria, diarrhoea, elevated AST/<wbr>ALT and decreased blood albumin, mostly grade1/<wbr>2.<wbr> One DLT (grade 3 ALT/<wbr>AST increase) was observed in the 200 mg QD dose group.<wbr> MTD was not reached up to 350mg QD.<wbr> Among the 34 subjects treated with milled formulation, 22 subjects were diagnosed with neuroendocrine tumours (NETs).<wbr> Eight NET patients (5 in 300mg QD and 3 in 350mg QD cohort) had confirmed partial response (PR) with median duration of response (DoR) of 13.<wbr>8 months.<wbr> The tumour origins of the 8 NET patients include pancreas (3 patients), duodenum (1 patient), rectum (1 patient), thymus (1 patient) and unknown origin (2 patients).<wbr> Objective response rate among the 18 efficacy evaluable NET patients was 44.<wbr>4% and disease control rate was 100%.<wbr> Sulfatinib half-life (t1/<wbr>2) in plasma averaged 14-20 hours at the test dose levels, which supported sulfatinib QD dosing frequency.<wbr> Following QD multiple dosing, sulfatinib achieved steady state on Day 14.<wbr> The drug exposure increased when the dose increased from 200 mg to 300 mg, and then plateaued from 300 mg to 350 mg.<wbr> Based on the clinical safety, efficacy, and PK data, the recommended Phase II dose is determined to be 300 mg QD.<wbr></P> </div><div style="margin-bottom: 10px;"><P style="padding-left: 30px;"><STRONG>Conclusions:</STRONG> Sulfatinib was well tolerated with an acceptable safety profile.<wbr> Promising anti-tumour activity was observed in NET patients.<wbr> Further clinical studies with sulfatinib are warranted.<wbr></P> </div><div>Source: ct.<wbr>gov, HCM financial results </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20151231&edate=20150901&rec=8251">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-10-30T16:26:58+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-10-30T16:26:58+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Takeda FY2015 Q2 Earning Key Takeaway</title>
	<pubDate>2015-10-30T16:04:27+01:00</pubDate>
	<wp:post_id>6768</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Takeda reported results for the first half of FY2015 and confirmed the results aligned with management guidance.<wbr> FY15 H1 operating free cash flow is well ahead of previous year (+55.<wbr>7B JPY, an increase of 30.<wbr>1 B JPY vs FY14 H1).<wbr> The grwoth drivers include GI, Oncology, and Emerging markets.<wbr> Within Oncology, LEUPRORELIN is being identified as one of the key growth drivers and contributed +0.<wbr>4% overall growth vs 2014 1H.<wbr> In terms of its pipeline, development focus of its oral LHRH antagonist (TAK385) will be in prostate cancer for US/<wbr>EU markets and gynecological indications (endometriosis and uterine fibroids) for Japanese market.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Financial &amp; Business Performance:</STRONG> First Half results aligned with management guidance </div><div style="margin-bottom: 10px;"><UL><LI>Underlying revenue +3.<wbr>8% year-to-year (reported revenue growing +6.<wbr>2% to 904 billion yen)
</LI>
<LI>Underlying Core Earnings +3.<wbr>7% year-to-year (operating profit -5.<wbr>4% to 110.<wbr>4 billion yen)
</LI>
</UL> </div><div style="margin-bottom: 10px;">In the first half of FY2015, Takeda continued its turnaround with underlying revenue growth of 3.<wbr>8%, led by its growth drivers of gastroenterology, oncology and emerging markets.<wbr> Operating profit was down in the first half of the year, mainly due to an increase in expenses for several recent launches and in R&amp;D, as planned, but underlying core earnings increased by 3.<wbr>7%, getting closer to underlying revenue growth.<wbr> </div><div style="margin-bottom: 10px;"><UL><LI>Gastroenterology grew by +28.<wbr>7% year-to-year, driven by Entyvio.<wbr>
</LI>
<LI>Oncology revenue, including Velcade and Adcetris, increased by +1.<wbr>6% overall.<wbr> Leuprorelin (prostate cancer being the main indication) increased by +0.<wbr>4% (&yen;61.<wbr>8B in FY 2014 1H vs &yen;62B in FY 2015 1H).<wbr>
</LI>
<LI>Emerging markets revenue grew by +7.<wbr>1%, led by Value Brands (branded generics and OTC), with strong growth in Russia and China.<wbr>
</LI>
<LI>Performance in the U.<wbr>S.<wbr> (+12.<wbr>0% underlying revenue growth) and Europe and Canada (+1.<wbr>5%) also contributed to revenue growth.<wbr>
</LI>
<LI>In Japan, products such as Azilva and Lotriga contributed to revenue growth, but as a result of increasing generic competition, total revenue declined -3.<wbr>4%.<wbr>
</LI>
</UL> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10737_1_ScreenCapture1.jpg"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10737_3_ScreenCapture3.jpg"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10737_4_ScreenCapture4.jpg"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10737_5_ScreenCapture5.jpg"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10737_6_ScreenCapture6.jpg"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10737_7_ScreenCapture7.jpg"> </div><div>Source: Takeda Earning Call 30 Oct 2015 </div><!-- Comment details --><a name="oncology10737attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10737_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(87,5 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10737_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(78,6 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10737_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(67,9 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10737_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(93,9 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10737_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(126,9 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10737_6_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(76,9 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10737_7_ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(146,8 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20151231&edate=20150901&rec=10737">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-10-30T16:04:27+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-10-30T16:04:27+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Key Messages from Bayer Q3 Sales of the Consumer Health Segment</title>
	<pubDate>2015-10-30T11:21:54+01:00</pubDate>
	<wp:post_id>6769</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Business expanded in all divisions of the Consumer Health segment.<wbr> The substantial reported increase was mainly due to sales of products acquired from Merck &amp; Co.<wbr>, Inc.<wbr>, and to currency effects (currencies added &euro;70M to the increase).<wbr> </div><div style="margin-bottom: 10px;">Consumer Care sales reached &euro;1,424M (from &euro;1,006M in Q3:14), an increase of 1.<wbr>7% (Fx and portfolio adj.<wbr>).<wbr> </div><div style="margin-bottom: 10px;">This increase was driven especially by gratifying gains in sales of the Bepanthen&trade; /<wbr> Bepanthol&trade; line of skincare products and antifungal Canesten&trade;, particularly in the Emerging Markets.<wbr> </div><div style="margin-bottom: 10px;">Business with Aspirin&trade; was down, however, as gains in Latin America /<wbr> Africa /<wbr> Middle East only partly offset declines in Europe.<wbr> </div><div style="margin-bottom: 10px;">Business with the analgesic Aleve&trade; declined against the strong prior-year quarter, due particularly to changes in sales phasing in the United States.<wbr> </div><div>in the <STRONG>first nine months of 2015, sales</STRONG> increased by 4.<wbr>3% (Fx &amp; portfolio adj.<wbr>) to &euro;6,889 million.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20151231&edate=20150901&rec=2614">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-10-30T11:21:54+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-10-30T11:21:54+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Axero Associates to Exclusively Distribute BioGaia's Products in Sri Lanka</title>
	<pubDate>2015-10-30T09:44:34+01:00</pubDate>
	<wp:post_id>6770</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: BioGaia has signed an exclusive agreement with Axero Associates (Pvt) Limited for the rights to sell BioGaia ProTectis drops and tablets, BioGaia Gastrus and BioGaia ProDentis in Sri Lanka.<wbr> The launch is planned to take place early 2016.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Axero Associates (Pvt) Limited's business</STRONG> </div><div style="margin-bottom: 10px;">Model: licensing, business development, marketing, sales and distribution of a wide range of products, both over-the-counter and prescription drugs, in many different therapeutic segments.<wbr> </div><div style="margin-bottom: 10px;">Distribution network: health care professionals through a team of medical delegates.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>About Sri Lanka</STRONG> </div><div>PR indicates that the country has 20 million inhabitants and a per capita income of USD 3,200.<wbr> The economy is set to grow at a rapid pace of 7 to 8 per cent in the next few years with an increase in purchasing power per capita </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20151231&edate=20150901&rec=2613">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-10-30T09:44:34+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-10-30T09:44:34+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Revance RT002 BoNT Study To Treat Glabellar Lines Interim Results Have Shown A Statistical Significant Difference To Botox With 6 Months Duration</title>
	<pubDate>2015-10-29T21:30:37+01:00</pubDate>
	<wp:post_id>6771</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The pII Glabellar lines interim results were presented by Revance today highlighting statistical significance when compared to Botox as well as investigator efficacy results when compared to placebo.<wbr>  A RT002 cervical dystonia pII trial has also commenced in Q3 of this year </div><div style="margin-bottom: 10px;">The BELMONT is a pII multi center, double-blind, active comparator study of injectable RT002 amongst 268 patients in Canada.<wbr>  The study compared the safety, efficacy and duration of effect of three doses of RT002 (20U, 40U and 60U) against placebo, and Botox Cosmetic (investigated at the label dose of 20U).<wbr>  The results are based on the interim 24-week results, with the trial continuing to follow a subset of subjects for up to 36 weeks or until they return to baseline.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>The <EM>primary outcome</EM> measures were:</STRONG> </div><div style="margin-bottom: 10px;">·  Proportion of subjects assessed as responders by investigator assessment of severity of glabellar lines at maximum frown </div><div style="margin-bottom: 10px;">·  Duration of response assessed by investigator assessment of severity of glabellar lines at maximum frown from the date of injection to when subject reverts to baseline severity </div><div style="margin-bottom: 10px;"><STRONG>The <EM>primary efficacy</EM> assessments:</STRONG> </div><div style="margin-bottom: 10px;">·  ≥ 1-point improvement IGA-FWS </div><div style="margin-bottom: 10px;">·  Duration of response </div><div style="margin-bottom: 10px;">·  Risk-to-benefit ration </div><div style="margin-bottom: 10px;"><STRONG>The <I>secondary efficacy</I> assessments:</STRONG> </div><div style="margin-bottom: 10px;">·  Investigator (IGA-FWS) </div><div style="margin-bottom: 10px;">·  Subject Global Aesthetic improvement scale (GAIS) </div><div style="margin-bottom: 10px;">·  Patient facial Wrinkle Scale (PFWS) </div><div style="margin-bottom: 10px;"><STRONG>Key <EM>interim</EM> results of the BELMONT trial:</STRONG> </div><div style="margin-bottom: 10px;">·  The 4 week primary efficacy measurement of at least 1-point improvement in frown lines based on the IGA-FWS scale for all three doses (20 Units, 40 Units and 60 Units) of RT002 was highly statistically significant (p &lt; 0.<wbr>001) as compared to placebo for all three doses.<wbr> </div><div style="margin-bottom: 10px;">·  All doses of RT002 achieved a 100 percent response rate of at least 1-point improvement in frown lines, based on the IGA-FWS scale at 4 weeks versus a 95 percent response rate for BOTOX Cosmetic.<wbr> </div><div style="margin-bottom: 10px;">·  RT002 efficacy showed a dose response.<wbr> RT002 40U was statistically significant to BOTOX Cosmetic on all three responder definitions for the IGA-FWS median duration of effect.<wbr> On the IGA-FWS duration of response.<wbr>RT002 demonstrated a 23.<wbr>6 week median duration versus BOTOX Cosmetic with an 18.<wbr>8 week median duration (p=0.<wbr>020).<wbr> </div><div style="margin-bottom: 10px;">·  More than twice as many RT002 40U and 60U subjects in the study maintained none or mild wrinkles on the IGA-FWS scale as compared to BOTOX Cosmetic at Week 16 (p≤0.<wbr>002).<wbr> </div><div style="margin-bottom: 10px;"><UL><LI>Subject-reported outcomes were consistent with investigator findings of duration and efficacy of RT002.<wbr></LI>
<LI>Across all cohorts, RT002 appeared to be generally safe and well-tolerated.<wbr> Adverse events were generally mild, localized and transient.<wbr> For RT002 20U and 40U, no subjects experienced ptosis (eyelid droop).<wbr> There were no serious adverse events or evidence of any systemic exposure at any of the three doses evaluated.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;">Dan Browne, President and CEO at Revance discussed at the conference call earlier today “The results clearly support that 40U is the right dose to take forward.<wbr> Assuming the duration observed in our pIII studies is consistent with the results reported today, we believe the collective data should support a 6-month duration label.<wbr>  In essence we did better than Botox and it didn’t rely on Botox doing worse than previous trials stated either in the literature or the label.<wbr>  In our case RT002 outperformed Botox cosmetics” </div><div style="margin-bottom: 10px;">Of note are the week 16 results when compared to Botox.<wbr>  These results were statistically significantly different.<wbr>  As well as an effect still present at week 24 /<wbr> 6 months.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_8222_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;">In regards to the therapeutic space, Revance has a pII trial with RT002 in cervical dystonia.<wbr>  Dan Browne commented “A product with longer duration will be of particular benefit in the therapeutic space because of the pharmacoeconomics, the potential safety issues that may present with larger doses in larger anatomies”.<wbr>  This notion was further supported by Jacob Waugh advisor to the CEO and the Science &amp; Technology Committee of the Company’s Board “In therapeutics there are so many potential indications.<wbr>  We would be looking at muscle movement; it’s collectively the largest area for Botox.<wbr>  Secondly the pain indications from prophylactic treatment of chronic migraine, headache to other potential indications that could be musculoskeletal or neuropsychiatric.<wbr>  We will look at our data set and look at our capital and will have to make choices” </div><div style="margin-bottom: 10px;">In terms of the next steps, Lauren Silvernail, Chief Financial Officer and Executive Vice President of Corporate Development, reported the pIII pivotal trial design will be RT002 vs.<wbr> placebo, the 'standard' comparison.<wbr>  For timings Revance plans to conduct </div><div style="margin-bottom: 10px;"><UL><LI>End of pII FDA meeting 1H 2016</LI>
<LI>pIII to start 2H 2016,</LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI>Efficacy work 2017, </LI>
<LI>Safety 2018, and </LI>
<LI>File BLA end 2018/<wbr>2019.<wbr>  </LI>
</UL> </div><div style="margin-bottom: 10px;">In regards to potential partnerships, Dan made it clear that at present it was not something they would be focusing on “We feel really comfortable with the toxin platform, we’re really capitalized at this point, so we don’t feel compelled to partner.<wbr>  We just need to continue with development and in time we might look at that.<wbr>  We will move along as a single entity and keep our rights intact globally.<wbr>  As we get closer to commercialization, we will take a look at that” </div><div style="margin-bottom: 10px;">Other key slides presented include </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_8222_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_8222_3_ScreenCapture3.jpg"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_8222_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_8222_5_ScreenCapture5.jpg"> </div><div style="margin-bottom: 10px;">The safety and efficacy of Revance products were of a great anticipation but also uncertainty about both products claims.<wbr> RT002 has shown some promising initial results, but final analysis needs to occur to confirm these.<wbr>  Long duration of action is of a key benefit in the aesthetic space.<wbr>  In therapeutics, however, it’s of benefit but probably not to the same extent.<wbr>  The real advantage lies in physicians being able to have a portfolio of BoNT A options thus providing a more individualized treatment regime.<wbr> </div><div>Source: Revance website </div><!-- Comment details --><a name="neurology8222attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_8222_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(63,4 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_8222_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(46,3 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_8222_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(39,5 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_8222_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(66,3 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_8222_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(54 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20151231&edate=20150901&rec=8222">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-10-29T21:30:37+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-10-29T21:30:37+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Boehringer Ingelheim Disinvests in Italy</title>
	<pubDate>2015-10-29T19:01:52+01:00</pubDate>
	<wp:post_id>6772</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Boehringer Ingelheim has announced a major restructuring of its Italian manufacturing operations, with plans to reduce the 694-strong workforce by 30% between 2016&ndash;2020.<wbr> Under the plan, a total of 176 jobs would be cut at Boehringer Ingelheim Italia Spa.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>About BI in Italy:</STRONG> BI Italian manufacturing unit is structured into 3 separate divisions: hospital and prescription medicines, non-prescription medicines, and a veterinary division.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Italian Revenues: </STRONG>About three-quarters of <SPAN style="text-align: left; widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 12px/18px Arial, Helvetica, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #444444; word-spacing: 0px; -webkit-text-size-adjust: none; -webkit-text-stroke-width: 0px;"><SPAN style="color: #000000;">Boehringer Ingelheim Italia Spa</SPAN> </SPAN>revenues are derived from prescription-medicine sales.<wbr> </div><div>However, in recent years the company has experienced a significant decline in Italian sales and profits, partly owing to patent losses on products such as the Parkinson's drug Mirapex/<wbr>Sifrol (pramipexole) and angiotensin II receptor blocker Micardis (telmisartan).<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20151231&edate=20150901&rec=11297">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-10-29T19:01:52+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-10-29T19:01:52+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>MEDACorp US Cosmetic Survey Reveals Strong Interest In Revance's RT-002</title>
	<pubDate>2015-10-29T17:02:22+01:00</pubDate>
	<wp:post_id>6773</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Leerink analysts have just published the results of a US cosmetic survey conducted by MEDACorp which re-affirms the stability of demand for Allergan's cosmetic business based on procedural growth of 5% pa vs 4% in 2014 underpinned by economic recovery &amp; increased marketing.<wbr> Specialists were enthusiastic about Kybella, the group's new submental fat product and interestingly cited Revance products as having the greatest potential for disruption of Allergan's dominance.<wbr> Specialists view RT-002, if approved, as having the ability to take as much as 40% share from Botox assuming a 6-month durable benefit.<wbr> </div><div style="margin-bottom: 10px;">As part of the survey 30 dermatologists and 30 plastic surgeons with practices across the US were surveyed </div><div style="margin-bottom: 10px;"><STRONG>Key Survey Findings</STRONG> </div><div style="margin-bottom: 10px;">Botox is expected to remain market leader  between 2015-2017, however, is likely to cede some market share to Xeomin whilst Dysport's share is expected to remain stable.<wbr> </div><div style="margin-bottom: 10px;">Overall Topical BoNT, long acting BoNT and Kybella hold the highest new product interest among specialists </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_8221_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_8221_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_8221_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;">For those interested to receive a copy of the report please contact Jacquelyne Cantle </div><div>Source: Leerink Allergan Report October 28th 2015 </div><!-- Comment details --><a name="neurology8221attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_8221_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(115,3 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_8221_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(85,2 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_8221_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(98,3 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20151231&edate=20150901&rec=8221">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-10-29T17:02:22+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-10-29T17:02:22+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Pfizer Reportedly In Merger Discussions With Allergan</title>
	<pubDate>2015-10-29T14:56:46+01:00</pubDate>
	<wp:post_id>6774</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Pfizer Reportedly In Merger Discussions With Allergan</span>&nbsp;<br><span style="font-size: 12px;">Comment: Pfizer is reportedly in discussions with Allergan to discuss the biggest takeover this year accoring to a report in the Wall Street Journal.<wbr> Both companies are known to be keen to undertake transformational mergers, Allergan's Brent Saunders (CEO) stated as much after the sale of its generic business to Teva in July.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20151231&edate=20150901&rec=11291">...</a><br></div><div style="margin-bottom: 10px;">Comment: Allergan have issued a press release confirming discussions with Pfizer in regards to a potential business combination.<wbr> These discussions reported by Allergan have been reported aspreliminary and friendly.<wbr> Allergan stated that &ldquo;No agreement has been reached and there can be no certainty that these discussions will lead to a transaction or as to the terms on which a transaction, if any, might be agreed&rdquo; Allergan maintains its commitment to complete the diversification of the global generics business to TEVA.<wbr> Completion is expected in Q1 2016.<wbr> </div><div>Source: Allergan press release </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20151231&edate=20150901&rec=11292">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld11291">View thread  PharmaWorld11291: Pfizer Reportedly In Merger Discussions With Allergan</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-10-29T14:56:46+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-10-29T14:56:46+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>NANETS 2015: Key Takeaways</title>
	<pubDate>2015-10-29T12:16:58+01:00</pubDate>
	<wp:post_id>6775</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: <SPAN style="line-height: 1.5em;">Just over two weeks after ESMO, the North America NETs (NANETS) society met in Austin, Texas, and further discussed all the key NET data that were first presented in Vienna: RADIANT-4, NETTER-1 and TELESTAR.<wbr> The NANETS activities revealed a slightly different positioning for these data compared to the ESMO feedback.<wbr> Everolimus, which has now been filed for second line in lung or GI NET in US, EU and Japan, was not positioned prior to PRRT as previously suggested at ESMO.<wbr> Lutathera was presented as a second line option for progressive midgut NETs while Telotristat etiprate data were highly welcomed as second line option in symptom control after SSA.<wbr> K.<wbr>Oberg presented &lsquo;his&rsquo; modified version of the NCCN guidelines, positioning Telotristat etiprate, Lutathera and Everolimus in the schematic of treatment.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><STRONG>Key takeaway:</STRONG> </div><div style="margin-bottom: 10px;">With the release of many new data, also at NANETS there was a discussion about changing the NET treatment guidelines (same as EANM by Caplin).<wbr> <SPAN style="line-height: 1.5em;">K.<wbr>Oberg gave a interesting new picture of NCCN guidelines, and in particular where, in his opinion, we should include the new treatment options (see picture below).<wbr> </SPAN> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8249_19_New%255fNCCN%255fversion%255fby%255fOberg.JPG"> </div><div style="margin-bottom: 10px;"><SPAN style="text-decoration: underline;"><STRONG>NOVARTIS ACTIVITIES</STRONG></SPAN> </div><div style="margin-bottom: 10px;"><UL><LI>Yao presented the RADIANT-4 data [same as ESMO]
</LI>
<LI>&Ouml;berg, who discussed the data presented by Yao, called for further analyses to explore individual subgroups by tumor location in patients with GI tumors.<wbr> He stressed how everolimus is likely to have different efficacy rates by location in various GI tumors, and specifically higher efficacy in rectal tumors.<wbr> Additionally, he questioned the role of everolimus in treating small intestine NETs, given the results from RADIANT-2.<wbr>
</LI>
<LI>There was some discussion about high dose octreotide for carcinoid syndrome (same data presented at ESMO)
</LI>
<LI>NVS presence was almost inexistent with no great messaging or positioning for everolimus.<wbr> While at ESMO few activities were trying to position everolimus prior to PRRT, no similar activities were picked up at NANETS, although this could be a strategic move, following the submission of the RADIANT-4 data in US, EU and Japan.<wbr>
</LI>
<LI>NVS presented a poster on economic evaluation of octreotide LAR vs lanreotide in the treatment of GI-NETs (see PDF enclosed)
<UL><LI>The poster concluded that the cost of treatment with octreotide was significantly lower than lanreotide (lanreotide costs $84,362 more over the lifetime horizon, according to the study), based on: 1)PROMID data; 2) an assumption that lanreotide has equal efficacy based on the lack of data comparing the two drugs and 3) that the NCCN guidelines do not differentiate between the two drugs (did not use CLARINET because they wanted to maintain &ldquo;equal footing&rdquo; between both drugs, according to the presenter, a Novartis biostatistician).<wbr>
</LI>
<LI>Novartis has submitted the manuscript with the Journal of Medical Economics and expect publication by end of 2015.<wbr>
</LI>
<LI>Physicians commented that they didn&rsquo;t understand the analysis, they noticed that CLARINET was not included, and are waiting to see if and how payers react.<wbr>
</LI>
<LI>We need to further understand the impact this publication could have on Somatuline
</LI>
</UL>

</LI>
<LI>Novartis also presented a poster analysing the &lsquo;Cost impact of non-infectious diarrhea in patients with Carcinoid Syndrome&rsquo; (see PDF enclosed)
<UL><LI>NVS concluded that adequate control of diarrhea in CS patients may reduce healthcare costs
</LI>
<LI>We need to further understand the reasoning behind this study in terms of high-dose octreotide positioning in carcinoid symptoms
</LI>
</UL>

</LI>
<LI>Novartis also had a poster in collaboration with INCA to describe the burden of lung NET through patient-reported experiences, <SPAN style="line-height: 1.5em;"><SPAN style="line-height: 1.5em;">including disease burden, medical resource use, and access to care.<wbr> (see PDF enclosed) </SPAN></SPAN>
<UL><LI><SPAN style="line-height: 1.5em;"><SPAN style="line-height: 1.5em;">The interviews run from February to May 2014 and included 1928 patients from &gt;12 countries.<wbr> </SPAN></SPAN>
</LI>
<LI><SPAN style="line-height: 1.5em;"><SPAN style="line-height: 1.5em;">T</SPAN></SPAN><SPAN style="line-height: 1.5em;">he majority of patients experienced a moderate to large negative impact on their </SPAN><SPAN style="line-height: 1.5em;">daily life, and many reported a negative impact on work life.<wbr> </SPAN>
</LI>
<LI><SPAN style="line-height: 1.5em;">Patients with lung NETs were more likely than those with other NET types to have </SPAN><SPAN style="line-height: 1.5em;">negative feelings regarding various aspects of their care</SPAN>
</LI>
</UL>

</LI>
<LI>A Novartis representative mentioned how the group is planning concentrating next year marketing activities around Afinitor in GI or Lung NET (once approved), and invest less on Sandostatin LAR, as Afinitor will drive the marketing of SSA too (need to further assess whether there could be a price bundling positioning).<wbr>
</LI>
</UL> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8249_1_Oberg%255fRADIANT%255f4%255fDiscussion.JPG"> </div><div style="margin-bottom: 10px;"><STRONG><U>AAA ACTIVITIES</U></STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>NETTER-1 data were presented by Strosberg (same presentation that was at ESMO) and positioned as second line option in progressive midgut NETs.<wbr>
</LI>
<LI>AAA recognizes high incidence of nausea and other GI AEs associated with amino acid administration and is currently developing an off-the-shelf preparation containing only lysine and arginine for administration prior to Lutathera.<wbr> However, the amino acid preparation is expected to be launched in 2017 and not at the launch of Lutathera.<wbr> At launch AAA will try to get the FDA to use the European amino acids for prevention of renal injury which has proved to be less toxic.<wbr>
</LI>
<LI>AAA will try to submit to the FDA by December/<wbr>January; as they have fast track, they might be approved by summer 2016, depending how quickly AAA can address any questions the FDA poses.<wbr> Further analysis on adverse events and subgroups will be likely presented at ASCO GI 2016.<wbr>
</LI>
<LI>AAA is in the process of finalizing the manuscript and will submit to the NEJM before end of 2015 and expects publication by mid 2H 2016.<wbr>
</LI>
<LI>The FDA has asked them to set up a compassionate use program that will include a broader range of patients than included on the NETTER-1 trial because of the amount of European data on a variety of cancers &ndash; most physicians believe this will expand to pNET too.<wbr>
</LI>
<LI>Oberg (in the discussion) pointed out whether possibly Luthatera should be considered for less cycles, then wait for tumor progression, and eventually do more cycles.<wbr> He suggested this could have an impact on safety.<wbr>
</LI>
<LI>PRRT was perceived as a second line option and with a possibility to impact symptom control as well as tumor control.<wbr>
</LI>
</UL> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8249_4_Oberg%255fNETTER%255f1%255fDiscussion.JPG"> <img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8249_5_PRRT%20Symptom%20control.JPG"> </div><div style="margin-bottom: 10px;">Lisa Bodei presented a very interesting overview on &lsquo;practical aspects of PRRT&rsquo; &ndash; the presentation and messaging was the same presented l the week before at EANM&ndash; see EANM Traction report.<wbr> Of note is the impact of PRRT on symptom control with response rates with Lutetium she claimed around 70% (There is an article in press on this topic &ndash; need to monitor) (picture on the right).<wbr> </div><div style="margin-bottom: 10px;"><STRONG><U>LEXICON ACTIVITIES</U></STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>M.<wbr>Kulke presented the TELESTAR data (same presentation that was at ESMO)
</LI>
<LI>Data well perceived with no issues on depression as adverse events
</LI>
<LI>K.<wbr> Oberg (during the data discussion) suggested the 250mg dose could be a better solution, having a better durable response.<wbr>
</LI>
</UL> </div><div style="margin-bottom: 10px;">Lexicon also organised a Symposium : ' Tryptophan Hydroxylase: A Potential New Target for Carcinoid Syndrome' </div><div style="margin-bottom: 10px;"><OL><LI>M.<wbr> Kulke presented the Phase II data &amp; Phase III data &amp; studies design (again)
</LI>
<LI>Pam Kunz presented the patient survey (lexicon also had a poster on the data &ndash; attached)
</LI>
</OL> </div><div style="margin-bottom: 10px;"><UL><LI>
<UL><LI>35 out of the 135 patients recruited across the 16 clinical sites and 5 countries completed the exit interviews study
</LI>
<LI>Each interview divided into 2 phases: 1) patients&rsquo; CS symptom experience before the study; 2) clinical trial experience
</LI>
<LI>Results showed how effective reduction in BM frequency led to improvement in emotional well-being and social physical function and the highest level of treatment satisfaction was reported only in the TE arm, not the placebo.<wbr>
</LI>
</UL>

</LI>
</UL> </div><div style="margin-bottom: 10px;"><OL><LI>Anthony Lowell presneted the challenges of serotonin overproduction and in particular:
</LI>
</OL> </div><div style="margin-bottom: 10px;"><UL><LI>
<UL><LI>Serotonin overproduction role in Carcinoid Heart Disease (CHD)
</LI>
<LI>Serotonin overproduction role in mesenteric fibrosis and pulmonary artery hyperplasia
</LI>
<LI>Role that serotonin could play in tumor growth
</LI>
<LI>Lowell hit hard on CHD with the case of a woman with high 5-HIAA, NYHA IV heart failure, and multiple TVR; reducing 5-HIAA at last resort resulted in marked improvement in her NYHA score.<wbr>
</LI>
</UL>

</LI>
</UL> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8249_6_Lexicon%255fSymposium%255f1.JPG"> <img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8249_7_Lexicon%255fSymposium%255f2.JPG"> <img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8249_8_Lexicon%255fSymposium%255f3.JPG"> <img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8249_9_Lexicon%255fSymposium%255f4.JPG"> </div><div style="margin-bottom: 10px;"><UL><LI>Pellika (Mayo) also presented on Carcinoid Heart Disease during the &ldquo;Future of SSA Therapy&rdquo; plenary session
</LI>
<LI>Anthony Heaney (UCLA) presented an overview of controlling symptoms of hormone secretion, presenting SSAs, Telotristat etiprate and hinting the possible role of PRRT
</LI>
</UL> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8249_10_Pellikka%255fCHD%255f1.JPG"> <img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8249_11_Pellikka%255fCHD%255f2.JPG"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8249_12_Pellikka%255fCHD%255f3.JPG"> <img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8249_13_Heaney%255f2.JPG"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8249_14_Heaney%255fSymptom%255fControl.JPG"> </div><div style="margin-bottom: 10px;"><SPAN style="line-height: 1.5em;">Lexicon also presented a poster: Assessing Treatment Benefit of Telotristat etiprate in Patients with Carcinoid Syndrome: Patient Exit Interviews (see PDF enclosed)</SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="text-decoration: underline;"><STRONG>OTHER COMPETITORS ACTIVITIES</STRONG></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="text-decoration: underline;"><STRONG>ARBUTUS CORPORATION (EX-TEKMIRA)</STRONG></SPAN> </div><div style="margin-bottom: 10px;">Poster: A Phase I/<wbr>II study of TKM-080301, a RNAi Therapeutic directed against PLK-1 in patients with GI-NET (Halfdanarson et.<wbr> Al, Arbutus/<wbr>Tekmira) </div><div><DIV>
<UL><LI><SPAN style="line-height: 1.5em;">The previously reported dose escalation portion of this Phase I/<wbr>II open-label study supported a maximum tolerated dose (MTD)of 0.<wbr>75mg/<wbr>kg/<wbr>week.<wbr></SPAN>
</LI>
<LI><SPAN style="line-height: 1.5em;">The study included an initial expansion cohort at the MTD in subjects with advanced solid tumors, and subsequent expansion cohorts in subjects with ACC and GI-NET.<wbr></SPAN>
</LI>
<LI><SPAN style="line-height: 1.5em;">TKM-080301 was administered as a 30 minutes IV infusion on day 1, 8, 15 and 28 cycle.<wbr></SPAN>
</LI>
<LI><SPAN style="line-height: 1.5em;">In order to reduce the incidence and severity of infusion related reactions a prophylactic regimen was used prior to infusion, including dexamethasone.<wbr></SPAN>
</LI>
<LI><SPAN style="line-height: 1.5em;">Evidence of anti-tumor activity was observed based on:</SPAN>
</LI>
<LI><SPAN style="line-height: 1.5em;">A decrease in tumor size from baseline for 50% of subjects including one subject who exhibited a partial response with reduction in tumor size of 61% from baseline.<wbr></SPAN>
</LI>
<LI><SPAN style="line-height: 1.5em;">Stable disease with duration of 2-14 cycles for 77% of subjects</SPAN>
</LI>
<LI><SPAN style="line-height: 1.5em;">Additional study of TKM-080301 in larger patients with GI-NET is required.<wbr></SPAN>
</LI>
</UL>
<P><SPAN style="line-height: 1.5em;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8249_17_Tekmira%255fposter.JPG"></SPAN></P>
<P><SPAN style="text-decoration: underline;"><STRONG>OXIGENE</STRONG></SPAN></P>
<P>Poster: Phase 2 Study (OX4218s) of Fosbretabulin Tromethamine (CA4P) for Treatment of Well-Differentiated, Low-to-intermediate-Grade Unresectable, Recurrent or Metastatic pNET or GI-NETs with Elevated Biomarkers<BR>(S Libuti et al.<wbr>/<wbr> Oxigene)</P>
<DIV>
<UL><LI><SPAN style="line-height: 1.5em;">Phase II single-arm open-label of CA4P on patients who have relapsed during or after receiving SSAs</SPAN>
</LI>
<LI><SPAN style="line-height: 1.5em;">Recruitment goal is 20 patients at 5 sites</SPAN>
</LI>
<LI><SPAN style="line-height: 1.5em;">CA4P administered as 60mg/<wbr>m2 as a 10-minute infusion on days 1, 8, and 15 of three 21-day cycles; followed for 30 days after the last cycle</SPAN>
</LI>
<LI><SPAN style="line-height: 1.5em;">As of August 2015, had enrolled 9 subjects with GI-NETs</SPAN>
</LI>
<LI><SPAN style="line-height: 1.5em;">Reported 30 adverse events for 8 subjects, 10 possibly related to CA4P (tinnitus, abdominal pain, nausea, fatigue, decreased appetite, hypokalemia, hypomagnesemia, muscular weakness)</SPAN>
</LI>
<LI><SPAN style="line-height: 1.5em;">Interim results from 9 subjects suggest that Fosbretabulin monotherapy might improve biomarkers , QOL and ECOG status was well generally tolerated</SPAN>
</LI>
<LI><SPAN style="line-height: 1.5em;">Due to the small number of patients results should be interpreted with caution</SPAN>
</LI>
<LI><SPAN style="line-height: 1.5em;">Full results are expected in the second half of 2016</SPAN>
</LI>
</UL>
<P><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8249_18_Oxigene%255fposter.JPG"></P>
</DIV>
</DIV> </div><!-- Comment details --><a name="endocrinology8249attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8249_1_Oberg%255fRADIANT%255f4%255fDiscussion.JPG">Oberg_RADIANT_4_Discussion.JPG</a>&nbsp;&nbsp;(867,6 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8249_2_Econoc%20Evaluation%20of%20octreotide%20LAR%20vs%20Lanreotide.pdf">Econoc Evaluation of octreotide LAR vs Lanreotide.pdf</a>&nbsp;&nbsp;(1,2 MB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8249_3_Cost%20impact%20of%20NI%20diarrhea%20in%20CS%20.pdf">Cost impact of NI diarrhea in CS .pdf</a>&nbsp;&nbsp;(259,2 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8249_4_Oberg%255fNETTER%255f1%255fDiscussion.JPG">Oberg_NETTER_1_Discussion.JPG</a>&nbsp;&nbsp;(865,9 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8249_5_PRRT%20Symptom%20control.JPG">PRRT Symptom control.JPG</a>&nbsp;&nbsp;(60,5 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8249_6_Lexicon%255fSymposium%255f1.JPG">Lexicon_Symposium_1.JPG</a>&nbsp;&nbsp;(862,2 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8249_7_Lexicon%255fSymposium%255f2.JPG">Lexicon_Symposium_2.JPG</a>&nbsp;&nbsp;(815,8 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8249_8_Lexicon%255fSymposium%255f3.JPG">Lexicon_Symposium_3.JPG</a>&nbsp;&nbsp;(934,1 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8249_9_Lexicon%255fSymposium%255f4.JPG">Lexicon_Symposium_4.JPG</a>&nbsp;&nbsp;(781,3 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8249_10_Pellikka%255fCHD%255f1.JPG">Pellikka_CHD_1.JPG</a>&nbsp;&nbsp;(909,9 KB)<br>&nbsp;&nbsp;11.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8249_11_Pellikka%255fCHD%255f2.JPG">Pellikka_CHD_2.JPG</a>&nbsp;&nbsp;(635 KB)<br>&nbsp;&nbsp;12.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8249_12_Pellikka%255fCHD%255f3.JPG">Pellikka_CHD_3.JPG</a>&nbsp;&nbsp;(660,7 KB)<br>&nbsp;&nbsp;13.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8249_13_Heaney%255f2.JPG">Heaney_2.JPG</a>&nbsp;&nbsp;(717,4 KB)<br>&nbsp;&nbsp;14.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8249_14_Heaney%255fSymptom%255fControl.JPG">Heaney_Symptom_Control.JPG</a>&nbsp;&nbsp;(1 MB)<br>&nbsp;&nbsp;15.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8249_15_101101779%255fUSNET%255fNANETS2015%255fFINAL.pdf">101101779_USNET_NANETS2015_FINAL.pdf</a>&nbsp;&nbsp;(856 KB)<br>&nbsp;&nbsp;16.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8249_16_Assessing%255fTreatment%255fBenefit%255fof%255fTE%255fCS%255fPatient%255fExit%255fInterviews.pdf">Assessing_Treatment_Benefit_of_TE_CS_Patient_Exit_Interviews.pdf</a>&nbsp;&nbsp;(282,3 KB)<br>&nbsp;&nbsp;17.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8249_17_Tekmira%255fposter.JPG">Tekmira_poster.JPG</a>&nbsp;&nbsp;(2,4 MB)<br>&nbsp;&nbsp;18.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8249_18_Oxigene%255fposter.JPG">Oxigene_poster.JPG</a>&nbsp;&nbsp;(104,5 KB)<br>&nbsp;&nbsp;19.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8249_19_New%255fNCCN%255fversion%255fby%255fOberg.JPG">New_NCCN_version_by_Oberg.JPG</a>&nbsp;&nbsp;(1,1 MB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20151231&edate=20150901&rec=8249">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-10-29T12:16:58+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-10-29T12:16:58+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Pfizer Reportedly In Merger Discussions With Allergan</title>
	<pubDate>2015-10-29T09:52:58+01:00</pubDate>
	<wp:post_id>6776</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Pfizer is reportedly in discussions with Allergan to discuss the biggest takeover this year accoring to a report in the Wall Street Journal.<wbr> Both companies are known to be keen to undertake transformational mergers, Allergan's Brent Saunders (CEO) stated as much after the sale of its generic business to Teva in July.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Background/<wbr>Rational</STRONG> </div><div style="margin-bottom: 10px;">Pfizer has been biding its time to try and acquire a European rival after its failed attempt to court Astra Zeneca in May 2014.<wbr> The scale of this bid if it proceeds would be even larger based on Allergan's current market value of $113bn.<wbr> Part of the rational for the previous bid was the potential to lower Pfizer's tax bill by switching its headquarters from the US to the UK.<wbr> The takeover of Allergan has the potential to offer similar advantages, although since 2014 the US has attempted to crack down on such tax avoidance deals.<wbr> </div><div style="margin-bottom: 10px;">The other rational for a potential deal is the boost it would give to Pfizer's top line growth.<wbr> Its 2015 revenues are expected to decline by around 3% this year, whilst Allergan's have the potential to increase by 39%.<wbr> </div><div style="margin-bottom: 10px;">Negotiations are reportedly at an ealy stage.<wbr> </div><div>Source: Reuters </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="PharmaWorld11292c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">Comment: Allergan have issued a press release confirming discussions with Pfizer in regards to a potential business combination.<wbr> These discussions reported by Allergan have been reported aspreliminary and friendly.<wbr> Allergan stated that &ldquo;No agreement has been reached and there can be no certainty that these discussions will lead to a transaction or as to the terms on which a transaction, if any, might be agreed&rdquo; Allergan maintains its commitment to complete the diversification of the global generics business to TEVA.<wbr> Completion is expected in Q1 2016.<wbr> </div><div>Source: Allergan press release </div></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20151231&edate=20150901&rec=11291">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-10-29T09:52:58+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-10-29T09:52:58+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>OpenBiome Launches FMT Capsule G3s in the US</title>
	<pubDate>2015-10-28T19:23:15+01:00</pubDate>
	<wp:post_id>6777</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: This week marks the first time such a pill will be commercially available to hospitals and clinics.<wbr> According to OpenBiome one dose of 30 pills costs $635.<wbr> Currently each pill is made by hand.<wbr> In parallel the nonprofit stool bank has launched a personalized microbiome banking service that will allow individuals to cryogenically preserve a sample of their fecal microbiota.<wbr>  In the event that they require a fecal transplant for the treatment of recurrent C.<wbr> difficile infection, participants may use their banked samples for the procedure.<wbr> </div><div>Source: <A href="http://www.openbiome.org/press-releases/2015/10/14/openbiome-launches-personalized-microbiome-banking-service">http:/<wbr>/<wbr>www.<wbr>openbiome.<wbr>org/<wbr>press-releases/<wbr>2015/<wbr>10/<wbr>14/<wbr>openbiome-launches-personalized-microbiome-banking-service</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20151231&edate=20150901&rec=2612">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-10-28T19:23:15+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-10-28T19:23:15+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Merrimack Annouces MM398's (OnivideTM) FDA Approval For 2nd Line Metastatic Pancreatic Cancer</title>
	<pubDate>2015-10-28T16:10:19+01:00</pubDate>
	<wp:post_id>6778</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Merrimack Annouces MM398's  (OnivideTM) FDA Approval For 2nd Line Metastatic Pancreatic Cancer</span>&nbsp;<br><span style="font-size: 12px;">Comment: Merrimack today announced that ONIVYDE&trade; (irinotecan liposome injection) has been approved by the U.<wbr>S.<wbr> Food and Drug Administration (FDA)  in combination with fluorouracil (5-FU) and leucovorin for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy.<wbr> With this approval, ONIVYDE in combination with 5-FU and leucovorin becomes the first and only FDA-approved treatment option for patients in this setting.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20151231&edate=20150901&rec=10727">...</a><br></div><div style="margin-bottom: 10px;">Comment: Further to the FDA approval of Onivyde in 2L pancreatic cancer, Merrimack and Baxalta announced entry of Ph2 study to evaluate Onivyde in 1L pancreatic cancer - the enrolment of first patient in the trial has now been initiated.<wbr> The study is to evaluate the combination of Onivyde + 5FU + leucovorin +/<wbr>- oxaliplatin.<wbr> The first centre to open the trial is St John of God hospital Subiaco in Australia.<wbr>Merrimack and Baxalta plan to conduct the study at sites in the United States, Canada, Europe, Australia, New Zealand, Taiwan and South Korea.<wbr> Based on the current design of this study, data are expected in the first half of 2017.<wbr> This triggers $62.<wbr>5M of milestone payments to Merrimack from Baxalta.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Study Design:</STRONG> </div><div style="margin-bottom: 10px;">Part 1 (n=6-18):m The primary outcome for Part 1 of the study is to evaluate the safety and tolerability of ONIVYDE in combination with 5-FU/<wbr>LV and oxaliplatin.<wbr> </div><div style="margin-bottom: 10px;">Part 2: an additional 150 patients (50 patients per arm) with previously untreated, metastatic pancreatic adenocarcinoma will be enrolled and randomized to receive either ONIVYDE in combination with 5-FU/<wbr>LV and oxaliplatin, ONIVYDE in combination with 5-FU/<wbr>LV, or nab-paclitaxel and gemcitabine.<wbr> Efficacy of the ONIVYDE containing regimens will be compared to the nab-paclitaxel and gemcitabine regimen, evaluating progression free survival (PFS) rate at 24 weeks, as well as overall survival, PFS, objective response rate, tumor marker CA19-9 response, safety and tolerability.<wbr> </div><div>Source: <a href="https://clinicaltrials.gov/ct2/show/NCT02551991?term=NCT02551991&rank=1" class="defaultlink">NCT02551991</a> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20151231&edate=20150901&rec=10735">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10727">View thread  Oncology10727: Merrimack Annouces MM398's  (OnivideTM) FDA Approval For 2nd Line Metastatic Pancreatic Cancer</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-10-28T16:10:19+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-10-28T16:10:19+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Novartis Q3 2015 Results: Key Highlights</title>
	<pubDate>2015-10-27T16:54:55+01:00</pubDate>
	<wp:post_id>6779</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Novartis Q3 2015 highlighted total sales of $12.<wbr>3 bilion, up 6% versus Q3 previous year with a core operating income +14% driven by a strong performace from Pharmaceuticals, (sales up 7%), and Sandoz (sales up 9%) that offset the weak Alcon quarter (-2%).<wbr> The key mentioned advanced launches were Entresto, Cosentyx and Zarzio.<wbr> Afinitor (USD 414 million, +9% cc, all indications including pNET) has been highlighted as submitted for advanced non-functional GI and lung NET in US, Japan and Europe, with acknowledge that &rsquo;the increasingly competitive treatment landscapes in aRCC and advanced breast cancer may cause Afinitor growth to slow in the future&rsquo;.<wbr> </div><div style="margin-bottom: 10px;">Sandostatin (USD 419 million, +5% cc) continued to benefit from the increasing use of Sandostatin LAR in key markets, for patients with symptoms of carcinoid syndrome as well as those with advanced NET of the midgut or unknown primary tumor location.<wbr> Additional filings are underway for an enhanced presentation of Sandostatin LAR, which includes a diluent, safety needle and vial adapter.<wbr> </div><div style="margin-bottom: 10px;">Novartis has also highlighted the 7 key franchises it is currently focusing on and, with increased focus on the neuroscience franchise, mentioned the acquisition of Spinifex for neuropathic pain (phase II assett) and the Amgen collaboration in migraine and Alzheimer Disease.<wbr> </div><div style="margin-bottom: 10px;">Other molecules of key interest: </div><div style="margin-bottom: 10px;"><UL><LI>Signifor LAR for Cushing&rsquo;s Disease (Phase III) is listed as planned for submission in 2016.<wbr>
</LI>
<LI>LCI699 for Cushing&rsquo;s Disease (Phase III) is listed as planned for submission in 2017.<wbr>
</LI>
<LI>LEE011 for solid tumors (including NETs), in Phase I, is listed as planned for submission in 2018.<wbr>
</LI>
<LI>BYL719 for solid tumors (including NETs), in Phase I, is listed as planned for submission &gt;2019.<wbr>
</LI>
</UL> </div><div style="margin-bottom: 10px;">The Italy Sandostatin investigation is now concluded: In January 2014, the Italian Competition Authority (ICA) opened an investigation to assess whether Novartis Farma S.<wbr>p.<wbr>A.<wbr> and Italfarmaco S.<wbr>p.<wbr>A.<wbr> colluded on the supply of octreotide acetate (Sandostatin LAR and Longastatina LAR, respectively).<wbr> In consideration of commitments to amend certain provisions of the co-marketing agreement with Italfarmaco, the ICA decided to close the investigation with no finding of an infringement and thus without a fine.<wbr> The decision has become final in October 2015.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8245_1_NVS%255fQ315%255f1.JPG"> <img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8245_2_NVS%255fQ315%255f2.JPG"> <img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8245_3_NVS%255fQ315%255f4.JPG"> <img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8245_4_NVS%255fQ315%255f5.JPG"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8245_5_NVS%255fQ315%255f3.JPG"> <img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8245_6_NVS%255fQ315%255f6.JPG"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8245_7_NVS%255fQ315%255f7.JPG"> </div><div>Source: Novartis Investor Relations </div><!-- Comment details --><a name="endocrinology8245attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8245_1_NVS%255fQ315%255f1.JPG">NVS_Q315_1.JPG</a>&nbsp;&nbsp;(82,3 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8245_2_NVS%255fQ315%255f2.JPG">NVS_Q315_2.JPG</a>&nbsp;&nbsp;(53,1 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8245_3_NVS%255fQ315%255f4.JPG">NVS_Q315_4.JPG</a>&nbsp;&nbsp;(74 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8245_4_NVS%255fQ315%255f5.JPG">NVS_Q315_5.JPG</a>&nbsp;&nbsp;(85,3 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8245_5_NVS%255fQ315%255f3.JPG">NVS_Q315_3.JPG</a>&nbsp;&nbsp;(79,9 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8245_6_NVS%255fQ315%255f6.JPG">NVS_Q315_6.JPG</a>&nbsp;&nbsp;(121,8 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8245_7_NVS%255fQ315%255f7.JPG">NVS_Q315_7.JPG</a>&nbsp;&nbsp;(73,9 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20151231&edate=20150901&rec=8245">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-10-27T16:54:55+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-10-27T16:54:55+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Pharmacyclics Is Up For A Sale?</title>
	<pubDate>2015-10-27T15:16:23+01:00</pubDate>
	<wp:post_id>6780</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Pharmacyclics Is Up For A Sale?</span>&nbsp;<br><span style="font-size: 12px;">Comment: Pharmacyclics have Ibvruvica that is approved for four different haematological cancer indications and Pharmacyclics' ambition is to add one more uses every year.<wbr> In November 2014, the Company announced a clinical trial collaboration agreement with AstraZeneca to evaluate the efficacy and safety of anti-PD1 + Ibruvica in haematological cancers and solid tumours.<wbr> It is currently being valued at more than $15 billion  and murmurs amongst analysts suggest Pharmacyclics are exploring options including sale.<wbr> The market reacted and the company's shares rose 17% to $220.<wbr>22 at the close in New York.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20151231&edate=20150901&rec=11110">...</a><br></div><div>Comment: Ibrutinib (IMBRUVICA) is now being investigated for advanced carcinoid and pNETs, sponsored by H.<wbr>Lee Moffitt Cancer Center in collaboration with Pharmacyclis/<wbr>Abbvie (PI, J.<wbr> Strosberg).<wbr> The study, a Phase II prospective open-label trial, will enroll up to 51 patients in two cohorts, 30 carcinoids and 21 pNET patients.<wbr> ORR is the primary outcome with PFS being the secondary outcome measure.<wbr> The study is currently recruiting with estimated primary completion date in February 2017 (NCT02575300).<wbr> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20151231&edate=20150901&rec=11289">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld11110">View thread  PharmaWorld11110: Pharmacyclics Is Up For A Sale?</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-10-27T15:16:23+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-10-27T15:16:23+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Eisai Is Progressing Into Ph3 With Its Lenvima In RCC 2L</title>
	<pubDate>2015-10-27T14:59:09+01:00</pubDate>
	<wp:post_id>6781</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Eisai published the results of its Ph2 study (Study 205) of its Lenvima (lenvatinib) in 2L RCC in Lancet Oncology this month.<wbr> Study 205 is a three-arms study to compare the safety and efficacy of lenvatinib+everolimus versus lenvatinib monotherapy versus everolimus monotherapy.<wbr> The combination arm demonstrated a significant extension of PFS over the monotherapy arms (14.<wbr>6 months, 7.<wbr>4 months vs 5.<wbr>5 months, respectively) Eisai is currently engaged with FDA and EMA to discuss pivotal Ph3 protocol for registration in renal cell carcinoma.<wbr> </div><div style="margin-bottom: 10px;">Study 205 was a Phase II open label clinical trial to compare the safety and efficacy among three groups including a combination of lenvatinib (18 mg) plus everolimus (5 mg), lenvatinib alone (24 mg) and everolimus alone (10 mg) in advanced or metastatic renal cell carcinoma following one prior vascular endothelial growth factor-targeted therapy.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10734_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><STRONG>Clinical efficacy:</STRONG> combination of lenvatinib with everolimus appears to be superior than either of the monotherapy.<wbr> Efficay of lenvatinib monotherapy appears to be comparable to the cabozantinib from METEOR trial (note that this is not a direct comparison).<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10734_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;"><STRONG>Tolerability:</STRONG> High incidence of Grade 3 diarrhea in combination arm could be a concern.<wbr> Lenvatinib dose reductions were required for 71% of patients in the combination arm compared with 62% in lenvatinib alone arm.<wbr> Of those in the everolimus monotherapy arm, 26% required a dose reduction.<wbr> </div><div style="margin-bottom: 10px;">All patients experienced at least one treatment-emergent adverse event (AE) across all treatment arms.<wbr> Treatment-related grade 3 AEs occurred in 71% of patients in the combination arm, 83% in the single-agent lenvatinib arm, and 52% in the everolimus arm.<wbr> There was a 20% incidence for grade 3 diarrhea in the combination arm, which highlights the need for recognition and management of this toxicity for the combination.<wbr> here were relatively few grade 4 events in any of the three arms.<wbr> Two grade 5 AEs were attributed to lenvatinib.<wbr> </div><div style="margin-bottom: 10px;"><BR>Grade 3 and 4 events occurred in fewer patients allocated single-agent everolimus (25 [50%]) compared with those assigned lenvatinib alone (41 [79%]) or lenvatinib plus everolimus (36 [71%]).<wbr> The most common grade 3 or 4 treatment-emergent adverse event in patients allocated lenvatinib plus everolimus was diarrhoea (ten [20%]), in those assigned single-agent lenvatinib it was proteinuria (ten [19%]), and in those assigned single-agent everolimus it was anaemia (six [12%]).<wbr> Two deaths were deemed related to study drug, one cerebral haemorrhage in the lenvatinib plus everolimus group and one myocardial infarction with single-agent lenvatinib.<wbr> </div><div><BR>Source: Lancet Oncology DOI: <A href="http://dx.doi.org/10.1016/S1470-2045(15)00290-9">http:/<wbr>/<wbr>dx.<wbr>doi.<wbr>org/<wbr>10.<wbr>1016/<wbr>S1470-2045(15)00290-9</A> </div><!-- Comment details --><a name="oncology10734attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10734_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(83,9 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10734_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(71,8 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10734_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(73,2 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10734_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(71,2 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20151231&edate=20150901&rec=10734">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-10-27T14:59:09+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-10-27T14:59:09+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Allergan Acquires Rights To Ironwood's CONSTELLA® (Linaclotide) From Almirall In More Than 40 Countries</title>
	<pubDate>2015-10-27T14:39:51+01:00</pubDate>
	<wp:post_id>6782</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Strengthening its commitment to providing innovative gastrointestinal solutions Allergan and Ironwood Pharmaceuticals have acquired rights to CONSTELLA<SUP>&reg;</SUP> (linaclotide) in the European Union, Switzerland, Turkey and the Commonwealth of Independent States from Almirall, S.<wbr>A.<wbr> and has also reacquired rights to LINZESS<SUP>&reg;</SUP> (linaclotide) in Mexico from Almirall.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Deal Terms</STRONG> </div><div style="margin-bottom: 10px;">The license agreement includes the development and commercialization of CONSTELLA for the treatment of irritable bowel syndrome with constipation (IBS-C), chronic idiopathic constipation (CIC) and other gastrointestinal (GI) conditions.<wbr> The financial terms of the deal remain undisclosed.<wbr> </div><div style="margin-bottom: 10px;">CONSTELLA is currently approved by the European Commission for the symptomatic treatment of moderate-to-severe IBS-C in adults.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Background</STRONG> </div><div style="margin-bottom: 10px;">Linaclotide was approved in 2012 by the European Commission and, until assumed by Allergan under the announced transaction, was marketed in a number of European countries under the brand name CONSTELLA through a license agreement between Ironwood and Almirall.<wbr> Linaclotide was approved in 2014 in Mexico as a treatment for adults suffering from IBS-C or CIC under the brand name LINZESS and was marketed by Almirall through a sublicense from Allergan.<wbr> </div><div style="margin-bottom: 10px;">Allergan and Ironwood co-develop and co-commercialize linaclotide under the brand name LINZESS in the U.<wbr>S.<wbr> and Allergan is commercializing linaclotide in Canada under the brand name CONSTELLA.<wbr> </div><div style="margin-bottom: 10px;">Top-line phase III data of a low dose version of Linzess&reg; for the treatment of patients with Chronic Idiopathic Constipation (CIC) is expected later in the second half of 2015.<wbr> An sNDA submission is expected in 2016.<wbr> </div><div>From <A href="http://www.allergan.com/">http:/<wbr>/<wbr>www.<wbr>allergan.<wbr>com</A>, see <A href="http://www.allergan.com/news/news/thomson-reuters/allergan-acquires-rights-to-ironwood-s-constella">original source</A>.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20151231&edate=20150901&rec=2609">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-10-27T14:39:51+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-10-27T14:39:51+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Allergan Has Terminated Its Last Ongoing Study With Senrebotase</title>
	<pubDate>2015-10-27T14:26:35+01:00</pubDate>
	<wp:post_id>6783</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: As of last week ClinicalTrials.<wbr>gov noted that Allergan's PhII study with senrebotase, its targeted exocytosis modulator) which was being evaluated  in patients with post-herpetic neuralgia (PHN) was terminated.<wbr> No reason is given and no study results provided but lack of efficacy, portfolio prioritisation and or competing developments are probable causes.<wbr> </div><div style="margin-bottom: 10px;">The study design for NCT01678924 as compared to the first study Allergan undertook in PHN is shown below.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_8220_4_ScreenCapture4.jpg"> </div><div>The drug may not have reached its primary endpoint as even results undertaken in a previous trial NCT01129531 were not totally convincing.<wbr> Additionally, there are a number of other interesting competitive developments occuring in this space.<wbr> <img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_8220_2_ScreenCapture2.jpg"> </div><!-- Comment details --><a name="neurology8220attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_8220_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(666 B)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_8220_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(158,2 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_8220_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(120,9 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_8220_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(127,2 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20151231&edate=20150901&rec=8220">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-10-27T14:26:35+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-10-27T14:26:35+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Amgen's Imlygic Could Be The First Oncolytic Immunotherapy Approved In Oncology</title>
	<pubDate>2015-10-26T18:58:45+01:00</pubDate>
	<wp:post_id>6784</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment:The European Medicines Agency&rsquo;s scientific committee on Friday recommended authorizing Amgen's Imlygic (talimogene laherparepvec) for the treatment of adults with unresectable metastatic melanoma.<wbr> Imlygic is a first in class advnaced therapy medicinal product derived from a virus to be commercially available.<wbr> Imminent approval from FDA is also expected.<wbr> As a result, Amgen&rsquo;s shares rose 2.<wbr>26% to $155.<wbr>75 by close of trading on the Nasdaq on Friday.<wbr> </div><div style="margin-bottom: 10px;">Imlygic is derived from a virus (herpex simplex virus-1) that has been genetically engineered to infect and replicate (make copies of itself) within cancer cells and to produce the protein GM-CSF.<wbr> It is thought to work in two ways: it enters the tumour cell and uses the cell&rsquo;s energy stores to replicate, eventually overwhelming the cell and causing it to die.<wbr> By producing the protein GM-CSF it also stimulates the patient&rsquo;s immune system to recognise and destroy tumour cells.<wbr> Once an infected tumour cell dies, copies of the virus are released into the patient&rsquo;s bloodstream to infect more tumour cells.<wbr> Although Imlygic can enter healthy cells, it is not able to replicate in these healthy cells and so it does not kill them.<wbr> </div><div style="margin-bottom: 10px;"><SPAN style="text-decoration: underline;"><STRONG>Clinical Evidence</STRONG></SPAN> </div><div style="margin-bottom: 10px;">In the 436-patient study, Imlygic significantly improved durable response rate (DRR), the primary endpoint of the trial, in the intent-to-treat population.<wbr> DRR is defined as the percent of patients with complete response (CR) or partial response (PR) maintained continuously for a minimum of six months.<wbr> A key secondary endpoint was overall survival (OS).<wbr> The positive CHMP opinion reflects subgroup analyses where the effect on OS was largest in patients with unresectable melanoma that has not spread beyond the skin or lymph nodes.<wbr> </div><div style="margin-bottom: 10px;">The most commonly reported treatment-related adverse events were fatigue, chills, pyrexia, nausea, influenza-like illness and injection-site pain.<wbr> Overall, 98% of these adverse reactions reported were mild or moderate in severity.<wbr> The most common grade 3 or higher adverse reaction was cellulitis.<wbr> </div><div>Source: EMA Press Release 23rd Oct </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20151231&edate=20150901&rec=10731">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-10-26T18:58:45+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-10-26T18:58:45+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>ASCO GU 2016 Will Feature A Session To Discuss Checkpoint Blockade Strategies In Non-Muscle Invasive Bladder Cancer</title>
	<pubDate>2015-10-26T18:41:33+01:00</pubDate>
	<wp:post_id>6785</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Programme at a Glance for ASCO GU 2016 has been published.<wbr> Interestingly, "immunotherapy for urothelial carcinoma" will be featured in one of the general seesions on 8th January.<wbr> The status of the predictive biomarkers and response to immunotherapy will be discussed during the session.<wbr> More importantly, Dr.<wbr> Robert Svatek (a Urologist, UT Health Science Ceter San Antonio) and Dr James Gulley (an Oncologist, NCI) will offer new insights into novel checkpoint blockade strategies in non-muscle invasive bladder cancer.<wbr> Additionally, BMS will be one the industry supporters for the ASCO GU 2016.<wbr> This highlights the significance of future anti-PD1 entries in non-muscle invasive bladder cancer.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Programme at a Glance for ASCO GU 2016:</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10730_1_ScreenCapture1.jpg"> </div><div>Source: ASCO GU 2016 </div><!-- Comment details --><a name="oncology10730attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10730_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(209 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20151231&edate=20150901&rec=10730">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-10-26T18:41:33+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-10-26T18:41:33+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Merz Has Completed Enrolment In The PLL/PUL Long-term Open-label Study</title>
	<pubDate>2015-10-26T15:54:52+01:00</pubDate>
	<wp:post_id>6786</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Merz has completed recruitment for the trial <I>NCT01905683</I>; Long-term Open-label Study of Botulinum toxin Type A to Treat Spasticity of Leg(s) or Leg(s) and Arm in Cerebral Palsy.<wbr> The estimated completion dates are now more reliable as are the date for expected submission </div><div style="margin-bottom: 10px;">The estimated enrolment number still remains at 360 subjects across 43 study locations.<wbr> Since recruitment has now ended, the estimated completion dates are now more reliable, however, Merz in the past have also changed these metrics days/<wbr>weeks after updating the recruitment status, therefore this needs to monitored.<wbr> </div><div style="margin-bottom: 10px;">Estimated Primary Completion Date: September 2016 </div><div style="margin-bottom: 10px;">Estimated Study Completion Date: September 2016 </div><div style="margin-bottom: 10px;">With the PLL dose-response efficacy and safety study as well as now the PLL/<wbr>PUL long-term study now finished recruitment, the timelines for <U>PLL </U>submission can be <I>estimated</I> for Q4 2016/<wbr>Q1 2017 </div><div style="margin-bottom: 10px;"><TABLE cellSpacing=0 cellPadding=0 summary=“,”Layout border=0 traction_rs="[[014]]" information&ldquo;,&rdquo; enrollment for table>
 </div><div style="margin-bottom: 10px;">Source: Clinicaltrials.<wbr>gov </div><div><TBODY></TBODY> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20151231&edate=20150901&rec=8214">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-10-26T15:54:52+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-10-26T15:54:52+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>New Name For Caring For Carcinoid Foundation</title>
	<pubDate>2015-10-26T15:35:52+01:00</pubDate>
	<wp:post_id>6787</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Summary: The Caring For Carcinoid Foundation, a very active nonprofit organization that funds research to discover new NET treatments, has re-branded itself to the Neuroendocrine Tumor Research Foundation, a name set to include all types of neuroendocrine cancer and better reflect the current medical terminology of the disease.<wbr> Since its initiation, the NET Research Foundation has awarded over $10 million in large-scale, multi-year research grants and is actively funding research at 7 out of the top 10 US cancer centers.<wbr> </div><div style="margin-bottom: 10px;">The mission of the NET Research Foundation is to fund research to discover cures and more effective cures for carcinoid, pancreatic and related neuroendocrine tumors.<wbr> The Foundation also run 4 NET patient &amp; caregiver educational conferences annually to provide info to patients on treatments and to connect patients and caregivers with doctors, researchers and one another.<wbr> </div><div style="margin-bottom: 10px;">See the new <a href="http://netrf.org/" class="defaultlink">website</a>.<wbr> </div><div>Source: NET research Foundation </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20151231&edate=20150901&rec=8242">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-10-26T15:35:52+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-10-26T15:35:52+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Allergan Distributes Only 3% Of Branded Products In The US Through Specialty Pharmacies</title>
	<pubDate>2015-10-26T15:01:25+01:00</pubDate>
	<wp:post_id>6788</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment:  Allergan has issued a statement on specialty pharmacy utilization in the US, highlighting that for the branded products, the majority will be distributed through the traditional channels of wholesale and retail channels.<wbr> </div><div style="margin-bottom: 10px;">Allergan has also stated that they remain to have no ownership or affiliation with any specialty pharmacy with one of their companies, Anda, considered a traditional wholesaler and not a specialty pharmacy as questioned.<wbr>  This statement comes to light after speculation regarding the use of specialty pharmacies for distribution in the US.<wbr>  The 3% of branded products distributed by specialty pharmacy include BOTOX® Therapeutic and ZENPEP®.<wbr> </div><div>Source: Allergan website </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20151231&edate=20150901&rec=8213">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-10-26T15:01:25+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-10-26T15:01:25+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Early Clinical Studies With BoNT Prove Positive In Preventing Atrial Fibrillation In Open Heart Surgery</title>
	<pubDate>2015-10-26T11:59:51+01:00</pubDate>
	<wp:post_id>6789</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Early Clinical Studies With BoNT Prove Positive In Preventing Atrial Fibrillation In Open Heart Surgery</span>&nbsp;<br><span style="font-size: 12px;">Comment: In a study presented at the Heart Rhythm Society annual meeting, 30 heart bypass patients were injected with BoNT A which resulted in a decrease in clot-causing heart rhythms post-surgery</span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20151231&edate=20150901&rec=8025">...</a><br></div><div style="margin-bottom: 10px;"><P style="text-align: left;"><SPAN style="font-size: small; font-family: arial,helvetica,sans-serif;">A recent study published in <EM>Circulation: Arrhythmia and Electrophysiology</EM> further highlighted the benefit of BoNT to prevent AF after coronary artery bypass graft (CABG) surgery.<wbr>  This study included 60 CABG patients.<wbr>  The injections were delivered into epicardial fat pads during surgery.<wbr> In the first 30 days after surgery, 7% of those who got the BoNT developed AF compared to 30% who received saline.<wbr>   One year after surgery, none of those who got BoNT had recurrent AF, versus 27% of those given saline.<wbr></SPAN></P> </div><div><P style="text-align: left;"><SPAN style="font-size: small; font-family: arial,helvetica,sans-serif;">Source: Neurology Advisor journal</SPAN></P> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20151231&edate=20150901&rec=8212">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology8025">View thread  Neurology8025: Early Clinical Studies With BoNT Prove Positive In Preventing Atrial Fibrillation In Open Heart Surgery</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-10-26T11:59:51+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-10-26T11:59:51+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Exelixis Initiates Rolling Submission of U.S. NDA For Cabozantinib In RCC</title>
	<pubDate>2015-10-23T10:45:11+02:00</pubDate>
	<wp:post_id>6790</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment:Exelixis announced the company has initiated submission of its rolling New Drug Application (NDA) to the U.<wbr>S.<wbr> Food &amp; Drug Administration (FDA) for cabozantinib for the treatment of advanced renal cell carcinoma (RCC) patients who have received one prior therapy.<wbr> Cabozantinib was granted Breakthrough Therapy Designation by the FDA in August 2015.<wbr> Exelixis agreed with FDA that the submission would be a rolling NDA and the company has filed the first component of the application for potential approval of cabozantinib in the United States.<wbr> The rolling NDA allows completed portions of an NDA to be submitted and reviewed by the FDA on an ongoing basis.<wbr> Exelixis plans to complete the NDA submission before the end of 2015.<wbr> </div><div style="margin-bottom: 10px;">Cabozantinib is currently marketed in capsule form under the brand name COMETRIQ in the United States for the treatment of progressive, metastatic medullary thyroid cancer (MTC), and in the European Union for the treatment of adult patients with progressive, unresectable locally advanced or metastatic MTC.<wbr> </div><div style="margin-bottom: 10px;">Exelixis is investigating a tablet formulation of cabozantinib distinct from the COMETRIQ capsule form.<wbr> The tablet formulation of cabozantinib is the subject of the NDA for advanced RCC.<wbr> </div><div style="margin-bottom: 10px;">The rolling NDA submission is based on results of METEOR, a phase 3 pivotal trial comparing cabozantinib to everolimus in patients with advanced RCC who experienced disease progression following treatment with a VEGF receptor tyrosine kinase inhibitor.<wbr> In July 2015, Exelixis announced top-line results from METEOR demonstrating that the trial had met its primary endpoint of improving progression-free survival (PFS); compared with everolimus, cabozantinib was associated with a 42% reduction in the risk of disease progression or death.<wbr> These data were later presented at the European Cancer Congress in September 2015 and concurrently published in The New England Journal of Medicine.<wbr> </div><div>Source: Exelixis Press Release 22 Oct </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20151231&edate=20150901&rec=10728">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-10-23T10:45:11+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-10-23T10:45:11+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Merrimack Annouces MM398's (OnivideTM) FDA Approval For 2nd Line Metastatic Pancreatic Cancer</title>
	<pubDate>2015-10-22T20:33:24+02:00</pubDate>
	<wp:post_id>6791</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Merrimack today announced that ONIVYDE&trade; (irinotecan liposome injection) has been approved by the U.<wbr>S.<wbr> Food and Drug Administration (FDA)  in combination with fluorouracil (5-FU) and leucovorin for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy.<wbr> With this approval, ONIVYDE in combination with 5-FU and leucovorin becomes the first and only FDA-approved treatment option for patients in this setting.<wbr> </div><div style="margin-bottom: 10px;">In the United States, MM-398 is being developed by Merrimack Pharmaceuticals.<wbr> In September 2014, Merrimack entered into an agreement with Baxalta, previously Baxter, to develop and commercialize the drug outside of the country.<wbr> In Taiwan, where the company PharmaEngine controls commercialization rights for MM-398, the combination was approved on the same day as the FDA decision for patients with metastatic pancreatic cancer following gemcitabine-based therapy.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Clinical Evidence - Ph3 NAPOLI-1 Trial</STRONG> </div><div style="margin-bottom: 10px;">The approval was based on data from the phase III NAPOLI-1 trial, which demonstrated a 1.<wbr>9-month improvement in overall survival (OS) with the addition of MM-398 to 5-FU and leucovorin.<wbr> In the combination arm, the median OS was 6.<wbr>1 months compared with 4.<wbr>2 months with 5-FU and leucovorin alone (HR, 0.<wbr>57; 95% CI, 0.<wbr>41-0.<wbr>80; P = .<wbr>0009).<wbr> </div><div style="margin-bottom: 10px;">In the international trial, 417 patients with gemcitabine-refractory metastatic pancreatic cancer were randomized to MM-398 monotherapy, 5-FU with leucovorin (control), or MM-398 plus 5-FU and leucovorin.<wbr> Per standard irinotecan protocols, dexamethasone and a 5-HT3 antagonist could be administered in the combination arms.<wbr> </div><div style="margin-bottom: 10px;">In the control, 5-FU was administered at 2000 mg/<wbr>m2 with racemic leucovorin at 200 mg/<wbr>m2 weekly for 4 weeks followed by 2 weeks of rest (n = 149).<wbr> In the combination arm, intravenous MM-398 was administered at 80 mg/<wbr>m2 prior to 5-FU at 2400 mg/<wbr>m2 and racemic leucovorin at 400 mg/<wbr>m2 every 2 weeks (n = 117).<wbr> In the monotherapy group, MM-398 was administered at 120 mg/<wbr>m2 every 3 weeks (n = 151).<wbr> </div><div style="margin-bottom: 10px;">Altogether, 61% of patients had cancer in the head of the pancreas and 68% had liver metastases.<wbr> A majority of the patients (83%) were enrolled outside of the United States.<wbr> In the combination arm, the median age of patients was 63 years, 64% were Caucasian, and 29% were Asian.<wbr> </div><div style="margin-bottom: 10px;">The median progression-free survival was 3.<wbr>1 months for the combination compared with 1.<wbr>5 months with the control (HR, 0.<wbr>56; 95% CI, 0.<wbr>41-0.<wbr>75; P = .<wbr>0001).<wbr> At 12 weeks, 57% of patients treated with the combination were alive and progression-free compared with 26% with 5-FU and leucovorin alone.<wbr> </div><div style="margin-bottom: 10px;">The objective response rate by RECIST v1.<wbr>1 criteria was 16% versus 1%, for the combination and control, respectively (P &lt;.<wbr>001).<wbr> For those with baseline CA19-9 levels of &gt;30 U/<wbr>ml at baseline (84% in the combination arm), there was a &ge;50% reduction in the marker for 36% of patients treated with the combination versus 12% in the control arm (P = .<wbr>0009).<wbr> </div><div style="margin-bottom: 10px;">In a subanalysis that assessed patients who received at least 80% of the target dose in the first 6 weeks, there was an even greater OS benefit with MM-398.<wbr> In this per-protocol population, treatment with MM-398 plus 5-FU/<wbr>leucovorin (n = 66) improved OS by 53% compared with 5-FU/<wbr> leucovorin alone (n = 71).<wbr> The median OS was 8.<wbr>9 versus 5.<wbr>1 months for the combination and 5-FU/<wbr> leucovorin, respectively (HR, 0.<wbr>47; 95% CI, 0.<wbr>29-0.<wbr>77; P = .<wbr>0018).<wbr> </div><div style="margin-bottom: 10px;">In patients receiving at least one dose of MM-398, the most commonly reported grade &ge;3 adverse events (AEs) with the combination were neutropenia (20%), fatigue (14%), diarrhea (13%), vomiting (11%), nausea (8%), asthenia (8%), and abdominal pain (7%).<wbr> To address these concerns, MM-398 was approved along with a boxed warning regarding severe neutropenia and diarrhea.<wbr> Interestingly, in the per-protocol group, neutropenia and diarrhea were less common with the combination versus the full population, at 15% and 12%, respectively.<wbr> </div><div>Source: Merrimack Press Release </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Oncology10735c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">Comment: Further to the FDA approval of Onivyde in 2L pancreatic cancer, Merrimack and Baxalta announced entry of Ph2 study to evaluate Onivyde in 1L pancreatic cancer - the enrolment of first patient in the trial has now been initiated.<wbr> The study is to evaluate the combination of Onivyde + 5FU + leucovorin +/<wbr>- oxaliplatin.<wbr> The first centre to open the trial is St John of God hospital Subiaco in Australia.<wbr>Merrimack and Baxalta plan to conduct the study at sites in the United States, Canada, Europe, Australia, New Zealand, Taiwan and South Korea.<wbr> Based on the current design of this study, data are expected in the first half of 2017.<wbr> This triggers $62.<wbr>5M of milestone payments to Merrimack from Baxalta.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Study Design:</STRONG> </div><div style="margin-bottom: 10px;">Part 1 (n=6-18):m The primary outcome for Part 1 of the study is to evaluate the safety and tolerability of ONIVYDE in combination with 5-FU/<wbr>LV and oxaliplatin.<wbr> </div><div style="margin-bottom: 10px;">Part 2: an additional 150 patients (50 patients per arm) with previously untreated, metastatic pancreatic adenocarcinoma will be enrolled and randomized to receive either ONIVYDE in combination with 5-FU/<wbr>LV and oxaliplatin, ONIVYDE in combination with 5-FU/<wbr>LV, or nab-paclitaxel and gemcitabine.<wbr> Efficacy of the ONIVYDE containing regimens will be compared to the nab-paclitaxel and gemcitabine regimen, evaluating progression free survival (PFS) rate at 24 weeks, as well as overall survival, PFS, objective response rate, tumor marker CA19-9 response, safety and tolerability.<wbr> </div><div>Source: <a href="https://clinicaltrials.gov/ct2/show/NCT02551991?term=NCT02551991&rank=1" class="defaultlink">NCT02551991</a> </div></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20151231&edate=20150901&rec=10727">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-10-22T20:33:24+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-10-22T20:33:24+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Cortendo's Strategy Disclosure While Planning For An IPO And Redomiciling The Parent Company to Ireland</title>
	<pubDate>2015-10-22T16:36:46+02:00</pubDate>
	<wp:post_id>6792</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">re: Cortendo's Strategy Disclosure While Planning For An IPO And Redomiciling The Parent Company to Ireland</span>&nbsp;<br><span style="font-size: 12px;">Cortendo confirmed that the company name has changed to Strongbridge Biopharma plc.<wbr> and will become effective immediately with the new logo and corporate branding to be rolled out soon.<wbr> Under the new corporate name, Strongbridge Biopharma remains committed to building a biopharmaceutical company focused on the development, in-licensing, acquisition and eventual commercialization of complementary product candidates across multiple franchises that target rare endocrine disorders and other rare diseases.<wbr></span>&nbsp;<br></div><div>Strongbridge Biopharma plans for IPO did not go as originally planned: of the $86 million the biotech was hoping to raise when it filed the papers last month, it struggled to complete a $25 million listing on Nasdaq.<wbr> Strongbridge had planned to allocate $12 million to the Phase III trial of COR-003, for Cushing's syndrome, a sum that would have seen the study through to completion.<wbr> Now with just $5 million earmarked for the program, the company will only 'support' the continuation of the trial (currently recruiting).<wbr> COR-003 is one of two key Phase III clinical trials ongoing for Cushing's syndrome.<wbr> The other program in Phase III, LCI699 , is run by Novartis, and is also undergoing recruitment.<wbr> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20151231&edate=20150901&rec=8241">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology8172">View thread  Endocrinology8172: Cortendo's Strategy Disclosure While Planning For An IPO And Redomiciling The Parent Company to Ireland</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-10-22T16:36:46+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-10-22T16:36:46+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Probi Reports Q3 / 9-Month Results</title>
	<pubDate>2015-10-22T14:50:32+02:00</pubDate>
	<wp:post_id>6793</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Net sales for the period up to including September 2015 amounted to MSEK 180, representing growth of 89%.<wbr> Key drivers were customers in North America, as well as NBTY and Pharmavite.<wbr> Probi estimates net sales for the full-year 2015 to increase about 60% compared with 2014.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>THIRD QUARTER OF 2015</STRONG> </div><div style="margin-bottom: 10px;">NET SALES amounted to MSEK 51.<wbr>9 (37.<wbr>1).<wbr><BR>OPERATING PROFIT totalled MSEK 16.<wbr>3 (9.<wbr>0).<wbr><BR>PROFIT AFTER TAX amounted to MSEK 13.<wbr>1 (7.<wbr>1).<wbr><BR>PROFIT AFTER TAX PER SHARE was SEK 1.<wbr>44 (0.<wbr>77).<wbr><BR>CASH FLOW amounted to MSEK 21.<wbr>5 (3.<wbr>3).<wbr> </div><div style="margin-bottom: 10px;"><STRONG>ACCUMULATED 2015</STRONG><BR>NET SALES amounted to MSEK 179.<wbr>8 (95.<wbr>3).<wbr><BR>OPERATING PROFIT totalled MSEK 59.<wbr>4 (20.<wbr>5).<wbr><BR>PROFIT AFTER TAX amounted to MSEK 46.<wbr>3 (16.<wbr>4).<wbr><BR>PROFIT AFTER TAX PER SHARE was SEK 5.<wbr>08 (1.<wbr>80).<wbr><BR>CASH FLOW amounte to MSEK 34.<wbr>8 (6.<wbr>3).<wbr> </div><div>See <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20151231&edate=20150901&rec=2038" class="defaultlink">GastroEnterology2038: Probi and Pharmavite Expand Probiotic Product Partnership in the US and International Markets</a>.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20151231&edate=20150901&rec=2608">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-10-22T14:50:32+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-10-22T14:50:32+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Biogen Announces Corporate Restructuring and Workorce Reduction</title>
	<pubDate>2015-10-22T13:03:30+02:00</pubDate>
	<wp:post_id>6794</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Alongside its Q3 financial results (revenues +11% vs Q3:14), Biogen has announced the termination of a number of pipeline projects and 11% reduction of its 8,000-employee workforce.<wbr> Earlier this month, Tony Kingsley (Executive VP, Global Commercial Operations) left the company.<wbr> Management indicated the savings (approx 250M) will support marketed therapies, and key pipeline candidates in Alzheimer's (AD), multiple sclerosis (MS), and spinal muscular atrophy (SMA).<wbr> F<SPAN style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 13px/17px Helvetica, Arial, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">ull year 2015 guidance has been revised; it is expected a revenue growth of 8-9% (previously guided for 6-8%).<wbr></SPAN> </div><div style="margin-bottom: 10px;"><STRONG><SPAN style="line-height: 17px; widows: 2; text-transform: none; background-color: #ffffff; font-variant: normal; font-style: normal; text-indent: 0px; display: inline !important; font-family: Helvetica, Arial, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #000000; font-size: 13px; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">Termination Projects</SPAN></STRONG> </div><div style="margin-bottom: 10px;"><SPAN style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 13px/17px Helvetica, Arial, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"><SPAN style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; font: 13px/17px Helvetica, Arial, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">The company terminated development of both </SPAN><STRONG><SPAN class="x_HyperLink" style="line-height: 17px; widows: 2; text-transform: none; background-color: #ffffff; font-variant: normal; font-style: normal; text-indent: 0px; font-family: Helvetica, Arial, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">Tysabri</SPAN></STRONG><SPAN style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; font: 13px/17px Helvetica, Arial, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"> natalizumab and </SPAN><SPAN class="x_HyperLink" style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; font: 13px/17px Helvetica, Arial, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">Tecfidera</SPAN><SPAN style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; font: 13px/17px Helvetica, Arial, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"> to treat secondary progressive MS.<wbr> </SPAN><SPAN class="x_HyperLink" style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; font: 13px/17px Helvetica, Arial, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">Tysabri</SPAN><SPAN style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; font: 13px/17px Helvetica, Arial, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"> missed its primary and secondary endpoints in the Phase III ASCEND trial to treat secondary progressive MS.<wbr> </SPAN><SPAN class="x_HyperLink" style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; font: 13px/17px Helvetica, Arial, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"><A href="http://pub.biocentury.com/c.html?ufl=a&amp;rtr=on&amp;s=x8pb1d,2diso,7y8,g0h7,lj6v,fd0g,gw9g&amp;MLM_MID=3990120&amp;MLM_UNIQUEID=aefa0c0754" style="color: #262261;" target="_blank">Tecfidera</A></SPAN><SPAN style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; font: 13px/17px Helvetica, Arial, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"> was in the Phase III INSPIRE trial for the indication.<wbr><BR></SPAN></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 13px/17px Helvetica, Arial, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"><SPAN style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; font: 13px/17px Helvetica, Arial, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">Biogen also ended its <STRONG>anti-</STRONG></SPAN><SPAN class="x_HyperLink_Bold" style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; font: 13px/17px Helvetica, Arial, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"><STRONG>TNF-like weak inducer of apoptosis </STRONG>(TWEAK)</SPAN><SPAN style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; font: 13px/17px Helvetica, Arial, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"> program, </SPAN><SPAN class="x_HyperLink" style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; font: 13px/17px Helvetica, Arial, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">BIIB023</SPAN><SPAN style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; font: 13px/17px Helvetica, Arial, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">, to treat lupus nephritis after a Phase II futility analysis.<wbr> </SPAN></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 13px/17px Helvetica, Arial, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"><SPAN style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; font: 13px/17px Helvetica, Arial, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">Furthermore, the company discontinued some immunology and fibrosis research activities; spokesperson Kate Niazi-Sai declined to disclose specific programs.<wbr></SPAN></SPAN> </div><div style="margin-bottom: 10px;"><STRONG>Product/<wbr>Pipeline Supported by the Restructuring</STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>
Commercial initiatives aimed at increasing sales of TECFIDERA, including new DTC programs

</LI>
<LI>
3 programs in Alzheimer's disease: BAN in Ph2; aducanumab in Ph3, and E2609 in Ph2

</LI>
<LI>
SMN-Rx in Ph3 for SMA

</LI>
<LI>
Anti-LINGO in Ph2 for MS

</LI>
<LI>
MT-1303 in Ph3 for IBD

</LI>
<LI>
Raxatrigine in Ph3 for trigeminal neuralgia

</LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG>Insight on Key Product Sales</STRONG> </div><div style="margin-bottom: 10px;">TECFIDERA revenues were $937M (vs $787M) </div><div style="margin-bottom: 10px;">AVONEX and PLEGRIDY revenues were $785M (vs $745M) </div><div style="margin-bottom: 10px;">TYSABRI revenues were $480M (vs $501M) </div><div>Source: Biogen </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20151231&edate=20150901&rec=8211">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-10-22T13:03:30+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-10-22T13:03:30+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Ian Read Discusses Challenges to China H/C System</title>
	<pubDate>2015-10-22T12:20:04+02:00</pubDate>
	<wp:post_id>6795</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: <SPAN style="text-align: justify; widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">Speaking at a National Committee on U.<wbr>S.<wbr>-China Relations event, Pfizer CEO addressed the government's</SPAN> <SPAN style="text-align: justify; widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">twin aims of establishing a modern healthcare system in China, and helping the domestic industry establish a position</SPAN> <SPAN style="text-align: justify; widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">within the global drug R&amp;D business, noting that the ongoing medical and regulatory system reforms will be crucial to China's success</SPAN><SPAN style="text-align: justify; widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 12px/24px arial,helvetica,sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><STRONG><SPAN style="text-align: justify; line-height: 24px; widows: 2; text-transform: none; background-color: #ffffff; font-variant: normal; font-style: normal; text-indent: 0px; display: inline !important; font-family: Arial, Helvetica, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #000000; font-size: 12px; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"><SPAN style="text-align: justify; line-height: 24px; widows: 2; text-transform: none; background-color: #ffffff; font-variant: normal; font-style: normal; text-indent: 0px; display: inline !important; font-family: Arial, Helvetica, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #000000; font-size: 12px; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">Key Messages</SPAN></SPAN></STRONG> </div><div style="margin-bottom: 10px;"><SPAN style="text-align: justify; widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 12px/24px Arial, Helvetica, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"><SPAN style="text-align: justify; widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 12px/24px Arial, Helvetica, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">Read acknowledged the Chinese government's achievements in improving health outcomes nationally, and raising the capabilities of the domestic pharmaceutical industry.<wbr> He underlined that the challenges in the future will be driven by the <STRONG>ageing population, and a rising rate of non-communicable and chronic diseases linked to lifestyle changes</STRONG>.<wbr> </SPAN></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="text-align: justify; widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 12px/24px Arial, Helvetica, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"><SPAN style="text-align: justify; widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 12px/24px Arial, Helvetica, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">The rising demand for healthcare means that <STRONG>China needs to address a lack of good physicians, and take steps to improve rural public health, with the focus on disease prevention instead of treatment</STRONG>.<wbr> </SPAN></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="text-align: justify; widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 12px/24px Arial, Helvetica, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"><SPAN style="text-align: justify; widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 12px/24px Arial, Helvetica, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">Hospital reforms and raising the quality and depth of Basic Medical Insurance (BMI) scheme coverage are crucial.<wbr> <STRONG>Read noted that Pfizer has recently worked with the China Development Research Foundation (CDRF) on suggested future directions for the health reforms, which are expected to be made public imminently.<wbr></STRONG></SPAN></SPAN> </div><div style="margin-bottom: 10px;"><P style="text-align: justify; widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; font: 12px/24px Arial, Helvetica, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">Read also underlined the <STRONG>necessity of tackling the 6-7 years required for new drug approvals, and 3-5 more years before BMI coverage</STRONG>, noting the negative impact on pharmaceutical industry development, and suggesting that a stronger and more flexible regulatory system be established.<wbr></P> </div><div><P style="text-align: justify; widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; font: 12px/24px Arial, Helvetica, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">Source: GBI</P> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20151231&edate=20150901&rec=11287">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-10-22T12:20:04+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-10-22T12:20:04+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: RCC Is Even More Crowded: Cabozantinib and Nivolumab Annouced Positive News From Two Ph3 Trials in 2L RCC Versus Novartis' Afinitor</title>
	<pubDate>2015-10-22T12:07:47+02:00</pubDate>
	<wp:post_id>6796</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">re: RCC Is Even More Crowded: Cabozantinib and Nivolumab Annouced Positive News From Two Ph3 Trials in 2L RCC Versus Novartis' Afinitor</span>&nbsp;<br><span style="font-size: 12px;">The days of RCC being a fast way into a solid tumour market are long gone.<wbr>.<wbr>.<wbr>.<wbr>.<wbr>.<wbr>It will be interesting to see how the 'battle' for first and second line plays out with Pfizer, Novartis &amp; BMS fighting it out.<wbr> Unfortunately for patients, the duration of therapy and outcomes in first and second line still have a long way to go in metastatic RCC.<wbr> How many more indications can nivolumab go for? What a molecule.<wbr> It seems that hitting the PD-1 itself and not the PD-1 ligand results in the greatest responses.<wbr> The data so far are great, but BMS's biggest battle may be in reimbursement when customers/<wbr>payors/<wbr>insurers learn the price!!</span>&nbsp;<br></div><div style="margin-bottom: 10px;">Comment: Both trials were presented back to back during the first presidential session at ECC 2015 in Vienna, and the data have created substantial interests amongst oncologists.<wbr> Professor Eric Jonash (MD.<wbr>, Department of Genitourinary Medical Oncology, MD Anderson) featured the two trials - CheckMate 025 and METEOR - in the <EM>Practice Update as the two studies will change the way metastatic renal cell carcinoma patients are treated and are undoubtedly going to further improve overall survival for this group of patients.<wbr> However he also</EM> commented the major question moving forward will be which agent to be used first.<wbr> Most likely patients and physicians will try treatment with nivolumab first, and cabozantinib is a very reasonable "alternative" for patients with autoimmune disease and other contradictions to immunotherapy.<wbr> Despite of these exciting results, the future entry of Roche's anti-PD1, atezolizumab in the 1L setting could re-shape the 2L treatment landscape and physicians' and patients' decision for cabozantinib versus nivolumab.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>ECC 2015 Saturday, September 26, 2015</STRONG> </div><div style="margin-bottom: 10px;"><STRONG>2:30 PM&ndash;4:30 PM</STRONG> Presidential Session I </div><div style="margin-bottom: 10px;"><STRONG>Abstract 3LBA</STRONG> CheckMate 025: a randomized, open-label, phase III study of nivolumab (NIVO) versus everolimus (EVE) in advanced renal cell carcinoma (RCC).<wbr> <EM>Presented by P</EM> <EM>Sharma</EM> </div><div style="margin-bottom: 10px;"><UL><LI>In this phase III study, 821 patients with clear cell advanced or metastatic renal cell carcinoma were randomized to treatment with nivolumab or everolimus.<wbr> Median overall survival was 25 months with nivolumab compared with 19.<wbr>6 months with everolimus.<wbr> The most common adverse events were fatigue (both treatments), nausea and pruritus (nivolumab), and stomatitis and anemia (everolimus).<wbr>
</LI>
<LI>Nivolumab improved survival and was associated with fewer adverse events compared with everolimus in patients with advanced renal cell carcinoma.<wbr>
</LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG>Abstract 4LBA</STRONG> Cabozantinib versus everolimus in patients with advanced renal cell carcinoma: Results of the randomized phase 3 METEOR trial.<wbr> <EM>Presented by T Choueiri</EM> </div><div style="margin-bottom: 10px;"><UL><LI>In this phase III trial, researchers randomized 658 patients with clear cell renal cell carcinoma to receive cabozantinib or everolimus.<wbr> Median progression-free survival was 7.<wbr>4 months with cabozantinib compared with 3.<wbr>8 months with everolimus.<wbr> Overall survival was not determined.<wbr> Cabozantinib was associated with abdominal pain (3%), pleural effusion (2.<wbr>7%), and diarrhea (2.<wbr>1%).<wbr> Everolimus was associated with anemia (3.<wbr>7%), dyspnea (3.<wbr>7%), and pneumonia (3.<wbr>7%).<wbr>
</LI>
<LI>Cabozantinib improved progression-free survival and objective response rate compared with everolimus in patients with advanced clear cell renal cell carcinoma.<wbr>
</LI>
</UL> </div><div>Source: Practice Update Expert opinion ECC 2015 Recap: RCC from Dr Eric Jonasch </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20151231&edate=20150901&rec=10725">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10587">View thread  Oncology10587: RCC Is Even More Crowded: Cabozantinib and Nivolumab Annouced Positive News From Two Ph3 Trials in 2L RCC Versus Novartis' Afinitor</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-10-22T12:07:47+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-10-22T12:07:47+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>New Long-acting GLP-1 Granted ODS For Short Bowel Syndrome</title>
	<pubDate>2015-10-21T18:24:44+02:00</pubDate>
	<wp:post_id>6797</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Naia Limited, has announced that its subsidiary, Naia Rare Diseases, has been granted by the U.<wbr>S.<wbr> FDA orphan drug designation for NB1001, its long-acting GLP-1 receptor agonist, for the treatment of Short Bowel Syndrome (SBS).<wbr> </div><div style="margin-bottom: 10px;">Mark Bagnall, co-founder and chief financial officer of Naia Limited, stated, "We are committed in advancing NB1001 through clinical trials with the initiation of a Phase 1b dose de-escalating in SBS patients by the second quarter of 2016.<wbr>" </div><div style="margin-bottom: 10px;">NB1001 (XTEN™-GLP-1) is a long-acting Glucagon-like peptide-1 (GLP-1) receptor agonist that combines exenatide with a proprietary extended half-life technology.<wbr> NB1001 will be administered as a replacement therapy (replacing endogenous GLP-1 lost by bowel resection), in contrast to GLP-1 agonists used to treat Type 2 diabetes, which are administered at pharmacologic levels in order to lower blood sugar.<wbr> Lower doses of NB1001 combined with a longer half-life will provide a differentiated, safe, effective and convenient therapeutic approach for these patients.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Why A GLP-1 Approach?<BR></STRONG><BR>GLP-1 is produced by the L cells of the ileum.<wbr> Upon food ingestion, low concentrations of endogenous GLP-1 act as a negative modulator of gastric and duodenal contractility, slowing the transit of food from the stomach.<wbr> Slow transit results in better digestion of food and better absorption of nutrients in the small bowel.<wbr> After extensive intestinal resection, SBS patients lack endogenous GLP-1.<wbr> Deficiency of GLP-1 leads to fast transit of food through a shortened bowel and diminished absorption of nutrients leading to severe nutritional deficiency and fluid imbalance.<wbr> </div><div style="margin-bottom: 10px;">NB1001 was previously being developed for Type 2 diabetes, and in a 70-patient Phase 1b study, NB1001 was shown to be safe, well-tolerated and lowered HbA1c in a dose-dependent manner.<wbr> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8239_1_ScreenCapture1.jpg"> </div><!-- Comment details --><a name="endocrinology8239attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8239_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(54,3 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20151231&edate=20150901&rec=8239">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-10-21T18:24:44+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-10-21T18:24:44+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>EANM Intelligence - Positioning Of PRRT In New ENETS Guidelines</title>
	<pubDate>2015-10-21T17:23:32+02:00</pubDate>
	<wp:post_id>6798</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: This year the European Association of Nucleur Medicine meeting in Hamburg (Oct 10th-14th) hosted a special session on NET therapy.<wbr> It consisted of three presentations with the speakers being Martin Caplyn (UK) Lisa Bodei (Italy) a European expert on PRRT and Anne Rinke (PROMID investigator from Germay.<wbr> Lisa Bodei noted that ENETS treatment guidelines will be updated by the end of the month and published in March and that within these a higher profile for Lutathera will be included.<wbr> Mentioning this she featured a specific slide which suggested that ENETS 2016 algorithm for treatment of SI-NETs will likely consider PRRT for "refractory symptomatic, non-resectable or metastatic forms at the progression after SSAs" Anja Rinke endorsed this positioning later in the session in the context of a question from Martin Caplyn on how "the costing of drugs will often drive choice and usage".<wbr> </div><div style="margin-bottom: 10px;"><STRONG>The Therapeutic Management of Neuroendocrine Tumours ( Martin Caplin UK)</STRONG> </div><div style="margin-bottom: 10px;">Martin Caplyn&rsquo;s more introductory presentation, featured NET epidemiology, characterisation and all recent trial results.<wbr> He did, however, acknowledge that PRRT&rsquo;s durable response with PRRT may be the factor that promotes it up the treatment algorithm depending on its cost and perceived cost effectiveness.<wbr> </div><div style="margin-bottom: 10px;">He also commented on the large no of phII combination trials now underway but as note of caution stated that we really need to understand the biology of the disease better to work out the most intelligence combinations.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Role of PRRT in the therapeutic algorithm of Neuroendocrine tumours</STRONG> <STRONG>(Lisa Bodei Italy)</STRONG> </div><div style="margin-bottom: 10px;">Lisa Bodei highlighted the extent of the therapeutic progress that has been made in the past years, since chemotherapy and surgery were the only options </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8234_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;">She also pointed everyone to the practical guidance document produced a few years back that is available to guide doctors on how to perform PRRT </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8234_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;">After 20 years of clinical trials with PRRT she summarised what is currently known about PRRT </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8234_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8234_5_ScreenCapture5.jpg"> </div><div style="margin-bottom: 10px;">Commenting on the slide above, Lisa noted that the most important parameter is the disease control rate (DCR) which is in the range of 70-94% and the impact PRRT has on Progression free survival (PFS) 33-36 months.<wbr> </div><div style="margin-bottom: 10px;">Symptom control was another important issue mentioned, with response rates with Lutiteum she claimed around 70%.<wbr> There is an article in press on this topic </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8234_6_ScreenCapture6.jpg"> </div><div style="margin-bottom: 10px;">In terms of strength of recommendation and how PRRT should be considered in terms of the level of recommendation in the pyramid, based on Ist experiences and a systematic review of evidence expert opinion between 2007&mdash;2014 rated PRRT between 4 and 3a Whilst with the recent results from the NETTER-1 study.<wbr> Lisa suggested it is now possible to think about upgrading the therapy to a level 1b recommendation.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8234_7_ScreenCapture7.jpg"> </div><div style="margin-bottom: 10px;">Lisa continued by highlighting the types of factors that influence PRRT outcome.<wbr> </div><div style="margin-bottom: 10px;"><OL><LI>pNETs respond more frequently than mid-gut tumours to PRRT but functional pNET tumours relapse earlier;
</LI>
<LI>Patients with lower KI67 respond better than those with a higher KI67:
</LI>
<LI>Stage IV patients are more at risk for earlier progression than Stage III patients; and.<wbr>
</LI>
<LI>Patients with FDG adivity have a shorter PFS than those that our FDG negative.<wbr>
</LI>
</OL> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8234_9_ScreenCapture9.jpg"> </div><div style="margin-bottom: 10px;">In terms of tolerability Lisa indicated that renal toxicity is more pronounced with Ytrium peptides than with lutiteum (0.<wbr>04%).<wbr> Sub actute toxicity occurs in no more than 10% of patients with no difference is seen between yttrium and lutiteum.<wbr> In terms of long-term myelosuppression she highlighted risk factors such as age&gt;70.<wbr> bone metastases, past chemotherapy and previous renal impairment and then focused a long-term toxicity review published in January 2015 which amongst 800 PRRT patients showed that Ytrium and lutiteum produce the same very low rates of bone marrow toxicity.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8234_10_ScreenCapture10.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8234_11_ScreenCapture11.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8234_12_ScreenCapture12.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8234_13_ScreenCapture13.jpg"> </div><div style="margin-bottom: 10px;">Whilst briefly highlighting the NETTER-1 results she noted that PRRT has in the past been considered as a treatment of last resort or as a treatment for inoperable metastatic tumours but that when the ENET guidelines are updated and published in March 2016 it is likely the status of PRRT will be updated and that there will be reference to usage in the operable tumour setting.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8234_14_ScreenCapture14.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8234_15_ScreenCapture15.jpg"> </div><div style="margin-bottom: 10px;">As she concluded her talk Lisz Bodei focused on the need for more randomised trials in different clinical settings, for example data has recently shown that combination with chemotherapy may be able to extend PFS in patients who are inoperable.<wbr> This needs to be further validated.<wbr> Despite some evidence of toxicity seen when combining PRRT with capecitabine we still need a proper randomised trial to undestand the issues.<wbr> Then there is the question of sequencing and whether everol;imus is more toxic when given after PRRT.<wbr> The fist set of evidence on this topic suggested no but more recent data has questioned this finding.<wbr> Intraarterial PRRT potentially offers a high rate of response that is promaising but more complex to administer.<wbr> In terms of therapeutic optimisation we need to consider risk factors and whether the cumulative dose administered can be lowered to ameliorate the toxicity but PFS maintained and whether if we administer PRRT after dosimetry then there is more scope to avoid toxicity.<wbr> In FDG positive tumours there is also some evidence that combination therapy could be a highly effective option.<wbr> Finally, Lisa suggested that gene signatures may help us to define better potential treatment responses to PRRT.<wbr> </div><div style="margin-bottom: 10px;">In the Q/<wbr>A that followed Lisa categorically stated that as far as she is concerned no dotapeptide has demonstrated superiority relative to another but that it is better to utilise the same peptide for imaging as for therapy.<wbr> In relation to a question about shorter PFS in pNET patients and those with FDG avidity it was mentioned that results all come from retrospective trials and that this si something that needs to prospectively confirmed.<wbr> </div><div style="margin-bottom: 10px;">When questioned whether PRRT could be used as a 1<SUP>st</SUP> line treatment for debulking purposes, Lisa responded by stating that PRRT is already used in inoperable patients with progressive tumours and that patients are usually left on SSAs.<wbr> To make this proposal a reality she confirmed we need more data which we currently don&rsquo;t have.<wbr> </div><div style="margin-bottom: 10px;">Returning to the question of the guideline update, Martin Caplyn noted that the ENETS guidelines will be updated by the end of the month and will be published in March alongside the ENETS meeting and that a higher profile for Lutathera will be included.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Future Therapeutic Landscape (Anja Rinke Germany)</STRONG> </div><div style="margin-bottom: 10px;">Anne Rinke&rsquo;s presentation focused more on what possible combinations or treatment situations could be considered for future therapy.<wbr> She highlighted that most combination studies that have been undertaken have not shown the benefit of combination therapy and that the NETTER-1 study is one of the few examples of combination therapy with a positive outcome.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8234_16_ScreenCapture16.jpg"> </div><div style="margin-bottom: 10px;">Anja returned to the topic of toxicity observed with combination PRRT and capecitabine </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8234_18_ScreenCapture18.jpg"> </div><div style="margin-bottom: 10px;">A new Australian Asian group is initiating a larger trial to properly evaluate this type of combination based on promising results already seen in a smaller study.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8234_19_ScreenCapture19.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8234_21_ScreenCapture21.jpg"> </div><div style="margin-bottom: 10px;">Another area that needs evaluation is adjuvant treatment and Anja mentioned that a French co-operative group is currently planning such a study.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8234_22_ScreenCapture22.jpg"> </div><div style="margin-bottom: 10px;">Finally, Anja illustrated how typically a patients needs all therapeutic options on a long terms basis and what is really needed is a better idea of how to sequence products rather than necessarily combine them.<wbr> The SEQTOR study is ongoing in Europe to look at this option but there are an infinite number of sequence options that could be evaluated which is an impossibility to undertake.<wbr> Hence the urgent need for both collaboration and predictive markers.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8234_23_ScreenCapture23.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8234_24_ScreenCapture24.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8234_25_ScreenCapture25.jpg"> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8234_27_ScreenCapture27.jpg"> </div><!-- Comment details --><a name="endocrinology8234attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8234_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(644 B)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8234_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(142,2 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8234_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(125,3 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8234_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(161,5 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8234_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(142,6 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8234_6_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(112,2 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8234_7_ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(132,9 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8234_8_ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(682 B)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8234_9_ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(70,8 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8234_10_ScreenCapture10.jpg">ScreenCapture10.jpg</a>&nbsp;&nbsp;(95,3 KB)<br>&nbsp;&nbsp;11.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8234_11_ScreenCapture11.jpg">ScreenCapture11.jpg</a>&nbsp;&nbsp;(88,3 KB)<br>&nbsp;&nbsp;12.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8234_12_ScreenCapture12.jpg">ScreenCapture12.jpg</a>&nbsp;&nbsp;(132,8 KB)<br>&nbsp;&nbsp;13.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8234_13_ScreenCapture13.jpg">ScreenCapture13.jpg</a>&nbsp;&nbsp;(127,7 KB)<br>&nbsp;&nbsp;14.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8234_14_ScreenCapture14.jpg">ScreenCapture14.jpg</a>&nbsp;&nbsp;(188,7 KB)<br>&nbsp;&nbsp;15.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8234_15_ScreenCapture15.jpg">ScreenCapture15.jpg</a>&nbsp;&nbsp;(144,7 KB)<br>&nbsp;&nbsp;16.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8234_16_ScreenCapture16.jpg">ScreenCapture16.jpg</a>&nbsp;&nbsp;(121,4 KB)<br>&nbsp;&nbsp;17.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8234_17_ScreenCapture17.jpg">ScreenCapture17.jpg</a>&nbsp;&nbsp;(109,6 KB)<br>&nbsp;&nbsp;18.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8234_18_ScreenCapture18.jpg">ScreenCapture18.jpg</a>&nbsp;&nbsp;(126,2 KB)<br>&nbsp;&nbsp;19.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8234_19_ScreenCapture19.jpg">ScreenCapture19.jpg</a>&nbsp;&nbsp;(124,7 KB)<br>&nbsp;&nbsp;20.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8234_20_ScreenCapture20.jpg">ScreenCapture20.jpg</a>&nbsp;&nbsp;(108,6 KB)<br>&nbsp;&nbsp;21.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8234_21_ScreenCapture21.jpg">ScreenCapture21.jpg</a>&nbsp;&nbsp;(110 KB)<br>&nbsp;&nbsp;22.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8234_22_ScreenCapture22.jpg">ScreenCapture22.jpg</a>&nbsp;&nbsp;(126,4 KB)<br>&nbsp;&nbsp;23.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8234_23_ScreenCapture23.jpg">ScreenCapture23.jpg</a>&nbsp;&nbsp;(97 KB)<br>&nbsp;&nbsp;24.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8234_24_ScreenCapture24.jpg">ScreenCapture24.jpg</a>&nbsp;&nbsp;(135 KB)<br>&nbsp;&nbsp;25.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8234_25_ScreenCapture25.jpg">ScreenCapture25.jpg</a>&nbsp;&nbsp;(107,6 KB)<br>&nbsp;&nbsp;26.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8234_26_ScreenCapture26.jpg">ScreenCapture26.jpg</a>&nbsp;&nbsp;(95,5 KB)<br>&nbsp;&nbsp;27.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8234_27_ScreenCapture27.jpg">ScreenCapture27.jpg</a>&nbsp;&nbsp;(106,3 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20151231&edate=20150901&rec=8234">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-10-21T17:23:32+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-10-21T17:23:32+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Cold Genesys' Second Trial In Bladder Cancer: Exploring Combination of CG0070 with Anti-CTLA4</title>
	<pubDate>2015-10-21T15:33:54+02:00</pubDate>
	<wp:post_id>6799</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Cold Genesys announced that FDA accepted its Ph1/<wbr>2 trial protocol (NAOMI) using it s CG0070 plus an anti-CTLA-4 checkpoint inhibitor for muscle invasive bladder cancer patients who are ineligible for platinum based chemotherapy.<wbr> CG0070 is an oncolytic adenovirus expressing GMCSF designed to selectively replicate in tumours.<wbr> The company supplying anti-CTLA-4 for the trial is not disclosed yet, although the likely players could be either BMS or AZ.<wbr> </div><div style="margin-bottom: 10px;"><EM><STRONG>CG0070 is currently being evaluated in a Ph3 trial BCG failure NMIBC setting and Ph1/<wbr>2 muscle invasive bladder cancer</STRONG></EM> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10719_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><STRONG>BOND 2</STRONG> : Patient enrollment in BOND 2 trial remains ongoing.<wbr> Initiation of new manufacturing and quality control process to fulfill FDA requirement.<wbr> Completion is targeted in Q2 2016.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>NAOMI trial</STRONG>: This Phase I/<wbr>II NAOMI trial is planned to evaluate the safety and efficacy of the neo-adjuvant combination of CG0070 plus anti-CTLA-4 in patients with MIBC who are ineligible for platinum-based chemotherapy.<wbr> One of the primary endpoints is to evaluate the efficacy of this intervention to increase the expression of PD-L1 in the primary tumor.<wbr> </div><div style="margin-bottom: 10px;">Table 1: Companies currently develop candidate that targets CTLA4 pathway </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10719_1_ScreenCapture1.jpg"> </div><div>Source: GlobalData, Cold Genesys Press Release 20 Oct 2015 </div><!-- Comment details --><a name="oncology10719attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10719_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(239,7 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10719_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(34,6 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20151231&edate=20150901&rec=10719">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-10-21T15:33:54+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-10-21T15:33:54+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>UC San Diego and Illumina Team Up to Speed-Read and Analyse the Microbiome</title>
	<pubDate>2015-10-21T11:17:34+02:00</pubDate>
	<wp:post_id>6800</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: U.<wbr> of California, San Diego School of Medicine's Rob Knight, PhD , and his team have built a microbiome analysis platform called <A href="http://qiime.org/">QIIME</A> (for "Quantitative Insights Into Microbial Ecology).<wbr> The software will now be accessible to researchers around the world through BaseSpace, a cloud-based app store offered by Illumina.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>What is <A href="http://qiime.org/">QIIME</A> ?</STRONG> </div><div style="margin-bottom: 10px;">QIIME is designed to take users from raw sequencing data generated on the Illumina or other platforms through publication quality graphics and statistics.<wbr> This includes demultiplexing and quality filtering, OTU picking, taxonomic assignment, and phylogenetic reconstruction, and diversity analyses and visualizations.<wbr> QIIME has been applied to studies based on billions of sequences from tens of thousands of samples.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Applications for IBD</STRONG> </div><div style="margin-bottom: 10px;">Knight, Smarr and their teams plan to apply QIIME to determine if certain microbes are associated with inflammatory bowel disease (IBD).<wbr> Eventually, they will be able to use this information to develop new tests that predict a person's risk of developing IBD and new methods for treating the disease.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>How it works ? What is the Process ?</STRONG> </div><div style="margin-bottom: 10px;"><OL><LI>Knight, Smarr and their teams will process fecal samples from a group of IBD patients and a control group of healthy people and send the microbial genetic material they collect to the UC San Diego School of Medicine's Institute for Genomic Medicine for sequencing.<wbr> </LI>
<LI>When complete, the researchers will receive an email from the facility director indicating that their data are available on BaseSpace.<wbr> </LI>
<LI>Once they log into BaseSpace and click on the QIIME app, the researchers will see their raw data and ask the program to generate a 3-D scatterplot of the differences and similarities between their IBD and healthy control samples.<wbr> </LI>
<LI>If there is a significant difference in the microbial populations present in the two groups, then the researchers will go back to the lab to further investigate those differences and what cause-or-effect roles they might play in IBD.<wbr></LI>
</OL> </div><div style="margin-bottom: 10px;">Two high-profile microbiome studies that rely on QIIME are: </div><div style="margin-bottom: 10px;"><UL><LI><U>the Human Microbiome Project</U>, a National Institutes of Health-led initiative akin to the Human Genome Project, and </LI>
<LI><U>the American Gut Project</U>, a crowdsourced, crowdfunded project in which Knight's team is sequencing as many human microbiome samples as possible, from anyone who wants to participate.<wbr></LI>
</UL> </div><div>Source: <A href="https://health.ucsd.edu/news/releases/Pages/2015-10-07-ucsd-teams-up-with-illumina-on-microbiome-app.aspx">https:/<wbr>/<wbr>health.<wbr>ucsd.<wbr>edu/<wbr>news/<wbr>releases/<wbr>Pages/<wbr>2015-10-07-ucsd-teams-up-with-illumina-on-microbiome-app.<wbr>aspx</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20151231&edate=20150901&rec=2606">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-10-21T11:17:34+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-10-21T11:17:34+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Reckitt Benckiser Posted Solid Q3 Sales Boosted by Consumer Health Products</title>
	<pubDate>2015-10-21T10:37:51+02:00</pubDate>
	<wp:post_id>6801</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: RB reported +7% like-for-like (LFL) sales growth in Q3, driven by Consumer Health (Q3 net revenues +14%/<wbr> YTD net revenues +13% LFL), and double-digit growth in emerging markets.<wbr> The Group increased its full-year guidance in July 2015 and increased it again in the Q3 update.<wbr> It expects full-year LFL revenue growth of more than 5%, compared to prior guidance of 4-5% growth.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2605_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2605_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2605_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;">China, India and Turkey remained solid, while Brazil, Africa and south east Asia were more challenging.<wbr> </div><div>Mature markets growth was 6% with a solid contribution from North America at 5%, and the rest of the ENA division was 7%.<wbr> </div><!-- Comment details --><a name="gastroenterology2605attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2605_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(37,7 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2605_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(25,5 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2605_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(47,7 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20151231&edate=20150901&rec=2605">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-10-21T10:37:51+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-10-21T10:37:51+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Immunomedics Reported Promising Results For Its IMMU-132 In TNBC, Lung, And Bladder Cancer</title>
	<pubDate>2015-10-20T18:54:15+02:00</pubDate>
	<wp:post_id>6802</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: At the 2015 World ADC San Diago conference, Immunomedics reported durable responses from its Ph2 trial of one of its leading antibody-drug conjugate candidate, IMMU-132 (sacituzumab govitecan) - most evidently for some patients with metastatic triple negative breast cancer (TNBC), and lung cancer (SCLC and NSCLC).<wbr> The trial also included a small cohort of 2L metastatic bladder cancer patients (n=15), of whom IMMU-132 also demonstrated promising efficacy with 5 patients are still continuing treatment.<wbr> The first priority for Immunomedics will be progressing with Ph3 protocal for TNBC.<wbr> </div><div style="margin-bottom: 10px;"><SPAN style="text-decoration: underline;"><STRONG>About Immunomedics Pipeline</STRONG></SPAN> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10716_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><SPAN style="text-decoration: underline;"><STRONG>Sacituzumab govitecan</STRONG></SPAN> </div><div style="margin-bottom: 10px;">Sacituzumab govitecan is a first-in-class ADC developed by the Company by conjugating the moderately-toxic drug, SN-38, site-specifically and at a high ratio of drug to antibody, to a humanized antibody that targets the TROP-2 receptor expressed by many solid cancers.<wbr> The ADC has received Fast Track designation from the FDA for the treatment of patients with TNBC, SCLC and NSCLC, and has also been designated an orphan drug for the treatment of patients with SCLC or pancreatic cancer in the U.<wbr>S.<wbr>, and for the treatment of patients with pancreatic cancer in the European Union.<wbr> </div><div style="margin-bottom: 10px;"><SPAN style="text-decoration: underline;"><STRONG>TNBC</STRONG></SPAN> </div><div style="margin-bottom: 10px;">The presentation on TNBC focused on those patients who relapsed after 2 or more prior lines of therapy that included taxane.<wbr> At the time of this analysis, 56 enrolled patients had received sacituzumab govitecan at the optimal dose of 10 mg/<wbr>kg given on days 1 and 8 of a 3-week cycle, and in some patients the therapy continued for many months.<wbr> The median number of prior lines of therapy for the patients enrolled with metastatic TNBC was 5 (range, 2 &ndash; 12).<wbr> </div><div style="margin-bottom: 10px;"><UL><LI>Treatment response, assessed by computed tomography (CT) according to the rules set by the Response Evaluation Criteria In Solid Tumors (RECIST 1.<wbr>1), was available for 52 patients.<wbr>
</LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI>The objective response rate was 29% (15/<wbr>52), with 2 confirmed complete responses.<wbr>
</LI>
<LI>The interim median progression-free survival (PFS) : 7.<wbr>0 months, which appears to be longer than the best PFS results in this patient setting achieved by currently-used agents.<wbr>
</LI>
<LI>Forty-six percent of these TNBC patients had experienced a PFS event.<wbr> Overall survival (OS) data were too early to report because 86% of patients are still alive.<wbr>
</LI>
</UL> </div><div style="margin-bottom: 10px;"><SPAN style="text-decoration: underline;"><STRONG>Lung Cancer:</STRONG> </SPAN>96% of NSCLC patients and 100% of SCLC patients were still alive at the time of analysis, OS data at the optimal dose of 10 mg/<wbr>kg are too early to report.<wbr> </div><div style="margin-bottom: 10px;">For metastatic lung cancers, a total of 33 patients with NSCLC, having received a median of 3 (range, 1 &ndash; 7) prior therapies, were enrolled to receive sacituzumab govitecan at the 8.<wbr>0 mg/<wbr>kg or 10 mg/<wbr>kg dose level.<wbr> </div><div style="margin-bottom: 10px;"><UL><LI>Among the 29 patients that were assessable, an objective response (partial response) rate of 28% (8/<wbr>29) was observed, including patients with both squamous cell and adenocarcinoma NSCLC types.<wbr>
</LI>
<LI>For the 25 patients at the 10 mg/<wbr>kg dose, the interim median PFS was 3.<wbr>8 months, with 48% of patients in this dose group having experienced a PFS event.<wbr>
</LI>
</UL> </div><div style="margin-bottom: 10px;">In SCLC, of the 27 patients, with a median of 3 prior therapies (range 1 &ndash; 5), enrolled at the doses of 8.<wbr>0 mg/<wbr>kg and 10 mg/<wbr>kg, 25 were assessable for response.<wbr> </div><div style="margin-bottom: 10px;"><UL><LI>Six patients achieved a partial response (objective response rate = 24%).<wbr>
</LI>
<LI>Interim median PFS for the 12 patients at the 10 mg/<wbr>kg dose level was 3.<wbr>6 months and 83% of patients had experienced a PFS event.<wbr>
</LI>
</UL> </div><div style="margin-bottom: 10px;"><SPAN style="text-decoration: underline;"><STRONG>Bladder Cancer</STRONG></SPAN> </div><div style="margin-bottom: 10px;">At the time of analysis, 6 of 11 patients who relapsed to a prior platinum-containing therapy and evaluable by CT achieved a partial response (objective response rate = 55%), with 5 patients still continuing treatment.<wbr> </div><div>Source: Immunomedics press release 19 Oct 2015 </div><!-- Comment details --><a name="oncology10716attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10716_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(95,6 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10716_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(103,1 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20151231&edate=20150901&rec=10716">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-10-20T18:54:15+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-10-20T18:54:15+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Probi Expands Business in Functional Food in Korea</title>
	<pubDate>2015-10-20T15:23:59+02:00</pubDate>
	<wp:post_id>6803</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Probi has signed an agreement in probiotic dairy products with Seoul Milk.<wbr> The company already has, through partners, established a position in the Korean market with its dietary supplements products.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Probi and Seoul Milk have agreed to include the probiotic strain LP299V® in Seoul Milk´s product range with planned launch in the market at the end of 2015.<wbr> </div><div style="margin-bottom: 10px;">Seoul Milk is a nationwide player covering all sales channels.<wbr> Seoul Milk has a long history, since its establishment in 1937, of working with consumer health, animal care and other related areas.<wbr> Among others, Seoul Milk established the country’s first cold chain system.<wbr> </div><div>Source: <A href="http://probi.se/en/press/probi-signs-license-and-supply-agreement-seoul-milk-korea">http:/<wbr>/<wbr>probi.<wbr>se/<wbr>en/<wbr>press/<wbr>probi-signs-license-and-supply-agreement-seoul-milk-korea</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20151231&edate=20150901&rec=2604">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-10-20T15:23:59+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-10-20T15:23:59+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>BioGaia Reiforces Sales Capabilities and Geo Expansion of its Business</title>
	<pubDate>2015-10-20T15:14:10+02:00</pubDate>
	<wp:post_id>6804</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Axel Sjöblad has been appointed Managing Director, and will take over management of the company’s operations, initially with a special focus on marketing and sales.<wbr> The company also reported that Peter Rotschild has been appointed as Group President.<wbr> This organisational change is reported to enable the company to increase the focus on its subsidiaries and associated companies, as well as the major development potential that the Board sees for the Group.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Axel Sjöblad</STRONG> is currently Managing Director of Getinge Sverige AB and VP North and Central Europe.<wbr> He was previously Regional VP Northern European Markets at Gambro Lundia AB.<wbr> </div><div><EM>Source: BioGaia</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20151231&edate=20150901&rec=2603">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-10-20T15:14:10+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-10-20T15:14:10+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Key Messages from Check Cap Presentation at Rodman & Renshaw Global Investment Conference</title>
	<pubDate>2015-10-20T14:54:58+02:00</pubDate>
	<wp:post_id>6805</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Key Messages from Check Cap Presentation at Rodman & Renshaw Global Investment Conference</span>&nbsp;<br><span style="font-size: 12px;">Comment: Chek Cap develops the world's first diagnostic system for cleanse-free examination of the colon to identify precancerous polyps and cancers.<wbr> Company claims that no prior bowel cleansing is needed because its x-rays create 360-degree angular scans that can "see through" intestinal content.<wbr> Clinical trials are ongoing in Israel (6 sites)/<wbr>EU (1 site).<wbr> Management reported it expects to initiate U.<wbr>S pivotal trial and launch the device in EU in H2:16.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20151231&edate=20150901&rec=2529">...</a><br></div><div style="margin-bottom: 10px;">Check-Cap has reported that new data demonstrating safety and polyp detection from a clinical study evaluating the company's non-invasive system for preparation-free examination of the colon will be presented at the American College of Gastroenterology (ACG) Annual Scientific Meeting taking place October 16-21, 2015 and the United European Gastroenterology Week (UEGW) taking place October 24-28, 2015.<wbr> The company anticipates submitting data from this study for CE Mark inQ1:16, and initiating a U.<wbr>S.<wbr> pivotal trial in H2:16.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>About the Study</STRONG> </div><div style="margin-bottom: 10px;">The study evaluated data from 49 volunteers and tracked the entire passage of the capsule through the alimentary tract using radio frequency telemetry and Check-Cap's proprietary capsule position tracking system.<wbr> </div><div style="margin-bottom: 10px;">All capsules were swallowed naturally without adverse events, and there was a 100% capsule excretion rate after an average transit time of 68 +/<wbr>- 31 hours.<wbr> Enrolled subjects were exposed to ultra-low doses of radiation with an average total exposure of 0.<wbr>03 +/<wbr>- 0.<wbr>007 mSv (approximately equivalent to a single chest x-ray).<wbr> Quantitative ultra-low dose x-ray 3D imaging was achieved in the colon of human subjects, and the system successfully generated multiple reconstructions of colon segments with polyps.<wbr> </div><div style="margin-bottom: 10px;">While colonic polyps were clearly demonstrated by the system, in order to get statistically significant results, the efficacy of this colon screening modality will need to be validated in a larger multi-center study.<wbr> </div><div>These study results represent a preliminary analysis of the first patients evaluated in Check-Cap's ongoing multi-center clinical evaluation.<wbr> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20151231&edate=20150901&rec=2601">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2529">View thread  GastroEnterology2529: Key Messages from Check Cap Presentation at Rodman & Renshaw Global Investment Conference</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-10-20T14:54:58+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-10-20T14:54:58+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Key Findings from McNeil Consumer Healthcare New Survey on OTC</title>
	<pubDate>2015-10-20T14:06:02+02:00</pubDate>
	<wp:post_id>6806</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: A new survey of &gt;2,000 U.<wbr>S.<wbr> adults found that while the majority of consumers recognize the importance of reading the label of an OTC medicine when using the medicine for the first time, only 20% re-read the label of an OTC medicine they have used before.<wbr> As a result, McNeil Consumer Healthcare has developed the "<A href="http://www.everylabeleverytime.com/the-facts.html">Every Label, Every Time</A>" initiative/<wbr>campaign to educate consumers about the appropriate use of OTC medicines, and the importance of reading and following all medicine labels.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Statistics on OTC Use</STRONG> <A href="http://www.chpa.org/marketstats.aspx">http:/<wbr>/<wbr>www.<wbr>chpa.<wbr>org/<wbr>marketstats.<wbr>aspx</A> </div><div style="margin-bottom: 10px;"><B>Methodology</B><B> </B>From July 13-20, 2015, APCO Insight conducted an online survey among the United States adult population.<wbr> A total of 2,038 respondents, 1,500 nationally and 538 from the DC metro area, participated in the survey.<wbr> </div><div style="margin-bottom: 10px;">Responses were broken into representative subgroups and analyzed by OTC usage, gender, age, race/<wbr>ethnicity, education level, income, US region, and community size.<wbr> Data have been weighted according to the U.<wbr>S.<wbr> census to reflect national representation on key demographic measures.<wbr> </div><div style="margin-bottom: 10px;"><B>McNeil Consumer Healthcare </B>markets a broad range of well-known and trusted over-the-counter (OTC) products.<wbr> </div><div>McNeil Consumer Healthcare is most widely recognized for the TYLENOL<SUP>®</SUP> brand.<wbr> Other McNeil Consumer Healthcare brands include BENADRYL<SUP>®</SUP>, ZYRTEC<SUP>®</SUP> and ZYRTEC<SUP>®</SUP> -D allergy medicines; <STRONG>IMODIUM<SUP>®</SUP> A-D anti-diarrheal</STRONG>; MOTRIN<SUP>®</SUP> IB pain reliever; and SUDAFED<SUP>®</SUP> and SUDAFED PE<SUP>®</SUP> nasal decongestants </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20151231&edate=20150901&rec=2600">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-10-20T14:06:02+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-10-20T14:06:02+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>J&J's Q3 Results- Highlights on the Consumer H/C Sales</title>
	<pubDate>2015-10-20T13:54:19+02:00</pubDate>
	<wp:post_id>6807</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The consumer segment represented approx.<wbr> 20% of Q3 total sales.<wbr> Worldwide of <MONEY>$3.<wbr>3 billion</MONEY> represented a decrease of 7.<wbr>7% vs the prior year, consisting of an operational increase of 3.<wbr>1% and a negative impact from currency of 10.<wbr>8%.<wbr> Management reported the company is back to a consistent cadence of new products as it continues to reintroduce products back to the shelves, as well as innovate across its "beloved" brands.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Domestic sales increased 8.<wbr>9%; international sales decreased 15.<wbr>7%, which reflected an operational increase of 0.<wbr>4% and a negative currency impact of 16.<wbr>1%.<wbr> </div><div style="margin-bottom: 10px;"><U>Positive contributors to Consumer operational results</U> were sales of over-the-counter products including TYLENOL<SUP>®</SUP> and MOTRIN<SUP>®</SUP> analgesics and ZYRTEC<SUP>®</SUP> allergy medications; international feminine protection products; AVEENO<SUP>®</SUP> and NEUTROGENA<SUP>®</SUP> skin care products; and LISTERINE<SUP>®</SUP> oral care products.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2599_1_ScreenCapture1.jpg"> </div><div><STRONG>Consumer H/<wbr>C Products </STRONG><A href="http://www.jnj.com/healthcare-products/consumer">http:/<wbr>/<wbr>www.<wbr>jnj.<wbr>com/<wbr>healthcare-products/<wbr>consumer</A> </div><!-- Comment details --><a name="gastroenterology2599attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2599_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(104,7 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20151231&edate=20150901&rec=2599">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-10-20T13:54:19+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-10-20T13:54:19+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>ONO's TSPO for IBS-D in Women Available for Licensing</title>
	<pubDate>2015-10-19T18:02:24+02:00</pubDate>
	<wp:post_id>6808</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: ONO-2952, antagonist of translocator protein 18kDr (TSPO) will be featured during the next UEGW.<wbr> The investigational drug works on the central nervous system to effect the abnormal brain-gut connection, especially under stress.<wbr> It has completed a Ph2b in the US.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><P>Tuesday 27 - <!--generated--></P> </div><div style="margin-bottom: 10px;"><TD class="xl68" style="WIDTH: 62pt; BORDER-LEFT: medium none" width="82">Free paper session</TD> </div><div style="margin-bottom: 10px;"><TD class="xl68" style="WIDTH: 53pt; BORDER-LEFT: medium none" width="71">OP169</TD> </div><div style="margin-bottom: 10px;">(<TD class="xl68" style="WIDTH: 60pt; BORDER-LEFT: medium none" width="80">08.<wbr>30-10.<wbr>30)</TD> </div><div style="margin-bottom: 10px;"><TD class="xl68" style="WIDTH: 53pt; BORDER-LEFT: medium none" width="70">Room E1</TD> </div><div style="margin-bottom: 10px;"><A href="https://clinicaltrials.gov/ct2/show/NCT01844180?term=ono-2952&amp;rank=5">THE RESTORE-4 STUDY</A>: A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP PHASE II STUDY ASSESSING THE EFFICACY AND SAFETY OF ONO-2952, A NOVEL AND SELECTIVE ANTAGONIST OF TRANSLOCATOR PROTEIN </div><div style="margin-bottom: 10px;"><U>Findings</U>: ONO-2952 demonstrated a greater potential to impact clinical symptoms compared to placebo in female patients with IBS-D.<wbr> Those given ONO-2952 60mg were more likely to be clinical responders on both abdominal pain and stool consistency, in addition to a composite of these endpoints.<wbr> </div><div><EM>Source: ARVAX (updated Sept 2015); UEGW</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20151231&edate=20150901&rec=2598">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-10-19T18:02:24+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-10-19T18:02:24+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Allergan to Showcase Viberzi (eluxadoline) During Two Major GI Congresses</title>
	<pubDate>2015-10-19T17:18:05+02:00</pubDate>
	<wp:post_id>6809</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Three new data posters/<wbr>presentations for eluxadoline will be presented during the <A href="http://acgmeetings.gi.org/">ACG 2015 </A>(Oct.<wbr> 16-21), and four data poster/<wbr>free paper sessions during the <A href="https://www.ueg.eu/week/">UEGW</A> 2015 (Oct 24-28).<wbr> The drug is expected to be launched in the US in Q1:16 for IBS-d (co-promotion with Ironwood).<wbr> It was submitted last May in EU.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><UL type="disc"><LI>Eluxadoline Demonstrates Efficacy for the Treatment of Irritable Bowel Syndrome (IBS) With Diarrhea (IBS-D) Among Multiple Clinically Relevant Patient Subgroups <CHRON></CHRON></LI>
<LI>Effect of Eluxadoline on Abdominal and Bowel Symptoms Over Time in Phase 3 Clinical Trials in Patients With Irritable Bowel Syndrome With Diarrhea </LI>
<LI>Adverse Event Profile of Eluxadoline Over Time in Patients With Irritable Bowel Syndrome With Diarrhea</LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div><UL><LI>ELUXADOLINE DEMONSTRATES SUSTAINED EFFICACY FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHOEA IN PHASE 3 CLINICAL TRIALS</LI>
<LI>EFFECT OF ELUXADOLINE ON HEALTH-RELATED QUALITY OF LIFE IN ADULTS WITH IRRITABLE BOWEL SYNDROME WITH DIARRHOEA: RESULTS FROM TWO RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 TRIALS</LI>
<LI>CONSISTENCY IN EFFICACY OUTCOMES OF ELUXADOLINE-TREATED PATIENTS WITH IRRITABLE BOWEL SYNDROME WITH DIARRHOEA USING RECENT AND TRADITIONAL ENDPOINTS</LI>
<LI>EFFECTS OF ELUXADOLINE ON ABDOMINAL PAIN IN PATIENTS WITH IRRITABLE BOWEL SYNDROME WITH DIARRHOEA: RESULTS OF TWO PHASE 3 TRIALS</LI>
</UL> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20151231&edate=20150901&rec=2596">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-10-19T17:18:05+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-10-19T17:18:05+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>New Clinical Data on IBgard® Presented @ ACG</title>
	<pubDate>2015-10-19T15:20:50+02:00</pubDate>
	<wp:post_id>6810</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Data from a post-study assessment of moderate to severe IBS patients in the landmark IBSREST™ (<U>I</U>rritable <U>B</U>owel <U>S</U>yndrome <U>R</U>eduction <U>E</U>valuation and <U>S</U>afety <U>T</U>rial) study and the real world, observational IBSACT™ (<U>I</U>rritable <U>B</U>owel <U>S</U>yndrome <U>A</U>dherence &amp; <U>C</U>ompliance <U>T</U>rial) study revealed a consistently high level of patient satisfaction with the overall improvement of their IBS symptoms.<wbr> In IBSREST™, the overall patient satisfaction rate was over 80 percent.<wbr> Additionally, patients in the real world study, which measured patient adherence and compliance, reported an overall satisfaction rate of greater than 85 percent after taking IBgard<SUP>® </SUP>with 61 percent of patients needing only 1 to 2 IBgard<SUP>® </SUP>capsules per day to achieve relief from IBS symptoms </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">In patients taking IBgard<I><SUP>®</SUP></I>, overall improvement was accessed at four endpoints, with results showing: </div><div style="margin-bottom: 10px;"><UL style="LIST-STYLE-TYPE: disc" type="disc"><LI>Overall improvement in IBS symptoms: 
<UL style="LIST-STYLE-TYPE: circle" type="circle"><LI>88.<wbr>3% in IBSREST™ and 98.<wbr>1% in IBSACT™ </LI>
</UL></LI>
<LI>Overall improvement in quality of life: 
<UL style="LIST-STYLE-TYPE: circle" type="circle"><LI>88.<wbr>3% in IBSREST™ and 92.<wbr>7% in IBSACT™ </LI>
</UL></LI>
<LI>Overall improvement in abdominal pain and cramping: 
<UL style="LIST-STYLE-TYPE: circle" type="circle"><LI>85.<wbr>3% in IBSREST™ and 95.<wbr>8% in IBSACT™ </LI>
</UL></LI>
<LI>Overall improvement in bowel regularity: </LI>
</UL> </div><div style="margin-bottom: 10px;"><UL style="LIST-STYLE-TYPE: circle" type="circle"><LI>82.<wbr>3% in IBSREST™ and 84.<wbr>6% in IBSACT™</LI>
</UL> </div><div style="margin-bottom: 10px;">Additionally, patients taking IBgard<B><I><SUP>®</SUP></I></B> were asked how likely they were to recommend IBgard<B><I><SUP>®</SUP></I></B> and to continue taking IBgard<B><I><SUP>®</SUP></I></B>.<wbr> </div><div style="margin-bottom: 10px;"><UL style="LIST-STYLE-TYPE: disc" type="disc"><LI>Likely to recommend IBgard<B><I><SUP>®</SUP></I></B> to family and friends who also suffer from IBS: 
<UL style="LIST-STYLE-TYPE: circle" type="circle"><LI>94.<wbr>1% in IBSREST™ and 97% in IBSACT™ </LI>
</UL></LI>
<LI>Likely to continue taking IBgard<B><I><SUP>®</SUP></I></B> for their IBS: 
<UL style="LIST-STYLE-TYPE: circle" type="circle"><LI>88.<wbr>3% in IBSREST™ and 99.<wbr>3% in IBSACT™ </LI>
</UL></LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>IBSREST</STRONG>: 4-week, randomized, placebo-controlled, double-blind clinical trial of patients reporting average daily IBS-related abdominal pain of at least 4 on a 10-point scale.<wbr> An end-of-study questionnaire, which was part of the protocol design, was used to evaluate the overall satisfaction with the relief of IBS symptoms for 35 subjects in the active arm.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>IBSACT</STRONG>: surveyed over 250 IBS patients who were using IBgard<B><I><SUP>®</SUP></I></B> in the general population to assess satisfaction and dosing frequency.<wbr> The general patient population was allowed flexible dosing.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>What is IBgard<SUP>®</SUP></STRONG> </div><div>IBgard<SUP>®</SUP> is a medical food specially formulated for the dietary management of IBS and is the first product using a patented, breakthrough technology called Site Specific Targeting (SST<SUP>®</SUP>), which delivers sustained released microspheres of an ultra-purified peppermint oil, quickly and reliably to the small intestine where its actions helps manage IBS.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20151231&edate=20150901&rec=2594">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-10-19T15:20:50+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-10-19T15:20:50+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Key Messages from Valeant Q3 Results</title>
	<pubDate>2015-10-19T13:26:55+02:00</pubDate>
	<wp:post_id>6811</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Management reported total revenues of <MONEY>$2.<wbr>8 billion (+36% over the prior year despite negative foreign exchange impact of </MONEY><MONEY>$172 million).<wbr> Growth was driven by the U.<wbr>S (particularly in dematology and contact lens), China (approx $85M +23%), South Korea (+15%) and Mexico (+10%).<wbr> Management is considering the sale of its "neuro &amp; other" business, and may also spin it off or take it private, because "it will represent only ~10% of the company's business going forward".<wbr></MONEY> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Valeant's key neurology products are <STRONG>Wellbutrin<SUP>®</SUP> XL</STRONG>, a once-daily formulation of bupropion for the treatment of depression and seasonal affective disorder and <STRONG>Xenazine®</STRONG> (tetrabenazine),  a medicine that is used to treat the involuntary movements (chorea) of Huntington’s disease and is marketed by Lundbeck; Valeant entered into a strategic partnership with GSK in 2008 for the development and commercialization of the investigational anti-epileptic drug for the adjunctive treatment of adults with partial-onset seizures.<wbr> Known as <STRONG>Potiga™</STRONG> in the U.<wbr>S.<wbr> (and Trobalt™ outside the U.<wbr>S).<wbr> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 11pt; FONT-FAMILY: 'Calibri','sans-serif'; LINE-HEIGHT: 115%; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 11pt; FONT-FAMILY: 'Calibri','sans-serif'; LINE-HEIGHT: 115%; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 11pt; FONT-FAMILY: 'Calibri','sans-serif'; LINE-HEIGHT: 115%; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"><SPAN lang="EN-US" style="FONT-SIZE: 11pt; FONT-FAMILY: 'Calibri','sans-serif'; LINE-HEIGHT: 115%; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"></SPAN></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 11pt; FONT-FAMILY: 'Calibri','sans-serif'; LINE-HEIGHT: 115%; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"><SPAN lang="EN-US" style="FONT-SIZE: 11pt; FONT-FAMILY: 'Calibri','sans-serif'; LINE-HEIGHT: 115%; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"></SPAN></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 11pt; FONT-FAMILY: 'Calibri','sans-serif'; LINE-HEIGHT: 115%; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"><SPAN lang="EN-US" style="FONT-SIZE: 11pt; FONT-FAMILY: 'Calibri','sans-serif'; LINE-HEIGHT: 115%; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"></SPAN></SPAN> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11283_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>MoviPrep</STRONG> comes in 21st position with sales of $28M (vs $21M in Q2:15) </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11283_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11283_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11283_3_ScreenCapture3.jpg"> </div><!-- Comment details --><a name="pharmaworld11283attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11283_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(35,4 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11283_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(60,6 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11283_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(53,8 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11283_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(22 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20151231&edate=20150901&rec=11283">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-10-19T13:26:55+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-10-19T13:26:55+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Zytiga Gets Green Light in Scotland</title>
	<pubDate>2015-10-16T20:18:46+02:00</pubDate>
	<wp:post_id>6812</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;"><SPAN style="background-color: #ffffff;"><SPAN style="widows: 2; text-transform: none; text-indent: 0px; display: inline !important; font: 14px/22px Helvetica, Arial, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #1a1a1a; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">Comment: SMC has recommended Zytiga</SPAN><SPAN style="widows: 2; text-transform: none; text-indent: 0px; display: inline !important; font: 14px/22px Helvetica, Arial, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #1a1a1a; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"> for use before chemotherapy in men with advanced prostate cancer who are no longer responding to conventional hormone therapy.<wbr> </SPAN></SPAN><SPAN style="background-color: #ffffff; font-family: helvetica;"><SPAN style="widows: 2; text-transform: none; text-indent: 0px; display: inline !important; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #1a1a1a; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"><SPAN style="background-color: #ffffff;">El</SPAN>igible men in Scotland can now routinely benefit from earlier treatment with a medicine that will allow them to delay or avoid chemotherapy and that can delay disease progression, prolong life and provide a better quality of life with less pain.<wbr> </SPAN><SPAN style="widows: 2; text-transform: none; text-indent: 0px; display: inline !important; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #1a1a1a; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">In England and Wales, men with prostate cancer will have to wait for NICE to decide whether the treatment will also be routinely available to them on the NHS in the same setting.<wbr></SPAN></SPAN> </div><div><SPAN style="background-color: #ffffff; font-family: helvetica;"><SPAN style="widows: 2; text-transform: none; text-indent: 0px; display: inline !important; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #1a1a1a; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">Janssen Management has indicated that the company "<SPAN style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 14px/22px Helvetica, Arial, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #1a1a1a; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"> .<wbr>.<wbr>.<wbr> are working closely with NHS England and with NICE to find a way to make this important treatment option routinely available on the NHS.<wbr>  We hope that NICE will now agree that eligible men in England and Wales should have the same routine access to abiraterone before chemotherapy as those in Scotland".<wbr></SPAN></SPAN></SPAN> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20151231&edate=20150901&rec=10715">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-10-16T20:18:46+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-10-16T20:18:46+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Revance Continues to Seek Investment To Help Support Research</title>
	<pubDate>2015-10-16T20:02:27+02:00</pubDate>
	<wp:post_id>6813</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Revance continues to seek investors as they recently launch an updated company presentation and Investor fact sheet </div><div style="margin-bottom: 10px;"><U>Company Presentation</U> </div><div style="margin-bottom: 10px;">The company presentation follows the same format as before, highlighting RT001 and RT002 in development in both aesthetic and therapeutic indications </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_8210_1_ScreenCapture1.jpg"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_8210_2_ScreenCapture2.jpg"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_8210_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><U>Investor Fact Sheet</U> </div><div style="margin-bottom: 10px;">The investor sheet is a 2 page document covering both proudcts and an overview on Revance </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_8210_7_ScreenCapture7.jpg"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_8210_6_ScreenCapture6.jpg"> </div><div>Source: Revance website </div><!-- Comment details --><a name="neurology8210attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_8210_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(143,3 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_8210_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(120,5 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_8210_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(151,9 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_8210_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(178,4 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_8210_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(181,3 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_8210_6_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(133,2 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_8210_7_ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(134,4 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20151231&edate=20150901&rec=8210">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-10-16T20:02:27+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-10-16T20:02:27+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Allergan Presents Positive Results In A Botox pIII Extension Study In OAB At The Recent American Urogynecologic Society Meeting</title>
	<pubDate>2015-10-16T19:26:29+02:00</pubDate>
	<wp:post_id>6814</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Botox has shown positive results in two pIII long-term studies in female patients with OAB symptoms of urge urinary incontinence, urgency and frequency in adults who have had an inadequate response to or are intolerant of an anticholinergic medication </div><div style="margin-bottom: 10px;">The results were presented at the recent American Urogynecologic Society Meeting.<wbr>  The 3.<wbr>5-year extension study included 749 female patients with OAB.<wbr>   The study showed consistently high proportion of patients reported improvement or great improvement on the Treatment Benefit Scales and Quality of Life scores.<wbr>  The overall median duration of effect was 8 months (38.<wbr>4% &gt;6 to &lt;12 months).<wbr> </div><div>Source: Allergan </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20151231&edate=20150901&rec=8209">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-10-16T19:26:29+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-10-16T19:26:29+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Hutchison China MediTech Has Filed For A US IPO To Finance Its Clinical Development Programme Including In NET</title>
	<pubDate>2015-10-16T18:14:11+02:00</pubDate>
	<wp:post_id>6815</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: HCM is filing for a US IPO with the aim of trying to raise its US profile and potentially seek accelerated approval from the US FDA for five of its seven drug development candidates (yet to be specified).<wbr> In general the money will be used to support clinical development of which reference is made to support for the registration of sulfatanib for neuroendocrine tumours in China and for phI and proof of concept studies in NET in the US.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Background</STRONG> </div><div style="margin-bottom: 10px;">The potential Equity Raise and Offering are intended to support the implementation of Chi‑Med’s current drug development plans.<wbr> It is the belief of the Directors that the United States represents one of the most important markets for the development of Chi‑Med’s drug candidates, and the United States also has a large number of specialist healthcare investors.<wbr> The Directors believe that Chi‑Med should obtain exposure to the United States capital markets to increase its profile amongst United States investors and seek to benefit from the additional liquidity that the Directors believe a listing on Nasdaq should provide.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Clinical Development Plans</STRONG> </div><div style="margin-bottom: 10px;">Chi‑Med intends to use the net proceeds of the potential Equity Raise, together with the cash generated by its operations, primarily to advance the clinical development of its multiple drug candidates.<wbr> In particular, Chi‑Med expects to apply these net proceeds: </div><div style="margin-bottom: 10px;">a) to accelerate and broaden clinical development of the drug candidates for which it retains all worldwide rights, specifically to advance: </div><div style="margin-bottom: 10px;"><P style="PADDING-LEFT: 30px">i.<wbr> HMPL 523 through Phase I and Proof of Concept studies, expected to be conducted in Australia, the United States and China, in rheumatoid arthritis, lupus and haematological cancer;</P> </div><div style="margin-bottom: 10px;"><P style="PADDING-LEFT: 30px">ii.<wbr> <STRONG>sulfatinib through NDA submission in China and through Phase I and Proof of Concept studies, expected to be conducted in the United States, in neuroendocrine tumours, and through Phase I and Proof of Concept studies, expected to be conducted in China, in thyroid cancer;</STRONG></P> </div><div style="margin-bottom: 10px;"><P style="PADDING-LEFT: 30px">iii.<wbr> epitinib through NDA submission in China and Phase I and Proof of Concept studies, expected to be conducted in the United States, in non small cell lung cancer with brain metastasis; and</P> </div><div style="margin-bottom: 10px;"><P style="PADDING-LEFT: 30px">iv.<wbr> theliatinib through Phase I and Proof of Concept studies, expected to be conducted in China and the United States, in head and neck cancer and oesophageal cancer;</P> </div><div style="margin-bottom: 10px;">b) to support its share of the development costs of its partnered clinical drug candidates, including to advance: </div><div style="margin-bottom: 10px;"><P style="PADDING-LEFT: 30px">i.<wbr> savolitinib through NDA submission globally in papillary renal cell carcinoma and EGFR tyrosine kinase inhibitor refractory non small cell lung cancer and through Proof of Concept studies globally in gastric cancer and VEGFR tyrosine kinase inhibitor refractory clear cell renal cell carcinoma;</P> </div><div style="margin-bottom: 10px;"><P style="PADDING-LEFT: 30px">ii.<wbr> fruquintinib through NDA submission in colorectal cancer and non small cell lung cancer in China and through Proof of Concept in gastric cancer in China and to advance fruquintinib through Proof of Concept in non small cell lung cancer in the United States either independently or in partnership with Eli Lilly subject to the exercise of its global option; and</P> </div><div style="margin-bottom: 10px;"><P style="PADDING-LEFT: 30px">iii.<wbr> HMPL 004 through an interim analysis in a global Phase III study in mild to moderate ulcerative colitis;</P> </div><div style="margin-bottom: 10px;">c) to progress pre clinical drug candidates, specifically to advance: </div><div style="margin-bottom: 10px;"><P style="PADDING-LEFT: 30px">i.<wbr> HMPL 689 through Phase I and Proof of Concept studies, expected to be conducted in Australia, the United States and China, in haematological cancer;</P> </div><div style="margin-bottom: 10px;"><P style="PADDING-LEFT: 30px">ii.<wbr> <STRONG>HMPL 453 through Phase I and Proof of Concept studies, expected to be conducted in Australia, the United States and China, in bladder cancer</STRONG>; and</P> </div><div style="margin-bottom: 10px;"><P style="PADDING-LEFT: 30px">iii.<wbr> other drug candidates through pre clinical studies and into Phase I clinical trials;</P> </div><div style="margin-bottom: 10px;"><STRONG>Other Uses For The Finance Raised </STRONG> </div><div style="margin-bottom: 10px;">To build production facilities to produce both clinical and commercial supply of its drug candidates; and </div><div style="margin-bottom: 10px;">To repay certain of its existing term loan from Scotiabank (Hong Kong) Limited.<wbr> </div><div style="margin-bottom: 10px;">Although Chi‑Med expects that the majority of the net proceeds from the potential IPO would be used to advance the clinical development of its multiple drug candidates, the precise amounts allocated to each of the expenditure items listed above will only be determined once the final size of the potential Equity Raise is known.<wbr> </div><div>From <A href="http://www.chi-med.com/">http:/<wbr>/<wbr>www.<wbr>chi-med.<wbr>com</A>, see <A href="http://www.chi-med.com/filing-of-registration-statement-on-form-f-1-for-potential-nasdaq-stock-market-listing/">original source</A>.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20151231&edate=20150901&rec=8233">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-10-16T18:14:11+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-10-16T18:14:11+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Janssen and enGene Ink Deal to Develop/Commercialize New Therapies for IBD</title>
	<pubDate>2015-10-15T15:33:00+02:00</pubDate>
	<wp:post_id>6816</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: This strategic alliance provides Janssen Biotech with the option to exclusively license enGene's lead product candidate, EG-12, for gut-localized expression of the anti-inflammatory cytokine IL-10.<wbr> enGene's vector system can be administered to the intestine through the oral or enema route.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">enGene will receive an upfront payment, equity investment through Johnson &amp; Johnson Innovation – JJDC, Inc.<wbr> and R&amp;D funding.<wbr> Furthermore, enGene is eligible to receive various pre-clinical, clinical, regulatory and commercialization success-based milestone payments up to a total of approx $338M, plus tiered royalties on potential net sales of products.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">enGene, Inc is a pre clinical stage biotechnology company engaged in the development of a method of protein drug delivery called GEMS(Gut Endocrine-cell Modification System).<wbr> The company is developing long term treatment for chronic diseases such as diabetes, obesity, anemia, inflammatory bowel disease, bone disorders, and hemophilia, using GEMS.<wbr> </div><div><EM>Source: </EM><A href="http://www.engeneinc.com/press/2015/enGenePR_News_Release_2015-10-14.pdf"><EM>http:/<wbr>/<wbr>www.<wbr>engeneinc.<wbr>com/<wbr>press/<wbr>2015/<wbr>enGenePR_News_Release_2015-10-14.<wbr>pdf</EM></A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20151231&edate=20150901&rec=2593">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-10-15T15:33:00+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-10-15T15:33:00+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Swedish Xbrane Acquires Italian Primm Pharma and Signs Spherotide Distribution Deal with Pooyesh Darou for Iran</title>
	<pubDate>2015-10-15T09:36:21+02:00</pubDate>
	<wp:post_id>6817</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Spherotide (triptorelin) will be available primarily for prostate cancer and endometriosis from mid 2017.<wbr> Xbrane claims to have a production capacity of 1 million doses of Spherotide per year, with the possibility of increasing the capacity to 3 million doses if needed.<wbr> CEO indicates that they will 'place the product at 50% less than Decapeptyl".<wbr> To be noted in Xbrane pipeline: Leuprosphere (leuprorelin Depot), and Oktreosphere (octreotide LAR).<wbr> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><STRONG>Management</STRONG> </div><div style="margin-bottom: 10px;"><U>Martin Åmark</U> CEO </div><div style="margin-bottom: 10px;">Holds a M Sc.<wbr> in industrial engineering and management from Linköping Institute of Technology and a MBA from INSEAD.<wbr> He has 8 years of experience from Bain &amp; Co as a management consultant </div><div style="margin-bottom: 10px;"><U>Dr Paolo Sarmientos </U>Head of Slow Release Generics </div><div style="margin-bottom: 10px;">Has a bio-organic chemistry from the University of Naples.<wbr> He has more than 25 years of experience from leading positions in biopharmaceuticals for Pfizer, Genetica and Menarini.<wbr> <STRONG>Last 15 years Paolo has served as CEO of Primm</STRONG> and successfully built up a service business focused on pharmaceutical industries as well as pioneering technology for production of biopharmaceuticals with slow release formulation based on microspheres.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Board</STRONG> </div><div style="margin-bottom: 10px;">Prof.<wbr> Alf Lindberg, former secretary of the Nobel Committee, Head of R&amp;D at Wyeth Vaccines, EVP of R&amp;D at Sanofi Pasteur and lead developer of Prevnar </div><div style="margin-bottom: 10px;">Prof.<wbr> Maris Hartmanis, formerly CEO of Medivir and BioPhausia </div><div style="margin-bottom: 10px;">Karin Wingstrand formerly Global Head and Vice President of Clinical Development at AstraZeneca </div><div style="margin-bottom: 10px;">Prof.<wbr> Peter Edman, Orexo, with previous senior positions at Sobi, Biovitrum, AstraZeneca, Astra and Pharmacia </div><div style="margin-bottom: 10px;"><STRONG>Pipeline</STRONG> </div><div style="margin-bottom: 10px;">Xbrane has invested in the construction and validation of a pharmaceutical plant with a total surface of 500 m2 for the manufacturing of a Microsphere Slow Release formulation of the peptide Triptorelin, under the brand name Speherotide.<wbr> The formulation is based on Microspheres carrying the active drug which following administration to patients it is slowly released in the blood stream.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10712_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><EM>Sources</EM> </div><div style="margin-bottom: 10px;"><A href="http://xbrane.com/press/xbrane-signs-iranian-deal-for-its-lead-complex-biogeneric-spherotide/">http:/<wbr>/<wbr>xbrane.<wbr>com/<wbr>press/<wbr>xbrane-signs-iranian-deal-for-its-lead-complex-biogeneric-spherotide/<wbr></A> </div><div><A href="http://xbrane.com/press/xbrane-acquires-italian-company-primm-pharma-specialists-in-slow-release-generics/">http:/<wbr>/<wbr>xbrane.<wbr>com/<wbr>press/<wbr>xbrane-acquires-italian-company-primm-pharma-specialists-in-slow-release-generics/<wbr></A> </div><!-- Comment details --><a name="oncology10712attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10712_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(48,5 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20151231&edate=20150901&rec=10712">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-10-15T09:36:21+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-10-15T09:36:21+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>CEO of Probi Appointed Chairman of IPA Europe</title>
	<pubDate>2015-10-14T18:02:20+02:00</pubDate>
	<wp:post_id>6818</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Peter Nählstedt has been appointed Chairmand of International Probiotics Association (IPA) the goal of which is to advocate for a well-defined status of probiotics and to increase awareness of the benefits of probiotics.<wbr> IPA Europe was launched in Brussels on 30 September.<wbr> Switzerland has recently approved probiotic health claims from Probi and other companies such as Yakult, Danone and DuPont-Danisco.<wbr> </div><div style="margin-bottom: 10px;">Switzerland enforces a similar set of rules as those that apply in the EU, whereby health claims are approved following a rigorous scientific review of documentation.<wbr> However, the two differ insofar as Switzerland offers the opportunity for dialog during the evaluation process.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Newly formed non-governmental organisation (NGO) that aims to support its members and disseminate knowledge about probiotics in the European food industry.<wbr> </div><div style="margin-bottom: 10px;">The organisation is a fusion of members of IPA and two other organisations – the Yoghurt and Live Fermented Milks Association (YLFA) and the Global Alliance for Probiotics (GAP) – which have now merged to give a stronger voice for probiotics </div><div>IPA members: <A href="http://www.internationalprobiotics.org/companies">http:/<wbr>/<wbr>www.<wbr>internationalprobiotics.<wbr>org/<wbr>companies</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20151231&edate=20150901&rec=2592">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-10-14T18:02:20+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-10-14T18:02:20+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>BioGaia's Lactobacillus reuteri Protectis Preliminary Results in Acute Diarrhea Presented at IDW</title>
	<pubDate>2015-10-14T17:52:19+02:00</pubDate>
	<wp:post_id>6819</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: BioGaia has announced that the results from a randomized, controlled pilot study in 76 infants with acute diarrhoea show that rapid diagnostic testing and Lactobacillus reuteri Protectis supplementation for 60 days was associated with a significant increase in 60-day adjusted standardized height and significantly less recurrent diarrhoea compared to standard care and placebo treatment.<wbr> The study was conducted in Botswana (please see full poster attached).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> were presented at the Infectious Disease Week in San Diego, USA, on October 10 2015 please see attached <a href="http://ci.beaufour-ipsen.com/traction?type=np&proj=*&sdate=20151231&edate=20150901&rs=/link%20GastroEnterology2591%401" class="defaultlink">@1</a> </div><div style="margin-bottom: 10px;"><STRONG>Title</STRONG>: Optimizing Management of Paediatric Diarrhoeal Disease in Botswana: A Pilot, Factorial, Randomized, Placebo-Controlled Trial of Rapid Enteric Diagnostics and Probiotic Therapy </div><div style="margin-bottom: 10px;"><STRONG>Discussion</STRONG>: The results of this randomized pilot trial confirm our hypothesis that rapid test-and-treat algorithms and probiotic therapy offer real promise for the treatment of severe gastroenteritis in the southern African context.<wbr> We have demonstrated that the integration of rapid molecular testing into routine care, made possible by the use of rectal flocked swabs, is feasible in resource-limited settings.<wbr> </div><div>The combination of rapid diagnostic testing and L.<wbr> reuteri DSM 17938 treatment was associated with both statistically significant increases in standardized height (adjusted for baseline height) and statistically significant decreases in recurrent diarrhoea.<wbr> It is very possible that the estimates in treatment effect observed in this small study were exaggerated due to to chance; one should also remember that there were baseline differences between arms.<wbr> However, we believe that further exploration of these interventions in an adequatelypowered multicentre trial is warranted.<wbr> </div><!-- Comment details --><a name="gastroenterology2591attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2591_1_BioGaia%255fPOSTER228%255f1624%5b1%5d.pdf">BioGaia_POSTER228_1624[1].pdf</a>&nbsp;&nbsp;(887,5 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20151231&edate=20150901&rec=2591">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-10-14T17:52:19+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-10-14T17:52:19+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>RedHill Updates the BEKINDA Development Programs</title>
	<pubDate>2015-10-14T17:43:04+02:00</pubDate>
	<wp:post_id>6820</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: RedHill has provided an update on the development programs with BEKINDA<SUP>™</SUP> (RHB-102), a proprietary, extended-release, once-daily oral pill formulation of ondansetron.<wbr> The company expects 1/<wbr>to receive top-line results from the Ph3 GUARD study (gastroenteritis &amp; gastritis) in mid-late 2016, and 2/<wbr>plans to start a Ph2 for IBS-D in Q4:15/<wbr>Q1:16.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2590_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2590_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><STRONG><U>Ph3 GUARD</U></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2590_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2590_5_ScreenCapture5.jpg"> </div><div style="margin-bottom: 10px;"><STRONG><U>Oncology Support</U></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2590_6_ScreenCapture6.jpg"> </div><div style="margin-bottom: 10px;"><STRONG>5-HT3 antagonists</STRONG> such as ondansetron have been shown to slow intestinal transit time in humans.<wbr> </div><div style="margin-bottom: 10px;">Alosetron (Lotronex<SUP>®</SUP>), a 5-HT3 antagonist, has been approved for the treatment of IBS in women with severe chronic IBS-D but is under a restricted prescribing program due to potential severe side effects.<wbr> </div><div style="margin-bottom: 10px;">Ondansetron, approved by the U.<wbr>S.<wbr> <ORG>FDA</ORG> as an oncology support antiemetic, has demonstrated activity in IBS-D in preliminary studies and in light of its good safety profile <LOCATION value="LU/gb.eng.redhil">RedHill</LOCATION> believes that BEKINDA<SUP>™</SUP>, if approved, has the potential to be the preferred once-daily treatment for patients suffering from IBS-D.<wbr> </div><div>Source: <A href="http://ir.redhillbio.com/releasedetail.cfm?ReleaseID=936545">http:/<wbr>/<wbr>ir.<wbr>redhillbio.<wbr>com/<wbr>releasedetail.<wbr>cfm?ReleaseID=936545</A> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="GastroEnterology2640c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">Alongside theQ3 financial results, RedHill has reported a strong cash position of approximately $64 million at the end of Sepember 2015.<wbr> The company continues to advance the ongoing Ph3 studies with RHB-104 for Crohn's disease and with BEKINDA&trade; for acute gastroenteritis.<wbr> BEKINDA<STRONG>&trade;</STRONG> is currently the only once-daily oral formulation of ondansetron, and is likely to be the first to reach the U.<wbr>S.<wbr> and European market.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Upcoming milestones</STRONG> </div><div><UL><LI>the planned initiation of Phase II studies with BEKINDA&trade; for IBS-D
</LI>
</UL> </div></div><a name="gastroenterology2590attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2590_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(29,1 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2590_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(22,1 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2590_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(11,3 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2590_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(52,3 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2590_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(87,6 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2590_6_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(139,2 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20151231&edate=20150901&rec=2590">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-10-14T17:43:04+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-10-14T17:43:04+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Novintethical to Present Xilaplus® (xyloglucan) Results for Acute Diarrhea at Next UEGW</title>
	<pubDate>2015-10-14T16:53:55+02:00</pubDate>
	<wp:post_id>6821</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: <A href="http://www.novintethical.com/">Novintethical</A> is a Swiss pharma company dedicated to the distribution of pharma products and medical devices in &gt;60 countries.<wbr> Company's GI products list includes Aprotecol (for meteorism in adults/<wbr>children), Gelsectan, (for chronic/<wbr>functional or recidivant diarrhoea), flagship product: Tasectan/<wbr>Tasectan Duo (for diarrhea and restoration of the intestinal wall), and Xilaplus® (to reduce symptoms of diarrhea).<wbr> At UEGW, Xavier Llop will be presenting the results of a Xyloglucan trial in 150 patients (3-day treatment (4 capsules/<wbr>6 h of Xilaplus<SUP>®</SUP>, 3 sachets/<wbr>day of Smecta<SUP>®</SUP> and 2 capsules/<wbr>day of Ultra-Levura<SUP>®</SUP>), which conclude that the product is a fast, efficacious and safe option for the treatment of acute diarrhea.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><A href="https://uegw.congress-online.com/guest/AbstractView?ABSID=11601">P1232</A> - XYLOGLUCAN FOR THE TREATMENT OF ACUTE DIARRHEA: RESULTS OF A RANDOMIZED, CONTROLLED, OPEN-LABEL, PARALLEL GROUP, MULTICENTRE, NATIONAL CLINICAL TRIAL.<wbr> </div><div style="margin-bottom: 10px;">Conclusion: Xyloglucan is a fast, efficacious and safe option for the treatment of acute diarrhea, with a rapid onset of action in reducing diarrheal symptoms.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2588_1_ScreenCapture1.jpg"> </div><!-- Comment details --><a name="gastroenterology2588attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2588_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(115,2 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20151231&edate=20150901&rec=2588">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-10-14T16:53:55+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-10-14T16:53:55+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Ironwood and Partner Allergan to Submit Linaclotide for CIC in H1:16</title>
	<pubDate>2015-10-14T15:18:23+02:00</pubDate>
	<wp:post_id>6822</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Ironwood reported positive top-line results (PE met) from the Ph3 trial of 72mcg linaclotide in adults with CIC.<wbr> The 72 mcg dose is likely to accelerate the expansion of LINZESS use within adult CIC patients by providing physicians an additional dosing option for this large and diverse population.<wbr><WBR> According to management, this lower dose has been developed for patients with mild-to-moderate disease, or for patients who tend to be more sensitive to the drug.<wbr></WBR> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Linaclotide is currently approved by the <ORG>FDA</ORG> as a 145 mcg capsule to be taken once per day for the treatment of adults with CIC and as a 290 mcg capsule to be taken once per day for the treatment of adults with irritable bowel syndrome with constipation (IBS-C).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The 72 mcg dose of linaclotide demonstrated statistically significant improvement compared to placebo on the 12-week Complete Spontaneous Bowel Movements (CSBM) Overall Responder endpoint, the primary endpoint for the trial.<wbr> </div><div style="margin-bottom: 10px;">Additionally, in a pre-specified sensitivity analysis, the 72 mcg dose of linaclotide demonstrated statistically significant improvement compared to placebo on the Durable CSBM Overall Responder endpoint, which is currently being requested by the <ORG>FDA</ORG> for Phase III CIC trials.<wbr> Both the 72 mcg and 145 mcg linaclotide doses were generally well-tolerated in this trial.<wbr> Consistent with previous Phase III trials of linaclotide, the most common adverse event reported in linaclotide-treated patients was diarrhea.<wbr> The majority of diarrhea cases reported were characterized as mild in severity.<wbr> The rates of diarrhea and of discontinuations due to diarrhea were lower for the 72 mcg dose than the 145 mcg dose in this trial.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><U>Reference /<wbr> ID</U> </div><div style="margin-bottom: 10px;">NCT02291679; MCP-103-309 </div><div style="margin-bottom: 10px;"><U>Design</U> randomized, double-blind, placebo-controlled, multi-site Phase III clinical trial </div><div style="margin-bottom: 10px;"><U>Recruitment</U>: 1,223 adult patients with CIC.<wbr> (Patients with CIC were defined as having fewer than three spontaneous bowel movements per week, and they also may have experienced recurrent straining, lumpy or hard stools, and/<wbr>or a sensation that they have not had a complete bowel movement).<wbr> </div><div style="margin-bottom: 10px;"><U>Potocol</U>: Patients were randomized to receive 72 mcg of linaclotide once per day, 145 mcg of linaclotide once per day, or placebo once per day for 12 weeks.<wbr> A 12-week CSBM Overall Responder was defined as a patient who experienced at least three CSBMs per week and an increase of at least one CSBM from baseline in the same week (Weekly Responder), and achieved both of these measures for nine out of 12 weeks.<wbr> A Durable 12-week CSBM Overall Responder comprises patients that were 12-week CSBM Overall Responders and also met the Weekly<I> </I>Responder criteria for at least three of the last four weeks.<wbr> </div><div>The 145 mcg dose was included as a positive control and supported the validity of the trial for evaluation of the 72 mcg dose.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20151231&edate=20150901&rec=2587">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-10-14T15:18:23+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-10-14T15:18:23+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Lallemand to Launch Probiotic 2.0 at Next CPhI</title>
	<pubDate>2015-10-14T14:01:43+02:00</pubDate>
	<wp:post_id>6823</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Lallemand to Launch Probiotic 2.<wbr>0 at Next CPhI</span>&nbsp;<br><span style="font-size: 12px;">Comment: The new concept in probiotics formulation will be presented during CPhI (Madrid Oct 13-15).<wbr> It is the synergetic association of documented probiotic bacteria and yeast (S.<wbr> boulardii), for overall digestive health, from oral health to gut microbiota balance.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20151231&edate=20150901&rec=2571">...</a><br></div><div style="margin-bottom: 10px;">With "Probiotic 2.<wbr>0", combining probiotic Bacteria + Yeast, Lallemand claims to provide an integrated offer for a holistic approach: GI Health and Oral Health.<wbr> The 7-page sales aid distributed on the booth at CPhI describes for each sphere (oral and GI) the synergic effect and the proven effcicacy of the combination.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Selected Pictures</STRONG> </div><div style="margin-bottom: 10px;"><IMG src="data:image/png;base64,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"> </div><div style="margin-bottom: 10px;"><IMG src="data:image/png;base64,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"> </div><div>Full document available on demand </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20151231&edate=20150901&rec=2584">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2571">View thread  GastroEnterology2571: Lallemand to Launch Probiotic 2.<wbr>0 at Next CPhI</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-10-14T14:01:43+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-10-14T14:01:43+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>A Two-Part Pricing Construct for Pharma As a Flexible Pricing Mechanism</title>
	<pubDate>2015-10-13T18:47:42+02:00</pubDate>
	<wp:post_id>6824</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><U></U> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11279_1_copiedImage%5b0%5d.png"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11279_2_copiedImage%5b2%5d.png"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11279_3_copiedImage%5b4%5d.png"> </div><div style="margin-bottom: 10px;"><U></U> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><UL><LI>
</LI>
<LI>
</LI>
<LI>
</LI>
</UL> </div><div style="margin-bottom: 10px;"><U></U> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11279_4_copiedImage%5b6%5d.png"> </div><div style="margin-bottom: 10px;"><U></U> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11279_5_copiedImage%5b8%5d.png"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11279_6_copiedImage%5b10%5d.png"> </div><div style="margin-bottom: 10px;"> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11279_7_copiedImage%5b12%5d.png"> </div><!-- Comment details --><a name="pharmaworld11279attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11279_1_copiedImage%5b0%5d.png">copiedImage[0].png</a>&nbsp;&nbsp;(39,2 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11279_2_copiedImage%5b2%5d.png">copiedImage[2].png</a>&nbsp;&nbsp;(42,1 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11279_3_copiedImage%5b4%5d.png">copiedImage[4].png</a>&nbsp;&nbsp;(35,7 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11279_4_copiedImage%5b6%5d.png">copiedImage[6].png</a>&nbsp;&nbsp;(73,5 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11279_5_copiedImage%5b8%5d.png">copiedImage[8].png</a>&nbsp;&nbsp;(39,9 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11279_6_copiedImage%5b10%5d.png">copiedImage[10].png</a>&nbsp;&nbsp;(79,2 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11279_7_copiedImage%5b12%5d.png">copiedImage[12].png</a>&nbsp;&nbsp;(98,3 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20151231&edate=20150901&rec=11279">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-10-13T18:47:42+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-10-13T18:47:42+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: BTG Expands the Geographic Reach Of Its Interventional Oncology Business</title>
	<pubDate>2015-10-13T17:10:47+02:00</pubDate>
	<wp:post_id>6825</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">BTG Expands the Geographic Reach Of Its Interventional Oncology Business</span>&nbsp;<br><span style="font-size: 12px;">Comment: The interventional oncology company BTG announced this week that it has begun selling its drug-eluting bead <STRONG>DC Bead<SUP>&reg; </SUP></STRONG> and <STRONG>Bead Block</STRONG> directly to customers in 11 European countries.<wbr> The former togther with its radioembolisation product TheraSphere<SUP>&reg;</SUP> (a competitor or Sir-Spheres) are used to treat primary HCC and secondary liver metastases.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20151231&edate=20150901&rec=10357">...</a><br></div><div>BTG has entered into co-development agreement with Mirada Medical, a UK based medical imaging software company, to develop dosimetry software solutions to optimize radioembolisation therapy with TheraSphere for liver cancer patients.<wbr> The companies plan to make the software available in 2016, an easy-to-use and bespoke tool to support physicians delivering ta specific radiation dose based on an individual's patient need.<wbr> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20151231&edate=20150901&rec=10711">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10357">View thread  Oncology10357: BTG Expands the Geographic Reach Of Its Interventional Oncology Business</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-10-13T17:10:47+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-10-13T17:10:47+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>New Model for Cancer Drug Funding (CDF), UK</title>
	<pubDate>2015-10-13T16:18:56+02:00</pubDate>
	<wp:post_id>6826</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: At the recent EPPR Conference in London, Dr.<wbr> Steve Williamson, a member of the National CDF panel, discussed the evolution of the CDF and outlined a speculative future model for the CDF (come April 2016) </div><div style="margin-bottom: 10px;">Key Insights from Dr.<wbr> Williamson&rsquo;s talk were: </div><div style="margin-bottom: 10px;"><SPAN style="text-decoration: underline;">The CDF was set-up to be a &lsquo;rolling fund&rsquo;</SPAN> </div><div style="margin-bottom: 10px;">From a historical perspective, the CDF was set-up with the intent to serve as a bridge for financing Cancer drugs prior to the set-up of Value-Based pricing.<wbr> The original plan was always for the CDF to be a &lsquo;rolling fund&rsquo; (i.<wbr>e.<wbr>, drugs would roll over from the CDF to normal funding after a predetermined period), but political pressure led to delays in de-listing, and consequently that meant a major funding shortfall </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11276_1_copiedImage%5b0%5d.png"> </div><div style="margin-bottom: 10px;"><U></U> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><U></U> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11276_3_copiedImage%5b4%5d.png"> </div><div style="margin-bottom: 10px;"><U></U> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11276_4_copiedImage%5b6%5d.png"> </div><div style="margin-bottom: 10px;"><U></U> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11276_5_copiedImage%5b8%5d.png"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11276_6_copiedImage%5b10%5d.png"> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11276_7_copiedImage%5b12%5d.png"> </div><!-- Comment details --><a name="pharmaworld11276attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11276_1_copiedImage%5b0%5d.png">copiedImage[0].png</a>&nbsp;&nbsp;(32,6 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11276_2_copiedImage%5b2%5d.png">copiedImage[2].png</a>&nbsp;&nbsp;(99,8 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11276_3_copiedImage%5b4%5d.png">copiedImage[4].png</a>&nbsp;&nbsp;(67,8 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11276_4_copiedImage%5b6%5d.png">copiedImage[6].png</a>&nbsp;&nbsp;(91,6 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11276_5_copiedImage%5b8%5d.png">copiedImage[8].png</a>&nbsp;&nbsp;(127,2 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11276_6_copiedImage%5b10%5d.png">copiedImage[10].png</a>&nbsp;&nbsp;(99,4 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11276_7_copiedImage%5b12%5d.png">copiedImage[12].png</a>&nbsp;&nbsp;(99,7 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20151231&edate=20150901&rec=11276">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-10-13T16:18:56+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-10-13T16:18:56+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Lilly Strengthen Its Cancer Immunotherapy Committment With New $1B Potential Deal</title>
	<pubDate>2015-10-13T15:50:33+02:00</pubDate>
	<wp:post_id>6827</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Lilly has strengthen its partnership with China's Innovent Biologics, adding another $1 billion in potential value to the existing alliance and bringing in three potential immunotherapies in its R&amp;D partnership.<wbr> The companies will collaborate on three bispecific antibodies  that target the protein PD-1, with Innova retaining any local right to the Chinese market and Lilly on hand to develop end commercialize each treatment outside China.<wbr> The agreement builds on a March deal between the two in which Lilly paid $56 million up front and promised as much as $400 million more for a handful of early-stage cancer treatments.<wbr> </div><div style="margin-bottom: 10px;">Lilly is now further promising more than $1 billion in payments over the next decade, tied to development, regulatory and sales milestones.<wbr> </div><div style="margin-bottom: 10px;">Lilly's deeper dive into immuno-oncology is in part an effort to catch up with some of its rivals in the quickly evolving space.<wbr> Lilly has been outpaced by Merck, BMS and others in the race to commercialize cancer therapies that use the power of the immune system to fight tumors, and the company is now redoubling its efforts to build a pipeline of next-generation therapies.<wbr> In addition to its work with Innovent, Lilly is expanding its New York City R&amp;D complex with a particular focus on immuno-oncology.<wbr> </div><div>Source: Lilly and Fierce Biotech </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20151231&edate=20150901&rec=10710">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-10-13T15:50:33+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-10-13T15:50:33+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>ESMO 2015 Breast Cancer Highlight</title>
	<pubDate>2015-10-12T19:59:21+02:00</pubDate>
	<wp:post_id>6828</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: More than 20,000 women per year under age 45 are diagnosed with breast cancer in the U.<wbr>S.<wbr> Up to 97% either have HR+ disease and/<wbr>or will receive chemotherapy.<wbr> These women are at risk for infertility and premature ovarian failure and ~50% of these women at risk would desire fertility.<wbr> This has been an important issue for oncologists and patients.<wbr> Prof Rugo and Rd Olivier Pagani discussed the role of LHRHa in this setting and also in ovarian function suppression in the context of SOFT and TEXT trial during a Prime Oncology Sponsored symposia (supported by Ipsen).<wbr> A meta-analysis of 12 randomised controlled trials was presented by Dr Lambertini (Italy) also concluded temporary ovarian suppression with LHRHa in young breast cancer patients is associated with a reduced risk of chemotherapy-induced POF and seems to increase the pregnancy rate, without apparent negative consequence on prognosis.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Risk Stratification For Early Stage HR+ Breast Cancer</STRONG> - TAILORx study : the first prospective study evaluated OncotypeDx, a 21-gene assay used for independent prognostic information in addition to clinical and pathologic tumor features.<wbr> </div><div style="margin-bottom: 10px;">Dr.<wbr> J.<wbr> Sparano (USA) presented the results from TAILORx study as BEST ABSTRACT during the presidential session.<wbr> The Trial Assigning Individualized Options for Treatment (TAILORx) is a prospective trial that was designed to evaluate the role of endocrine therapy and chemoendocrine therapy in subjects patients with estrogen receptor (ER)-positive, HER2-negative, axillary node negative breast cancer whose treatment was guided by a multi parameter gene expression assay (Oncotype DX Recurrence Score [RS]).<wbr> </div><div style="margin-bottom: 10px;">In the study, forgoing chemotherapy in patients with a low risk of recurrence, as deemed by the Oncotype Dx recurrence score genetic assay, did not increase the risk of disease recurrence or disease spread at 5 years.<wbr> The trial enrolled 10,253 women with localized, hormone receptor&ndash;positive, HER2-negative breast cancer that had not spread to the lymph nodes.<wbr> Patients were assessed with the OncotypeDx recurrence score test </div><div style="margin-bottom: 10px;">&bull; A total of 1,626 women (15.<wbr>9%) enrolled had a low recurrence risk score (&lt; 10) and could receive tamoxifen, an aromatase inhibitor, or a combination of the two for 5 years, but not chemotherapy.<wbr><BR>&bull; During the 5-year period there were 88 cases of either invasive cancer or death as well as 30 deaths from other causes.<wbr><BR>&bull; The rate of invasive disease-free survival at 5 years was 93.<wbr>8%.<wbr><BR>&bull; The overall survival rate was 98%.<wbr><BR>&bull; The rate of freedom from recurrence of breast cancer at a distant site was 99.<wbr>3%, and the rate of freedom from recurrence of breast cancer at a distant or local&ndash;regional site was 98.<wbr>7%.<wbr><BR>&bull; The addition of chemotherapy to adjuvant endocrine therapy can reduce the risk of recurrence by about 30%, but many estrogen receptor&ndash;positive patients are overtreated with chemotherapy based on clinical and pathologic tumor features alone.<wbr> </div><div style="margin-bottom: 10px;">&ldquo;<EM>These results cannot come soon enough, given the already widespread adoption of the test as a key component of guidelines and routine clinical decision-making</EM>,&rdquo; Dr.<wbr> Clifford A.<wbr> Hudis, MD (Memorial Sloan Kettering Cancer Center, New York)<BR>&ldquo;<EM>This result is numerically good enough to exclude any potentially meaningful benefit for additional chemotherapy.<wbr> But for the many physicians already using the test, the gap between this cutoff point of 10 and the higher &lsquo;standard&rsquo; cutoff point of 18 may be a concern.<wbr>others will wonder whether chemotherapy is beneficial or indicated even in patients with scores up to 25</EM>.<wbr>&rdquo; Dr.<wbr> C.<wbr> Hudis (USA) </div><div style="margin-bottom: 10px;"><BR><SPAN style="text-decoration: underline;"><STRONG>LHRHa as an option to preserve fertility while young women undergoing chemotherapy</STRONG> </SPAN>: Chemotherapy can damage the ovaries and push young women into the menopause.<wbr> They may experience infertility, sleep disturbance, sexual dysfunction and osteoporosis.<wbr> It is psychologically distressing, harmful to health, and affects the treatment decisions of many young women </div><div style="margin-bottom: 10px;">Dr Matteo Lambertini presented the study that aimed to evaluate the efficacy of temporary ovarian suppression with LHRHa during chemotherapy as a strategy to reduce chemotherapy-induced premature ovarian failure (POF) and preserve fertility in young breast cancer patients, and the impact of this technique on patients' prognosis.<wbr> The data has also published simultaneously in Annals of Oncology.<wbr><BR>&ldquo;We found that temporary suppression of ovarian function with LHRHa significantly reduces the risk of premature ovarian failure (POF) caused by chemotherapy.<wbr> It also seems to be associated with a higher pregnancy rate in young breast cancer patients.<wbr>&rdquo; </div><div style="margin-bottom: 10px;"><BR>"<EM>Major international guidelines from ASCO and ESMO consider the administration of LHRHa during chemotherapy an experimental strategy to preserve ovarian function and fertility.<wbr> This is mainly because of the lack of data on long-term ovarian function and pregnancies.<wbr> However, these guidelines were published before two of the larger studies became available, the POEMS-SWOG S0230 trial and the updated results of the PROMISE-GIM6 study</EM>.<wbr>&rdquo; Dr Matteo Lambertini, MD, (IRCCS AOU San Martino-IST, Genoa, Italy)<BR>&ldquo;<EM>I find this study by Dr Lambertini and colleagues important for several reasons.<wbr> At the 2015 European Cancer Congress we want to present and discuss new data with the patients in focus.<wbr> Thanks to a global collaboration with data available from several studies, it is possible to reinforce a benefit of LHRHa treatment for all the women with breast cancer who still want to have the option to become pregnant.<wbr> Survivorship of cancer patients is of major importance for the cancer community and, at the Congress, teams from different professions have a chance to evaluate and discuss new data</EM>.<wbr>&rdquo; Professor Peter Naredi, the ECCO scientific co-chair </div><div style="margin-bottom: 10px;">The meta-analysis included 12 randomised trials and a total of 1,231 breast cancer patients receiving chemotherapy, with or without LHRHa.<wbr><BR>&bull; In the eight relevant trials, the overall reduction in POF with the addition of LHRHa was still striking : Rates were reduced by 45% with LHRHa, and this time there was close agreement in results from all studies.<wbr><BR>&bull; The use of LHRHa was originally developed to preserve ovarian function rather than fertility, and only five of the studies reported on pregnancies after breast cancer treatment.<wbr><BR>&bull; In these studies, overall there were 33 patients with pregnancies among those who received LHRHa alongside chemotherapy, and 19 among those who did not.<wbr> This was an 83% increase in the chance of becoming pregnant.<wbr><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10707_7_breast%20cancer%206.png"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10707_1_ESMO%20Breast%20Cacner%202015.JPG"> </div><div style="margin-bottom: 10px;">Early Breast Cancer Treatment Management: preliminary data from a EURECCA international comparison&rdquo;.<wbr> Breast cancer - early disease proffered paper session, 09.<wbr>15-11.<wbr>15 hrs (CEST), Sunday 27 September, Hall D1.<wbr> It is the European Registration of Cancer Care (EURECCA) study  compared the treatment patterns of 119,125 patients aged 70 and older in Belgium, Ireland, The Netherlands, Portugal, Poland and the UK,  who were diagnosed with non-metastatic (stage I, II or III) breast cancer between 2000 and 2014.<wbr> The study also compared the number of patients alive five years after breast cancer diagnosis.<wbr> The research presented shows that the use of surgery, hormone therapy or chemotherapy varies substantially between countries depending on the stage of the breast cancer in elderly patients.<wbr> </div><div style="margin-bottom: 10px;">&ldquo;<EM>Based on a comparison of data from Belgium, Ireland and The Netherlands, surgery was omitted most frequently in older patients with stage III breast cancer.<wbr> The omission of surgery was lowest in Belgium at 15%, followed by The Netherlands at 28% and the highest was in Ireland at 37%</EM>,&rdquo; said Dr Derks.<wbr> </div><div style="margin-bottom: 10px;"><BR>&ldquo;<EM>For instance, the use of adjuvant hormone therapy in older patients with stage I disease was the lowest in The Netherlands at 21%, while in Ireland, Belgium, Portugal and Poland the use of adjuvant hormonal therapy varied between 82&ndash;88%.<wbr> Chemotherapy use was the lowest in The Netherlands for all stages of breast cancer in elderly patients.<wbr> For example, in elderly patients with stage III disease, the use of chemotherapy was the lowest in The Netherlands at nine percent, followed by Ireland (26%), Belgium (30%), Portugal (58%) and the highest in Poland at 78%</EM>,&rdquo; said Dr Derks.<wbr>.<wbr> </div><div style="margin-bottom: 10px;"><BR>Professor Peter Naredi, the ECCO scientific co-chair of the Congress, who was not involved in the research, commented: &ldquo;<EM>I am very pleased that collaborative groups present outcome data for different tumour types with a national perspective at this Congress.<wbr> In this presentation Dr Derks and co-workers show how differently we treat older breast cancer patients in different European countries.<wbr> These kind of data are absolutely necessary if we want to be able to decrease the inequalities in cancer care throughout Europe</EM>.<wbr>&rdquo; </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10707_2_breast%20cancer%201.png"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10707_3_breast%20cancer%202.png"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10707_4_breast%20cancer%203.png"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10707_5_breast%20cancer%204.png"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10707_6_breast%20cancer%205.png"> </div><!-- Comment details --><a name="oncology10707attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10707_1_ESMO%20Breast%20Cacner%202015.JPG">ESMO Breast Cacner 2015.JPG</a>&nbsp;&nbsp;(226,3 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10707_2_breast%20cancer%201.png">breast cancer 1.png</a>&nbsp;&nbsp;(224,7 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10707_3_breast%20cancer%202.png">breast cancer 2.png</a>&nbsp;&nbsp;(178,9 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10707_4_breast%20cancer%203.png">breast cancer 3.png</a>&nbsp;&nbsp;(195,5 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10707_5_breast%20cancer%204.png">breast cancer 4.png</a>&nbsp;&nbsp;(188,9 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10707_6_breast%20cancer%205.png">breast cancer 5.png</a>&nbsp;&nbsp;(134,8 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10707_7_breast%20cancer%206.png">breast cancer 6.png</a>&nbsp;&nbsp;(173,9 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20151231&edate=20150901&rec=10707">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-10-12T19:59:21+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-10-12T19:59:21+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Suitability of National HTA Procedures for Orphan Medicinal Products</title>
	<pubDate>2015-10-12T19:35:33+02:00</pubDate>
	<wp:post_id>6829</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;"><SPAN style="font-size: small;">Comment: At the recent European Pharmaceutical Pricing &amp; Reimbursement Conference held in London, Alexander Natz, Secretary General of the European Confederation of Pharmaceutical Entrepreneurs (EUCOPE), discussed whether HTA procedures in Europe are fit for purpose for Orphan Medicinal Products (OMP)</SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-size: small;">Key Challenges that result from the applicability of existing HTA procedures to OMPs are:</SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-size: small;"><U>Uneven availability of authorised OMPs across EU countries due to differences in Pricing and Reimbursement systems and societies willingness to pay </U></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-size: small;">An analysis of the acceptability of surrogate endpoints by the English, Scottish, German and French HTA procedures for various OMPs, highlights this point</SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-size: small;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11272_1_copiedImage%5b0%5d.png"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-size: small;"><U>Suboptimal value assessment of OMPs, given HTA procedures, which are not any different from that for non-orphan drugs, do not place emphasis on the severity of the disease and of the unmet medical need</U></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-size: small;">Traditional HTA approaches are overly reliant on cost effectiveness, and this is despite the fact OMP expenditure is only a small fraction of the total drug expenditure in the EU</SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-size: small;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11272_2_copiedImage%5b2%5d.png"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-size: small;">The relatively small budget impact of OMPs is explained by the fact that the proportion of marketing authorizations to orphan designations has remained stable, and not increased along with an increase in the number of designations </SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-size: small;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11272_3_copiedImage%5b4%5d.png"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-size: small;"><U>Delayed access post EU marketing authorizations due to P&amp;R decisions </U></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-size: small;"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-size: small;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11272_4_copiedImage%5b6%5d.png"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-size: small;">Some of the solutions proposed by Alexander Natz were:</SPAN> </div><div><UL><LI><SPAN style="font-size: small;">More national HTA procedures to include OMP specific criteria to take into account social value, severity of the disease and severity of unmet medical need</SPAN>
</LI>
<LI><SPAN style="font-size: small;">Facilitation of earlier access to patients via different mechanisms (e.<wbr>g.<wbr> Authorization of Temporary Use (ATU) in France, ongoing pilots on adaptive pathways&hellip;)</SPAN>
</LI>
<LI><SPAN style="font-size: small;">Removal of restrictions on paid early access programs</SPAN>
</LI>
<LI><SPAN style="font-size: small;">EU wide rare disease care and diagnosis programs</SPAN>
</LI>
</UL> </div><!-- Comment details --><a name="pharmaworld11272attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11272_1_copiedImage%5b0%5d.png">copiedImage[0].png</a>&nbsp;&nbsp;(107,6 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11272_2_copiedImage%5b2%5d.png">copiedImage[2].png</a>&nbsp;&nbsp;(37,3 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11272_3_copiedImage%5b4%5d.png">copiedImage[4].png</a>&nbsp;&nbsp;(45,7 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11272_4_copiedImage%5b6%5d.png">copiedImage[6].png</a>&nbsp;&nbsp;(71,8 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20151231&edate=20150901&rec=11272">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-10-12T19:35:33+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-10-12T19:35:33+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>FDA Approves Allergan Juvederm Ultra XC Filler For Lip Augmentation</title>
	<pubDate>2015-10-12T17:33:29+02:00</pubDate>
	<wp:post_id>6830</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The FDA has approved Juvederm, the first and only filler for lip augmentation.<wbr> This new filler has a duration of up to one year </div><div style="margin-bottom: 10px;">Philippe Schaison, Executive Vice President &amp; President, Allergan Medical reported "As the leader in medical aesthetics, Allergan is committed to continued research and development in this area.<wbr> Providing physicians and patients with premium products that allow them to achieve the aesthetic results they want is always our goal.<wbr> Understanding that the desire with lip augmentation is to achieve a natural-looking and lasting result, we continued our research of JUVEDERM<SUP>&reg;</SUP> ULTRA XC for the lips.<wbr> With this approval, JUVEDERM<SUP>&reg;</SUP> ULTRA XC is now the only filler that is approved to last up to one year in the lips while providing natural-looking results.<wbr>" </div><div style="margin-bottom: 10px;">JUVEDERM<SUP>&reg;</SUP> ULTRA XC is a smooth gel formulation made up of a modified form of hyaluronic acid (HA).<wbr> Allergan have previously highlighted that they remain committed to investing in research, especially in products that have already progressed to later stage clinical trials.<wbr> </div><div>Source: Allergan </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20151231&edate=20150901&rec=8207">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-10-12T17:33:29+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-10-12T17:33:29+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Merz Has Initiated pIII Studies For AUL And ALL In Japan Only</title>
	<pubDate>2015-10-12T17:29:38+02:00</pubDate>
	<wp:post_id>6831</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Merz has initiated Japanese only studies for AUL and ALL both in pIII.<wbr> Under the drug name NT201, both interventional studies are expected to complete April 2018 and October 2018 respectively.<wbr> </div><div style="margin-bottom: 10px;">A brief outline of each of the studies are below </div><div style="margin-bottom: 10px;"><TABLE border="1" cellpadding="0" cellspacing="0" style="width: 680px;"><TBODY><TR><TD valign="top" width="274">
<P>Title</P>
</TD>
<TD valign="top" width="104">
<P><STRONG>JapicCTI-No.<wbr></STRONG></P>
</TD>
<TD valign="top" width="57">
<P>Sample</P>
</TD>
<TD valign="top" width="113">
<P>Dosage</P>
</TD>
<TD valign="top" width="66">
<P>Study start</P>
</TD>
<TD valign="top" width="66">
<P>Study finish</P>
</TD>
</TR>
<TR><TD valign="top" width="274">
<P>Non-blind test Shinobi of test period will consider the effectiveness of the different 2 doses in the treatment of upper limb spasticity after stroke NT 201 and safety and the non-blind test continuity test period with prospective double-blind randomized multicenter collaborative placebo</P>
</TD>
<TD valign="top" width="104">
<P>JapicCTI-153029</P>
</TD>
<TD valign="top" width="57">
<P>99</P>
</TD>
<TD valign="top" width="113">
<P>400mg per intramuscular inj</P>
</TD>
<TD valign="top" width="66">
<P>09/<wbr>2015</P>
</TD>
<TD valign="top" width="66">
<P>04/<wbr>2018</P>
</TD>
</TR>
<TR><TD valign="top" width="274">
<P>To investigate the safety and efficacy of NT-201 for the treatment of lower limb spasticity after stroke with Shinobu of period non-blind test and non-blind test continuity test prospective double-blind randomized multicenter collaborative placebo</P>
</TD>
<TD valign="top" width="104">
<P>JapicCTI-153030</P>
</TD>
<TD valign="top" width="57">
<P>164</P>
</TD>
<TD valign="top" width="113">
<P>400mg per intramuscular inj</P>
</TD>
<TD valign="top" width="66">
<P>09/<wbr>2015</P>
</TD>
<TD valign="top" width="66">
<P>10/<wbr>2018</P>
</TD>
</TR>
</TBODY>
</TABLE> </div><div style="margin-bottom: 10px;">Allergan followed a similar strategy for ALL, which was presented at the WCNR in 2012 but these results were available before the Western studies had all completed.<wbr> For Merz, a submission for AUL has already been made and the results for ALL are expected to be available later this year/<wbr>next year, well before these Japanese studies have completed.<wbr> </div><div>Source: <a href="http://www.clinicaltrials.jp" class="defaultlink" title="http://www.clinicaltrials.jp">clinicaltrials.jp</a> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20151231&edate=20150901&rec=8205">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-10-12T17:29:38+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-10-12T17:29:38+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Allergan Has Terminated AUL Study For The Elbow And Shoulder</title>
	<pubDate>2015-10-09T20:36:21+02:00</pubDate>
	<wp:post_id>6832</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Allergan have recently terminated the study OnabotulinumtoxinA Treatment in Adult Patients With Upper Limb Spasticity with the primary outcome measure in the elbow and secondary measure in the shoulder.<wbr> This is a key study in which was thought to be a stepping stone to indication expansion.<wbr> </div><div style="margin-bottom: 10px;">The study which started in May 2014 with a primary completion date of December 2015 was in phase III.<wbr> It was conducted in centres in the US and Canada.<wbr> The reason for the termination is unknown but shows that Allergan no longer want to focus on extending the label to include the shoulder </div><div>Source: clinicaltrails.<wbr>gov NCT02145676 </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20151231&edate=20150901&rec=8204">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-10-09T20:36:21+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-10-09T20:36:21+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Allergan Has Partnered with Humana To Address Population Health and Caregiving</title>
	<pubDate>2015-10-09T20:20:20+02:00</pubDate>
	<wp:post_id>6833</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><UL><LI><UL><LI>Variety of Diseases &ndash; Improving health of patients with central nervous system conditions, including Alzheimer's disease, as well as glaucoma and other eye diseases with opportunities to expand into other therapeutic areas as the collaboration progresses.<wbr>
</LI>
</UL>
</LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI><UL><LI>Patient/<wbr>Caregiver Relationship &ndash; Obtain a clearer picture of the attributes associated with caregiver burden from the caregiver perspective, and how self-reported caregiver burden relates to healthcare-related utilization and costs.<wbr>
</LI>
</UL>
</LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI><UL><LI>Interventional Research &ndash; Conduct research based on interventional practices and predictive analytics, with a focus on treatment adherence, to ensure patients obtain the right medications at the right time.<wbr>
</LI>
</UL>
</LI>
</UL> </div><div> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20151231&edate=20150901&rec=8203">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-10-09T20:20:20+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-10-09T20:20:20+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>The Study Investigating BOTOX® In The Treatment Of Knee Osteoarthritis Has Completed Recruitment</title>
	<pubDate>2015-10-09T17:02:18+02:00</pubDate>
	<wp:post_id>6834</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20151231&edate=20150901&rec=8202">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-10-09T17:02:18+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-10-09T17:02:18+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Heat Biologics' HS-410 Completed Enrollment For Its Ph2 Trial In High Risk NMIBC</title>
	<pubDate>2015-10-09T12:44:54+02:00</pubDate>
	<wp:post_id>6835</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Heat Biologics announced that it has completed enrolment of the full 75 patients into its 3-arm Ph2 randomized controlled trial to evaluate safety and efficacy of HS410+BCG versus BCG alone in high risk NMIBC patients.<wbr> This represented a significant milestone in light of current BCG shortage and therefore anticipation of delayed in progression of the trials that are targeting this patient population.<wbr> The Ph1 results are expected to report by the end of 2015 and likely will be communicated at ASCO GU/<wbr>ASCO 2016.<wbr> The topline results for the Ph2 will be reported in the Q4 2016.<wbr> </div><div style="margin-bottom: 10px;">This is a multicentre trial including US-only centres (~16 sites).<wbr> Lead centre is in the University of Chicago.<wbr> The safety profile remained positive with no serious adverse effects reported.<wbr> Data read out is expected in Q4 2016.<wbr> (NCT02010203) </div><div style="margin-bottom: 10px;">Patient population: high risk NMIBC patients (Ta, T1, CIS) </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10705_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;">Heat Biologics is also enrolling an additional 25 patients to evaluate HS-410 as a monotherapy in an unblinded, open-label arm, which the company expects to complete by late 2015/<wbr>early 2016.<wbr> </div><div>Source: Heat Biologics Press Release </div><!-- Comment details --><a name="oncology10705attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10705_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(60,7 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10705_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(60,9 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20151231&edate=20150901&rec=10705">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-10-09T12:44:54+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-10-09T12:44:54+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Ascend Biopharmaceuticals' ASN002 Entered Ph1/2 For nBCC</title>
	<pubDate>2015-10-09T11:40:16+02:00</pubDate>
	<wp:post_id>6836</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Ascend biopharm, a Melbourne based immunotherapy company, announced its ASN-002 has entered Ph1/<wbr>2 study in nodular basal cell carcinoma (nBCC).<wbr> Unresectable nBCC currently has no alternative pharmacological options and therefore represents a high unmet need for an estimated 0.<wbr>5M patients across US, Australia and EU.<wbr> Other applications for ASN-002 also include cutaneous lymphomas, bladder cancer, and ovarian cancer.<wbr> </div><div style="margin-bottom: 10px;">Ascend Biopharmaceuticals entered into an exclusive world-wide license agreement with Transgene in July of 2013 to develop TG1042 (renamed as ASN-002) as an immunotherapy for multiple cancers including skin cancers and Cutaneous B-Cell Lymphoma, CBCL (a B-Cell lymphoma that involves the skin).<wbr> <BR>ASN-002 is an immunotherapy based on a virus engineered to destroy cancer cells when injected directly into the cancer.<wbr> </div><div style="margin-bottom: 10px;"><UL><LI>a genetically modified form of human adenovirus type 5 engineered to express the cytokine interferon-gamma (IFN-y)
</LI>
<LI>When injected into the tumour, the adenovirus infection produces interferon-gamma and interferon-alpha (as a response to the viral infection) locally resulting in an immune response against the cancer in addition to shutting off the blood supply into the cancer and causing the cancer cells to enter a process of programmed self destruction termed apoptosis.<wbr>
</LI>
<LI>ASN-002 has been modified to be safe as the virus will not replicate after entering the cancer cells.<wbr>
</LI>
</UL> </div><div style="margin-bottom: 10px;">Previous study reported the delivery of ASN-002 into the lesions resulted in 54% of treated patients with a complete response (where all lesions disappeared) and 31% of the treated patients with a partial response (where at least half of all treated lesions disappeared), demonstrating that more than 80% of lesions responded to this therapy.<wbr> </div><div style="margin-bottom: 10px;">"Primary cutaneous B cell lymphomas are rare but a disfiguring disease with significant unmet medical needs.<wbr> Intralesional TG1042 (ASN-002) therapy is well tolerated and results in lasting tumor regressions&rdquo; said Professor Reinhard Dummer, Principal Investigator on the study and an expert in Cutaneous Lymphoma at the University of Zurich.<wbr> </div><div style="margin-bottom: 10px;">Primary CBCLs has an annual incidence rate of approximately 3.<wbr>1 per 1,000,000 persons and comprises about 20&ndash;25% of all cutaneous lymphomas.<wbr> Currently, treatment options for CBCL are confined to surgery or radiation therapy and there are no registered drugs for this indication.<wbr> Radiation therapy or surgery both show a high initial response rate but up to 50% of the patients relapse following the initial treatment </div><div style="margin-bottom: 10px;">Other pipeline includes ASN004 in breast cancer and ASN008 (myeloid targeting) </div><div style="margin-bottom: 10px;">ASN-004 - Breast Cancer o ASN-004 is an improved version of a vaccine and platform developed at Melbourne&rsquo;s Burnet Institute.<wbr> o Treatment can address breast cancer which afflicts over 500,000 individuals in the US, Western Europe and Japan.<wbr> o Predecessor to ASN-004 studied in a series of investigator-led clinical trials by the Burnet Institute in Australia and Overseas over a 15-year period.<wbr> o Study found eight out of 15 patients (53%) in placebo group had cancer recurrence compared to one out of 16 (6%) in the treated group at the 10-year mark.<wbr> </div><div style="margin-bottom: 10px;">ASN-008: ASN-008 Myeloid Targeting can preferentially deliver a variety of different types of biological and small molecule payloads preferentially to Myeloid Dendritic Cells but also Myeloid Derived Suppressor Cells within the Tumour microenvironment.<wbr> </div><div style="margin-bottom: 10px;"><UL><LI>RNA alphavirus vectors (expressing cytokines and antibody fragments against checkpoint inhibitors
</LI>
<LI>TLR8 Agonists
</LI>
<LI>Small molecule chemotherapeutic drugs effective for treating MDSC
</LI>
</UL> </div><div style="margin-bottom: 10px;">Company Key Personnel </div><div style="margin-bottom: 10px;"><UL><LI>Dr Clement Leong, CEO Over 20 years&rsquo; experience in biotechnology and venture capital.<wbr> Former SciVentures Investments Director.<wbr>
</LI>
<LI>Dr Paul Weiden, Chief Medical Officer : More than 10 years&rsquo; biotech experience.<wbr> Former Medical Director, Dendreon Corporation.<wbr>
</LI>
<LI>Dr Geoffrey Pietersz, Chief Technology Officer:More than 30 years&rsquo; experience in immunology and bioorganic chemistry.<wbr> Co-inventor of key technologiesKey Personnel
</LI>
</UL> </div><div>Source: Ascend Biopharm Press Release </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20151231&edate=20150901&rec=10703">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-10-09T11:40:16+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-10-09T11:40:16+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Norgine Reports Positive Ph3 Top-Line Data of its Low Volume Bowel Preparation</title>
	<pubDate>2015-10-09T09:31:14+02:00</pubDate>
	<wp:post_id>6837</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Norgine has announced that top-line results from the <a href="https://clinicaltrials.gov/ct2/show/NCT02254486?term=noct&amp;rank=1" class="defaultlink">NOCT</a>study met both of its primary endpoints (efficacy), however no data were disclosed.<wbr> According to the company, complete results will be submitted to a scientific meeting in 2016 (date and place not specified).<wbr> The NER1006 Ph3 clinical trials programme also includes 2 additional multicentre, randomised, parallel-group clinical trials, MORA and DAYB, expected to complete in January 2016.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Norgine @ UEGW 2015</STRONG> </div><div style="margin-bottom: 10px;">Free paper session on Tuesday 27th October: <A href="https://uegw.congress-online.com/guest/AbstractView?ABSID=10178">https:/<wbr>/<wbr>uegw.<wbr>congress-online.<wbr>com/<wbr>guest/<wbr>AbstractView?ABSID=10178</A> </div><div style="margin-bottom: 10px;"><STRONG>Key Intelligence Questions that we will try to address:</STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>What is the potential label for this product based on its efficacy results? </LI>
<LI>What are the regulatory timelines for the EU/<wbr>US ? </LI>
<LI>Do Norgine has partnership intent ex EU ? </LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG>Ph3 Programs</STRONG> </div><div style="margin-bottom: 10px;">NOCT study see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20151231&edate=20150901&rec=2050" class="defaultlink">GastroEnterology2050: First Patient Enroled in Norgine US Ph3 to Assess Novel Low Volume Bowel Preparation</a> : PE is the use of Harefield cleansing scale to grade bowel cleansing efficacy </div><div>DAYB study and MORA study see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20151231&edate=20150901&rec=2105" class="defaultlink">GastroEnterology2105: EU Registration Trials for Norgine's Novel Low Volume Bowel Preparation</a> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20151231&edate=20150901&rec=2577">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-10-09T09:31:14+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-10-09T09:31:14+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Walmark Acquired Fellow Czech Company Valosun and its Biopron and Uroval Brands</title>
	<pubDate>2015-10-08T17:22:29+02:00</pubDate>
	<wp:post_id>6838</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: <A href="http://www.czechmedical.com/en/company-list/category-pharmaceuticals/category-drugs/walmark">Walmark</A> is one of the leading VMS manufacturers and distributors in Central and Eastern Europe (CEE), and also manufactures OTC medicines.<wbr> Valosun's Biopron brand offers a range of probiotic and prebiotic formulations.<wbr> Financial terms were not disclosed.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The deal is reported : </div><div style="margin-bottom: 10px;"><UL><LI>to complement its existing presence in the key Czech and Slovak markets</LI>
<LI>to extend its digestive health position, and strengthen its female urinary health segment</LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Founded in 1990 </div><div style="margin-bottom: 10px;">The Czech company has foreign subsidiaries in 7 countries – Bulgaria, Estonia, Hungary, Latvia, Lithuania, Poland and Romania – and sells its products in more than 30 other countries.<wbr> </div><div style="margin-bottom: 10px;">The company's key VMS brands include: </div><div style="margin-bottom: 10px;"><UL><LI>ArthroStop for joint and bone health, </LI>
<LI>GinkoPrim for blood circulation, </LI>
<LI>MiniMartians for children's health, </LI>
<LI>Prostenal for prostate health, and </LI>
<LI>Urinal for lower urinary tract health.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2575_1_copiedImage%5b0%5d.png"> </div><!-- Comment details --><a name="gastroenterology2575attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2575_1_copiedImage%5b0%5d.png">copiedImage[0].png</a>&nbsp;&nbsp;(572,1 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20151231&edate=20150901&rec=2575">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-10-08T17:22:29+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-10-08T17:22:29+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>ESMO 2015 Prostate Cancer Highlight 1 - Focusing On Astellas and J&J</title>
	<pubDate>2015-10-08T17:11:48+02:00</pubDate>
	<wp:post_id>6839</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: J&amp;J and Astellas are the two companies that both have an approved 2nd generation of hormonal agents for metastatic castration resistant prostate cancer.<wbr> During ECC 2015, Astellas sponsored a satellite symposia with an emphasis on patient-centricity and treatment personalization in mCRPC.<wbr> J&amp;J, by contrast, did not sponsor an ECC 2015-affiliated satellite symposium, instead holding an independent physician forum on the 26th September.<wbr> Both companies are evidently competing to increase share of voice to achieve leadership in prostate cancer.<wbr> More importantly, Astellas communication strategy on its booth was encouraging oncologists to use Xtandi earlier in the mCRPC setting while suggesting Eligard should be the choice for backbone therapy (either with 2nd generation hormone agents such as Xtandi or with docetaxel).<wbr> Notably, Astellas has taken backbone therapy concept forward making it one of the main key messages for Astellas on its Eligard promotion.<wbr> </div><div style="margin-bottom: 10px;">Astellas Communication Strategy at ECC2015: </div><div style="margin-bottom: 10px;">1) Booth Communication: Astellas communication strategy for prostate cancer this year at the booth includes a dedicated section for both Eligard and Xtandi to encourage oncologists to use Xtandi earlier in the mCRPC setting while Eligard could be the choice for backbone therapy (either with second generation hormone agents such as Xtandi or chemotherapy with docetaxel) throughout the disease continuum.<wbr> </div><div style="margin-bottom: 10px;"><P style="margin: 0in;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11268_33_1.png"> <img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11268_34_2.jpag.png"></P> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11268_1_copiedImage%5b2%5d.png"> </div><div style="margin-bottom: 10px;"><P style="margin: 0in;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11268_2_copiedImage%5b4%5d.png"></P> </div><div style="margin-bottom: 10px;">2) Industry Sponsored Symposium - focusing on patient-centricity and treatment personalization in mCRPC: The symposium was chaired by Professor Johann de Bono.<wbr> In the past, the communication strategy for Astellas had always been focused on differentiation and defending against Zytiga.<wbr> This year at ECC, Astellas' symposium had moved away the defending strategy and shifted the focus towards treatment personalization in prostate cancer.<wbr> </div><div style="margin-bottom: 10px;">Dr Gillessen discussed the key takeaways from the first St Gallen Advanced Prostate Cancer Consensus that took place in March 2015.<wbr> </div><div style="margin-bottom: 10px;">Do: </div><div style="margin-bottom: 10px;"><OL type="1"><LI value="1">Measure testosterone before calling someone castration resistant
</LI>
<LI>Baseline staging examinations including imaging before starting a treatment for CRPC
</LI>
<LI>Perform treatment monitoring (including imaging) for men on survival prolonging agents for CRPC: PSA alone is NOT sufficient
</LI>
</OL> </div><div style="margin-bottom: 10px;"><OL type="1"><LI value="4">Inform your patients about the possibility to join a clinical trial
</LI>
</OL> </div><div style="margin-bottom: 10px;">Don't: </div><div style="margin-bottom: 10px;"><OL type="1"><LI value="1">Routinely add bicalutamide in a man progressing on ADT if abiraterone or enzalutamide are available
</LI>
<LI>Stop a treatment with a life prolonging agent in a man with CRPC based on PSA rise only
</LI>
</OL> </div><div style="margin-bottom: 10px;">Dr.<wbr> S Chowdhury (UK) and Dr A Heidenreich (Germany) discussed the clinical factors that physicians should be considering while making clinical decision for mCRPC patients.<wbr> Prof de Bono closed the symposium by discussing the importance of molecular stratification for CRPC identified with critically important therapeutic implications.<wbr> A range of potential biomarkers - namely AR-V7 was discussed to help individualise treatment and hence to optimize outcomes.<wbr> More importantly, genomic sequencing of metastatic CRPC in hypothesis driven trials of targeted drugs is feasible and can impact understanding of prostate cancer.<wbr> Novel and adaptive trial designs focused on characterising predictive biomarkers are feasible and may de-risk clinical development.<wbr> Olaparib (a PARP inhibitor) was used as an example.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11268_3_ScreenCapture1.jpg"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11268_4_ScreenCapture2.jpg"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11268_5_ScreenCapture3.jpg"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11268_6_ScreenCapture4.jpg"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11268_7_ScreenCapture5.jpg"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11268_8_ScreenCapture6.jpg"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11268_9_ScreenCapture7.jpg"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11268_10_ScreenCapture8.jpg"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11268_11_ScreenCapture9.jpg"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11268_13_ScreenCapture11.jpg"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11268_14_ScreenCapture12.jpg"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11268_15_ScreenCapture13.jpg"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11268_16_ScreenCapture14.jpg"> </div><div style="margin-bottom: 10px;">Ph2 Xtandi's data in neoadjuvant setting for patients undergoing prostatectomy for localized prostate cancer was presented by Dr Bruce Montgomery during proffered session.<wbr> The objective was to assess clinical benefit of neoadjuvant therapy with pathologic complete response rates (pCRs) as the primary end point.<wbr> The neoadjuvant concept is with an aim of early treatment can optimize local control and treat micrometastatic disease.<wbr> A total of 52 men were enrolled in the trial (25 pts in EnzaLeuprorelinDut arm versus 27 patients in enzalutamide monotherapy arm).<wbr> In the treatment arm with EnzaLeuprorelinDut, 2/<wbr>23 (8.<wbr>7%) achieved pathologic complete response and in the monotherapy arm there was no patient achieved pathologic complete response.<wbr> Dr Montgomery noted that pathologic complete response rates observed in this study with Enzalutamide +ADT is comparable to previously reported studies and long term clinical significance of pathological complete response , near complete response, and residual cancer burden remain uncertain.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11268_17_ScreenCapture15.jpg"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11268_18_ScreenCapture16.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11268_19_ScreenCapture17.jpg"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11268_20_ScreenCapture18.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11268_21_ScreenCapture19.jpg"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11268_22_ScreenCapture20.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11268_23_ScreenCapture21.jpg"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11268_24_ScreenCapture22.jpg"> </div><div style="margin-bottom: 10px;">J&amp;J Communication Strategy at ECC2015: J&amp;J did not sponsor an ECC 2015-affiliated satellite symposium, instead holding an independent physician forum on the 26th September.<wbr> This forum was positioned as an education debate specifically for oncology professionals, with the invitation only advertised through the Janssen Oncology portal and ESMO oncologyPRO online resource.<wbr> The Janssen intention is to move towards more patient-centric, physician-focused conference events and avoid the &ldquo;participant bias&rdquo; that often occurs due to a large number of industry participants at satellite symposia.<wbr> </div><div style="margin-bottom: 10px;"><P style="font-size: 11pt; font-family: Calibri; margin: 0in;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11268_25_copiedImage%5b6%5d.png"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11268_26_copiedImage%5b8%5d.png"></P> </div><div style="margin-bottom: 10px;">J&amp;J Booth Communication: Janssen booth panels focused on patient-centric communication highlighting Zytiga&rsquo;s data (e.<wbr>g.<wbr> related to fatigue and seizures) and details of the pan-European prostate cancer survey.<wbr> The survey results highlight that prostate cancer is a disease that not only affects the physical functioning of a man, but also has a huge impact on his emotions and the lives of those who care for him.<wbr> There is a variation between European countries in terms of management to address patients' quality of life.<wbr> </div><div style="margin-bottom: 10px;">Key Primary Insights on the development programmes of Zytiga and ARN509: </div><div style="margin-bottom: 10px;"><UL type="disc"><LI>ARN509 trial (ATLAS) Ph3 high risk patients : Randomized, Double-blind, Placebo-controlled Phase 3 Study of ARN509in Subjects With High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment With Primary Radiation Therapy.<wbr> FPI has just occurred in Sept 2015, and recruitment currently still ongoing.<wbr> and Development of ARN-509 continues with ATLAS the second phase III trial now recruiting
</LI>
</UL> </div><div style="margin-bottom: 10px;">Experimental arm: ARN509 </div><div style="margin-bottom: 10px;">Participants will receive ARN509 (240 mg) daily, by mouth for 28 months plus bicalutamide placebo by mouth, once daily, for four months from randomization.<wbr> All participants are treated with gonadotropin releasing hormone (GnRH - agonist) for 28 months from randomization and radiation therapy to the prostate started at about 8 weeks after randomization.<wbr> </div><div style="margin-bottom: 10px;">Active Comparator: Control group </div><div style="margin-bottom: 10px;">Participants will receive bicalutamide 50 mg, by mouth, once daily, for 4 months plus JNJ-56021927 placebo once daily for 28 months from randomization.<wbr> All participants are treated with GnRH (agonist) for 28 months from randomization and radiation therapy to the prostate started at about 8 weeks after randomization.<wbr> </div><div style="margin-bottom: 10px;"><UL type="disc"><LI>The phase III Zytiga+ADT vs ADT in high risk newly diagnose metastatic hormone sensitive patients (NCT01715285) has completed recruitment.<wbr> The Actual accrual is 1209 patients
</LI>
</UL> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11268_27_copiedImage%5b10%5d.png"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11268_28_copiedImage%5b12%5d.png"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11268_29_copiedImage%5b14%5d.png"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11268_30_copiedImage%5b16%5d.png"> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11268_31_copiedImage%5b18%5d.png"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11268_32_copiedImage%5b20%5d.png"> </div><!-- Comment details --><a name="pharmaworld11268attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11268_1_copiedImage%5b2%5d.png">copiedImage[2].png</a>&nbsp;&nbsp;(1,9 MB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11268_2_copiedImage%5b4%5d.png">copiedImage[4].png</a>&nbsp;&nbsp;(1,4 MB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11268_3_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(53,9 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11268_4_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(64 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11268_5_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(54,2 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11268_6_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(48,2 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11268_7_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(51,3 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11268_8_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(56,3 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11268_9_ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(51,7 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11268_10_ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(61,7 KB)<br>&nbsp;&nbsp;11.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11268_11_ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(48,7 KB)<br>&nbsp;&nbsp;12.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11268_12_ScreenCapture10.jpg">ScreenCapture10.jpg</a>&nbsp;&nbsp;(49,5 KB)<br>&nbsp;&nbsp;13.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11268_13_ScreenCapture11.jpg">ScreenCapture11.jpg</a>&nbsp;&nbsp;(61,6 KB)<br>&nbsp;&nbsp;14.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11268_14_ScreenCapture12.jpg">ScreenCapture12.jpg</a>&nbsp;&nbsp;(63,2 KB)<br>&nbsp;&nbsp;15.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11268_15_ScreenCapture13.jpg">ScreenCapture13.jpg</a>&nbsp;&nbsp;(50,2 KB)<br>&nbsp;&nbsp;16.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11268_16_ScreenCapture14.jpg">ScreenCapture14.jpg</a>&nbsp;&nbsp;(60,9 KB)<br>&nbsp;&nbsp;17.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11268_17_ScreenCapture15.jpg">ScreenCapture15.jpg</a>&nbsp;&nbsp;(66,1 KB)<br>&nbsp;&nbsp;18.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11268_18_ScreenCapture16.jpg">ScreenCapture16.jpg</a>&nbsp;&nbsp;(51,6 KB)<br>&nbsp;&nbsp;19.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11268_19_ScreenCapture17.jpg">ScreenCapture17.jpg</a>&nbsp;&nbsp;(55,6 KB)<br>&nbsp;&nbsp;20.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11268_20_ScreenCapture18.jpg">ScreenCapture18.jpg</a>&nbsp;&nbsp;(55 KB)<br>&nbsp;&nbsp;21.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11268_21_ScreenCapture19.jpg">ScreenCapture19.jpg</a>&nbsp;&nbsp;(44,7 KB)<br>&nbsp;&nbsp;22.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11268_22_ScreenCapture20.jpg">ScreenCapture20.jpg</a>&nbsp;&nbsp;(57,7 KB)<br>&nbsp;&nbsp;23.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11268_23_ScreenCapture21.jpg">ScreenCapture21.jpg</a>&nbsp;&nbsp;(52,7 KB)<br>&nbsp;&nbsp;24.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11268_24_ScreenCapture22.jpg">ScreenCapture22.jpg</a>&nbsp;&nbsp;(46,1 KB)<br>&nbsp;&nbsp;25.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11268_25_copiedImage%5b6%5d.png">copiedImage[6].png</a>&nbsp;&nbsp;(517,9 KB)<br>&nbsp;&nbsp;26.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11268_26_copiedImage%5b8%5d.png">copiedImage[8].png</a>&nbsp;&nbsp;(300,3 KB)<br>&nbsp;&nbsp;27.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11268_27_copiedImage%5b10%5d.png">copiedImage[10].png</a>&nbsp;&nbsp;(112,6 KB)<br>&nbsp;&nbsp;28.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11268_28_copiedImage%5b12%5d.png">copiedImage[12].png</a>&nbsp;&nbsp;(86,2 KB)<br>&nbsp;&nbsp;29.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11268_29_copiedImage%5b14%5d.png">copiedImage[14].png</a>&nbsp;&nbsp;(97,1 KB)<br>&nbsp;&nbsp;30.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11268_30_copiedImage%5b16%5d.png">copiedImage[16].png</a>&nbsp;&nbsp;(124,9 KB)<br>&nbsp;&nbsp;31.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11268_31_copiedImage%5b18%5d.png">copiedImage[18].png</a>&nbsp;&nbsp;(1 014 KB)<br>&nbsp;&nbsp;32.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11268_32_copiedImage%5b20%5d.png">copiedImage[20].png</a>&nbsp;&nbsp;(142,4 KB)<br>&nbsp;&nbsp;33.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11268_33_1.png">1.png</a>&nbsp;&nbsp;(1,6 MB)<br>&nbsp;&nbsp;34.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11268_34_2.jpag.png">2.jpag.png</a>&nbsp;&nbsp;(1,5 MB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20151231&edate=20150901&rec=11268">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-10-08T17:11:48+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-10-08T17:11:48+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Synthetic Biologics Initiates Second Ph2 with SYN-010 for IBS-C</title>
	<pubDate>2015-10-08T16:00:59+02:00</pubDate>
	<wp:post_id>6840</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: As the patients complete the first Phase 2 clinical trial, they are eligible to immediately rollover into the second Phase 2 clinical trial of SYN-010 that will evaluate the ability of SYN-010 to sustain the reduction in breath methane levels, and the frequency of CSBM, abdominal pain and bloating.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">REF NCT02493036 </div><div style="margin-bottom: 10px;">PE: to evaluate the sustainability of the effect of one dose strength of SYN-010 on breath methane production in breath methane-positive patients with IBS-C.<wbr> </div><div style="margin-bottom: 10px;">Secondary objectives include evaluating the reduction in abdominal pain and bloating, and the increase in CSBM.<wbr> </div><div style="margin-bottom: 10px;">Recruitment: Approximately 60 patients, who complete the first Ph2 clinical trial of SYN-010 (NCT02495623), are eligible to immediately rollover into the second Phase 2 clinical trial of SYN-010.<wbr> </div><div style="margin-bottom: 10px;">Design: multi-center, open-label study </div><div><EM>Source: Synthetic Biologics</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20151231&edate=20150901&rec=2572">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-10-08T16:00:59+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-10-08T16:00:59+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Lallemand to Launch Probiotic 2.0 at Next CPhI</title>
	<pubDate>2015-10-08T11:08:21+02:00</pubDate>
	<wp:post_id>6841</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The new concept in probiotics formulation will be presented during CPhI (Madrid Oct 13-15).<wbr> It is the synergetic association of documented probiotic bacteria and yeast (S.<wbr> boulardii), for overall digestive health, from oral health to gut microbiota balance.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">In addition, Lallemand will be presenting a new range of probiotics targeted to the immunity market as well as its full line of ready-to-market probiotic formula and strains for custom formulations in other areas such as gut health, emotional equilibrium, women’s health or oral health.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Lallemand Inc.<wbr> is a privately held Canadian company specializing in the development, production, and marketing of yeasts and bacteria.<wbr> </div><div style="margin-bottom: 10px;">The company is divided into two major groups: </div><div style="margin-bottom: 10px;"><UL><LI>Yeast Group (based in Montreal, Canada) and </LI>
<LI>Specialties Group (based in Toulouse, France)</LI>
</UL> </div><div style="margin-bottom: 10px;">Has developed a portfolio of probiotic strains and strains combinations to address various issues of immune health for different target population groups.<wbr> They are prevention of infections or atopic disorders in children; prevention of chronic or acute infections in at-risk adults (under chronic stress, athletes) and immune modulation in seniors susceptible to lower immune response or chronic inflammation (inflammaging).<wbr> </div><div>These strains can be formulated into specific solutions, associated to certain vitamins or minerals for example, in formats adapted to each target population: capsules, convenient orodispersible sticks, sachets to dissolve in drinks or food.<wbr> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="GastroEnterology2584c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">With "Probiotic 2.<wbr>0", combining probiotic Bacteria + Yeast, Lallemand claims to provide an integrated offer for a holistic approach: GI Health and Oral Health.<wbr> The 7-page sales aid distributed on the booth at CPhI describes for each sphere (oral and GI) the synergic effect and the proven effcicacy of the combination.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Selected Pictures</STRONG> </div><div style="margin-bottom: 10px;"><IMG src="data:image/png;base64,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"> </div><div style="margin-bottom: 10px;"><IMG src="data:image/png;base64,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"> </div><div>Full document available on demand </div></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20151231&edate=20150901&rec=2571">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-10-08T11:08:21+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-10-08T11:08:21+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>ESMO Update - Expanding Horizons For Immunotherapy</title>
	<pubDate>2015-10-07T13:00:44+02:00</pubDate>
	<wp:post_id>6842</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: A host of immunotherapy (IT) data was presented at ESMO, including phII results with Roche's atezolizumab in platinum resistant urothelial cancer and BMS's phIII nivolumab data in renal cancer.<wbr> Merck, Roche and BMS all held satellite symposia focusing on their expanding portfolio of indications and potentially effective combinatorial regimens including chemotherapy that may expand the numbers of patients ameanable to treatment.<wbr> The registration strategy of these companies is to focus on the highest unmet need and then expand usage to earlier indications.<wbr> Metastatic settings are currently the focus although one of Joaquim Bellmont's slides during the Merck symposium did highlight BCG refractory NMIBC as a disease state ameanable to immunotherapy.<wbr> Both the Roche and Merck drugs are currently being evaluated in this setting in phI/<wbr>II studies sponsored by the NCI.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Roche's Registration Strategy</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10698_14_ScreenCapture14.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10698_17_ScreenCapture17.jpg"> </div><div style="margin-bottom: 10px;"><STRONG><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10698_15_ScreenCapture15.jpg"></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10698_18_ScreenCapture18.jpg"> </div><div style="margin-bottom: 10px;"><STRONG>Roche's Immunotherapy Activities At ESMO</STRONG> </div><div style="margin-bottom: 10px;">In addition to its symposia Roche also hosted an investor event focusing on its immunotherapy portfolio.<wbr> A mix of slides from both events is shown below as the messaging was fairly similar.<wbr> </div><div style="margin-bottom: 10px;">The latest findings from a phII pivotal trial in metastatic urothelial cancer were presented during a late-breaking abstract presentation by Dr Jonathon Rosenberg from Memorial Sloane Kettering Cancer Centre in New York.<wbr> He highlighted the results from a study undertaken in 311 heavily pre-treated patients with poor prognostic factors including 40% with &gt;2 prior treatments and 31% with liver metastases.<wbr> Treatment results in a response in 15% of the overall population increasing to 27% in patients with the highest level of PD-L1 expression.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10698_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10698_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10698_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10698_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10698_5_ScreenCapture5.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10698_6_ScreenCapture6.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10698_7_ScreenCapture7.jpg"> </div><div style="margin-bottom: 10px;">Dirg Jager (Heidleberg, Germany) Chaired the Roche Symposia and introduced the meeting by stating that even more impressive than the complete responses to therapy seen with atezolizumab is the long-term control that has been seen.<wbr> However, we do need to understand why some patients do not respond to help us to consider intelligent combination therapies.<wbr> </div><div style="margin-bottom: 10px;">George Coukos followed with a talk on understanding the microenvironment in order to build effective immunotherapy.<wbr> He noted that responses have been seen across all solid tumours with IT but different phenotypes and biology have been observed.<wbr> Tumours with evidence of pre-existing T cell infiltration are likely to respond to IT whereas those who do not have this infiltration are not.<wbr> Some tumours apparently establish a selective immune barrier by expressing epithelial death ligands (e.<wbr>g.<wbr> FasL) that can apoptise T cells as they approach the tumour burden.<wbr> Attenuation of the FasL barrier allows T cell accumulation.<wbr> Hence if immunity can be allowed to resurface then the tumours can be successfully treated with checkpoint inhibitors.<wbr> Clinical developmental strategies based around remodelling the surrounding vasculature of tumour and overcoming this barrier are now starting to be pursued Roche slides </div><div style="margin-bottom: 10px;">The next speaker Priti Hedge focused more on optimising immunotherapy using biomarkers.<wbr> She highlighted the different expression profiles of PD-L1 seen in different tumours.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10698_8_ScreenCapture8.jpg"> </div><div style="margin-bottom: 10px;">Finally Dan Chen (Developmental Organisation Franchise Head at Genentech) spoke about we are placed at a &ldquo;special moment in the history of oncology&rdquo;.<wbr> PD-L1 he suggested is the missing link to unlock the immune system.<wbr> We are looking at potential therapies where best responses are not months but years.<wbr> He postulated that &ldquo;in the coming years our ability to develop therapies using this insight will be unprecedented.<wbr>&rdquo; </div><div style="margin-bottom: 10px;">In his talk he chose to focus on the 7 steps that control normal cellular function that provide the body with the innate ability to heal itself.<wbr> PD-L1 is important in step 7 but Genentech is now targeting steps 1, 3 and 6 as potential combinatorial approaches to achieve even better outcomes.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10698_9_ScreenCapture9.jpg"> </div><div style="margin-bottom: 10px;"><STRONG>Option 1</STRONG> </div><div style="margin-bottom: 10px;">Chemotherapy was the first intervention he highlighted stating that we have learnt so much about these drugs but there is still far more we don&rsquo;t know and this outweighs what we know today.<wbr> Synergistic activity has been seen with IT; in fact he claimed some of the strongest preclinical activity seen in pre-clinical models.<wbr> The concept needs further validation but even now it extends beyond pre-clinical data.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10698_11_ScreenCapture11.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10698_13_ScreenCapture13.jpg"> </div><div style="margin-bottom: 10px;"><STRONG>Option 2 </STRONG> </div><div style="margin-bottom: 10px;">&ldquo;Not a hammer approach but a scalpel&rdquo; OX40 proteins are turned on transiently when T cells see an antigen it helps proliferation to occur.<wbr> A combinatorial approach with and OX40 inhibitor is now undergoing clinical evaluation.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Option 3</STRONG> </div><div style="margin-bottom: 10px;">T Cell bispecific TCBs &mdash; this uses the ability to develop engineered molecules that can forcefully drag T cells to the site where they need to kill.<wbr> </div><div style="margin-bottom: 10px;">Phase I testing in humans of all three approaches will represent the next wave of cancer immunotherapy with data likely to be presented at ESMO next year.<wbr> Dr Chen believes that the less likely outcome is that one IT can kill everything.<wbr> Treatment is more likely to evolve along a personalised cancer IT paradigm.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Merck&rsquo;s Symposia</STRONG> </div><div style="margin-bottom: 10px;">Merck&rsquo;s satellite symposia echoed many of the concepts conveyed by the Roche speakers, particularly regarding immune escape mechanisms.<wbr> The Chair stated that these are exciting times.<wbr> Things are really changing and we are seeing a revolution in how to treat difficult to treat cancers.<wbr> The focus of the meeting was on reviewing activities ongoing in different types of cancer which may be amenable to immunotherapy.<wbr> The belief is that 12 cancers will be treatable with IT with approvable drugs.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10698_19_ScreenCapture19.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10698_20_ScreenCapture20.jpg"> </div><div style="margin-bottom: 10px;">Joaquim Belmont (Dana Fabre Cancer Institute) presented ongoing data with pertuzumab in bladder cancer noting that BCG is well known for being the oldest form of immunotherapy for NMIBC.<wbr> He reiterated comments about the huge unmet need in the 2<SUP>nd</SUP> line bladder cancer setting and stated that the phII results with atezolizumab presented that day will lead to approval but that agents will move earlier in the treatment paradigm and potentially in the refractory BCG setting (see slide referencing this below).<wbr> 14 trials are currently open or about to open in metasatic bladder cancer patients.<wbr> He suggested that IT will be more impactful than taxanes and the most important drugs to be introduced since the taxanes.<wbr> </div><div style="margin-bottom: 10px;">Currently in the refractory BCG setting there are two ongoing phI trials but both are being sponsored by the NCI, one with Merck&rsquo;s pembrolizumab and the other with Roche's atezolizumab </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10698_21_ScreenCapture21.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10698_22_ScreenCapture22.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10698_23_ScreenCapture23.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10698_25_ScreenCapture25.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10698_24_ScreenCapture24.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10698_26_ScreenCapture26.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10698_27_ScreenCapture27.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10698_28_ScreenCapture28.jpg"> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10698_29_ScreenCapture29.jpg"> </div><!-- Comment details --><a name="oncology10698attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10698_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(70,2 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10698_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(66,7 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10698_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(83,3 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10698_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(67,7 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10698_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(52 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10698_6_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(71,9 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10698_7_ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(62,5 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10698_8_ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(65,9 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10698_9_ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(64,6 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10698_10_ScreenCapture10.jpg">ScreenCapture10.jpg</a>&nbsp;&nbsp;(64,4 KB)<br>&nbsp;&nbsp;11.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10698_11_ScreenCapture11.jpg">ScreenCapture11.jpg</a>&nbsp;&nbsp;(49,3 KB)<br>&nbsp;&nbsp;12.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10698_12_ScreenCapture12.jpg">ScreenCapture12.jpg</a>&nbsp;&nbsp;(59,6 KB)<br>&nbsp;&nbsp;13.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10698_13_ScreenCapture13.jpg">ScreenCapture13.jpg</a>&nbsp;&nbsp;(56,3 KB)<br>&nbsp;&nbsp;14.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10698_14_ScreenCapture14.jpg">ScreenCapture14.jpg</a>&nbsp;&nbsp;(53,7 KB)<br>&nbsp;&nbsp;15.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10698_15_ScreenCapture15.jpg">ScreenCapture15.jpg</a>&nbsp;&nbsp;(80,9 KB)<br>&nbsp;&nbsp;16.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10698_16_ScreenCapture16.jpg">ScreenCapture16.jpg</a>&nbsp;&nbsp;(103,1 KB)<br>&nbsp;&nbsp;17.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10698_17_ScreenCapture17.jpg">ScreenCapture17.jpg</a>&nbsp;&nbsp;(77,8 KB)<br>&nbsp;&nbsp;18.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10698_18_ScreenCapture18.jpg">ScreenCapture18.jpg</a>&nbsp;&nbsp;(118,1 KB)<br>&nbsp;&nbsp;19.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10698_19_ScreenCapture19.jpg">ScreenCapture19.jpg</a>&nbsp;&nbsp;(80,1 KB)<br>&nbsp;&nbsp;20.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10698_20_ScreenCapture20.jpg">ScreenCapture20.jpg</a>&nbsp;&nbsp;(44,3 KB)<br>&nbsp;&nbsp;21.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10698_21_ScreenCapture21.jpg">ScreenCapture21.jpg</a>&nbsp;&nbsp;(65,8 KB)<br>&nbsp;&nbsp;22.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10698_22_ScreenCapture22.jpg">ScreenCapture22.jpg</a>&nbsp;&nbsp;(76,5 KB)<br>&nbsp;&nbsp;23.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10698_23_ScreenCapture23.jpg">ScreenCapture23.jpg</a>&nbsp;&nbsp;(53,2 KB)<br>&nbsp;&nbsp;24.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10698_24_ScreenCapture24.jpg">ScreenCapture24.jpg</a>&nbsp;&nbsp;(56,4 KB)<br>&nbsp;&nbsp;25.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10698_25_ScreenCapture25.jpg">ScreenCapture25.jpg</a>&nbsp;&nbsp;(75,5 KB)<br>&nbsp;&nbsp;26.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10698_26_ScreenCapture26.jpg">ScreenCapture26.jpg</a>&nbsp;&nbsp;(74,5 KB)<br>&nbsp;&nbsp;27.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10698_27_ScreenCapture27.jpg">ScreenCapture27.jpg</a>&nbsp;&nbsp;(55,5 KB)<br>&nbsp;&nbsp;28.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10698_28_ScreenCapture28.jpg">ScreenCapture28.jpg</a>&nbsp;&nbsp;(92,8 KB)<br>&nbsp;&nbsp;29.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10698_29_ScreenCapture29.jpg">ScreenCapture29.jpg</a>&nbsp;&nbsp;(95 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20151231&edate=20150901&rec=10698">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-10-07T13:00:44+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-10-07T13:00:44+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Acino Acquires the 9th Largest Local Pharma Company in Ukraine</title>
	<pubDate>2015-10-07T09:59:24+02:00</pubDate>
	<wp:post_id>6843</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><A href="http://www.phs.ua/index.php?showSection=0&amp;showMaterialsIn=63"></A> </div><div style="margin-bottom: 10px;"><U>Growth rate</U> of 41 % (CAGR 2011 to 2014) </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20151231&edate=20150901&rec=11265">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-10-07T09:59:24+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-10-07T09:59:24+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>First Approval Of An Anti-PD1 With A Companion Test For PDL1 Expression</title>
	<pubDate>2015-10-06T17:45:45+02:00</pubDate>
	<wp:post_id>6844</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: MSD's anti-PDL1, Pembrolizumab (Keytruda) has become the first immuno-oncology agent to be approved with an companion dignostic in oncology.<wbr> Keytruda is approved for 2L+ metastatic NSCLC patients whose tumours express PD-L1.<wbr> IHC22C3 pharmDx test is the approved companion test for detection the presence of PDL1 expression in NSCLC tumours.<wbr> The approval highlights the importance of biomarker driven strategy in oncology.<wbr> </div><div style="margin-bottom: 10px;">Pembrolizumab is the second drug in the class of immune checkpoint inhibitors to be approved for NSCLC, the first being BMS' Nivolumab, which was approved for treating squamous NSCLC in March 2015.<wbr> Pembrolizumab works by blocking the PD-1/<wbr>PD-L1 pathway that cancer cells sometimes engage in order to apply “brakes” on cancer-fighting T cells, preventing the T cells from doing their job.<wbr> Blocking the PD-1/<wbr>PD-L1 pathway releases the brakes on T cells and enables them to fight cancer cells.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Clinical Evidence:</STRONG> </div><div style="margin-bottom: 10px;">The FDA’s approval is based on the results of a randomized clinical trial of 550 patients with advanced NSCLC.<wbr> In a subgroup of patients who received pembrolizumab after their lung cancer progressed following chemotherapy or targeted therapy and whose tumors had PD-L1, the overall response rate was 41 percent, and the treatment effect lasted between 2.<wbr>1 and 9.<wbr>1 months.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Challenge Of Dignostic Test</STRONG> </div><div style="margin-bottom: 10px;">While immune checkpoint inhibitors are one of the most promising classes of drugs to be tested and approved in recent years, the need for biomarkers to select the patients who will respond to anti-PD1 and PDL1 remains a big challenge as there is often variation and contraditive results reported.<wbr> </div><div style="margin-bottom: 10px;">"The big issue with all of these drugs is that each company has a different biomarker.<wbr> In other words, we need a uniform biomarker.<wbr> Also, in the pembrolizumab studies, for example, researchers looked at the cutoff for the biomarker.<wbr> If 50% of the tumor cells had the biomarker, there was about a 37% response rate.<wbr> If 1% or less had it, there was perhaps a 10% response rate.<wbr> That is why, if you look at all of these drugs for lung cancer, there are about a 20% response rates.<wbr> There will be a number of these anti–PD-1/<wbr>PD-L1 therapies approved.<wbr> One would hope that if they all get approved, then the companies would challenge each other and maybe lower the price.<wbr> However, I don’t think that is going to happen.<wbr>" Dr.<wbr> David Ettinger (Source: OncoLive) </div><div style="margin-bottom: 10px;">Recognizing the challenges and in an effort to develop some solutions, the FDA, the AACR, and the American Society of Clinical Oncology (ASCO) held a one-day workshop in March this year in Washington, D.<wbr>C.<wbr>, titled “Complexities in Personalized Medicine: Harmonizing Companion Diagnostics across a Class of Targeted Therapies.<wbr>” </div><div style="margin-bottom: 10px;">A significant development to emerge from the workshop was <A href="http://www.aacr.org/AdvocacyPolicy/GovernmentAffairs/Documents/FDA-AACR-ASCO-Complexities-in-Personalized-Medicine-Blueprint-Proposal.pdf" target="_blank"></A> pre-competitive space and analytically characterize the performance of their individual PD-1/<wbr>PD-L1 companion diagnostic test systems.<wbr> The project is continuing to make strides, and results are expected to help build an evidence base for post-approval studies that will help inform patients, physicians, pathologists, and others on how best to use the tests to determine treatment decisions.<wbr> </div><div style="margin-bottom: 10px;"><UL><LI>The Six companies include: </LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI>Steven Averbuch, MD Vice President, Development, Oncology &amp; Pharmacodiagnostics, Bristol-Myers Squibb </LI>
<LI>Kenneth Emancipator, MD Executive Medical Director, Merck Research Laboratories </LI>
<LI>Ian McCaffery, PhD Head Companion Diagnostic Development, Oncology Biomarker Development, Genentech </LI>
<LI>Abigail McElhinny, PhD Vice President, Assay and Reagent Development, Ventana Medical Systems Inc.<wbr> Doug Ward Vice President &amp; General Manager, Companion Diagnostics, Ventana Medical Systems Inc.<wbr></LI>
<LI>Dave Stanforth Director, Head of R&amp;D, Companion Diagnostics, Agilent Technologies </LI>
<LI>Jill Walker, PhD Executive Director, Companion Diagnostic Development, Immuno-Oncology, AstraZeneca </LI>
</UL> </div><div>Source: AACR, MSD Press Release </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20151231&edate=20150901&rec=10697">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-10-06T17:45:45+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-10-06T17:45:45+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Ferring Research Institute Awards Innovative Research</title>
	<pubDate>2015-10-06T09:12:11+02:00</pubDate>
	<wp:post_id>6845</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Ferring Research Institute has announced the recipients of the 2015 Ferring Innovation Grants.<wbr> Each recipients has been awarded $50,000 to support research in the fields of Gastroenterology, Prostate cancer/<wbr>Urology, and Reproductive Health.<wbr> The list of the five winners is provided below.<wbr> </div><div style="margin-bottom: 10px;"><P class="bwmarginl1"><STRONG>Steven Cohn, M.<wbr>D.<wbr>, Ph.<wbr>D.<wbr>, </STRONG>University of Virginia, School of Medicine: Immunomodulation of RELM&beta; as a treatment for IBD</P> </div><div style="margin-bottom: 10px;"><P class="bwmarginl1"><STRONG>Nardhy Gomez-Lopez</STRONG>, <STRONG>Ph.<wbr>D.<wbr>, </STRONG>Wayne State University, School of Medicine: A role for exendin-4 in the prevention of preterm birth</P> </div><div style="margin-bottom: 10px;"><P class="bwmarginl1"><STRONG>Peter Gray, Ph.<wbr>D.<wbr>, </STRONG>The Salk Institute for Biological Studies: Targeting Cripto in castration-resistant prostate cancer</P> </div><div style="margin-bottom: 10px;"><P class="bwmarginl1"><STRONG>Guiying Nie, Ph.<wbr>D.<wbr>, </STRONG>Hudson Institute of Medical Research: Improving fertility by targeting a novel uterine barrier for embryo implantation</P> </div><div style="margin-bottom: 10px;"><P class="bwmarginl1"><STRONG>Laura Parry</STRONG>, <STRONG>Ph.<wbr>D.<wbr>, </STRONG>The University of Melbourne: Treatment of vascular dysfunction in preeclampsia</P> </div><div>Source: Ferring </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20151231&edate=20150901&rec=11261">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-10-06T09:12:11+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-10-06T09:12:11+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Oncobiologics' ONS-1045: A Step Closer For First Avastin's Biosimilar Entry</title>
	<pubDate>2015-10-05T20:50:24+02:00</pubDate>
	<wp:post_id>6846</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Oncobiologics, Inc.<wbr> announced that its bevacizumab (Avastin&reg;) biosimilar candidate, ONS-1045, met the primary and secondary endpoints in a Phase 1 clinical trial.<wbr> This first-in-human study for ONS-1045 was conducted by the Centre for Human Drug Research (CHDR) in Leiden, The Netherlands.<wbr> Oncobiologics has begun both in-house manufacturing of Phase 3 clinical trial material and clinical site assessment in preparation for the initiation of the global confirmatory Phase 3 clinical trial.<wbr> </div><div style="margin-bottom: 10px;">ONS-1045 is being developed as a biosimilar to bevacizumab, an anti-vascular endothelial growth factor-A (VEGF-A) monoclonal antibody ("mAb"), which is approved in many countries for the treatment of a variety of metastatic cancers </div><div style="margin-bottom: 10px;">A 3-arm single-dose pharmacokinetic (PK) study was performed in 135 healthy male volunteers to compare ONS-1045 to both the U.<wbr>S.<wbr>- and EU-sourced Avastin&Acirc;&reg; reference products, and the two reference products to each other.<wbr> All of the PK endpoints met the bioequivalency criteria of the geometric mean ratios within 90% confidence interval of 80-125%.<wbr> These included the primary endpoint of area under the time-concentration curve from first time point extrapolated to infinity (AUC0-inf), and the two secondary endpoints: maximum serum concentration (Cmax), and area under the time-concentration curve from first to last time point measured (AUC0-t).<wbr> Safety and immunogenicity were similar and no neutralizing antibodies were detected across the three arms.<wbr> </div><div style="margin-bottom: 10px;">Source: Oncobiologics Press Release </div><div>.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20151231&edate=20150901&rec=10696">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-10-05T20:50:24+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-10-05T20:50:24+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Telesta Announces FDA Advisory Committee Date for MCNA - 18th Nov</title>
	<pubDate>2015-10-05T20:41:20+02:00</pubDate>
	<wp:post_id>6847</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Telesta Therapeutics has been granted an FDA advisory hearing to discuss the biologics license application (BLA) of its MCNA immunotherapy as treatment for high-risk nonmuscle invasive bladder cancer following first-line BCG.<wbr> The joint committee meeting is scheduled for November 18, 2015, and will include input from ODAC and the Cellular, Tissue and Gene Therapies Advisory Committee (CTGTAC).<wbr> </div><div style="margin-bottom: 10px;">The details of the advisory committee are as follows: </div><div style="margin-bottom: 10px;"><TABLE border="1" cellspacing="1" dir="ltr" style="width: 623px;"><TBODY><TR><TD valign="center" width="11%">
<P dir="ltr">Name of Committee:</P>
</TD>
<TD valign="center" width="89%">
<P dir="ltr">Cellular, Tissue, and Gene Therapies Advisory Committee and the Oncologic Drugs Advisory Committee.<wbr></P>
</TD>
</TR>
<TR><TD valign="center" width="11%">&nbsp;</TD>
<TD valign="center" width="89%">&nbsp;</TD>
</TR>
<TR><TD valign="center" width="11%">
<P dir="ltr">Date and Time:</P>
</TD>
<TD valign="center" width="89%">
<P dir="ltr">November 18, 2015, from 8 a.<wbr>m.<wbr> to 5 p.<wbr>m.<wbr></P>
</TD>
</TR>
<TR><TD valign="center" width="11%">&nbsp;</TD>
<TD valign="center" width="89%">&nbsp;</TD>
</TR>
<TR><TD valign="center" width="11%">
<P dir="ltr">Location:</P>
</TD>
<TD valign="center" width="89%">
<P dir="ltr">FDA White Oak Campus, 10903 New Hampshire Ave.<wbr>,</P>
<P dir="ltr">Bldg.<wbr> 31 Conference Center, the Great Room (rm.<wbr> 1503),</P>
<P dir="ltr">Silver Spring, MD 20993-0002.<wbr></P>
</TD>
</TR>
<TR><TD valign="center" width="11%">&nbsp;</TD>
<TD valign="center" width="89%">&nbsp;</TD>
</TR>
<TR><TD valign="center" width="11%">
<P dir="ltr">Agenda:</P>
</TD>
<TD valign="center" width="89%">
<P dir="ltr">The safety and efficacy of Biologics License Application (BLA) 125593, Mycobacterium phlei Cell wall-Nucleic Acid complex (MCNA), submitted by Telesta Therapeutics, Inc.<wbr> The proposed indication (use) for this product is treatment of non-muscle invasive bladder cancer at high risk of recurrence or progression in adult patients who failed prior Bacillus Calmette-Gu&Atilde;&copy;rin (BCG) immunotherapy, e.<wbr>g.<wbr>, in patients who are BCG-refractory or BCG-relapsing.<wbr></P>
</TD>
</TR>
<TR><TD valign="center" width="11%">&nbsp;</TD>
<TD valign="center" width="89%">&nbsp;</TD>
</TR>
<TR><TD valign="center" width="11%">
<P dir="ltr">Meeting Material:</P>
</TD>
<TD valign="center" width="89%">
<P dir="ltr">FDA intends to make background material available to the public no later than 2 business days before the meeting.<wbr> If FDA is unable to post the background material on its Web site prior to the meeting, the background material will be made publicly available at the location of the advisory committee meeting, and the background material will be posted on FDA's Web site</P>
</TD>
</TR>
</TBODY>
</TABLE> </div><div style="margin-bottom: 10px;">The BLA for MCNA was based on findings from an open-label phase III trial, which demonstrated significant activity with MCNA, an immunotherapy that is comprised of mycobacterial cell wall fragments complexed with nucleic acids.<wbr> In the study, 25% of patients treated with MCNA remained disease-free at 1 year, which met the criteria established for the primary endpoint of the study.<wbr> At 2 years, the disease-free survival (DFS) rate was 19%.<wbr> In patients with papillary-only tumors, the DFS rate was 35.<wbr>1% and 32.<wbr>2% at 1 and 2 years, respectively.<wbr><BR><BR>In late August, the FDA granted a priority review to MCNA for patients with high-risk nonmuscle bladder cancer.<wbr> The agency is currently scheduled to act on the BLA for MCNA by February 27, 2016.<wbr> When accepting the submission, the FDA announced plans to schedule an advisory meeting.<wbr><BR><BR><BR>In the phase III study, 129 patients were treated with an induction dose of MCNA at 8 mg weekly.<wbr> After 3 months of induction therapy, those who remained disease free went on to receive a maintenance dose from months 3 to 24.<wbr> In this portion of the study, MCNA was given in 3 weekly installments every 3 months.<wbr><BR><BR>Of the patients enrolled, 91 had carcinoma in situ with or without papillary disease and 38 had papillary-only tumors.<wbr> Most patients had high-risk disease, 107 were BCG refractory, and 68 patients had received two or more prior BCG induction courses.<wbr> The primary endpoint of the study was DFS rate at 1 year.<wbr><BR><BR>At a median 34.<wbr>7-month follow-up, the median disease-free duration in responders was 32.<wbr>7 months.<wbr> The progression-free survival (PFS) rate at 1-year was 87.<wbr>3%.<wbr> At year 2 and 3, the PFS rate with MCNA was 79.<wbr>8% and 77.<wbr>7%, respectively.<wbr><BR><BR>Adverse events (AEs) were mild to moderate in severity and did not frequently lead to treatment discontinuation.<wbr> Only 2 serious AEs were considered to be treatment-related (hematuria and urinary tract infection).<wbr> </div><div>Source: Telesta Press Release </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20151231&edate=20150901&rec=10695">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-10-05T20:41:20+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-10-05T20:41:20+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Teva Expands in Mexico</title>
	<pubDate>2015-10-05T09:55:59+02:00</pubDate>
	<wp:post_id>6848</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Teva has announced the $2.<wbr>3B acquisition of Rimsa (approx.<wbr> 10x revenue), which will add manufacturing and distribution capabilities in Mexico.<wbr> The deal will boster earnings starting from Q1:17 (Copaxone 40mg lost of patent).<wbr> According to Teva, the majority of the Rimsa business (&gt;90% of revenue) consists of branded products, and over 60% of the business is driven by the private market (ie, not government), which is the most profitable segment of the pharmaceutical market in Mexico.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Rationale for the deal</STRONG> </div><div style="margin-bottom: 10px;"><STRONG>- E</STRONG>xpansion in emerging markets, and Mexico in particular, has been a priority for Teva.<wbr> </div><div style="margin-bottom: 10px;">- The acquisition will provide the company with a growing and profitable business, as well as a large sales platform (&gt;900 sales reps) to help Teva commercialize products that it has been developing for the Mexican market (and some products that will come with the Allergan Generics acquisition).<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Rimasa Snapshot</STRONG> </div><div style="margin-bottom: 10px;">Privately-held pharma company </div><div style="margin-bottom: 10px;">HQ: Mexico </div><div>2014 revenur: &pound;227M </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20151231&edate=20150901&rec=11258">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-10-05T09:55:59+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-10-05T09:55:59+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Merz Pivotal Paediatric Lower Limb Study In Cerebral Palsy Has Now Completed Recruitment With An Estimated Sample Of 300 Patients</title>
	<pubDate>2015-10-02T22:49:29+02:00</pubDate>
	<wp:post_id>6849</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Merz Pivotal Paediatric Lower Limb Study In Cerebral Palsy Has Now Completed Recruitment With An Estimated Sample Of 300 Patients</span>&nbsp;<br><span style="font-size: 12px;">Comment: The recruitment for Merz pivotal study NCT01893411 in PLL has finally completed with an estimated sample of 300.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20151231&edate=20150901&rec=8102">...</a><br></div><div style="margin-bottom: 10px;">The dates of primary and study completion have been revised by Merz to much earlier from </div><div style="margin-bottom: 10px;">Primary completion March 2016 to<STRONG> August 2015</STRONG> </div><div style="margin-bottom: 10px;">Estimated study completion July 2017 to <STRONG>November 2016</STRONG> </div><div>Merz only updated clinicaltrials.<wbr>gov with completed recruitment end of June of this year.<wbr>   The recent update of completion dates occurred only once the date had passed.<wbr>  This highlights the delay tactic Merz have employed in not keeping the public informed of the status of Xeomin Trials </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20151231&edate=20150901&rec=8197">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology8102">View thread  Neurology8102: Merz Pivotal Paediatric Lower Limb Study In Cerebral Palsy Has Now Completed Recruitment With An Estimated Sample Of 300 Patients</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-10-02T22:49:29+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-10-02T22:49:29+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>AEZS-108 Met Its Primary End Point For Its Ph2 Trial In Post Chemo mCRPC Setting</title>
	<pubDate>2015-10-02T18:09:51+02:00</pubDate>
	<wp:post_id>6850</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Aeterna Zentaris reported its AEZS-108 (zoptarelin doxorubicin) met the primary endpoint of the Ph2 trial in the post chemo mCRPC setting.<wbr> The primary endpoint was Clinical Benefit (CB) defined as remaining progression-free by RECIST and Prostate Specific Antigen (PSA) after treatment for 12+ weeks.<wbr> The data was presented at ECC 2015 by Dr.<wbr> Jacek Pinski during poster session.<wbr> Zoptarelin doxorubicin is also being evaluated in Ph3 for endometrial cancer.<wbr> The second interim results are scheduled to release this month.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Zoptarelin doxorubicin</STRONG> is a New Chemical entity composed of a targeted synthetic peptide carrier linked to doxorubicin that aims to an improved, targeted delivery of doxorubicin with improved benefit risk profile.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10690_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><STRONG>Study Design<BR><BR></STRONG>This was a single-arm Simon Optimum design Phase 2 study of zoptarelin doxorubicin in 25 patients with CRPC.<wbr> Patients received zoptarelin doxorubicin (210 mg/<wbr>m2) intravenously over 2 hours, every 3 weeks.<wbr> The primary endpoint was CB, defined as remaining progression-free by RECIST and PSA after treatment for 12+ weeks.<wbr> Secondary endpoints were progression free survival (PFS), best overall response, toxicity, pain and overall survival (OS).<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Results</STRONG> </div><div style="margin-bottom: 10px;">Twenty patients had measurable disease, with a median of 1 prior chemotherapy regimens and a median PSA of 255.<wbr>8 ng/<wbr>ml.<wbr> Eleven patients experienced CB; 13 patients achieved stable disease.<wbr> Median PFS and OS were 4.<wbr>4 months (95% CI: 3.<wbr>6, 5.<wbr>5) and 6 months (95% CI: 4.<wbr>2, 10.<wbr>7) respectively.<wbr> Forty-four percent of patients demonstrated improvement of pain score at 12 weeks.<wbr> Maximal PSA response was stable in 20 patients.<wbr> Zoptarelin doxorubicin demonstrated good tolerability with grade 3-4 hematologic (n=7) and grade 3 blood and lymphatic system disorders (n=5) adverse events as the most common events.<wbr> </div><div style="margin-bottom: 10px;">A </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10690_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><STRONG>Other Pipeline</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10690_2_ScreenCapture2.jpg"> </div><div>Source: ECC 2015 Vienna, Aeterna Zentaris Press Release </div><!-- Comment details --><a name="oncology10690attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10690_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(647,9 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10690_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(207,7 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10690_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(178,1 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20151231&edate=20150901&rec=10690">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-10-02T18:09:51+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-10-02T18:09:51+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Capsugel's DRcaps™ Capsule Suited for Delivering Probiotics</title>
	<pubDate>2015-10-02T15:32:49+02:00</pubDate>
	<wp:post_id>6851</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Capsugel has developed a technology that makes its acid-resistant DRcaps&trade; hard capsules suitable for liquid-fill applications.<wbr> The company claims that because of their acid-resistant properties, DRcaps capsules are ideally suited for highly acid-sensitive supplements, such as probiotics.<wbr> The new offering will be featured at SupplySide West 2015 held October 5-9 in Las Vegas.<wbr> </div><div style="margin-bottom: 10px;">DRcap Capsules <A href="http://www.capsugel.com/ihc/drcaps">http:/<wbr>/<wbr>www.<wbr>capsugel.<wbr>com/<wbr>ihc/<wbr>drcaps</A> </div><div><EM>Source: Capsugel</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20151231&edate=20150901&rec=2567">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-10-02T15:32:49+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-10-02T15:32:49+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Merck's Consumer Health Counts on LatAm to Grow</title>
	<pubDate>2015-10-02T14:34:11+02:00</pubDate>
	<wp:post_id>6852</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Consumer Health is the fastest growing business at Merck.<wbr> The division reported net Q2 sales of &euro;227.<wbr>6M, (+16% organic growth vs the year-earlier period).<wbr> All global strategic brands outperformed with Neurobion, Dolo-Neurobion and Femibion being key contributors.<wbr> Key geographies with strong growth momentum were Chile and Mexico for Latin America.<wbr> Two days ago, at the Financial Times Latin America Healthcare &amp; Life Sciences Summit, Management stressed that 'along with a growing consumer demand, Latin America sees a rise in the need for healthcare products and a trend towards consumer goods making daily life more convenient'.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>In Brazil,</STRONG> </div><div style="margin-bottom: 10px;">the Floratil consumerization approach drove a 34% net sales growth in 2014 versus 2013 and the franchise is expected to be the second fastest growing in the Latin American portfolio by the end of the decade.<wbr> Bion is expected to become the fastest growing brand in the region, after the successful launch of Bion3 in 2014 in Brazil.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>In Chile,</STRONG> </div><div>thanks to a consumer approach with focus on digital already initiated in 2010, Bion3 has become the 2nd biggest OTC brand and the best-selling multivitamin with a market share of ~60%.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20151231&edate=20150901&rec=2566">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-10-02T14:34:11+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-10-02T14:34:11+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>TELESTAR Data At ESMO - Key Takeaways</title>
	<pubDate>2015-10-02T13:08:41+02:00</pubDate>
	<wp:post_id>6853</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: While we were already aware that the Phase III TELESTAR study for Telotristat etiprate was positive, M.<wbr>Kulke presented a more detailed view of the data at ESMO.<wbr> He commented on how Telotristat etiprate significantly reduced bowel movement frequency in patients with carcinoid syndrome taking SSAs, a durable response was observed in 44% and 42% of patients receiving telotristat etiprate 250 mg TID and telotristat etiprate 500 mg TID, respectively, versus 20% of patients on placebo.<wbr> Prof.<wbr> Cunningham (The Royal Marsden, UK) raised few interesting comments to Kulke's data presentation and in particular the need for more data to clarify the impact on patients Quality Of Life and a careful assessment of health economic evaluation to introduce the treatment into clinical practice.<wbr> </div><div style="margin-bottom: 10px;"><SPAN style="text-decoration: underline;"><STRONG>M.<wbr>Kulke &ndash; TELESTAR presentation</STRONG></SPAN> </div><div style="margin-bottom: 10px;">Statistical Design: </div><div style="margin-bottom: 10px;"><UL><LI>Primary endpoint: Daily BM frequency averaged over 12-week, double-blind treatment phase
</LI>
<LI>Study powered with alpha of 0.<wbr>025 to detect a treatment difference of &ndash;1.<wbr>5 BM/<wbr>day for each telotristat etiprate group compared with placebo
</LI>
<LI>A blocked Wilcoxon rank-sum statistic (stratified by baseline urinary 5-HIAA levels) was used as the primary method to compare BM frequency between telotristat etiprate and placebo, and a Hodges&ndash;Lehmann estimator was used to measure treatment-group differences
</LI>
</UL> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><IMG height="534" src="data:image/png;base64,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" style="width: 496px; height: 334px;" width="859"> <IMG height="546" src="data:image/png;base64,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" style="width: 606px; height: 332px;" width="908">  <IMG height="541" src="data:image/png;base64,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" style="width: 477px; height: 330px;" width="842"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><SPAN style="text-decoration: underline;">Additional secondary Endpoints:</SPAN> </div><div style="margin-bottom: 10px;">Reductions in flushing and abdominal pain were greater on treatment with telotristat etiprate than placebo; however, differences were not statistically significant </div><div style="margin-bottom: 10px;"><UL><LI>Only 39% of patients had at least 2 episodes of flushing per day
</LI>
<LI>Only 39% of patients had a mean abdominal pain severity score &ge;3 (scale 1-10) at baseline
</LI>
</UL> </div><div style="margin-bottom: 10px;"><SPAN style="text-decoration: underline;"><STRONG> CONCLUSIONS</STRONG></SPAN> </div><div style="margin-bottom: 10px;"><UL><LI>Telotristat etiprate significantly reduced bowel movement frequency in patients with carcinoid syndrome taking SSAs
<UL><LI>Durable response was observed in 44% and 42% of patients receiving telotristat etiprate 250 mg TID and telotristat etiprate 500 mg TID, respectively, versus 20% of patients on placebo
</LI>
</UL>

</LI>
<LI>Telotristat etiprate had a favorable safety profile and was well tolerated in this study
</LI>
<LI>Telotristat etiprate significantly reduced urinary 5-HIAA in patients with carcinoid syndrome, suggesting effective inhibition of intratumoral TPH
</LI>
<LI>Telotristat etiprate represents a promising new potential treatment approach for patients with carcinoid syndrome
</LI>
</UL> </div><div style="margin-bottom: 10px;"><SPAN style="text-decoration: underline;"><STRONG>Cunningham Commentary to the TELESTAR Data</STRONG></SPAN> </div><div style="margin-bottom: 10px;"> </div><div><IMG src="data:image/png;base64,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"> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20151231&edate=20150901&rec=8230">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-10-02T13:08:41+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-10-02T13:08:41+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>A "New" Smart Capsule Engineered to Deliver Medications Directly to the Colon</title>
	<pubDate>2015-10-01T17:15:28+02:00</pubDate>
	<wp:post_id>6854</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Inventors of the capsule are part of the Purdue University in Indiana.<wbr> The researchers claim that the device tackles the complex problem of drug delivery to the lower part of the GI tract, and could potentially make drug treatment for Crohn's disease and irritable bowel syndrome more effective.<wbr> The team has outlined being currently working with a 'private biomedical company' in an effort to start clinical trials.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The device is comprised of two parts, one carrying a drug payload and the other housing electronics.<wbr> </div><div style="margin-bottom: 10px;">The medication is released after the capsule makes its eight hour journey through the harsh acidity of the stomach and 20 feet of small intestine, ensuring its drug payload reaches the colon intact.<wbr> </div><div>Source: <A href="http://linkis.com/www.reuters.com/arti/1DHsz">http:/<wbr>/<wbr>linkis.<wbr>com/<wbr>www.<wbr>reuters.<wbr>com/<wbr>arti/<wbr>1DHsz</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20151231&edate=20150901&rec=2563">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-10-01T17:15:28+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-10-01T17:15:28+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Synthetic Biologics Appoints Manufacturing Executive</title>
	<pubDate>2015-10-01T17:04:41+02:00</pubDate>
	<wp:post_id>6855</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Management has announced that Raymond D.<wbr> Stapleton, PhD, has joined as Senior Vice President, Manufacturing.<wbr> He will lead the manufacturing team as the Company begins to prepare for late-stage clinical trials for SYN-010 (for IBS-C) and SYN-004 (for <EM>C.<wbr> difficile),</EM> and continues to move its monoclonal antibody (mAb) program forward to address Pertussis.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Pharmaceutical and biotechnology executive with over 15 years of experience at Merck &amp; Co.<wbr>, Inc.<wbr>, in manufacturing, operations, quality, science, technology, engineering and process development.<wbr> </div><div style="margin-bottom: 10px;">He most recently served as Executive Director, Global Vaccine Technology and Engineering.<wbr> During his tenure at Merck, Dr.<wbr> Stapleton contributed to the scale up, tech transfer and manufacturing product launch of multiple billion dollar franchises including ISENTRESS® (oral solid dosage for AIDs), GARDASIL® (HPV vaccine), KEYTRUDA® (anti-PD-1 cancer mAb therapy), and performed process development for the cholesterol lowering therapy MEVACOR® (lovastatin).<wbr> </div><div><EM>Source: Synthetic Biologics</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20151231&edate=20150901&rec=2562">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-10-01T17:04:41+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-10-01T17:04:41+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Novartis Symposia At ESMO - Key Takeaways</title>
	<pubDate>2015-10-01T16:13:49+02:00</pubDate>
	<wp:post_id>6856</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Novartis leveraged on the new RADIANT-4 data and future everolimus positioning with two key symposia on NET treatment at ESMO 2015.<wbr> Novartis is clearly trying to position everolimus as a strong player in NET, and in particular in lung NET - also considering Afinitor is going to lose traction in other indications (e.<wbr>g.<wbr> RCC).<wbr> Novartis is trying to establish the right line of treatment for everolimus in NET but is clearly facing challenges from SSA as well as NETTER-1/<wbr>Lutathera data.<wbr> </div><div style="margin-bottom: 10px;"><SPAN style="text-decoration: underline;">Key takeaways:</SPAN> </div><div style="margin-bottom: 10px;"><UL><LI>While it is widely accepted that high dose octreotide can be used as a valid treatment option for progressive GEP NET , it was the first time that data were presented in a NVS symposium detailing a very good safety profile
</LI>
<LI>Novartis has sent strong messaging to support the safety of everolimus after chemotherapy and after PRRT - data presented seem like NVS might try and push the usage of Lutathera therapy after everolimus usage.<wbr> We need to anticipate what Novartis will do in terms of positioning its own NET portfolio relative to that of AAA.<wbr> Further data (Poster 229, academic sponsored, no NVS) also suggested a benefit of SSA/<wbr>Everolimus prior to PRRT therapy.<wbr>
</LI>
<LI>Marketing materials of Sandostatin LAR and Afinitor were presented alongside at Novartis booth &ndash; with no clear indication of any RADIANT- 4 results.<wbr> As we already predicted at the Global Somatuline Forum (September 18<SUP>th</SUP>) Novartis is likely to invest heavily behind the new indications bundling everolimus promotion alongside Sandostatin LAR.<wbr> We need to closely monitor this aspect at the coming up congresses.<wbr>
</LI>
</UL> </div><div style="margin-bottom: 10px;"><SPAN style="text-decoration: underline;"><STRONG>NOVARTIS SYMPOSIUM, &lsquo;Challenges of Treating Rare Diseases&rsquo;, Friday 23<SUP>th</SUP></STRONG></SPAN> </div><div style="margin-bottom: 10px;">The symposium focused on NET and adult Soft Tissue Sarcoma (aSTS &ndash; Pazopanib treatment).<wbr> The intro was given by Stefan Sleijfer that described STS and NET as rare heterogeneous diseases and explained how applying lessons learnt from the clinical trials, with regards to inclusion of homogeneous NET patient populations, may produce meaningful results.<wbr> Also, although OS is considered the preferred endpoint for clinical trials, it is a critical limiting factor when patient accrual is difficult (both in NET and aSTS) &ndash; he therefore commented on how other endpoints, such as time to clinical deterioration and PROs, should be considered.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8227_1_IMG%255f1920.JPG"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8227_2_IMG%255f1928.JPG"> </div><div style="margin-bottom: 10px;">The next two speakers presented &lsquo;real life&rsquo; case studies to address treatment optimisation and long &ndash;term strategies for NET patients.<wbr> </div><div style="margin-bottom: 10px;"><SPAN style="text-decoration: underline;"><STRONG>&lsquo;Question and controversies in NET: Finding the Right Therapy for the Right Patients in Real Life&rsquo; (Rachel Riechelmann)</STRONG></SPAN> </div><div style="margin-bottom: 10px;">Dr.<wbr> Riechelmann presented a case of a 49 yr old men that presented with well-differentiated pNET, with primary tumor considered inoperable.<wbr> The patient was investigated as strong MEN1 suspected.<wbr> </div><div style="margin-bottom: 10px;">The patient treatment was discussed &ndash; few highlights: </div><div style="margin-bottom: 10px;"><UL><LI>CapOx in pNET &ndash; a retrospective experience
</LI>
<LI>The safety of everolimus after chemotherapy and after PRRT - data presented seem like NVS might try and push the usage of Lutathera therapy after everolimus usage.<wbr>
</LI>
<LI>Everolimus was shown to provide well-tolerated disease stabilization in this MEN1-related functioning pNET case.<wbr>
</LI>
<LI>This patient case demonstrated the importance of proactively managing adverse events with everolimus, including atypical infections, to support long-term use.<wbr>
</LI>
</UL> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8227_3_IMG%255f1951.JPG"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8227_4_IMG%255f1955.JPG"> </div><div style="margin-bottom: 10px;"><STRONG><SPAN style="text-decoration: underline;">Addressing Current Issues in GI NET: Emerging Evidence to Optimize Treatment (Diego Ferone)</SPAN></STRONG> </div><div style="margin-bottom: 10px;">The second patient case had a discrepancy in grade between the primary tumor and the metastases.<wbr> Ferone addressed two points in the treatment management of the case presented: </div><div style="margin-bottom: 10px;"><UL><LI>Functional PET imaging is recommended for NET diagnosis
</LI>
<LI>High-dose octreotide is a valid treatment option for progressive GEP NET while maintaining a very good safety profile
</LI>
</UL> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8227_6_IMG%255f1997.JPG"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8227_7_IMG%255f1993.JPG"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8227_8_IMG%255f1995.JPG"> </div><div style="margin-bottom: 10px;"><SPAN style="text-decoration: underline;"><STRONG>MANAGING NETS IN 2015 (prIME Oncology) &ndash; A MULTIDIMENSIONAL CHALLENGE , Sunday 25<SUP>th </SUP></STRONG></SPAN> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;">Yao kicked the symposium off describing how to control tumor growth in well differentiated NETs &ndash; he went through the already known PROMID, CLARINET, Sunitinib Phase III, SWOG S0518, RADIANT-1, 3 and 4 data &ndash; summary of the positioning of the different treatment options is shown below.<wbr> </div><div style="margin-bottom: 10px;"><IMG src="data:image/png;base64,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"> </div><div style="margin-bottom: 10px;">K.<wbr>Oberg gave a very interesting overview on managing symptoms of hormone excess.<wbr> Key takeaways: </div><div style="margin-bottom: 10px;"><UL><LI>SSAs will remain the first line therapy for functioning NETs
</LI>
<LI>In patients with carcinoid syndrome Telotristat etiprate, once approved, will be added to SSA for symptom control
</LI>
<LI>Everolimus has demonstrated symptomatic control in hypoglycaemia (insulinoma) but also glucanoma and VIPoma
</LI>
<LI>Interferon can be added to SSA for symptom control in patients with carcinoid syndrome or WDHA-syndrome
</LI>
<LI>PRRT gives significant symptom control in NET
</LI>
</UL> </div><div style="margin-bottom: 10px;"><IMG height="347" src="data:image/png;base64,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" style="width: 473px; height: 358px;" width="468"> <IMG src="data:image/png;base64,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"> </div><div style="margin-bottom: 10px;">Fazio concluded the session presenting two clinical cases: </div><div style="margin-bottom: 10px;">Case 1: Non functioning lung carcinoid (treatment sequence: surgery &ndash; relapse &ndash; everolimus+SSA &ndash; Chemo &ndash; PRRT) </div><div style="margin-bottom: 10px;">Case 2: Functioning small bowel NET (treatment sequence: octreotide- PRRT and then octreotide usage) </div><div style="margin-bottom: 10px;"><IMG src="data:image/png;base64,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"> </div><div style="margin-bottom: 10px;"><SPAN style="text-decoration: underline;"><STRONG>NOVARTIS MARKETING MATERIALS</STRONG></SPAN> </div><div style="margin-bottom: 10px;">Marketing materials of Sandostatin LAR and Afinitor were presented alongside at Novartis booth &ndash; with no clear indication of any RADIANT- 4 materials.<wbr> We need to evaluate if Novartis is likely to invest heavily behind the new indications bundling everolimus promotion alongside Sandostatin LAR.<wbr> Interesting info on nurses support and patients support on the marketing panel.<wbr> Novartis also had two panels marketing the NET Alliance resource library for patients and caregivers - MyNET Manager App, available on AppStore and GooglePlay.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8227_10_IMG%255f4678.JPG"> <img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8227_14_IMG%255f4681.JPG"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8227_12_IMG%255f4680.JPG"> <img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8227_13_IMG%255f4682.JPG"> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8227_16_IMG%255f4685.JPG"> <img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8227_17_IMG%255f4686.JPG"> </div><!-- Comment details --><a name="endocrinology8227attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8227_1_IMG%255f1920.JPG">IMG_1920.JPG</a>&nbsp;&nbsp;(1,2 MB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8227_2_IMG%255f1928.JPG">IMG_1928.JPG</a>&nbsp;&nbsp;(1,5 MB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8227_3_IMG%255f1951.JPG">IMG_1951.JPG</a>&nbsp;&nbsp;(1 MB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8227_4_IMG%255f1955.JPG">IMG_1955.JPG</a>&nbsp;&nbsp;(1,4 MB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8227_5_IMG%255f1973.JPG">IMG_1973.JPG</a>&nbsp;&nbsp;(1,1 MB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8227_6_IMG%255f1997.JPG">IMG_1997.JPG</a>&nbsp;&nbsp;(1,1 MB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8227_7_IMG%255f1993.JPG">IMG_1993.JPG</a>&nbsp;&nbsp;(1,2 MB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8227_8_IMG%255f1995.JPG">IMG_1995.JPG</a>&nbsp;&nbsp;(1,1 MB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8227_9_IMG%255f4678.JPG">IMG_4678.JPG</a>&nbsp;&nbsp;(1,7 MB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8227_10_IMG%255f4678.JPG">IMG_4678.JPG</a>&nbsp;&nbsp;(1,7 MB)<br>&nbsp;&nbsp;11.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8227_11_IMG%255f4681.JPG">IMG_4681.JPG</a>&nbsp;&nbsp;(2,2 MB)<br>&nbsp;&nbsp;12.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8227_12_IMG%255f4680.JPG">IMG_4680.JPG</a>&nbsp;&nbsp;(1,8 MB)<br>&nbsp;&nbsp;13.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8227_13_IMG%255f4682.JPG">IMG_4682.JPG</a>&nbsp;&nbsp;(2,1 MB)<br>&nbsp;&nbsp;14.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8227_14_IMG%255f4681.JPG">IMG_4681.JPG</a>&nbsp;&nbsp;(2,2 MB)<br>&nbsp;&nbsp;15.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8227_15_IMG%255f4684.JPG">IMG_4684.JPG</a>&nbsp;&nbsp;(1,7 MB)<br>&nbsp;&nbsp;16.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8227_16_IMG%255f4685.JPG">IMG_4685.JPG</a>&nbsp;&nbsp;(1,7 MB)<br>&nbsp;&nbsp;17.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8227_17_IMG%255f4686.JPG">IMG_4686.JPG</a>&nbsp;&nbsp;(1,9 MB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20151231&edate=20150901&rec=8227">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-10-01T16:13:49+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-10-01T16:13:49+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>BLU-554 For HCC Received FDA's Orphan Drug Designation</title>
	<pubDate>2015-10-01T12:04:44+02:00</pubDate>
	<wp:post_id>6857</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Blueprint Medicines has received orphan drug designation to its BLU-554 for HCC.<wbr> BLU-554, a selective FGFR4 inhibitor, is currently being evaluated in Ph1 for HCC and cholangiocarcinoma.<wbr> The Ph1 trial will enroll patients at multiple centres in the US, EU, and Asia.<wbr> </div><div style="margin-bottom: 10px;"><SPAN style="text-decoration: underline;"><STRONG>About BLU-554</STRONG></SPAN> </div><div style="margin-bottom: 10px;">BLU-554 is a selective FGFR4 inhibitor.<wbr> Aberrantly activated signalling of FGFR4 may be a key driver in up to 30% of HCC patients and may also play a role in a subset of patients with cholangiocarcinoma.<wbr>  BLU554 has been shown to have significant anti-tumour activity in preclinical models of HCC driven by aberrant FGFR4 signalling.<wbr> The Ph1 trial is expected to enroll 50 patients with advanced unresectable HCC and an additional 10 patieints with advanced unresectable cholangiocarcinoma.<wbr> </div><div style="margin-bottom: 10px;"><SPAN style="text-decoration: underline;"><STRONG>About Blueprint Medicines - an ocncology fous biotech company</STRONG></SPAN> </div><div style="margin-bottom: 10px;">Blueprint is headquartered in Cambridge, Massachusetts, the US.<wbr> The operating loss of the company was US$39.<wbr>7 million in FY2014, compared to an operating loss of US$21 million in FY2013.<wbr> The net loss of the company was US$40.<wbr>3 million in FY2014, compared to a net loss of US$20.<wbr>9 million in FY2013.<wbr> The company reported revenues of US$2.<wbr>7 million for the second quarter ended June 2015, compared to a revenue of US$0.<wbr>7 million the previous quarter.<wbr> The company has completed an initial IPO of 9,367,708 shares of its common stock at a price of USD18 per share, for gross proceeds of US168.<wbr>8m.<wbr> </div><div style="margin-bottom: 10px;">The company's development focuses on discovery for selective kinase inhibitors for genomically defined cancer subsets.<wbr> It has developed a platform that combines kinase inhibitors with genomics, which helps to develop selective compounds against clear genomic driver targets.<wbr> Blueprint identifies drug targets by sequencing cancers and mining public data with new genome analysis algorithms.<wbr> The company&rsquo;s programs include KIT D816V selective inhibitor, FGFR4 selective inhibitor, and other programs.<wbr> It has partnership with two genomic and cancer research institutions such as the Massachusetts General Hospital Cancer Center and Wellcome Trust Sanger Institute.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>BLU-285 in Unresectable and Treatment-Resistant GIST</STRONG> </div><div style="margin-bottom: 10px;">BLU-285 is a potent and selective inhibitor of KIT Exon 17 and PDGFR-alpha D842V mutants, which are key disease drivers of metastatic and treatment-resistant GIST.<wbr>  GIST is the most common form of sarcoma of the gastrointestinal tract.<wbr>  Patients with the KIT Exon 17 and PDGFR-alpha D842V mutants are not adequately treated with existing therapies.<wbr> </div><div style="margin-bottom: 10px;">In this Phase 1 trial, Blueprint Medicines plans to enroll 60 patients with GIST or other relapsed or refractory solid tumors at multiple sites in the U.<wbr>S.<wbr>, EU and Asia.<wbr>  The trial will test the safety and tolerability of escalating doses of BLU-285, with the goal of establishing an MTD, or a recommended dose if the MTD is not achieved.<wbr> Once the MTD or recommended dose has been established, patients with treatment-resistant GIST and PDGFR-alpha D842V mutant GIST will be enrolled in expansion cohorts.<wbr> Additional study objectives include assessing early signs of biological activity using disease-specific biomarkers and clinical efficacy as measured by response rate by RECIST modified for GIST.<wbr> </div><div>Source: Blueprint Medicines Press Release </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20151231&edate=20150901&rec=10689">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-10-01T12:04:44+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-10-01T12:04:44+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Borealis-2 Trial For OncoGenex's Apatorsen Completed Enrollment For Second Line Metastatic Bladder Cancer</title>
	<pubDate>2015-10-01T08:42:22+02:00</pubDate>
	<wp:post_id>6858</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: OncoGenex announced completion of patient enrolment of a target 200 patients in Borealis-2 clinical trial evaluating Apatorsen in 2nd line metastatic bladder cancer.<wbr> This is an investigator sponsored randomized Ph2 trial that is designed to evaluate apatorsen in combination with docetaxel in the 2nd line setting.<wbr> Borealis-2 is sponsored by Hoosier Oncology Group and is being conducted at 27 sites across the United States.<wbr> </div><div style="margin-bottom: 10px;"><SPAN style="text-decoration: underline;"><STRONG>Clinical Evidence</STRONG> </SPAN> </div><div style="margin-bottom: 10px;">Data from the Borealis-1 trial previously reported at the ASCO earlier this year showed that metastatic bladder cancer patients with poor prognostic features (low performance status, liver involvement, low hemoglobin and high alkaline phosphatase) showed a potential survival benefit with apatorsen 600mg added to first-line chemotherapy (HR = 0.<wbr>72) compared to chemotherapy alone.<wbr> Patients in the trial with a Karnofsky Performance Status of 80 percent or less, a common indicator of poor prognosis, experienced a 50 percent reduction in risk of death with the addition of apatorsen therapy (HR = 0.<wbr>50).<wbr> Based on findings from the Borealis 1 trial, OncoGenex and the Hoosier Oncology Group plan to evaluate overall survival in patients with poor prognostic factors in the Borealis-2 trial.<wbr> </div><div style="margin-bottom: 10px;">ClinicalTrials.<wbr>gov Identifier:<a href="https://clinicaltrials.gov/ct2/show/NCT01780545?term=Borealis-2&rank=1" class="defaultlink">NCT01780545</a> </div><div>Source: OncoGenex Press Release 30 Sept </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20151231&edate=20150901&rec=10688">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-10-01T08:42:22+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-10-01T08:42:22+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>RADIANT-4 Data At ESMO - Key Takeaways</title>
	<pubDate>2015-09-30T18:28:19+02:00</pubDate>
	<wp:post_id>6859</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;"><P align="left" dir="ltr">Comment: The RADIANT-4 data were presented by J.<wbr>Yao at ESMO 2015 and showed that treatment with everolimus is associated with a 52% improvement in median PFS compared with placebo in patients with advanced lung and GI NETs.<wbr> While we are aware of the delay in tumor growth that everolimus plays in pNET, this is the first time that data were conclusively showing its effectiveness in other NET sites, and in particular lung NETs.<wbr> Novartis is likely therefore to expand Everolimus&rsquo;s label based on the RADIANT-4 results and focus on positioning the drug as a major treatment option for NET patients, especially considering the new threats that Afinitor is going to face in other indications such as RCC (also data presented at ESMO).<wbr> Based on the released data, filing in non-functioning GI and lung NET is still believed to take place in 2015 with estimated approval in 2H 2016.<wbr></P> </div><div style="margin-bottom: 10px;"><P align="left" dir="ltr">Looking ahead we need to closely monitor and understand:</P> </div><div style="margin-bottom: 10px;"><OL><LI>Novartis&rsquo; strategy to market Afinitor in the new indication and weight the threat of Novartis bundling it with Sandostatin LAR;
</LI>
<LI>The role everolimus could play in symptom control;
</LI>
<LI>The line of treatment for everolimus - while physicians still believe that SSA will remain first line of treatment, the debate of treatment for progressive patients will remain.<wbr>
</LI>
</OL> </div><div style="margin-bottom: 10px;"><SPAN style="text-decoration: underline;"><STRONG>RADIANT-4 DATA</STRONG></SPAN> </div><div style="margin-bottom: 10px;"><P align="left" dir="ltr">In RADIANT-4, 302 patients with progressive, well-differentiated, nonfunctional lung/<wbr>GI NETs were stratified by tumor origin, WHO performance status (PS), and prior somatostatin analog treatment, then randomized 2:1 to receive best supportive care plus either everolimus at 10 mg per day (n = 205) or placebo (n = 97).<wbr> Patient median age was 63 years, 53% of patients were female, and 76% were Caucasian.<wbr> Disease status was grade 1/<wbr>grade 2 in 64% and 35% of patients, respectively, and WHO PS was 0 in 74% or 1 in 26% of patients.<wbr> The most commonly reported tumor sites were the lung in 30%, and the ileum in 24% of patients.<wbr> The two arms were well balanced regarding prior treatment; 53% versus 56% of patients in the everolimus and placebo groups respectively had received prior somatostatin analog therapy; 26% versus 24% had received chemotherapy, and 22% versus 20% had undergone previous loco-regional and radiotherapy.<wbr></P> </div><div style="margin-bottom: 10px;"><P align="left" dir="ltr"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8223_10_IMG%255f2069.JPG"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8223_11_IMG%255f2130.JPG"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8223_12_IMG%255f2133.JPG"></P> </div><div style="margin-bottom: 10px;">The primary endpoint of PFS as assessed by central radiology review was a median 11.<wbr>0 months with everolimus (95% CI, 9.<wbr>23&ndash;13.<wbr>31) compared with 3.<wbr>9 months with placebo (95% CI, 3.<wbr>58&ndash;7.<wbr>43).<wbr> A 52% reduction in the relative risk of disease progression or death was observed with everolimus versus placebo (HR, 0.<wbr>48; 95% CI, 0.<wbr>35&ndash;0.<wbr>67; P &lt; .<wbr>001).<wbr> The &ldquo;robust benefit&rdquo; was confirmed in the investigator-assessed PFS, which was 14.<wbr>0 months (95% CI, 11.<wbr>24&ndash;17.<wbr>71) compared with 5.<wbr>5 months (95% CI, 3.<wbr>71&ndash;7.<wbr>39) with placebo (HR, 0.<wbr>39; 95% CI, 0.<wbr>28&ndash;0.<wbr>54; P &lt; .<wbr>001).<wbr> </div><div style="margin-bottom: 10px;">Secondary endpoints included overall survival (OS), objective response rate (ORR), disease control rate (DCR), and safety.<wbr> ORR by central review showed no complete response, but 4 (2%) of everolimus patients and one placebo patient showed partial response.<wbr> DCR was 82% with everolimus versus 65% with placebo.<wbr> Progressive disease was reported for 9% of everolimus patients compared with 27% of patients receiving placebo.<wbr><BR> A pre-planned interim OS analysis performed with 37% of the information fraction favored everolimus (HR, 0.<wbr>64; 95% CI, 0.<wbr>40&ndash;1.<wbr>05; P = .<wbr>037); however, OS difference did not achieve statistical significance.<wbr> Next interim analysis is expected in 2016.<wbr> </div><div style="margin-bottom: 10px;">Safety profile was found to be consistent with known safety profile with everolimus.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8223_7_IMG%255f2079.JPG"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8223_8_IMG%255f2088.JPG"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8223_9_IMG%255f2092.JPG"> </div><div style="margin-bottom: 10px;"><SPAN style="text-decoration: underline;"><STRONG>E.<wbr>Grande RADIANT-4 Discussion</STRONG></SPAN> </div><div style="margin-bottom: 10px;">commented on the RADIANT-4 data showing a very good picture and comparing the key data from PROMID, SWOG S0518, RADIANT-2 RADIANT-4 and concluded that, while everolimus is the first drug to show in a randomized trial to have significant activity in lung NET, we do not have the full picture yet.<wbr> We still have to clarify the following key issues: </div><div style="margin-bottom: 10px;"><UL><LI>There is no biomarker/<wbr> no molecular selection of patients
</LI>
<LI>Low radiographic response, which is a recurrent problem when assessing clinical outcome in NETs
</LI>
<LI>It&rsquo;s unclear what should be used with patients presenting with functioning tumors or lower tumor burden/<wbr> good prognosis by primary tumor origin
</LI>
<LI><STRONG>When should everolimus be used? &lsquo;Unknown&rsquo; line of treatment</STRONG>
<UL><LI>E.<wbr> Grande was questioning if everolimus should be pushed after SSA failure and if so whether single agent everolimus would be better than maintenance of SSA + adding on everolimus
</LI>
<LI>To add on this key issue, we would like to highlight here the messaging that came from the Novartis symposium on Friday 25<SUP>th</SUP> and a poster presented on Monday 28<SUP>th</SUP>.<wbr> In both instances everolimus was recommended in advanced NETs prior to PRRT and chemotherapy, hinting better efficacy and safety if used in earlier treatment settings (see data below)
</LI>
</UL>

</LI>
</UL> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8223_13_IMG%255f1954.JPG"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8223_15_IMG%255f2312.JPG"> </div><div style="margin-bottom: 10px;">(Left picture: Dr.<wbr> Riechelmann, Novartis Symposium &ndash; for complete commentary see Novartis commentary; Right: poster n.<wbr>273 - for complete commentary see Novartis commentary) </div><div style="margin-bottom: 10px;"><SPAN style="text-decoration: underline;"><STRONG>How will this new evidence presented at ECC impact on Somatuline?</STRONG></SPAN> </div><div style="margin-bottom: 10px;">During the last Global Somatuline Forum (September 18<SUP>th</SUP>), the Global Business Intelligence team together with the ENDO Franchise presented the potential impact of everolimus on Somatuline ahead of ECC (see picture below).<wbr> </div><div style="margin-bottom: 10px;">After the data presentation and various ECC activities (posters, symposium, primary intelligence) we can now formulate better possible strategies to be considered and confirmed: </div><div style="margin-bottom: 10px;"><OL><LI>It&rsquo;s very likely that NVS will try to bundle the promotion of Afinitor with Sandostatin LAR &ndash; at the NVS booth the two drugs were already promoted alongside (see Traction comment on NVS activities at ECC)
</LI>
<LI>Most likely everolimus will be positioned in earlier settings of the NET patient journey (especially in lung NET) but still after SSA
</LI>
<LI>We need to further evaluate the role of everolimus in symptom control (see further comments on the prIME oncology/<wbr>Novartis symposium)
</LI>
</OL> </div><div><IMG height="393" src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAgwAAAGJCAYAAADmE2v5AAAAAXNSR0IArs4c6QAAAARnQU1BAACxjwv8YQUAAAAJcEhZcwAADsMAAA7DAcdvqGQAAP+lSURBVHhe7L0HgFxXdT7+TZ/Zme29d62klVa9W9WyLfeCTbGBUAOEXwIBQvgnQCCEEEIgoXcbCBgDNu69S7J6rytt773v9Pb/zn1vdmdXK7mCgcy3e+e9d8u557ZTXjVUfOLJKBJIIIG/KMiijhoYotxjMKhVzggG2Q1LGoMhEgH4H8NUGR2yL0dSUpVjXhXDiIiUl32Jk3Kx/JJZoJeNSAnhIVZ3NIIIM8XSFPRyihXuqxCP2GEsXjZqN455g+zHiMTFE4olvazUbIijL7wZeRhrt/SVBKPEI6wdCAVJl6CqkbhpqPaxXVKPRkfysnVqX4P0huKKccaIpKtorWwcT8KLQKMZhYl0tNIaDCyreFRx0peMlCDtFx7UsZZb9b2qSztWzPM4zGOJUv2i05EIKRvjWeqRfaPKIeWkPXoZPU0rKe2WNmnx7DEWkDiJkH0hKjuSkyWEDvOpGSDx3Jc88icRql4pyvZInyp+JEnoqX3ZkiuZgFptWnysvhimyhGqYdyqENsh9LoNBr0nptIknpsZJGNpMyFrKKoY/iMiEIU1M4KMHSEk1QUQ8snYqR69EGbOIYMRE/ssGHzCzDaZwAgmzJn7kpC5kEACCfyFQhOEmjCcloAitmOCOJZ2IUQei2ERobBV4pDZYyJpStTIjhKyc0GjrSkCDTG1MBc0fvRUXYDPwFSaHl4J4mjGlEI8NAUxDSX4GQyiYEQDKu2rUqY4n1lCQ4x0jF5ctVOQQzEApkjOhVlpkjeea0mOZbkUGYHKqzLF59TMjBim8jDM6B0ez+6bS0KnMRtCY5oMa4g/VttZhfRD4UXaHr2gs2ZwqeV/NXwm8LqQMBgSSOAvFSJwlTCNCVQlhlXQ/qZT5sKM3LLD3JJf7cZDEqcIxVGUjFK/MkqmS718zS8DKTrVLtJSpC9Cby7D45IQhcogPM8wprT9iylR1cyLsDAnhNxcrOlxU+M2S2HGF9PGUPu7ELG4ePNAcHEm9Ro1sPhMr/tlIFmn2HiZ/DPyapizBPNcYOTN5mVW8gxcQDQWcalCrx6vatzfSKj+oRI3GF82SD/OPU9eHRIGQwIJ/AVCZJgEJSKUQNPODahA4aEC/2acmmfmePUiukpOj0vQvD29vJasoB3zT68oPk07lgSVqEPfn5lxZhZBvBSO7c5WHjHEK3a1H1+W+/HlJCkuOR4q25SC5lbKKnoM3JVTvgL1G0dDiqgwRTwuUYeKkfIxXvVsspEY1b8S/zLQi80BbSw1PrRjDXF16nEzxyRGMT5omylDQUjofRErFYN2BkDC7JRpTKcooorHWDXTiI+IZeD8ifEwC2rexvE3s7yk6zszEONkjsQ5C1y8TdOYs6I/AsibjAc3tAeUJpd94xxBrj4Ymajmt7CrWH5tfCcMhgQS+AvDtEzQvAr5Ux6zDrm8IIJ+Thk5K047VCaBJp+FzDQp7jM+/liHZNXKzkwUZaUUlpJecZhV7wXplwQLq+z8eU10NG41pahzKJ0j5FQnKY51xPZm0qUPp9WlykmZuTCzzJyYKvoK8uqQsYnPrpGQCJWi7wvkSMIs2nKoZY8VvhBMFyPzgrIxsN9i+lvD9MFMkvE0LlaZxMfSLlGnwqXSZoN5FdmL1ftqEc/nHxvaHFVTjj/qTIx0xUVCLJ++o6JfCxIGQwIJ/CVDl2ciJzTECbmXkRrqvgXmUQaG7M+BmfG64FK4WIk3BlLLqzrNqhQaebogu/A5HVSyKHyVVeJiRUT5asczIDR1TTmTtMTF55fU2XHxuFTaK4eiEKe5lf2i7wvikl4ztJ7QCcXoTU+wucF8U3XLNlY8FhcPiYsZXXOlC6S6WJfOhYuyc7ECc+GV5X25pv8hIWcOTAxmNthEbS5nE2ZsY/sMGpvyGwuvHgmDIYEE/hIhypQyQb9dUUEJeZGBr1BmTouWOOEyu+zL0tLr/GNhilV95xXVHWspofLH7avTJ/rxJaApUAnMK3fwa4TeROi8KMR4mT6e23C4RDslvyo0Z0GFiynOS1C9CPQSymi4eH2vHq+GVnzeV9+CPxZkplnIn1XfXixYGTRl//r6M2EwJJDAXyA0ERcTDjQblLCXWD2IHTFtS8wJJa+ZJ1ZqLlws/tXi1YkxXT2zTdpePF7tcax1061Ue2pXfjTlOreCJSSjVmwWZkcKAYmbM7OO6bT46mL7qq0zGBHe4o8vhKReOofg5XO8LC7g42I0L9X+eOh9NZWd9KZIMlL2JUj6XFXNjovlf6UQQ1HRj1Vw8cIvNwZ/SJgYLGTRYjDSMDDCyq01fqvvm400GKQprxMJgyGBBP7CoOQChZj8ydkBtUftr84USOKU4Li0BNEo8E9oKQEal1/fVTcCKnmpCc0p0Sk7Epis6dTYCX5GzxKwir6Q0WlegFh8rBw3EhUL05D0qVq0zVQG2Ymlx/LoUO2TljKPMKuyaBxrXGtBkVJF+RM7ZT4Delnth1Al4qDFxzvO03VIWbkTQq9RzzSbgkCL0wnomM4ne7EjLU+sBrWndridKhBPZybNGCRWxkbd16HAbXwjiKka9b68OKSfY+UFUlLbn2JJgUdTk0LSGXS62pyLi58KcZDkuXCxeJZXfClIplgQXKQOQstxYfwfA4pD/shNjxLEIFDHcwa1+skqeVX/r43nhMGQQAJ/gVDCgZA3LsiRJi5kXw8isKeEto7ZhywyFeSYIUZ3BkQiEa9WCMXyK2EWq+BS0OvRwH11PBdH8YQkPUb8InmnKo8FQfz+qwBpxf5mlFeHr4VmLP9cvM/EtJ7W8ird8GqrmwWhFOt2jdQlCOpJM4ZpFqaNCUVZ241Bkl5tH10s6+z4Oap7WbwRHfgHhlo7qm3kM/ZI0xxBy/NqO+BCJAyGBBL4CwbFhQYlK/gzpf317SWgZBDLxPm9WsKrQLzHqVGYpjElvl6pkogT3kolC+1XUm6qprnyStocgVkltxYuXofWPv1AFdKMM/m7EDH6egHJLoG7Wm49fmr7xuOibZHouKQL8umMqrbOSIo/0Pan+yMesYIX9kss+8X7+cL4qZi5upm4GKU5QRoq/6sq9OZjaqZJH4ihSsPgUuGNQMJgSCCBvxDEZGdMNOhyZGoriJ3kVnFqLx4zhYocXSoIYltBPD3Zn6lMNcSMB8EUDWaelU0y6ls9COI9pAsKEFN5JZ9OlCGuVCwlDpJJXmwT3zMCRYjQS0jdyhiYCfHwhH/10mO9bq1krLyG6bjp+Pgc8bFajXqM2siPBK326bySS/i6ME4uIak4NfCxVI2yMKyNg/ZKZz0nodF/OUhXxF5DzBGeqkJt4kmwjul5J4exxLg6L1aletWy5GMGuYk0jvDUjbwXKzsbMSZmQzGl7U6PbFzknzikS9SlCKM8IaE9LXHJINpeNVPv19eAhMGgIAvIiLAsAs4VtR8xqteMv5n4U+HjlcNAXvV+1GMuANMiqk2XyPMKMaN/SC9+/2X5eK3Q+f+D0H6DoIljCoSoSeOVYYpXEZ4zlMjFodaCbNXRKxUwWv+E2D9Ks0zJejEehNIrpUNwDEFaM1kVUfcqaMzKOlVW8TIN7SgWp20lp8o9u7rZx4TKyx8pKUo0FjcDU4pL5dZ2dWhlGCSaHaaP4FQuSZ1ZInY0O4dQEpUan1unLRuJF0YvgJ7nlWB2trii2ljriOtjqXJGtbGkWeMwA0zS5szMPNr7ByRurnbMgtgW8rmJi97gq9GfWcPMo5eFZA8xXLSOPwzUHGE/yL0LRv6ZLhWkq6bW/atsXxz+BAwGEe4XhtfepNeCWMfLViZkhFabtv/mgjwZyYvOh1joWv9oxxrYV9Jff9wOU4jxM1211oeqH/WYCyDp0rf64SvBdLung9SpjZO8918OdLr6/tR4CoE3EkKT9fxBaL9OXDgFpE8iMBvDFBrasQQtn7Z/Mch8Ul2pB5V3+mAKc80BuWYq/SNEtHk5q9ArhXxMSQX9WEFTiHNiKp+kM8xZrV42bnHPnl9TxiCzyChHIhKv05wLTBeHWNalRuOiORWE1EXzqPhLlb4UpFx8kDbG09L6TrVXtUnayaBnj7VBgVv5Lpl8bEx9n2wq6GX1Yyk7FfRys6HaS8KqHn1Q5ONT6qNY8VAZ9DjJJnNoajudV/iPkofpSi8B0XAStGr/MBDassD+kHVcBKIbtDMIsq+tu9nBpIKw9/oZNKWve9cX9P03ATJZdQ+IWzUR1CRWKfFr+g+HiAVeRxfWLnoad5SNwe/NRDj/RXyg7jQKgmVoc9vgC0vH6/n/GCBPHtsAFs5/Du9f0AqXpwotHhMCYfEUNW9RWdmSl/0WiZiUES2T44/JZjRqpnCN8WKGL7kJ25c8hVuLfPCOlaHDF1b9NsWngVxmH8c7VxzFImMKekbSMU7OlfV7UWjtkzMG2vzgNmyBzz6A+fOeV/2T5C/EYNohvGvZftSaCtBi7MD2pU/hmkwLhscL0Rt4uTpeART/EUQzT+IdK5/H5hQn+sfy0B8Mw/zH7PRLIMZGNGqF1zKK4rLd+Nt1e7ChdAC20UJ0e+zwy+yRhSUb9ueloL0+OhZmQRWl4giblHMl4yx5Qpn1eM+anbghw4b+kTx0BELsH11U6XliuNi++pqeZRyl8/bjn1c2othfjHOTFgTVZNOyyEbf1SAHU0RiqXoOKhbtSPPcp6EpzyjXleRR7rGaZ5JXE7LqbAkVozr1q5dSxASSj0EUqLAm+i/MfVHKSlhPZ9Mhe9JncjaMRCSPbLREhal9fS0L/fh0gYonLUlTOlboSqTaF0yX0KLiVAUjwiG2iUuRzdLXLiPZ9nCIgUdG6Q7yF+LAKqOCyaLwpZ3q21zqWNoh+6L4JQ9r0HkWaPxJ7bEY2ZdfKcwgHSZR0klaI/QsOg2VzD01JhL0SIFYMeRVZZQQi4+HCEQL4FpvxD9+2IjVSUBjO+D2MX5qIAkpGqNzAZmLJmiQDuQkMa2y4ZMft2NbbgRtrWGMTbKMZqH/4cD2WV1RZCxgGwvYqxwrNb9lrc0KRvJi5KBOtBsxcpa8cY4bXqNCe/MMhigVoGEShQUn8JaVe7Cl8gQ2Sqg6jQ0FfrjHMtDvsSHyKr3RVw0qPZ+jByurDuDydCuaBkoxnrUXb6/sRXhwOY4NO+CmKf26Fc6rQDhkhzOjAZvnH8Zicwl2nyvBiKkDW9c8jx3zTmGxJQ09kykY9JnhyDiHbUsOY12qCYN9GZjQJcwfkt1IxAyj2YOammdxQ8U4IhMcKzf7KaUZ2xfuxZaUFDR01eKcJ6T6TeOFAoaCwWAYwJpFJ7AmzYaWwTw0uU2wcowvhCao4GjF5Uv24praw5wfp7Cp5jDWZwW5Vk0w5hzA20omMDSwCA2207ixqhnJk7U4FOzDpvn7sNxSiJNdlWj1BmGJFxKvCeRH+jbzNG5ddBTVkXIc7ymhUfRG0H4jYUCQCiEt8zyuXHoIS6y52Hd2Ps4MZ2KU8fLlScoQpWziMSWT54AI/ql7D2QwGUIhC2xJ/VhbtxM3FkcwMpiGwQCNh6x6vHPJcSw3FOBQZxka9f6RYiJfY2Tk6Y34+mbUzfkFyxhKqo7h72qG4O9ZhF2DVvhF0Qih2VCNmUFBg0TpdQu0pTGdLxyyMj2ApctfwvvX1eOmumZcsbgR11EAD4+koTU0gsvWnKBROg7TaA6NdhYSGjpBkUwBvxer1rLNV5zFjYs7cNWyQVQ4uBabXRiTea3yyo82n8MhN9ZtbMQH1o7DMuFE45AZJpP0jOSQPw2xV3fH8x6DRk37U0/BxNqvOldLleOY5FQxHOBQMIKk5Alc/45u3LZpCGucNrQP0qimgksqGcMNNw7jihwj2s+bYF84gg++fQjXXTaKqy8bw5WXjePKjRO4QrabJrBt3SQ2rnZj26ZJXLdjEhtq6By0kZ5bjCfNYIrnWRt9cuU3wJEfwhW3enH9QgN6zxsx6mdGWUMqf4xrQYwAywqxIOnagaU3RvGuHezPrii6B9hOTpcLIFYsDYakFQZ86HoD0nqi2H0CGJMxnFLmpCl9Nt1lcZhxoGOaMwVpEvk2LbHiA7dZUTIWxJ7DYQxMMN8f3GCIwkIjKHOBgQYDWXklBkObEcP15I0Gg3p64jVAhulNAicwAkhJa8WqklaUGHJwvrcCx7vKcbo/CwNeBzxBehXKEmeHyJkAvx1eCj1palSOA3a4/VRUDJ4QvWwZe3ZQiILAxzRv0IbJgJwhkIHmBBPPnfGTehl30IwQyxjZgcGQjTSMMAaT0dOwA1977mbc28U4WnKiwL1BK8uSHstNBkifAjPAeO3YBq+qg9D5ElphcmoUw4h8SF1yHOWxP6DXz/YIb9IevTRBXiKTyE/pRU2qA70DFTg6wUVkGsH80rPYMO84ti4+jVqnBw7yAfsgqorPY2n2KJLVtWqx/K2Kfqyd0jfKqGe8xy/9oUnRKAWz9JNHeFN8TfentDGg+p4CgOVi/emWtsq4kEYqldKKoj6kG80cF1q8E+V4bt/t+MreVTgy4YeZf9JWxQf7LyBnCiaqcLzXCR+VTYHLDbt4KjofXuFT7wU1XvyNmkdQXXwWKzPC8IyW4Uh7FU4PpWF8PAstZ6/Hfzx/HR7rEy+Q/HPc/SRgGqnFfbveia8fmY/zNBaM4nGzPZKu9Qvbybq0fpf5wnFW8XrbpY/0eTYFEYDyN7gMv3rhnfjmiQq0+qdp++JoS3/PKEvIswYB9oFPBX0esR6Zz1o6oc+dGB9u6WcSknrDYUmzzWwDx222DtXqCSLZyn6jEdndsRz3na7F8XEHJkhP2hWbl37Scwfl7FSMvtZHQlt4c9MAUPTZdpkrMj8mfKyb+dwMQf4VFJzH2oJRJIWZTtqGwYW469nb8PlDVTjl88NqIH22edLH8WXwk26A3qEaZ/IQJp0I+QK3YDr83Ea56ELJaD29BX/36JX4UbsFbllfpIMZebkv8dIBclbCZ4sLzONn3yrPVyqbiUjQCIdjGNs37sX7Vnah3JON083FONBYhL7kFmyd14EFGUHkFLVje1UfKpI0hR8bV+1sF1A6vxE3rGtHddiFE6fTMWwdxI6V7dhSFpjKE2NAdiORAIpL+7B98RCq0sLKSxfIGEc4Fl4vx4FrSfIa2CYvnQJ3kGmkFeR4eHjs85sw6bZgwmvmOMXkR5TGC+M9zE8j3MPgdRs516QLVM0cwyjMFh9qlw1T+Q/h+muGsSoziCTmRUoAi5aNY31VAM5QBK48DzaumsRCuw1n6p3Yf8KJIyeTVNh32I5BUxCrNngwP8mEcwccOHzWiuYRyq5J9jlDOMAaVdsF+o7w4eNco7KqWBbExkUR2HgMv5YsXjNocETHtQBR7nI2QZVnYHqEeTNrgM3rgTwz+2WSSQKhMcYwrgevVmeU7Xczj4fpqq+F5gSDGBQCMVYoXzHOMMkgZyC0ojO3Qm92YBvVAHORelhWzl5o8kvS4oOK1OjMiGeICbzZ8bEyl4IyCOT+hNiNjbI/d9C+WCmFSPt14E28JEEhb/AiO7MNi9NNaD5zA75/eCn2USGcGTKhsPwwtlcOwu5PQe+4FWnZjdiw4DQWJNnRPeRC0NlKD2oftlacxqriJlRYUtHnTqGh4UZ16RksKmvBgux2prcgO5JDT5ZKMfU8rqenurXqNJazTLUtCSOTGegyDqCusBELramo76lCp6EXVck+hH0ZGDb2YRWVdFXmAFaUnKeXe5LK2Qe7fQKZWUdxY+1J1GUPIyOcQ0+WiyW1AVfOO8mF5sKom16XpRvL6RlvyAxgcjgHXusAli7chSvmncLq4hbkR3Mw4KFSj8TuVaCBgWFUUkmuzwV6OxZh94ANdgqimrJuhL1pcDrG4fLkoZH0hh3tWFIwzEVfjBOtRegx+ZGUdRo3L6JHXnEGywrbUGpOQ7f0YcEx1tuJzGgyukftcKR2YPWC41iSEoHXM4mlS/ZjW9UprClqZpsCCHpT0DceRgl5qatoRE1mFzaWN6HcEUZO2QGsyhtAlpXKKbkbucZ0jFDgJSX3oMhqxdBoNmV2D1Ys3M3+OIVVhe3IiRSg35cCv6MJ82ng2CcK0dKfh1B6I9ZUn8LCJBsGx5xsPztCzW5ObtsAFhd1IW1iKR46dhkeaaxE00gW+iKcO6n9KHeGKVRT4OF8WJ87guBwLY6MRZFGgyvHmIw+TxS5BQ1YShp5rg5cWXsEqwp6UG5zomXCQQXK9pUcwdbaQ9jMti3Kb8Tywj7k2SwYGHWRFxoKalzUD/kZQXnGEFKiqeilMVJcdB6LSK8opQ1XLTqClXn9KDK70DJp04xR1QwKUvMQFpP+vBzWndGMq8jHitxh5JiS0Txhp8xhHlczrlxwSPXXcs61+U4qSncWOgITKM9vxoqyDmQ7unEF5/BqKrIahx2dbicmqIC1yyJi/ESRmX0elzHP4hQfHFQQKRmTsEb7sa6iHhW2ZAx7UjBk7cTaeaexNg0YnbDBlduItRWdpN+DHYuOYX1JuxqPjkkHRmkkGFM6sGb+Idy6mPM/1YschxclNQdxWdYEUq0+pKdyLkRlXILI5X6u0YnB8UwMUIqXlZ3Ee5bJGcQGrMof4nrMwrkJGlX2PmyrbUVxyiBWlDbi6sVnsTrLR6M9BZ2eCJypg6ilIgt4uI7MA9hY24aC5CGsr2zElYvOMS9djkAyekfNcDB+zbIjuGFRC9PbUVfSRbngQ4Be/CDXfuxMpVKvYriafMil7Pj79Q3IHVqM7z+zHA8eqcCZxmLsGqbRxTU5HA0hr6AXiy0uHG8sxQkqFUVD72vBwpUncGWVFz27VuFHB9IRKWvGFXlR9HWWYE8/jU49ryamo1RaftQsGMKiZBtOnsnGkT6a1ZwkIXMAWZX0/JcPoCBCp2XSBF/GIK5dS9lkt3AdRlBWO4iVNezPnFHctK0LG6omUWa3on7QTGMijPkrenDN5l5ctXwYy+ePYE2tB/lWE/q6zAhQWYc5NxxOPxYtdyNCeeBk36aNOXCyzY7+FDfW1vrhGnBi12EromVubCiPovOFAvznPWk4s9+JU2cdKpw5ZsdIuh918yLo2pWO//l+Co34KMp3jOLmq9zYuNqHYjoLvexHj3i+7APpgago++oArr7Fi/VlNEqcUWQXRpBKQ7NzgAZRagibrgvh1hvCWHNZGEtLqDdHgb5hdh0Vq41zdeM7orhyGZDtpKgtBHJpN/a2AxlrDHjLhw3Ytt6ANdzPS4mirY3rr8qAq5cZEDgfxRNngaorTLjjOtKjkdDZZkDGKhPe9kEztjJ+zSojcmkAnOvhaIlxIYyLQrcbsfhKM5Yyb0mlCTfebsW6ZdRRtijOdnJMS824bp0J5vYAnt8ZRcZGO275kA1b11nJiwlZSUBHQ4T6zoDkNTa85a12XLXDioVsT293mMafEWWX2/C299qxeYsFqxZTjnrDaO0VHvQwG+TPSrpZC4DkIhpOqp/FgLgwxM4wjLE/htkHYqi/1lMFr7HYGwfxXKLmCRRXPIMPbPo9PrrxEdxcOoLSvHPYsngvtuaPwBngwFIJXll3FCsy3HClNWDLwkNYkUJLNkTPyTCIZTX7cHnJINLYk7m5p3D9+p24qrIDBRTEEXosVlcrNi/ag6tLmccSRVLmWWytexbXlvbQUtU8OXWZxOhBZvE+3LFyJ7bk+OmF9GDVgpfwtmWnUJvsh9PZgRXzn8e7lx7F2mwPLPYRLK55ATfUMt0ZgDWtGVsX7cKOoiFkGukFWvtRW30Q11Z0oZiKvrLiEK6uaUc+PbKwOiWiCaEpyPXAJA8X0wQs9KIGJ1PVIBmM8tgWPYqBCrRN+lFQdQzL80aQFrXoRiqFHIW1K+08+4l9UTBOZRFCWt4x7Kh7Edt5nJ/ZjrWLdmNHSR/S6WG5Upqwue4ANhVMwGoPwEYPTnmRji6sW7gT15X1ItMQoQI6g2vW7cQ18yjcVU3kWW7GVPXSW1X7XJRJXVhZ+xTeVdtA72wc1VUHcRUNlGx6rSEuRPFUZQUOuNPhpnea4fAgCXbYU5uwdclzuKGyD8mahL0kxPMKWkZpVO7Cu1fsxoaMqFygUF6YeHXhFI7B0idwO73EPLYrN/8Yblkl82MA6ZZJFJccxHWLaOi5/DC72qlcT2Jt5jhsUY5P+XFsr25BsVnoSet0CG35Y/9etexJvK2qF1k2L4qKDuM20t5SNIxUyzgqyg9QaZ1GbVIIJpl7qjCFoXEENUx728qD2JA3rs4AzKvch+sXnEelNQyTrRurF+7BdVQaOXSOZR5dtuhZ3FjZSeMljPScU7hxxUu4urIL2TQCcguO4uq6I1id7oE1mERPM0l5/+MBevDkVQwV4V22ZmMI1kzyXbcbVxWOI9Vgg9vei+ULDuLGim5k0VvMyDmDm1ftwfXzupFn9SKv8DhuWHYU6zN8MNiGsGz+S7h9fivK6Lxn53TispoWlAt9hmjczafh1BZcv+pZfHB+N5VVCAWFJ3HH8pPYSOVutNKYrzqE9yw/gu3ZQa6tIWxadAh/s5bGMRVQiquX43YI76qhwUYjJLf8KBU6+zOXXq+TXvkyyduAlalUdGnduHLlEY7xADKZt7C8Ae9c0oUqU4DzuhfXrqzH9lwvUmS2yjKTYdARjdDjSnJz7HqRF8jC0WOVOOIdxcpte/GeW3aSJsfHwLVLoaym7ByQtoowPn+iFIc6bMhechZ/85Z6bEqmwn2pmoatQ3n8ondkJOLrvwBh8bo5BlWdeOe2FlxRFIGdtIOZQ7hyazturPYg2RxEeW0n3ndDO65Z6EGGzY/q5e14x7Y+LE/n+OaMYcf2fmwsoAwy0ChY048b14yjzCLzWFaskiKaAcP2j7ekoGkogqL1w9iw0I8suRclrq1R8hSh/ChY2Y+PfqgL7/vbHty8yYe8LM5oGulOKkuhKMoorcCPFVeP4z3X+lBBjz4oHrJuoGlnWHTIOLBDlQLjIZ1emEz6vSJJEay8PogP3BDCvEzO2YIott4awvtviKAmm5m1haQrP+6wjNEc5dzmbjpZ4ry00rCQkwTZ6wz44LuNNBxl7svlM/LkARZfbcT7P2nE9lquD8YVX2bC299mwlLKD/cE6RTQGPgrM65aCjjkMofUKfzbjKjdbsFHPmXFDSyTmWJA7Q1WvP8DVmyYz2S2Qe5zkbzRLAOsVgMso1FMktGiy+3467+yYmU54xdb8Y73O3DLZQakOQxYfJMFq1dasGaLHbfdYkElHTH3JI2KhVa89X02rJ5H/lUnMswJ6WNNrk4HWYdzBckr0H5fK6Tr32SwAYYwbI4R5KcNoChtkILYhsbOSnohPhRlDCM3YxRJTg/MY6U43pMCaz4NgnldsHkz0Dmch/bxFEQzD+OKimYsSDZiImCBLZyCns7V+MHu7XisP0rBdQw30OPoPL8dP37hNnxr/2qcMbRhNQXNomQqOzm1qbgRa01OGWuXC+SGO1GijkABdp3cjq/v3Yjdo24Kwwg8ndfhW7uvxNO08JPo1dU5g7BHtNPNcsp7+pKEnOKlF0njIiu3BdU0DXt7avDCkZvwYBs981BQvQ9cQRSThcrb5oNFPw2tovlnIm/J5GN3ezE67Y3YVtGCeUmc7HIDEPmMUrDXlB7DFdlmnDx5Hb7//C34weHF6HKcxZbyfkRHKnF00IjMtH6UZNJIcI7D5cvBufZSdAXoMQ+xL4dz0TGeisGwjMUoCpJM8AbNsIZSMNCzHHfu3YZ7G+dh17Ht2N3vhNtTSo/kOvzmXCG6/BSPNODk9HPAMUjDrQ1VZie6uhbiuSM34MFOF8bCYXr1TKdnb7Owv2xBeMeLceDcGrzQkQk3J/YFoMAzJ7dg5byXcOuKF2gINqOCnpVf71efLkymoC5xkA91qcUIP+tysveCoyvxvV3X4pdN2XAnNWNlpgep2Z0ocaag+dhN+Nozl+OF/lz0DRbiTFshxnUlOAPqsoFcLpDT9XIZJEylZMXE4Bp8a+c1+HVrKkLJjVidFoSTAkNsQoGB9XuDIaQbHejv2YD/fnEH7utywJzSglUZXhTmn8R1NJQn2jbhzhfehv9+aSMO+vtQV3YaK9MM8AQAC+eG2bMYd710HX5ypgy9llZlQM8vqKeB9wJuWfYi3lFXjzx/Pnafm4ehKL3r9tX42b4lOE6PeZzzWi6ByDsDjDKv5dKDulQm85/02Y82z0L8iO343qkydFnasSqT9EtP4vKqbjj6V+KHj3HtnFiMp9pKsefweuwdYdtHFuL+l67APVRCw1QYoSDr8tNIpDG2YT6NAWsO7t95A7761FX43tlsRHJP4uaSMaSZzRj1hZFvTMNLpzfiC8+sxe9H/CjN7kBdipl0bBjzy2VBbR36OL8KjJl46shG/MszK/HYxASVSR9qcieQnjeMrLEF+PEDV+DLeyrRNJmGk/WFqKcHHTFxHDkOIlwFMl3MJjoWdgrooJNz3kIjNIys9DEUlzXhHdt342OrulBNrSGXuOaC3NMRDvk58hYq+wiKF5/F7ZvbUDpSgQf2FqOdxvm2uiGUUcFJ3bJ+1dTW54PsKH6mNCqNBo7FuMeivHKJNVCJezx0EugwiTHs9UeRYjBhguv/338xHz8+SqMkfRgbi4JILxtHucuBkw/Nx5d+VIKn25LQ1ezC0ZNJGKFinRIv/JPT12meJDx51IWmpAncsGYCdVlRyk3hIg5U+rbkAIrz/SgrDNBrj2hySvGs8y28poaQVevFIsqKrlMOPHZ3Bn77kgUDPip0dX8B87KcgUpy8KwN9//agb3dBow22vDzbzrw+wOUuvMCuP3KCGz1FvzPl2z4r6+YKRujqN0YweX0okE6/mEDnrvLiEePA5Pcf+L7Bvz0XgN6qWQ9fVE0ngQaW4DWAdaVQgNBFC41nAxh7lIj/updBjhORPC1fw1jT4cBdTcbcfMa8tEURdO5KNpGgIy1ZrxrO2VkMgtp1p5i3+0G124UIycC+NdP+fDNhyj/i024eYMBqfT0g5KXbZR7hIbawmg4FkJTcwitg1yzqTRKVpuw+AY7ncUoDn/fgy9+ehLffiiEvhQrLn+7FVtrgL6zITTWh9DpN6KChsYdW4ygmJvmYwb0PqVHoD0NweGKCyK3Zu6LMaEXjY3da8CbbjAYaOoZqIzazl+Dbz/zDvzXs2/B79pS0NGfj54JK5LSB1BZ2YByelLR0UI0jJlgpnVtj0SQll2PtZXHsblwEhP9NTjen4qxSAAWCgP/SDa6BvLQZ/XD5fAhmwvLHEpF96iDnedHcCITAxQqUXpTdipn1ftzQHUyw9hIJsZCXLw0i8MRO4bcyZyoTljNcko8GSEq96AoexkYFlF3DXNPngCRO6JNbGfQl4mzTXU4MTaK1Zt/h/eJt5ntoQE7rVguBeElAgfqG1bRaMhEUt4pLC3uRprJQgvXCJvdjZy0ccCbjp4xOdUZgm88B4M+F0yOCYQnM9E2mAKDa5B92oyS7CE4Jotwvt+MnNRTuHLjU7i59jC25A1SmBuo2Gn0kC+jMYzAeDq6+wvQy76y09uxWSgslRcRoVDgeLAfRBBJM2RMA94cnGpYjNOTg7hs62/wPnqr6zJ9bKuBvEo+GkksY7cFqGwX4pG9N+J/zxZiVE3saQGnDCgGo2MA5XkNWF12FnU5A/SyRWFr9b0cZLH4PS4MjaViknW6aQAi4kOSnaUDNGICHuSVHMeOFQewPCUE/2QGhikJKetfFsKr152CIRqtQlvuczFE2UcOLmJZXXEMyuJ1T6RiaDIJk/RKPFSqktflCiI7g2NBBd8z4mSf+xGVy2ucoyH2s4NzVMY+QEN0aCQDE5zfbhpL0XCA/RdGWkY35tFoWFF6DisLulCa4qUnJmaAeHP0zq1y4yH3yUNsXsp8UXfq65A+CrJfBoczMG6OUHnYESF9B5VqDXlLszvROppC5e3DWH8xnjtVg2auQ5kDJhr8VivzUjFJG0WfiFebljKKfCqccc6dPrnWzLTBwRwMhyxw0MMXpS0G+uhwGgYC1AhcW26vkWvKjySHxteM8SXvw4PMS6NHjEiv18B5yHE02eiZ0UBx9mHzquO4vq4dRT46DPTwQ/FSX6cmrZa7/OVSjtUYgMsq9w1l4YmnNuBLT8zHvj4n1FMCzD7dQ3FQcxJwZXThHdfXq5sHT+wtx74uO0w5g/Qaz+ED157C/9vSiypZI6Q1ZXdMszENqUQGR5/36t4H7ikvX3jQmZDHhr2jNvQP2jFB626CxoSB68jpZBm3BaOBAMqW9eKa63uwJp0e7hDlFNtvJt34ipUcoeFxZHcWnj5mg6tmFGvr3Miidp0ycOWsIcekY28evvQ/Jfj8fxbi+7us6BHrPG5hiJfvH7fg2AtO7GkNY+PfD+If3zuJzQsjSLKwHr37Ve3yY4lybUTY71IHDRKuE3A55ldEkUbfqKPZSGOf+SjGutsMoL0IVxrzSFlOLhOVs510pUvkpj8D0x3kZ93bDHj/Pxvwlk3AihLqWBoyARqv8uin9G1qrQGFLmDkQAQNXYzL5dyhMraxbOkaE66+zogNxVGcfSGCI62UfVJO9ZsGI+WhuyeCnq6wOpswcD6KcbbNkU6eTJockidIko1mbHq/HR/4nAM3bbagrhDw0XCykufFFaRLy7zpjNaFTb/3Y9+5MIY4fq4kI2q20qC4wYJFrjAOPxXE6R62Qwjr438hmMDBnH5pE+lKYHvlzETs09axfVmbrxck86cBtUAkcLGE6U3Al4fm4XQM27qxoZxeVhItybFcNHslFz2GSBI6zt+Ibzz5Xnz+kXfj3594N/7n6HycoyVopzBmBnWaVAZGaPrDRgrNACcqPc0wZ5mZgoaCNBKycmIx18t0ppzW0Sw5bVGLojDKqR7hOm5i0d2QqwpqgIIUSCLsU2iwyBMCSUZ6Y31L8fPnbsaDrelIqXoUf7WoGQVcNH79DIcC2x+mdyGP8YlQnYbWS5ZAMfacm49jwTYsL23AshQReDT2Wbd4RBYqCbPBQq+RAsXihcPCSU7vBd5cdI7kotso14xPYlOaHyOj9IYM41i48DBKUYLnn7sD/7l/MRq9Ji5EWTU6pL16f8ZgEg+cStJIj174nRLNVCBOruTh7hW4i219pMOJrJqH8VcL25Bjlb6iEDMmUTnYNQWRNIyyvGbMp7esnU+Jg/Q3DZbgwHI8uOcd+MLD78O3Dy3HkUkahiKM9WwvC6EjY8j+kzEUiACzk28/JUtKXj02lfbB3LcED9fX4hTjZLG9IvoX0JZ5rCVdAKbH5pG2gDnfOT/lRlSTkYYYJ06I8zNCo8xBYwo0RP2BWK/PrEfNOx53tGzB/z7/Xnz5sXfjiy9uweNdyTTMNINhCqJ8WJ+ZpORsmtPuRbKdhgnrjkeMvjantXb4OB8jNGKSbSGmUZNbfTRMh5DFHDIHwHlipBEQkjoUFSlJj5BtClKK2jmH5bt5sjZsdhpT5MHno2cuDElevT+0vtHW68X6Lz6vUnysySJnoNhHAesIFi9sxhaXHfuPLsWvu2gMRtkPM5uo5nHIZ0f7QBq8LFNVOoxCKzOJIUKe5OZAUc4zBawwpDGl+ozpqZV9qEkNYuxYHb7+i8348kMVaEnuwo3XHcNt+VROvWk4G2AfsMxsQStPLQRF7vjlZlIRFoykvGBTlOwQZZecEkCSLaIM4ylI+6XPhQUVzR+m28m7zxdG+oIB7FjsRaQ+F7/cnYHTXjkrwL5ShXXox7ZJF557MRV7PG6sXz6BdTkcFy7iqa7Xm6yekBHLhTzJXJUOjeURBymZC8VzzoVv/lcGfvaCBc5NI/jkrT6UZzK/tEtllh8G/st40MeBUYKfB8zj9quWUF7KGSruUIY7U5lOxe+VmxjjYGK3iaFgYj65LyJ3O7BlGzD0mwg+/3dRfH+PdmZB+keMdrmHtvH5MI42G7D8DiO2XkYHhDQjssBHo9j5wwA+9X6/Cv/0t358454wBqlHtOsBGsQYMFMHORyM476NvFnJB/1TlSbtipCf+TfbsGmzEd0/cuOfPuzGXTRQbBS90n1epltJMyU1SkOW45htQmqKgUYG50JHEA98ZQKf+uAE/uEDE/inT7nxo4cj6gbYi3ouZEX6UtaEFmLHFwYjf2QrY/96wO58MyGN5ISml5Ca0oOq7A7My+3EvMxRpFnsaOkvRFegFzUFTahWNxGm0KqzYWKkAK2hMCqLTmJ+Xiuqc7pYrhtFTnqwajGH1FkGmQ+i1EMhO3pH8jAYmEBBHunnd2BF5TmUidfUXYxWeuM2C40JvYx4yFaTPD8unS1KW45FkArHVJrqWPOoJcao8gdhZo7oeK7ybJLS21CRexabitupCCcpOE0w24dQXUZPOz2MvrZq9IaTKMf9HHcRAEKLoDAweumBupMpAP1IT5rQhbDGh0VOr3LQx7trcLi3GGPWcWQ7R1V7g4FkdA1n0zgfRik9zfn57VhR0YB8QybOd+Wh3+dC72geWifHUUIFKTdeuSfS0U+FMEHvNWr0ICerCyty+pFJwS7CQNosZxgsen/EIO9DUE+VOPsxL7sdVS4qAlmkVHrqU6tJ/ZhfcQxruDi62+ehP+pgW+V2xij5HadXGKFwsqgnL1KzT+C2zb/BBxe3I4Oer1IYej2xdkv/iyBVc0bFx/o9Nk4aj8qIUGMWpHGoK9e4fAIxQKS/JG9y2gByTKlobFyH+w5chfuaCtAVciNTzmBo2WdC5qtOW7jUaGvzRp12nlXXNOiJq3ZM55WycrbGEDWjf7QAvV4vcnI6UZPfhWUV9ah2mdDTW46GESss5hCNiTi6qr36mQMRAlMCQ+sfo6TTmFPzJULlPJaHbiqmlIxWVOXW4/KSDlRneGi6afmjBvLGOoSeIi9nDcib9PvAaBHaRv3Iz2vEyoperKpswLbqFnUfzqR4WWndqMvpRrlTKy997yCtCU8mmug+Rez9WFDcjeriVlxW3g2HuxAHOjPUKXAHjXabjK1ql5Rln+h9JONkE55Uu9jvqg/YXsWhllfOcCQluVHANWYaLMMDL63BD/cuw330ztSa1QjPhChcnxODTfPw1IANmXX7abh3YFnJMCpyJpDj1JR5IMQxYx/azJxPcWSkj6XXeocy0DpCwyF3CKsXUcP0pePoqRx0h63oH7awTAjOdI6vJjimII9RmulE5OeOoaJ8GPOLxpFjMcPbn4IearfCsgF6o324YcE4CtKCU2c6pJzNwrJaB8DAY2mjhXFpBR46zQ6c2FWEu35XgbsOOtHtDyDVRoNUldYDeZf8Nnr6JnMU3lM0GOqdGEoKIj9Tzs6yZVIft1Z7hGvThwXVXlTUeLGgIogsOSPAMVfpNP7NlAPG5BAWXjaBHVURdO5zoMNHp0x6SLSkqpeQXQn8kZsvJ2mEpJYEsXpBGPlpwGCHEc19UWSSxuKlEVRuiWBVdRT9pw04ekb4lrIEh26CRoIpJ4q6WlDuM84HjE8CzgJg+TIDVpYzO40RkRcGKmsHjQvbWBQvvhDFKZsRO64xoi45irbTUQy4DFi91YSyWiPKFhlRym2GGCpabVOIkmdjlhHlyyxYu8GELVuMSPdEUd/APqRSF0PCxjo9ExE6QYCr2ITVK81YVs7+YVrYF0Xz6ZA6S73yJguWLzdj+3ttWEujavxEGN5CM9Zut6Cs0ozyBWaUVJmQ5ppu9pxgfwqfsu7FMJJ5NvuGR7lkoYLs62VeD97UpyTCBh/SkqlEs4eRktyBxUXnsLKsAStzIhgazEbTsBmZ6SPIS/Giv2cBDrcuQIfXQms0FW3BCSwqaMTS4nqWOYdV5R3I8NGDHkqCjQqsTJ6m6KlA/aQBprAdfnc2eoz9WFR8hvnPoi5rFO62LXjs/CKcjFDpUeAVU7Ge7ivGsLUDtS4jevrmo943ibKcASR5S3C8Jw+dGMF85s2L5OBM1zwaLmPIy+pAqdWFNirGpvFsTNrbUZTViuVljUjxZWLSm4OJoBP1jeUYNPZhzdqd2Fg4AnugAs8eWIz6MRoOFEpqknJgQ1wQ6ek9qC0egXGsBHt7XDDbRlBZOATLeDlO9qdhnPS6AlGk0WAoddrQRr4b2ivYP6kYsVLpl51Wp6gXpPjR13AlHmktQWcwROMpjBQq7GIK2FEK2OPNy3Bq3MBFGEVJTgeqChuxQK7JGU0UelU435uOcGo7KlLM6OuuwulxmkWceaJoxmlgLEjrI1+NyIoWoNNLizm1EwXRfBxqmIdedGH92l24rGAMZk8lnjpQh4YJC0oqDmB1ahLOty3Avr4U2NNocGQNwzxZgWPdGfDIzGY/qNlND7AmbwDJ/kKc6s1DD4WDVfrI7EZORhdqbA609Faj1dCL2jQv3EMLcNzjRUlGP1zeChxhXxlS2C6nHR0983BiMgJXahfqUuhFDNTgZGgIC3PaOf6dKM1rwZrqg1hNIWmYkOvgwof6Vzvq8bSkPiymQWucqMKRASds5L3CnowW9s0pTxAZaV3qnpjevoU4M2ajdy7KkHPdNMF51IMCYzoauipx1udDLvmfn2RGZ/cSnOyhERwZRk3hGawuP42luf2I9K7FU2dW4hBdrPwMGtT0Rgb6anBszASTswdLM9zwDs/HiSExpGPKXs7QBZGW0s915YVvqBz7ezPg96chnNSG4uwWzotmOCdzuY4yMOZNQz37PJTSpe7aHuidh8MjHOOkXqzIEvrVeKmhFg00tnNzz2F91VksTjJisHMpHhk2wWOZxKrsHpTRQE33l6ApQM8yg+vFXYJDzQtxYMwIU1orDYx6rC9rQaXJhaPHLsfd3UmYMA9jBed0qi8fezu4dsPjqMjrQ0U0Ewe41gbsPVjFddjK/jrmncQCuQGaxsaejkz0YQzzCgZRHMjCS/TkJyg/rijicX43Vlc048ra81hmzkHjYApGA2Jkx8ZRgyh9vycV52hIu5Nbsbq6Axtr2nFZ0Rgybek4eLQUL3QCeSUDmGd04URzMc7QK1UGGftZfUthLB2tPj+KSjqxjcbu2oU9WJZlw6kjFfj9GSMWLhpArSWFxpE82kyJRwaidEkryseRR8OkMGsEG5Z2YVOJH0ljuTjUTaM9ncZV2RBWzOMc47h5YMFAdzJOdZqRXDyKeVzrjfVZHKMwMvLGsSIziq6mTBwLe7CCdBdUTqBm3gi2bOjFllLqV87/+hFpP+dFOApbkh8LaulY9SVjf4MFQz4L2mjrpDgDNCCNaDzjwuFTFkRy5SmIAFKyvFi+ZBKbV7uxaUEUY20WNHaYkFFJQ6I4gtFGB158yQyfLYQt7x/H1SuDXKt2PHinA4faTfDTqBDDOvYnp47kBnOPPare3VC6mO2gw3b6mAnHuDYrl4Rw+dYQNiyPwtFsxAO/NeH5NhZTmlEkQgT9tN6WlkSxcDVQRCV9+EiULhKwkp79kgUGFNJA6OFYtRyL4hzbvaqU8q0+ivvvi8CTY8Dy9ZRfPH7suQi6uVYv32jCuk0mbL3KhMvWGuBoDaOJBqd2XxuZtRuwYK0J84qoS2hwrLzcjIWuCLp2+vCN+yOYSDNh00IjQi1B3E+afrsZy7dbsXSBCblW8jIWQdNzfrywO4yJHAvq1lqxcZsVlaMh7H7Sj6dOs658GhBbrFjFcPm13C6mG1kfosGtnZ2YMXkFMpZOzs9aA9KKyCU7dcp44FbmmtoymDhfxbkdbTHQAGOEdKYkvAYYKj7xpLDzpkAG32zWrrGaxCtUpi0TIjZMeO3wslPsNj8cFrl0YFfP6gc44VQHmnxIt8s1VPHOhZoRAb/cLW6CwSrXNan0gnZ1w1TsQykGiwep9NrlVJJ0mt/vUjdIBo1+8sB6DHJjmg0how8uWtChkDzuGKIXRMs7Ku9hsMJP2zmJ9O00YeW9ED6qTrmO6qAnI9eY5dSyweImvYC6NCLXhWPv1ff5bAizLpfTw/KcYHJzpcdGipI+PQxB8pBVuBe3rN+Javc6/OrptTgTDcLu8MPMvpH3JgjNMOjBkG8nvQX1jL884y59apV2BpQnEpWbxXzJmAzJpRLxiumVWAJsA927kLwTIIk8sw/p7brsXuXdiUcaZD+HaWj55Nqy2auuR4bYFulPgeLWSIEi/UkvLEIDZoJ1mJjXwb5x+9hu9mNykhc2aWvQgTG3lYqzAzde8TiucpTjt3svw6NdLqQ4PGqMjWybm/XN8OwN7G+b9L+F7ZZ3Ochwi/KmB8x+d3JlyM2PfgP7lXxEww64I2HYLX5YhB77yiD8U8gE5WZFzimTmX1Gzywa9WHx8kdxc3o2Xqivw64eM5YsfJGe0gQGzu7AnceKMUYvVxbfFOQufPafMSLvQWB7ZeyZIcD2ediPZtbrovEXYr96Qtopeiku/MojjnYaYurdFzQkhH8XuzcQkLxGRMlnitwjQt5kfgYCLs5nzjn2gV145jhLP7qpfAwmP5KtIXo+ooxkPohgVg4Y14ecBZExlnStT+VaqJHzMsnGfuOakVPycglJxIyX6VGuJyc9zzDpT8qpcYMXycwb5bqbkBsYTR51GSOJeSDz1pdEb4nGENdvOteomXM94HfScGHfM87Evh/nfPRxRiaxXJqVtMijvPDJ7XViVOacgR6wI8hxMjOvhWuLa420nORJ3vUQ4lpJpRccYH+5aRA5ZR6ELUwzk6qsQ4aAid5cPd699hzKBurwb0ezYLQN4KbNh3CZsRo/eXIxHqciDlvknpTpNabeUMg+lq3NNqH4kzMZYnPJ2x19btbDDrLbOd5cux6flZ6kGknyrdExyCUYjkOq0wsnx1y98ZBtmfSaOVeDSHeGYOQaGvDIvQFce6xLLqo77BxPVZ+cLWA/yM2NbjvGuCRtNs4Bu5wZYrvJQ1TSA0Z106vRzjUqck1uhOQcMHENO5mPKwBrb2rAOzJcuHdnLvY3RbH8ila8dWUYDU+W41uPOTDKuSOXWgxc305nGGbOXfGEA4yLsA4naadQ0fq9RkzQyTKQv+QkmUd0ZJhuFKEbpHdP52LSb4TZzjIOjqmPyniC/cC1l5LJdpGbUMCA8SHyL93ELouy7SLrtUsbMkM56yhPMqh05axJcNyIMXrmYfKYSs/faWUelgm4DRgbpwyVyTs1dkyjYJMbDR3kIeyNYmSM7bKxbCrkXU3qMkiAZYI0hNST7klsuwesg0VJPzWZTWGZsQnyQaWblWqAhfNM2JPLF56REPUP2ySsSt2pJtz8aRv+mv35zI8DuHuPsBflHAljVN7hwH5Lc7HPKJxG6WRYkgzkxQCS1O6lEF6YTy67mFPIu4tFuO7DkzR0yIdcTrYyPoN8qfue2GdyecM9HOFcn275DLAuVy6w+K0GFK1hX3tkfs2dV+4zMVLuNDwDnPgNc3COyk2kF6F8SbypBoP0jPbqVTlxHA8uJHVaUqxik0qX05MmCbJmWU4UobzUKb6cnOI1c8XLopUbU4yzTg3LC4K0G+40CE3tPfusQ+qRekVBRCmQpLzQE+9QruFSvJo5ueXxvSDzUkUyr7zJkIpYypJorD6tHmkTJ7J4JHqNJlHGUalL7lQXxNqpDqYQjVAxWrqwtu4p3FpiwZG9b8X9fWb1cijt1LsofvJPgRckb9JW6RvtJjLS1vsmhli/aDHigWo8yKlZuRlT9RH5kpcxaXxJXq0u9Ra6i/SnegyVZaR1cirewvGSuqUf5ZT/jLYyk4FKz5K7D59Ydw6ujo34xfEFOBcKcr1JG4TOdNumwDbKS5nCkiaCS08U/qQdstjkVL9J+FfzRHjU0rQyrFilafmEf5kfAY6ZwexGRvkL+JvadmRRgvVQsKenuRGi1/7i4cvwIj352E2sU9D7SQwAoS0v4orRjrVfXngll2bEYJsuK3NZFLs25jEeZ/M1Pael/xkv84NjqsaMeVU/i1BhvdL36vLb1NhyqISOEGBfBCisROHYhU9GheTlSjI/hAdRYKoEhQn7XFtPMleEN+6odrCdpC+XNzTeOBZSRCk61ittEsMmxrP0PTeyPtS7OKWdNGxVn6itYky1Qe4RkLENSxs4TtSspEuOWJYZ2Sk8llf4caMuZAu3klckuqSxHeqeA8aZspqxbeURfKw0hJZxKllTEJn0HJsOrcXPTueixc/+Ucay4lJBKS8d8hKnqY5jv0iQfhcDQuSP3IchckFuMWQiWdHKyil3MRKConRVYDrTZJ1Qj1Nxsc3cUaf5ZRUo+hIv7RYKehwj1Sl+YYFNlXGQqszsd6lDekjGOMQycje+ugwhzafQ8VOxGGhkFaxuwWc3T8DF2dJH7zo9P4BASzYefrAAT/dyfIUI65J7EELsD5nXcslK44txpCPP8ouWEyOGU0/dg6X4U/OBWzJgojI3U2CF2LawEgo0fGWYyEtYhKZqDn/kUWHVXdxnEKNBfY9D+pf/6tXOIjTlWDSr1CF9IqcfZPzVHND4YSaNjgLjWTdolKiy0tGSR2jp00QDj5VjyKCsZQZZZPKiJjmWpw9kHMWqUWNBcFeVtzBCBA3JxwyGm/7Bhg8vD+P+r/nxwyclgek0ElX9Urfkk/krdcrxbEhnyBio5/djYJxYOIIZ8TqEXykzF9jXyblRLH6bCcXrxLjkmAlbc0AZDCYTzj1twPF72Dau5T9TgyGBucEFScHodIwizxmkJZuLflryYqdzCv2ZQsQ1J7V9DMXOAMLudPR7bVz7IsjfDGjqI2yeQFHKKDLpSQof8h2GiYlM9E8kw0OpebH1+icJNkBkhpKtMUHNXXlHhtwXEmZfRyjUxNONFy4qu/rVoLxvbqU/JJu86lciROmoXDHaIiAVtPwq6GVFfko2ZU4ymxwrhaHyyUzQoOXXykxBz6cQ25U4/isvnYI+LgePg7A6xjE/zaPO6kmFclaid5BzjN6wvCdCtTmuVLzBoF1rZzo3RiohkygiHVouvb9iRSSjbFQ24UU0jm4wSF5J0PmN3bCoVq/wwKDqZhbhR60KRU5MfQp21q0V4b4YC6oMI7il2cZcmo4SGvJ4rKqE+yGrHxU5fmQmCS9MoXE30u9A34AZbjE8JBv/pIRBlLHwwKOpnpR05VIzXaJUuvQHy0h75IwQB1ENOZPk8UGlsFVerW1SRLVRI6bKq0i2Q3Gr9uPWu5TR61QGggLziDUleVUdEiRafqSXWJcy7iRIWwUqg7YbQ6ycQOgIeUVDi1Q8CF+qHnE/JDlWQG9XrAyVa2ahEXmuKIa7I+gZYbxGQNHQ6P6RoRsMde+gwbB22mCYi5OYwXD+aeDYr4VnMRheG88Jg+FPFDKF5VFNMdpNJnm6Q0/4cwcnq0+8SHrgcgOgKLM3FTo/4nlpQoOs0UOUGwDFWfizAhugyTg2gkHJW/6oS3LizVOiROg5GUTwx6162Z1SHISUF1US6w9R9ipeNxhiSm+mwSB/Uo9sNTmqoPKRHnl47QYDf/StUp6kp9qoIFKScSG5Zqbzo9IYb6XLyTZL7EyDQcrru4RmMIhRIcpYlLQoLCE73T4RxlPF9c5TcUJLO+/yigyGWLywJ3FyIIfSLlniBmUwaPlEWWtBlVYGgzjKyibivhgM4rmr6sIGeGNnLpQiZyZ6wDaz3Iyt9b/UJDUapl63LFQVMXU4l8EgxoXiR9JkIohylbysVGuP1KXta0+3SD9LnGwlScuj6pb8pDPVq0JT0dCDFjttMGhMqU0MqidoDKm4P5jBIPkZ1KFsGXzqQPP6Y2cFhKjKp6f9MaEbDEvebkLpeu3yiDy+OzWecRCDwaTOMABH72b66zAY3lQ1JKfUw+oaq+2iL0j5U4VMMfnGgvCufavijYUMvBgKDnl6Y45RkjvrfaxbfUNjjknyJwtjSN1fINfp33RjQaDz45T7XhicNp+6w/9PzVgQdRK/Vl75iEsf6/3MjcjOuJiLQrureu5csm7l/psJuUfhIutW+A2QV/nmhJ+CLJ5S/NGl6plGLF1TSBcIaGmUWW4AYJBLaAILlTi160VaoG+FlE5LJ6sdM33KWCD0LBeD5HyZLBpomAa8dALkdD5LaFVoJeU3XthLWowDLU07jsXNgESy3Q57CM6kIJIYHElhOOTywRwFxIbRAn+mKpquW0HiZkVpEC7jOOVOyMf54Jb5qcfpUHmEDsc/4uWOfMdBGVWXgBR6mSxTiB+jl8OsrFJNrBVzU4mLlV15nFLClLEQg0bjTQHZkS6QRybVpVrqiamnIuYKr6a/LoI37ykJua5pHUdR4QlcVdYFVzAXg37x9GIL6eVA4SEfU5LXGcu7FKg45dSZPBcuikj+RKFrH+yxqOuq2j0K00JElK4/qCldMdNjX9WTVzCLMlZ0w3K9m3XI/QOkrV2XMyJo8CA/7wwur+xATjQdPV7txrI3YExeFmLJh5wdWFddjyVOIyYm0jBJS5xz4g8CEf7yQS95KdF0f5jVjZHSn7F65Z6FgCi1oAVyU6a6WUpPkw9/Xdin0uFiGDEfy8r7B+SGzohcC4+1Rd6syDGSD16Jn6Joyuiyo2MfJFNnCPSxFdtK5oW8nVLOX4T1erU65d0Ulqn5INf3ZTxnd9uMucN88lnumfcj/JEh90mYJ5FbcAI7yjuRFpKXcXGOsl+0D4np85L9I5ccYlB7/JH2yK94iiLexEuVmEuKOlVOyxPLJ6TVx9Ms4ygrOYkby3uREshBLxWG8CI3bipeWNJvHMPiytO4tnSUejwNHVQYQi+G2XVfkpcYphiRHx5wLNkxwpTGnNyEW9CEW2rbUIRU9LjlDJ0mT6RIfP3x0OI1Q0Pmj4SZIH3KK7/cIE2nVh5nlHktdooGXfWIFibkvqUYlLRhvPj20axBXL2yF4vsZoyM2jEha1aVlHKxUdJ+1D6TYnHxyk2CHMp60GpQMYS2nTJ6FLRyMUx70cSMbNzR02JRki6P7KokOTMwk5S66TPsCKFs+SRuXhOAy2NF9wSHRe9zRZ95IhkBrNrqxRXzowiMmDDgVoS1euL5EahyjItFy768V0/ei+BnUK+dZiYZJPHuhZbclyDX5MXKl2EUw0TKyLHkUxURzKYgJya8DGLt0sZU90OIIRDLJ/cgSLq6L0IP0qCYFyF0pE6570CEvpoMWpJC7L6I+KAt0DcOrNfmAvIWG5FeynGQ+0nYWDXXZwX1Om2TEYNNQM8J5uManmOSvyK8eQYDBbLH3ou62sfx/xZ2ITywEsdGuSg5Gi/btyJAZWaknsc1NSexpqQF1blDSA66MO5Ngp+95AsHkZ7RhC21x7C6qAkLs4aQQcXeS0Grxj9sx7h1ALUlp7C9cJQGuhN9XisXBi1zRx+WzjuFlcXnsYxl6xiW5bhh8LswwjwRAwWkYQw1lbtxR10bksZrcHDQoeZFTEH+4SAVGBBIP4O3rjiEVeZ0nOsqRW9UbsDUcryxkBvd3MjLbsa6qrNYUtiIpeyPxbn9KLUloctNhc2hkHdQeK3DqCk6i8urmlFgo9KYTOV6psCgwrUm9WBlZT2WF5/D0sJmLCGNRVlc1b4U9E84EHSMoSC3HhsLe+EKZWE4QAOCwiLs7MaaijNYX9qF9EgS3B4n+57xdGdSUrqwYv5JLMkaQA4VRL+fCoJj60xrxqpy+UaCB3kZzbhs4UnU5XaiOrsLNflN6nHXRXlDcPnSMSplOOemx418RwLIzGzFxpoTWJQ5gixDMgY4b/5YBuEFiNLosQ6iat7z+MCCTkSHluHkuAFpecexrmCczrUT4z4aVMoSmGZQ7fEn3mBQUZKNW+3oQmjx8qvRiuVT+jBiVd+hWL3kaXxmUS/8PStxcDKIvMJT2FTghYHrb9RPY8vSh+0rXsL7q90Y663C3iGaETQmYl7OFE2OcUwZvmIICRoL8qbFNVXtKLfbMDDsRNA6ibyF+/G1jedROFqDXb1OTIalTq2IVvNMTMdrxma8ASlqXv3SaLQlTWJRTStW5VBHjdE4oiIUI0Dl0f65r5W8wGBgkBtNUdyOj+1ox1J/Ko42p6KXsiZmGEtZLaf2o/ZJJrZVfS/7etDuX5CgHcdjWgdL7dO8aLkJna6WUYjLgexqO1P0VD7NYBDlHNcsBS5rhFL8WLJjFJ/eFoS/0YV9nYzjQlF3+0vpEMkU+fDOD0zgo4sNaDpixYl+Icz2Ct1pZgnZJ5cxRkWgmqNIWxbF7TdFsXQVUF5JidRvwKAYBa4olmyNYl0tdTQNlZERks0A5m0wYP0S5hsGhiliYn2nIGdBkg1YsM2Et1xvRO0KEwpyuOa7tTc3KhbsBqy+0YzLrzJh+QozKrOYNhrFhDxmLUZKxADTIgtuutKMedlAR588Dcc0aTMFkKXYjLXX27D9cgtWXGZBRb4B7voIxoR2PC+vB7rBUFBnREYx51eQ1ZO+sDA7yPsozBwQMRi6TzDTn6XBQMjCMkWouMeKcLqvEF0eCsaQfLJXPFUKcglyOpP5pk+tyem8EByuLvW89fyMIaSntmNV1XkssCehfygHnRSmyZnnsK3uELbke2CwDKOiqB5LXUnoHqR3RoFmdPVgfvVu3L58F95SGMTwaAn2D7poMASRlXkKN23aheVJnBjy9Uf7JNKtDvQNZ6LXbaNnSg/fQGWU1YZF6Qb0dtVhd28K5PPMcoZEebrMI5/M9sujgMqzlSctxJvWBkzS5BPZQXq+cm1ZOzMi8donkIMsI3ely7VCre2cFOL1Ck3pF0cXVhYOwDVZgmPd+RiYw2BQXr06AyP1MMiEYj1yh77U45ezMuRF4/HCMwYKTPdy5S2etxvvXnESZVYLZfUYSguoxHO8GB0roCdHhU/6lpwjuKl2J966qAE5DiM8fVU4T+8zTJWcnHECd6zbhcuyvaTPtpr7saKcwj6FE3kgFx0YxKLap/GhBV1UiEtxcpT8sWRGyQt4/6LD2Dy/CRmRLPT2F6GdDYkGfSjIP4Hbtj6Fq4o7UGTOxdmuLIwGaHGX7MLtq84j3+eENyjfaehBcUYbVlWfRl2mlzJIHmk0YnKoAN00AOMNBnlMMepooyHyAu5YegpLaBileapxeJCGigiKWX0sClDORshclfGSfhRhrl6uo/pWGy+t/zmXpf+ZJk/SyGfPVRq9V1E+Jppdauw5Dmo+yNM6Mk4yR2zjnG+tWJZsQnvHShwdNaJ84X14Z7UPw13VODPsoC6n1IiSFxlPet7Cj0h1OWUpqkPOBiuhL4FQAlsCx1yeklD8UGiqJ5IM4lHTqNfPGogCCKmzPWwfadqjNgroQhzqLEV7IIAlSx/GB6qj6Gotx/ERO6K2YSws6uSaTMbxlnk42mdnm2UuiPdJjTCrH5UEk7MF8vlqygD1RIRoDtlIZvKi0riOVAP8SUgrOYYPbaDBGCrCM+cyEDCz/exD71gmDncW4NyEDQEf85NWlHM9SrpReXyVHSFPfURZXzQoPr60j33OegJ+9psYq8wfknsCmBZmv1hThnD15ftwW34KDp7IRoefY2nSzqZ4JT8NTykTFq+b/aN9c8GIIOsIkWY0yDrTh7Gp0gNjTzb2tToxQK/dQvdPygXFkaGnKy+MComRQzkh9y74yX8oRL7YBmmLPLkg4yhPDEldXr+cRaPdLY+akqegeENsi6xjeZIh6GNgWWmTyBl1pozt8su6lEsjEqh8tPsUWJdXoyfXveWauDxmKU9ASHpY9rm+JESoGNXNsK4wijgH16Qbce6oEwe7SU/Ks34xgeQeCxmvKMu2nbPi0DntKQ75zLWywMWTlzMHwjfbrBkRErhDGsV1UWzbFsWCfCrHRVFcfQXtLtZ/7nwUo07gjr8H3kdDou0EcLaRJMoNuOqvDfjwZmD0QBQnBmV0YzQZ6Mgs3mzEpssMqM5j2GjCDhoY1p4oTulflKy51YIPv92I/BQDUhaYcSXz2ociqD8d4bQzIH+dBTd/xI5Pvd2Mxc4wHn8pjEn5ZDaNiaQiM7Z/xIHbNptRyGnszDfC4oui7WCYEo6Q9r0RiDMYMuV9G5SJIsNEHs0OcobBxAU8wP6ZNhheGyNvssEgFqgD4+509FHpBMyjKMsegtM6gYps8Qgp6B2UE2EbxjjJleKU+x6MXqS7BrDEVoLfHl2NJ2it5+S1YVmRF2ODhTgxEMTSpS/h2kIbDrz0Dnz/VCV6TJ3q88AZ4+VooIeQVfMo7ijvQZHdgklfJpp6y3FsOIlzlJ5rMj3RAg86jr4b3zuwDo+dW4zdbfno46IzmuXUnHZJoiC7DYtz3PB7kgFHH0pSR5BrpSANiKL2ozC3HQsK21GV3s80Lw1Xq3oXgcHkRW5uExbmddF67UeGIYlCx4nRkA+5mR1YVNiGqsxeFLn8MAVT6G3LwANWMXJIsyanF8nOEdY9Dvtkvnrpz0yDgYtW+sk2xIXWhgW5XShNpxduocFBQTsakVf7DqIgfRTJtlHUFrShLG0M2WaL4l0ZFlO0jFxEbhTlNaPWmYojh27H14/MR5etEatKWpE9sQDnRtIx4PdjUdVBLHUkoW80G+NJY+plVycGHSwvBl43lhYMI9K5HT/etw33naxEn40e4vxzqEIm6qmQndlNWOq0oLVrMT1oeaRxAivnH0CFvxKN/hCsNiPco4U4NybPRAWRntaDKhpN5pAdTqcXgZ5SNHEeIa0Jy/O8CPYuwtMn1+DR8wvR6gvScBhEtG8jfvzc5XiqpRytHE91GSuurd5oAPMqT2JtzhB8AwUIOUKY6J+Pw0NJ6t6BmQYDhXckhNSUfhTIWQ7nGMemD5nGJIzIc/uYRGVBC8e5ExWZ8gVGKmE/x5nj6bCPs085B2Rs0kbgQjLcplFUZHUhn0aZfDzLbRpHYVYPypOi8IXD6hPvq1MjGOivpLBsRU1+M0ppmPlFQkcc8PhdCNsHUJXfhFrSLU5xwxZOxTiVJHWLElacSUpwqmbobZHHHi3WcRTntaMsmUJzUowoGloFXahOozSnASLvN3Gm9aMmexjpRhsGJ10YmUjFYCCCPPVJ8E4U22hcyrN/IbYx6kd5USvnjAlDkzQoU4WWB6ks20clJ5A5rSACjP2YxrYuK+1EZc4AeffDGEzGqCgWOgjZ7MPaom7MyxtEBiVgUjL7uqwRK7K8sLC8vBgpGCZPdAbGJpLROcF5Dg9K8vuRk+pGCfmeX9iP4rQQLJYAHCl9WFEqH1jzwhl10ImgLAr7UVnWi7oyaec4yjJDMIoDY3Kjdn47VhSNItNkxmSQijecpN4dMRn2obR4AMsqB9nvoyhh/8FvV/TkcdWkjBEsKR9CNcsmp3qwttSHaG8mDrW5lMFgCEWQnDaBukUDWFgwjkrO22yXAZ5JGgh0VipLJ5GZ7EdxLvNUj6EijcYIDbcej5TzYF6pFy6bH7VVE5hX7EExy054yaMnjJwCtruY45jpx8IKykyDBf1CN8mLJQsmsbjagzJ6/7l2I8YnaPqwLxbN96lvSoyOkH97GKXMU5VHV2cijLz5XtQu8rEe+SAV1w0V9wjHu2SRF5tyDWg6LgYDdRkVp2YwyNiKgpK7+I3o6zWhY9QAS3YY5VXyPogIapdyvyys2jxIDz4snroUFC3viKKmIoKcAQP++7+N2NVqwLItUSykUdCwC2jyAEs2AeUc+53P87iLVSUbULHCgFo7cOKFKE4Pa6QUxGBINeCyeUDXvjB++J0wGmlMbbzGiBwaSIeejmCy1Iy//UcTXC+F8OXPBXD/SaBkk5nOEdByIIT+MgveQmPhbcXAGNs10RTE47tZTi6ZUD6tfr8T772O/H3fjc9/w4unHgpg734aC6K8YvP9jUDMYFgiBoMYftI4qePCIAaDQQwGdYaBvaEMBo3Mq8WbeA+DXJLo40J5FB9f3ArjaA06rKfxtg37UZs2gLrsdiyuPIqtRTRHvbk4M+RS3pk6KwEKVG82Tg8m0/Jmh0QnMa+8ERX2VJxrrsFJUBjUnEdNoBj7zlfTIw3CaOHCLepBWpAe+YAFqZmcXfSA+9h/6Slh9PVU4siUwdCJZdUdSPGn0bse44IdQZZFroEzyGLgn7qHIasTi6mwnLYJGjfNqCuXz/hG0Tmcj06vG0uqj+Oy8maUZTVhbWUTauxONPdkwJZzGtev3oV1NBZKaBik+EvRNk4PLPUkrl50AptLupGX3oLFub0otqShcTgNAcsgli56Au+qPY/5NKbyXT4K1SA8Q4U40zvzDIN6IY1lGGXzduIDdWdQm9ODiqITWEfvPuopwhn3JJYueAm3LT+LEvsoVpaeoVA7jbXpNjT2y/VxC/taX/CqrZMoymnDkmw3gt5keEi7JKsXORHW3VJNT86OCVMH1i88hZLoInpPeYikNaDcnI7GjnyMULnbXV1YWdwHh7uC3mY6JqjgevxRZKSex8pkK3rlzYPO81SIRvXmwxNj9Azsjdhe2wbj4EbsHQwil3Um+3LR2JeJCSqk7HQaXPlj8PQXwuHsRLY1HU1DmfA6W7CikLwOlOJMfzomjQFkpnM+FffA6SnFsc4suEV60IMP0dNU7+CQQ3r7puxjuJzKodhXjb3dAVRT6HoGa3B4cC6DQV7C5MaCqt24ifN2RcYwlqcPwuwvRv1kEJn5R3DLonNYnNeLgswGrMiehDWYgyZO6bKyg7hxOcswv3wV1ES+Ol1H8d41z2CttRAN/SVosp7FjWtewK059M56sxHMaMDq5CiGhwtgKjjI8RhGhjXA+dqP5FA+uuhR51Xtws2Lj6OOayg/xYPIeDWaPTT62D7lcQjbsi9b/oiYCdEgsKW1YfOax/CO8gj6G4vRa2zHzVc9gfcsmMBEZxHXGoXwsmfxsaUdsNKA9+bvwueWtCHNnwNH6WGszBpHOnlJSxlEaiAfjeNmZOZyzmTQULZ4Ma/iNHZUtmCVy4VDXek0Ylh5jAkD+4rG4k1Lz+Kmyj4aVx1YWdCPBfYUnGS/m1PbcMeWfbi+qB/zc/qRFUiDLYOyo1LeSkql7BqloW7CxEQGxkv24WtbzmCerwyH/AN4x7aXcOv8ASzNHMPyqnpcOb8fS3PdNDY7sH1hO7Yt4FxxpKC+l8ZGZBybVzRx/Pswr7ALVy7pQynn6bDfi+Wrz3GsgnDaqVBTJ2Ebz8M5Kj9nfgvesYF0qkdQmt+LdaXjyDe6cKrHgUjKCLZvPYa/W0MDpGAEZelhlGVEMNyWiaPtYjDQ8w4HUVzWhxs29qCORsXSRb24el4QI63JaDWM4I7bWnD5gnGu4UmsWdmF7UvHUEIHY3+rmU5PFz76djoRmV6snTeGlat6cN38ANyUleeao1h2eTvueEc/NtAoWFdIw2/UhSNjIVSs78Znrh/FChoDNUtGcWVVCP5eB3zFI/jgewawkevx2F47Qpyvt3+0B2+fZ0BjPVC1dhJbVnuwYL4bOzZ5UUEZfqjFgIyFHmyhtx5vMMjbBZWtQGUeKfbjjg9N4BMrqHQbzTAu8eETH6LhkRnhnAth7dYgrqs1oLnBiJ5e5hdlJnODSrG7hYq/iQdce1YqyLU7osgaM+D5Z6DONK7cAtSkAf103+UkVP4CA5YuN6CUOvHMrniDQWY6QW//7JkoWrp5TOMkrdyIddso446H8cQhA8xbzXjrUgPaHg1h79koHTkjSpeZsKosikYq2w6u+YpUoHV3CNGlNCx6QnhqV5gGGmlX2HDj2yxYaQrj6JkI3NQZuflGddP6+BjTY+16IyAGA42jIhoMGcpg0Fo5y1ZQQb69YdQNhq7jzPc6DIbXWOyNBC171Yv01tSNe2NYkJKKF4/chP/cswrHDB1YSs9nkd2kPN/ZiFIZpdHjLqLgGO0uQQO9XZODAsHqlT4lWTnNJadr1AHzy7ELx09eh9+eqUQTPWP5BkIMIlSDIXpOk/R4C3fj5lWP40Nbf43/t4pCODXIBS6nMDXIg07yQSn/4Ar8+Jnb8OOz+RhNOYxrigdRkpqEpubleHzP1fj5yeXYPzaJgoxWLOOiLCk/jsX2HBw/chV++sy78LOGHHSY63Hzyj1Y40rFgaPX4c4DG7BrjNb9vBdxTeE4snNP4PLiSbjbr8R3nno7nqPRE7BS0RhmDSEnQ8jgRVbuUdxe041Q1zZ896n34qv7V6DZcQxXyL0ZKRa46RnlOjxIDy3E9599C+5qyoA/4yw2ZdKjMWkKJh7qFK5ciqh8Bu9Z9zjeQgu748xGPNOfSkEbhSOnEyUuI0zj6TjanUth6qLn3Yn5VHAyviI8NGjjIael5ZsZE14nQjYfku0elU91Lg0eeTmPI68NpeYUjI+4cLijBB2BEEqoKMSrFv7k1L98Ttw4VoaXRqywFh3ElflD5N+kHkfVEKtPP1THHGcan65k0qLRV5Xdhar0CSqDYSylV1xlSMahhvk4r9gh73KqVk5j6xRmg81HehKFpLcKP3/2ZvyiOQmG9BN4F+dM1sRCPHnoavzs8Ao0WM5hU81xbCnrQnn5OVRGK/D8nhvxwxduw70dDkxG5FKAVo8EYVl7VE1qEbAOUxR+fz52Hb4Rj3WkYdxdhuf3vxU/PrwAHa6TWFPZjhzW+dDzt+F7O6/BY33Cn6wrElF9MEVsCvJSohFPMs725VCwjCMvMwhzmhuZcknMNoYsR4BKeQj5NGycoRT0TlByUyGIIPK4i/D4vqvVp8vHJyvw4M6b8Y1jxWj2B2BjnWlJZvR2LcPXH74aP+k2ITnvPK7J5NhS9Ei/qfY5OnHj6kO4Js2BF/dfju/uWo2HBkOYt2Af3ls1hpqa01ifnoSGo2vxtQduwtdOleHeAytw9+H5qHfb0XzmMnz50bV4lNa/zLbYipB+kyf3ypOScPDIGnz6odV4ZGQEy7JHkdW/Hn9//yb8ti+MzKozuCZX3kqahFNH5+PXT6zG9/aXc82O0QnoRV6gGr9+cgWe7zdjtGcefnzvZfjBySQMJbfjfVc1YLkpE088vRLfe6IGO91jWEvj4pZKevblbbiRHnLH4aX43P+uwHNDYQQ517Vv0DDIHGVXjgxn4Nn7F+J7T1bhV2eoqF39uKwyiHQKJn/Ijzoq48Yj1fjMj+fhwQEP5i/qwg3lNKjZgXarHwtSnfj1r+fjC/fn4JR9ENcvH0NtNkCbFbkZ1C39Gfivb1bg+8eo3Kv68fHLPQifLsAXvl6FT9+difrUEdy2fRzlEfZTO5Bd6MWigggsyQFkk4f+BgeaYMXRZ9Jw90+z8b3HuT5Gg1g034tlJVyL4fhZJfMsdqStPYE0Vc1sDkqIfGel0HM3WfD1LyXhSw+Z0J8fxLULI5RJ7BfS0+aqDrnS5AQKaXAUkETLXqBBLmtYaAAzrzHfgC23GvG3nzbio+80YGO5Nu7T60YQR1B2aT+Zcg2oWG6Eqy+Kk3sj6KNMyM8xqBdtyb01chkuVkzmqcXOsToaxN1f8eHeY9qlDvlSpNZ4/mQZQFsL1gwz1t/mwN991onPf92Jz37cikU0Mqa65Q2CsCYsmkhYe1KCruwcwTC1rxdSDL82ZmZpmz8+ZCC0Z4TZFul7CqmxoQJ00ZNtdadgzB9EsmMSKVQS8RNAyoUpYJ2OBtyw6hhqzCV4sb4KZ0bN6mMx2kSNDaaWX6tDi1BvJFRxcUQ5BSwWE8bHF+B3T78DX33iDnztmbfh3rZ0RPL2YSu9jnKL3Feh5Za34oV8SRgYLES7z0kvsAT9IRNSXONIigxT4O3CO664F3+77AjWZHkgb4QLhuzoGqaHG+nCZRsewC1Vfci3si1JE0ixhJGTcR6XLXsAH12/B1vyJ9QrfB3OYRTkdCHDmIJ2epqjnkwc7CpB+1iyeqNiPOQ6sdni48TvQhY9HfFMRyhU+wcK0TmRAotzHGkUWtLqoJdezmA+2vwOdE0m08AaR2ZyCBazjIlGLwajKQiDPxenTl+DH1A5DWIEdRUdSLEFEQxHUEODoYgLakhO88vnnWmtmSj4KvJG1Q3Is8gR2ngog052OBYxSN1ms5eeeSdSog4MyGec5Vpo2I9UGgzFmW4KCskfUW+d8/pysfPkEjR7vfQ6z6M41U16cl/A3JA+MhgDqKh6Bu9cfz8+svlB/M2Sc1i74BCWlPbTa85G15ifitJPZSqXQibZZ9oZnLloyrXs4Fgm2juqcTpogU/uG2A/Z5pDKCyiZ7zqIXxk9XHUOCPq0bNg1IwOCnE4ztBTexTXFbmRapbWSL+LItX6Qs4UCa+x9TENCumQnB3hLvPI/ShiQMl3Idr7XXDlHsDNm5/BFTkhOKjYtTcsCj0RhLJuxADSFLYC8yBAg2WMxplcFikchittDI6+UjROcu1lTaCAczGNwnx8WL7PIJ+IF35lrGbzYoGftIW0vOnRxznXNZTF9WxH65hdGSQ5Lm3ctDFncLrV3M/LbMUVq5/Ep7YexC301CN+zhxzGG3DmeibHMf6Tc/gI8vl+xsUfmEzlanWhgj31b1PigdNnki8UJcqJgYy1ae5B92cSx4bxrgeWvuy4PHaOM4uhJiTtg8sgXGs3HQYH711Jz5zWQtWZAW0t6uyXQHWJW0U+eQPaPf7RDjPMsl3Po3M66/Yj09d14DNhUF4JyxIzhxHZekoUkJOnGtJwfBEMp6tz0DXKA1bUUj6iBomqaQKe3Hb+47in288j/cunlQf45J3MEoWadJETzL7IAk9PU40t7sQSAoiJ50ajwsn5DNhqC0FTayzqSkZHWMWODO4Tlz0gEki0O1Aw+k0HJJ7D6wRlFd7kGNm3nN2DI2YMNLkQHO/Ba6cAHkx48w5GyIpftSs8iGz1ouigAVnj9MpGg5i/bsG8LFP9eEfb5jAsrwIPEHtUumF0NqmQfbZWjZErpypFJYJTRgw0GhC/QRwrkfuA4kiJ4dLgoaBanQMcsMG10zxkig+9IEIbC0G3PMAjZgRxluoKGXdtEZx37cj+OSHIvj0V6N48LTMPU7rGbzF8aREpgGrbjbhXbcY0PFsGPc9KeuEJPX3EyhdE1dESFHn0mFkfYyfbdMoMN1sM2D0qB+/+OdxfOqv3fj2wzSO1lhxy7V0pmSSzRTXrxvSRrmPRhS57ItjMFdQRkUcxxfw/grxphsMF4ICTbx4eqDKM+SsF3E5s4EUCBw1h6MXm1bvw7KUFBw4uAa7OzPhpoCXm4VkwLXPT3OhcMGrG7dITwTmFPR8Qk+92EaOeRSJWDFJj2uEBsvgRCraRzPgjUwgK9kDly1O0OqYOlTlNRoV1QextnwI7sZt+OmujfROXNrX/8LJ6Gnaim8/dyX2eQKorvsd/rqugV6QnCELwTOwCM8cvBXfev4WfPOpv8KXn7kev6X3GaFxohSvzr+0TON9bogHLRNEUz56RrZR29N/mRamAJTXu+oR0hUXgZRhfm8eunrrsHeQEzCnBYvsfrgczViUO0IFO4zK6qfw8SuewPXFw+rte8Wl5zCfVZhYt6qFdYqSkRu2DDSsMqgsjDS2Rjz0ylUdcnMWDY6U81iV44MjqQPrlj+ET27dhVVpXljSulGd34YyKl0Rqtpb/BwYH6rDE000plIOYnuxPMEhl5CkwgshN37K67cbz1+Fn+16K7713Fvw9YNLaPSFkWwcQVruYRp6D+H2mi64zGNsw07cUjaslLqcaZgLokjUJ8lJW3Sh3Dgoc7e/fTN+s0fG81Z8/fH34yt7V+Jwby4azuzAN3dtQoO5C6tX/Bbvm9+LDBpq2iu9tT6SszDq89EXgH2v6mF/UdnLvJbXLcs9Izv334Bv7V+J/tTTuHLNA3hnxQQslCSxM0ZC02qmASbvmuC4qGgaOOagE5OjBTS6IihI66dX24W+wTp6nBkwWkaxsrgVZRYzWgdz0eSWuSVcCuJ4YVACSsVrkH5Rc1DaIZXNmrQxGvLOEc9AFR586Rp8/rEd+MyDb8GHH96G751Px2DzMnz5kS34XY8NxUufwufWn8WyzIi6RCReoFw+i83suSDyRM49KMOINYqjoMZR8aTJG9lfuuIMNlUE0Mv+++qjC/BCnw0O5W2K7JCxYGnZSn8rSixG5T7WWol7HluPz9+zFv901xZ87J7FuLvJRKOXhhFzxZqsnBZ9X6Sa3OSZXTaIy7d0In8sD/fevRDfPZgKN40TVQe1sdQR7y2rtxwK9I1ApcsOf5R8iKXJMddZkPTkhkLh38itzEtZfzEomSV9OG5Fd5sdzdEgFi0fx7U1PmAgCccHgJorR7GlFmh/MBNfuTMVuzqNcMj3KXQaGuRoVsyFUQoSH6IhMDVZJE9cmxQkjoZE7vII3va3nJcDBvzuv4D9HUwS5RsD6UyOgjJAe1JCvr9wIXTipGkIArW3mPG2vzLC91wId38zzLWvMUkfVBkGotyVAUrIPQAC9Z6oGI9xfa695psgHyqOztLEaATjg2F0NYRBGw4OOlNvNIQVOXsg71iQdSA32sulh4uFC/r3NSA2XG8edCGjtUUWCY85eVVnSODxzIbKZOcAJHVh29qncHmhHaf2bcaTbbkYMclLeEJw09vrHE6mhzuIEnqjNpuHHncPUkELvD8dHnrB4v2oO9FV/bpA0PlQn/a1BGEz+2G3DqEqm56CLQftgykYokcgC08gRobVLp+E7kWB1YfC3A5kURBPTqYiSuPASQXjnczAhE+erJDne8ywJo2hvLgJBd4yvLB/PerpPRdl06sN0eL32ZHk9II+CNrpyfWwHQPuZAzQO+ufTOZosWzOEJz2UawoaENJ+jjUNyHiIO0JRszoZ7kw6OW6AuqzqxmZ3ShMCWFsOJt0bWwDFZrefq2vpe+5o62bOSDp8snjEALBZBzrzaOB04naXDfb04bS1ACGmzfi3t034ad7GA5uxHN9QWSkNKE2R+7OFsJCQxvvSKQf6yvOYHWOE+d7KnFySLuzW4SZnCEpyG9CkZVpJ67Cr166Hne+dDN+emIpTkwMoDKrExUZciZDo6eUKhVec+NCnPEbkZE+gHRbQBOeU9Dyah4ReWGa152F7pFctI/koMttQ3v7atz34rvwn8/dhB8d2IjHW3PgCzvR170ST3WlYYICQWvHbJDu1FzivigozoExCvdMlxc+n4t1ZKN3PIMhBWFnLxYUdsDZvxhPHFqOXo5necYIbDSchumhO5Im6GWOYH5up7rJUM4GCMtTbVC7Yixx3Jg3g/3l4JgnZbWhNm8YgeY1ePT4fEym9KM8fUzNa3W2ggXCjlZcs+H3+Mz6E1jCKeVTb0cUD8SKCY/cF2SDLaUHS9LMGJ90onEgHZaUDqwgv+le+YJsNoY5D4RmbO5ojPCYBmC2fExO4gg11nq/qGP2nXhB0xCFwzQ3DUa/HU4X22Ew01DJRP9wGoZHU9S9KhUVzVhqzMTTL67BznET58YgcpJoXlPpReRyltODPKHLIPSm+JIo7sv19Fi9khbjXR2rNC1/ktOPJGYcH0nBJD13Oasm5VRRtlE+sGSh05BL2WFlbHQsCUN+M9LS6J2HLejrkbMpLvSN2zBAj79jxAaLxY2akkkkO9zYPH8IRRka38Kp/JtsNFKdIUQ9dgzLky40/DQDSIwLtoZzKDl/EkXpPmRleVFWzLnhtWBolDKF88JojSCzdBJljjBKyiZRyHXoG7Fy7Mxa2zh1NKMzijANh44hC/VaANnZYdhtQEq5FxU5UQx12NDXZ8XAoAMneqIoqBzFFeVkcNiKZnkiJDUMFztjotcKt4eKifWK5BG5IR2k+olB69VpqL6TbSyPOuC+nAFgkGNR0NP6LI6CB8hfEcV7/r8oljPT/V804gkaC2GbdJyWT9ElHYt4U9yauLUI7Sl6cZAibMuiW034wKeMcB0M4xdfCuGQGAtyKYQiuv1ERL1OvGKpEWkZBljmcb8UGG2MoK2Z+SjTBeoMhs63ScWx/MkQmjsisM03obKcGZKNyFtiQu5klHMjwvWnZXsjIf0v/Rp7edNcQTkwEt6Ayt+8mx5pIgYtYyjJO4e1qUa0d9eiMdKNlaVdSHZX4lAPFaalCxtKG1EaKcLxrkq0+kIwy6NmZjeyig/inbUNVNRU7PY+LKg4ga219SiHC8P9lTjhBaypLbi8+hSWlZ2gR+LDcNMOPNSch97gBJYtfga3rdyPdbmjcFknkZ11Hou42KL+TARzd+PDq/dga/VxbKg8gxV5FjQcuwxPnC9FF70NeUQlZJhEcW4PBX2QRoQHly04iDVyx37fZbjvXBUODYdQkt2FxWVnsTynF2Xpk/R409HWWoP2SCuNnZewvrgLxc50HD2xBEfby3A2FERBViM2Vp7E8vIT2L7wOFbljiM6UImOyRSY00+jtqgJS0rOIT/qRJLdCO9EDs53F6I/dtOjCEJ6z34fPRVbO5aV1mM1+2Z9+Xmkji3Hs2fWYM/4BMoLz2NlVgQD3YtwYCwKZ0YjtuWPwD+0GEdoGMlXB7XHOeWmxwmU5ssd6WEM9i7AgQEbIkEv5le0otpqRoRlK5NcaDi/Gk82laDTIy/NMcNMo25d4TiswVwcmRwn3500cjpRlV+P9TXHsS3dhZPnN+BXZ8rRbxxFacF5rKISGx7NQUrJcVQa6DGfWI69Pbno9aSRZpDGWTvWiYCjkm8O92Nl+RD7Zz4ODbjg8aegxzCGRZl9KHFZ0dJWifr+DIwaQjQiOrCUc8vlLcUhGpdjVADy5T71USEKVNlGQk6MuenR0sjrosC1p7RjbYEHo51r8FS3S3s/zIw1J9dv/SgsaERdrh/j3QtwZNTCWHlELgXt0TEsKarHqvKTWFt5HFfUnkKN3Y7B7kwYMs5ix9q9WMU+TzXmY8+hpThF7x3p5zBfnjooPYtiVuay2BEMpNGoykQo6yw2ZoTR27MUR0dNlOU9WJPfgbqi88gzZaJ7IAVJ+Udx7aoDWJnrgZFG6YuHF6DRa1VPSYjyDKc24AbOq+pICY52lqs1JS8sk2ucPhriUesA1sxrQaEtC6dPV+LgaBDVleewqngS4x2LsLOxAs1GGtFFDdicbkBrx2LsH49ijGtwc2EXlpY0odCQgza3CdkFsraTcK6tBgcnqNQLmnB1ThA9nbXYM2xhf0aUckQgGZ3+MNKz23DdfM7X6nO4fim9/aIJROWT8sEh7Nh0GNfM68CiDDtOHp2Pp89nY8A6jgKurR2VbahI9yPszcFAchuuLXBjvKcau8c9WF7djupoNvY256M5NIpFVW1Yl0SvubEax32TKC1rxaZsAzoaivFsrwElRf1YPb8d6wtpxGV74PWko5lz+qjbB0vGIK6q6qMBQIOFc7q5L51yxovqsm5sl89bL27DTevbsDYvCG9rPpomzEgubMeqeQNYWdOHwpADzlRgrCcdJ1tpWFCD+OW5/SQP1tb1Y1n1IFYX+GF2RjDcUoBDgwHU1Iwgl3Ipn3JqyxqOd4YNjcdK8KPDVtizRrF2oVuduVy8cABbl9HIDGXgvhdy8EI9ULZ0iGs/it7TGdjbzQlAg8E3QYWfPIn1y0exac0ILl89jqyuTNz/VCb29BjUEzeODB82rXTD6bfi1O4sPNtkRI8nhLpaH5avcmNDlR+lhWF4h2043mRBoMiNKwuBlqNOHOiSszeaolLg8EbTg1i9JoAlRjN2HzFhPCeEq5bQAz9jwdPnmLEkhJtXR2BpN2PXSQOGvFKIgfJp2Q0RfOhyGnM8zigHNt4SxTVXAfSx0DhpwJItwGJ67wf2AfVtrJeW4+INBixLAc68GKUjQnEotMSolZvaqoy46V0m3LyUCpZxRctNuIrHW1caYDofxsmmCM5yLWzbZsblO8zYdoUZ+T0hPPjLAHaeMSB9mRl3fN6O2681oyLXAGeOSX2uupqGXuu5EOo57wuXWnHNFVas3WHDJhpdrY/58KNHI5iQx0e51t4QsC12trF0qQlZZUbIFzrZIs0w4E98MFIxiM7qa4ig/Sj7gM5FzOB6tXjzviVBjydk8iIjtQ/ldk6S0UIuoFGUZIzC5s9B62gyRqlEKjMHkBFJp7Weg8GgvLuPnWOkJ5BMIyHFx4nJOHq98lyyid7J2HAh2sSLjtIISOuhgBlTd6kG/MnooeJtpSERNdCDzWlHSYpbPZLnpaC0Wr0w0ljoGMnDqLUTdRmTVA5yY4tco82gYMxHr9+EqIXeFYcmDD/SU0aRnRSEzx+hBzCmPmU7MlKGenmxS5SeN2d1YeoY7KoOE9wUGKNDBRiKUhgVdyDHbCRfmWjpysGw34ZJ2yjKMnpRlUJhL14PBzvgS0NHTyl6QlTq6U0oJ8+ptKJH6BkHzLRagw70j6ZjPCp9o0O8SW4srk7MzxxBGnmWt1eODpejeSQdIxhDXtoAlWqU3lQhWrhArc5+1KR4EZgsQtuEvIxJPEMhprU1I7Vf5Z8YLUDLhHhfbhTm9SMraseEwQs76G2NZFGwyBMWlE3RID0nKpYML8KeDDS6Q/SuRpFq88JGJaHuovbkUaHTw/eaYLfTU6ZHXGajF+NOQ9Q1AFckDe2DaRgLsscVTR+yM/pRIY9gDWewTzwozXQjMpGPVnnmngIgZBnGgswhZDos6B/kPBinIcEWOJOGVf3WQBZaaRCJTLq4wS1tDiDZNYhyCmv/eD5aJq1QX3OcUYb5IkGkpQ6gMCUMz0g+2jzklXzIvAlaB1Gb1a+8YSkmjzZJ/zX3ZsLv7KPS7UF6VD5xnoXmrmyOoRFJaa0oSR1Flp1jM5ZFPsV9MXOMXerMRJUzitHRYrR7OHesQ1iQMYwsetjeyRI0UIGFkztRkyt9l4SRMRpVPRnwUDiEOJ+kyUnFT+NTa1sRrb8cP6PibTZSEaoU9h1bbbUNozpXHvNMQWtnFrqCPhTn9aEomQJ+KBet9L5HjLK2BlBNr2yA662JnRmxj3DNDCMzyQ/3aAlO08u1p/aigm5s50AuWnx+pLCfaklniP3UNGnieGk3KcqZN5BmbmY/lqR7OO95KGvWm4Imrrv2gAdVFV0otXMe07hoaMtGp9uGsGOcfAyjLnMS0aAT7X156DINYRE9fi/XR4PXj+KcYeRESKc/BQMRDwqzh1BmtqKd864j4ENmBueok0ZqbzrXQQhl+YNcg+wTKks3rSyPz4Ghvky0+wNI4lpeRm8/yUwDqScfZwdtGDaNoqZgDFVpcmcevT32tXcsGU3NmegK01DN57rK9INTFgO9Keox3SDXVzfLjlPoh7nO0tLdqC2ZEIcUEa9FPa7n5RxtjQ7i/bc1YZ01DTuPZlKuRGD3OtDalYwTwz5UL2/Dp28egaGhEE83UvZxHKJjLhztsGFoPIj8Eq6PjChGupJwXq75qxMNUdiy3DTefchwyKU5YKjNhbNdrJdOgskQgSvDj9ryAMxclwNtrI8OBSUD5lf7UURlb/EYVN9MjpvQ0895yDWykIZ+XzuN9GG5FVw7+6CdIWEdSSEaZiEUcl2cb6WT4wpjYWEEnk4jTvcyY3qYxjyNxyEjzrdHMSnXmmReJEWRWxzBwiy579EAm3xum82IhgzoPgGcGwEKqqMooBxsaYyiZ5izmEq0oMKAYlsUXfVRzhPyEDMYxMWXFzuV01BwkSbXhC2Jst8E+NnG1iNhNI0wDx3YusVGFKazGHXDcFMIZxrCmAzIUzFG1NDIyKL88rkpf1k2yUYjsDGI0zQ2Jg0mFC0wYWGJKGrKrMEIms6G0CLtlLMgZOMNQSCC1Hxgw3utmL+JfSrfO2cbyf0FkPs8zCYjjj0Sws47mS8sp2Gkj1893tSPT6l30pN5L3m3mAOwUhXLzUtRYxB2uWRAQekLWjiwIfWNffl8sDArp1bCUk5exqKR0kFFZAqq0+ZmOYPBPOrVuXqa2eyHjQtaTvfJjWLyMpTpbiNVucGN5U3R2bS1SxTxnxEWHtTHobhw5NSfvGpYYDT5ySuNF/75ybuky7VTdS+GXCu2sB1sl7xmlkNHkLZVaHOR0fKTlzmpl1WpNNajLo9obZf398srqoUv+SSyuiGInrH2oaTZM1H6yKrdGKbHGE0Btl9euywvgKGHx8VgYr86yHqEbZGX9Bh5LDddSWti7RfLNT6/+iIg+1fGRl5SI5+WlicWTPR0xBjQymj94yNNA/vUQU3rl5vjZOHqiHJcbeRd6lMvjZH83JW2ySleUWA2i/Aboyk3n2l8WGQ8VB+TU7l0pMaVNOXlQuomPLmBVeaC8CeKXV4Drs8tGlCxWXExxPNv1OnP7mGBGHUh4YlCTPpO+1qiDp0XcWxiUGMgnxVmmvDDppAG553MAe7L9yLkldkSry4bSSH2rbRD3o4qa0XmsXqyR6cv9z0YzT7OEyaS5wAN27Bcd5ePaFllLXD8KDQNhn5s3/Iwttlr8Py+tXi614KITe4B0RlkW8Kk5wlo9xCZ2X9yDV7msZxdMXB8ZR2qT4kHNV4sFtZLXqJhM9wcC7kPCFwDcuNxhGssKI2XOcVo6Sd1vZf8a9eFxSBnulRPmurFTbJepmYeM6uXUbECtkk7TcJ5L9+JsDCPzH8Z/yDT2Vcgf8p7knysU1l3XGfq2T72gzL02RZOdpZnO2LH8r5nmSvMH5B3RKg1K3OSLIgjIvOaFmuI/Kn1LP0lY802SjaPKsOg5ikj5D4qK9d6hPNV6peL4dIPsmb5Lx+FMnMOmklH7lWRl0cF5fXEqt3MKxvyZ8vpwmfe24CtoVL8x68q8UQ961Cflya/NhpRK5rxxdtGENyzCJ+8PxV9o9IOprNuG7dBH40yGTi2XT5BrSlOKlD2ZSig1yWVyXzkGjSzK+UyXkjuAZBvP0h7WFbWZzQYpfPCOCkifa22/GE7wPminmSwca3J+mc57QNlLCfbELd+6TfmtzKdRdTHnGS+yjhKfT4GdSyEJej5ZJJJuliREi9KX+YDjR0lpORxRqHrYDzbqMpInPQ3jQF2Mn8IRZI/iiaDWpQSGQPpCw1Zv3ImQNozNQ8JdRmEW4lXj+tJUEQZBCwvC1j4kzpmgGny6pg3EjQY0gqiuOy9tmmDgesh9jbXeMglExMX3NFHwnjxTjaAMuLP0mBIIIEEXj9kAVMsKydKoL5aJ0qKxyqOx9oHyoaxZF4LXOPVONWbTY+bnrReJgZNp2giQcpotHU6CqIEZBuLEKU/XUYgslgJLv5LmiabhR858zKdT/YU33FlFRQTslUH8qPHidEj+Vl3vAKZAU1Z6buKTWFFM7O19ig6+lYiDDQgqIIUtM9JqwJaukA2EmLCWOVRO/yT/iAfU1m5o+hqNaqMTKf9peKn28qtxBGSU920yX/Zl6C+3WCfxOraURRFXTh8PpXer3o3ENPooBiCSM8dxfpqHyK9mXipyYIxKhGtHcKf9LdUKXTFMJGuUj+aYS2uM3lT/cD86kkaCVKGRSWPfF5bjZdStEKP+8KboqkKanSYpEXpfceg2sByEif5VR8JCR5rBeVYn0vqR8A49SgFj1X/S55Ymg7Fi3DH7RRkPy6flI8dKp5JTOhIWR3qC6XCl+xzLk2Pi9TJTexQ7UwdxIFxepvmTv8DQzcYNimDwUCDgYwoNi7kRQwGI38OPxyiwUDriwaD4YIbVl8ZtPmVQAIJ/HlDk/yUYfKEhRzLORL+xTS9upaShYMnN+CZ9nSM0FgQr38GWE6cdnHgpvAyUuXC5BgjU3skqqTqNERQxwv1+P2LQQwEIRgLqsDsQnqcMiYEL0dUcmi8XZBzRkSM3lwQI+hS6fGQjp0rbzwNbStNMHlSsHtXOf53dzoax2gsiIcrfNH6kDtlxrsycd8TRbj/lA0TdBxn3l9DSFcoetMJU0OrRwm5+NERw2Z6+CVl1tjpkHKKFSEkO1Ngfs2a4lavZLp6DTLeF5C9eF2XxisoM4O/vyRwpNi38nSEXLKVy3jakxJzBM4dyfN68QaQSCCBBP40EJPMIkRjUlKL044isMlnvOU+HArz2XJU8znif7XSs+X9TMykEnPUVBldYcymMV1CNxz0/RmILzRlAMyFWeVmHc6AMkz0DNzE9JoGqUMitEhp//TRNNRxXGRsd3a+l0d8fQxzESCDdkcQTgcNBEpqjX3pM8lOL94chispBJc1qu550kjIb2z/FUIrMgtxEbE+i4fqPAYapJpRoh3Oian46QzCoTq/MRftl4XUp9epIDTij18hXkvVf2KI3dSoLvHRMLhYkCV0yWX0CpEwGBJI4C8BFH4iw5VQ0H5UtCAmFy8lLySPOhnBHbkMLfuxcpfCbJpKVfFfxevK7QJpxX0RdFNxal/bvQCSpjSkxo32ewnoNDVjQDOKLlVG5Zbq4+tXHSlb7fC1KTUdsaJqG0dHaKp2T1Wi/3LLtDg1PI14nmYgjm4MzCexmoExR/ocUfFQZbXdacQihIf4xDl5IqRelW+acXU4Fz+CqehYBXPlu1hlrxVvNL0/FrT+0R6nnA6yri4a3oC2JgyGBBL4SwBlgdw3oGRxnOBVImKGnIhlmMo0A5L1YmIllhafZy4qlE1TiNudwgVxip25cs7GK8kTh5fJHs+72te9ZXWDstqfSUI71q7Px5+fieVRzdB2p8HEaUqxnIR0krLKtHgtD6EfxxCjNzNWoB1pvMRS48NcuIC7CzCVQyl7OYovE9ufpj9VI3/i+0TLG3+sg1FRXYG9bsxF4iLVzgnh+TWzEavklVb2RkKY1kZdFLgyFtRWDAjZzhU0g2LuTnvlMKWtffO+VplAAgnMxEXFT3xC3L7apQyYId/VzV3iq8r9DHJ9XI+PXe6V/Nyo/DpUMn9iUXJNPUZT4qaDHi+ZCJWP21ic3Fgnt7pFKJy0+rmvpynvWW2lnLavMRETYtxXrAuDcYJNbqxQ+fW8alfPO1VWEL+vZZG8Oof81/YEU/dQxDaxzAzyG+NPujKWVUvW2q/Rkj+5cW86Qyyf8uxlVxEgPZUQFy9/kk8dCbSK1GhpGVQQPuRPtUySSEj7k+z81f5JX+NDxWkxkkEdx8ZEu5dE4uQ3RlmiJELtyUHcbixddrkvBqmMq0TyR07EqLGVoKLkV58RUpVWUItXNwhq9asCAjmemnR6fHyHS5iePHq8fqzap+eNIbYr26k8ss+f2WkxxgUqTo71fRabPpZtbD8W9LgZvP2RA/vOnhxF5Qoz8irkyZaIeq+EzBNlPMQFedGg2WhEV30YzYcDLCs3NDBhLrovEwwFf/eE7L6pkEUw1YDZmCkDtDyxuPj9eMymE0/7YvUI5qIluFg9gkvRiq9TMPt4NubKP7vsbMxF+1J0BJdKn4tODPFxs/cFs48FEheffrG8sWOBxMWnXyxv7FggcfHpF8sbOxZIXHz6pdJikLjZtOKPZ6fNxlxlZ5Wbi8TF4uRYdKuIdnWsC0KVT4Q7hZ/2okim6497qfwSROipCPWvZKDsiZCRrNoLb/gfy69ycattWJ+oHV1x6pFSRv2JNyNRUzc88lhBL6xvFIMCSRYasewKPFbxDEJHNFQMsqvqnBUnkDLSDzHE8sW2Kj0uXoKqV0VqUdrPVLKGWBy3aldPjCku4W9Gms68xMUeF421dyofoZKkx0UJs/8lnkGe2JB3GsSyyVML0i51LHcnTtEQJa4ZDFqcpMXXozKxrB4n0OtTlUt8jJbKOyu/qpf7Umes72JpsTIqMC5GV8XLcVy7VT08VMcMaq7qcarvJI++1bPNGEepWMXpM1TVRUgVgljWWFvUoylyrAf5UVsi1mbldROyr+2oaqYzyja2H49Y/MXS/9AIw5VjxFUfcmHZlRa4J9gXqjsu5EXefmkym7Hrtz489yP5Drd6/lOlvVoY6j7z9JvR2mlwvGLjnUAC/9cRvxbiF+ZsmSiQODnWgr4XE5b6whIlonSVxOjCV+WUtNiB2vCPefWsiowofzmWvOrpCcms5xcoD5NbXYWpX6Xe9DxCT4410aRRjtEUyJ7kmcqhl5uGTll+GMT71rLwV8VpCTF6WjR/qASmHq0kZF/MGoF63JRQvpjkic9H+qKkBbG+0JS3VoO8m0Klsh+FV3nEU94/IkV0s4n7Wt2qGP9UvNBSZ0kkUhSdbBUlBUmRutVW8go9bjWDQaMlMOrKVY7lsUkhobVTr537WpB8Gh2JF65VrpiSJ1QelUHGgPtKUQsllap+Jb+UVHpX6MbaL3Xq+RX0elU8aam+1velB1QpVYdk5o9Kk3Jx+4q21CXHEqFv+KN4UlF6fjEYhCkpH0vSIU2aKq/aJ4EUNGIqXuHlDIbZ+eOg2scw1WZlYv9xEfZFkFkYwYZ3Ags2RuCd5EzRuuMCmMycS2Yjjj5mwIu/MLLrrDCYtbF5tTA8eqh17l75A0Mmh8BqMcNhlzeza8OQQAL/l6GWsPy8isUQy6ptRQzMFgRKFPNvmqjsSYjPqRSb2uPvLB50VTEDs7Ko47lklpbnIuUZHUuR49lQafLDxClFrPYlQUOsnFKW/NNu8IrLwN2pPPp2NrR0pl4kg6RPJ7EOZUSwthhhHdIeTVHHIHsS4jiYTpyKnaav/cqx0InZGQJlHEjyVJx+LHvTBLiN7WiIP4plU305xagWGyOr9bLkieVVh4S2o6VPzzKlOKeg78dFabzNjNdq5MFUPtmZzcf073Q+Hep4duRMxMpPPVqsQ+rVYqb3ZtCK7V6E/PTcim3/+AaDvFxQvnh8PvAQeoL7YTY6yNfMdsYQQYjdH0GJ5XLU2G9hf8iL2YT3ufNfCgb3uLwL84+P2CSz2W0wW+WVXAkkkEACCSSQwCuBOzyAR09+GwfaHkaSLYXqf27DJRQJIBwJY9u8d+HKeR/VY18bjKEw7Y83I4S0EJQvlSSQQAIJJJBAAq8YwYB25kD7uJQE7QbHCwNNCYaIvBL9dcIYCEfxpoSIFuRd8zNPaSWQQAIJJJBAApdCJBLR7gmiURCVm224VTfdzBHkLZCS/6LXWV4h5BFNdSXjzQwJJJBAAgkkkMCrg9gI6iWPDHITrtzDOTto72Gg0SAHrxNSTwIJJJBAAgkk8OcE3RgwqWBQX5a9WJAvNM+0F17bmYaEwZBAAgkkkEACf2YQ/S9PRsS/+vlSf7MshteEhMGQQAIJJJBAAn+GkCdG5VyBPCCqvYlz7iD2wky8NuMhYTAkkEACCSSQwF80pt848XqQMBgSSCCBBBJI4M8QsZMH6pLDy4SoOhfx+mAYHBx8/VReA6Ze3GSzweVyqf1oJPyG3Mn55wTt3fsczMSjpQkkkEACCcxC7MueJpM8DzGNEU8Xnj3/fZzofRx2q7y4aW7dGY4E1Yub1pa+DVfV/B1jXruOfdMNBrvdrsL4+DhGx8YQkXeJ/x8yGqSl6tnWBBJIIIEEEpgDDocDmZmZsFjkw1EalMFwjgZDn2YwyNcq58KUwVD2Nlz5l2AwJLEzBkdGcah1BIcGTPCH5dvdKvkvFtJ8kzGKpZlhrCxyIistmZbDTAsygQQSSCCB/7sQPTkxMaH209PTYbVa1b7gAoPhFZxh+IswGJxJYjCM4cWmMTzXZYEnZFDPlv4lQ06kmGkwbM4PYnt1CvKyMxj7F97oBBJIIIEEXhVGR0cRCoWQmpp6yTMMf4xLEn9SNz2KkWClErWZ/u8EabMynuI+PZtAAgkkkEACohtizvWfAhJPSSSQQAIJJJDAnyPE4ZQtf9QTE5cKqsDrQ8JgSCCBBBJIIIEEXhYJgyGBBBJIIIEE/kwhZw7UGx9fLmjZXxcSBkMCCSSQQAIJ/JnijTAEXikSBkMCCSSQQAIJ/JnCICH+XoWLBS3760LCYEgggQQSSCCBP1PQFnhF4Y1AwmBIIIEEEkgggT9nzHlKYWZ4I74lkTAY/qwRRcjtgc8desMsyAT+jyA4iYnJSbiDiZnzehDxj2N80gNvSI9IIIHZCAfhd49ijJNEXtj354yEwfAnjSgiQR98Pgl+BEIR9YGuMGed9i6PZjz8L9/Bt/71MTRHIm/cZIyGEQrGJjd5ULRZZySEYMAPn1944T758vsDCDDO7wsgeMG7p1gmHELAT/6ZLyT0oqSlJb5+KJ70/pi9neoL8k8eggG9D8nkdDdFEAzKW9D0GOEtFNT4lfboSiBGU4NWJhTWW8EyYfZF7Dgqx1Lf7L5h+nS9RJT9Egy/zJgJ7zo/pHVh/74GcGzDHE/3gR/huz+7C78+FdYTXh+kj9TcYB8Hw9L/Mm/YPj39ZaH6kf0lc4v9cslu0SFjfEE+0tH48GnrRY9+oxF7z9rErm/gqz+/H0+2aMevCtJmNS85VwKvrM1vBC4cK857WeN6+iuGKsfy+uElIfNBja+0VZMt2rrS018hYjJI1lbo0otnCrGxiofIBLWuArpc+gNByaGhU9h7zxfwxcc6MfnGLLcLIfW8TLjYmyBfDRIGw58whk7ci6/esgqrVq/Gmm034G/uOoijv/s8vnj3ThwcYIbe/Xg6GsTJsX04+Muv4b92TmoFXyeGn/sy3nPVjfjwj49gpOslPPLw/fj500dw5Kd/g9XkZf211+FDP/g+vrh9O7avWo3Vq8jjqg/iqw+cxbhOQ2H4LJ77xm1YvWYN1mzagb/+8X7y/wX86y+fxd5uPc/rQd8R7Lr7C/jnu/fj4D2fxefuOYA9v/4XfPmXT2FXp55neD9++2+3k2/ysGYddtz2RTyg6qYy2f8/ePvV6/FX39uHVhEqDb/Bf35ok2rPylVX4e0fexhn3K049tvP4B/va0S/h3nO3om/vnEt3vLvj+K0GBQdD+GbH7gWV3/kLhzq6UXXvm/i4z/+Pv5p42Zsmeqbv8H/PNUEt1Qr8JzGk199K9bd+H78+JhwchEM7MKd//xW1X/rb/0ovrZzRu++Jgw99UV8/icPYVfSW/D2G2/CNdVmPeV1IDiB1vs+gZu3c56S1xu+/Bief+AHuPNnP8ZdR1+Z6x069St85YObVVuv+eDncW+znnAxBA7hV9/6If7rJ0fg06MQGkTXQ5/F5nXCxzr8470N6HnDPX8PJs//Dv/fp+/GrqZROJe/G++78XJsKNKTXwVan/gvfOJyzrWVV+HWD/4aJ/T4PygCY2j+7cdw4zZtrG78yuN48YHv4yccq58ff5XarP73+NWPvoyv7pya2RdFtOFBfPtvL1frcP1bP45//90eHLj7M/jn+xsxODWALwPfIM7+8iO4aiPX1ZrV+NjPj6L5kmXdGK+Xsfo1djeP6XFE33P40Wfeoni55v2fxe+a9Pg3EtHTePSuH+IL39iNsfQqLLn6b/CRjXlwvgHLbQaUIcAgH2x8mSB2w+uF6dOf/vQX9P03BWazGVaLBR5au+0jfrRNGGnx/R/4+BSDtLHEFUFZhg3JSQ4Oapz91vEi7v7t3fildxu+8Hfvwo4rt2FTXQlsZ36GX3VXYdnShcg49J/Y5c3Dgsp8BNuO4kzmTbg+twlHHv8RfnLGiZT6O/Hzc8mwnvsNvvPlz+AL/30nXhzKxpKyJJz45T/gXX//H7jzt8/hWV8lrl2SB7Ne/fj+H+P+x1/Er0dqsCy9F75xL1q43hyjx/Hr4FX41t+/DRuXLkbtvArk+vfgoGMzrr39dtyc/Cx+t+s0zpvqsDTPRIV3EgdfegZH89/OxWLFgRe9yAw9g/+9+1e451f34Uy4AsWWXjzz7b/B3//7T/DQ/jaYC2oRfOITeM9nvoUftGRhe0kXHvzXz+ITX/suXhrLRunCauTaND4xeBZH9jyOp8cXoG7icTw+vgg140/ihdESlM+rw4JM5qHB8LvfH8C+5Lfgs3cUIXDyVziW/VZcXmxDx/3fwMmhPvzOW4e1tbVYMPoQvk5X0bvi4/jsZX50nHsKTdaFyG59AI8HNuOKhXkYe+zbONPZgN/5FmF+9VKsjO7Bznvvwo8a0hFMScaa4DH8dnwT7thai0rswT7HFbjprW/HTVsXosgl0sKN+vufx88/+zN0zxtD1tKPYEuJNhcuQN+LuOvFDnQUvx3/8ddXozp6GM/94Bs4nr4ZJcE9+M43D8KS0oYnvvMf+PS/fws7x/JQlOTG3u/+FT7yuUfx0mgSqhx78cW3fxhfvvN36C3YhqLeh/BIdy6yQh0YGZ9ET3c7zv/6U/jQP30TP/zNvbj3pefw1Jf/E9/59SmE61Yiu/lO/HSfG2PnnsWBs60409aDll9+FB/69yew07AAN9ZlU1GPo2vnT3Bv4Aq8+5pSDJ6hB9j+PFqSsuAfHOTc3IVHz1KpnP0t7m5MhfPgV/D//r//wDePJ2NlXTXyXCaOyz24r9kOR1Yx5rlG0ZuzCkuHf4dPv/sf8D+/fRiDBVuR23QnvvCZf8C/v9CP7n0P4qUf/gg/PTwCb+VKXF6VgmDvSTz188/j6ewP4x8+fDuuXLMQySe+ix+Q/5HzL+LY2QYcaxtE572fwvs/80385KF96EuqRvrx/8LHPvUFfOP7P8fzE2VYURXCoe/8E97zD1/Boy0G5OVno/2XH8R7P3cXfr7zLJoe+Tp+ei/n20QllphOoMntxp57fogTJzoRKq/C0O4HcffDzUi27sO//dUn8Y3//S26869AbZkTDn2NRc/8Gl/53S6cyroBn3rfddi4OBWjL3wFH/3Hb+Ln99yPvpxNyGv7X/zHP30CX/xRC8wlZozuuRMf+/i/4Tf7W2BfuAXz06n/hw/hwX/7JJ4Nr0Blagt+9f3dOH/0ETxKw/mfv38SPTl12Fjh0ioV+EbQsesu3B/ZgfdcU4T+UwEEO55DkyMP0Uk3hh/+DD76xR/i3hdOwla5AXnnf4A7Psgx+O6z8GWHsPvO7+BL//HfeHYkG4XpBpz83Zfw5e/di4efP4Sx/GWoDT7LNn8Y//zdO9GYtgG11VlIpigI1T+IB06OwbryRlxT6MeeZ9qR4TqFne5FqO25G3efc8B49h48dNaPsbZDeEFkwnePoS2zDluqkjXe3b1o2f0rPBi9Gtfnt3Ft1qKuNIz6n/4r5/vX8USrEdnZaWj5+Qfw3q/8Fr+lQeehZ/+tXz+Gx9zl2LhyPvI517qf/DfcubsDaTv+FZ966wYsdfXj7HN34WdnHUiu5/ZcKpLq/xdf/+I/4V8pMx9qT0auqReH7vw46/kOfvr4MfiKlmHexGP4/O0fwud/+At0cnxLBx7Gtz/3//DZn1De7H0Ce+7+CX6xfxDd1jTUhvbjgbODaP75l3DQsgplzgb84ts7MRLqwunHf4C//8xX8eDpUaTVrkWl3twY5AyUnLGT7y7Ff+LaR0O9hePfO9kIs8l20TMIcgZJQlFaLaqy1jLmtSvXxBmGP1GMNO9D/9AQNtz6XtT6d+LeBx7F82dHEDS5kJJkg93ZheOPmJHprcTGtakIG+xIsltEgqCvYT/2nu9Df8M+7D/fg+7zB3DeUI7CtAiTz+Hu3zyLnuEwKtdsxkJDC1x5FPpTc4imjNmBwrdsRFl9D4afO4u+7BQ4HUlwRr0InnkSd9/zEJrDC7Hiptvw9h2LsWgjF/DbNmPppiuwYekyLM7VJ7XFAUvEh54Dj+H3Tx7FRHo60tOzULrsKmws8aG/8yyae4bQf2YnnnvuOfz+/ufw5J5D2P3kXXjSswC3rKuCe9e38d3v/Uql//iHD+KJ03GegtEMiy0JSTYzzPpWO7bAEpvZ5iSkWD1w1z+F+5/vxNCmT+Kjyx0w4Ryeb1yFOz7zKdze342B410YddphzVuERVfegbd88t24blMennqpFVGjE6lJEfZxA146uwDXfvwz+CAV/9hLzRi02ZG1cQkqczJg/PmLaLC5kJpdi0133I63XlmHxZuvw23vvwxZB76Kj159Fd7xrptwZ1MPsu74JD5YR96SyKL0faAFT37pdtx21VX0nA6jOci4JBfSA30YPPQgHnzhCAb9LoQmzuOZE+3oPPQAdg/7cOKxH9LLuxPPsn9++pNH8Qi3x1u7cS73MlxVOokzj9+FkZod2DEPuPeex7GnywNHRgpMPQdw5ORJnDh9BofOt6OxcDmuXpgJ31M+FF17FdYVnMLT++px7tg+HG/qREvDSZxvbsX+3U9QOTyL4ylr8Y7V+aqLYTDBZLbBd/4FPPbI82gKW5Gen490uxOWiRa0NpzAkYZO9DYdwe6Tjdj3xI9wX38htq9fhOIUzeUy2FNgHKjHmaOHUT+RhqzwEHb+7HP4HtvzzGP34XO/fJae8DdpcBhRsWQzLt+xFkWLV2N53VKsr9AkrDG5CFXbr0Ht0cfx4G9+i4PtHox3nsOJhjY0N5zGuYbzOHnmDNoHRhApXIbVOSO458Vj6Kg/iLbkZdhaYyOfLfjtD7+MYyMRLF+zCrbOI/jeT36D3U312Gtainfs2ICNmzehet4mXL2qAhmTB/D0gVb09vdwLrdhz779aG3ch50d/Tj083/Gt58h/888hs/+6kU6RNOnO3pPPYUJOLHtw3+Ht7zlOlx5/ULk9J/GM2zvc088iHv3NKGnfi8e77Ehe/UmLBzfid986z/wENMf/P4v8e2nGxUdk8EGi7sez56hIbf3fhxk204dfAT37zmHyfINuHJ+mso3BZOF/1Z465/Do4+8iOaoTY1VqtWOXIcfIw0vqbX2yL1P4YGdR3Do6Z/BW3UNrr/jeuSe+wV+9YMf4HGm38W5dv+RLmRVrsDGDWuwKmcMdz78Anbd+y10l27FNYtdeOp+GlWnBrVqOb7m8XacfeERPMZy1pJCZCSlwmUMYaKVcqqhF90Nh3C8uRuHnrsHv9l7GsOlG3BNLa2iGExWGKkwJ8+wj452wZKcC/eR+/HrH34XT5Onu+98GD/49T149vkHsNO4Ch+4ciWWb9qIypoNuGplBfKcmlBw1e3AusIMDD5xN+7bdQqdQz70NR6krNRk5r7z5OX8fpwzVmJFTSaGBlpUm9vHgrCVLEZdxgh+fP9TeOnB72Og+kryaMfDv2Nbn3kQD/WaYJW5cdVlmL9kDZbWrcXWqjDaTryIF+rdCI+dpRzvReu++3FgeAxHdz2AB3/4dUX/dz+4B3ftjp0afYWInWGQIPsXDWJOvHZDIYaEwfAnCovFpq7vDQWsyMjKQsbAM3jgSDcGvUZYzUY4WvbhoVAVvKXrsMA1iaDRBkcKJ0RGBpKTXcjIzEJWZgZSHWYKCDuKNrwNb73pCiwvNCJqscBpD2F0YBzWnGvx7usKYZuaCdo1TU/Odty+OoBo/0v4/WEqGXMEISrfJC6YtauXoyyFXkOIAmYigIBnAuMiF9KXY92q1ViRrxsMcvGQC9yROx91m2/F3354E+ZnO5C+9C249fqtWFJgwZmTB+Baeh3e94nP4WM3ZMNjK8DWv/0pfveJdfBRwD/27LPIft+n8OUf/xq/+Mq7cXnR9NfaXhHkOquBRlaeBQ7DOPp3O1FcmAxLx/P45TMP4V++cCf2PvIDvFTfiu5RF/uWi0L6wu+Bd2yYVr1NGSamSBjWtufx+12P4F/+7ed48b4fYn/9GbT0WRBIrcPaZfOwNeUF/GznILxyfXh8DGOT9LTZN2MUSMiswqI1q5E91oTd93wHvz/2FH559xCee+wl9IS5oo1JyJ63HCvXrsWiYno4srblPhF7JjIql2DVompU1S7G6qtWoevxn+Bn3zyL8vVLYRmqR96N4uWwf/6dXnWxH7byy3D93/w/3LomFRNdPVj50X/B5/7mWvja6tEyMIQQx8RgSYKDHovFGEF61Trc8NF/xMdvvx4bk1fhmk9+HB+8tQChMblRy4TU9ExkZWVSqYQ4Vrfhvf/2LXz+6v+fvbMAkOLI+vhvR9fd3d1hYXEIDkkg7u6uF3cjrgQIQYIE96DB3WGBXWRZd/fd8ZmvenbJ5e6L3B25S3I3/6WZluru6lev3vu/6uoqD86cKKbOKuRuqNwDCUqZyJ23j2RkhiChXXpBshSohGPwknTYWY2zdwQD7pvJqudHoKit4Gx999S9dmYjMrdA0nr3JcZdzdalSzne1MGlr8znm4Ur+PKmZPrc9AHfvH4j4aZONK6BBAiiOnjQSC6NdbNeQ+4SRObED3npYbHfNZ9PV+3lWKUOP19fcX8hR1cHVJhwjBzA5Xc9xV+u7UV7WxNmB2/SrnmKlx+6hjAvGTm7t2KJG8KTzz7D+CgVx47kYA5NZdQtguRdfRnjx48kIn4i917Wi/gwT8xGZzLHTCAmuJN1k75k/wknUrO96ahrZvwL3zDr2yVMvy2ZIIe/Guz21kbsTBo8LkST7TU0Y8+VT3zEa3dego+qg06jnLgRt3L34yNJM53DEJjB3R8v5Nsln/NY3+4T5a7hZF8xDtPpFXz1xjZUIVEMffhNJr31HBNiDRw/U2tN9wNEfRDSRukRTFDqRO66YyTD03yQ6cxUlJ5DHjWQW598k2dvS6S5voySmjqG3f0cLzxyHX3tCgifeCcvTlvIvEm3MDagFZ1fBiNveZynrutNXXkRBWfPknDbS7z82HXY1xWTX9Fiva2dqD8ylQOOwf0YOvYKHrw5HQ+ZBZOk+0IXrTom7JWr0ojH4Id49v03uC7FwnFBjqU3gVZIkbKoi+4RKQztl07b+ULWLl+IQdiWpyYvZP4Xj3LrmEFc+dxUvrwmnNpiId+BQwhPvZr7RVkFSk0dAq4x13DnIy/z6Cg19QX7mLThPEp7N3x8fbrzYC8T3MSR8FH38fSDt9Av2onq+ibckkZxzd2P89gV6VQUn6WoqJi0e0XdevRqqMznfE0zwcNu5NZ7b+CKy4aTlDWM3n3GcNPIcEF0nPDxi6afKCv9qWV8/eZOXOLS8LKUokoew6NfiHKd/QZ3pIgI4g8MG2H4g8I5bhRpceGUTHuQt5fl09AuKpygima9cM4aC8XbVtARZ09Q/0CcNCaaz2xh6WsP8dIz77Exp5mt01/lla+3c7ZGh8zYRWtzA/X19cLBGwUzN1Cydz6r533JlzsKqfqx1Rcwa9toqnEh7f4+uDrUkrfgCDpxb4OmlYbGJnGdBgqr6oU/M4nIWOSnSycIizixSEQd69ayqbAnkhLX0Sucib32Vd55/lGuzQzE0dhETX0dDVJeOrTWzpRdzTWUFhdRVttKl8GCvvw4h+a8xotzDonKNJw4eZeIEM9RrTXj4PCjCiV1CNS0CXkI0vKj33aRH/2F17GGNuq1nsIIPcUnb97MSNM8bv9kPss+nYkhRRjx0F6MvNaFo5Xn2ba/Gsey7Wx4/z4evu0TFhVF8MC4SOFk2qmpyWf7lK9F1BOCX0QvhlzpSbGmmLWbz6JrlOPdN42UK9w48/U2mlv1kk22yrGtU4tGa4//gBt54LU3+Ujc9+ErrmWIiFJ0hhb0dqrujlEKPzKve5pnX3+dey6Jxl8KvA16OtubrTIvr6ig3OBEYEQ0ngenMeWYLylxgQy4bAz+Fi3Fknw0ZpQKFUpjB3Z6YYyFIwz2cuGbp2/m5ufn4JqYRaKPE9rWDjSaTro0Gto7u1CbNSgtJuoahI40NdHcUC/KuEWUheCfHm5Ub53Gp1MXsORIs4hUjOhO7GbTlPd4/rsSrCbYYsCo78Jt8L08+dYL3Dc8lnBVCzUt7SidPZFVHWHF1Hd5a9kZmkUZGmtPk7fobUFytnC+sbugLIYuqxOVdLS4tIwOB08y+g5CXSgMcUEBdmrBUDvrqVozjUmfL2JHuYXg9gOsnf0VUw51R7Hm9goOznudxSV11Ep6LqJpX29ParZ/zRdT57HgQCMKJ3dMxbtY8t5jPD51D/FxKYKcaTk540nuen4yTQZ3xo+bSP3ueTx0/wPMzdUzaFAWvro21EJGohagk+mxOzKTFydvEKSxVtTJDoxRg0iRF5F3YAObmhO5ZmCMIIhDUBfnk5+fL8rXSRD3vzYn+2VfQZi+luUPPsjDD7/KW2+s44yunYqyAgrLqmgRddqo68BREBxR7TDEZBEf6iMc3DnO1zViL57DCrkjnon9iD47mxlHLLgHx5Dg3Un9tu/4duocZqxcx+a1M3l/c2l3erMBg0GD+9D7+cvbL3DvsBjClM3UtnWiF/VZ11pHaUkhhRW14tJeRIcEs/L1u7j1vkmsM8QL0qigSuShUiPIo5s3rcdXMf31R3lq2l76ZPUnJSaK1W/ewi1PfIY+NJleMd7W2xo7GjD4pTDg3jd54d6rGBolo6uzmQ5hONxFUHN22STenraGHfldyEyizuxdz+LPJjN5b/1f42JBGIxdLTQ1Cj2pqxNkpAa/jEHEe9pTIfS/rE2DvaMLujOH2DX9LR5edpY2kw7l0Zk8P3kjZ5u67VJzzlKWrlrJMUFWdVoT7u4eOOpq+X6aZDN3U9Qo6pFSPOeat3jyxfc4WGpHRmoaXafW8M07T/LCnCMM6jeE+JBAFr14E7c8NQV5dAapgR64Cz3WW/tViKCs/ST7F07hrQV56KVnFbbQIyGb6DMz+eqIHR7+oQwTgVOImyOVIv+FTW2iXLvJ7z8DyXxIXU8twkb/4mJNeXGw9WH4nSAV3S/2YXD0IS41jqjGXHKa5diHD+Tyyy9jRIo/3tH+lC3cgW/KKC4fEYubjzcuorKbRTSrdA0ipf84AuRtuIRnM+rSKxmbHoBPVC8yY0OIik9Cn39ORA8y4oWyJns3cUp9KVcnqnpubIeLuwvOIen07zuAFN8AQkKSGHzpUFI9BWFpa6Spy4JP+hj6hqhx83TFJawvyRFueDQf53C5MKbeCST4SMZRVHARObv4x5MY7IjCzoTJaEDmm0JKqAceAVFk9+mPv10rZ0sbcYgZwZjeIaiK1rOzLZ6B193Ik9cMR3b2BMfzi2hyCCM+IYkw4TuskL7mkDvjFpxMWojIc3AqKUEuuIrtxIhA/JykRCYMdi74hqRySUYonpF2lLaqCBeGZfhDn4lIaiyjRqWInLoR4O1GipdcGM0GmuWxZF75BA+M9EEhZGLnGYK7yUi/29/hL3dfIZxKBo4Kd1ydHUmNjSQgtS8Z4SG46R1JHD6UzDBHZMK52vmmkh7ph5coXglyjwhSho5i/Kg+9E7yI2vstaS6/0xjoUyGTETAuoYqqjQqAlOG0CdEROtqBR6jruOq4QnExMWiyc0jL7+ABocIYqKjiAoOwDskkRQhKDd7J87knUfrEsWN997HyBgX7D2iiAvxwjc4irDgYEIDA/EJiyfeTYncyZ/YgZF4ye1Q+6XRPzEEc1MFrTI/IvtezvAgQRpP5VLpNZjrbrqUERHdhWE2mZF5i2v4++BuL6Ru1GN0Fc+anEqYupPqJi2O0UMZnR2Pa/k6tjeE0XvC9dwiHKu7vXh+8axdDdXUtlpwih/MY4/cydAwL4p3buVMQzsEZxDcvJ0DpYKADr2CW64eSLKlkUphLxwSe9E/zBmLtpGCAyvYckyQLEUoN910G5dmhdNRXUibnS8hGSO5LM5CzamtbKn0IjYlm7uvHol76WqWHWlH5hPP1deICHF0H7pqSyis0xM1aAL3XHMJwQ5KXIQOpQcJPXZUoKitotwpisz4QEIik4mMTSLBwYi9kEHyhIlckRmBl6cHZbsEaa9twhTal6wYX5x7Gsjs/ZIJVppozD9FSbsdrgHpDBqbQc3JPHSuiQwaPobBMW44+CcQGxpEqCCK9m2inhw/TpnQBe/YPmQGSZ15ZIJMueEtSJtz9kRhI/oTVLedbXtFfUq/nFtGBKEWROqMJZYR8Z7dRFZE9XLvOBL8fHATl5DKyuASTnbfgYTZazldUI08uB9XjB/FsMRgCs+cpqVFTtrVtxCqraPkzBlqHcKJTUgkXNlGXZsJ+5AsHrr9BrIiPMg/LdIrApl4x31M6OWL1LBiEUTF6OBPYJAgNJJtEPbKJMiya7gou2hP2mrK0ThFkjbkcvo75VNwqgZzzChuvn4EvQN6Ko/QEbNeQ2NlNQ34MOSqm3n05ktxqy4mR8itVhGAn7sS4/n95CqzuPLWa7gyzQ/H+kpKRVn1yYgWNkHoWel+9u05TE61kqDkYTx80wRC7TupKK9D7p/O4BEjSDfsZcPhMhrs4xg97kquSdCTs2cTexsDSczozyPiWdODnEXdOkOHOpRr7r6PcYleqN1CiQkPJ8TVCSdTM+2CuJpDRXnGB+AW3pv0CH8CZEYcsidw2egM0mLjkNVUcvpkLlUmF4Lje5Ps2/2a7gJ+rQ9D7T/Uh0EQbPfki+7DYNfQ0HDxtONfwIU5viUhOAln2dDcau3JurNKgcZkh7BX/9WQvghSyCwM8DMKtu0inJWHqBDdynBcGIXDhw8jU0h9FRy7XxdI7FrbhcaiQm2Xw+LHD2Aa1Jdhl8biKlNhLyJvB6Wd9fMoo9GISiURABFlajvRmJUo7YzCdcpFhKjh3JrvOd3uxfA7YqjYuIaPilN5/9pUnHo4g0wldc4yotcbsdg7CsdoRqfRYZI74CKiASkvBk0HnXpzd9O2zMDQYcMICgnrvoANNvxRkTOVD5fs4Uy/b5h5mfDeXcUcnnYfr9i9xZSH+hBxgTfb8D8MI+Wzrubhiht44J7rGBMgTN7et3hlbTltw7/isxE9yf4DkPxkS0sLJpMJNzc3lCK4voDmrkq25k/lRM0G7FUuEnXsOfK3MAmyZjKbyA67jtFxj4k9NsLwp8MvEYZZs2YxdepUsSY449/JQZKanVANhb2Ie6Xv/6Vv+X8i3Y9xwalL4wdI3/LLFApr64bZKM6UK6xkQit9+35BE8TFrJeTdvxw4e47/xWW7vQ9aT/88EMGDx5sPWKDDX9UWAo3sGrPKYojH+DJQS6gqSV/02TmG6/hzlGp1r45NvyPw2Kgbsv7fFXbl+HDRtA/SDjd00tZeLCKtsR7ebBvT4vHfwC/ShjOTeVkrUQYXJFJU1L+BH4gDOHXMSruUbHnp9P9I7ARht8Jv0QYfmsYGwsp0bri6eWDp33PThsuGubWcspbTdi5hRLq9m/uDmRpp7GyikZVBDG+qouo8jb809A0Ud9YT7M6nGgf9Z+q45e5q47mtmZ0TnEEXuhg+WeEoZPW+nKqZSFE+Dih/pGpNLeWUdZqQe4WQsiP66FZj761hrNaD6K9XXD8J/tL/xHw27YwXM/oiyQMfybd/x+Ens7qYgoLiykubUHXs/efRcfx+czdeJCcxp4dPwkT7e09PQVN7bTpfnY4oR9BR2tFGSUl5ZQUF1GQX0p1s77n2D8KI5pOYQzaf6sRdnS0NHeh+9Xh2wy0V1VSXtFI+4UekvoOmiR5nz9PQVkNLdKnjf8PPdc3WLAUrGfldyv57tw/kncDHW2ddHRd6I35t7CYdbTVVdDcoRMSMaNpqKaxoR2dRay3tdB4Yh8HNsxg9uEGcW8tTc06a5uPRdtEU6denPNTMGHsqKektIxmzd91eTJ30NbWym8m9p+Ehs72Fuu9rRCGS9NcI2ReT6dUPvp2mto1/+FhlY3ou1ppuZCnfwTNuRxeP5NvDrf+/CBb/w/SyIYaazn9fjBTs3sOc996kqXWkSiNdFUXcv7cOc6Jpbiug672Zlra2un4J6utRddGa6s4V/OPS+SXYRG2rozifJG38yXUNmv+Vta6avK3fMVXuypp+Tt9MZ9fy4rvVrG+4O/K1NxK8+HZ3PP+eo5Xdf6t/v+34IeHkkjAry0XD1unx98JUjn/YqdHYVzL983m7Xvu4uVpS1m5UUfY2Hj8xH6dTofJTolcOAR9Zytt7cLJ2MlRyIzCQHei1RuwU6h/GIhJ4R1LfEw0Ea523T33O4TDE35LIeQuteRYzPWU75zOE68fRRETimvO27yyvIQGdQQRHnJUKgUW4aQ6OsS1DUZkSpU4z4JJs4+vb3qAZ97/gC9mzWXewhM0u4SSlOiKuU0rnJ04V2Giq60DjU5YJIWIjIUR7RIEQSPK2ySe16w5yIKP5vLNdi2p/cNwNnYJR9ZOe6dGnC+Me7swZl0GLOJclcisUddl7dlvEPmXC90xiedpFek7teL64ripcBHPPr+RErkPydHe1nMkmPTSlyItdOnNyMVza6oW89boW3lgcTPhQ7NI9XXAfGI2rz//CM98NI+lO0/T6NWPgaHCkHWJZxH5t0j3L1rMC89voNDOm9RevUhMTCUl2BkHOx0dkuwl+Yi8ShFRe1ubyLsWs1yBuXkzn72xmE3nlWSkB6AydgiSJJylWSGiA1GSnWdY/ewNLGjJJD5Tzp77r+T9dUZC+geSv2KeMJRuTLz7SrJD7Gg5OIu/vHUCVWwozqKsXltdQZsoqzB3ubV39w91RxjZM3Me4bLHv+RswEQGxbuIfErEpZXaTZN4f+0pCuQppHsLYYoytTMZRNnoMZu1Pc+swyxTIbPo0bQLciHKRG+WifoqnkeQq+bmVrqEItkJRTOIMu2SOmfJVSjlFpG+hYYdX/L58q0ckfVnSISIjNoL2fXxnVz34g46kvuR2biQt7dpUXmFEmqvob1Lg0HUfbl4AJNBZ9VRO5MOrdnOqjedHUIvBOGSCX00a8X9WwWhEvmxF9t2xm75a3p0307okfSc7eI5pLqiVtqh62yj+dBcZi1YxDpdf0ZFymhrarZ+XSNXO6CwM4pzxLYoF+mLAaNBI3ReyEHlQ0hCbzLCPXFE+ppD6KRGEDZxH0m/DF0dopy7866Q5C9EbzaWcWLN17zw8Vl8smIIsjcL2YmCEfmUhmOWhs02Sl/2SCRS1AW9UY9W6HGXUGOlvVS/zHS1CIcs6qpZpkZpJ+p6z5DkFpOInCWZiDJoaxf3FpxELspV2ymIvtYs9E8p6r6kBFUcXX2EQwdiGPtYNq4VW/jywRt59vPFLFqylIOkEVU1n/n7yqlxziDdv9tgmMVzS3WlQxSAXK1GZpBk2Ua7RiprpShfUQ+OfsUXy7awj34MCRUy0As5mUSeTNqe8hI61CHpjFbQFIWQv8wq/1ZhC7p0RkGfRbn98NWIBaN2J1/f/jDPffwVs+cu4UhHANEDYvDRiWeS6onFGd+YXvSOCcBXbRR1S+RPlK1ENuWeUSQkpJHor0JhaBf1StxDBAFylRsKJwf0S7/HnJVMiL8Hf8YG1l/r9FjXUYBS6IjUwiCV+t8vFwZuCnFPIuoiOz3aCMPvhF8lDIXr+WbpStYHPMrCdx/m6suTsN/1Grfc8xzvfz6dk/YDidbtYcaLN/LIpJM0udvjUDyXu654iE+WbqI17mr6RgjjLXh60/YP+eKocM6l21n18SM8/NpU1hyvwyVjJMmewq/UHmbR848yef0uthji6a88yeYl3zB79hz2NXiRmBFK9aK/cO2NT/Hl2r3oEq+jT4hMKK8nkdlD6eNyinM+Y7nuyWe5N/Ykc16+nYde30O+nROBXat5aNzdvDN3GRVBYwg7P5nHH3mIl9+fxiGTH4bCE2z96GMWFWhoFE7LffeLTHzwfWbOncOsHTvZ+fnnfPHVagq9e5Od1MG2Nx/h2gdeYsHxZpwDI2lZeicTHvyA2YuWUu2fRv2SD5k3X8itzoPIjExS/NVC2CUcnvsWt9/xPDM2HaHDvzddS+/mve8KqY6ZwD1X9SfGU4n+7HdsqPIkfvwNXBYEObsKMBV/wPV3v8HUuYupEtdvXPYx385bwdqWIALNxykqLqcAVxQ73+W6ax7l8+/20RU6FNd9z3LHw6/w6ZTpnHaJp2vfGr77cgYrqhwEYRGOYPF9XP3KBvar0rgmy184STnmok2sbkuml3cTuUtms7A2moEJSuEY2jitcySk5TtmHe+gcsZLzNiyl02irAYqj7Nh4RzmWMvKhdDMTMJ7vjxtryjh9LrFdEVEsLk+jKsyg/CqnMdDDzzB69PXk2cfi2fNTop27aA2vB+K08uY9NEhtCWfcffDL/PJF9PJ9xxBVNNaPnnxfv7yzldsLFESFRlM9bKHGH/fe6zedA6TUzFT7nmAlz7+nByX4QxQH2fyKw/x2Mcr2dfsT+YlExgWrrCO1Fexbx5rC/XsbgvmCq9z7O2IJMFbOLaPn+Tax15jZYECTxc7KnbPYnauAqfcqUw+7YPHsXd4+MmX+WBZJ+GxLRyZNYl7nnqbleeMhKZnYN7+OjcJ3f9wySaaQkbgc/xNHnjsOT74/GsOk0GWZy2rPrifO99YyNZKV1KHDCGpaib3XfEI7wsHVSl0s3f7Sp56/BFeeX8Nebl7WLb4Q974+DBnqyuwaI6zscgZ+x3PcMOD7zB1+iwKfUaR5V/Mkqfv4aZn3mZNoYzAjGxiBDFvK9jCnGeeY/ruU+w1htGrZhZfn3aBU3NYmdtBbeFRtk1+kHtfmcLslStZvH4dmz74iGkrC1D1H0ic/nveu/0BnvzgC/YZkwnVHGbL7v3sySulJXcNC/MFwfn+IS5/fDrzDprwbZzB8y++xsc7ZUSnpRLnLUir/ix7z9RSFjCGOzLq2bnwUz7SXc8nrzzCLddfzbj+SfhXrWZNiRNe0f3pEyTsj6WCE4snccctzzL1u520Bw/F7cALQpdf5OMVHQT2TiHZ3xFL8WY25tajibycUU6H2L5sGlNzHfHI/YIv8nxwE78vPvc8b30ynb3aGDJ8tWz/8iFu/cuHzFyynX3KdK7t5dftugQhOTL1LuabRnLzs6/zdJ96Np1toqysgs6Vj3LdcxvZWdiGu34rq8pCiKuYx8NPPMe7n3zJjFNqPNsPUlRZR25xJcXzH+DGpz/n23W7MKTfSJ9Ae8wnX2OXfCgxkSFIYvmz4ZcIQ0ljD2GQSLLU30wS6N8tgp6KpfsriSjvvj0H/jXYCMPvhF8jDI0nVnIg5yS+V3/Izb198fF1xen8d7w+YydVjS20BA9niPNpthTpcBn7HM9llLBu8mvMOdxAU3UzpUFDuW1gGE4KO1oPfs2CsmD8NKepkwfiHhhOolsrZR7DGRMjmKlg/2pZB7l1Gdxx3+Vkqw5zSFSwQREynL18qCo7R/Hyd5h/rJnGynbqIoZxe79AEV2pcRLHvZp3sc+UyaAxQ8my7GTWljI6Bj7LOyONHPj6aT7dXWf9tj/fox+3hRaxePkGTpW2UO3ShyvGpOItntsSdilPXetG0cHNfOdxNZPuSKRriZaUR+9mYnIRJ9sC6chbx76FX7HhbCvVTQ4YPYThtzvDSe8ruCGkiFz7AYzNcKS2IZj+Ey7nxqERuKhlNOyfzca9R/AY/iQjXPKZc9TE4Gw3SjsG8ehzt3BFqk93S0TtcTZ9t5zvvj/MySZHMocPp49hOx8vO0FLfR2W5Ou4bYgrVXWB9L/iGq6OOMX2M1pKquto/O4tZhxupLGmiwqPOIbJ93LA7UomhtZSoU4iMzUQpc6JgH7XcWN6Ad99t57TSc/x9T3ZBLiKyi5T4OHawYa1ragqNmJICKOoJQ2fyl0oYwNwcAvFsWQzh9SXcFW6ShzL5I57x9NHfpiDiuEMjTSjcLDHFDCQ7CDJqIjyLTjBjoOejL49g46pZ/EaFkfbwTc4rhjH8N6R+PgH4SvUzkHWTl6bE54VgsBIMnQ+xmdz9lPXIqK4iLEMVh4i1xJHeJAXYT725BWVoKjcgd0VX/LsZVG0bXyOL9YUUdPaSq4qg/Cqb2j3ySY1sw/R3qKOR41geKQSOuqoKNvLUbcsgleVE5XZwQn3LNyOTmfT0qXsKmqlot0LJ3c7wkyFHOqKJLFrJ9u6Ukho/565bX2555476VvzGVtbIhgxcgT2TRUs23qQjuOfMXuvpPutFHqkMkK+m0MuExgb2kybayzNJ5bTLncjLOty+oXbUdNph8PZ+bT0e4lbEpqYtbWZjrOTaY2/hWvuvYfrgvJZc7oL+2FP8uYYE2WnDnOgI4Ik7V4OCv28PrKC8/aZKI9PYcWiNRwqa6W8xQXfzCGiTjmjsBdmWt9JkWYAjzwwlIj6NSyvjSdWd4i8Ll+cusrIFXXJNPwmHg13oO5QAJe9e6WI+Y+yvSUc1b63KQi9hZsH+nHsRB3lxQfRuLjS2QluXefJ6QoioHEby+1v5MN7huB26kM+r87mnjvv4cpePjhKQ53WH2fz4XMc9xnMTf5FHNy8CPPgVxnVNZ93P5/B1o4EEhX5FOi88Y3uS+9AGc1HF7Fp21bx3M9ymV8pM7e1EGi3h6W6oTx8101c3jtQ1Ck5por97C3RIosdwyVu58g5sIPd2kTSu7axpTOVJPF7xHEUQ0OFs3MPouLkOdw9XfBI7E+KvIawK25nUID0KaCwhUYt+Wvfpyj2Pq64Whz3b2D3jmoKC4sw2HdQEPUgX9wUjOH896yqTcA3fyN2Q+8glRpCeg8i1aOSU8Xt1td5juZmanyHcal43hNOoxkXo0JW/T3LG1JJj40h5E/Yj+MXWxgEYaht//XPKiXK0P1Z5cURhh+FtDb8kWA06NF2tmG+8L5OVISzxfmMe+Ubpj5/NdkhZpraNIQm9WPEhCziHJqEJQni7hn72Ld/C/NvT8DN+jmvxdpEq1YprE29zqGppIkoNCXYAZ22++IytTshiUn4BmYyLDUYL2c7FEHpZKQnEeWjovLcSWRhaTw0V1x7z3d8dV049j9ojoVOacAknRaNNAeNxoBfTAbDJlxCiq8eE/bc9MUuduzfx6qH0+koO0zKvVP47OU7uTTOHlw88Y9JICIiiawYNxw9hDMedzVjRw8gWR1E/CDhbAaF4iLTUXQiB7d+E3lp6T72rvqE14d7YOfkQ3jaIAanhAjSo8AvOhLvkBR6J0cT6NL9PbO2vooOi5rMURMZkepPc20dquA4fH3iSAv3xknVXYGkmUEVgeLca17ijecf5bZsOxo7TNzxzkKmPDmaACfh1MPD8Q4VaZKiiQ52tX762lVVgMk3ivtmCfnsXs3sW2NwcxZRW8IABmTG4C5k7x4UiE9kItEh/vQddhMPvfUlr2fUMH3xEUqs74+VqKOEQTtZydGtZ9FlJ9HfrZEjC05zqtmX/r1VQtL2uLp4ibJK/qGsPJ1lKIMzyBRlFe4pR3vhnbKhmdYTq/hkyXQeu+9tvj82iy257ZSVCAeQ3J9L+qcR4SrHN2MYSTEKdn/yMSvWKkjv50dzUy3XvDOfqc9OIMnHSGuXEbeIXmRmphEfYE99XRU6mQN9xg9kwDCRFzoZ9dYSVu3cz/bXxhKhqMXin8LggX1IDlSiv9CfRHrFhDuuwUO4Y+Q5Nu89wxnx8O3lZ/EdezeTVu1jz4KXeaK/KzqLCkdHR5ykz4oF6VWonUgdeKnQi1i8uqowe0UzcswoUv1UnD64lxbXQO6cLvTiwGYW3Svy5CpkFduP/plx+DtjnTND7RfDgMGD6RPpRHtzo6g/nUSPmMjlg5PQ1FZyrqwUn+TBjB2VRUpqEEnxQo/HC4eU4IejXIlK6LzcyZPQ9MEMzozCWa4TdeMUodc8wcffibwveoP7e3UPvKMQ6UISE/EX9eiStEBcnR1QqR1wcnSyDl0urDgB0ZkMv+IqcTyRGJcYMseNYECKE50tbVSXlOCWNozLRw3E29JBRV0zdo7OOEvnC2KotDOLuhJAv2HjGDc8nUEPLOH7p7OoPraHNTk11jyg04s6rqXNaMLO3hGlvQt5FU24Jo7j+kQd1YIEV7QKovmj6EzfWCPSy0gVdWVMZiiNFeV0yOyt4yOMHZksyG13iG7ttC6Ti3IRGw4OqNX21rxJ5SV93i1T2OMd35/szHj8ncz4hPhh13SKbet2UMxQRmW6/OC2pF9pHA6pc59GIzZam2gXz2cv6lB4cAKDxk0gKyMEF3EzV2d7ImP8OLNpIRsOOxGWlElavDMWO4W1E7naJ5K4THHfWG9Mep0kZuwdvDAYjNLAqf+dsArwl5cLqxcLG2H4g8IjfRxZwunliOhkzJiruOHarzlpUnJq73IWbzhAfp3wMmY9SrMOXRuYQnuTlhTL+YWTmTzrWw5VSAOjSFeSIp0uurTdTr1L6oTWLJxJe6f1HXE3VMgdjMj2fsr9737H4fxGawdAKV1js3AwvS4hNSKAk/PFtect5XitHdLr2AuwXl/TM7qiUYfcpMHQKe7rGUt69gDqlk5h6tQZ7JZaQzwDKd+/mmXrdpFT1oHJwxufjqNsm/kBj886hcKsRWUx0Sai1ea2NtpaWmlpkoZZ7iJq2ARiHY1s/2Yy09bs4FyTAqO23WpopLx2SqNEurrgdW4ur787mxVnu2fR80rMwrOzjBdvGs5tXx6g/9hRhMn1tDWIiLTT6q2tMHW1YvSIInnMdUwY2oukCHfhog3sXj2XJZtzRVQqmLq7K97583nz/dnM3VGBzNCBV/IA0uKiOLtAyGfuEg4L2eu1GvEMLbSIfHV06dC4CmJUt5kFU6bz2twdFCyfxlefTGP2yRa63yAIgdqn0Td+K1vLVbRZLuemASXUmEvIaYgg0UODTtNOG4L4ORiw2y2V1VqOFjRi0YvoStxHGlXSYOmOQOpyNrF97R7i7n6OB+98iOcfC2PTkdM4eqVQsOQl7n7ibb7eXo06Mot4dzPGvC1sMvViTKqncLYqjq6fx5KNhyhpEnph0XV3XpT0QTizwKh0/GXtvDNxPNdc/z5nwsag27WUb6Z8wdqT9URmjKb++8955NFn+HBTLYoLnWnMBrStXRjUAaQ/PAjzgRPUnywjdtz1hOtrWT9rMtPXH6RZHYZr2zmWvv84D089THWbwapTKsGepQjbPWMITTu+5sbrbuLrYxrufvY5RiUlU7poMl/OnM+BEnEfrchzm5TnJlo6NMSLc3Q5q3jmoXt5dsF5fENiiPFx4aM7L2HUE7MJHzKauyZcRd70x7l6xG08M2kDRXqVuKfIt7ipTid0XHr3LsqgpaWZpqYmOsR2otCV4JZCVs2YzIxNhyntuvCWXBAdZSttG9/jvk/30Gmyp2zZS/zl/QWsOdmBUmaw1l1pNM9mob8tUh8Bqx6LIEHhQHp6P/Z9ehejb3qGs+oIbr5qAvZHFzP1/Td4dXmRqGsma98CpZ0dHe16qg7OZ/6HH/DV8kNUdPbI29MLH6UDPsLpa72S6D36SgJX381dT7zPzM1F1o6OCrPG2vdEPIoV7rEZ+JubeO2WS7j+w+2CZI8i1kGOvUHI84cxmgVxUqpoObKM6feN4c4H3+G7I/Ws+uARHvx8t4h6jdbyarfqfwud4jG7DNWc3r6WI/vWs+LYSYp+PGWCyGPSyCswf/cRD4wZw5jrV9LiOYC7ro9G2S6Mm0Q4RRnqdRqRZyP1tQfYteQ7DuSuYWduMy0N0oBwOusU8LpOYTeEnrYKeUr9W6Q+H00Np/F0E0TLOpDbfxckKm5dflj5heU3gO2VxO8Eqfx+6ZWE3CmQoJBwPE06ZP7BhAojPWziWHzlFnyi+jDskpEMTY8kOCKB2JAggvwC8fIKQNYhXIqnHyHx6SQFOqEQBkXu4I5PWBIpMZFERicQFx1NTEwc0ZFRhHtIUbhg546u+Emjk0mRvoh44uJTiY8KF5F/HBlZ2cT5+2Lu6EAl7hGWkE6iv31PGXVf3zc8heQwX7xcRBTkF0tceChhfj54+YUjb2vEzt2boPgsBvfNwllmwiUknQFDRzEiK54wdwdcvf0JTEglOzWJMHHPGF8PEcmHE9s7An9vHxFRx5Od3Z9QV0fBSQw4+UcQLdJLQ9FGRieSJPIaFp1MQniQSGOPfUgcSSlR1smNlB7+eLj5oxARVmzf0dx+3RjivN3wCQwnKTEQj57vraQJkNwDY4gNDiTYVZSFgwde3mHSOFWEpF7CuJGD6RUXQrCLGvvgGBJTkkhNFEtmXxKDA7BIspfkIyLTtLhIIkR+kqLCCBe/cVERRHrY4xQk8hTqjrdwoioR6d123Qj6BQtLZpWlM75RSrxTxzAkbQB9El3xT+9F76wBpAe4iuyEiegqiYRgb/wlAyjKqk+qKE9RVglSWYlj8eHBBLrYYRDkUO6bzpX33M74Adlk9UnGxc2Xgb174ePiiEdYGgOGjRHyjxE64EV4Sm+yBAEYmeCPj1+U8O0GfOMHMmr4cAamRhAi9CwhWuhPZAzpqb3EfUKRWxQEx2Qw8NKJRJjbkTm64CNt9+mLr7iHa2AsfQaPY3x2jMiTkKdMhdo9kPDYZFKSUgjzDCOjfxZDhg/CX8hD+ECcg6JJSs0kMcQHV3dfYrJGcfnwfmTEhRMUkUhCoDueQRE4K51w8Ayl38jLuPO6YUR7+SPYJTKr7l+QfxKJ0UL+UYkiQu1NgKcrTl6hpPUfw9Wj+pEcFSlkriQkZTC33SIi/cxU7EV9cXMNEKRnAH0HDaFvVICIqu1x8BL6JupOYnSE9boXyrVv32xRJ6XvUWS4irwnSM3e0pwuSIOuueArCKZbbCoDMpOt9SsgYQBDhg1neGY0oULPo0NDCfX2wj8hiuiUYLzcAsX1pblJ0nBQyHENTeHSq67iSkFgvdVyPIJiSek3hssGZxAfGUGYeLZYbwWG+nOUqzIYecUVXD0wGi9pWky1jqpd+VQetJB6Sx+igiJJtBcEQS1IetJQxo4UZZsiyjZS0psA/JzsULj54SHKSJpLITprJLffMJ7UsAACQ+NJCHLHuacPgMzBDWdXHwK8PAiKzqDXgBEkh7gT03sUl44YSO+EcOt1k6LDiRJ2p+PgKTROKVz96KVEKSv5vimNG3p7ddsQOzlOIfH4q+xxdHfHL34E11x9KWOyAlE5hRMjyinCU+iORzA+0jDQa3OJues+7hpuz55Se5z9MxjRJ0nYNVF3xRIVHUd8dJSQoygL+0K2vn0Ix7FXMCDJF0kN/2z42VcSIlCwzlbZ2d3pUXol8VO8wCy9khDn/xavJGzjMPxO+E+Ow2CDDTb8L6KD3JnvM3/pWaK/WsLdv+NArOemv8SUDWdQpfnSWCqCwsueYvYVkf+8ndcW8e0dd7HJJ51IUyV7XMdxzz03cZ3UR+b/oYW6vV9w+ZMOPD/jDsaneInQ6M8FyU/+7DgMnT3jMNRtwEHpav1K4qec+d+O9Ggbh8EGG2ywwYb/B2cihw5gzH3p+P7kmCL/OQQPySQlUU1pbjtu0cN54bJ/gSxIUPjT69p03JoryW0I4+axwxj3k2RBQDyzyj6GIS+MJC3Y7U9HFn4VF+T3Hwz5bS0MvxNsLQw22GCDDTb8En6xheHHIz32tDD8lNv8LYeGtrUw2GCDDTbYYMOfGlIALo228PN/vwVshMEGG2ywwQYb/ozo4QHSoE3SIv772eW3oAw2wmCDDTbYYIMNf0YILiDhr60Iv7ZcHGyEwQYbbLDBBhv+jBAcQOIMUu8FO8uvLBfYxUXARhhssMEGG2yw4c8IwQG62w7En92vLNaUFwcbYbDBBhtssMGGPyN+1MJwYe2Xl4uDjTDY8P9hyqGo9gB1Ha09O/5DaDvHuS3TeGV9FR2/83fjNvyR0IH+yFe8tuwYJ+suNkoyUnbyKJsWbqOuZ8/vjoYSao5sZ2uTlLufQNFyZi1bxfwTup4dv4BzC5i8ZCMrz/XISZPLkQ0zeHtr428QX/4PwNSJ4ch0Xhe6llPzJ5DYBQ4gEYdfW3qSXgxshMGGv4VmK2cqDlkna3JUSjPL9KDzHHtWzODxr3PoNDaiyVvG0hPt1P91KoZ/ESXknTnJnrNCo1188Y7qwyUxLtj/xFgsnSe2cOj4SXHG7wxdDjuOFZNfL9bbDnLswFY2VXYf+nPgDHsOnuJwfo8DslRRUXKEzXliXdtE1a4V7BPO6+ch0pceYVPOj92bGfJX8tKD13L5peO4/s1F7JPkczHQV9F0XOjZSQsdvn0YlhhAgPtFmj1jCWUVpznREYi6pZQDs+7nw01FNEsEVX+UOX+5i0vHXcqj077njDQR0r8Mkeeq7Uy5Yhzjxo1n3F9WkNdqguZdfP78bUwQMhp39Yt8tEEojqsdnbImSo60YvfD/C4/gncyGYnxpAX+qD7+HHzS6JMYR5pTLt99/iC3vriQPIdeDI5w+CcdRivttYdYe1ToiDRmd8FyVh6p7Jko7V9BKXmnT7H3XM/mP4w2GksPsGpv8y8QnmJyjh9j58meyS6M9RRv+ICrLh/PpVfcwrSDLXQ2n2Dhc3cy4bJxXP3WMo6ePs3umU8zYfw4xt/2BJ/u7rm+TIUsWNI1fwI9fwsX+2/GBaFIWf215TeAbS6J3wlSOf/SXBK/C8y5lNadRy9PIsQnBVfVhYl0BFrzOL12BjNOKPGLTyC4ZDnL27Lo5V3K5o/f4b0ZizincKU9v5XGijrcI7Q05udyqN4dp/yFvPbZXDZ+X4glMo4Iw3FmfzqJL5cc59SR71g7fTpf72/DLyScGJcuOuwDcSlcyQefTmVdnR8JkYEiL8JPn9zFd2u+4KN5mzlT7kZ8mg/te2fz4ucL2LKjAnVsLKEdB/jq4/eYddKOwIgYAqQJZ7RlHFvxOa9+sIoDTU7EeJex9P3Pmb9uEw2evUnwb2Tb5Em8MXkJxcI+ttWcYsGXM4QDrUDpl4rd8cV8s+Bjpn97Gkt0MM0bP+DtF2eyvM6HZOdyWhrr2Xzel4C6HGSRLsgKd7GhKgg/dyX20lhclbv4ZvZ05iz5nhJdAH6eCsq//5KPZ3zFql2deKXEIz+1nkULP+CLGQdp80siNcTA4Xmf8uqHX7OzwoirRwDmooOUOnjh2JrLjlMW5IX72LD2Qz6aso1qx1gyopTkLf+clydN50BhK2ZlPas/+pIVuw6iC8wiSrOfT96bxFdTprHknAuRqX1JDZDRcGIJU556mQ82F2PnHoHrqQVMX/st85bkYReeSoLyDEtmf8nMRZso1bth13WMpc88x6S1Z7CL7ENmmCNy9FhOzGHmOR/8YpLJTI5AfqaE2toOvCO1NAhSeLAjCP/2Pcx++zO+3bCFJu/exJhymTv5Lb6Ycx5LsBOGM6t569XPWHuyGpegCByL17KqVeiZWy1ax1CUxTnsWfce7329jbN5p9m/Yy6L9jbg7B2KrHg/RWofnNpPsivPjHfrIeZ+9TEzT/BXXWg6TGFFM9WumaTXzWTyjvPkGQcxJtmDpi3ivmeM2Ee40tbmiJdzBImhol4213F6s0g7bwZLVuXTUL6Zr+esoMwxjUChbyvmTGPu8rVsOt2MzDeRKE9Rj1vzObNzJovzwomI8yHYVMopu1Aimrew9VQrDe7RpLk30tBlRBOWQqiqnaIdNYT1CcdRLqxD0UY+/uhTFha4EOsODq4+mNvKyVv7OZ/PXcOGAyepNIfhVbKe+Ys+ZsrcExhFWcW4tKJVt5OzbB4fPP0F64rN9Jp4BemR/jhVreWjJ9/jm5XH0JorWLFqGatX7qLeKQI/eTu56z7ivSlz2VMgF9y9lW2vPsjL8/ZT6xpLuuZ71jbF0Xo0H3s3Mx6OZZzJFSTAEESEdYJOPV1lu5nx5ucs2rSFRs8wqtfloA9RU19TwIFpr/HF5G+YfbCVwOREQlp3M/WtL1m2Y5+VDLqXH2L9yklCl7dQro6ld5SW/Qs+4bX3Puab9SdpDRzAUPdc5rwj6c5mGr16kyg/y5zJ7/HZ518y/6gWz4QhZIcrRAU+T/mhDazoTKNvopnSIk8y3U6y8ZgWhahbWX3SiWs/xYm8PEpD+zMwIZxoobNxfmoRiQsS3FxMjTwcdelJ9m14j0mfr+ZMp5+oL0H8HrNj/+r01p3d01v/HCv4LeeSsBGG3wl/GMJgbkPXuYeiJlEpG3JodxhMjF86TqJc/gbt5eg7yilSpQjH1UJySD15sgw8Tsxj14kyGlVa6jUe6PecQiYMSIfQ34Y926mM6k3AuSnc8tR09u7firHXzYySb2fe5tMUEUFcgIauulaaPTIZnKTEoXw7i6sicdn/ErcubiZz8HhGpPjiKLJjqtjDvrOFFNdLU/La4xAYhFvel9z2wjcc2HMQ+4E3kFIqtr88hF30GK4eEIWnxHnq97Nv0yoWlAaRIpyB6fDL3P/aCnYdOMBaXSaZmjNUlp2hUOdMgF0R2+d+wCcLt7D7+1OU+KaRVjmDBUUKZO2NNLlE49N6jqIyDZaofoyINlqn8K5vsODTsJtDyiQU2+dwNGAAyX4OOEn1u3M7Hz38tHDCezlsTCQ7Sk71jq9ZWeaIi0VHszJYyPELFuQb0Lc20eaajHPNDk6K/OWa7dDoFWiKNLi3H+Z8YAqBTbtZuEeJd8EMVhV30tzYjNY5BmWjcNAnt3G8ywFfVRfF2z/mpalr2bd7BzsUg8iqXsiGc60YFErkXkn0ysgg0U+Gpj5P3CuPYlUsfXrF4d+6g12VMmStDTS7pNDbp4AFLz/JZyt2c6AzhD6ZURhyj3DeLpysQQPJCJEIgxkqhDzztMKoeZDVvz/eJfsoqO8SeZPRcmAP+X5hdC25g9vfWsnuA/tYZ8jiGnfhKA4WCl2IIcWxiKKc/RzXKDCYdGja/En3qeWcILAp9QtZXBOLfd63bD9TSGlxA3VNTZS21WI2ymnr8MK7ZitnA9IIadvDkn0qfAom8+CCXIgc9YMuGItzKa5oQR+ZSJJjDS3uScJ8RtM/ypHSlRuwv+kJnrn5CuR5+TTWKEntG4i8/CC71s1geZEaddUZDgkbpWw7S4Uim+iab3nvlS9YuuMQucZkxkwYSqKHHZ1F+ZzYnUfQ2x/zl8tHMjwmn5WHnYk2FKHscwujb7+Juy4LxlBVzKGiIIb4Csd2/ADyof2EDupp/O5Zxk87j2/G5Uz03sO2QhmV1aXkTHuUdxcf5OBxJ1KvyMIv50vmnrXDrr2BJucUUtrWs70ecvbW4hEYzJjLsoh1qmNHVajQsfnsqgWl2ouE0FK+ePJd1uzZSaHXCPq5FnF81yq2V6kEYRH5V3njWnGYU10BJGVl08epiFy7NPzyN1Dl5E3d+WKqC8/RHNmXFFdhRjqK2T3tdm5+Z7Wo5/tYb0ploKKC8wcWC50w42jR0tbSRrt3FoMT5ZR8ex+3frSW/eL+2xUDGNS2hE3nG6lpaEXnEou64gi5+zZypMsLTzcfvAJDcdz7GLe/uVLU2/1Cd3qT1bSevWfLqLc4ChITRkJ6f3qHCEOhb6S+IIctZQq8BXnSq0ReYjrIy6ulxSQTBC6R6FhfXMzNNFfJ8Q8fwcRhgVgbNQ0dGI/NYGppPI5nFrIz7yzn67WYhU47hSQSL8j+fxr/KGH4ua8gLIIwSOfbCMOfGH8YwmDRYOzaT0ndBpoMfYkK7oOLKJP/J/5WwdrbhVFzGcLAwpnsFmVVYZ+NcvsCfB/+iDfvuRWZNNd+RwWhw1xZvUuJS5cTg4eG0nyukoDweNJFBCyLvpTeqiJ0aXdy7T0TuX6IO3KfLJKHXMc1Wa00FhaSp+pHVrgzYalZBAcFE+7tgpuDHM25TRS6jeDqRx5gZEgzO/ZAuJOB4KgEMqJlIvqfSFqYK0HJImITEWWolwv+UtNEYy4NskDC7nqWp9NMHJ4zhaasu5k4ZoRwminY7zlG/MNP8ORtN9DfmMOBY8V4j7uLCeNGkRisIkrViP0VX/L6NWpOn3VnQC93HLJu5MqxwkD5nebEOYMgKAmkhZQxZ5UJUyWMvSGLQLVKOFKoOnEak0cskfFe1hklpXn9/T0cSbzrXR7q386ug2ai5OdRXP45r93mT121grPfLsN99HU899xzZAcaOb7gKNFJztj1GkqyvIJjRc5EWE7BqEm8cHcilg448M0J4scN4/EnH2d4ooLzKxeiG/oQ14weQ2KMiJhyT9L/jak8d3sWjl1KLHJ/EUELB+Elw1nIy6v3A9w/UEvL2cNoxnzBWze7UliooKukluD4BAKjvQkNiSOu91AG9gvBKe1RHhoskQUBiwm7sj2CyJTS2iaMU2Jf+qaa0KubWH/AHje9B/0yEM8xk47se7li9Agy05MZ5HKezoxHuenxcfQ5vZHj+igenDSJq3s7c2zBCZKiOzmp6EW67DRnZYIsCdIk6/MoD0+MwS0gishLbuL2Pi6cOt5BlHs75l7DSVOVcbTUi5gIP0KzMgkNi/5BF7TCkRdV1iMfMJzMsHQyXM5ytDGe/rFONBzcRqvId6q/ThDMHEGCQ8nODoS6PMo75ERd/QaP96rjZNBDvHdrGPX1rlga6gntHUlyvzt55O4buSyte84CXW0lJafPwKAxCB4MXbnsKPAhRV1CvXMsroEBRAi9KhB1o1ITzyWhFmrPHEQ7cChhMosgTHI84nsRHhlDOGdoJIjGTlHmXgYC+17HjTc9xF1jHdAU5mEZ/wVv3uhC/nklgdoC6l2zCXLzYNBY4cwHZRCurWRvkT9uFWVM/Ow9br10EGFNpcgCY0kUz+0ZPRA/UwMuIZmMfOAJLg1t5kxZABOvjMGY8BwvXOaDQ90OtrYmMTjbQmV9C2uXdoiyCWHgwBicxeNpSk+zfdFsuvrdby3bXpmDeOBmOXsmfchWuyu4/+UbSYmKI2H4NUx0P8m6RcsxDn1Q6OZo0pKjSLecQD/oLZ67Nx21zszexSdF2lE8+dorXJ2u5sCOOrSnlqAdcC8TRo+06o59zhFSHn6TVx64lFClhRZtoLADghUamqg5sY0ZmyuwM9hzyc030yegmm3Lt3O8tBq7wESyRg0kxV1H8eYtHKi3Q+fqQ2KQK3aCrJkrj3LQmE5I5xFR3x7gwQfHEGxpo6whlKzYH7W6/ofwWxGGEEEYoi6SMNj6MPyvQ+Yu2PnVpAVdSlT4eNyEM/tJdTLrRcRnxM3bi5R+Krav3kNjm56w9DDKv5vJh7M/41C1jpBxg1HXH+b0/g1UhA3Bv0WQgPxKDKkpZMT4oBbRi0GvoUNE0o2N4rpGBbrze9m3eANH89pFZdfSiRqlIC3RZ6fy/JzdnKrvfrFrEk7HSSkiX0sdzR16OutaqC8WIVNmMimRnuJZRCSucCGxciWT561i7Q/v6IXj6myloU4YcqMDERlj6J0qnIVwJhP6J5Gd4cCBlTP5ePYCFh/pwiPjEtIzsuibncao5GgUZnFfdTNtba106kzoVEo0B5bz3YqjFJXpUIiopMMzHCcPVzyKp3DefzChdo7dEYtA66lCGpy9SUsJsU6b3aF1RCWO2ytEVNjSLiq+HIvRE1fHdjo7mmjtNBKYGokhfzufzP6cJTur8B+aiNJUw44pXzD5m42cbTZgNvni7qhB29VIU7tRECe18G0beX/2XBYuOSGM/Wh6J2fROytDRNiJJEf5cXjlVKZOm8bqo+XW57DCokZffYbcpd+y5XAHer2XuG4r7e0tdAjj3XKqiAZHD1JTwwhzldMhjJah5ix5S79mW357d0c9ySgZNLhE9qHXsGy8lcJ5+0fg0Hbcqgul/v2IUrgTmzmaXsndsp/YLwFfR8HnmhqE8xVmLDwYRXMuX8+cytfLz+KUFNytd3oTZkOXkJMZvdYLFwcDel29MF5yoU8W6htbwdkJlbyJvdO+4IsZa8lt0qN39CKpYsXf6ILC3ozcXomuSUPT6ZV8+tVqtqyaw+rjVahDTZxd+S0ffDKNfSYn/PuGIc3mbDQ6CR1wwl7ZQGdnF+5O9kI27bR26ekyuRAUlUJmVjiBnkIu1ruAi784P7KdjS/MZOpXXzH7k23UObnj4edE2Z4VLP5qFrM+nc/+IiNhWUHopRYVi6twvmZxtgialM4klyzk/bkb2H+qFXu5iTadChefaNKzkoiPlmNuFuVn8BB6I8qqrUXopigDcR2dVIdE/loahS61ttGh0aMWZMlNXcbM2bOYNmMli5YfoyY0hozEALwc7ejUuOIoAjcF9UInu9AplOjbayhfNYUVu4tp79Ba5zPoihxEcMtGWjT5tPn1xa/7ca1TwcdkinqVnCFkIepVH1/KdlXjPVKQeF+oPnOKsuJD7F2wkf1VriRkjaRPcm+hm1LaeNwEeXVQiftqRJ1o0xEQGoih6igzv5nEh/O206D2ILbXWLJS0sX105nYXzj9lDDObfuWyTM/Y/6OfDovzLOgaUHlFcw1769g9aKvubO3C47GRuQjnuHDr1fx2f2jCK86zr7j9ThdMoC4sAqO726xzu9j7R1o1KDp0TVXeyMmg8hTu46f6l7yu0MYaynbghGIrP/y0pPyomAjDDYILXDD3v06gp2Eo/458mnvg4dvMKFBwkBl3cQtg2LoF+FIr6sm4Coc/qLJG9B7BxI7dDD+eDM6Sk5Yth/KIE9hHDzZ/uUMPl9bL4ybEq+gWML8PPGVXrspYggThsIkHN2+chGJhqQQ79DEmc3TmLJXx+heiSQGOFizoPQNIcDPFzeVCy5ugQwYEkZMiiPrP5nJlO1dBDhb6Dw6n5kb6omLSuSSeEEiJDj44RUYicguar9g0sYMoX35l3z29jt8tfU8PgOSMBYcZsHkGRy2C8AjwJOjn7/NpCnzWVNgEpFXDKHOalSOgUSHCccenky05hylx/eR3xZASGgwwQ5y3ESEk+3bSMDIeEyqvwoyYVwyHSe38OWMQ5xuVArH7YtnYKh4fjWOrsHEC7LjERFLoLM9KrU/4QHu9L9+AmGKZjZMnsupSnuGPTKegDBvKoRTX7ipDOcAF7xi4wl0EcRD7UuQnxdDL0tEbahi9eSprD3XhktGL8pnvcN773/G3CO1hA+OpXrnOmZ+fZAao5yAgJ5OdMoQ/FwccMlfx+ZiA+rgWEJdRF4cAokK8WToNal05u1kyvR9nGxQCdkKJ+PsgHvBRr4/09ZNGGQq7LzjkZ9ZyXdTJ/HFqkMUGOOIdQrs0QUf5P6hpI8YRMuSz/n07Xetsm+0jyMx2BOpf5lbv+EiyrNn/5QZ7DpuJOvafjgFxhPjbY+DbyzRgl34hkfg7y6cm2sQfkIXAlydcHP3JyUrmsCYIOqWf8uCDeXYeypoyfmGWevr/kYXVL5KlG72NBS20pS7n4Ubi2g/v5btBQ0Ejr6KwKpDLP72IM4hiQzr52M9R+bsiVewuK+TkLVPDNHeSuydg4gJ9STCs5EDG5cwS+jLZ/O/Z19NT0dQ70RiBlxK+KGpzJg+ncm7LAR3VqB3DqSj8gjHFn7JlyuasISM4O5kM400U2kII1wmnLbFQPmuGUze0kxmfDx9evXCw8OHVN92Kk9v735vL3Rz+XlwCokjRNRbq26Girop6laIjwfBYYH4+vnj5eqJs1c42anC4Wb4sHfKV8ycvgpNUgjnNgjCtCCfJp2SuJhgvEV6D5WQp0cQUdGBuHgGEly+ia25dbQ6inIKcsZF1O0YvZ7M3iocUr26n1XAMTic9JEDaV78KZ9IZbvtGPv3qki58UGuS3NA3dWF2kGQuGPryFFGkjG4N9XfvMf7733CrD2V6ET5Rng7o1b7EODjzZBL43AwV7Lsi+WsO9RE/MB4eol627L08+7rby3Ab0AC2tN7+GbKDkGgISik206gEgTfN5pwB7MgYd27cAghJsARtazb7XeUH2LrvI94/53pbNhdR/Klycit3lCOnVcccX6SroXj7+mGk8pT1JVAwoTu/FFhkYjDry09aS8GttkqfyfYZqv8b4OFuuNH2bFsA/6vPUd/a7Rmwx8OupPs2nacvdX9eOrOWGsLwsXgwJxPKLIPIDKwlX15jngkT+SOgf+/a5zFWM6Glz+ivN/NjL68N+E9+60wlnD8yG6W7kzi1SfSUat+Oo4r3LaaQ+dK8MsIpuFsCWecb+S5KwJQ/0fNhpHDn02j0D+Q3tddSXTPXhv+PZD85D80W6UIoqTZKn8KP8xWGXYdo+MeE3v+dedqa2GwwYbfBEb0ahMm7yRC7QTh7dlrwx8M6hj83EMJ15znF78c/QfhzlFWffYqd9w7g8NVDqRmSW/0/z/sFCGMe/1d7hiX+bdkQUJLPfZtrXgNzhDpft4ke9qXc3rjlzx0xyt8sbKV5Gz//zBZkNBGu3sAbi6h+PfsseH3x/8bc+H/LVIPh4uPwm0tDL8T/qdbGIwaOo1yFErVP2fwpPe8BiE4uRqHn3138k9C5KVD5EUl8qK6KPFbMBmld+sW1I7qP06nXemTKumdtlmFo1rxX1+v/hGYDAYMeiNKJ4eLJnZmTSONLRq0RhkOrp54uNn/7TWlvh1GIX+TGid7+U+bbJMeo0GPTumMozj5Z4vI0EFrSyttWgsKtSuevq78AyMz/MawoNfqsNgpUAt9suHfi19tYTg3lZO1UguD688SggstDP3CrmNU3KNiz79uBP4ULQwSt5DohfRr7ZjyT+DCuVb8A+f/Tfq/wy8ds+GfwOl5fLJ0O5sK/sluRKXfsXD5MmYe1fbsuFgY4eRs3lu6lz3lP87LL5Tyzx4SJFehwsHpD0QWJOhradg7lVdX5VPR3rPvD4HfrybJhdG1/w3IggSZgxc+AcGEhATi/fdkQYKxhfYDX/HqilOckzr5/oAfPb9chcLe2foJ7k+rjkXYHpFeEAo3nyBxr2AC/iGy8O+QsR0qEeT9e8iC9Jz/ec2QviKQyL7BYBSOVbq7BbPJKEicAaNw1CZTd75+DItZEMEL6z1pDca/7vsj4rfI2x+fMIinlB70giJdeGjr9o/2/bC/Z7kAacKNCyRBWr9w/MfnX0D39o/S/ziN+E8a/EI6Zt2Wdknrf7/ds25DDxpKOLv6a9ZVGflhkLjIsVx/SSbZIb9msoUTr9/EnLWnyC0T6wEDGTXsEi6L/63iKmH0oi/llktSSXfYy5rNe9meL3YX7efAusVs//uRsc1GajfOYO2JQsp6dv0qGr9n3rocckr+SXJ0MTAVkHd0PXO2NIPaC/fUq7hnSCj+v8eoMz8FXRvla79izdk6/saH/mlghroNzFydy9nKnk6OPwelK47JV3DP0HBC9d8zf30Op6RRQU+sY+vWzRz+R7hvwVK+27qTDf+w0nVDf3IbezauZHdHz46LRctWFqw9zIH8v3tmUwVleWuZsakew8Woee5sFmw/yYF/15jd7dtZskHk/9yPxp3XFHJk1iP07dOHPsMu5/EFp6jfM5U7rxhCVp8srr32SoYOfJJnv9pP98ClWkr3fsEr425m+nEt7Z0HmX7FcAb27k3v3g/z+ZYiesab/M9AMEzJ51gJ5S8t3amkMy4Kf+hxGCzCO6u9nBkSoMRFJcPD05Ex3hZONJnQCdYn/nWLQNRfk5CcndgSxE9sinUhJLmI9pJDnOmjNlCos8Mv0JVRHhYaO43U6yXW2H0NidWbBDs0OnSn7+dgpKDNTJc4aBZ5kD50MijtGRnrQIDCTGWzCaM4ydCTB+kKdiKdXsqH2JaJzP90pPBXSKdJz/iHGunxF9HI+Y1f8OBtLzBv01lMHg3Me/wp3p78NfmegwhtPc+W+Y/w+FuL2LPrGDs3fcanK85hH56GYfebPPLK1yyav5iagKGkKM5T0OWKpriIY8ue5KGXPuf7c+6k9PGnZcMkrn/ifZasKUCe4EPRrBd5553ZrO8Mo7dXGzqjhS5nZzq2fMi9d73AzM1HMEcMw/nITD798mleeW8brUEZxEe509Nnmpp9B8nNK6DFqZZTC9/mgGowQcZDrNytwafzOEVyJ04smsqs1z9lTpkKf2c3dEcm8/rk6aza0IDXgAFEOkulbKFl/2RenvQpX321gCPt/qRkhlC96l0eeWoSC/eewym6H+45n3HPs++yptGe9lUfM+Wj2axo9CI+NZVwV5EhzXn2zHiBuz9YR6E5lMCKbZxUB+OhOczaA3r0eUv5+qPnefndr9lW60yAjz15sx/g7mc/Y97afZA0hljjdj686wGe//RrTjn2Jsu9hmXvP8Rj729gx6G9HJz3BV9+fwa9TyKZ6hMcbFJz8qtNdIb7EKjfwYYcA10qO2pWvstDz33AsoOFqBOGEu8hScyIuXo9b935OC9+tobmjlJWrprFJx/N4HhLICmJ9hR8+xw3PTZdODF7kgLO8tVjzzFpxhzOO2URG+WNq+CC5Vu2c6a6iRZDDoeXTSfXZQC+nftYvtOEKn8dC7/7mA/e30yDVwZ94w0cnCb05OWP+e5MM86+yWi3vM1LH77MpzPPoEzvR4yPursjqeUUy994nvte/IIT9Z00lu/lnQeeZvqPdWHas7z24S5K8rczfep7rKsIItK1hW2T7+Phl6ewdE8BLnHZuB7/lNsef5tv5h3DmJBJkmkvHz73MC9+dBJjsAOmvEU8/fhbLNx/HtfobNzzJnPT3U/zxfSFHFb2Z2S/OAJd7ChZ/z3nmjtp6djDgVULyHfri3vrPtbs1hJiyeG4zpGT017i0/dmsbojmAiFsHe7P+TFD2axM0dO2JB0gqTWZkMbxWtf477HX+fzqd9wWpRtirqIvAalZGWo/e4FHnhlChsPaQkcmIxHxXJeuvEx3pi6Fa2/mb2zpvDOR1+wq9WfYFcdh759geffX8D6nSdxzBhFaNNqXr/lfl6dMovzngNIjPHC5RfNjg7Dsdnc9eAzfDR5Dts1KYwOb2X/gld5+p1ZHK1zQOlQxfqnHuGdlQdp8M4go3UVf3nxDSZ/vZk6z3iiYryRBtmk4zRbRLnc/Zdv2d3oRJzbcT6692k+mrOECp9BJOsPsLspAD8/OdWL3+Lhlz5mTV4L/hEJGHe/zXXCLixcWYB9Wjoxzet48Ykn+PCoI2kJjpQvfZ8HX/iQVTlVOCUOIEaqZ5Z22vZ+xV1Pv8XXs+YxZ+YcFixczs46R8KSexEt6XrTKUrzT3M6/F4eu24g2XFByI9/x6mQMYy9cjyjA+pp6awmxxJNWGAcsW6F1O2YxdzTrpiis4gsmsYWwyUMGj+C0UFFHG53QeETS5zHb2fLf3EchoYj1HUWoFTYWzs9/tTfbzkOwx+cMEgBkhN93FQk+spRC81ur9BTbe/IxDRXBgQ64Gs24R/qQpzaTKtORkKYI7GOwkk0GTC7OpAS4ECCWSsK0g4fEWINcTRSKZx/n0hXxkY6kSmirnrh/X0EmbgxyYUBPgrs9QZqhFO6PM6ZvsJoBJjM+AS7MCzOiQxnC3XtgpS4O3GdSJ/hpURlMCLzdeUqkX6IUMKydpMwkoKw2P18wfzZCENz7gmO796HJnUAaUG+mM5tpdInk/QsN6orfPAvWcopgxMKpRtywcLrnHxI9ldR0x5KnF0BjRH96ZPqQGWpNxnarewxRKMp2EF5bTXtXslEeijRO/rjV7WEpz9cw7nTJ3EZchsDvJuo1IWSNHAkl3ge4piIzo7l1WM+u42GxIHEBiupyDUT1LSQrZY+pAQKpy4LJcQ/kADXbnnqz27kyNnDHFL5U7lvE/mFESRqd3NUHU9cx2Y2NYbhptQLkumEZ/poxkU1Ul9TRI1rH9K8u6gkiT5RzijlFtrz9pGviiWtbyhmrQ+m3C0cXvQyn2/K58yRUmH44ogrn8HzJ2O5++ox9PauJr8tlMR+wxieEdw98mTpFmbPn8e3+vG8Pj4SzmzmlG8mUZbjbDiqxqloN1X2Xvj2TsDB7IT2ZAkOpmKq4waTHq6k+KQCl7MLOe2cRHxvLxqqvYhrPcA5QYQbBCEb19fN6gQ0fiO5aoAffrUbWVCdjM/ZrbTFp6E9uIcqlRcy3QFWv/Y0M3YVcPqQeN64y7g9yxNLVwe5y5ZQ4BVBTGov+qWb2DN9Cst3nSRXGM6RWUGYRdntsB/JxExvurY/wzNf7CGvoICdHXGMGCgMuofQgmOL2V9ezgmLipK9+6kqDSDGdIhDynhCu3Zw2i6VpEAlOsdoKFzGqk/fZJ5w5Lmn2mn18CK5fRN7pBEqA7qossSREuaFq1o457WrOdWgEWXVj3hTPTWlhVjSBKH4QRcWsc2cRaqqhjyTcJw+JhTOUcgryjF2VdOV2p8oYdDb6t1IVm7l5TcXc6JgP3a9bmO0wxG2FoF98hAucTvK6s/fEETkrCjbMs45x5BYvoozPgMEwXFH4ZlFv5RwoWd2dB2ay57aRlEHTBTtPUpdmTfhpqPkKKOJb93IquYUIu3raLWEEN9/BMO9T3NOGkHQO0nkxUS9IonscKEc2hYqti3loFMmvft6irL1Js5UTqdnOG5+rnRu/pi35u/jVImG8D5jcTq4mpqIVBKTUvGqnM2XHyxi99kCjpS74hPgRZKnCIyS+xIngq6iowacCpZxxjOTRGH4qssEiQ0OJNCrncOzPuStl95n6oIFLFiwjh3H7YgZlYCntpXcRZ+yW5FK7xR/HDwzGJxg4PTiT5n83TGOtXowYPgwgg0VVLsO4qpxmSTIdvHOI1+xqyCHprDRjBgQi5/E9Gr3c+x4Lic8hN6kOVC79gmennWU8wX5bDWmc110Ox0e6RgKv2P9Ry8zd6/QheNNmDP6Mki7hqc+WE3+mTxcBt1EYtnXPLWhi7SRt3CVajUfvfgK3+4rIO9IFa0pl3Jjmruwp0YMJWt4+S/fcEjoZrtXFCFJo7lk4ACGZobhI/wEhgZKjm3n2y1n6Wx2JHHkQMKC7NGc2MaOnXbEJTsSODadmkIv4Ve0ODp3UrQ5F//RKTSbYnE9uh+/h57ijiGZpA5xIHdfmwhUfEmN+enOr/8K/tGBm5D8jeRy/m4xW//+B0Z6FDJC4aQiPsCRDDczpRXtrK2GtCRPrg5TCwEIIqEwUekoSIKdgQYhtGQ/JV4GvWC+RuTi3CA3JW4aLcc7wNnFnmiZXhhjJ7KFY9fKFAQoLTi5qHB0UhMlN9IkHH1nh54Se2dujLInWJCVAKOOAkFGXB1lIgDQUaxTkBDjxvBAFaHeSgLtzOh83RktKn5etZaTzSYM4hl+qYPZn40w1O0XTLxJzjUikrhERFWt3y3G+/kpPDisN2X7inGoOo7j+Ie4amgU/t7CsPe+llsyZMJAmEjykRH35DPcPiCFfGGNI5WFVAX0waGpGLfogYy65Sp6ezSxbYeRYEH8+lw2jrEpKjTBV3BZHzUdARO4YWQsoeqT5IlIvSSnFBcRHY97/mWu7+/Krtm5xAZ2oJrwNo+NVVFQKMfDI4hwq5USxt+plrqaE2w87Y3aOYPQxuM0tMiJHT+IeONpjnSk0i/DDYfwbPoP6ke2Sy75Da4k3vQk18TUsO+sD9nJXtgrzLTkHEd16V94cPxY7NubOD7jW+TRISTd/SoP3nQlA9IiyEhLIzPOnxq9JwPTVGhDruHqYSnEXvhsXeaIe3gk0eH+VNd3EairQicNeuNWw8liZzzbaom45iFuv2wC/nYt5K89ReqowQy4+z5u6O/PjulHRPh+kNDXZvHQiL7UHxfyqDuBasg1pF52Gdf2dsXe1R9VwvXc2E/oYkkuR2SDGJ9WxRlBKnZvgYH9e+FbsYnj9YIUP/gy999whcirIFKBLhha2jmyYj/Jb77ODdnpBNaUYw7KZKgog/jwCOwdvAh3Fwbs0ge4P0VG7uK5mCeIa9x5AxMG96JPtB8eDnJRp8opKjnF1sIw3J1j8a89IuqXOwmjMvGoPEJH32d59CovQc6UnF+9GnlUPP3ufU4QrfH0DdDhJjPjfdWr3J/dysE8NxIi/fF0tuP0gi0oR07g/msmkGEuo6BSw5gXX7Xqwm5JF4I6RRm9zqOZDRR5jOf68Sn4qhxoOF1L4pBLGH3zbUIW9mydcRofNzlpV06wbusDR5IsL0QTcwVjbxtC7/Pfs6sYMh96jQduuZIUQWopb2HcB5O44RIvKgudCQ7wJcBTjpNzKecK8thZEo2XSwQ+1YdpFo4jfVwGAc25HDX3Z2yWGk3QpVwzMoEY7V5Bvnox8vab6Odew9HiYIaIIAhtFy1FFfjd8wr3Dc2mPqcMj8ZTdIkou+i8iRAPV7LGD2ZEmjOV+gxcz51hyGvPMzE7Fced31AafxlX3f8gN40dSIpdPa4RvRh2+51c1ded7z/bi7L9LNHvfsUDgzMo3lmEr3cgoeFq2muqadbIcPITBNNP7ItIFMFAGI6tHRzfcJSs1z/iztHBaBsdqDpWQUiv3vQbkUJmmD/OMUMYmu6EIepObu9nT9nuHDxHXsZlfV1QBWYTJnQ9QvKfjbnUmv3xv0akC+0UOrYSx+vf4eFbb2D8wFSy1LnkCXJevWszeAXS//7nufuacSQIQqZoNdJ7/HjGpsrpEDLslRLHgAw/tGofqjYtRusjdOe+57jnusvpL0hcvL8T+uZ2zh7MJ3zcBC7v5Ux0796o0x7msctTie8eYgO6yqksOM1RQyL9E6NJyUogzD+KQFroMmkp3LKWXH0WKd7gVzGDNU3R6OSRDI+q52SXIL71u2hJGkOqCBxl2hy2HjLgEijN6yKxkd8Gv0gYmo5Q0yERBtXP0gCLxSQWs/CXSYIwZIs9v+CYfgV/XA/1A6RGFbO1d7zBZEegiFz8nWWUlrSy+lQzyyr1HCzVoVOpGRCjRi6cfZ7Yp1OI8wTjchC/zkLG0shdCqVMkBOZiCTNNNa0syq/k5w2M1FeatSCsOwpaGVbgxm1SOMijNXZsnYRNRhEVGChtMFAtSA0xyo0VBhEHgRROV3QzNITrewU5KSguIXF57WiQtjhIZiCSjACiRT8t8BDVAC75p08+uRfeP7ZKZxxd2PTXx7mwSff4ryzF25h0SiNXWg1tRj1RhSC3dc3tWGQiYi/bCvv3/UA9z32NKdUHtZWI22Xhq4uF9R2wqFJHfNaRbSl6aK9Mp8DlVVU1DRbXwnp1Apal73Jx9N2ca5YCzoNPmnxeJrzeffhR3j4xc2o+ySJCuMpriWNbNdIm8b4N51b7fyz8FF74HjosHiOBAJdDzK5NlCQRTWOFhHV6PR0Obqg3zGDuZ8sZ9NxEcHLhAGw1NHY1I64XA+EThmLWDHpPu548na+OVAqHPv1JEWGoamqpLa9EycnFxrObef84jd497vTlOtUGL97j8+nrON4Q/dVtJ0tNB7YxN65HzMlR4O9u47drz3Kg49/xKbCZmSuXeyd8Tz3P3U3kzedx6VfAlXHF/P6ww9z31++RJOeQdKwGA6+dj/3PfkSOYhoMsGH9rpa64iJmNXoyw5z4OO3WbhNRNRdHejlShwT07Hb/CF5Bhlmz0DCYlKJjQigXeS9SuTdzb17cCOZk4LoiGamPX4/Dz35LtPmbmFXRQ0VVcKpiHIyifqj72ymtkYUh9mBuAHD8W6ro7KyUmJnOPRMNSoLG4yv1oj61DkC4sNxtD/EtPowYkSZOhkcUcpbaWutp7G1i+DMAcQF+dAk8lInCL6rkz92erXQI3G8uYUOUX8vFGl4uoLDSz7gzidf4MMt56jUVPKh0IVHf9AFoWOSLrQ0invIhMp0iHvoRABh5vyOr3j+8Qd5YtIKjFGRGGqLOVReSWVVo3UUT4STaG9poFoEJgYRuSfEhtElyUfockRkuAgQOvn8yXt56K7XWXu+HlPPZz6yiGH4tnWgPFNKcEIQcuVRptdFkmgvDL1J6JjIv0atpGPFJD6fuo19+U54iKDQZKihoakT/YWHU4mASXuO+U/fK8r/frY1y3AI9UEn7JO5pYmaivOcE+VQU9uOg7sImvzKmfTkozz85EdstsTjLpxKoyiHVosKHx8Vpzd/yTOPPMQDL8xFPqg/8b392fLYg9z3xCQK3XzwiJReFrgSP/Y2nnj3Xd61Li/z9AODCRNH5PYqosLkLHr1Ph558AXmHS4XxrSJsvICSkU+mkT90DmqRaCez6nPX2DKmvM0lJZwSpDMyqo62rsM1le6VpgNaDvEMwjZ6uWCOPYbhludkG1lBfaOrqLMzLR1dBKQLvIZ7GXVhVqtAR/xTO0V+eyvEnahroVOIcuGilxq1nzBJ3M3USycYGakL80ifXWXFnc363s1AT3GqkIOV5RRVV1Do52c9nWfMO2LZRwQumuFyJNRqxH51NPRVcSRIwUcX/kuc/aWUKfPoyS/gPPn1EQPCUZUAI4vLSVonNCxlg7MLo5EDvUm55VneODhJ3nysY20+wSTmPLXAa3+k/j/n1L+7fJb4A9PGGQKGfJ2HWeajRh8XBgvosbWJgOdwolrjRZq2wy0NGipE4Qhw8OOrk49p9pEJRX12NBlpFVjwT3MjSsS3RjhbycMnkk4CAuO3k6MjHAkRgT2+fU6DKJiSK8phvgocBAO316QBqUwUVLfCKVMbJvNmFRKeoc5ECaMQFmz1HtWGAGdmbp2g3BuIq+eLtyQ4EC41BLxY4/1XwDX+CjisqSJp4qobjMRPPJqYsxt1BfJyRwYT8K44UQH+OHtG0t4dDxJfm74BCYyqF8YfskZ+LUKZ1Yup9fgBLx7jyJdGMHEjAQiIiIJcPDBPyiOsePEeYNSaD9RxFltlJC1M14BKfQNU+NgbqXLKY3EyAiGD8skrd8AXISh6dT4MOzKXgT3HUS8uxOOrvH0TQ0hxPuvTBy88Y8ZxTXjshk1wI/47FEMGt7LaogIyKZvjLh/QCzJIk8BigaancOISE4lUjh/j8BUBqV4oLI2VshxTe5LhIOetqIO/MOCGfnAdSQmJkDuQQ7mnBHGvInG8iIK1X34y4QsYuP7khaswkkmOQ1rZjB31VNe1YVd0GBevak/EdmDCNE0UN/uRXK8H4E+drTUiej8XBPufsH0GRSKpq2eigLhCFqdxfP2pfe1NxNr1ynkbyG5TyxhQ0YSFxFFsmQrZcGEhMaS6dVMvc4RVfhABkU64+SZyoC4TG6cEI9vkAzH5KGkJ8ZiOiXl/TTnRT2QoHB0JH7UIDzaW6kqKsdlQBZ+Sj1n80Wd8AwlIyYY35i+ZPuC2l2U49grCG4u4MyhgxwrrKetZ0RuCCIiSUT44zIZlh1EYv+xDBiUjKe9I55J2VYdcXKOIT0uiMHXXkpCWBDaHJGXU/mUmj0JTutLvKsjzt4pDEqVhsHuvmqgiLzDvF1pLSqhKyCRpAGDcPsbXRhIvIfQhZBsekV44ucVRkJMOMnhStqbayg7Vy0CCC/G3NKP9LF9MOadJ7c1jNRQV/xi+pAWHYIIunGW5JOe3FO2gvxZHIkbJqLUqgaqWrxJTRTRsjQzpQS7UGJSL+WG8WkM6RtC4oBxDByYgIvCGVXIAAZGu+Lhn0xWuKMgqa20+yaREBdDoIMXgeEp9Ev4URO2WUtTZRklBUYSe0cTPHAkUQHBjBmXKEiLD5Un6qiSxzAyw4OUkf2wF+ymsqgCt8GXESNIUc2Rgxw+W0GTVwwRUaE4CEfXqXFn+A0DyZh4HZH6JupLFPQemkhoiLV3wc9C4SR0YWQ2rq1tgsS7Ehnux4hbBhPoIqPgjAjUXKPoE+6Od1ASvX3a6LBTEDt2EE5VZZyo8ycy2I8Y956LuQvbEN+L3sKfqryDSRl1GX7VuZw4eIjjxY1ofPrRN8qXweMvISEipFsXTuTTLI3kOSSVrlPCLuhi6ROiQt10jlOdsVx3STb3P3A9USE9uiPqYFFjd0VTebiTMq4/CmGzchoCRfkM4/oMJxFAttF2oQe2WyTeIQmEtR3k6LE8ca4IWhpLKDx1hEMHm4i8/lFuvH0gMXEZxI15llsHJjMgSlwjvA8D43wJG3gLw33a6awsokjRj3EDetFX+Jn/GCQyIH6ksPrC2s8t3WkuDn/ocRi6Oz060c8NGjtNaBzUZKqNHKiXMSjZAT9BmxrLW1lVbiIoyYdbPfR8nye2a0y4CQNvEJGUl6cDQ1OdiBL1WieY5NacTpr9PbglVhhxk5GCsnY21RjxDHBljL8COxFtnqzo4ojZnmuj7EWkaaGpuo11JWa8hNEd421m73kdVWp7JkaqcNAbKKnTUOrsSn9XC+bmDhYV6qjWmlFL7xx+BhKfsI30aMNPoX7hG6z1vITM0QNJE9vGI2vYkpNPx3VPc/Uf5UuHPyG0O+awrsKI47V3MfZih3j8N8EiCM2ZRR+zb/DzXIYIzo0AAP/0SURBVJvkIWJ/G/6XIfnJ32qkx35h11/0OAx//IGbRDrrlwh2gh+Jdal5S/LD0tcQ1iuI/TKxpKf7MkKuYU9+Kzta7bqnFRaQ7mPqSSutyxRyAqO9uNlJw3YRJe5oshNRgPVgz32kS4r7izOMF9rSxLY0AJtEYKQ0cisR6L6ulF66vzVv4phFbCvEcSnFL8FGGGz4OTRvn88Bh0TCMzNJEI5Nf+4AJwpLaMu+nuE902PY8M9Dk7OZw3U65P0uZcAflHhZOpop27GUk7FX0j/GG69fMyQ2/FfjVwnDOUEYajfgoHK1EgbJhf09/nZo6P/2gZt6CIHko62OXHLO0q/YYV3Efpn4U5r15DfqqOy0oPzRU/1NWrGIfxi0Rmq6zGjM0uuGbgLyQzrrPf7uPGn7R9cSP9Y8XUgv3U46Jn1Oac2f9c422PCvwWPYzYzN7iYLElRx2WSNs5GFi4VD+kgGj/rjkgUJds4ehF16L5fF2siCDf8AenREIhbWIPyXlp+kE/8c/viEQUBy0JJcrL8/Whf+ucfZmziR18LGMh3VFhk/mijQigtpJQcvE4JrqWxlSaGG/E6sQ7H+OI0kWCn6l3Dh+tb9AhfS9Gz+cMyap571C2n/62DU0FZfSlFRMaUVTYJsSULS0lRRSrHYV9umlcZNFLtaaGuuo9X6jtCEobOJqqoqqmsa6dD/sUdCs8EGG2z4c0JyPFKw+st/F4s/BWGQyJE0ZKd1Ees/5XT0Ui9ko8Xa2VDyZb/kmMxmM1KH6P83Rpvw+tJXFBdIhA0/Qt1R1n94I6NHjWDiDa+y+Hw7LeeW8OaNExgxajj3T91NvlYQiO1v8vpbzzL1mDjHVE7evAdITkkhLftBZp5sRdN9NRtssMEGGy4WPY7uQtAqvRL/2aU76UXhT9PCIJfboZAWsS7+/Q0kQiEdV4uDKvFrjfIl0iAWiTz8mEB0r3dzLWuynuPSFw92jirSotyZGCi3jgkv9WGwpu85+aeu9z8D7zRGPjSdpbPf492bnDl7pomdi3YSdN+rTFs6iRSptWHRLPJaOzmnGoBzp9RT2Yi+vZHmpibqK2po1pikwZ5tsMEGG2y4WEhO6IIj+w/hD08YDEY7AgNduGmwL88O9eHuVEfCpE6MPU6724Gr6JfuxRPD/Hh+qC+3x9gTKjOjF4m653/oaXX4u23pAhf2SSTCpDVQUNnBrgYzJmnfhbRSUut9LpwrHZNy9z8ElQteoUlERXpRUZrA8EgFcp03iZcMZGRGH4LrqygzJJI8agIT07xR6jWCxYWQfOtUDu1ey8aP0igprKam+X9NcDbYYIMN/wb0EAXrGAs9y4/HXfh/izX1xeGPTRiEVzYqVcQGqfCWButoNuPiq8TJ1O3EJcdtJ7MjItKFLAcLpWVtbKo34+1pT58IJ9ISvHlCEI0n+3gwyFOGo7crd/b35alBPjyV4Uiom5rEWE/+MsSXB5OdSHWV4eWmIt5DQXikJw+Kc58e7MNVQXIcXO2FY/TmKbHvqWx3hvvLrfNZiHL4H0EHxbtXMfu5XLxvv4oRcY7Y00BTsx69vpIKmYmu4Ew8PEOI9hTlIpc+PVHj6BdD1sDxjO7rQnNTJ10/fKNvgw022GDDxeBCA4PUCv/XjZ9ZfgP8sQmDeEiT3oJGL8PTSY6lU8vhfAMe8U5EipzLBWuQBOXhqcTYrOFoYRurC7VUmGWEBTgS5yjHS2amTZCOXn5KEoLUKNq1tCsU2JkgxMeRRBc7GjtMWFzsGRLpRIyHPSmeCjxclITITbTIFES5K+kV5oCbwdg9IZVcjlovzhEZ/I3K4Y+P+pPs/vYNXp7/Ph9Meoq75p7EJ82dvc/fw7jRr3HGN5b+oWdYNOklHnv6Zb6YNZmv1u5h3TuXcdm40Yx/ppFe2UEEu//PSMwGG2yw4d8LKWL9B5YLqxeLPzRhkDo5Bvqq8cdEUZOOKgc1SZ72pPkJhy/1LxBprEIQ/0mfNEqQfqR+DhI0nToKazo51CScu2AWXVIvfbkMuUUanEmHUSHHUavl+/x2jnbZ4e+hQiUIgU5c2GQwUVXTwb4aPe0WOwxSh0ohLrm4cUW9ltN1JsTp/ztQ+pI07laemnQ3Q4JCiQn0I2rk7Vw6rD+9s8dy65heJEZ44hM8hMsnXMkNwyPx93TFIziBhJQsMsdew029A/GSJl+ywQYbbLDht4Pk835p+Y3whx64yWw04xzuxS0RSuxFdN/p4kimNIJqp4bVx1rYXG9EbycjMNRTpJGhbRekQqUmTCdNACWif1cF8WYdh+0c6W9sZz2uPBCvQi2oxuFDtWy2ODMsRIWznQW5ICU6rYlSo5JENOzCiUvoYBvODBa/O7X2ZMc6kaKG2pJm5h5vI98iR/kvFobUh8I2cJMNNthggw0/B8lP/tLATdvyp3LSOtKjq+AFP+2MrAM3ifOzw6+76JEe/9AtDDLBGhrqOtlfrafDLMTR0sX+0i4OiuheLuQmF7mXRl+srOxgX50gDyoV/hYDOZUaDlZoqWrScbLRQFWdhvwuO6I9Ia+4k+3lJvx91DjqtRxrMGIUhdLUoGGHOHa+UcuJRiP1jRqOid868ZvTYCbAU0ZnXRfbi7W0i0JLC1D8dSRIG2ywwQYbbPgPQwq7rcsPKz+z/Eb4ww8NLQ25rBeO2Wj9rKEHdt2jLKou0B0pjalnaGfBnqyfYNpZrMNHC56BxWjBUeq02NsVV0EmCpX2DHfSsb2wk831JtTiOlLnSYW4rjS4pvTpnxTrS78y6d5ia3C2B7EaPWc75KR5Q2dNO7PLjNiLe/0rfM3WwmCDDTbYYMMv4ddaGC4MDS21MPzaXBL/E0NDS30PpPEX7BWyvy5i+8fDP0sEQvnD8QvDPXefJ800Kf2ajSbKGyEw3IlRQXC2Wkt+qwknwTqk89QijfixEhHpnB9+xX6VXJwr9VnwcGBkpBJju5Z9VQbr8X9d9DbYYIMNNthwEfjBAUnR8j+yXBz+8IRBgiQT4f//duk+9AOk7Z86Jq1LTt8iCEPemQY+21HHuzsaWVNjpNWuZwprweK6Wye6ceF86Ve6nkQ+qsta+GaPdG49c/K1lFpkP3SutMEGG2ywwYb/OITfsvop6c/yK4s15cXhj08YhECkryWk/gJWjtTj3KVf6TWFQWxIv9Y0Yl3atu6T0vSkv7BfL3ZqDN2vL6RXAtJxO4UcN3s5roru7R/Dem5POum/C/cQ/2ywwQYbbLDh94XgAJI7kkYEstj98tLjyS4Kf3zCILPDXinDQTh0iR/JZTJrnwOZ+HVUCUcvnL2zNP+DWHcWB6TFRexzEuG/TMhHSuckEYKe/R4O4lrimoINYBQsROHhyLAoJ/p72KET7OAC+ZD6M8rkIq28W0hSK4SUg+4ZKbvzYoMNNthggw1/Blw8XRB+7w/9WaUI5e19XLg0wYmItjaWFRnB3Z5MuY7dFiduj1YJ5w/NlRrqPVUEOCpwtV7VRGl5O98d10GwM5dlOhFm3S9g0bH9UCsHm01opLknlHLclOJeBhNNeiEQiQkIwmAnCEhIiBvDZF18X66jVCPy2tMn8bcQmNTCYev0aMMfCyISEfXSIiiyxKn/p2GVgwS7bpvwL8JikWZolea3+W8SqKQn0u/FyebfDmsZSn9/XvlL9fHXOj2e/Cc6PV7sZ5XyZ5555rWe9d8FCoVCOG0lXVodZc3CMbfLMFq6J5CSlFLl7khSgAMZzmYrkai3U5Bkb6LMTs1QBz3rzndysFY6V0+tTEWYwkRNVQcbK/S0CsKhNUpEwIJZrSRI08nGYg0VDs5cnuLG2EgFjioVPsJPezkr8Qlx55ZEZ7L91TgbDGhdHElTGaixd+KSBDcuDZGj7TRwvsOM6iItqlTfpEuEiucK91TjIkgTdr91g4+4i+Uk825ZRL6rL+GRHqh6jthgw/9D4xkOLn+fzwui6BXpieDf/7PQH/2aL9fs56RdBr0C/0Ui31pIzopJfHw2lKQwH1z/I5WvkDVPzmPPeSP+fUJx6dn7W8Jw6Es+W3uMc8oMMvz/iI3UXdTk7Wb2rbM43rmC+WWhJAT6SbHmnxJardZKHKTgWi7/qy5qDe0UNx6htrMAhVxt7afwU7CSVnF+sHsyUd59xZ7/YsKgdFETJtihv5OZOsmCNZpwlRs5b1HRx1+Ju6MSZVcXp2u0VMjtiVKaKBeEYWejBaXKDoPORL3GjNxRRWCXIAzlBjSeLlzhB2U1XRzSqcjwlGExm+l0FsQgQIGni4iwOnSi6qkItRjRejgzxM1CQVUnO2uMGIXApRaQi8GvEQZL6Q42bVzB+pYE+ob+q5puhHMreHzjXnIWLWLL0m+Z/u085s7axaGDx6iUneVIewa9A/7NlV7XwJllb/DEW1toi8wgSbuNbw60YG4u5NCCN3j81U9YeOQYpwsK2PHMc7y9YBEL585m9twq3Ib1Id7tR56rdBtzPnqaZ96extzt52i198Hx9Fy+rY4lM9yJi/VxxnOrWbHjMPsKmtHmLmNZfSxZ4Y7ITJ1Ubf2EyTlqvAOC8Dk/m6+2nKfaJYk4zQ42fv8935fJ0G+exHNTTmKfkkJIzRqmHDLi6OmPn2E3n73wBB/v7CCsVyZBv1CknQem8PKLf+HtL1dzqtWXyKwIvC5S3/4GhuN8O3Mf51udSYxw69kpIHTQ3smXoJAIwrxV1k+LL8CYM4dZW/MoUiSS6CPpSxNlx7YwfVE9sX1Dcfot81e1l63rFrOqOZl+Yb+m+2Uc3ryVZVs1pPUK4K/x18VB7uCCi3cYkSEBeIuq+Y+jnONbt7Ho+07SBkbi7ORDQJCQp6999yBvJ75mys4qmhzjiPboPuNvoGmgePNnTM1zI8jfDw/p8Rt28fkrT/DhtnbC+mYSLK/gzMoPuf3Jt5gx4xsWrjiPIiWLGF81iop1vLaiiPaILCZk+V10ffgxWnd/ypf72zB6p5ESEyFk4/dvGbnVdHIu32w5Qb48mWTff8E2aco4vXs1r5/y5Y5bR5IWFU2kn8O/PMje741/lDD80OP/7xaz9a+bMET/1xMGVweS1GbaDSYqlI70Vxlp15soEoSht4OJ4zU6zjcZaBG+Ue3uSKqz4Jcdegq6QPAFK5T2CgKFZkeh53S7BTsXBxItWnYVdnDSrCZZnCN9jtkl7mds6iK3U4aryShMkYowi55T1Rr2CALiYS9DLbVYdJoxiQz+62L/RwjDNjZs2cw+xwlcHdFK8d75LMh3xKl4JWuLRahSvos1X0/ig+lL2FtjT2ykHzXff8hDL3/GkrW72d4ZxsBwVxo2vcS2gPGM7JNBqnYf26tMqFOvYmJKF0U7v+LdKRs5mZdHp7sP5cs+IccSR7BbLesWHKYgdzt7tkznw4+/4dvtO9i+fzubv/iKpQc68UgOR567gIWnlSiK17O1yEBXzWkOzXuVN+fmUuYWT79waVhOAW09xWve4pNlp9hkn85E+wNsKHLBQ1vAnpPnOG4/iPsn9ichJBg/cxO1FXs5Yj+c8QOzSDauYmGuHQ5eYQSKy5nOLGfhzjPUBWTTx62dQ/uacGn5ltc+W82Ozbto8++LX/1m5k79kK/mr+ZoozM+rjLOLXqGlyZv5wCB9LM/ybQX3+Gr5aup9uxDZLCL9dWWBNPZFSzfX8S5FiWe1ZvYaB7J1RluyM2dVG7+iGklMWSkJhBeNIMp+9og6hIGWLaxfvt+9ncEE33mUz7aWM1x90QuZzvzCwOIio3C5+R8dq2bz6zmKOxDMhkd0eOF2so5velLZhT4ExPkhbMUhRr1WFyDcBb3L2jswjlrHCnWULGdc4J4Pffht6xat5kGryx8qtYy4+O3+GxhBR0ake+dU5n0/izmf7+VrUd2s+2zqXy7pRqnjEwi3OTIaOX4zBd57YXpLClS4emhoX3r+7z00VZ2FugI8GqmqMMD9anZfPLFdL5duoYCRQJeDTtYn1Mu5DuCYRHiKufXM/upJ3hz8UHyhCEaHVDGoldf5o0ZCylQJRAT44vg3QJNFGz5lrffmszao7l0OrhSuPhTTqnTCHYoYfnco5SdFXLeMIevZi3nQJUMF6Ug60fXs6UlisS2DawsEnpftILVxQ7YFW9i2ezJomxXcVLYiq6qPFa/+BwfbyqgPjyJQeoTTH3hbaav+NuyNRdvYf7kN3hnspDd8XrsnNzR7fuEFz+ez+oN22n27oNP5Wqmffg2n+3Qo5K3CCMsp6Gxjqp1r/PiB+vYWedAnE8hc19+l+nLVlHjmU1yYDvbPnmVZz76mqMae+xaCvnuuaf44PtCSt2CyVSWcE7nR0Trbt5/63Xe/3waa5riuWRQFOyZwSvvT+f73EocY7IIl8pYkOui7z9nRlUKA9KirTpfu30eBzZ+y6yWCNQR/RkTVMHRlQt550goN1ydgeOJqexSDqJfiqiTu99gI4kMu3QITvum8cp709l6vpIus4lzS6dx3qMPAaaTfDs7B4VbHfsXzuCDr+ZxtMObACc9J+Y/zasfbeZAqyNRzrlMfvhZPluygZaggfgUSzbIDXe1sCFyC21N1ZSufZeX3p/JvO82sOnkAfYIffvmu0LsElPwqlzBspwu2osPkltUQWFNMzVrXxP1cCt7zVGMTvQShk5L1bYveOvj6SxctoZ8WRxeTbvYmFOJMSSd8IL5PPP02yzcX4BjZG+Uhz/jlTc+Zuai1ZQ5Z5IabuLonI95/Ytv2F2qxSc5Gb+GIxzatYCKrIe43LmQM+3uOBau4utP3+Xzb1aS0+FFSFw4Xr8Vu/w34x9uYfgZj/TjFob/esKgcncg08NCY52OYpM9QyPltDQKkoBY97ajzWiHwmSitks4cTdHslxFhNamI7dDnCsMhXQNO7WcQG9HEtByrFkIz92JDLWR8mY9dQ4OZLlJLQyiAihVJDnboVIrcNCJ+9mpiZMZqLQocPN1ZkKoHH2rjkMNJuunmv9WwtBwmpMF5TQET+TygGrObBJGsiyO+JoFLKsKx6dmI1tPVlFaXoZO4URTiwnZ+U0c1PqiOLuNtr7XMjqmnV1vbMJ12D3ceesYsoNEBVcm0e+eB7mjr46S/cfJbXLAs/MkZ9Wp+JyYxveyYcJJr+PbHa0Yag+z/dgxjls8iWyp4dReHUFp9nSWnqZARNZB+V8zpyyS0JoVfF/rS+eJb1m8ag0n3K7i9st7EePV0waraaOxaBsnPKJoWqdnYGILBd4pxKu6aCg/Q16VkVDfENLHjWfoyCRCtWcpy3yVjx7OIsJUTZk5kNAgf3wcxbXqTrLnyCkKmgTxMxgxOEbSy09EdQ1e+DXtJd99KP2VR5k26SOW7cphb2ckcY5l7J7/NrM1l3P/2BC0657g7vfXczAnh/XadC4fmECIS3dFNFcd4UilEb2DPxF2ZRR7juLyFFdBGHQ0533PbkMvBqTHEtq0k+3VrvgnD6KP+iynihupVUST5ZHLSYc4cY9W+mdrOCkcY98EJTUbi/AdmE2YiDjbT+jpMyoS6XEwauloqaXJIZaEQDcchRGTuxipOXqCHYeKcMsQ5RHYxva33+Lb7zeRc3Y/X85cR86xw9SETyC7bRFvrzqNxn8ko4NPCLK4hV1aH5KMdRzf0kFgugu6ksOc8RpIdpSXcMaCcIvtvcfbUCVcwqiYCnas+pZvqjK5ItMRY8EyFtWmMahzFU+8Mp99Qka5ToMZKPLQopNjHyHWQ0Ud7argvMhjXmcEGUNTCc7/lOUnHHA0lrDjvAyn0Fh6BzmhK93InNce5Y3F+4URP0aeczwJJfPZqh5DinY5s3ZoCbYvZ/O3n/Ltxhz21HoSnxiNv7mSUlMgweWLmF8dR2zVPBbXxNDLLoeZH3/Gsp057Gr1IyslCseKsxQrU+g3OBS775/mvg82/FC2EwcnEuwsQ3/iG6Z+d4iiVrkQeQv5Zn8yyr/m0c82kHP0IA0REwjPeZZnVlfj3fdmrnT9ntWHqiiq66T+4Dd8WZzKlf0CMex7mcfeW2e9/jpdBhkdSziaV0eLVkNhaQMVHUp8TLWUC2vTX6R3PzOXKYVRBJ79hDVFzqgVMhyiBpKgymPf50/z4Srh3Ladoy55Ijeluwl96KA+bxv7yWZYegT+TnVsX3qekMHZhLv60nZSztDRrtQd2sXKnE6CPBwwxKcwuv8lpEUYOThpDcbI0fSNLWLZM/fz4ZojHNhbQrmTL+Glq9juNIrU5nlM3qXAuWEZ897/kqV7hCwLnAlwb6N0jyAmVb2YkOGIPvdrNhT44aXLY32JL8HK89S6pRNav5WjJc2U1TRStm8xc6q96O3cwrE1jfik+iCrOSR0JoPQ8gWsKHRFUXOA/FoNZ87kkLP6M+Z2jOK+awaTFugkKoAO7YFp3PbcfA4ImZ50GMCgoC46cUUryLQ+dyV76n2xbznD5mJHEQzMY9ZJBzwaD1DoOgDfpo0sfesFvt6cw75DzTiMGEZ28ym2zauj9+0jUB74iC/PRxJZvZhFORo0NbnU4I177ADSfS7Ggv/n8I8SBpnwm9IT/f1ygTCE/Le/krDCzg6LNBFUo3DcXcLYCXJQWq+nQmvBIuseqEmuM1DWYaLDJE7SG6lqN9GoFw/Xcw07qalGCKyj00B5lwWD9BWE1kBFp0lcT9zLaKRQnFChBTe1DF2Hjrx64VA7zXSKc9oFkQhWiTzUaThQrafeYLEO2nQx+FXCUHuCY+fLaYq+mnFJZlrytnPMYQTDXU5zxk4wRbtCOuOuYXTvMCK9LMJQuZHoVE0xYYQK53PrM+MIExX79SV+DL1mIOnCeOtPbWBjkVC8sGH0Nx0lRzyLIutu7ost55jdQK7rY2anICEli4/iOv5KhiW0Ua6LY/izz/O4IFUtpencuehOenXtZr0w3umyUxR7iAjbqZAySwi+UakMGJ5JSEi8cO6OhIe4dzeJahupOLuL3a7juUoYj0pTKbvV/Rnl00Fp4Vlymx1JiQ0nIiGZoM4Szh7Zyn5jFkMS/XELTiY1socsCFhqjrJ9736ONvgRnZzFhMsz8Ws7TWXq0/ylVwO5phj8WvaiC+lLTEQQIUHeuERnc8mwOJIyBuFcdUYQn+mCUL3CnddeytC+aQyIC8RD+hxGwFxxgP0lGjqVPoSaznPOdWQPYdDQdGItOxnC6EGh+NZs5pscE169hzPQSRCTvQcok6WS5FRMnutorqkQzt2unVMOg7g2tJh1337H8pxS6vbvp6FZQcxVw4iQ+JTKGY+wdNJDu8mCFbJ2yk7kUl7dTpVDCDK1GfuiQio7mjE7CEMffwVjos10BfQlS3mG80HX8MBfbmOiTy7byvzp+8SrvBJjT+OxKG5e/ihDLDtYV5vK4JQQvB1UeEWYOVUQwIDLruem/pXsOA0BN33CB1c70nTqEMfMqaQY9tASNZ6BEXIUQenEqSto0SuRhw4UhEGOyk2NWtSVEt043n00ivxlr9N65VI+uyGY9WuO0uwZJ5yOP027ZrH+0Bk8Ln2Zu6+bSL9eCQxP1LJmbzk1a7ZjN+Im+nrm06mOISQylqgIH5ycXQi0VHCOWFIV5yl0H8EwEe2eIpXQzoNogvoSFxmIv18IaYP7kervQrvnNbx+g4zts96iutdL3HHdZQyzlm2Q9csofeFWjjgM4dobbmFEaAfzDjcwwqeG+uArGRFlpiNwEMN6C5IzpC9B3uG4dxwn3+SNk1yJm5MIIK75go9HaTj4zZuUZ7zIHTdMELqTgsP+t2js/xJvPXQ1LUcOk2N0ZdTYTIzKcXz4WDj1uQfY1xmPe+Ec/G5dyBP9RGAi96T8wBo6zXKCL3uK264ZQ6/kKDKFDqBvo/bEpv9j7zwAoyq2Pv7b7Cab3SSb3nvvCQECoTdBRCw8e3367L377L1jFwFRUBFQuoBIl957rwkJkN6zvX9zN0Hxvaf4lE/Rd/94ze7duXNnzpw553/mzp1hrXoIF/eJJlCxic/em8Gc3cep27CB+mYNXYZ3wbFzMVM2HydAWc3egyXcfvNgMpSrefkLBQkDR1DYOopvRXSfNOIRbrj0fHp1TaVbspGZiw7TtmIryvOvI/rAKCpC+tH30hv52+CedPEvp45QIq55l9d61bJh7mQiH1rCqwOtvDdZtKG2FH1Ed5JFKot3sLCBbjR+AYRf/yLvDgynYWEoI2Y9zsUhG/j2WBIpjgPUBRWTFdCGU1gCW0wPBg3KITOzE9FqP6JTwvAVTq9y03RKo4bRP9Ubn7hC0tVVmJXBlO3dikbrxbmPT+Sa0H08P/kgRfku6P00Dxe1UuGVStuasTQGZpB/8Z1cNXygIEpeGA/u4fODfbnj71G4j6wRtqQLxT4HqM+7k+u7+qBUa3CG96Bn/A/29mzGmRxh+K2E4ayWmLRcs71VOOljZvZaXOhbTSzY0cbaOuHE6/RM29rIRxsa+aLUSoNDEAvx+xqRdo/e/f2y0VIeCMJRWaVnaY0To9ONudHIskpBUKxCxHqR/wkzB5rt1Fa2MmFTIx9vb2VJlZ3qaiPfVdvZeaSFaZub+GyPicMG0Ul+6wSGXwCFUAzT8Z0sH/8qo9/8kBX79WyZ8zFjp6/hQI0VL6cZfUsjDQ0NNLXZ8I/wpWX/TD57/QleX1Ar6mKmVhilpvNyiY8L8Thuh0Mwd5MJs0N8cdmx6pvF9fXU1zdgUvkTkt+L1NKv+GxrEClpBXSONqN02lGJo0bcp7GlmebGBhqa9DgUKgKEwziyeAIfT1/OpqN61KHxJDTvY8mHb/D0vHLPq6keuB1Y20xCwZMY8HgK1Zu3sH9lOW6FnTaXcEJhKcRFheKWngm5HNjNevSC8EmLbZkPLmD+xoMcbWnPymGoxxnbjaFPfM7Y5+/i0kI1VmMTdXX1oi6N6C0OWpuqsbi90apVQk4m7JooYhytlE18jn9MOUJMUV/SQ8IJCQ+jc2YCIX6njE06RBRiFnIyW7GJchikrUslCDLnsrRxeOE4PnjxbWaUCidTXsrKN97g7VdmsuJQIAW5aizNNhT+GfR/OJpD89ZzbM9hdn35JYf0FdQ6vPCOtlAfdJTpKxra8xVkqnLbXObuqKFV1FlC464dNKlEpB1jo7Z0n0g/jNtGfcrod5/h/IAaQSAC8VfasdldoowGgr0FAZaubW0R5x34CvNcW98o2quFZtG+jY1tmIXeC5vRDiFzTeUqvp4+h4VrTxCmdqAV5JtWAxaRX6vJQktjFXZVAP4+LpxO0X4WEyYhF2kdk3aoUNjqqF45ife+KSUwNIHdU1/liVc/oVYbKwhghCeVOiGV7Lw8wnThREaH0qWogNj8YsI2vce7S1xExyUToqmjSQQAvr5qvN1WTFabKIceGz5oXXq2zh7N2BnrOSxIvLm1WsSkovyibVWCxOmFofQxlLJ3/ueMXllPape+pAaHEdrRtsHC2UtQCgdl3buAyWPe4YuVlaREhwl70oBbI2SpsmJ1KfDRCT05PJvXR07g05XHUHk5MAhZaN3S4RJmxJeUrn1JDg4lJCKErplJFHcu5sSKSTz7whusqvGioKSIoNbDHFoyhffmHcCgb8Gu8CYxPplt00by6pgZfLevmZicAnKyMtEFhROVGEdhcpSnnJKeOU2N7J8/mreFnr39sMi3qY5maaE40R8bQsqZNl8QLLsGv5L7eGfCqzyi/YYXvlgtHPw09L2iCc0LJSEyjfTsDAIDhdwFaS7qWkxseirq5SLPpf7kpMfRbVBPEqPiCQgNJyktnuRQjejrJnyFojhUOiIC/Zjz1hM88c5sfJNzhFx9seiFDkh6YDYL2ZjRilbyF8ShXtiHBmEfWoQtaWho8dgYXYAf9ZtmMHn6fBbsakQZFEOcvYnDk17ihvE7xZUCLhG0NUm65o+fINAu0f+tFtGuhjaCY9LwM5xg3EtPMHLOXjK6dCbcZaG5rlbYrHpajBaicruSlZJKQHA48aK+caZqyqs3Y7+shGRpXwBTK21m0VckvW5u8JSzxWDhezX+s+MUVyTi7J8/OtL9Fpz1IwzS6IBKfJF8tPTZW3yQvktEQPrsI47vl2g+Je2PIL5L6ydISz9LP53MU/x3yjXiu/gr5Scdnt/F4flNHCfv9W95/0pIjSey/ckRBoXorM6645Tt30t1i424gsF41e2jVRlF0TlXiKg3AG10HpnxYSQmpWCsrqZl72G8C7qRG9/ALlMi7iXLKLzqHoZk6zxvR/h427D6pZBVkEGyNHFNEUBQYhHFcd54pw6kf048qvWjWZp1CX+/sg+ZfhZM6mQyCwrJlIbKdcni3mkECQKgTu7H0OwAKvZuo9IeQeaAqxmo3c6uFbupjx7M9f+4hG6RHWxY44evMESupN4M6d+TyAYD3nEF9OyWiF/dHg5s3cT2KhvB+YMojrRhMghnESUigCQ/3PunMeNoIFFxKcTrhNzMgiQ5AwiOzaMoRjgDqxmT0Yg1rJCiMDuuiE6c3z2X6l2rWXegGW2OiDRjGji+eDbf6bMYcfuN3NE7lV1TPmfB5q1UBnWlW44gDR2Tt9zCWDcRTEhUIumh3ngJclIiTXoU+mFvqWT/jh0c2rcPW7GITIP8MG2ay4r6MLL638cd18QKb98m6tmTfj0y8TlcT2B+Lv7G4yQOupcHX3mMO6/oTpi3mhp3lGiXEGHQ6ijfNIdFLRkUpYYTIORcu/4jJk6ez6IyDcVD/sFdV2aLEgmI6zQOG/PnLaLCGkFhvwsYlCKC0qAMslKFfJSNgpSEEpWWTZqXcK4uUa5ByfgLo2kO7UL3tDACPIogoqyybWyu8sIvTjj3pAjU8V3oGm4VDs6AIr4nFxZGs3HZt+yq9Sau+AKG5fqjDowmKimfXM9ENLVw2A2eRycHQ4q4qlcau9YtZ3OFjV5X3sHfh2QSJJrfV8hR3dbEimnTWHm4FkX6IHpnhBPcfAx9wUX8bUQPemRHULZ+Hev2VqNI7M/wHsLwBwlSkCBkH25m89oNHh3L73cRNw0poGLrStYfbMEnZQAXXdibLCqEDh2hIbM/1/ZOY89XE1nY0bYlom2D1aJdKzeycMFClh12EZpewqO330C2Xxtz5y7iuDOeor7nkl41kZkrmtB2upgbzkkiPiKBoNBI4iVHGl1Ej8xwwkMD2T5lIos3ifyDu3FR7wKaD25ixc4qYnteyh23X0C6/jBHdpVRHpxJv2QRFcaXMKwwll1rv2NvvZLIgiHcdO35hDccYcHMOaw/bsAvow8lCaKgQrTWxuPs376dA0LP9le56Xrdq7w18iFuvaKECLWWOqs33eN8aVbnMFToenpqK6vrLFR9+TXxPS+mj5BfbGISVBxl2ddzWHfMSED2OfRO1OLbUou115VcfVERhfkp1CxdyoKly9ltiyFZEJe4UNHOsUV0y9AR4LIyf/5SSvUBXHrngwxP9cKmSSJVBCeB4fFEhocTE6pDmyB0ws8udCeQ9CHphNhaMOoK6Z8dTuOBTeytcaHLu4CBEcKZL57LGmsB5119CZcK/VeofIgK0LJy0QL21CmJ6XI+5+cJe6WLJK9TT5IUtcxftoE2ER3fesfNdA3QYxGfC8KduMJyGDikP/6l2/jmmwVs13ujP3YC484yim+6g85BTiwGEUQEdaJzhBPChL0MU3nmQ8UnZ5MV9oO9PZtxuhGGGoM0wuDzk+MGbrfTM8oQF5RLWliJOPPrndhZv/nUXxU/tw7D0aNHOVJ61EOmlCKNJCpJXtIiVFJju0XE7xQRh5dCmvsqCcrG4fkL2LTfTd+HemNfPY6b5xrosi2YYeNuoFtyMGqRh8JLRGUiC7dg8Q63UiifyAMRQSI+CxLgsBjY9tmNTHFfyxUXXUDXaJUgYyK9U3ROoahSWZwSNZc+i6ucIg+VyMPzyMdlxyEYvTQyopRWFnM4sDlPRueCfCm9RUwq7iE9AvJW0bkwj8Ag4TBlyPgdYFryGE8sc6A77w1e6PfncBT/HbYx4erVBNw4jCGD0znl3Zf/ITSze/p8Fi9QMnTCVeR2nP0zQ7L7P7sOw6Ex7JS2t/b+BeswJP32zadkwvAH4ecIw9ixY3n3vfcEIZCcseeUR14ex+z54hLXC+fsWe6z/Zz0WqhbpJdGQ6TfHULBhGcXJKOdcChUanxE9hLZcAhH7hLXSflJu3NKpEPaFVQqk0jhuaeneUR+kqP3bPTltnvmfgiy6hka8VwnjQRJ95MglelHeYprRX2UbhtWh5RVx3nBIRSCZHw46gMGDBjYfq0MGf/PsGx8n1GbnPj1uIc7up7Jlw3PIvxgDv6n4bF3fxE5/BLCsOu/IAy/deEmmTD8Qfg5wiANQUnPCP8bKLzayYVLkAFpJMFbRPFKhQOr8NbSvZymJlpsKnyk98vVPy1c6VqJA3hGE0ReDlMLrRYnbnWQZ/LYL4XbbsRoMmNRBROqVf5bB/b39/+R8v8SuC0ttFiEmHwDCfT9f1QQmwG9NIfBWyr77xONurFjqTPhDtKhPfk+sIwzB6cNm4dD+3iIswwZfwb84hEGeXvr/11IJCo4OPi/OoKEMgXqAjs+B3hImK8gB4FB7b8HVsxi2rL17DCF/Oi6fz2ka3U6cb2/Dl1gECGta1m6dB4Lq0P/Y/qfOkIcZexZMZEph3wJCfn33385WRCu1C49egH7ri/45ItPmbxbmrV5OrTvFXLyqch/hWPLmDfpLd5f2yq+uMT928mtW3I6/yk/6RGPvcMh/SoIstC4krcve5dvtlXQIsrtuaPbgd3h5Fdn+99AGpWySUTV1j5ZVRgZmyiHy+nAZjZi0LehlybMisPYpkdvkM5Jfy1IG7Sd9ZCIgo9MFmT89SC5/98rxDj7X6v8i0KysVIdf2rS4/cQhtzzyMAjj/bHAD+K1gUDdYsT0qnvH1u0HWXH9Gd5ZVcM2YlR7UuiBsSTmJRGSpg/p74U8B9Rv4CXXlhKqSOY/LwsYhMzyYwWBEIamTjlfu2QHj+c+r0D3jqCY7PIjhMExfPK4k+kkyCNNv2oUichXFfVNzz34krqfMPJzc8lOS2XnLig9sl7/4ZT7mFYxeiR37DumC+dC6PaX++Ufv9X+f0naMKITMonL9FJ3YbpvDy2kqROIZhXvsRLq1WERCcT61lIqR2uw/OYPnMyM1s6MyC1Y0GmH0Fq7X+56Uk5Sj85hTPePI1/loYzLK+ORZ9vptwrjnTrLMZNW8pGZxdK4k8zjP59u0h1lMR5mkr+azs27WDea3dwy9t7CehaQEL5FF5ZpySucRFvPvcIj708im8qKzm0fDkz/vkoz338MR9/8iVfL3GS9rcuJHr/VHwjQ4aM34JfMunR20vtGWGQ+uC/Hv9b6zD8RXFawmA6xOrxj3PZHS8yc+EhnLoqPr79bp4f9RFHws4huelbPnj6Dh59eQzjFnzLvK+nMvW1t5i00U5010wcaz7g2dc/Y9bUyay3ZZNkXs/GY3ZaTuxi7Uf3cPtTo5ix8QSa2GwM8+7l2ntfZ9zELzkelkXNjLf4+IPPmVkTSpjqGPr6asqVIfhtH80/rrqf979ehSV5AIGbX+bu+/7JGx9MYLsrm4ychO9XT3NXb2XDhtWsqtGiWP4k19/9IqPGTaIibAD56UH4iao69n7FyKfv4sEXRvP52koc2iAsCx/hyvvf5NOps6kOy6By0ouMHiscU2MUccoj1NY1Uefjh2Lt+9z0j8f5eNFmHPE98Fn9FLfc8xRvj57AIV0GrcsnM+n10XxV7o2PRk/brPu47pl5LCOXS4sicBsPMff5d9jpn4Z/xWSenL4Xq7KN6tVbmD79Owx+x1i26Rj73v0nby3czBp3Kt0MCxg75hMmT/6K3Y4UUvOSiRDExX1sLSu27WePMYyYiimM36slYO9HfLI/EN/9nzPy2Ud55s2PWdkUQ6cEHzaPv5er73+VT75axkpFJ4YKYnJo/suUZg9Du3w8kz+axPTqEGI01RxbNI6RY75i7aFjtDps7B7/EjtC+pNgW8s7b6yn4fBk3n/3JZ5/5UM+XrqEBdMm8cUb7zFzv4a4LD/qln7I2N1adPvGifIEoD4wmXeffpCnZjXgm1pIYbS6vcGaD7N/0Vg+3elkjyArF2p2MLcmkc6KHUwqCyR7yI08dNkgivPy6RRjoc1cR2uXB3ju5r7kJYeJ9vyLd1gZMv4g/CxhaNhCnbQOg+r3WRpafiRxlqJl33fs3LWZmAvv5fphGdjWfkxL7kVc2SuKZXMW8u3ieSxsCSRy6GAGC3bpPpFC3xsGkKXaxOx1VTg0EeSdcyl/7xXCtsOlbN/4HbsOHWX//t1UOnT4J2SS5nWIDYfr8GotZ8X69axftYy5m+qJLOxGfvFAhvQuplNoJTv27mPxwm/ZKPIIHnA15yWaGD9+Fhv2bOBEVF8R/TqoPn6IvdUSDepA6zGO7tvEun3HaawtpzmuH33imtl95CiVJ9dUqN5JqT2UtMKupPvXs2BnBYrmUtaLsqxdMp9vt7cQU9yT/C6DGNanM9l+R9m69yCrln/Hgk/fYI5I9930Wbw1YyU15Xuoj+lHj3gLpWXVKOLzKOzVnwG9+1Lot4fZy1dyMHoAt/WN89xbgZpAtvDt1o3Mnfg5874UznvRHNZVlVJhaKNmx2YOWSLJH3gOhXmDuLxnIsHBQcR0v4RhWS6aqg6y60RHfZWClGgD0DhaqD+6g+3lDTSWb2dbWR11pds5HlBEboIvCn0pX361mAarH50GDqObfwMxGYEYDaWsmZlEv7wM+o3oQ1JeP4b0LKQg0Q91Sh96F2eTrKhg06FGsFawfFcFxzfOYJPJibH6IGsaQ8i4eBC92twoDPkMvq6YGNsGvl4pCFbZDnaUN9JYIf6K8uz47nNmlCtJ7dGf3skdq2FJcLjRpieTWpJD5KTVHLY6cQVo8PHREtSwk81zxjNtcRlehYV0+9sA+ogy5fS/kEF90wn/q084kiFDhgcyYThLYaw9gcknmBEPXMc1twwhznyCnCvv58FbLkZZW8aR2ibiel3KtffeyVVFXeiSfA6X3H0NQwuV1FY14VD6k37eLTxw43DC/By0WcFfq/bssqnL6E2/oRcwvEskNccPUyd+u/rxD3n51oHE+nkTV1hAfP5AhvXvTte8CLyE0zBXl1JvVjD49oe4e3ghVfuEg3b7kiQIxOVDu5MQKJyXqaPwEqRnxr5az46H3sFxFAy9mquGFhKosgjG3J5EmowZXHAeV15/I1f2TebQgZ00Kfw9ZXnplkGE+fqQWFREfO45XDywmKKscFEWP9pKd6L3j+Hat79m9rwpvHp+OP6BIST3u5IrhhYTofYmOjuTpKJ+9OpSyLkXXMM/nvuQF8/Vsmn9QSqlSQG+URRf1ANj807WN2ZxDmaalq3gqDZKyKYQP6cvkTHxZPfpR0bOedw8OI1gnQ+BRRdx0ZAepIS4RX1PIUjSEL/oTkpff4JDQjzzNgJ8VUIMvoJkjODioX3JiVTg4++P1svAidJKHGEXcn2JD9bj25gWOpT82EQK+hYSnTOQCwZ2pyjFB0dUEd3PGc6grBA04al0HdyFyvnjGf+2nu4XdycvJ5KMbpdw/f23c1lmIZ3zhnH5nZfRP8NJdY3JI6+Q0FBCgnQEaNSkXPYOn7z2d1KoFGSuyjPS5YHThtk7ltjMnlybvYmZq45yosmJj9KNIySd7B6D6d85mWCHqGqLAaPZhs3Y2j7fQYYMGX84ThlU+Mnjt0ImDGcpglJyCbLV8da1t/PgHaPZ44ziq2ev4Yp734bUIoriwwi0GrFbTNQ2NtDU1ESTtOqjMOY2acWDxjKWvXUHVz70AXZVFImhWprbjJgtZkxt7StESm+m2FxKFDYDpXu3setAOQ1GOxathsAjM3nv/S+YvuKY542HkLhswl3NvH7HFdz0wXLhSPuSpHbTWltDfUM9rUYbjlO9h9OKxaRHb7ELx9K+oqR0z1aL4/tJfNKOgMZNE3nzmUd4d34FJQX5YGnl4B5RloPHaLK4sAmS479fkIL3pzJ3/XHc1jZBeDqTn5NO0/aNbNpzEKtCi8OiF/XvuIfJilHjT1DlEqZ8NIEP5x3EtmMp34x6k2cWVLTvwigIjV9GDqGLZ7HHXUz/AYE076nhUFUU+eku2lpbaHZ7o3TX07T4fe4dtZqKqkbMHatjelaLO1lfhwWToQ2njz/+tnoWj3qCx0cv57BgYl4OEy2eFeaklekcKDQmSldNYsGM8Xwi6nNkfxMV2+bjN7yY2BAR8TuU+B2axlvvT2bm6hN42Vo9dWoU15sD4olJySK2dA4zbEX0z4wj3rsNhVNayc4o9KDRowfNUvpmA17SGzHOJpaNFuX5cBn7a0UbNZVxdNbHvDd6GkvLBFM8CZeQWYMgGGFpdLs7i5rZa6g+3CAIgR19YxUnysvYcbCCE40irVvoiKkN/clVMGXIkPHHQ2L/P3ecAchzGP4gSO33c3MYfIIj0Cp9qSqvRKVLpfu556JsFlGpfxKX/eNmzsuLxi84nvTkBKLUGoJSU8kojMRfFUREcgF5kWrhqM04A1O55LKrGJATjiYsmYzEGBISkj1HalwUyTk9KEmPpvxwKe6wAvqecx79OicSaWmk3juSpMw08jIyyC7oRk6ElvLjdWhTunPzP66mOMYP/6hschNCCUvIISsplmj/joaTKugXQXRiDnkJYYQk5FOQECT+FpKfKMiOWvioY2tYtG4Xh6WNenoP4p5rR5AW6svhw+WoojozcPAQehXEEm5qpM43jozMZLLTMsgr6U9eiC8VO3dQaVOJunehKDmM0IQC8uODxd9csrNTSVa00KKKQBemQF13jJqw/lx5zfkMTtGJwilw+wjSUG0npqeInoemEhou6tC1Nz1z/fFRhROTWURhjA8qvZ62yBx65cYRmdKJnPhQIuKzyUyOJzZAqq8bt5+QZVYRBdG+NDe2oYnvyoBzzqF3RihBcaI8CRHEJqWg37GXVnMYJVecS2HkEb5ca8C5aB/db7+dbola1N5aAkxNNPrGkJqZSn5mNvHxiaTFRxMhiGJ+gIWmHVPY1v02buubRaS0LHR4NnnJ0YR5+xGWnUZaViha71ASMoroFKulpbEV3zhBigadQ7Z9E7tPBJDebwTXnd+FxKCTkylFg6kDicjqStf8HCKcWjJ69qJrTjSBthasbc0Y/eLJEqQuKVDUWSPaNiWfvChpDXsZMmT8f+Fn5zA0baHWs9Lj77OXhLwOwx+En1uH4X8FpgUP8MhqX2JGvMqTxR0n/+I4+MnLfPbdUcIHp9G6fw8LFMXcZEig7xvDyPBTt49+/AwMpcuZ/NTtbBw2nRcuKyCuY0lrGTJk/PUg+clftHCTj+4nCYO8DoOMvwRU0Z3onJNFquaXrKvw10Bs92SidKV8PX4Re1t78f4z93HbhyPI/gVkQYLL25+IrH9wac+k7/e/kCFDxv8ofudwXx5h+IMgjzDIkCFDhoyfwy8ZYZBWetR4B4jo/zQjDElX/ualoeURBhkyZMiQIeNPDLfgAKc9OtL+FsiEQYYMGTJkyPgzQrAAwQXE0f7/nz9+O2TCIEOGDBkyZPwZIXiANHLgecR/uuMMjDHIhEGGDBkyZMj4M0JwAM/4gWdfmNP/+62QCYMMGTJkyJDxZ8TJEQbpn+I0hyflb4NMGGTIkCFDhow/I06OMHT8//THb4NMGGT8O9wHOd64nUaTvuPE/wOOzmPy/O/45vBvZ70y/gXNu9j23VeMWttyBmKKn4C+lCOrJ/H28lrMv8cyGm477JvKqG+2srnqDCxJbSinfO0XvPVdLcYzvcJ12wH2rZzMuysbflg+/I/C76EL/59o2cuu5V/y/uomnLKp+FkoJPLwc0dHut8CmTDI+DGsGymrWkOj1YrS6xT1sNVwYOEo7r/rdh546gs2Nrl/28ZDAZFEhAQTpTlG2fGj7D7ecf5XQ/QI6wHWH9BjtnWc+je0YTi0jCVlLk7ZReG/RBmbdlZwtOZnvKTNQP3Wpexq6/j+X+M4u/aWsv/YT1YETizi3Tee4aNl5TR4ilLBvvITlNaKj1od/sFRxAepfrWRcDuq2fDJEzx69wPcf89d3P3IGKZvber4VSAgCL/gaOKDfVCdXF36JCpXs3HPYfackvw3QyFuEhBFXKg/Qf5nwGz5+eEbFENSsAul8SBrD1pxCoV2HlzJzmNNnLqP2i/DcQ5WVHCgSnzUBnhkkxDsjfcvLqoBc+sB1h06Xa8y01a7l1W/VLkCQ9AFRxL3G3ThjMNRRd3+Vawst2I1HGLDISuun6q2yp+A8DhSY0P+89o8dRuYOGU+07YJZXMc5uiedaw80fHbGYLj8GYOHDlKXcf3sw3C8v1ukPeS+IMgNfLP7SXxh8BdSnXdFlqcScSFdyXE95Ttj5u2sm3Z13y6z4twezVVAZ0pDq9h3fTpfP3daqpVCaTEqjiycCKjPp0rjGcjjXU7mTp5AevL7ARTRaNvKP72cnaV2lDZnYQlhtG682smvvQO47ZYiYqLx69iMTPmT+ObJRXo67cwe+5CjilTyIhXUbp0FpPnLGF/iwKdIBz67dP58uuvWLKxFW2imqMTH+OJtxay251MTlo0QWqp4C2UrZ7NmHHT2bx2PbUtpaxV9KWnbj/fjh7rGeWo0WWTHtDKhtkfM2l9I/5xsfhVrWXKxK9Ze+AYPtE5hDSt4aOPPmHO5I+YfDiKrJxsUkM72stSxcG1c/h89jJ2H7GijQimbck4PlmxiG+XlkFEGukRbg5/9zWTv17M7gYX4RERGHfP5qNpi9m6S5Q/OY5I4w4+/2QCM78cy8Qd3kSlFZEXLS3mZaJu9xI++eAzlu3ajyVQwean7uGWd6fTkH0VF/WIxbj8NV548lOmHlGTmRRPSqQ/3uoQbHu/Zc6Cr/h6UbmQ51bmzvuWw/Z4MpK0HF81h0mzFrGr2kRAXAqhHnl1wNlGxeZV7Fgzn6XlDvSaNDrnaTBtn82nUzZztFVNWmYUIYHhqI8t49Np81m99ij2iARi6mfxtdCT1qBMCkKlzMw07vuO8e99ysItB3HHdsL/xBaWL5nApBk70IekE+NdznrR7rMXr2bdgWqcQXFEGDbz+Zvj+HrVViwxhcQFgEac92s6wYF1nzL+y8UcaosgPl7B8ZVf8cWcFazfupUyZwJpMaL+onkqN2yjWaPBUrmMvYersQZFYW8o5+ARN/HRPriUFnaPe5Cnx66g3DebmPKlLFg1lQkLdtFiDyM+PZz2XmDHXLmd2eOnsmTzDsyhucTbDzLvq0+ZW2bFtHceU974iAm7IDk5kfRIDd6aCBwHljJ/8WSmzy+lrX4n3377DXuN0aQF29i9fCpffbOao00qlOrjLH/tEZ6ZvAtbdC4F4c1snjmdGUtXCSoSI3TNxc5Fn/PR+NFMWrCNo9renJfvDy4LDTtm88mnX/HNwpXU+GWQEmBg05yP+GzaPuptvqTlxOPvHYT133RhAUecoqx+rWxeOo2Z34qytPgTnehH25ZZvDdhHsv22qGxEp9EQTyMu9lcrsDqGyD68zE2zZvIhMmbKHeLa3wrmP/JNJZt24M9PI9Yyx5mT/mUeeVqdJYmrDYzZm+nIDuVlO4rw3FiOVMqQzHOeJgXP1lJhTabooBqVs35nC93mAmMTSHKT5K7A1dLGyf2bGPld5P4dnkN6rQMovxV7dFu6TQ+/mgai+yd6BNdx/Edm1jnU0JnxzomCt2Zs2YThvBEWtYfFv1GQ4jyCLuPivby9sW2bzGTvvqGLeUN+ISm4z64iHkLJws5lIm22sE3387ngCWWkIZ1zJj0PuMW7+VYpZ7Q7Cz8G7Yy+5MfdCHWuo9Zkz5m+oLjog/Ekhp+iu38jfjZvSQat1BrPIK3tJeEQoG03sL3Tx86DpfnX/teEmm/cS8JmTD8QThrCIPbhN2yiyr9EQzNG6nz6kZGVAk6nx9WFPPAeIzK8mMc9e1G3z55ROt0aHa/zJ3XvMJnixYxqzGdvAA9Deum8dW2GjTWFlqqhJP9To+vdwAxLavZF1ZEsujIU1e4CKucz2bR1jv31dG2eS171CnkxflhX/s2768q54ToiNvq6zi6azlHVL1IdXzHF4/exLOfLWDOFhM+wWH4b3+X91Ydp/FEE4aIZLx3LWDdngYcKT3o0ymFCNFn9eUbWDlzEjO2VeIwK4jKEM5Vm0XUnrF88fUGdtfsp9SaT0HTXF4e9SEzm4u5squdTe/fyvUvT2GBcEIHI/tTWDqadxfs5URtC86YXgwqySUpqENJBdFa89Gj3PTMREF0ThA77GJSm5eydPt+juwsoyW0Kwks4/OHbuapCfOZt6aBkK5did3xIpc8MJYF3+xCN3AEibs/5O1ZGzhc2YotrBO9ehSTHe6FuXoLa74ax8Q1pVS2lnOsUYdZOFFl0ZVce8uF9IzT0rjha+Yv2sfxkDx6JrZhPbaFaWXhBGx8iVGry4Tz3872+nrKdn/HYUU3UhBk7OmbeGzcN8xbVoazeATnpwkd7IBCqSOheCjDuthQdLmX6+6+gGHBG5n+8QQ+Xq8iJsxKqG0737QWkl01mquvf4lZi+bQnHU5Q+JaOW4ORhOVRm6IoAu1O1g/XTiwFYdF2Y9TY80m/sAoxq/dwY5tpbSEdCHJsIhxTzzIG5MXs/igjpz+mfit/4hx8/dQWn+ESkcBJcYZTK1JxLrrG9atnsmsdUfRK+II8Tdy4KOruOvtBSxecBCfIZczLDsUX9GdSie+whpVGBVHvmbpwsPYbYEom0V5KlzENM3n44pE1NtmsqGsDe+s/nTVHGLngW1s3HiIJncEYdl5pOuUuEyCaI67jcseHc/8hfNZqR7AIP1n3P7mbI4EdaOLcHb7V2zjkDad4hQXPsdX8sXReII2vszo1Yco3SDqWt9A6Z5lHLDlUZxkZc37t/HA2zOZfwCySvIwr5jJ2holEQU9SKt8nweufoZx3y5iRnUCuT7HObhsEtN26jE7NcR3OY9zs4VHFf2sdMZLvL7wIJUNBykz5dDVtY1FC6cxeZuW1LAGVLYK5pUKsr7h33XhoKsLveIb+ebVW3jsw7ksrAihf/8MnCtG8tDXLcJIhZBYv5RD8T3w2/Alq1oC0MQnkdiyiGmffcYnm5XECVJrWv8C1/5zvCBE81jvP4j+zeO48c1vqIoYxGDnNvY1CjsTpqJh707W7FaSH9PMLlsc6q3TWVtmRJM9gF6tn3LTy5PZ5O7KxQMKiRV8SEQUbJ/0CnePXc+emgqayk7QEt2DoqQg/KSRrZrtSPvzHtJnEGeqIihGyzFTCJqN7zH+273CoR7kqCkF5aJvacnPRVu2mI3HhTlTVbPhxb9z57tC/vN3UBNdTMbBdxm95gil67d/31aHXUUk+VtpOLSWLUdFoNRsF843HPeKe7jskU8ESZN0YSAj1IsZO205a8uDyS0poFBit2cIv5gw/AQROHXzKZkw/Elx9hCGNmyGheyvmk+jKZPkhN4Eevv8u0rZazkkItIPPl9HlSOOoRd3pmrqC2wL7EpB1y7k5HVGvWUvaeeP4KGnH+PCQaEEWyHkhpG8dXEs7sM7qMscQOegevaUB5CsrKDOJ5O0wgzyhGPMH/APbiyooOJEPaF/e5/n+zWyLep2Xr8lH5c1nBOzP6AMf0IK+tKlqDspgU0khgeTeMNonhhiZeu+aEYMi8PV6QEevaQzacJRSSibuYqGsFzuH/ky1/wtl7jGfXxXLdKtnkXa69N5687hNG46hrexBXWvPhT2uYjU48IhrVqHJWcovXr2IjAohJBjpQx6/yteujMXa30gocGRJEW2j8WbBLFpqGrD5RtIapofmuT+ZJrXYx8yitduT6SxTi0CoXFUuFQEFvSjuFMXYqODSfMRxkehIyVNhSLxfLy2rqPn8x/y2gO90Zq0ePtEkxXvQ83yRWyvsHLpZ5N46KJUtk3Wc9GQIFIfeJLzc0IJFK0VmqTAljKM886/lOE5lRwrb+WoI4w0VQW6i0fx0sAWdoT/g+dv7oy/Moqjs8ZSYXXhX9Cf4s5dSckppF+atIvnqRBaWvYdK5uEU46MI7VtE9V+3ely7z95uL8KS0U5O+lMiv0YPj5+hEco0OZcTHd/YViFY1ZFtBOGutXL2HqwhQsnTuGJK9LY/Nkukv0P4rp4HC/fnoaxQUHjkTqCo5z4xg/j+r/fzfAMoSdLt9Nr0ixevraI3bOOkOV3lKNhJYQ0bUCRew3/uP8GeoQb2bzJSnxgK6YIQRQH3sMjD/QkQdWuwX62Zaw8amCPMYcAiwb/A3tRRUeT2jMVv9oyygIHceWQSBw5/+S5yzKIqZ7B9ti7eejhEaSq9FTUxdM1wxfTkW0snDSWyuTh9OrSjdiMHHrECfslkYzOAzi3twZdzrn0OOcaLu9SR015LQelkRz24TN8NK8OMbA37BoevbGEKN8QWgQpjAr0xar1Izk+ipSSy7h4UKwggc/w/Hk69n32ON/5FJDXVfSNgq74HN5NSp8RPPLms4zIgKO1cfTOF07JbKSltJpk4bzeuGM4+l1V+J/YiGbILfS/51Zu7mymvkKQCvt/0oUiNK5gLPVNhAUGYPfTkJiaRExMpiBJZvyvfIfRN+dSEHWArzb6cXhZA90G5ZCfHImmajPVuu70eOgx7o8/wZLPP6E6dTi9i3sQnZZJSZwSVc5AepZ0J9e4h3r/eOKyY/FpbqK6XkFSQANluoFcMVjIPvcxnr8snVDHccpCiunRozdFsX6E+YugxVLLia1LWCXa7/JnxvP6pS427/UnMzFKEEXRxlVr2aTpjtbsTXzpJDbpsmg85sa7dBu9Js/ixau7sO/rOvrk1VAbl8Km+c3kdMomvHUJy5buQdlpMCUlvYiP8iFflEl9wRheGaxnd9h1PP6PboT5BGPce5SsC6/lxiefYUShjpVvz8FUtYDKlOH07FxMTGY2Q4LLsfZ6mlvuF8Q79cyRBQk/SRhs7btV1gnCoPJqJwyS1v/r4SEM4l/8Gdit8g/wUDLOKniFogm8lE5RPYhPvJggb+1/Vid9I7qsc7jpnfG8dk6ZiGZrRfDRh2FXCUd/7308fs0AhhUHU7F3PXNWrmX78l0cN9gxGvA8n/TWOqlYuVBEZ2s5WG8QLN2J02HHJsiJq+YgB9du43CFII9eEYQGGnHYrYQFB+ESaQwmC9rQPLqfexmX3XUfD95yEZcXCaspXGWwzojJbMYqfJtD4cS08zvWbDtOc8fjf79wFYaaPcxbuZrNSzZR2mLDrfYlNNqfimXz+HrlcuoU3vgUDuH88Fq2zv+Y55Z7Udz3AkbcfB/33fF3nrioM3FhoRzeICKwOcvYJYy9U/VD12ndf5zaNj8G3HEN1/RLwC2Igcsu6hFsF3U0YDTb8A3NptvgS7j0zvu4/47LGR6qEk7dSefbr+fvQzLQqL0JDAynZtdSFixYxKayRuyqduPgGxGM1quVdfMX8s3iQyiiAnEK+Rj0RqxOTxIBHxwVO9i17iAnaqwo3FasNg0qIggJMgt5mgkLChSN4aDNaEIdnEXxOZdwyR2iPHdfx02d/TDUlbGvxnLK5DJJqDZsdkf75D23+GsxYTSKz1a7+FXkVWfg2LY6Yq++ltsv7Ua0zhuzxYzd4cDR8VzaN1xEg94GNs5byLwF+3BFhKNUxQkn5cDtNGAWeTVYgsnqeQm33Xctw3tHEK7UEuDvZMfM+Xy9aDvWkEB8NApxWwc2q6hTgA8aHz1Gk5Vms4aAhH78477bufWGTsQ4vaSSe6DrMpTQo1toKNWQJghRresQi5tS6RwmyJrTisUtAhSXBf22xazaWSvaMZKIYKEPSj0Gs0NoaTtcKh1J+cO4+Nq7uPPe23n68h4k5PfnEt8NfPbVNGZuMxPQeIC96/dQUSmYssuG1aHGyx0p5G4W7WX0yN9L4cYsZHNiQymGwDSuuG0EFxZFYBK9zm5uom79AlYfaEYd3Yshl/6d60Xf+ue1A7ioOEu0TymrV81i/tpDNHvGngWUCiHDRnYvmcXsld9QZhJ9TeeHzWTAILWTzYbTaRHO5T/pghOzkOexNaWYo/O47ubhnJcXiskq6i3SGNqkBwI+iIYh9PAo9roFOdWm4OHiHbqg1wtVcAnZFJ7H366/h7vvuY2nLishIa8vl6tWMXrybKaWOfBtOsTK+UtYseMYBmkRIaFXVuF+HE4zbVsWsmJXPbXBPbg+bD9fz/yScZs7Jly7bditKuH0wggNMgnnacbiOOUFQVE3g15L125Ctl4VzJixC01okOhLbnZKurNwK7aIEGL7FWHe/BmrahUoA1JJVkeR3fd8Rtwq9ceruLN/rqhpBEGCKDntJnEvkZ+4i8HiQKGwUrlnFfOXz2PphgMoYtNIKhDXXn+30IU7eOZyQRr83TS3Cn2UZP57wcMGOg7p888dZwgyYZAhjE4k/mG3iqg9APVPKZdPAL7aQOLTEonrfwmplla6n9+H1hnv8eStt/Dw5+vwLkjBWf4dr9x6L699tJoydbyIpoSSBQYRVZDI8bEv8MTz0zhgsKGNiSc0QDiF+BQi9EeomDOWyfuEgQ8TkYNahdI/iqgAEaX46IRj0dDjmosIrtzGmLtv4c6Rk/j2uHD6EZEEenuhUgcRHRWEb1QSkds/Z9r8texvaS92Qs8EvFq389atd/P0G3PZZosQjiOSHiP6UTP+Vf5565e4c3LwN83kg1dmcbDGl5tuv5S0RD+WPHoLtzz0PBP3GsjopmPBa89x3z+/Yl+bjYAQYUg7ENU5lkDlId649xVemVtJuHBmgZHRhPiq8FLqCNWJ8l99AWGN+xh3zy3c9upnbFMEkRTdwHv3Pcc/vzgiDLma3udGsWLMG9x//+esP2EgMLx9O8rw7t3IyQhg/oP38fp7+8m6pJiQlGSCBGn5fr5hQCaxdZvY9vXnLDviS3BIBDHBvviFCiPoI8oh5BkpnLlKtGNwgJoeVw0nou0wE0R5bn15PN9uPsDxbXOZsLHpFBIi4CccaKAfOulG6hCCgoIJlarupcXbL4IsEU3ld/Vh+rNPcd+762izuAkLF3UP1HXMIYHQLl3JE45o8cP38fLIXaRdXExYRqogp16COEijNUFkRjSx+ZuPeOq+23h85FR26nLo3DuTTU89yNOPryZ6UCdCs7II8xXEKjyMQH8/1EpfNAGhZMXaaDn0Dc/fdyf3P/QqE7e1YjpZh6AupGvj6Juro0snHYroSPSh8fgq1PgGhBMVJvQ6LIbQjeP4YuF2jrijiA32E4RBiy4oiDBdO2kLSMugqE8+u1+8i3tuv0+08342zXyJl8esRuETQdeePQmp387B2R8z/4CKgGBJ/moh/0iCJD2Q5Cjk7yPkr/Pzp895KRiPLOGZB0czYW0zcbFhgiAJp77kHSZurCX+/OG4FwnyetstPPDJCuxZyahqVvHsLS/xwbzDaCI6Hh8JHXBay5k38jEevuUtTujCiCjpRpBGQ7DUZsoA/AQRjf6PuqAThNufvsNTaNw+hycencDUbQbiw4VMAiOJ0krPvgUc+ZR4HSKxXyyKGOk5gUCHLgi/jDo9h8KSbLY+dzt33vUQr39zgI3Tn+O5cetEVBzJeVcORnl0DeOefIMxi8vQxIogRRdBZJhOEOlIQjZ+wqTFO1k7501GfrhMEIoI+mRGtN9H6SdUMJn0pAiChb54qYOJDtUiTEQ7tBGekQjfjCJyug9iWKSRzM6ZFPZq152n/rmCqHM6E9ppCBk1R8jP88cnyZegXn1I01mZ9aDQ/6fe5LMdVtShMYRpftxWoUEBRKUGUbNtNh/e/jAff72XzndfSee++ex67k7uue0eXp17mAZlLAmhGvx+GAD43XGSO/zc8Vsh71b5B+FPt1uliEydThdOpQ/eXi5sFidq4ThMbXpMIpT0UvuL6EOFwyIiG7NTOAIf1FoRYYn0aqlaIuIytOixuBTC0QTg7y29ZeGFQiU6qLjGaHGh8NWiUQojpVShctmxIc0yd4ooxAtvbxGBGaW8bbi8fdEKvVGLcriU3iilaMelxEclyiVCHotCg9bPt2OGuhOrFG2Z7J6y+EplUqnFtXaMLW1C15T4iWjC22XEJIiM01s4igBfFDYTbW0mHKJN1FpRXpXd890ulV/rj5/Gh45RbwGnJ9pqE9cLK4yfn58ouYhgvYRRVojfpPKLxA6zEb2IiF3i/v5+WnzcZprbrLhFff38A0TdxT1aDdiEs1NphKHUnKyDEJ+IetpaTaK+IpoO8kPpsOIU+SuVwoh6Uoh43yTawi7KJ65TC92yu4UcpXIIGf1YngpUkqM5pTxacY2PSGHGF3/RYD9UzSoiSEHgVIK8ue2iLuJOIj8fUS+X04FDIfTBbaG11SiiUSW+/jr8RDtIjxWFoE8pv4gkRRqp/P6i/KqO8qsULpGngv3zp3LE7CIxy4d925uoj7qcB8/Vom82YBfO3T9YkFlRPpsoi5fQRRFOovBE124qd25lx5Z16IrzcJZu5zvzCB64OJVwXfvNHWZzuwxUbqw2u7ivKIO30B1RfilvHy8HVqHHVpXQP9FOXqKu0gtCTqHXboVK6FW7NNxCFnqhwzZRN5VWh8ZtxGwVeit0399PdAazkL9V+DjhrH2FHnvkL2Tmubf4K8lfJXTWKclfah+LkL9ZSM1H2MAAoTMuq8hC6Jw6gACNAktrm2hPIfCOvuWyGmkziYhX6JjW399TVndbPQe+fJ0FqddyTl48yYJ8+Ym+5ZSGicR9vRXt/dbxH3VBnBdlkf5ahS4YRJ9WqrX4iz6ilNpayEbqu07Rf1a+/BLNV15H7/xcIiVhiDw8uiDa0EekcTss6CXdFdqo0ghddhs8svDy9Ucn2QWhm3rRB92i7/qJ/CX9aZe9XcjeIGQvCKDQPqtgq261n6cMHrG7nThtVmE3RP8WBkfkhM0h2QPRRtLvTkknhC54i/qJMthE5/ESfUcljRqd1J2Q9kDIYWrDIUimypOP6C/SCInBLGyaN2pxjVb0DZfqx/KR2koh2RerSdRH5O0t+p8g0CqhC22n6EKAjzRmKnRTKfpJu7qcEUh+8pfsVukryM1pd6tMvIJzM+8TZ359AWXC8AdB3t5ahowfcGz2I7z0wRzWN2iI7XI9d756PxdG/bL+YNz7NWNfeIAJ+zRoAntx3TtvcUsXnXAAHQn+wpAIw+FZY9hQfCfDc8PaHxecUbixmY4y660VJFw+mC6Z8cKxy/i9cFrCcHAMu2olwqDD6+Rjqn/BD9tbX/Gbt7eWCcMfBJkwyJDxA+ytFVRU1FBv9MI/LIGU9Eg8b9X9ArgtTdQcK6WiUUTIvhGk5KYgPTH6i5uQdjgdWFsbMWpCCPCVRhQ6zp9BuEW03lxvxjfIH636X96ekvH/ijM5wtAj8crfTBj+Bzi4DBkyznZ4ByaSVtCdHtIbM/8FWZCg8A0hOqOYkh4lFBeleOZY/E+QBQlKFeqQSEI0/z9kQYLCy5eQyGCZLJyNEIGn1Oy/ZGnoMzEyIBMGGb8MdVv55o3LGThoMBdd/zbLaiw4mlbyzt9HcM7AwTw8aTPHRDLL5jF8POpZJu5sn3Vma9jK5NsHMWTocO76Yi+1Zs9pGTJkyJDxWyG4gEQEPCP2pznOBGWQCYOMXwYRxcVm92FIr1yKww6yaFuDZ5XHqpBUOg9Kp7GsmurFs9m1dxXT9jipktZRbdrPgTWz2Rd7CRf+7W8MyglD+/20fhkyZMiQ8ZsgOED7+MHp/7Wn/G2QCYOMXwZdMkUX3MNjz91E95h8svyc1B5S0Ofhx3njyafo42ylep+BoOLB9CzuQaQ0Vdhey5ENi5m/p4qqqiYsEtOVNU6GDBkyzix+ARf47eMLsvmW8Ythp7lsK3NGbqEq4yKu6xZAsFqBtGEP1FHX0khN0nAycvswNMWNl7Qur0qHrzqGqKBGaus2MWXqdurqf2ZDJRkyZMiQ8V9BIgLSUlZuxc8fZ4IyyIRBxi+D/iCrxr/MM49PZEfraiatP45ftJENY0fx8vPj2RORSGZsLZsXTGTsZ1OYM/8bNld4EZ2cR+e8LnTunE5yUAAqd/vcBhkyZMiQ8Rvx258y/FeQCYOMXwaTGa8AFcEDXGweP405e9tIHTaC8KMbmb+ompwuRfRObWX36sOUlR2ntXIDu90RxGbFUffVBL6avIO4XrkERf6wwZEMGTJkyPgNcJ8yh8F9muMMsAt5HYY/CPI6DDJkyJAh4+fws+swGCtZdrhj4SZvnYj+//N7ED+sw/DbF26SRxhkyJAhQ4aMPxs6/L7nrcmOf54hh5842n//bZAJgwwZMmTIkPFnxr/zg387zsSgvUwYZMiQIUOGjD8jOoiAQtE+R+Hn/p0JyiATBhkyZMiQIeNPCmkAwQPBB9w/d3Qk+y2QCYMMGTJkyJDxZ4PEAAQRUIjj94JMGGTIkCFDhow/GySiIEhDxwuHns/S+kw/eXQk+y2QCYMMGTJkyJDxJ4fgBD97nAnIhEGGDBkyZMj4M0J6JNHx0fPhZ44zQRpkwiBDhgwZMmTIOC3OKsLgFBTI4lT8Tx0OUWfplRh5lUcZMmTIkHEqJN/g5eXV7iP+E04ZNjhlMOEnj9+Ks2JpaK1GQ2NzC7tOtLK3yQubSwjpTNTuLIZUfaWXm6xAJ7lRGoID/AVpkAd8ZMiQIUNGOyQ/aTQaPYQhJCTkx0tDmypZdmgMO2sWoPEOENH/f3aaJ5eGLkm68jcvDX1WEAbpaG5upqaxFYNNWsBS8bu+KvKHQKq+qKNW5cbPxwuVUh5hkCFDhgwZP4bL5UKtVhMeHo6Pj0/H2Q7CcLBjLwkfneQ1O375Mb4nDIlXcO5fgTCc3HxqbVkrq6tVnqH6/5XNp3pEOuib7E9UmLz5lAwZMmTI+AEnN5+SSMO/bT51ygiDr88vGGHwEIb7xJm/CGFYLQjD8sr/rd0q+0Q5GCDtVhkeIlpDfiQhQ4YMGTJ+gEQYHA7HTxKGXRJh6Nit8j/hh0cSf7HdKqVqSEThf+kQ/7Wjg0DJkCFDhgwZEqTA+mRw/R8h/eT5uX03yp/715HwN0EOaWXIkCFDhoy/OH47XZAJgwwZMmTIkPHnhDRK7TmkFwVOc/yGRxEnIRMGGTJkyJAh40+Kkw8bTnecCciEQYYMGTJkyPgzQjCBk4RAGj/4qUPCmSANMmGQIUOGDBky/qQ4lRT8f0MmDDJkyJAhQ8afHCdHGv7TcaYgEwYZMmTIkCHjL44zMQohE4azFlZsjiaMVnvHdxmnhwsaD7CttIZqw5nk1b8XRJmbDrC9tJrKtv+y/G1lHCg9yqEGZ8eJsxjSQjJ1+9hS2kCT+c/YTjJk/PlwJnqaTBjOWhgxW/ZRVfsdzcYyzMIX/kc49FSX7mTD2tWsXruNnRX6jh/+Wzhx66uobrVh+al7nTEYRZ0c2M+4bxNd4sQa5m86zOGW3+up3m+Aw4ypuUFI4xRUrmPBpoMcaP4l5TfQaHS3r/nVuJ01W7ax7th/I1SLIKQWDDbx0WnC2Fwvcvwd4LJgL1/JnC0VVJp/op4uM211x9l9tAWH2wGmGmrabNgMjZTt3cz6NavZuK+UsvKjHN6yjnXrN7Jx3UY27a/FKC2jKkPG/wJE95G0/fQa/8tSnQ7KRx999LmOz38IVCoVPt7emCxWjjVbqdB7CQPxP7BbpTikOib4u0gKUROg1YjGP5W/+aJWKlCYv2FP7WbsXln4qYRclOofs7yaxXz86pPcO3IKC79ZzZbmYDr1zSZCYaGxspr6lhac3mpsrRYc4n4+3jZMJhtWfFDaWqipqqXZYEahcODcPJoPj6YTH6VB2XCM8kphfN0++KoVGOsqOHailia9BaVWh5epifr6Y1TWmnHa9dTX1dJm98HfT42jrYGqmnraLA5UPlrchnpqhfGvrrPgJX63H5zIOxP3UmGJIDVOh1olVcSF3djI8bJj1LYYUGgDUVnaaBT3OFHdhtPHH43SQktdDXWNzZ4yu1Ua1K42Thwpp7qxFbc2CE1YCvlpScT72jG3HhdlrsfoVKPVKrA01VBd30RLa4uolwY/X1W7nllbqa2vo7GpFauor1Yjpa3iRE0zZqU/AWpJ4sIxm5sFgaujudmIU7SDjyh4e1s4serrqSg7TpPBjsLHRVNFhahvIw7fQHxERK1vFPKrbhGyN2Noq6Wu1Y5XSxV75nzItMZI/ATxU2pE+UNTyBXlT9CKPFtE+Svr0NvU+PursLfVcby2Eb3BgULtwLDtE16bUo5RHUNSUgrZ6enkxgk90tdRfvQEjQbRVn6irYxN1NVJbWUCjR8ab2kRWTeWym+ZMnkJi4/Fkq0sZ/+iScw3i7LYHPgG+Av9c9BSXU1tUzMWhVpcp8BQL+pR2dK+fLurlcqaRtr0DlF2oZeWRqpOnKBanLMoRTnsblwOq9ABt+BGRlodviIPIS6FCmVwMnlpCUSJNjU0HxN5imvcvmj9fNplajzE1ilvcOMkA0U9kog+MJ4xh5OJq5vHW6+9wshP57KpRdSh+iCb3nuUZ8dNYuKsjWxti6XfwCzCRB1lyPgrwGKxeFZ7lLZRUJ6ySaFF2N2jDVuoMx7BW/ILwm9K5uxfD7fb5bk+PiiP1LDuHWd/HWTC8Afh9IRBNL6XcKZ+XQjwdmBteJP91cdw63IIVGl/kE/lWsoUWWT+4w3euzWHVOdevjocTE7jRO654HoeeusDdgQX0jZzDY1+voRrdrJ+3RH2KYOxf/Mof7voLkbOWEZr8jC6qXazTVFEFhuZ9uSD3PfWWFY0RZPgq2fj6Bu56YVP+Xr1buxRfdGtfYVnP3yBkW99x/6DKxn/0WvMr0qhKM+f3R/cyoXXPcr41aUQ2wu/FU/xz3df4YOPt2DJSqfl27F8/v4kFhjCye7SncwQQRccx9g17XVuveU5xi9cSXPkYKK3j2Hk2Cd47rUFVEb2Isv9HaMfuIIbHv2Az9fUoM0qIPbgWO685jE+mDmHqojBdDPNY25VOIYdq1k6+V7uenYCm+uTSEt1sv3tyxhy0yuMnbSQsuhBDMoLRyv1v7Ip3H/zP7jryQ/Zas+jdwGsfv1aLnhpOa6McxmQ7idaw4F783tcdNnNPP36VI6FdaGoOJFg0Q4uezlbvniRW+5+lbmrK7B7H+aj+x7n3c8/40DwEFIqVzDt0/t48OWZrF+7iUXfvs+4RSfQppWg2fUej780npkzZ1EZdg7drN/ybWUILbs2smrKPdzx7CesPR5BQfdI6qfdR68RD/LJzENou2VQ+cVrfDJ+JqtV+fTV7mJftZXjwpE3znySG+97lSlr9+KI6IP/6pd4+v3nGPneKlpTelKQGYq/IIiHvhnDB0+NYcZxCwExuURWTOXdce/xxVfCAHXtQ5Z9Ps9ffi03PzuSJcZsesRaWPn+zVz31Cqq3UoCT4zhnAvv46MvDxDQawDhO17n3gef4t3xk9hsS0d5+AQtjaU4wizUrJjDbFsJ3aKF3jvasG/9lPEVKXhtnc20zx/ggeemsMuYQGafbKKlNdPNddiOLGNXq4Z6VTZFiq1sdeaT6dhFXUQ/el1+B/dd2I9+vXrQp1cqndIF0bn0fd65IY84f0GG/+L2Q8b/Dn6WMDRtocYg+quXz0/SALfb6SENcWeAMMg0/KyGaFhnHcbmLzmuF9G+bStHa3dicjg6fhcQzMNXF050fDTR6Z1JL87Da91m1k1+m7W1zRiMRpZvqMQvtA5vPxtLFplxWZWEODayZOaX7DMYaa5tYMGGnZgdbtTillunL0Q95BbGzR/PZbkBlIrILbrLlTwxczrvPD2C1iVLRJR8nOjhoxj9cGeUWRdz2wP3cnFRBBsnfsLSZYupEvlWV1SxaO0yEY0aSL/yE8a8PBB3lYvUnucx4vHXePrvlzIgvr0aTVu2s++wiau+nMk44ZRcGzbQUrkD3eA3GfX+30n1buXg1hNYLQ2iTr4kJvYjV9Rpx4YKzp0wlc8nP4zfvv3oyw7TYnWhb9qJI+1qHn3zDa7trWSncOQWk3StTWh9T84dGIeuYx8XV0AAoYKkGgx1lFWJSHtfFeXuYGKG3sptJYHfdy+XTke41YpBf4j9FdXUdTz9qV59mOq2eJ6YP59xz15F1L7ddH/tEyZ+8zpxguTVbZuPu8t9PPvoDfTtV0TmRY/y/N8LqNpzgoC4/jz6xTQmTX2coNLD6A8fosXmok2U355yKQ+OfIt/9Pdm+7ZGfPwCCDYYaKrZxKHqUHpecyN/e+gdnr9mIFkRrTSYrGydv4YKQwj3zp7J209eJNpqEUZDJbF/G8e4ty5A09zA8WOS/qhI6TuACx9/nHtueYgbO+uxB4bR9/ZPGftcMQ27y1k69i1WlR716NCu7XvZtn0T4d0u4dp33+XJm0oI89EQIsrT2rCRPWVGUWYdQx7+gPHzP6RviBcBIvrB387UGWYqj5jIzeowOJIBMzd7RkCMLTuh8H5eeu8phmbY2bOp4wGNw44yMomIzv0I27iA4y1t2HykUR0NZYtG8cGjd/Pe9B00ibYLjI8lPiac8NgIYoI1eP96eyhDxp8OHnVXKHCf7vCk/m2QCcO/QBLqmRDsGYGriraGCRxuc4kI8EN65b1K1+giNKofb4MtDfsKPyaiskraysuo8g/C7pXH7VO+Y+XOnax66TIuvTaT1qZNzNks2KpvIQXC0PulncvLS3eyc918pt5eSIivC5PNiaHJgCYmhU6ZnUgUBtiht+AfnkR2p87kZcagNFpQqZPIK+5KSWEEGTld6dy5iNhgbxqF40gadBOj1u1k24LxfDAiFV+/FHK7d6VbUTTeDiUB4RFEpGSSFhtFQMf27najGavTh8TOnSjMT0Jttog+EE1m52707JFEsLedgzXxDL9/PKt3rmL6W5fT1W1GXEZ0JxHtF2Xg77DhFqRH2iXc7Q4lNr0LvfvnkhQGR6s0RPV6lMU7t7Fh2ctcnaz73rHsmVdFp3vfZNXCV7m7j46qkGKuueNO7k/bz+Oz9+OZdmqxsW2pnhHjprJ+xsMMzwuiodVzOfY2K06vQDIyM4RTjBPlcBKZ24nO2XkE4cBhCSQhu5iexfHkZIs0nXuTnRAi2kvI0SeI5MIudC7MxN9pE23pElGEyNQVQmxqZ3r3yyMtXsORNcepbs3i7fXfsuTtC0RbadFGRhGRnE1GjA5fjRKFqLitzYBDpSOtoBN5GTF46a2etsrvXkz3rnFohLO2WyUNV+AbGkZEagqJ8TGE+Wnw9Rdt3lO0ZX4YLuHMW+qCuOjVSczbvpONY27lvCxvbH6xZHZPIc5so7Y+hZHrFvDdBxcT6qvEZNcQm1Eo9KaAKDVocnPQ+FWybdlqyulNP+3J2Eb8X5RVJYwYikiShf706ZtBVKAKq6FjDobbgY1AQqPSGJq6i4+/3seRSiEvhZ3kQbdw2/MjuftvnYmW0posQpQ2bBbBM86azitDxl8PfxrC8Ls4cnEDl8uNsNlnAZppM5dRb+tGQeoL5EbmEqxNJ8g3uN3QnoSIOsuXfcJLl5VQ0u8BnlkczB239aT38F4cHfsyzz7yCKOXHaEtvj+Ru+diE9GxIS2O0IxcstKCWP7CIzzywpt8vduAWZAFyZB3vrg3VZ89yTklQ/l8l5P8q/M4sOAtbu3WlRG3foi1c1fh6PxRuvSYTCbP4xG7sNatrQZSB/Yn0aeFqU89wmPvTmBJqVAxlw9KjBhFWpvbjTM8HGY9y+svvse88vZqhHbOIyWihddKijn/0in4DuyEX0gIXg5RLrNJOCMFEf4N7Fg0XkTqD/HqR99SG5tFTq6aj/sX07/vB1i7ZhGcoMNmtuN0+IgY2iHKpUcvSEWQ1oL+yAJefvRhnnxxLIvLbe1EQCAuzsyK6WN49uWJLNlvwnFiO9+++hRvjZ7BcaNvu5PzVpIQ2sCXH7zOk2/OYsvRNjTCKUqI6hSIs3Yul5T04vyb32N/bCQzLh9C7+5PUpkoouSsJBQ2kyB1ekEIhIxdDvQmG0pfBY2l83hYlL9nj9s4GJaIJjoEh9WGQ5RfKZENWxt6o4PQMCXKts288OQrPP/pOlocXijDArF+dg9PvTGLbWVOVIJwpA3sRoRtB/cXC9LzwDIiLijGx0eLl8uAScjRKjzq9/3IRxC47dOY+dRDvPmdWRAo6Z4G9G0iyvfxpcuFQ7Aum8Jrjz7Cy7O2crzNG6XDRJsgSi6dG2/TNl58SujYBFEeQUJ8fU4w6YHhDCo5j4m76/HpN5gUUxXpgevQd+pGh7gEpI5mx+4UuuBQC32WCK8on9WB66Rqu104LWbc2lCi+/cnon4P7rYWUKooWzWVL955lsdHfcniUpHWWyR3irY+K/qtDBm/Lzy+UZr5fJrjFK/xq3HWz2FQiIpKhkUydFL0IG2iIVXeKvk2keh0QnAKAuDxg6dJ63K58PJXkx/vT4nWQZlRGDPP/ToSnGGIrE8zh0GkUfjh65tPiH8kPzmHyzeEwJBYMpJTPZFr74GDGZYXSUhsAgEqP6JTM8jK60R2UgLxwZHkdi0mKzuGIL9gQiLjCNIEEp+VIxxvPukpacTHxZGVlUJ4YAhRCfn0H9SPLkH1VByrx51/ARf17cd555WQnBRDZKSITMPiiIqKJT4sjOjwSLLy04mJiiLIP4zk7Fzy8nLJyUomOiqG0IAw8Vs08bGxxAQHE5OVRUZGPOGi6kpNsIgmEwjVRZNbLN2jiIT42PZ76MKJCo9GY6jFoYugU7cElFYLNd5dObdHOiF+4WQW9WXY+V2Ji40nIiyG1KRo4hLE56BwwoKjCFHZhVOykdC9iFT/Zva0ptI5OQitjwKNcPD+vqFEJnenT/8B9E7VofULI7Xnxdw4tDOxOil698I/XpTBJ5SEnH4M6t+bYnG9RrSLKjCQQCGHsNAkOnXvQZ8hA8kMCyctt4ShF5SQlZFAuCh/ZLioS2QCCRHhRIdFkpQk5JaaTGx0Gp2KejNseD/SUxNFumhSPOVPICI4nNDASDKzEkhMj0OjiSW3ZAjDeheSLOUj7h0j5JyZnU1iXALpaYnER8cQEhxPUUl/zh2ST7T4HhURTVhAuJB/DIlRfmilZ09eAQTpgolLSiKlUz7ZmckiXaRop3ChB7FkFmQQ4qsjPDaJjLwC8jOzPJMr40ODCA/xJygyGq2nPELneuQQWrWOI/455HcfzMXDBlKcEQW7j2IUnSj+omFkdIwmSZMevQJiiYqJ97RTbLzQgcAwIkJjSIoNJthfKYSqFaqdQFxMlCh/opBhDoWdCkhISBT3DiElMZnMvEIKMxKJ0PmjDUkiKTqcSD+RfcdtZMj4K+Bn5zA0bqHWcET4UXW7b5SU/18ONy5xuIkLyiUtrKTjh18HRUNDg+S7fnd4GJGAJAQ/4SwbmltZU9bKyipV+wxsqU4ijclHTdc4DZ1DhNE2W9lSbqLCS02XMBfbjtpodbhE1CocvhCCj5cQjfgsjRBIvtclopFE4YxzdU42HbUiAk1BNNqJgJdKgQjwcIgvNpFeEqiP1oeUIB9C7BZ2tzjRixBUKoZKeGtpovyvF/O/QyqnSpS3V6SD/qkBwoEEi0L9+FHD2QLLyskiIm/D6+o7GN7x3P+PwJEZz/Hpt7to8dNi98mj81X3cHtX4SF+AfR7vuWzD95ih08iKrOGiAuf4MEhMQRLSiDjDMBC+cfPsrTTnZxfnNj+qED0uC1fzmdftY2+D15NkuecDBkyfikkP9kivenmdBIoggNvEVyfRLOpkmWHxrCzZgG+PgFI7z79JzildU9cTkoSr+DczPvEmV9v887qEQaXcOaBsYFckORLlMvG7nqHMEFKcrODuDDRh3AhxBq1L8WJfvSOUaJR+5AswtVugmAkaRTo1N50yg3i/Hgf/K12DttVdEn1oyRGQ7TCQZ1LRU5iAIOSNHQKUxEsos0muxuVaCSjRsvwLH9K4tUE2ew0WVxYz+DbGxJdOt0Iw9kCtyBeKhEBBgbGEn4ySvwD4O1upLauhapWHUkFA7lwWIbnLYVfAi+3CVNrNUeqlWgjShhxWQ+SdV7yJJ4zBYmFe/vgGxpDSIAfWo9gnThU3uiiEkiMDZGeHMiQIeO/xOleq6w1HkGlVKMQ/uk/4eRrldJbEn/pEQan00VwRBDDUtSE2kysPGanxeVFniABAwKcHK0wsFIZwA3xXjS1GJlTqxTRuj8FASLjVpG+3IIhRkdvrYMDpQbWINIWiLykG9c2M7FRRZjGm/xgL5QuBxX1Nkql0QvhXJYpdFwR5qTW7GD3YT3bmhy0igZR/XpZ/wh/phEGGTJkyJDx++O0IwwHx7CzdgEab93pRxiSrmBI5r3izK93Ymd1gKVSeVF7Qs+ychMnNH5clONPDxGR7zhq5liTkemHrLSaXejr9Ezf3sa2NhetrRaONFo5bnGjtzjZXWGmvN7IvHIHMaE+2BvNbBVEY02DC4fSC4vBytEmK9uqrWw9bvc8olAJFpfg58XuvQ18sKJBEBEHeiFk+XUtGTJkyJBx1uB39klnNWGQ3lgIDlWhFQxpR6WVMguESq+PiX+aADWdIsRvKjDaXJ4RiagAb9ROB5WtdmrtIo3CjULhhS5QTX6Ykjajg5omM/uqTKwR+e2ucxKTGEjflACKtNJcCEEKpCEEtyAedjcxUX70TvUj19/LM8Pb2V4sGTJkyJAh44+Hu4MzSG7rdIfngt+Gs54w+Adp6JkdzHUZvsQqHGyrMqM32KlyqiiM8kblcHDCKM0vgGN1ZmrwJi1UTbSXk1qDk2a9gwaFNzkhXpRXGWkJ9GdgTjB/i1fTJ06F0u6gotmBW+1DdphbkAo7pS0ODtZaUIb5c052AMWBXvgKcUuPaX8/SKMdeixnfsOFsx8uG/bmCg5WGzCdWn1TLZXV1Rxr/ZPJxFDJ0ap6pJWZZfx/wYSxQehMneUseS36v4BdT1t9BYfqrJ5HlTJ+BSwN1NaIfiZs+f8r7G201Ym2qrefEQf8Z8NZPelRehXSbLBxoNLI+nIjG6qtnLCBzWZn33Ezm2ttNDRb2N/ipNWhQG23c7TWzPoKI2srLRyzuLFYbOw+ZmZ7ox2TWcrLxDoprzoXobFqNK0WVpTb8fZTEWW3MrfUzJE2p7ivhS3HpLRmDkmERFC4MzXhUYKkbD8/6bEFvWkvNY3HUat9RUv5/eflbl0WWuorOVFVR5tFEBudBpX0Go3DRL1QapWvCpV0I7uBetGhqmvqqG+y4vD2w1/txG42YHD54qsSJXKbqKu34eWtxFspyuIQ1zQZhdP2xk9tx24x02a2Y6gpp6q+ldameur1Lny00r4XJ8tuw9DYQpNw6uoANb9qVoazmbat03h3Twg5CYH4eKmkZRBQVC5ixqojHPDKpmvM7zHfQ9TZbMTo8kGtsmO0KfH5NbctncnHa5vRe4eTqBO5Sh7NYcboVgu5id9doh1MBhw+atF2p4OkOT+UxW1uxazw/enXbk/C7cZh0mPzltY96Dj3q+ESPq6OygY9bt8AfH+PpvgZuB0W9HVlnNg6n0+OJtIrM9DzVtPp8S+yNP1SWYr+ZW2lza7ES6X8cb+0mrGKIARh034yG+F0DFYhQxHI+EiJ2g6wb/0ivjiRQv/MgJ/oM3ZsnlfLvYSOWLGaLDh9pLVGTgcnTpcDi0Pq0x2nfhGkV8eEbEQdf5XOfw8bwmR4Rnp/1n66DNTV1NBqE/7AV9TrF+moDZNN2GWRsVf9Khau2sFaYya9kk43M9vueU3f5fLie7P1S2HYx+51S5hSlUS/NDVmq5CPQ49V9Uv67q/DL1kaWvULlob+n9hLQpobKa3DYBPU2yGt6tL+n2eugd2zyosU+beflNre6TnfvvjSyaUqHOK7XaTxXCd99uQnHJ2flsJ4DT2ivfEV919fZuK4UG7pupPrP0h5OaXv7VmdMZyeMPgKY+IU/WgGu2rWC0PfBZ2wLl5e0iOZU1C7lI9feYS7nvuIVXschPXtTZZGdL6NX/D467sI7pxNUpAaxZEpPPHIP3li5Hi+mrmFUr9czslo4PiamXzR0oMeMQ5s+ybz6PMbUKSnkRnph6JiBs+9MoVptYlcmFHFkc0L+GSHkX2vXc0/R37M2InT+HKLivw+nUkPbp+M47JtY9rjY/h8URvpFxUQ0X4Wp8VAS4swlAYzLtG51CovbIYWmlv0WETH9VZ747boadWbhCH1xz8qg8LUUAKrpjFqVjUmVSSJicmki7KlB3njLfJUSrd02LE4BaHwcmDW6z165BKdRymsuEdObgdWYxutrSZhXkTnVrkwtRlERxfMU+rkbhtGfavnFVovSdlEvi7R2J6FgOr3c2LTLL6oTiaqdjrjFugJCI0kIkD4BZFnm8UlHIYwbqLZpAWZHHahKaI/O0U9bF6CLIn2swrHoAhIJCtNyFT/Dct213Goshn30cXMNBQLuYtbGpsom/0+s5pDhVHwQtMhH4fFiN5oFnooOqp3+0ZZbnsNlZsm894iN9GRIbBmPPNOCIcpHHeQyhu18AouuzQKZxIGxSHIn5CFJAi7hRNz32NmtQ8uXzX+otySI7BJhFE4H7tTgUryKHYTbUI+FrdKlEGBTRAZo1k4JyE7lXCOCiEfhzBSs1+4gb+9MBdFp8vJ9WvBKC256SOcrcKBsbWFNr3N81qzjyQcAbfDKuRsFM5DErRK3EYQU7WgtjYbTpsZkyAzbW1G0S+FLviI81YDbUYLNrvojaLuCrtwDsYWWtusuKWyC+tsMbTSUrOW5avWs+x4FkP6d6YoORydwopZSittBCbqL+6GWdTDJOphsTmEfgj9EUJx2ysp3zCFD5Z4ER8ZiH3lOOZWC/1Q+xEorlML5uASZZNkaRXtK7W1R5aCSDukjdoOxxMcpMXfLepltgoZqXAcWsWaZd+wziedOKVd1NFXOD8RgJyim6pDk5ixtYmj6nRygkV+3jqCYjLplBQq8rIIWQr5nSy7R4+FPatfyow561kr+mKu4iA7F09jhSqDSKWwY6I9VQoR1Bj07W2lEEGCkLtUVKd+G2sXf8uXm/3IF47UZBByEKrv7aMQBFKQ4Y703l7CJnbogsfOuqooW/cVoxYriBcKr3LrMRjtgtuKdhBtZXZ4iUBGJWRoEX3aKEiS0H0hH8Gw29vJU37RjtVzmDBzH4daI8iI9/uejEkkr7VRkGhxf2lymH3Fm/ztqpv5qjGXbiVZREmb5In2lRaDM9tdqASZVtiNIl9ByKzSvUT/qJjOmJll1NgiSE1KICklk4IEHRovqU+LNhGBpUJan0DonkcfhO5IRI6mZUyfvZH1leHkJWk9i5G1iPQ22tvc08SiPd1C393inhJREw0h+riwCQQSkZhFQYyV1j0zeW9WE/YNU9no1uEW+h8g+qB3h+zPFH7ZOgy+wkeJu/6H44d1GKS3JP7ihEGqs5f4X/vxQ1W///4v59u/tx/iv1OuP+Wz+CJF3UZh1I7UWthVZWJbjY0KszBO4nx72h/ykb6faZyeMIjye+nw1eZ55mk4GkdxsKYShS5LKKXoBB2pqFzNflM8CQMvZ3i2g6NtmRTqLOycNAtjaAP6tN6khmvRHlvEDu8+9LjhYZ66UI218QSrjyrIUh5lm19/uuqs7PliFi2+x2jL6EFCdBC6+k2c2LOOTfY8IkXx/FoPsydsBLcOL6JfgpHmns/xzxsHUBIvFFkotAs925cf4Ni2WtKHphCcl4nkD6WNhPZ8cQ+X3/kioz8Zz37/fnRLaGDB83dzwxNvMK/Ui7TkOKom38zQJ7+mPiCHYsdSvq7RsGvsi0wYO4kF9nRKdMdotlQy9asjNOzYj28nHwzrZjKtOYv4uik8ftkNPPzmB2xVl1CQF0+YFGg0rWPKK3dw/aNz2efwJ94+j3vPu5kXx0/hRPwwittmcc8dt/H6rlCSRMdraK6n2d9N/b5NLN1oJtnvCMubA6kc/QBjJs9kk283Bvms5bVHb+XRhVZSO/fybJ7VsHULm5eupDLKzd6Pb2e+uR9pig1MX21GV7mUbcYgbM1V6EVEpHd6E2o9yh5NL/pLe2m4jKIZR/HP5z5g4oTP2O1dQnGqke9evp3L736Wr7Y1EFh0DvkhCiy1m5j06F28/dUCdgf0oMBxmFULX+f5F75kryOL7r382D/2US6/7mHGfLsBR+7ldI+TdN5B86ZPeOqlt5nw8edssmZSHGNh8ds3iHu8yrc71WT1SsM69yEG3/k+WwVB7RO0mfdvuZlbn3uTZa1xpHfKJV6j58D8j3jlmelUarLpkt3Ap7ffxRufTKIsciglot2efehWHntrD7a0fHplhAhdrWTX1Je57tJ7eG/2fE4E5tPwxdc0pCnYumg/jetG89aYV3nmlTEsFLqQmpZEw6x7OOe6J/li3gkCi0vwWz+W1959gMefn8txYfR6RRxm4vN3cvNTgjDtd5GanU6BayPzqlPwXjGSl99/hGdeXUZTUh/SDLN44/4buefZD/l8fTXe6YPoFqvEXLWeiQ/ewzszlrBfJ3TGvp9l377GCy9O46Aij5ISFTs+eIjLb3iUjxZtw53/N7rHSA7cgqv0O5ZYiuhkXcH7T9zM3U+NYbs1m9xcJXu/epHHXhnPzIXrcGadT4Z+Ok9e+nceGPk+m9U96RbUwDG9Cmt4Np2kV7aad1Oxdz0LqxNRLXuJZ955jBdHrsKQ1pP89CC0wk3tn/0ebz3yHpNEUOMXmUnokYm8/uFIPp1UiqZ7H7KcS3jlqhu546W3WK5PIrNTNrEaBdUbvuTDR15g0uKFbF67mNfe+oSpOxQUJB1iwn33cuezb/CdKZOSWBtL3pF04XUWHwB/oZfrX7iXtyfNY8a01axZM4oPRy1i584VjP/oJb7aqyO/axLVXz7MZdc8xJhFW7DFDyRw3Uiee+cRnntjJYb0DAzLJ/DJ82P4slpFUqfe5IcLy+Vu4Oji97j1svt4d/oMjoWFsvXVj5i7vYW0i27g4r5JhJTO4t2nbhOB0BhmrC1Dl9GT4M3PMfjSB3jvo/W4OmfQMOd9xr72CbP10RSFtGBqqmGfKxyvlS9w9Yi7eHPaQhrjziN65wTe+fAB0b/mUhOdjnPfN3zx2FtMPCZsb0I4lm8eYMijUzge3o9zcoNQuRxsGzuWA2FR1K5+htmr6yAoiNrDO1i/qZow9zam7rOx5+17+GDyPL5ZXUvZwS+ZNGYuZb555HaOI+gM+ozTEYY6afMp6bXKH7zCj/Dj1yr/4oRBgifwOwlx/ky1hbRuf5vZSZPZhVFEMm5x0zOV9+lwesIgQTBVl4hkG8cKxdhDs7UOvTuRCNGbv38EYCln+bRP+XRaKbbU87j9gjgROexl4WYdI66OY/tKO6mR4YQ4t7HXWUh69670yg6mramN6vU15CQ7OBzQhRzdbhas8eX8KxM5uMVJuCaSGPU+yr2jqG5JJOP4cmyx/tQF9+O8wmCiLYfZG3UFF3VTcvidv3Pz3R+xavsenLmdiU/IIiNMRFzJ6R7C4NY3UbN9M8YBd/CPvxfQtF+FYcEk9Kmd6H/rlaRpNDSv2Uxty06WhNzIh1cmo6teyTxDCX0zhT5EDuT8YefRL3Qzm0/40tjqTWpILQetMdi37UTZNZnaibfzxrTDVLW2spdsBvUqIitURBPVa9lbL6LlIXdyVyczWyY8yFsr62hpqmOvfzEDXEuYVJvOkBHXcaX/Hna1KNEmhOCqLOfAcR+yghs4qOnJoCwXhqhLuP6ifmTXTeaFrX50GnI9t/SORituo2zYxqGDi/mOLFrKDnBiXzBprZs5nlhEhnsn21uj8HMZUCh9sHlpiHDXcFQ4/D5xUhsaaTqwH9eAW4R8ijAe9cWy8n2+/XYGyw+1Ut0govvcAVxaEISXtxutRuhs9NXccmExqYY5bNWcz/BzOxEdHMaxdUvYOnMkX+1opqHSSH3KAP4hyqgS8W/Lnq2Yul7LdTf1xl3lRSitWEqX88nCvdR6BVPYuSvO3VP4gst46epuKJY+xPPCOB9pbKXUHENu9x70iPPHq7ER35g0si4SbXdkMRphxK+9IoMTW13k2NZTGnsuXS+4lMt7JhDi54354BK+fOsJxm9uFGVqpTJxIHf0qGH2y2+yWTuIwkATqqSuDLj5UlKEPbBWm4l2bWLs5PUcb9aT0HcEmfXT2BV+FVecmyD6aRgnhAO0hcbQ67pr6ZcagcqmJtVHkLvWZBJqpnEg8TauHxxCqyVCELbVrFg8jzWHnEQXXsHNN3YjwVfYGG+XIOQuWmOu4bYLi0homcM2/4v525A8QnThVK6dz8YZ7zJjVwsNVWaa0wZyY49I0W8duI5tYL2jiPzoZvZMncy8nRW0RRbRJTmVCEFUU667ixE9Iji4rAbnhsd5d9YRjgnd3Ecu5yabUQVE4wgVJEciDG2HOHHkIGtaY4mvn83h1Lu5caAfNa3hxEVEEaUTOqlppUWTSlrP6/l7YR21VYcxFd3Djb28OFgViHXZY4z+aguHGlo5YomlQLRV91hffHxNOPyj8Y/pweUFVlq6Pc79IwpQrXxMkLyNlEpta0mim6hXwN5FfLRwD9UOHd2HXUmfNB+MwYMYkbgPU+c7uS7f5nGI3bunk52QTs3WFez++g0mbxO6VmujJjiJgaqVHEm5m+sHBlJviCY3Rok6qTtdel/I37qHE+CjoPXAVjYsWIzvNf/kqgsSObpOTSedkZx7n+Sqv/UhT+eNde9Gyqxh5N16K/2TtVTvdZAbupcvxiziSPNhAkpu5bLuOmwhxfQZfDHnJezjYLWLXRVNVH71AKM3NNJULeoWnMcQ1RKOxN3ApYNjsdvDiA1SE56eQ2pP0eezyvlu2WKWBF7Dezf2IDpAJWyuHcP2sSwxR1LR3MyJvaA7egLvIHCGB+FXv49tqp6ck6PCGD6Uy3OqUXa/jauHJOB0+guZJ5AWceYeUJyOMJzcrVLyCJL/+tfjh0cSuaT+xnUY/tVDnXWQHg20L+/c/lhC/Pkep/IICf/6/VRIv/3r79Jogo9Kga84fJTCgHScP2vgEgShYRz7m+pRR75DSfbTFIioxPfUB29WMyF5g+nRM0dEGVvY3+BEv3kqH37xEtf9/SXee34a6xoMoPHGSyiNZz6YrRpDSyMtIaIHeKlQWUzYt3/Np1Nf4oabXuadpyex+kQL0taVVnUOfbNVaFuWM+rb+nZVM5swmK1YDNIwpYrEIbdy/zN30NlrN3Meu51HXryHv9/7Ae+M2ojIRVzjhY9fHMXnXcxFfc4j3sdJ3Z4yfJI7cX6fi+iepMXsU8CFdz/FWwMMfLDkIC1WL/zV/sSLyDGp60D65EcSGKzCJhxDiohsYtL1LF+1nz2m7vT1cWDXR3DNx7OYv24dK1+9lJ4x7Y9IRA9GF5tDlyHFFEpDq955PDJtFSvWi2j0wb4UjniGiXd1xlC7h1nbGwiSFh3SaoWBFsZW9E2X53FAAIn5eaR0GUyfrGB0fR/g4wfPIdS6n6lbaj238U1LIC5Zw/GVO6nzv5o87TaWH1SSmhBKbKT0jo30vPSUfRxOhbiHQhVC3qCLuLDP+ST7uajcXEPmZY8wevk61s4dxRP9wzxJlepAkgoLSetyriBT4ei8A4ktGMjwi0tIjVBSvrWO0E4jeEVEt+tWf82YyxLaF0zybLQQQGbv87mw9wUUxGjYNn0vQT1uZ87ij/joplSafBIoue4lpl/pw6TvdrJ+q5MRb37CtDXrWP3R3YzI0Io8VOiCY8gpyiY+JQ4fk5Os4RdwwcCBhDuEHplsROf1pfeQfFEerUdf9Cf0qKN68/RcUZd1y5h6Zw+6dg9EIUirWThOn8B4sgr7CV0YQZ+CGEoX7aNF2Yvx301j7uuDULu9sLljyO99HhddUEiUxkXFER8SCwdy7QVD6d8pHqECgoxJ83WUeGuT6NT/PC4clkuwl439dRlc/8IElqxby+y3/k6vwPb+o9QIWXYSJLrLEPpmSM4siPhOg4Qsu5EcJsmynojuV/L6YlHulTN4f0R8+/wCYYSk0UrJCG9ZWE+3B95j4eznuX+wINc1NnRR2fQZOoQLhnRGcaKG5togrp4wk288uvk3usS5aRWByvdQSHMhRNnFX1//VLoOGsYF52YRID1OM0saI/pCXCzJ3UroUpRBYrgval0GJUPPY0jfeFzNRmpKvRk+cjwzRFutGn0HF6aLAETANyyC5K7FZHfqS9+iFAr6CvLbNQVVg5bzXhnH9LUi/Yc3kXy8Fq9ON/G10IUxt+TjcAWQUNjJI5tze3Sh1znncl6/VNHuveg7cDCdknXU7q0lMO9CXlog5LNiOh9dloK/fyJ5fc/jgvOy0blVBEXEkNy9NyWFOUT7tzsqe4ueNqOSghFDuXBQX4ItauISIsns1onEKK1HX6U9RiLTSxgy8Dxx32yatpVy5EgkL3w3hyVjbiA9RCdIUCLJxX3pVRBLaJi4SqXEUK1HFdGLp+aIMm1YwtSbCwjXxZDW/VwuGl5EuI83WkEGk7v3pHNOKtFZJVx025O8PdDEqCUHBMEUN/fyJqlvIe6DK9lbJXQhNpjGyr1UCCLWJ9cXl9sHP/923UntfC7ndM6l+wAhn2GCtIsuYm47pW3/vyHUwyNVSSE9n053/Dac3YRBkAWzMNzF2SHc3Tuch7sFMSRc4Zm/IL1KaRaHVZqrIIiERRhEk/gu/bVI5EIcUjppKWiHo/03afvm/2iwz0q0oDcfps6STmbiM4Kp9yQysCsR/lGCTZ7SbOZWEe0VMvCuWzinWwAL31tO2WYTlz1/L9ffcBevXG3kQG0bx+t8ODD9eR4VnXTo8LeZUx7LJRfFCdlZqDlm4MCKJoY/fBNX3XAfL1wjHLq+gb2lNlxGC/55GcSkhohofg0eOycNcUnPKm3ShCpfooqGcP5lV/CPx17mgbvv5fYBPejbPYfCouj2DYd8vLC0buHtKwcwcOilrLBo6fnAlRgXvMOFQwfy1uI2wruq2DD2Zca8N5aVZTYcdis2oeA24cDNXzzIc6/NZushG2qXCWd8CgGGauzrxlOd052IwEhhZHujXziFT0aNYvb2alodHQxfmvBlaqOhDhxhcSLyKqDi8w8ZM+ZjVhzWs3/lp3z1+st89s1OnBkZ2DZN4t4LruTmkQuoEp1Q4TBjUapxqOw0jLqVR0evYeG3X7HgndcZP3s9NTbJiQr4ZRIUmE7k7i1EZKWQFLSLCS2h+Cj8EHGa0FdBauw2z2GzS5tKWYQ+tl8qEmBr2cw71w6g/9ARzK+H4ntuJdp4nDljRjFm7gqOtJ3cukkjZK7nxFs38OBH69hTq0GnFuTN1ExTs4GEkhIyonxZO24UoybNYEetsl3nBSF2CYLzyd3DRBucz+d79aT3TaF8yzeM++gr5m2pwdJWx/apL/Dh66+y6KCFzKHD8NmxhM8/HMUXaw5QZ2ufTOawmYQTrEcVGkxqfgBThg1i0LmvUJeWTGiSjrZGQUYlptgBXW4eudmx7Bov6vLFZyzddoCvP6wk/9EHKarezNF9C/nsk4e59Lx+PDVpC7GDCrFUrmf0mM/5bMFu9FZh6pxqUQUDBn0LLUYHBcWRlC1+j+HDhnHdy/Oo9kzSFTK1KXCKcippQ69vw2h1E6RuZPfKWXz04btM+lZE1R3lEo2Gy95ExcjruV9E24fqhCx9rIIPC1k2GUjq1YPUEAUrPhrFh1Nms7u+Q5bi/9Kze4vdTYRfK+uWTGXchG9Ye6CFgEAXR1aM4rZB53D+Va9h692HbiOGYVo01aObs4RuGq2iLRxCD076FaGjTpGf2eaF2yZNlmxtL7uwWcK0tUMVjnvjJL566gXGLLfgI5yxl7ARzc2tQjfVFA4bjGLLIj4TbTV57SHqO9oKRSju4xtZ+/Q/eOjzvVTWOT2BV+bQc/DaupjPRJkmbTiK0teLE7sX8rHQhbnrjuL08xdKWcPBF//OjS9sE5GsAZetTZTVhU0EKfUNLcQWdyMz1o91H49i9OSZbKtWCXlKk0Yl2bcK++DAFhaOa8GbfPD8G8wuba+MLjOFtBQ3Hw4YxLkXjcJSlCoIkJLm+iZRZ08StIF2ds19hZvOHcR1j01B07sIrf2wKN8EPpq2jqo2O4SGYp/5HG+8NJGVuy0obUaCs/PIz41n3wTRZuO/YF25qK/oo95eBs/cEINZ9MGwSFj/KVNefJWxot9v/eI1xr4/lhXC3nlKqBABTuY5RB3cj06poSDTwDZzAytMiYR5Wzz6b/IRuuNspvy1G7jhxQ0crDMIWyFtdCfa0lOD3wmCA0hl9hzS5588JN93Upl+Pc7uRxKifmY/Decl+JIk3Me6aivH9YIkaLRcVKijb6waf6uNKtFhBmQEMjhVQ2qoiEBFZBzgryIwQE2WxGpDA7g4TUs3HRwV1wt78+OZzX8ApKb7+UcSTlyCa6vUXYgKTPzpWd/efqj9IohNTCYuKo4QYUgSi7py/kUX0kd06M59YgnwjSU8SESjIpOggGCiUnrS99whnJMfgso3nKCQGGJjExh6yaUMKO5K576JhPrHEOQfTnRsNBFxcSRKGwClpZGVl0dsgBKFNoyQiERRdu/2mf5SUUISyOjclZJ+/enfvytds2KFSRZ1FaSmdvdqdpJGRko+Qy8axoB+hQQ47NgUwXTtK74X+2MRxEaVMYSbLx5AdmIMwZGJJESFECaMqU9cBpk5WZ4NlqKiIomVRh9i4snpW0xcoC+BMZE4altxaXVEpBWSnxIlHIW4uUqDb3ACseFCRiEBBIWHYq1txis4jOgMESH4NtDqm8fAc4dz5dBO6BRO7AhHKCKpIf2LSImNIUzUPSEsgGCnHXVqPilBekyqFLoNuoAr+6QR4ivVXoW3Ooz42HgKeopyhoUQlNGNHqmRBAjj6xeSKKKnMCIiY4mOjPRsxhUVGU2ssMvSVG2l0GncWsIjMug37DzOGViEv3CAJhMERCeRkZlNSogQtLSjpNoPncOBNr2A3JwkEZ0liigqiED/MBGpZxIb6o+pySyiyxiSsgvJFgTCS5BMldAxtyAcoSGp9DhnCMPPLxAEzEybLYzUrsJ4d4rD11iNIXoAN1w6jMF9slA0t2H30hCSmE1eWlL75k7eatQh0SSkpJISF4mryUZATCfOv7w/GYlRBAQJfQkXsu7wWd7+IQQGBWJtEO0rIt7Y1DySgxPpfPEgsoXa+7btodStQxtRQL+e/bj4khKidG4am9VE5fRiWL9ispJCCY2OJzIgSBCzKPILY9H4qrC7o8jucrKtYgmLjBNlCiE8JoEIXSBBQdH4GyowKH2JjlHR1OpC75tN51hROIXUv4QsnU60mYXkZSd+L0tJ97OLMokO0mJutqCJEBF+VgFZkWrP/CaFOghdZBKd84VDNAly65tKYUl/BndLFteKfL1CSU7vwgVXDKUwJxZXXSNO3wDC0zpRmJFKbHwSMWHBhEm6o/TBOyCayGhR9vhQoW+i7AE6QkS/TIwOwF/a70QpImqFCz9dCFEFoqzpoq6iTGF+OsIj4ynskoay1YBNOLjQxBzRVolESFzWyw9flRf+PlqCi4fQpyiDtBAv/OJjUQgS4BD9IyQ5j969cjzpWyyhQvf7MrRPPnEBvgSIgMu/qD99+xSRFhVKQEg88eGi3EGhZOYLXQv3x9xoQh0hypot1U3YGkn2AYEEB0eRkBRHhMKBWpD1pLws4gMUQtdF3SLCcbY4hF4VM/yKvqTHh4v+Hk90gNazoZvj+E52V9TQGt6ZXkU9uPjyAWQIP9BQ4yAwqZjBA/tQkBhNsMOET1Qy6Tm5JMbGkSxkmxKpw1zXijI0krisIjplxhEVJ+Th0Z1IEpLjifJ24xsUJWxhFIEiaPJKl+xOf9FX1O2+RynSasPJ7Z5HdlqEsC+Z5ObmkhGqQeUXRWSssAnBWgKdDvwK+9KnTxcyIoII0EWSGCNtoPZTBvu/x88+kjh1aeifGEFon8Pg+usvDS3Ra0OgP3/P1JIlIrxVx8xUGl34RwdxbriTJmE8owx6vhMMsluAWzBfK2UKDTlCAaoEAa0TRjzfy8qR4GCGa8ws2dvG3ErplRph3s9ce/4qSJHD/8rS0K76cnZPG83W817l+hSlaBUZMn5A68zXmafpTu6w/hR1nDuT2PX5Y8zc0YIyWEmTK4fCC2/gxs6/bNMyGX8M2haNZ0mjN7qrr2dwx7n/RUh+8nRLQ++qlTaf0uElDSX8B/zPLA19Ei5B+bQaFTF+SuIDVYL5Ktizt5EJByz4ivCuR4Sa5hOtTFlXz5elFo7Z3Fhs0kiCtA6Dg9JyPfOOWCi3KwgQ0YG3Z3hGxu8FhTaQ8MJeZPiYMXsmUciQ8QOUqZ1JiwsnwNpx4gwjOj0GX3szu3aZCIjMpp9MFs56qJPzSE1LI9LYcULGWYGzfoRBH6zjnjRvVI1tvLzHQkSkv2dhlh6Y2KfQUKwys8WuJRkrVS0W9ntp6SuCdWnNghanG1V9G1/p1XRJ9OeSADOjNujZrZfel/9jJzn+L40wyJAhQ4aM/x7/zQjDTz2S+PH21n/xEQZp6efjrXYqRfQRqPbCYnZ4llBV6DQUaF1sKzey7KieaqU3GYkB5Pg4aZRmuqq8CLTbOeFQkhWjpYvGwf5qC8dtbpyKs/CNCBlnDi1H2HO0UujN6YYzxO9Nh9h5tJYagzzmdEahr+DI0XIONf7LFDCnBWvtfraWt6DvmOAmQ4aMPwfO7hGGDniSiu8nT538Lj1XOPnRg440HVm345RznrQd3/9o/D4jDCYaW5QEBf3KJZp/Ecw0tbrxVWvQSpOzfhNcOFqPc7DaTHB8FjH/1cixiWajlmDpmn2fM3JnFJmdB3Nh5s9RQ+HMdkzgxf2Z9O3dl37SIkr/DWwtHK81YfcNISXchUVvwuAVTICtkoOlVZjsbjQxyYTapbcGzFiEErrREhiXSFq0/38mra5mKkpPYFLHEB8Tir804UPcp7bsAGXNQmm8NYTEppLib6JFEYJO88Ok018Ce0sdBpU/Gq0W3/9P1nzsaz5bb8WR/jdu7vxDVISzgab1XzGyeiC3Ds0hOaDjvAwZMv4NZ9schj/Hwk0dfyVnfxIuyfiK79IwjJTW89KIJ2F7IknQ7u8vkFYhlPDjfP9ISEWVyvLzCzf9AjjMtDbXU9/YgtmmRC0tC2luoqL8ICe2fcWYNd6E+PgRHCTtx2DBaBFO2eHCbqinpqEZk1W0gVoNxhYaGiupqTOBxg+Nt4u2WhGlV9djlpaKddtprq2j1WxD5euHSnKWx49Su2sKo5dDcFgscSHSUqo2kVU1VTV1tJi80Op88bLrqSk/Rk1jKy5fHT4uG/qm41RWN2NxqdFqO9bdN+1jyYs3MOS+8TSlXEhxhg6twoLBItrSasXUViWuacTo8MHfzwenqZHK8krqGo5SvvlL3pvbQkBYFFHxaeRlpJIZqRIEpIbjJ2potbrwFuV2GxuoqxPXNNlR+fnjE5pMbmoyCVoH1rbKjvzVaDReWIVzlWTUpm/D5PJFq25fnvl7nPiaN16dwITyeC7Oa6Z87bfMrksmZsfLXPbQ+3w97xv2qONxrvyYz0e+yuufTWPqwgoMEbkMKIrCW9JLWxvVR49T2yTJxhvz0je5/Mob+Kw6kx79OhGn0lO5cTLvPfeIuH4hC9bupjkomy5NXzHhRCbREbr2mfY4MDaIulbW0CYid7WfFndbDccqa2kyi3bw90XaY6R27gcsaA1AHRtLpFNaPldaKllaJlnSDZGNpZn6+ipqG6x4af3wdrbR2CCcfHMLrRYHCm8tQgwCbpyWVqpE2eta9NJ7cKhdRmqrRF0abXjpEsnKySUnVJRMXyfOScsFG7G6O5ZBToshVGFG33yCyppW7F6+nrce/j85jAwZf0acdmnok29JnIyG/+U4dWnov/xeEhI8cviX7yeXbT55/uRSztJ36Ti5pHP79/bffmTs/2CcMcLQtIpxT93CFXe9zPy9GnL6ZGD/5gmG3fQqk+eupTGhAJ8FKzElxRJlX8GSLU00WS0c+PQmzr3hGWasMRNT0hkWvMiT7z7Da++uojW1D12jjjDzqXu55cUJHBbOrHznLB669i7e+3YLpJ9D4t7XuPy2p/noy+84Ht6f8/rlEa9TYN+zjCmj7+PuFz/k2y0KEvoW4Ld9FPdd9SAjJ35JWdgQkioWMmnCfdz/7GR2mRJI7RZPgL6G/csn8s7TX1NqSyYrsg1rSiEptpV8+Z0Zw6alLP36n9z51CdsqIklr28crfNe4Y6bnmbU5KlM/Xo569Ysp1TXlT7K1aypCcDqamDPR4/w93++ydd7mtCE5ONc9Aj3j3yF0Z/txZ3Xg8K22cwqD8eway3LJt/DHVL+dQmkpbnZ+e5lnHvTK4ydOJ/DkQMZmBvhWab7ezTspLF0I9vsWehUPkS6KtjlSKPAvZNjuQ9x/63XctWAYrr3HcK5BU7UeRfR7+YHuHdQHAGeVaGaOLb0Pe688lE+mD6VoyER7Hl3Et8dtpIz4gb+NiCFwF2TmfTdXhr7j+Tdey9h+HlDGZATQkDdOpbbupCfGEi4IAwuwzq+fO5xbn/2HeYcsBCfnI594f0MvnUs35SH0vecfCLVXui3L+WANpXY9DhCN81iyZ7jtAj9Mx5ax4ylZlQbX+HRd1/i/XHbsef0Ia70fe67+SYeeekjph9UEFvYz7O8r9tZy+Fv3+b26x5n1Kz51McOpbjlK+6690FendxIpGY/dSod5UeOsOm9Sxlx11t8NGcLrZG5FBsXMLU6A9WGT/n4k0d47MUZHFJmk1OSTNjZ1EllyDgL8HOEoaypYy8J5U9vPuVyO8UhvVaZ+5tfq5QJ/Z8cbn8tAQoVplZpeHw3a9bXcuCwiX988ClfjH2IvrGpZCcZ0LvMLFlgQGExk5gmLSbkI6LvVo5XbWd/aRMmay3Rw0cx+o3h+LXUM+e1NQQPuZ6P507jsZ4qTiyYxL7WNmqOVzJ53nK2bjzOiBfH8fl4QU4ywlB07EPtbNmFSbDYq58exePXhrNmyno2L9tLz/c+5/OZzxBaXkb9roW4ih7gubeeYHiRnQUjR/L0BUO47bmNJN19D89Mfp9rU0R+DmkozYreaMPQsBVb6tU89PrLXNtPxdx31lNR6c8tc+cyZ+4Uvnz/Hq665x2eHNGVOL9GavQ2Ns5cSr2ukOfmTuafV3Wlat5sjG4HOdeP54NnuqMvraaxopIWs53Wxh3Yki/jwddf4dreSnauLscsIvTWNgNWRzfOGRCLrmNdge9ht6PtMoC4wGC81i3kuJcPal+NiLxbWP3h/fzzrpHMP2hCFRJORFI0MXFxxCaGE+rf3rkNwpluX3uE/mO+YPzkx9Ed8qagUxGPTvyUR//RmyTROyvLlOhEZHDxYB2VgjDddN/jvL24ErPLG4238nsSfGTWIppjevLK3C+494JsTsxZhCo0iaHPTOKTJ4aRJr3cLr2PLa2GKG2QI67zshkxmcxIG/U67VZaGk+IfE2kXjGO0S/1wX6ihsrDlbS1NQk5BJOVIS193H7Dln372b2lkmHjp/Dx+Lvx3rGLNtG26de8xvOiLS4o9KGttolGvRVTS6W43iICgxLO6ReKytlEbYsBY+teVN2e5PV37qIo1MD+7dIQhwwZMn4pOrr/7waZMPzJUb7oGAHdbmLuqgl8dGsujY1eOBRpDBjeg57FqYT4BpA1MBlzwzpm7VQTGJSPbm8Z5pgL+HLtVL56tBs2i1AD7yQKepTQu0ciWpw0HjfgH5dOt5wskrQhpHe5iJErdrB9+TQ+vjwLhTuR4kEl9OmVTpjGW0Sc7Q99nE4dEYmd6TOwC7kpOoz1bRj0TmK6lFDSqYAgt0041EBS8kroPyCLMLVwiGkXccvIj3jr6Vs5LyeK2LQEwvx8PDvbSdviqiRSrQgjPrOYfgMLSY5S01zZhsMdQEZODrm5Iu+iVOJSC8mO1aEWeSq8vDA1tkFAJIU5JeSlhOFqsaDRZdKlTwndO0ehklZcdCgQPlTUJ4S4DJH/oEJSIhQcrdQQ2fNRFu3YzuaVr3NdalD7VsSnQlpzXplKSbYfYc61vDurSnAcG2r/EHrd9DLPvv4AF+QEt692abJiFZGC+O97OM3SqoIQXyzKUyTaxelLWFiQqGcqUWHSIwQICTPR1HyENQeCybv0Dh69Jh9Xsw2bVRCqU6yFuaEVZXAsnURdcxJDRZoWVAFhpHTKpUtaKNqTgUn7czsPFF5KT8Ti2R5YyMtLoUYTkE7nXiX06BKN0manzNSVR8fOYf2ORXz88Llktq84jNNoxiz0Jql7d7p1y0ZrNeNyuAlPK6JTl3hRDz+8RVuf0EeQP+I1lu3YwsqZD3GetIiUpwheKJQxZHQqoW/fTMK1CiyGf5kgKUOGjJ+H6EuSGZAezSvcpzlONRi/EjJh+JMjNNbF0S0zefmFMfwfe2cBJ1d5/f3vuO3Oursl2Y27A8GdUihSoS1OkVKgghSKFIq7exLiTtzdN8lG1t3dZ3d29D13dlNoS4G35N+Gdn753Mzsvc997vOc5zzn/M6de8/z/tpiYpNCSAot486pU5l07u9YXdmOZsQZhO2eic3Tgj09gcCIPpoL1/H0n17hjRUncHnEcXiVxUts2Gw27OJEx083s/XtBzhzyvn8dnWF7/XWjU8+yEPPv8P+Nj0ZKV08ccUMJp5xD3OP1uO19N+r97ilHolk3a5O2tt6CE5JYPi4MOZePI2pk5+kKSONsLREVBLd9vV10tUpUXrcMIZOPZNpUwcR0N2BUyLnoEQtG++4kvMv/y1zjtbh0geil1jY6ZB6O1ykZQVh6N3C9VOmccGPfsuHpd3UvXkbv39zE8X1LjTizLMumYqhcKmUmcD9b+aSeMVE1NJXtafTtxyzkj7c63HgdHnE0Svr2bt89Xf1erGa7XSVruPZhx7k0affZWO5kqr67+B14ujqxTgojYSsZCzFe4VqaXF2t7J3wYu89vzveWpBNmVdUlbrFnIi25de3AhISyZzuJmPz5nM9DNeoGtEGgHRZrpaOugduFjAmIsZE+/g4L0X8sPbX+CtBfto9nhk6rt8y+4O8DTSrpiO9+AsfjhlIo/OLiP1ytF47D0iXy8DN3/Eqgg5Utew9MkbuHbK5TyypYTjh9by4IU/5CdPLqVKpRfDojxP0k23sqy21B2uK2ftzFd47OFHeGfZQSoGqgrKymBQBrw+fQLnnP0O7olZBMUGYOvooKtbCjhEXm4VwaZuag8v4emHRBavzWNfjeiGp18OHqeyXLSQqN4u4VNufKvV++GHH98eMmcU/q08o+BL//x1W/8Z3wnfi2cY/huhDJ7Sx+/6DIMhMoxAiWgDQgYxavI5XDJtMMlJERJlxzB0zFlceP4UhqckERsYxtCJExiUHklIWDDWIIk6A1IYPukcLpqSRUpyLFHRcYRLVBodGUPmiCSswVFEx6Uz7uxzGS8RcKzRTGzGYIaNHMnIYQkYjVEMGj6dC86bzrj0UN/v++qAIIJjkogJiyBUiXDTksgYkk6QIZjkoZO56IpJDE6PJzwilsigcCLCY0mKDiQ0QIPHq8UYmUh8fDwx0VEEG4OIGzaV886dzpTR6cQlJBIh54QHRzJoiJRLjSfAEsvQEWMZPWEiI2NCiM0ayuDBg0mITWTI4BRiw8KkH0lMmDqDc8/JIlJZ/U/6F2YNIzY6lvjkZGLiEklJjCIuMYGIYKX+KEK1Qh7E4caMGUGqpZXjXRmMTg7Gov+SYhpCCIqQdsRGyZbBcGXNhGFZUn+UtNNKSmoGQ0aMYVhiCBaRf0hkCimRVkIGloVQ6wMIlXZapZ604VO5+PIJpEufIqPjiQ4YeItB5BYbk0BCmJngJGXp3OlcOGMcg9JSiYmNIyG4/y0JfWgcYdL20PAUJp8xg7POEAceFEuCyDEmoF/XFOuikzLBYQlkpA1l5JlnMSoznYTIJEZOmcFFZ41icEYSUVExPj2IlU91cwWq+EGMzTLQ0K7DZcpgaLQOjcEqbU8gyBhGxshpXHzZOJFBPBERcUJYjZjNoQRJW4L72oTYeEgdN4RwTTuFvUOZPGowifFxpCZFExsn58iYRobHkBwXTLDFH8P44ceX8W1SQ+s0RuWenez9x+1ULm/9vXit8r8R/sRNpze6T6zjk9df4KgpGV2PnpCL/8Bvzo8nzPRfrph/h92v/Jz5eTIf9U5skRdx6Y9/xGVpA4znW6Bh24d8PHsplYFR0BdK/A8f4YFzgpT1tvzww49vgOInv/a1ysK3yalfg1EX6CMMX2Wd/va1yl/Lnn/dhvnpvB9+fAWM4VEMGTkEtU2DNnQcF0+JIfh/jCwoSB4zipggE92OBEaNHMGk/w+yoCAoOY1BQ5JxdxsJjJ3AJZP8ZMEPP04Z/s3hvv8Ow38I/jsMfvjhhx9+fB2+8Q7DlxM3/ZM7B19ODf0/sfiUH3744Ycffvjxd/iS71dC8G/aviv8hMEPP/zwww8/vo84FSzg/wN+wuCHH3744Ycf33OohDx87TZQ7rvATxj88MMPP/zw4/sGIQE+FnCSCcin9+u2gWLfBX7C4Icffvjhhx/fNwgJUFjAwPsD/xb4CYMffvjhhx9+fN+h/OzwddtAse8CP2Hwww8//PDDj+8jBliA8vrlN/07FTitCIPSJbf897+0/fV2krIOtx9++OGHH34MQCV+Qdm+EUqRb9hOBWk4LRI3mU0mWts7yKlq50Srmj7P/0DiJtk0MoCZwW6GxpgJCbT4Vg88KRc//PDDDz/+t6H4g56eHh9pCAkJ+dvETbYaNhUNJG7S9Sdu+irv8eXETRd8x8RNpwVhMJmMtLZ1UFrfQY3Ni9P7P7L4lPwXY3ETFySkyaD3LcnsJwx++OGHH34oUPyBw+HwEYXQ0FD0+i8Sq/sIQ6EQhsYBwqC8CvEV+Nu1JP4LCINZCIOSGjqnSraW/5E7DNJ9pY/DQlyMjLUQalWWFPQ/UuKHH3744Uc/FD9ps9l834ODg/+WMAykhs7xpYYORPOtCMN3W3zqtFpLYntJB1tq/rfWkpge7eLsdCsxESEyGn7C4IcffvjhxxdQ1pJwuVxfv1qlEIZvs5bEBf9Nq1UqP0NopUX/S1v/Ty/CHvw/Rfjhhx9++PElKIH1yeD6KyGHFBfSv7D1t9m+G8Rl+eGHH3744Ycf32d8Ze6FL28D5b4L/ITBDz/88MMPP76PEBYgXKD/TsQ3/DsV8BMGP/zwww8//Pg+YuDOgS9Xwzdsp4Iy+AmDH3744YcffnwfIVzAd4dh4P9v3r4b/ITBDz/88MMPP76PEA4gnEE2+ef9hs1X8rvBTxj88MMPP/zw4/uIL91h8Kq+YfOV/G7wEwY//PDDDz/8+J7i5B2Gk9++ejs18BMGP/zwww8//Pg+4ks3Db6KJnyx+X+S+C9HJzZ7EQ0dHQN/+/H/haoNLN6wnXXFzoEdX4Kzg+6jC3lrUylVnV9zm85ZRdV+Kbejif7krP/X8EDxCj7ZcIgDNe6BfacZWg6xb9sKZh7uG9hxCtG4l62b1zDvaO/Aju8BylYzd8NetlW4BnZ8DUqWy9ge5mDt/8fYlos8Nuxma9m3qP//GqWfM3PDQfZWnya6Wb6S2Rv2s6vyNJ0rfw+X2PSji3h7UzEVHd/95wEfWTjJCJTv37SdAvgJw+kMTwu21lkU1i2j8Z/Z55aj5BWWUNrcQ+3emTz/9kdsLe9fDfM/Cxf21kL25nb50mD/Der38enCbWwp7oa+Aoryj3KwceDYd4G7jEMlPfQpHEFvwmTQo/9SKtW/QqVGpQ8gwKBGo/8K1t1ZQlXBAfZUaeW4hQB1F47C7ewosSEt/mrYK2ko2M3uuoG/vxL1lNfWUPx1fdVZsBi0GIyagR3/Krrp7ijlkOiCD14n7cd3ktf2HTVDr0dnMGHuq6C5cBe7agb2/x16i49QUllL+8Df/wgP3Sd2kNvi/MKWaQzoDcpCbF/X9xqO51dRWneSCLbQ1FzBCUXuznYaj++m0NF/5N8CnVnaq8MoY/ZP4Sll37F6WntEbnotOs3X9U+cX18JB0v7cCtDpTdjMFgIDvma+v8JHFUFVBQXitb9i7BLu4/U0Fm4jT1lnTS7pa963SnQze+CPjwV29lZLGPttPjk+Z9tzzehg872Mo5UyFetTlRc5rdeg+Y/sPbBqeAMmt/97nd/Gvj+H4FWq/UZ9R57H5VtfVR0qXF5/0dWq5Q+JgZ4SA41EGg2+RzZFxDjqTWj95ZR3VmBxyWO0NGHzhSOTnmv9iTKlrOlqIxt2eVsf+xn/GlWGXHX3MGMeDfeir0sXLOZAwfLsAfFESKGa++ahSxZtZ28Zg/WqHA6Dy9i5oJ17MzOwxs7lGh7PquWzGP1zlbMcQa6crcxd+5Kjrd24ySAthMV6JLM6FpyOdQcTKiuhePr17Bm135qvOEkhqgp3rWU2fM+YN7q3Rz1TuSikVbfq8B/xfEP+fPrKzlgnsiZIcc5kl3A8YDRZHXvZsFHC9h2rJC+0FjaDxbjCg/A6inieK0Gj62FkkNrWb3loOiKkYg4C/bcjXy8aC07Cqqo3/IKf3l/JyWkMjQhlLi4RBLMPdTsW8KibYV0BqaREqoYXq/IXk1geBIxvQVsWbWItaUQEhVHqFEO127lYPYRtrimcE66idBAE8a82czunEpI5VLRUTOWEAvNBzewbMNOitq9hKg7aDq2ns9qx5LSkY8qNhBzRx7ZdWa0RgMWnYuG3e/y4hMfsDjfhsHZyIHly9h+ogxVwgiiLQp7F63wuDFLu0JszVQcWcSC5dsp7Tag03qoz6lCn2hC05zH4dYQkX0zR9euYu3uA9QSSYLVS/EOGd8D5TS3lZP9/tM8tbQcc/pwBoXpaFn9Lh/t3MjaXeW4THGkxZhoyNnK8jVbOV7XRWBYHFRsYc7n2zlyrAFVpPQxu5RuvYEQYw2lNb202IOIjwolQt0kBGQ1M2vHkdgm/Y2R/nbnc7jWgMpsxJAzk/dmz2LevnJx6H2EZaRgaj7GuoWr2XOiAEdgCs4ds5m7ay0rpT1OUzyJ8cEEBYYRIk7JlreWz9evZPthGyHpSYR1H2PB3IWsXfIunx42EJMylCHRGtpPLOT9p17hzd19RFkDsO94jw/2H+XQgQYM8SnEW3vI27SOldv2UN6tJTgmikDFv/TaqD+2jTWblrFxZxPGlFSizW3krF7Nmp37qPWGoGp34uhpp09VT03OTuosGQQ6yzla4iXIapL5KfW4nZjCEgl1dFKbs4SFn28SXTWRNDgcV9EWPvhkNuuXzGJJVQaThsaTmpJMYngPZVuWMXPRJiprW2lpL2bTpl0UVfaiDbWTP/MhHn5rF1XGdIbGhzEoUU/lru2sWraKnBaZt+HxOBT5bFjBlv0dBKQmE9GTx+qli9lSrSMiKppgg1D2/DUsnP0m7+yooqGqAV1EKvqGXOrUMlbOavKr3DjrZVyPLmP+8p1U9IaTkWKm6dAaPp79CUtXrmVbQzyTnStZ0DqcpMgg0hMTCO5ppfLIYuav2EJBSzAxCUZaDq1myfq9HM45TJkzmvjIQPp5XxuF2zfz+eZdlPc6sXeoaCmqwSh98jbkc6Q9jHBNHQdXrWLD3oM0auOIlzl7bPM8Fn2eR7NClpwFLP1gPptzSiBC5kbhTD6qGkxSdAiDkqU9ve1UHxHZr9tDfn4ddWU7WLu3FFVoMqbGPGrVAZjctRRWOTH01nF8x1KWZ7egFXnEBIhh6mul/MByZi5cy879x3BGDyXWWcK6ZXNZta0JXYyR3qIdzPvscw7V9RIQmYKnUObRlpVs3FEjQZ3o9abtVBNHaqyWss1LmSU2Kb/LJfpRy+aXHuPpz2sJShxEepSF8JhkYs2NHFq2gHmrNlNQ2UVj7XG2rF9NTpWOqMGxBH7JXtrtdl9iJmXdJc2XyKbd1UVZ80Hqu4vFPsi8U3ItKOf93ebx/fMSHzyM9PCJAwf+NfgJw38I30wYBCoxSqZRBKnKaK3/C7n1JdhNmYQZQ9Ce9MCtuVSIQh06VEPriRrCrriHG68bR4rRiSfnDX5w2e/5dPlCapKvZKxnN0s/fZeFhwopaZbr24307fwzT67Kp6T0BE2a8Uzsns9j769kW5FVnEwZxzeLYdu8n8L2bpqKxAjl7KF79GA0mz9mpXc4YeXv8Mj1d/H8/OUsqI1jqKWZglWv89bGShptWhLGX8bFQwP+ljDU7qND5SK/I4NB7mqZuKG02cXC7XiRlxbs4VhVLpW2FLyrV9AydiRBJxawriaIyMBm1j31c+5+bi6fFwYw7ZyhsPlpbv6ogKY+Dab6PWQfq6E7fhozDJvYUqGlsbKQtW/9ht9u0jPjvPMZFaOTmdZA5973eKN8CDF5r3Lj4x9yUDWWi6cNI1Yct3KHoVoi3zZPINFVC5ndKGTGdZiVe8tpyV9HW+gwovsO8PGvf879byxg4Z52QgaPYUxYJ8daogg9PIcTCaOx7PyQldKP6NgIogwuavYu5/NlB8ipKaFJIvC9+w+RU1ZAs+UczsgMQK8RrTj4Km8XxNJzYgv7Nr7Le6uP0eK20N3SQ/vOvdhGp6Pa9AkrVSMIK36dP1x7Ly8tXM7C+iSmhFax9M2H+dOhYManWWlZv4RNVX2EjDyfM9ICxYGtYenOnezdcpSmwFGkhBex7tFfcMtfZrNkTS7ekWczovx5zv/F0yxbthHXuHPRrF5DXXQC1pYd7MnroMcpkXLhITa1JpNlquNYZwJhB2ZKf8dg2f0JazrjCE8Qh9G2j9UbtrL7aD5FjW4hutG4N9/DD+58lYXi2PYGXcpZAQVkH9nOtg1HaLAMY6j+OPnF5Wwu8uDc9if+siqH4oI2XAnDicx+mSdmbuBQQS29ERM4a9pY0U9xPrmbWD17LQd6zMRnDiehfRPLhbwe3VtCZ/wk0nsX8/xNN/LYR+IUD9mJnXwekxUdaMxnz2eP88zqbHKPVNObNIGkxg955Ce/4i9zRJerIglqrUXbW8wxTxPZn73Joe7JDOr6nPllSQxLCyVQVJYjb/JhXhBNeYfI3fQqb6zMoa4jkICIIOxrn+IPc3OormlFO/hcLtOsYFltLN3VhRSueo/3thSKA3AK0fiM+x96nUXryok6aypsn8uGg5XYU89khm4jc+cv4aXZh0QWu32r+Wp7Dbj2Pc0zqw5TcKIBV9JoknKf5cpH5lFsmcjFk4cQaRbz0ZbHrq1rWX9A5ntNPe12cZAlizgYOoJExw7mbBV9k4Bh4x4JGlYeoZEkIgO6KV/6DE+uKKa+xU7I0BmcF1VLnnYUwxrm8XlNKC3HdnFo01u8I32t740gJEJD1YfX8rPH5rFiudiHcT/kohHRBAihshV+zJM33soj7y1i/rFWca5CtkuP0SPkybVpNmt0Iwg9/hfuver3vL5sOUtbh3BudC17lrzFKxv6CA8Vh1e0hHfm7iSnopAW7XgmWMso0I9iaONC1tRYaTwm4735Dd77/CglR3PZX3KAIzn5tBjHE1cwj/1BQ0l07WHBNheBxYt49vWX+agkkQvPnUZ6iNTfdIIdHz/G45/nU1Z6lDrNBCbblvDMh0vZkBdAWng1RduW8snGfeQ12HH3haE7+AzPrj7EMQleDteVc3jnCnKZTLoqj72LPuCjHdkUtblwdmrp3rWMLQ0qojKyGN06n3erMgmsEFswaz7LDx1h35qNMgaHOCI6VFYDxmGTGRX+xR2lf0oYnEIYWg7SYBPCoBHC8E+IgNcrdEHOTxDCkOYnDN9PfCvCIDG9s3s9RVVvUuceRqDFKgwykQhLnDiXgbLNorSNkWgChnHl2bEMufVOLpJJ5nU4aKospr1LFNAK1uEXk+F0kHr2Ndz+5BOck+glZ/YRRk0ZzoyX3+eJXw7n+IJCMgNK6bv0Be7/3WUM2j2X/LCzePDN1zk7Tk/NlgrOvMjL9qYEOvY3MuaiITQufoItHbHEDRH2OmQs+rJcUsedxz1vPsOPh6gpbUpm+ojAv1XR6h3sDjqHsOZOoqqWciRsDC1i+LQtNVzw2WIeunoQxxbWc864RkrDB3NiVR2Z4weREeOhtbyTdrWWuJR4EpJGMCSwDeNVEjnfeQZnjwmgJeleHrx+HOn6A+xviEIlvkEfGkzkpB/xw1HhQjqU0KsbR7U4bPdYUnT1dCZN45wzz2JCgoUgk0zUjkIqGrrFcCQxRFVCgWEswzrX8tb771E48g0ev2kilvWPMyu7G/OgsWQNGU1qvI4hEhlVBA3n3IxiFh0Mo3FXLeMvH8lgiYRkqhOepEY/4kqiHRGcM0jHeR/N5f6LYzi0qI4Jk1IxGWVMa3az1z6U0M6DqNMv48f33sGZMS4qyrVMH9/O9rp4OrObRfaDqF/wOFttiSQOGUrqoDEMi+zDlJBBzLjr+MlZkWSOHYJp5B946soI9Ooemo4so2bsszx57wRMHiM5c+dQWV+KPXECw7NGES7R2hiLDUebG2uYh8BRN3FFZgNtwcHsW9dJfHwsE8a6qK/soUUXS6qnmDIhHucPKWFpThg122oYd/EIMmPChFjm0Dfqeu585ikuGWxh1yuL6apaSVHYNEZljSYoOZ2p2n30TnuWh++ZjMUhBrCyBlN4MPWdTonAnCT94h0eu8zFlu1eeo/sZ8qzH/HifZPQdFkJMMeQEafDGqXFMng0KdN/y/3TWqkvPozrUil3YzBFxUbqlr7ACVcw1vSRZA6Stg0bwcQkC57WAqrrarFe/zHP/djAoRwtrSufJUcTT2SG6HLGWCYPbiZYV82ahgx0zlDMhZUSmbcTeP4FDI3Uo/AF6vZwsCcDS9cJDInTuPSeB7l2RC+fL27E6uzk6k8W8Odr46itCSNTWyTyGkH15zlkXHYRv3/iUa48KwV9RQWtdi0x8UaiJ9zIzy6Iwpl1P49eP4J4XTaP37eYjmn3s2bh80yUOXBi/iYSh4cS/bP3efIHbg7kmIg1tNI95AIuPHMyo+MsBBo19BTm0Rs1kWtefIXbZ0RwcOZx0iPahXSex0iLkL3yQMK6duMe/ytuv/fHjI92sGZOAVEx4fzy4094YEYg5VJmhKmQo7oxZKkKqNCkY2k/hCb1Aq759b1clNotxNcp7aykWj+YEWPu5A8PnSt2ROub8/mznuDzIjeBg4R0DxJHmBXCmaPsbKqMpu94G2POT6Zi9mPs8AwiJTOTxLTRTBIHbZV5Mv2393OzTgjAwXoumreYR65JE50tZHh4JccDJjGEQqrVaRjbc9ClncOV113PmUMM2MbcxbM/iuL4CS2plNAz4hxGBtVzotyCVdWFPW0Ew6ddKvPUSphFh6uxni6biekvfMjTt4wlb1kJgw2F9F38NHf/4YeMOrSY48Zx3P/221wxWM+Rz7aTOkRP0A/e5Mmz2zgUeTPP3DoKnSeCkrmzsZx7HQ+/+AITrU7ac21ccvs5BIx5mEcvkwCw8RBbbMPpXTOb0J8/xotPPITx2Lsc7JzGs3Ne4/LUFg4UxnLG8EBFu3z41oTBl2uhnw58eTtJGJQ7DN+VMPy9h/LjtIELl7OEltYddGimkpzyGlOyXmRK4lQCdF+wTzxSziVM1ilbX1//7/cCt62X4l11pNxyJ3+66wIyo8z0uB20VRxj/5Gt5BQ3ookIxtEthmPbLrbtzKHbYEatVeEUsuGUevSRwXjaKth7ZBtHC1sJHZdBWCIUbpzFPp1MWG0QseGjOefnv+b+Pz/DC3ddxo8mDKGvs4X8w1vZdayaHpddrtFERbMd58mfz1199PSEcNZ0C22teSz+vJAAcRQmXS95W3ezc1cZmrhIYqcOpm3PR2xuiyQ8JI2+XSewxY/n3kd+yU+nxGGTzrqFBPWJs3EpD0pIhN5XIgSqsAWbzSV8qwd77EguGhlFyPGPuH1+Wf/1lVt3Sru8WoxZF3BnYj6fLVrErMPCrhR43bjdIk+3B4/It8/uQC+EbsatvyW2u4jjR5ppUw9m6g9+xu1PPMNfHv4lN06JwW7roi8gAu2goZiPvcoh1WAS9TEE9dcq1zXgbiqjqbqU8qZWcnfuYc/BGtThVjEESgHpg1tIolzTIaQiNNhKcKCdXptCBOIIjXORt+kzDhqmkKkOJDZyDOf98l6f7F/69WWcddZFXDTIjCr7I363pBqdEKOOvAPkN/bhcmtQe6KJDNdh0PVh77Wj0icw6txruemxZ3jm8bu5IzOEihO9jHvw9/zxpmlEBOoIGj2YvryFbC7vg6ARhCs/jbndUp/IxiHfA8LRZI4i4PirHPakEGuM9/XXo7bTVHqYPaIHh/IrISyBxGGXcMPv/sxTf/4jL98whVhTAoFWDUaDtMch9YnM3aKjDmcgJn2ktNUput2HW8bJGhhFZ0U2e/YcoKCuC/dJwqzSQ1cD9ccPUy7RmZpoYiK9YhLtUqcbY/BwzrzmNu56SiLCB3/BdWMifKe53WK8NdFER7hljJV548USNprzbribe0Wez4s8f3TdpQRIf7t25WOIm0hs0F5m1SQwLEzHX825R9o4MF7BgUGEBElfRCE1OuUZGTPVJ7axfddRajodYrRFbi4hYsFqWitPsOfIMfbO2kl+RxQ/+tO9/ObyTIkZ1KKXbuxFBzla1CZj7yIsLkgITjm7j2wht7IDfXgcJm0kUeEiL6foh9DRwKxLuCf2IG/NlSj9RP8juhqNi/aaPA7s2cme7BK84WGix17qDuxix+4jVLb3yDjGEBFiJjDALkGb6LlJiJGItjRnC9v3F9Lc55Z2i066vTI+0lcZe59uBoluWvt8tqLVZsSYeD6/f+YJHv/j+Qw1yZgMQBs4mClX/pw7nhT5//Yn3P7TiRLAtHN84wIOm89gqCqAuNhJXHzL/fz+adHjey5mYrJJAp1exJyhCgjAqBW7sEXswt5KvKGB0i8PDpGj0h73gOxDrEEEBfRg1OtFLmG+drlEljqTl/rDe9ix6whlzaI3gy7ihsw+Cjd/ylObmnxtVGyew1bP8R072br7EJ06E2qdWupwSt3Sh3DR6M5qsZs7xG62oguPEd2JIirCKWGAU3QoAp1Ef3YpHyA2091Uyi6xsbmV3RjjwsSzt9Ny/ABl1d2iZ048op3WSCvdJTlsO7KLskYvMUkBhFpF9/vEnv9/PsN50v0rP0d87TZQ7rvATxhOW3TQ7ZBoQHudRDp/JCNIL8qpQEb+y9AHEmCRyDjQiMFixTxwWBtkZMQ4A4ufeJBbn1hNSYuLxGgnh5e/zO+vuoV3VhWRcvl42so38+JNN3D7nR/gHT2MgKQ0rFovaiEM0VdcSLgw2D9dfSOfbmxl2E3nihGMZ3jjXsKmZqELszL8yguwr3qHP/z8p9z2xjp6UhPR1G7kvmt+w2OzjqFW1VGy6lWe2VSJcIZ+GEMIMqjQDj2DkaNGM8XYyKBpY8kcEsgSactvH9pJwg+mEpR1BoNK95I0IgxVnInoiZG05Czhvjtf4f3tjUSLoTMEhBKsF2OmFhIVHk/Ijtf4cP4WCtqCiY+NxXN8NZ88+RqL99uYlpnQf32VGk1AFGFGD6VL/8gjz6yk0xnEyKTQ/uNaMyazGESzHp05mBCTCNUST9ywq3j2vFb25J6gecS5JLYc4ZWbfsrPH/+Q1UUaAoLEaEkUYPYMZrL+EOFnpUOI8lDEAMzpBJdto7VYDFhjDwt+8TMe+cshUq8cgzlAmYrCqEwhvusqdVlMRjFEWgwGA4GxqQQI+RjeLLKfMhSDEKyRV56Pbdkb/F5kf/f729iwdh4fPvs2aw73MHXyOCzqXroXPcnL62tElzSYg8OxGoQ4qA0YdTrGX3UecTTwye0/5ae/e4FVjWpSU7p4/a77ueOFHfSIDgSmTCZNnE56ohfDMDGcXgMmSyBB0ka9yEjpr9GTxWTNISIlWibM1N/VSCNlWz/g8R/dzKsLjzD61z9j1MQM9jzwc37xy9t58vNSOvQRRAToREeMosMmLGL0TaYAcbwmTOJ8LaLwXnUA8fGBjDvDyvInfsfPb3yDLeXtmMIG5GpMIqS3kqrPnua1PV1oAsN9v997VWZx3kYm//gydIc+58+/+Ck3Pj2TjeX9ZlOlk3ZbQ3y3zb0qExHhgUy6/lKc6z/hjyLPW19ayoHeTJKCBzM+RMWYiaEEhWsoFuIapujaSRiCRRYyPkGBmC2ij2qNqJeFrBGRJCe28eyPb+Wm++dSJl5AFxYp8jIw7YJYKnfN5Z6rf85bm/ZTZivkT7c+wiNzC2TcLViiogjc9AJvL9wtEaSV6+6/mszeHTx09c18ttPG6J9MwWgJlvH1ojGGisid5C9+gN8+txaPJoys+GBf00zhZhpzP+eln/2CR15YS6yMd+LoeI4/JeTwvg841GrHEhuN1WRAp9Kh1ZgZOzWOIG0+f7zmdu75y3raxfnrgiMJNWtlvJW+Duim2Yxe+qo1BJEa5aS3bCW/v/lGbrntUT7a30zXgNMbcvWlWEt38sKNP+UXj3/AuqZkIo3hjOg4SMiUYdLGcMZdcQ4tnz3L/T8TPf5gBwWdoUSGBGAQZ20YMYqhmQEsuVmxC7tIuHQcVuU5Cp3K1x6ryD5AyIvFJO3RGTAoOmmQuaQ2E5MYTvzIeAqfv59f/eZ99rcKgTr8Bq88MZNDVTomD4rxtVEt87u9Zgev3P5zbrvlTfqGDiEwNUPsoBwT0hJx8flE2Y7x56t/wbufNzNS5G8KChH9FLsgtixUGJZaYyJAxnbi9ZdgrdzKwzJW8/f0MOLnF2HxdNKx4HFe2lRPlyqU2FAzk667kL7173Hn1b/lcM9QJl8+A40EfTpDIKG+h2y+JQaIQH9Spm+zfTeompubv3st/wKUWyQKlNssFonemts62FnawbZaLb1uFf+Bh0j/rVACYq1M+KlRLs5KCyQmPES088uKokQ+Limnl4n8NcJw9WIXebk9wqaF7XoMFpQ72z7lcHZRV99GnxyzhEai2v4eKxo06MdfzIxomWxthWSvX8SBkbfzgyQDEVExWMXJ9HoMMvm04qzc9LY109jRiz4gjHAxqlq5Xk9HBx5rNGLrRV/7aK9vosPuQmUOJUocpNvWSlO7zDS9BW1rEydWzKPn5vs4X5i6Er3g7MbmFkNklL71CilSigYFo+1rp7G+Hac2gPC4cCE/Xvpa67GLUTSLYdDJtTpbWmntcopPDyRMInC9V9orUYpFghqJE+iWtnRrJdJTHLBGj6vPhl3a26OxEBIaJk5XEY0Hr7MHm9eEqqeBjm43KosY3mCLGEE57u6TCMYt0tRL7Nbni+BM8r9duY6qi7Y+rTg26Xxnq8imR2QeIBGOEDeti15xFuqWOna++iy223/LjKQ4+s23AulPRwvdvRIZ6aRtXRLx6KyEx4aicBLfmDls0i4jGomeVBJFK5GOVwyJS5yaSSWy7/w72deJ7CUqUcv4BOkkIuruplcjsokIwejuoqOpE2dgJOGBYv1EFn1qo0RHbt9dGZ1ei8fWRlNrNy6JqoJCQrGquqlt6MCt0hIUES0OQou7o8HXL0OgGHG3nT6XV7RTJ9KRKF4curajmZ0vPkXHTb/mrPQUJKaSMbbR1tZKZ48bjSlIdCsEnaOLptoWkaRa/Kw4Ib0LrzhuRc8cThVqr+iQ9Nnp1kjtDjx6EzqJ/u0uHWZNDw2N7fJddMUqYxUkbRmYLq6eNtrb7HgDhTxqRbZ6cR7KuDllnIRX9LQ009ItSmYMJCQkTEiTnKTcyXH04VLeQvD2CTnSYTF46Gpqok3GB1Ow6HswJumHvc8jkbIJT48Yfm+AkBz9Fz+Zii73yHxRSeStTF+VzBuVS8bLI/PM00VNYycekaU5NIIw6W8fQta0brpkXrWJ3pmE7BuE8Ha02XwkJiQiSsa2j+6GJmw6cUYWFSqJgLvbu+jq7kEXGEF4iJCyvl7pp0n030GPQ42qt5G2Hq+0M5wwq8jNp8e9dLW30ibzRbwrYdGRQmZttNQ10+1RYQyWyFwnJFV5el+u4fbdApTrOTqoa7Hh1RiwypwJ0jpkpE3ScruMivTd3T9Oap0Gr8yTurx8ju/ZhH7cSHSVB1nbcSm/unwIiWHKALmwKfLvsvvmSWhYOIEqm+hxN54gIUYK9/LaaVP02CG6EhAu8pX+CKl3a4R8S/DitnfQIHbBpQ3snytumbseIXwD7VFJe9RKexQ7qdwZVIn9Ujnoc+swaftoq2/xERij6FygzF9bZy8OITrhIUEyFjKEZdnsXTWXPcNv4/JkCUyiYrFq7GIHdeiEWOsVO9jeIjatB61F7GCYBZXI3yXjZRAZ94hsTBondqcao5AVh8xxn82UsYrwlRW9aZY5FhhGqMFJn5BZs150oLGR1h6P6ECAkJ7A/odonXJcSHlAvxH3+cn29nbcol9BQtSU9pxEW08Nmwre5mjDGox6q8yfr/YTbo9yJ8bNpORrOX/wPbLna/zJN8BPGP5D+GbCcOrRseoN1nqSSbjkUqaIPnqL9rB7xzaqL/0D10YOFDrVcDnFyXdgjAqXqf2/ADcdDXksf30PQ+/6ISOjw1DswH8vPOIQCljy8k4G3XY5YxKixNn78b8Ee/EmPvzTzbyXJwReN4wfPP0id54RJeTt+2HEnSWHyN66lrJLHuL66IGdpwm+kTAUvk1OvRAGXaDQ8K8nDJOTr/MThu8r/hOEwdVWT7tXIvugUILkUl57N92dErUFxRMuUdd/ucj/TfAKR7LRXG/HGhXse0/8vxsSAbp6aPa9bhbsyyHhx/8WvPZWaoqOkFfnRm2IJnP8UKKV2/QDx093eO02sYNt2K1xhBlVp1W7v80dhpyGNZiUOwxiwb/Kmf/1DkPStVzwHQnD92VM/TgF0IZEEx7aTxYUqIwBBEbGE+EnC6cQKrS6AKITwv8HyIICIfdaC1HSXz9Z+N+EyhhK/PCzOe/88zjnzOHEfo/IggKV0dJvB08zsvCtMGC4+5eWUujCN23fDX7C4Mc/R9VaFq5czYLjfQM7voeo38n6tUv48MC/J7nzKUPFauatXMviXMfAjn8BPVVU7fqU5zbU0H7yDZVTgbajHN40h1e2t/5jFs//FtRsZOnqlczJOfmk7v8xeiqo2Pkpz2+opeP/crq5uug9PJMXVuVS1HoKB0+i3drdomvrq2j9N4ns34Jy0YGV61me/x3m4b8DA3xA9XXbKQgL/YThvw32etpy17Ou2EXPwK5/GQHKK2qRxFhPPn3gwdV6jE3Z7fzTzPa9RWyd/TR33HwjN//+L3x68P/HUXtxtyn1t+Ec2PPVaKSmtpADpQN//j3chRwsbKC2Tb4HhBMeEU1i6D//Zb3r6BayC8qo/utFG8g7sJVZ83MHZOig9/gS/nT/7dxy6+MsyK7/v19bIiKRxKhwogL/rt2uVmyFG9mQ305b/ma25TdS/8/IgMaEKTSZjAg9xrK1vPj0Q7y5vowm5Qn2rqN8/u5D3HH7r3jyw900Orqo3v4+v7rlJm669dc8t66MTpHz/lce5X4Zyxuf/IzVBQOJsfXBBEXEkxr+pYf/vgr2XAqO7md3/9tr/wRlHMwpJb9aLNqpQE8eO/P+RePuymdPvvJQrXwPiCQqQnQ/6Av5ezoU3Wyl75SQr0ZKi/PYnz8wSzUWzGFJpIUr6bH7d506tNPRkseuApGx1og2OJHUCCUF+XdxIM1UlOayN2+g/VoThtBE0iOMvgdNvxoNMm+LyK6Sr30t1GZv5ti3IUe2appObGR9qfcf7ELv8R0cr6j7mhTkfXhK1rEht4W6vzOIjYeX8I7M6dvuuIu77/wt972wkoM713Hsy0uZWKKJjYwgMvBUPIHVi6N4HevzOvrnoA815OYVcqTkX2SJPiJwkgx80/bd4U/c9B+CYh6VPn594qZvga4idq9fxNwVW8iv04tzdNKTs5yFPVOZGFTMhrff4pNl66mxDCLS20vR9vd4d/ZKjjWFkpBilAB8Lh8t2siu/fsodsaS5ilg+bxPWVpqIDEkkIjIaKIsDqp3zeXlt19n9udbydVP4Lz4ejZ8+hnLt+6k2ZIhxMKCUfrTd3wln6/bxgFVLElhwcSkpJHQvIk3Zq9i955qVPFJBLQUsXfj+3zw2VbKnXEMT9dSKhGrUv9nyzdzXDuRc+OrWfHaW8z6fCMNwUMZFNDKzkXvMutQA51VB1n/0nO8uLmZ6JQUIhq38M6clezcLZYoLpjmtc/yxBPzWNMUxvCkCBKjQ9B6DHQfWcRnS8TxSWQcmDWEaFP/Y0It6z9iS3cQ5uRU4sU/2CuOseWDt1hd7Sb5vAnEe9rp2fsBz+6GYE8VtepUEhLjifW9CnkSfXSU7mHeBwvYfDgXd9RwYrqzmTfzY1ZVBojsKzi48mM+nruGQ7UuorPSMVTtYt7789l06ASumBEkGstY/ebbfLRkF012GcuscQzRt1K6ZwGfLN7EsXIvITFaOL6Y2Q3DGda6mM+b0+jOqyYw2EuQqY7ionpKXZHEBUiTPE7U6m7s3hZ2PHg3d7yxhJYh13LptARCqxYzb0M+x8ubMIvu9ejD8O7+gM+aY0gNMxKWMpzU7kXMWZBPYa8aY0QyQ4dlkiEkAZcNr1qPzhCK88Rqlqz8hIWrKtCmDCE5uJHtH7/PO3M3UiVE7FhfAJWdYST3FVFvsKLrKOJImYowkc3HH37EwllvMzsvhOHD4tDmr+Hj+as4XNdLeEwS7hOLeHP2anI9KQyJC+x/g4Uqdsz8hHc+W87xzgBSsuKxZS/m3Vc+Ydn6xSye8ynvLj5Ed+gQhmqLWDbnQ+aursMQZ6avZCefzVkhDqub0LR0jHXb+fgvb7Nk2z5s0Ym0LH+Kx59ZxI6eeEbEBxMtZDlS5mfjvvm89OYbfLZsA0dUovvJzWz7bA5LN2+nwZBCdFQgokri2Mo4tHkxs5Zu4kQlWBOicB3fwLLPP2beimKZ7ENINZXz+awP+PSTt/l0Z7Po61SmpolM3X143W50wXEE125n1qzP2NgQTJLUofB1d30Fh7bOFD1Yz8FDldQUr2f+2mNoEkcRry1j46ezWSLtqTemEuboJn/He7w3ew157QEEGEtY9ac/8PjSIjQxQxgSrvKNZ5y5gT3SlrdFJnl9oeIUrTTt/YSP5i9i2xEXsWPSCe7OZeUHs1ixbSetgZmkmxrYMP99Pvr4LT7dVoczehrTM/rbr7yhoAqIR1O8m40bPuTT+YfpCk4mMVbGTixeU/Zs3nzkOV7bJfK3huDZ8z5vb9rOlq1VGFMGi+50kr1kPp+t3EhBl56weOUVT5Frey4V2etY1j2BUb1bpN7lbNtejCMqGXPxPN776CNmbjxMVQvEZqWiLdvGnA8XsjmnAE+IyKNkNjNrh5AQF0asWdGhfnTX55K3Yx0HThzjYF86adGxxNSuZN7OjaxaI+MVM4iUMBUaYzixRhvlWz7m/ZVHaQvKZHCEQiSFOXYcYt6L7zFr5UH6QrWUbF3F7FmLyOm2EGwxYZfApskYgLq9mMO5HZhLFzCndSwjDKWsn/chn818i5kHHAQlT2Rs4lf/pPdtEjdpB1JD/wNHkM3j++dPDf29xikjDK7DzH3sHn7/2jJWHFcx4cIZpDhLOeHNIirvAxasOsCJxiJKezOJr9nKvgNLWby3Cps3nECrl+qZP+X251excV0+ujMvZWLdm1z3l3W0xJ7LlRH72Fli53hhHXWb3mDm4R6cHhNRg8VI5T3GzXe8zoING/i8ewTnTMkiOVCDs6Ubp86DMWAIE8ZdztVTA2jc+hcuue1lNqzfgHPc9Qyrm898OW9rdjndxjRCnFXkrXqHTw/bcHl0YszHkV49mzmrj5DfXEiZfQTDm5fyxBsfskK+z0jxUrN9JzmuGEZMGEpixdtcccsLrF2/BvuYS0luPUz23lKa48dzVkQR5RVVbCoWie/5C2/uqaetqpHuhCmMSQhAWbfGVrCPcnMy0UlJxOps5B2oob2pmwk/jKWoOomxkW7c1QfZ2pnGiJHDSE5KZVB4OGEnHwYRuDuOsu6V27j+T7NZv+ZzsoPOY1rD6/z0la30JJ3PBWxj6cpVbK9poqFD7yMwXat+xdWPzpLyK9ljvZCJnVvZumMX+yt6ifIcI8cRi0GitarZd3Pb0/NZtaudzEsuJtNVwAnVKEbp8inWDseavYJaazjdlXkU5+VTGzeekcq7nB3F1B38jNfyQulYtxvjmGv46S2XMynOgqE5hyM1QpjUJlLiIlGnjiDT2IU5NI1BGRdx5WUpNC2cRdOlD/LbB27iZ2eN7CcLCup3kHNgN4sqYgja95TItJLa4ho6IscRW7+V7ZvWs7WkixCzCkPGWLTNNvQV2yiKGUx4w1ZmbVETmvs2b2/Jo7qxC0/cGUwKPcr6Z37F795dyaptNagSUjBse5hfftbB+LMvZnKa1UcYmnd/xOx5m9hdXS62IgiLzUNfzjwWHKigsamZZmWzaYkdPoWpjqU8N3c3Oc1RjIg8weqX/8Ajby9n9dZyuuJHkVzwIR+tLxC7U0ylI42wyl0cLmiiO2kyZwcdJKeiiwOFrbRueZUPsrtxucWJDRpPaumf+dXNLzJHdHhZ2yDOmDKSdEUXPCdY+ex9/Pr5hazcb2PwGVMwbP8zr+8spbKwio6IccSXzGeuOMQDlRJtmhIYPvEsJiqOojOfyn1L+LQmg/B9j3DVq/uxDBG9GRNPkIi9L3s+c5bNZdneGhqLCjlYX05dWTHNgZOIzvsTd/3yOWYr7enIYpQ7hxNS1wIp2+u14NXrhfBuYG9HIKnDhjG6bR7vV2ViLF7GltUb2VlVRrktkuDGCmoOfcAHMkdsbaLzMSnodjzAL2SeL5K6V/aNY0LvNjZt3sDO0h4cxhiyJpzNlGRxnl2ia/sW8F7FEMIOvcgnu4+Re7SMNrEDqYMSiVFyHRTvZMvKveQRTeawwcS0bmJNTgX1RaI7USKblk959tZ7eXnxBlYc6iNmynlMjZPO99bTWl9HRYCSDvo9brjhKZZuWCbk9zomhzdx/OBBCusbqO00YxAf3rzsDq790xzWr/6cw2GXcEVMLaWGUWTEh0iQ0K/CCgJishh/7nAmpUdivvpRnrwyUcj4cpYdLKUqr4LW0DGMtK9ja7mGxqoC1n34CI8fiOIHl5zD0Cgtrt5Oytd9wtyNYqfqXRjteWQfOEpOZRFlEoDoq1tQtR+jPDqVwOqtLNhjZHRoLQXGMUQeeZ/Z63aSW2vDaR3MuElTGRXz1fb/awlDqxCGbiEM3yI1tJ8wfI9xqghDZ00Vba3CgkOCyBDFj0iZSJamgF0tybi3LiDp8dm8cOcPsR2rFXu2FtN5t3PdXbdzXkIXu/a6SQpqpzd6IlPP/DW//fVEwr0ddMdMYcqkCWQacmn0xHIiu1Ei6iTufuNN7pgWIM7Yhm33m5SnnM/4cWPIyBrFmcPTiJNwQBeZSJi3kv0ffsaGBivGYAsB3S2YtEEkxIBx6JVkOvbjGH0vv7n3EtItTtbPOUHSsKH8Suq/6wwLB3bZceVsJOPlZTx364U07inHYO/GfMZ0Moefz/kTAkkePYGEyXdz+3Q19YVlqDVWX/2moTfw4wvi0Q+9mh9ffg6TYwvIrdbQZleJrJ0k/vIdHrmwl73HghmZEUmgOOTu47upDBXCkx5DOCVs37iKlcds0NPEzjVqLrg8HlXZFl76ZD37sm1MuOpCJg0N5ct3XjuPbmXNkkV0Zl3BmRPPID49nUmJeunvOUwaJ8aqtQjL2Xdw74O/56xkPTtemkt3217aBl/BWZOnERmbhPXACSa9+ioP/fxHTEltobbFRLs7hHi6cQeGkJ5uJSTtbEZwlCOM9H3mksX00RL9tLlYu7ibzNRIJk4f3J9d0t5IR3UluZpLuXp4H6m3/oaLhkUQohxrP86G1evYVNKGSz+IyWdPYIr0qfKzt1h6pJcOSyiG/KOox09jSGQwX7KzIrBy6pu6KHVGk6EuIeCaD3j2pyaOn9BRs3QfYx59kD/+6ibOGu2io66Xmm4rSfpW1COnMERdxc7jJjwFR5nx0qc8ded4GdsIKlZ8QoXdSeDoc5k0cTLJCaFkpYSjH3kp545IICnMjE6jIvvt1+i+5Pe8+NiDZOg72fz0RhKnjuGG557ljh//hGunWeke/CBPXZWApX0nZUMf5v6HLmX0sZksOdBKyITzmDxlKoG9rVjqKpgyezFPXD+WvBUNXHpxLOrpv+H2KyYwPPgYx1qs5B/tIi4sjNvfeYd7Z1g5LNFgz47XKE0+mzHjxpKZNZrpI9JJDNbRVVdDS5MLdVAIgzNCMQtxGyQkQv+D93nuF8EUFuooW7OD0Xc/wp8f+gmZZjVtvXGMzRDp2ptory3hmGYCQ0PtosdnM23MUAZFWAg0aOgr2UBp8Dlc+ZMbuDATWkb8mpeuj+Fgtp2ebS9Le85k9LhxZA4dyxjdYdRDf8KP77mVaeE2alqjufTqkZhGP8SDl1kwNWazpWc4PavnEPqzR3j+ofuI7munRgh35PQzmXDL09w9vY91a1ro3f02lTLPJ0hf04eOxnzsAFk3/I4n/ngjI4NUNHXHMX6wtL+vRfovUbQ7i0H2vXjOf5U/35FOZ71HnFwCGbE6rNEazBljSD3jTn41qYW6ohOofvABz/3cQm6ejvrlr1AelEri2GmMGzmW4cOyGB1nlnlYS2tNCYe8Y0jpq8RkDiJKqSvzUlJ72km95Cbu+u1vZa6r2fnyLLo6jtAx5HLOmHgm8RkpnBNUSo5qLGnJQhj+/ueelkIqSsrINU5jirmB5sIddJ77Ds/dFktdlZaQjhK6gxMkCDITnhBJ7NiLOUPGNj7ESF9TG/sW7mPSB+/z4I8vJWb3fLqm38qfH3+UQdoOSlccJHFMNDoZk1QJio5VWRkVXEK2ZxSdO7Yz4QEl++UlQp8MOLyxDE/56t+ivpYwNA/cYRDCoORhUNzm32/+tST+C3CqCEPths3k9ekYfrY4PJ2GzqBMsjxH2e8eQ2bfPooa+2hoL6ZYnHe8pxtDajIh8TrsNXUcKbcyOFrN4AuvYPrYNJKiInwrYcZKFPS7dV1Eu1oIi0qgtSOAGEceefZ6ib5PUGhLYVxoF4FTf8z5507nwiljGRJn9SXScbSUUN7oJmTcIEJC2tm/vIvQriK8l13C2eEd1AadSXJ7Jd7EFOIju6kq76GzQUOsuYY8iSTylfrtKYw255InxrextZCS+mAGjRrGCPUuPvw8h1J1JJM1ZWw/6CBcQoq63btxXngx54Z3UhdyJiPiOijZdpCyrghSAyqoa3VT1R1NmroR15BMojqPs6cqkUnD+gmD7fhqNhbUUd3pplcM4qHtq1lzJI/8QyV4tVZCzxxKYscJWqY+ywOTjnO0IhCLWY/G66DDaSLIqKK3pZ6Odhuh597GVTPGcc6EEUQHG4gtnsN96/sw9DZjdjVytL2Kkvwm7L3BDEs3ETLjFn545lguGJeJtWY3e5qbqW0QslJxkDxNOu0nWjGr2kg4bzyZehfNQWMZ6c1mv2e0RJIHOOIZRurEDLzZH7L1iJPBU3/A5HTl9wiByLOt8hh7HCOFsOyhLnqEb8XBIEXNanZwuDOBhBnnMSy4h7Jsr+hhJ/bU0QwZ0saBHRompBxjd46D0roWOrqcaCxBBJtkkDsLqaqp51jvENGxMuyZEq278thdHEayo4A66Wdhkxi50sMUOcJw6KNI6MlmT0kLDUVHOdE9iNGaKqrUXTQU7GFHaSiRagfJQzJIuuA6fjBtvIxNOmE00bt/Nr/eH8uPpqQRKnLuLt3B0aoOquxVlFVBsMqLVV/M/l4NrqYa2ror2b2pFmN4KFG2fezqzCA2LprghjxaDfFkXPoTLp88mjMzrNgq93OoRkNTVTHVtmjGZfZwZGchDc4okvX5lHWY6egJI8Fxgty+JgoO5JDXmcLY4E6sU67hnPPO8um+kllRuVPVuE0ixhYHgy4QImF0Umscz5CeInoyR5NKAXuLg4kTEtpr7KSyUcblcCfamNES4Yqj6BWnWHaUPbpzmR4vRL54Jrevh6GZWWRF6uktzKXSG0xopApdaz0NIWMYJHRxT2kYQy2tBEz5EWefP4OLpG/JnVXU6SOIFGLaVVFHnTucdH0Bmza3EBUbgLV9P9v7xpLiyqW5tY0yWwWlQqqtTg/hcUFo0+IIaC5kv4zLiBCZ59N+zIXnyTyfNIbkjkoKOySa78hlb3YbRI5hyiCZREJO2yty2O0Yy+COAvoGjSTNWM6hAi1h0ckMEsKAu4mSQ9nsO+ImLkSPq6YC2xAhEB7RnSIhxp5mwsaeyagLLuPiqeOZOFjaodzUslXRUl3MrrZMwo5uxqW8jRFro9k6jbjefCqq8snrrqG0oBWnPYihgyyEnH0zV501lnPGphPdtofNvaMZau2mu7sXu1ohYQMORllorqKMEwFncUZor8y34zSliWz1JewvksBEVUqT6G9v1GCmaU+wb+Ma3qsfxq1TolC5emnJ2cTuNhttNZ00V+ZQ1Oagvq+a0govIdL4UEMte4saqZPxK7EnMTmogAPe8aR0lCkLs1NTfVgItJvgxBGMTlJ+5vhHfKufJJQ7DP/kJwmv7wcJ/1oSfgiSz0zBVb2dJ3/3Lh/t6SAh3II+IJL0pDAm/vA8Oua/xiN3zsSemMyQC8cRYFSykhkxBUYyJN5Db+UGnrr/1zzw27/w0a4aDi37M3/64ADBwXGMGZrpW4t/yplxGF35PP+rJ3hm5mGChyUy8QdnU//+4/zhjtt5ZJ44547+9nTlrmDmU3dy56/+xAcLTzDupnPJGqnm0989ygPvHMEjZDAqPk4mk5LL30KARAtTz03C7C3khV89zp8/ziYoM0HaPoOGj56Tti9CO2Io5u7FvP7cSqq7gznnrCkEOZppXfkWK+u8ZAzTMvfhx3jg3UM4PSpCUzKJr1jP9pUrOVgXQkxEODEil4DQKIKFVGmN4cRFGCVi7W+zKTqAio0f8davH+EPTx1CNe0BVh7Yz4FtM/nwd1E0lEuEp40mPsxAwsU/E2dixLDmbeauWsXK0v7HsEJGjGT42FT2P3Y7v/rNQ7y0Np8DCx/nT58cIjJM5JVp5vCqt3j69j+ycHsVkx/4OSPG9Je/49d/4LWddaROjSf741d5+M5HmbWrHYclmhnnxKPrPsJf7nuF1zc1ExsqYxcSR2yQHkNQDNFBSla7eIaKPIaP9aIdHuVrjw/Kg2hBscRJ9GuJiBGHq/siqVKo6E3hBhY++hAL93UQN0LP1neVcbufBx9bRvAZExj8i3sZdGQBsx65m7ufX8iG4oFHPXVWLEGRxElbLOHRhOi1qPWhxEYFMvWSZPJXzuTxOx/k3ZVldEgfsqSfESFOtj/1J554dz+6uEAmnBfF5tee44Hfz+dwfSeTb/whcX1VzP7N7dz17KfM25rN1o+e5pUNzZw9LNWXflfB0GuuICB3Lc/c+TT7Gyz86PHzMXuKefPOu3j4+c857AwmcO/7zN5aJOY4nqQwkYFb/NrFF5LgrWeO1H/HE++w2ZHA2DOHkfPkH3j84e1Enzua8DETiM1dxLpVmzjRGi6EL4TJ02Ow6sp4SfT5qQ8PYh4cz6Srz6dl1rM8LLr/4Ow9FA08cRc/NRl9ZzbP3P8qb2xpIUGubY2KJcQg8tFKdBsRyPRLUyjd+BkP3fU2K462EKSsa65ASUcenkKsppmcBQ/xh5nHyUiQOSsOXoHGGk5IcBAWowVTUARRARo0+iDSBsUw8arzaZ/7Eo/cLu2Zs58iT7Tod7BvngcGBAtxSBBirEa95U2Z44106uJIjjQz+fpL0R1ezp/vfI4TPVZGXzMFi8VKoEaLVhfEkOFJjL/sTGrf+xO/k7ofXZhD8IRU2vYv4eFfvcni7EaCYgYeCpBr6X26picgUnTNpEMjdUSGWQkaGDsMKUS4m2lf8w4zj/YJqYsjXJiWWidzVHRn8k9/gOnoOl6+63bueWUB2yqVsEqgtaALiCYzJZCREwNY9tTj3PfaXjr7IDUjmKqdc3j1zsdYtq+eab/7JcOHxrH3jzLOv3mY1zfX0W1OIjlCxqJmKyt2ZLO36q9PHIouC/kPjvGtUqvS6qRNsYSZtNL2EKLCArCExRAZFYehcCPzX/mUjYU6LhuT5DtVG2Jm+JQQ1jzzOA/c+RRHE8biKdvNC3c+yd5aA2c/eBUh2jY2Pvm42M1DeMLENocKSQ8zMuX8OI4seI/f3fsxm0s6CI7+0sMV/yIUaX3T9l3hT9z0H8KpS9zkxtHbg83ulolnwGwyoPW6cCkPpald9HZ2Y3erMQYGYlR7cMuFlTSqXo+H+tzjZO/YiHnCaLSV2aztuITbRJFDA0T+QhTM4l0UB6+kXFUWGupSFhdQ6zAFKOmn3b70rn1KfVLWoqR5FrvgcfbS22vHIXNSrTVgCTSjESbeqaSGVWkwmgMwyLnKd7X036OUk7H2uOxSv6O/fovUrzlZvxqTNRCdp4eeHpdE/KIvFgNq33VcokBiaNVOqb/3r/Ub9SrcPd30epR1GHS+drm8ajQiK68YQ43Ix5d+WA4opNzrVhbD6sWpvPqhEqMRYMZ4Mkud10GfS4tOpaRnFocrsnA5XBR8/D5FCUlknn8RQwbKKvV0d/ZIObWQEuX31B6ULMOKLO1rX+PzngjCpl/KWaEm6YMRtZS3SXmnMH6tKUCiKQ+2bvlb9F+vtFuIiV5UwtXXQ7f0VaXV+x5Q1MkZTvlfK/+75X8ZTnJee4X82CTG/OgqBvtaI1BuRXqkr14x3l6n9F0+Rdi+1ooM+npFhkpaab2QSCET7t5OX3sROZoCrb6o2dndSY9TxksiGJNc2ycXr/zt9uASiSqy9NUrLXHKWClpdHt6enyLOel0Svpv0UeJilQyvjaJ7lxqrYyROD2Nk24ZMyUbsSIrizgYr13pp0OuJWRI+q9x2nxjaBTZGHQnf6H14LB1Y3N40CkyM2pFPhI5Krop55nMerzSL5eQJZNO9EslzlotY6/y4pL6bb76ZYyVNojedHfYfLK0BAcI8fLitHVhRy86pOinCFbk5XX0Sv0OvD7dVHRDiLZvXonu65W2Sx99PlFkYJeyMlZqGSuTySRz0em73pfl0yu6ZpeOq2V8zb71QuRU31hJGa8IvU9k7lKJ7AIwKWt/KIeVhZaUW87K+MncVVJ3K3W6Ra91GmlP10B7lHkrY6TMcaWsV1kkTOyKVvTYbuvzpc02S/vdPl32/lWWerOy4JdSXiakzBGVtMUtV1BsSE+nbWCeBwjxUPnsTa+co9gbRSd8D6P+g65J+1SiI6LLarm+oqMKPCJLu110xiC6JPbob3RHi7THRo/ML6/YDrNZ5pBiEqVu38JkSptxyFzvkTPUGJS5Ln3vk/b0+eRpIkDmlcol81DK9M9DsU0D/dUoi4zJdZSxOZlWvF+X3VJWL/0QfXGJnKVNWrmCS4IPjfLAoMwHj8shembHKeVMyjoaJ8+XOazYHmVsFLuhciqLj7n657PoptLfbpsdt+iOUZk/Mv4u6YViT2y2Hhwur9gHZf4Z+vXg76D4yW+bGvrkDPl7nMrETX7C8B/CqSMM/zrsxRv48PFbeOOwTADzWH768sv8amo4AzGPH18Dp0x2t1bjWxjq26hq+6q32KBOI+m8C5jw1Q9Dfwe0sO6ddfTFpzHj0olfrKTohx9+fK/xjYRhIDW0Sdef6fGrcCrXkvgKTuPH/woMiRO55vElzPp4Jh+99zg3jgvlu98Y+9+ATok0vyVZUBB4xnWcP20Kw/5PZpyVyddcwowzRzLw9IIffvjxPwKfDZL/vN+0+Up/N/gJw/8wVHorEaljGDd+HGNHpRJm+Gcc1Y/vCk1gKEGBgf2rdZ5y6LCGBhEYaPSPnx9+/I9BIQL/rp8J/IThfwnly5m1ZDmzc/4vc8/64Ycffvjx74ISJPhSP3/T1l/8O+F/njB4PV7f+v4Oz6kR6L8bPbm7yDl6lPKBv78WQYMYmpHG0OiBBDynAp5jbD7cSIOSNdh7giWv3sUdz88le+CtiX500HNiKUuPddHs5yp++OGHH6ccwgm+djsVOO3zMJx06HafU1eeelbxD8use5Xj4rvk2Ld6WHKgvFs+TaEWJokDjVG7qOwVBiXnn6zC7fag5I3XSL0n23OqoAygUud3zcPgzlvOh++9xCsLdnO8sInQ4aMJbd7Fp8++w6JNW2kPG0tilBG90v7uGjrVIWhsfTTseovXZi1g/aZS6kpX8+HCrXSHjyK0diXvvf4qn85dRQGJDAr3kLPqbd78bBU5pWpiRiViqN7EWw89x4dLl7Dis494d9Ya8jQa2jfM5eXfvcuKQ61Ej5PrxhjwNOaz/0g7AdUrmN85iWEJFqS7fvjhhx9+fAt8Ux6GeiXTo1bve+Or/3bD325e3LJ5iA8eSnr4pIED/xpO6zsMIiO0FgOj04O4ZlQw1w2xMCoQnG4v3eLJux0eeuR7n1rHmAQjSWYVbqcXp0uOKcflu3LnwHXy7y+VH62Utwg5kX1OISJKnSfP65KtT4QaGm5hWpQOZf0Zqeq0hPJqll5nxKTuoKq6kPVL9rD7k3u46+lneOaZp/j529sobRt477hqI9uzj7Fpz34O717DjuPVlGWv4bM9xTRW7GPd3ipKtq3hQFkdTc5q9uzOpbwgn9zVr/PsM8/wwLMfsvZwK/kb1lMw8GqY063FqFOImhtHvYPMS3/CzT+cQFj1PvI7OmiuOsTG7HacKgtWo/J6W39T/PDDDz/8+H7htL7DoNxdMEQEcnGamcHi3K0BOqK0bkpsGkanmBkRpsMkTj441sqPRlgYpPdQ0eFFYzUyMc5Aolnte2fZFGxmYryJIaE6LEIMQmKDuHq4hcEGL/Udbhp7xdmp1YSGmhgdpScpUCMOWMrFBXFxkFyvw0VjH1/5nuy/ilN1h6Er9xiOQZfyi9/9lqvGh7D5xZU4GjbTPfFGLj7rDIaOGM7ZWYmEKKvjNB0mtzsaT08rEbHJTLjmXn46vJPSjHt58ceRFBabSOhrJvO+1/njz6/G0FBP1Z4iEkZkYI2PYczQcDr7RmAtK+GS11/mtiuv5MpLgumJuYlbrziTc+Pa0U68gFHDUol3d6IfOY5ERzW51YGMsJZwRDeJkQlmQk7hLyJ++OGHH//N+MZMj/9fa0l8tzsMpzdhEK+qCzQw2AwdHQ5qXRL1CwlwaM1ckKEnLkRIgM6DNshAjDj5QJeLKqeWwRnBXD/IzJgorRAKF46IYH6SqicmTByi24FbysdbtQQ7ndTrzQwP0xInDlUXE8INcrHRMQYsPXaq1VLO6yC/zUWrU8mbMNDoU4BT9pNE5W427drBjppqCo+W0aNJZ0yKF9WgC5g0KoOp48aQHh3Qn1yldicHW4OxdZiIN4sSRlmxNhZQEjiJLM1x9pSFk+Y+yK78InLL95BbZ8Vc34I3xEtwVhyRUkVX2DgyO9axqqqNuoIG6UQD+1YeosEZQWhHHtVOI9qQQLyl+9iUXUTB8XxqSWWyNY+96qmMTvT/JOGHH3748W3xrQiD+KpvIgwJwcP/+1NDKx1VmfUMizcxSCuRfqeHkBA1x4408WZ+L8ZwPc11Duoae1hXZKNJpSUj0Etjm538Zge9Wj3ePicFZR0srHLgkB6fqLBT0dzDhpIeDta7BjIBQm+vk7YuqcvmwaxkWBsgLaczzHFROOsPs/q5N/h8ezUTbr2SsedOpvb9p3jqkcd4bV0RTSfXdw9M8KVJTogLJTgiWshXIKbwJJKDtRgsMaQnWDHp29i/+F1ef3oO1Sorl/z2YnStR3jnL/NZcMTFpJFhDBkbwqaXXuK552ex1RZLfMseDu7N5oQnnoSIMFJGDCbC4uDABx8ye2MV1vgQTNGDSFPuCP17c1P54Ycffvz3QvyT4v7715H4+u1UuLLTOtOjx+3FLM7mmhgVPXXtfFrhJizcwuQMKymd7RzQBvCDECerimFEmpbO+m6OuiyMjlDhauhkZ6sHj1FPamwAU7CxhQDO8naxuE7LmVl6XLVdbO0xc2YEBGi8VKInoa+HOpOFTEc3W1RS3tPF0lI7hTZp6yl0dh7p/qnJ9OjF41FSp3p852sHcrD6UpwqyqTWCis9yT2VJUjkm7Jfec/Gt7d/n+9bn43yz55iTfK1nDFxGJlmje+BTyVlrVupTK0eqN+Ly+nynafWalEr6VW9UocwLLWinAqE1SoPjSplFFasXO/kdfzwww8//PhmKH7y22R6VFJDf32mRwn2fKmhfy17/nUrfPrfYRCn093npsupOBxo7XFR3O4iPVWIRIKWymobJc19VHi0jE00EWjvo6BHzaisMG4faWVqsAq7002nnO+Szy6HF7fNSbVTywgpnxWiotPhobzNSU2fivRE5RywOT30Ofqv63O8/c05DSFOWiEKokgnyYICtVbnUy7tX8mCgv7v/T795N4vjqu0Uk9AKCFBVqwWJRd8/xGVr37tl+pX+a6nk30KsVOOa+TYX8mCApUajZAJrdR58npfOuqHH3744cd3xYBv8m3K93+6Kfb3u1vg034tCZU4IuV5PSWC7pUgWjlLq1UTrBcHJX/12N30uEEv4X+gROzdfeLg5ZwgvThSuYbyJL9dhKWXsg4RmPKpvFKpkfMDNV65ltStvK4pFXskgrYqi9zIecpiJnYpb1DKC2NQfrI4lQ7v1N1hOIWQfrt7u7BrzRgUgnAqO+yHH3744cf/F77xDsOXFp/6xrUkkv4H1pLwutx09rnpFseudFNpsFsi/7pOJzWdLjpkv/ABentc1Eoh5bVJR59873BS3eWiTQiEcqeg3fHFp3IzXVnpUCnfJYRDed2yV8nzIOcp9dZ2y3lSznGy/CkmC6ctVELUzFYsej9Z8MMPP/w47SF2Wgmilfvv3+bfd8VpTxgUJ6ZV/22yJuW3coPsUDad7FcOKb/TG2RT7kyoTx6XP5QHGpW/lVciT37+TXmlbtn+/ry/L++HH3744Ycf/8sQd+jH6Yk2OnuOUd3SMPC3H3744YcffnwJA3e/fU8oKM8pfN12CkLf054w/J+t9aA8p6DUO5AE8fSDAZ26D3fnRxwpf5/qk69G/j06j7Pyrd9w/XXXcs+Tizn6z8p9GziOsHZXBbUt/6JQWrNZ9PLdXH/NtTzwwiryZcygi7bSzbz2+k7KO52+YkrGydceuYXrrv4hP7zhad7b2So7y6g4vJbPS5QCfTjqt/PGa1vIretRdkDdFt54Zx4f7GqSduZRlreFBZt38MlvfsSPrvspP732Oq59cCEHGr8sgGI2vf0pb765h/qBPX8D11HW7S6jUrn836CGyoqjbMvzdeAb4SjPIXffdnIH/vbDDz/8+LdAnOJff5JQfcPWf8Z3wmmf6VFnNTE6QkcELsptHhw+J68QCCWVc/93jxTuf1BxgAQMSEZ5LdP3bIKU9Sq/z3s99AyU6VXrmZBoIFTtoanLg1rTz7+UVwF7pYxv3QqFk8k5yjoWyjkuOa68CaD8fPFdoTRR6eM/T9ykQ6cJxKjtpc3ehrc3jzabDa0lDkP/awf9qFrDur0l5LVoSDD30Rkzhvjyhfzl7QVs2laJJiWdJEcOc99+hQ8Pe0hKC8N+cCmvvT+fncXNhCYOQVe4kEefepF5M2eytmskZ4xJJSpAuUY9Bxd+xLOvfsyOqj6CYgbhODCT9z97h/mrajBlDSfOquWvj2qWLWfFvhqqvGbCNH20BE9grLmTY7NfZ+nhcszTZpAu5bV5M3l3azOt5mhS9fU0eMwyNu2oyvexXn0WZ4T0UrrgLebvOIZ64nQGRZjRly2V9i1ho2sUk6LaaM4/wHrbYIZ0Z1NZcoQDrmEMyhzF2TMGy7X7m1Oxfxsb311HQ2Q0KWdkEe3ba6Pr6HIee+ol5n/6Mavbh3NWRAM7Vs9iztJt1KlC8LbuYs7vH+OFTTWEiPxi69fwwrvz2bCpGFd8KrFhJhmdL+AuO8GO5W/w8tItZB+wET0+iwj7YWY/8Sxvz19BddAwNBV19KmddDfv5NiBbJpDB6FrPc6BErW06wQLXn2X+es30hwUT/OOQtq1KiKtleTlN1ItbTKUruad12ex7lA+6thRhNet4+WXX2POpnaC0pNJDDZA4x42HyjgsC2WzEjtQOv88MOP7zO+NnFT80EabN8m0yMDmR6/W+Km05wwgDEykHNjtISq3LRbLJydZGJUlIGMID1piWZGimE02l30GQyMTApgcpyRwRYVXvHqweEWpsQZGBSsQ+9y0WkwclZqAOPjTIyID+D8DDNZFmhRHqC0K0t0qAkKNjEjw8LocB1GhxNHgImJSRbGxRiI1XqwKQ9Jevrb913wzYRBoDKgNQzC7NpLfd3rFDQWY9MPJsIcgU49ULYjn6NFzdR1QGxEFHETxhGR8wI/uu8ddmzfChN/zLiGD7jppTU0xl3Kj5OPM+vB23j0041s3lRIXVgWqXnv8skxF3qJ7DXJZ3P++BS5hoqWQwv4fPkmDnb30mFXS9TvRFfwLh/nuvC2NdIaOo5RSUFYlAdJFIgDzM5vol2TydAxwxkRG4PZ3UD27m4u/mUUBVUxDAk3Y27fR3nyjVx/5w3c8oMYuipqOLavjWFJKirDxpNprGPP+nYuuiGCspYYkkKCCOo9SocIrKQjncSuUkzCClqTL+fGa87komQXtvP+zFNXx9H++eu8N2snVa1V1HqTSI5O5owLYtBFxBMuTXS2VHBk3rO8e8SBTuVEm3IOP0gr4uOH7uXVxVs46MpgbFYkHQf2kq9OZeKUYSTWfsS1v3qNzTtW0TPip5w1KhLrl4ZK1SZjcGwXe8sciCLTYUnFmvMRy/ZV0+xpoKI7g4DspTQFqjjeeJS9q/bQ1BFHdO8+NraEot3xG276wyzW7tjBSvtgkvIPQVoS7objFJU00WRxUPjKz7nt1ZVs27CZE+Fnc6lnCS9tbBJ9SGXylEySQ4QwdFVQVG/HZklmWJSfMPjhx38DvjHTo0IY1MYBwvCP2xepob/74lPfg9TQRtINEvGLoCLjrFwWrUFt1DMyTkeAsi/USLzDQVtggJAJoxhOPelCAjzKnYDoYK5PNzE0Soept4/W4CAui9MSZFBhNGgIMahRO11UtDoo7fZgtBgZnmTlXCkTHChEw+DGZg3kwng9seFSt9ot5MJBmb3/Ycjvgm9FGOilr2MBx6s+pU13KTGhiei0yYRZotGfJAxd+ezZtouddU4MIUOIM5oJdXYQEZVMZpIazaAfMEwIUmjWSIaPmYxu90yO1PQSOeMaLjhvBhHiV4I6ernm44+470fx1JeHkBYfRUSQmsJZH1CVeiGPPPkEZyWrODJ7G6mjwon92dv88eI+9h0PJCs5kpCAk+Qlly0bt7J6dSG6xOFceUk6bcc/45l5hbhddaz5rJPRMwYRrzrCgfZ0YpKiSNC1UlDYRmd1F+nS3krTENI6F/LMrGM4PI2smd1CxvihZAQeZ797HMFONTFFM9ngTiYgcSKTLTU0FWaz2zOBYZGdVG+ax6pdZVQcWM2Jzm7K6+rIyy6mOWwQo0V/7FU1HNpdwhUfzuT3P06huSIQTXMj4SnphCdYiU4YyehJ05kwOY3I8Xdw02QVNbllBEYmkZWkQSfyHC2EIvJLtxgclfso6w1m+C0vcO+ZPaxdZ8OdvY705xfy5A0X05ZdSbz2KF2BfWyrHUKwOgxr0XE0IZGED4uhctHrNA69lvPPPoORI6Zx9fh2ukMC2bjOyaCkNDLMx9i5aifaM27gkrPPIyMjmqnBjfSc/TyP3DGB4QpZUBCQSFpqup8s+OHHfxG+ljC0HqSxuxidxiDh7ldThn7C4CEheBhp//WEwWpkiLk/V4JT/rZXdTKzwk1QpIeDuzvY69AzNEAcuUYIhDiINVUOOj3iVMxqquwQJ05e+Vnb5HHjCDTTW9rIp0c6WFqnIi3ES3GVjc3lLtRiY8MjzIyI0FGR38zSTi3nJxkkslahb+lkQ7sKAx5f+uiiHvrXZvgO+GbCYMfRV0RT0266dGNJSvg9mVHTiAmM/YIsKGjYR06tHs3Q6YyK6SZ/Sx/hPfm0TZrEaH0jteHnkxWjIq5kHo+vaaKtz8z5I+PQjz6PM0ZkMjUtFm9FNltrKinZvpm97YOYMjqJSImG+1qOk5tXyP6maopL7Oi1ISRa7dgHZxHdmcOu8jjGZkZ9QRgqNlEafgVTr5jKBMNR1uy1EJ47l4WllVTl16PptKE+60xGuo+xems+uaW1tB3YwtHOMBKGRxDtbeJwexrR+z9maVkxxXnNqJtbUU0/g1HafI7XR5MxPBJD4Rze3uQm63y5VnAznSX72eaZztTUMLKmX85VP7mKwZoyDq/bS86RAxypcKJLm8CFo2PQ9NloPbGP7dWVVOzezO5muV5ZDra0eDIT1HjVcQRmpBFSvpkNW9sINGlp27eDxnETGWdupj50BuOiHLS0dtHtDSDYpBLCUEZVcy/qwckEN+exvzqSkdZ8cgobKKw6Sll7JNPOHok7bxsH8iMZNSoae/0aNnA+N0yPRN1QgyPtXCaOz2La2NGMGmnm+PqZrMoxMerMi5kQ0ERzhx3j6MuZMXowk4enEtGyhw3dIxgcE0SEsV/8dJVTVNVIjSOIqJNj4ocffnyv8XWEobxlgDBoDfSnh5YDf7cpP64rTzAoP0n8168lobxWqRPPqtOocXoUIXkwyHe9sp18BVL6rxIPrDbpSQ/TE6n3igDVhKq91DT2kNst4pLjNmEcyoqUo+JNZAqh0Gs1xIfoibWofNkclbp7hKwkRJgYEaLFaXfRK/t1ynVk00s7FIEpzv7/Hj30upy4TDcwIe0ekiwDu/8eoRloxbHvfPMZ5q6rYuod55E12sTSp17hmSW1BBrV9B74mLfmFmC1JnD7vT8h1mhnw5MP8uBLn7C1Q8egURbWvfgWr36YjdOixzJwvz3p0ktI0Tay6KnX2FWgZsJPpxIUnUiEXkieJZbUuACM+i8pX2ACEQEGksZMJGXMWViKK1DHX85nW7azc9dmNn80lTC3mg7S0JRtYMNbf+bPsxpQxU/n5+cmYw6NI1jG226dwTvrtrN753a2zruQVHGIDbY4EoXQBaQNJ2va5fxkZAByeaG8JgzhqTLu0qa/arOazJ/8hXc37mDr3Hks/PBhfn/jaISSYYwOYsjYIDa8+hYvvrMXu1nPmdcPo2H7Up55bRtHGiA1PYFwvRvPvvlsb9UweFwwG156lafmlfnIrenAPOas3cbu+v6HQzXWMEKjYwnT69GbIxk2LIEJP7yQvrWzefOpdRiGpJIwcQYJ1kzOGxnBhPFhhKWk4o1LJDYilrEXnknrnBd45sGHeGHlCWr14xgten3GcBNWYcvGoWMZlhXH4RdlzJ56mVn72nAGpTM40oj5C/sBbcc4kL2PzaV9Azv88MOP/3ooDukbtpNfvytO+7UkTNFWzgvx4pTv7RotkW0w5aWFAABddElEQVQ2djkNnJGlofSwjZawQGaY7BxTmZgUZyLF4KGhtpNVlQ6ICub6BC24XBRWdLLGYeKGDBOhOhdHj/VgjzYxOsTDnuOdrKxxojIbyEq28vMUHV6nmxPFbWRrLUzW9nHCayBV46K6oUeciLTry4b6X4BHuv/1mR775fNt1l/wuF24PcprJBohN1KH14NTWetBpcaXmtnjxiWH1cJOlbwTcgJOl9t3XCPHNXKV/vIid5Gxr8wAlHUkXFJWJfuV1NC+cZNyylImXiFXCqn9Av3EzMd0BUp2TpVa/aUy/ef4Pj3SZhlTr7RZaaPvknKy8l6CQv6UXBsncVJXfBi4tiJAr1K3sk+O++T0xSnfAJGPo38tDCV9tXQLt+iINNcnI18KbJGhkl1NufWkkXHyyUeIiNLW4++9Q/WIUQyfNJmE/gb4+u1rm9IWXxvlKk4hfNJfJa32yf75IN+VPnmkvpMP0Lqdjv4U5ANyVsZMqUe56+QrIu1R1u9QHsRVK2WUJsr3v+mz0mZFsUSmShf88MOP7zcUO/F1mR43F77N0YG1JPqtzj/iVGZ6PO1TQysW8eQzdcoZikF2SYcVv6gQCp/Rl/8Dk0K5PtRNYXU36xo9vn2K0zFq+424QjgcYryVv5W63S4vchmf4VUcV5/iqQRKsibTwDnKGxku5fpSl7hM390Fj3J9xSb3F/+X8c2EwY/TFS67RPC+tTX84+WHH3783+GbCIOy+JSPMOi+RWro5P+B1NBI5GyX8FhZz8GhfIpjV55nsDskShSnq7wG2eMSIy77HMoiU/b+haaUaM0l5Tt63bTLScp6E16pq1uOt8s+mxRQfoLolGPKehKKCJVNiYpPnuO7llK/HHfKp/J6pfKzyHclC358v6E1GvxkwQ8//PjPQomglY+Tzks25fs/3XylvxtOf8IgEb5yi1y5K6BE/8qnchtW2ac0XrmLoBPbbavrZHFRD8dtYNVK2YHyOjlB2bS+85Q7E/1/K/UodZz8fhJKmZPn+PYr5yh1+drRX68ffvjhhx9+/Eeh+CKFBZwKJvAtcfoThgF8k1xcfS7qbW46lJUov4VT/yYZ+67n9aL8rv1vHA8//PDDDz/8+HY46esGHKTv+a9/tvWX/E447QmD7/kDl5J9ceAnAen4V0G506AXpqDcDfgnRb6Ar87+nxf+AXKy8lOGQ6UmNjGYa1OUty7wpab2ww8//PDDj9MNytN83/TvVOD0Jgzi2G16A6MHhXDHlAjuGBnIhEAvLrfXtyS1stnd/Q8t9g78rWy2ga1HeWhxgACcPKYsf92nNXBGhpnMIDWuPg99yj7ZlGcg+nRa0hKtXBglx2x95HW4sQmz6JPNd75UKEV9z074rqMc+16TCbv0rYCalrqBv09TlK9kzurNrCwe+PvfDXcvrmNzeW31MU40D+xT0LibzeuX8uHB7oEdpzNEcQsX8d7aHI52Duzywze2ThnbV1cfJ7dlYN/piJa9bNuwhA8O/Au61lNN9Z7ZvLip1ncX9luhr5m2g7N4cV0pNfaBfacTipfw4apdbC0XJ3C6oeXfZxeUOwf9ORi+fjsVlOG0TtykvAURFB/EpUlGIl19HG9xUtMp0b/ZxIXDApkabSDA4aA3wMjElADOSDIzOkxPRrSZMYlmMkxCJOxeQqIDOS/ZxPBIA2EeD1GJUmemhaFGL21eLaEWDQmBWgIseoYEawgKtzDZ4CTXpsbodeMKMPvqn55gJNXgpcXmISAsgAvSzAwNkfb3OWh19Q+INPtbQSmr9PHrMz3+O+DG42nG1rqe6vZserQjCNZ/xQN9rgYKN83iyZc+ZNnG3ZQbsxiWHPg3ayrgKGbT3Lf5dG8HkVmDv5QNUUmZXMyukkDiw7Q+/f3/hrudhh4TVk8tXe0tVLY70TTlcLAnCRlOVE47rUd3UWZJJmIg8eEphVqH2t5CtTOSjPAWimuV11AtBBq7aO2WDgUmMCj8azIs1u0hu8JGkyYcUU9BF/V75vDC3O3YYichnPifoJPGuhqK2kKIln5+Z/R10NJUyrpFC9hd4SEyJZXwbyWvCvLKu+lwWGW+DOz6D8JRcICiDieEBuMTZ18NzcXZ7OlKJj5E9cX6Jt8Gyuu5vS3UuKJkDJsprnGj1lsIaD1KfmUzfRGRWAeK9kMcVPkmXnz5DT5bsIzt9SYiE1KJ/pfl0k5HayU5NWHEhw7s+jKa95FdInrgNqLk6PJav0HXvgqePvpsPbRqI8iy1nKw3ExUsM73XNY/hVaCo26Zd4ST0XOQgwdFvq1hWEMCCNIrBRqpra+npCWU6GDfGd8a7vZcduRpiY0w9bfBVcT+Yi0Ws/Txb4zK10DGrM4RRER4NDGBA/vsddTmnqAhKp6vEuX/Oep3c7Csmya3Ad/qDsGJZIjN+y74Z4mben2poQ/Q0F2EVqOkhv5qeMWHKef/168loeSnsugMxAeq0bmcFAthaPWoSYq3cmakGAWTkWFmifItAVycqMciDjckzCBOWHk/XUucnKeyu+mNDOang0xkRBiJ6uujXqvzZcJT2fooVxnF6WuIF9KgsxoYbXBT4dYShYs2ayDnW910BFiYGqUlJthAlFoIhJij2LQQfpBsZFCU7JMB3dvq8f3E8W0fijx9CINWlDCYAE0zDbZaXM4auns6UBkiMWq+UHRXxT52Lp/DguYwEqw6gpNHMtx1mDlLV7F9ZyGOcDX1697ngZv+zKI6HSlpERSuXMr+0iqcYgGOvv8bHnlvO1XGwVjrKvAG67FqKiksbaPaE+Yztj31jVTll2IPVdO8dx65nnTC9A0cK7Sh6XMRGpdEePsecorqfItthdRvYHnfDM5OFlm6uqlc/hSPzd7Alj0HadUnkpZkpWHP53y2ZB1HajqxxKf1O0evHXvRFj5auJqdu4rpC40jMsw8QH46KNu1nHffX8ShvAa6bUXMn7ucbQVO4pODiYgPp3HNszz39HxWN4UKaYoiMTKEULGY3vKNfPjyTDbtLcXhrmfdho3sFtnYQxOIbVvJ6uN2GoKGMjrcTtOxxbx40208PfsAutQ0ig9u5sCeCjzRiSQEt3NgwWw+nrecDWtn8+msRSzc10n80EHE2Y8w96X3WLJlH7aYkSR5ilk55wMWrK7AHh5LWqT5a8yBCltTJSWb3+GFR99nbVc6F159JmnOVor3LmPesoVs3GcjfHg6EZ4iVr31HrNXbqI+MAbHsUW89ae3mZ2nIjkzi6QgRVedYp/3MvuFj1m+pQBvlIZjKxYzb+lqSlQxRBr11Oz9hJnLN3Iwu5r68s0s3nAMT8QQzNXr+GzmZ6xYu41aYyqpAd0c3ryAxWt2UtpqJjoxENuR5bz20XJ2lHiI1Zewas06tm7LxWZNJLBuNZ998g4fbs6lur6XYJmb9mPLWdI3nclBpWybM4+VO/bQZEwhOjIAowilNbeI+nYbDlUVFQc2UW3JxOooITvPSWiA2BqxE3WrZWyfmc+6thhS7NXkbXuf1zfkUFHqJXJYCqGKvXb10LzqVV49JNGjSeZuZAYjhobRvmcp7328kH1V3VhiBuE5sZKlaxfw+foKOpuyWbFqHWXeZNLNrezbuFCO7ZHI3SS6e4JVTz3Ck8vL0EUL8egqoFYbhNldyYmyPshfyvYamRP6dMaLTpu0ZnqOr2DBinms2d5C4JBBxBjq2DVP6ty8gypPOBExoVi+bE48YrU0YqD0bvI//h1/fGMThdp0hg2OwpN3gnqnl76uHIqP5tASlIahu4ScfDdREhCZwuIIL/iQOctkvnWPZ3hmDMkir+bDs3nzjy/y+vY2YrKGkOQtZOXH81i/J5vukCys7eUc3PYhn8yXNrljGZqqpWTrAt58/y3mrthItmcKF48NQadqJOfDP/D751Zxolfo09HdrFm6jINNXkLTUghTJmZfL/WHN7J8zWyWrK1EnZBOfJAXrTmGhCgHlZvn8fbHK9i7OYfjxzawcPchcg93EpKZQZSmmm1zF4iO7qRGFU1kjJBMn2x6aMrdwYI5K9hfUobdEEHj7lxccVaCeo+xv0qcvtFF7W6xIcs3kNsKkZGRdB2ezxsfrWZ/g56U6GY2vf8xc1ZtlnkymKTOzawvFN9hTOsfK42JnmPLZH4uYf2WKjob97Fk5WYajBmEdpdT3yvOXO+gK38/KxetYM2BfNqknkHhX7CmryMMJU0HqO8qlv36fzrvPUIYlHQA8cHD/7sJg/IWQ3urgxa3l8AIC+NDtWQFqXCa9TTkNzG/TSfOQo/dqcHaZWPp0R7KhCx4O2ysPaEsHCWOy+ihxiPO3iNKJXNP22tnQ41MfrObI6VipLp1wriVnzS8PjISKtFDvbiOeDGGFV4dsV4nVfIZJPXva5dywgrixesYTBq8rTYONzqo7XZR3KXQGxmKbzkWpw9hUKBBpR9EkM5Gd+NLnKjeTZsmhWBznJCGfgV1tXfTKzIMjBrO2OGXc92FiZhKP+C6Kx5mztql1KVMJLCklGZVBGdcOAzn5uf57fMzWblkC8Uxk0guW8s+iVC1GWeSUbqcfGsyrpJ9nCisoil2FMMkeu4pOMiBtfM5HJVAycI/srZiHMOdO1lfZSG8fi27ZIK2SDQfZPDSpQkjUVVDScA0pieKLL0O2o6tZunuYhrqCyjtHUyi9whr/3IL972xjM/X5tIz5mquGCzxqKqX3uw3+eF1T7B47RIaUq7gjAkJhIj4u8r3sW3xTObvr8DV3SP8YScvrWrCqw1nimEd8xsTseXsoeBQATVRYzgzqoSqshLWVUcQkP0On2wupLldRXRADg/e/qQYtyXUp17FBSk91NvMqKOHMCKsj6ZDm1m3sY6UK27i0rid3HvnX1i1dgXdI65npOcYO8R5rzleSX1trURxbdiMsQzOiEeX/R7vLT1CQUOeOIaxTLF/zusLN7C9yMqQCaMYnaQXI7iLdfNXsmn/fvbvP0TOCTtBQ+II1anp3f5n7n12LXXxF3L7Xb/kkvFxBJSLjOe9xFs7K2kWYmWPHUZYnjj6hTvJrj5BWV8iQXVFlB0+ToEhgTETJzM0Uo2js4H8VR8ya90ximud6BxH2LHtEEfLj1Pck0RUYy75+z/mky1l1J3I42BtCWX5udSbJhN//DXe2niUktpCirsHMSmqifWv/or7X1nK6pIApp89FPX25/n1/Ca0QQlMC93GvT9+hFmrllERdxlTkx0U79/KwdJaqiSQ0GsTyQpppUAzmJADv+e2G59n9tq1rOjM5Kwpw0gJ1NC0cQ67ikvJV7VxaP4HHOkYx2D7OpaVhzGkeR6z6mLoFGdVcLiQuqhRiErQWbaFNbtLaG4Uo50+lXExOlRuF50dzejDE4iOPZOrrzqbVM9mVrw7k8XHSqgQO+bstmLMeYHXtpVQvu8wh5oaKTmyiQImMC2+nsVP3MRDby1nc0MIWSMSaV2/jD0dJmLShhJXsJj91qEkePezZLuTwJ46XBFpWDpL6azNZXWRHu3up3hluzicshZ640cTU/wy91//EO+sWsvCshBGTp0sevalyLajkJp94lTLk9EdWca+/Ba8GWdw1thE3GveYnNrH6Vth9m5dD3VPRlEd29jTZmFtJaFfFw3gsHePMrrO2kIP5Npw6JIEILfWrCNjUt3kUuM9EGEtek3XHvP26Lzq1mvms6k9s9Zs2sja3cV0W5USGgVJ1a8wft7RZ97PYSPupRLRwajVbWSu3oBaw/Uy9zNo7qwkNzqIgqa3JjCxzBOAjOEfBye/wQvbi2kPLeSjqixjOlYzJLyYJoqq6jb9ikLDtbg7pNJbGgQ0lBIfUU79vgRhOf9hV9f9xjvr1nLopoYxk+dILqiwdmyk0VP3saNz8wRO7WRHMsYYvdtoHPcWEz7ZrPRliDEaQtz7r2RP360iuV7OghNTyHixJv8bkkb2oBIErpWsWD5fo5WH6fIPoxxlja6ApOwdhbRVlvAumIt6t1/5vVtFVRn53CwsZ6yo2ITtdNIKN9AIQEERLkpeuN+rnz4fTZ3J3PR+ecwIvpbEAZHlwTRB8T/lKAVwqAkllPyEv395vJ6fIQhQQhDxn/1apXSycAgnS8qbLarCNCrCNN4KXbryQoEi9VIIg5KHFqC3Q7K2jwExhqI9Aor7NAQJRMmVlh1m95AWG8vFUIEIlx9nOhQkSTl4tQeal1a4oK0JFm1vlUXjS4hDGodqWoXlWo96Won1fKZoHbTqdGJU/EgRWhSyIcQk4PNUq5DDIhTOiNt/rZDcXoRBiE79mxKKv5MpTONoMAEGZd4gsxJIpN+xdWERBER4iL/wzdZdNyLJz5CSFoDKm0gwWEqLIN+yoy0aM689jIiLL207VhHb+b5TBo/hdRRo7j16iwcWY/wxDUZZKXKRCrQsXt5B1mZsYyflO675WtQ19LRvJOVlXH0qVKwVrdgqKsgYMYMhgfVUtQViVVrR4uLdkKI95STbx4gDBKBtOWXEHPnmzx391V4xVgUfvwyVTKm+syzGD9mPMlDhnLO4BDcvQ4aykqFElqIiFBjybyUMZmJxIpdKl28nWaJju558Rl+coWQjp5G1D98nXduHk506z622yZz6YwoAkb+iGuvOJ/p8QUUN6rJOaYnorebH7/zBrf/6HxSukqEYJkJj9AQkHUpE6ytNDoMvuh6RJieACGxsRkxJP30Dsb0lKN1G4mMAvOwH+LefJQhN/6M3z/wW35xwwQyM0aScc6d3BJbwpaVuxn98XKevXESBZ8Xk6rJx33x49x494+EDCnZ3mxU7ZWI6K35bDh2jGPHCiiqCGb45eOEPGswdp7gSJGFmOsf5tc/H0uyyN1Zc5AKm4nMW97k4YsdbNxgp2/XCpL+PIeXf30VHYdayIrXkXjVDZx51o+5emS/nnYUVnJkaykXf/weD/z0YkxrP0Z9w3O8+uBtGBtaaN+5mqBzruK8q2/iB0Od1A29l5d/HMnxPJlXqg6GPvQBf/nVFfQV1NNdUklkcgx2mavJaQlExWeRae3Cct1rvP6zYeiEWHR4AgmV8QrKPI+kPicp0y7npkcf48IMPYXLshkyVMPe1njsa5+iKGoaI8eMIm3IaM4YmUFisA6z6igFNflsbhqEniisQh60zj4iz5tOmv04hxz9Y2sZcQ0/ufI8zjJu5nDPEM6++yluHN3GnrxIpgwTBydzIiBlKJ6dH7Nw6WFKLOk4ti2lJ2Ea973yClcMNZA9cwdpQ/UE/fBNnjyrlcORN/P0zSPRukLEUbUSZg3AYTYSE5/OiOmXc/6ZCVjGPMwfLzQKcT5AdepZjA0XAlRpIc4rDtISK7Re7JvWJQ5dT6Kxg7gb3ufJH8KufV7a175AYdRIBo0Ukp05ijGjRpKlrCx3EvYm2qtKKAg4l+sviMCVdS8PXzOChADQOXdxqKqGPe2ZWKR9gQX5aE0G4s8eR2xnLjneMYxWHSa/vInK4OlMzlIIgwprjBpTxliGnHM3tw6qYM17z1MUeyGTxowhZsgwJmv345r4R+779YWkWtxs+OwYicOGc+dbb3LHBJ2MRSwTM0OE7AWQMthAR8ZdTGvLZfiPf8Z9TzzF2IAOyva7mTwtFm9nNXWVBeh/+BHP3xBAfqGBRGcRjeFDKVtVQPqMM7j/8T9y7RlG1K0dxP7iXR69zM22nU66NrxIYay0c+RYskQfJo5QIngJPnYuFZK+g76sC5g8abrYhyyuG9dEjieRwnVNjD13FOrs99mU5yZs9HSR6XjSol0MS4wg5Jcv8tw5oRTOnUvYY/N59Z7LaM2uJrzxMO0Joq8SXFm04l9sGpGxnYSrXuTBqc0cibuTl28eTEd7MNa6XNRDx5CRHkjDgcMUOsdx7a9+zoyMYGKDTy4Q8/V3GIqbD1DXrSxv7fuNyOdX/n5zD9xhSAweRkbEf/FaEkqCpoBgExMHK6tOGn0LSW0qsVHU7MAaHsCUYC8nKm3kt9qpEsZql/KdXS4au5UHEcXB94iDk+ijsMWBKSKAEQFe2qRcT7eT4i4vkSF6woQQlPWpMJu0xAtJqOqW82xCEmxuugc+u+SzrsdNu9TXYneTV9NDUYeb8KQQrh4SyOTQ/hxbMibfQ4gyuWtpb90mTjiLmLinGJ/5AlOSLybSpKy+0A93dwN1TRqG3HI3N1yvZv+cXI6vKiHqR9dx10+miiLq6ejqpruzDac6giGTL+Gq2+/jfmHn914yFJ2qj5b969h5vBlb4gxiGxdJRNOIM2gscQPXUEWlE5MyCNW2DfRYpjMq4TDz6syYDUFEmnuFUStpql2+NM5KamuPy4Hs6odosqevkaObV7B0xyoK23vFqEsUMuOHXHO3tOOeG7hlepKvqEvaWXGgjtjrf8Zd100S5q2nx+E7hCVci63xBKt37OLgpoOUdfZJNCST0y4FhGwqCbycOi3O4n0c2l9OY7MwRYk4jYE6NK4aNsp5W1ZvY+3aCiKuu4G7rp9CUohB6uj1tV352UqB0vY+ew+NFY2UikNO+eWN3HnNJKIChUwEe6jM2cHyHXs4UVBNQ0MVZbuyyRUSHBQMeStWsWJTNj3WQAwWDb02G7ae/nohiCGXPcA7e/awx7dtYcPn93COOEyfmZA+9NpknOQEJTGZArdLomFdKKFBNnpsYpy0OkJjrdTuXCtt2EKdkBtDRBiu8hyO7z1IZWe/ouvMGsy6FrZukUhz+0GqNAbqDu9g2Y61lHa5fWt8BCrPApg65dpqIoKtIkc7DpmnHk8HeVtXsHznKsp6vdTnNtMTnskNt1/JZSMj6O2TcXb0SiAhUX6bTfpfSdgVP/Lp2qAIkxjLbmpzd7B2+0q2HSrHGx6Gx9GD02sgKu0cLv7prdz2m/t49OdnMyKmX491g6cSrXLQs6cAS9wYooP2MbM2kaHBWqxqO72ugbEt2ke2jG1NYzAhFivWgG6Rr4y9yMt3B1ECkvbyY7hH/5TbHx6PurqU2go1eiF+66XvO440oI9NQKeOJCyoB7fTTkRosNgHl7RbAowdRfQljuGXt13GRUND6ZJ63d2N1O3dyJGKHlQmFfX7NrF23W7y6ruUGSq6c1L3+7A7AjBowgkL7qG310afS01owhTOvfqX/PLe+3jwNiEg8T20tDRS0TowQZQoU85Vst26vE5sOZvZdaTOF+iYRpxLZLuQkpwOolJS0RgOsaAhjbFhXnRe0ReXjJcy1/pERiIE5aHvfuhxN5dTsms/J2rFMQ69mB/84k7uuu9unlT0PiARxYTotF1iQ/sICIpE72jnwM4lLN96jCaHVHTSA8ln74ntFDU2U3g0R+T4OdmlXZgT+p8e8boNQpgiJGiRcXCK7ko7vBIkOuQzWIhRa1k2n+/Yzb6N5TS7Re6KbHpsYh80hCVN47xrbuIm0YeHb75AbJuyCI3UaYoWO3URP7xN7MNdv+QP100kcUwCdZveZocjhQhjtNiGdMZceBXX3XMfv/3V1Vw7Phq71NvVJURbpSEk2kzV1tWs2LGdRpUBkwR/TiGzfztWYYQEdcs+B5GhIbicTp8tM4SY6CrMZuOSz9nnzeKSKQmYst/m9gXlvvZ9KyhjIfNJ8T3KJl//YevfL2N4ChzUaU0YNBo1LXWdLNzdyLNbG3n1cCeH2j00VbXxnPz97PZmltS4qazqZGlpL2UOB7n5nawvdVDfa2d/SScbahw0VbbxopR/bmsTH8qxdlG0A0dbeHZvJ8frejiUJ9+V+vZ3sLrCTmFZB4vK+igua/d9FsjfK8rsHCnrZGNpD0fanFRUtPGScs7uVpbWKlNahPmvE7f/IProczfQyjmMzniGoeEyqQeOfBn2yt0se/5mbrn1fh77y1riL57I5EviWPPsn7j72S1UtLlIiI3AqDUwfMZkMuJ0rHpAJul9j/NBtgNVSAyR+97i49U5VPcOYRK1ZEmUoc6MGLiCQBUpDnu8ROMmJk+JIC3BRGNcOma9THB9qEw6C1arlQBrMKFWM0ZrJFEnHzSTqE8f5GLfe4/yh5ufId9t4tzH7ibWVs6nd93EzX98hfnH+r2qQcjm8Almlj35R+5+aSfNPR4i+20ICVMT0XQe4vmb7+Dhp5eR444hWo4pibswRxEVZMAYl0FsyWq2LF7MvmqrRIthjB0bTkxkC6/cfCu//9MH1ERpWfTMU9z9wjbqhYRGRkYRHBTEyZWoVQYzhsBwUiXEyxypYtaDD3PPK7uwCS+54AcpFG+cwx9vvpNXVtfS1d1E3aKXWdERyagZwzn62AP84ddrCZk+nMjhWYQadRLN9Nf7jTBHEpuSRGKYCcOA/VCbAgkICSNQ5ptKa5UIP5qJV59Ly2cv8tub36NTnF/KeRcQWbmLnCWfsKK4/zH7wMRgMjK9fHj7HfzqjmcpHTKZ9o2zxSi/QKkuguE/mChkTwif3ihjFU6EkButIYS4SDNqbxUrX/wdv7nxWQo1QVx039m0H1rKgw+8x2yZhwkyRoagaN/dRVOAnpHTQtjwssjzL5spbfWQPjiI2oOLRN738fHaQuIvnCYEJoy0lAgmXjGD+g8el7bfxO9n7aGo3ddc0ZFBRFqzmBZrYsLkcEKjA2mMTidMojOtyCVSxtbgG9tVbFqylA2NQcREhBKgFcJkDiVaAgxfgOfpIW/xH/jdnbdyyy2vUOw2cu6f7iK2t5A3b76HWRvbGfOzKQSERhKkrJNiiRL90qLVWwmxBjD9khQa9i3iD7/7mEVi0xKSo7Dq3DhWvcjHR7qwDM+g+ZOn+cOjczjU3Is5Lo7QwACCRPctgSES6JiwhEQQpJPxEtklJIQy+fpL6F31Ho/eehO/fm8LhzZ9zqpl85h1YuD1Bq0JfYDob6hFyF884fvfZ/aqfRQpb8uYR5FgSWd6qoVx44NFzUNojkghVKXHoJxj1aK3RhERm0hymPELXTOkEuGopWbhSyxpCmHk2eMpfvYe7r7pNh5ffJwmfSwxwWYhTqIDomOTz03C6DjOUzc9yBMfZ8NJeSqPqEamEZ3zGSVqPbl7tvPqzX9gfZGGMVdl+C4lwhNnLHNIr0atCxbHK/MnOJogo4lp5yfQUbSJJ26+iwff3kqxLo5gnQaNNoik5EgmX3Mx3Yvf4JFbbuI3723i6MBbTpHTppCZFMC63ypk4lHe2WfHHTKWce0nSJ8YjyZKT/ylFxLRmMPbv7qJW5/+lHWleqyh0UToRC/DQhnj07U/88DNn+JITSX5jDFYDQafneofK3P/WOl1aEWWkQHSLtGDCBmH1Blj8OxbyAt/eI3ZMz9hzrI5LDni5sKR/YHNN0NZj0Z5a0/JF9SfM0hZUujvt5P7TwFfOP3XklCKKcxIKa0srqHYbeWXmZMsV3mdRGE9Io9+hy37fWXl+0kB/UN53zGFcfVfR6ldYWJKSeWYUo2vPmW/sk++D5z+V/x9nd8mWdSXoVzv9FhLQmGnLmnP3y469ffwuuz0dHeKQxN5KEuJBwdjxE57e7dEXioxLFbMYkgUkWjEeXv7bHR22oSFayX6DpJI00NfRxd2rUScFj1HXniG4syRjLvkEtK/dFnv/2vvPACsKO4//nnt3vXeuUq5o/feQTA2Yosxlphu2v//T2JPLInGGLtiBRUVUVQEBKUjvTepRz24xsH1xvVX7v+bfe/BgSAKGsHMB+be7s7s7OzM7Py+M7s7K711h/TmTQH+mJ0N1LpsYnT8sImwUb0Fk0ndlVPlY8Yi6XaIqvc3GjApq2Y55rEGHNKpsoeEExJgw1lfQ430ml1iFAKDw4zbWkYqJe7KqjqcEo+/bA+SSDzq2UmT9MDVKJNFGin/IEmH9Jz9LbKPS3oMLZIWmwl3bTV1Tjm3QLs0iJIeKTuzo47KammgzZLmYBuNdQ1SR0ye+G2eC7pF8s74qqacp1N93MomjaZKS3Wd9CTNBEi6gyWv6mqOUd/kwhYULMeWnm+9A5PkcZClmZqKYzSLrAuJDMXf5BDBJ42QtLzquyhnRc6hodFFiwg7u119eMyT52quejWyYOSpGlGwuqirqqHeYSJQyjpIEu2sl3NuMknDF2LcvlP52CK9vYqqeikPK0Ei6NzS+1KvOPuHyT7SqKrXj40PkLnlfMUA2UxOmquryJ3xBPNSbmRktzTaR0QQGmCm8Vg1xyRtFnuAcYvOIj3hZl/5uhqkrkl98ta1IL8WKSfJo0apCSJKgkMCsUpHwGGW8zI7qJX2RI0YmANCCZUyVGWkcDc3Ga9lm0VktTQ1UE+ANPCSPm/Z+sl5uSQddW4pJ6l3kkVSZuoDbp588TcKr4Xm2gqONbikfKX+qPrtrWvVtU1Y/EMICbVjkg6MW8rb2tIstVfiNrmkbqov7bqMXqqapt4iaQ8R8WuVOlBfI/UlMNS4VupV3kv1sMq6RGXUd3VcT7sjZa2uWamfKo8cUv52qV/11er6dGKS45fNmcEek5nU62+it6rzaljaKflp9pf8kTouYRstYsy8eeNqbDSuBasqZ8mjJpPki/QcVC++SeWL1Dg1uuaS/PUTY6zmu1G4mmqpl2vFpK4tq0PqZo3xmrklUPJE0oSILfXxNqliRtvqlmuk6pioYqlrgarNkON5onIZaWqSa0cSavTSLSovgtXIgiAWzyU9dJdci0YdcprlV3ryJslfib+5/hjH6uUM1DUrdcdPDLSRNyfVZZeRN6FB4m9EKulqqj/RTgVLmyF57ayrwWkPMc5T3QZqqlVxN9FiE6Gm3uKQ67EZb72Usq2trJG6ZiEwQq5zOVazU9kpTzvlckueSs6qemCRsGo/P0m/qgc2yZ9miVvVAyOwOJNF7GGwXPNeUabs1Jm+JVFed5j5u19my5H5BNhCpPRO3wCob0k4Jf+Gt72JcV2/7x+f+p5y4QiG74JS5jw3H3O3rgwf0xtv517z30JjFQenjWdNz99yeXfprXk3a745nLW1xuRz/kGBZzAjmouBLxUMtYXMNQTDPBFevq9VftGcewSDSwTDzVzd9U+y5dyNq65Lmu+ACIb99IcMG9CZC+CVfs1/Gr8Qkq76LVe2jyTsO+mufP+xSi81UIuF7zWekXE3brd6C8LzJoTqiJ7WGbckZOE80fVJ8x1gJSw6nJCQUyYbqd3L3kUvc/+cQmrVWyea7ydmC/bIeKIC1TC9d5tGo/naKJGgbnUef07hTE60QkvL+V9sWjBovhotheQfWs+cLU3eDaen5eB8Xr/3KsZcegU/u2syG+u8Hj6qVvD8Uw/y4vvbKfbNmlqykV3r5vFxfhyxHYdxRZcwAk6MvH19Shbz1N23ccfjTzBpRR5bD30NZV27k3kv/S+Xjx3D2J/ewUtLD1Gy4kVu/uFYxo4Zw68nruPgMRVwJ9MmTWfK7GzketRoNJr/OEoEqGfxlCAwxMNpnNP7q/6dz+0IxQU9D8P3GVV06hwvjHkYzk7Ztmm8/Jf7eXLeXiwdetPVsoUJdz/Is1OmUxDeh3bp4QSpMnPUUlXnxt9SJ0a/hVy/dFyf/onHJi2mMGIgtvwsXEcWsc3cl7jkVFLVW1NFa9i6J4/trk4MCC2m2N0Gtooxnvpvnpu4ifrk7nRvU8+GyS/z+Gvvsbagicj2nYhXryq7qihdO4V7n3iLOfP34G5rIuuFJ3nwmRl8tuQzlq/dzIaDNSR2zSTmyAKefvhFPlqxCWfSAJLLFvLYo/9k4sdFBLRvZ7yu17xjISu27Ke0kwiGnhlkRgXh+nwmK4IHM6x/R+M97s4pkdSvnc+i6dM4FJ9Oeo8ORH/P66tGo/luONM8DHXNNeyVztbhajUPg79hU07n1Dt8aoqC9MhudI4fJFvOHT3CoPlKWPyCCI2JJT4hnoDGCvbM/5BdTTaCYhrZvHo3+TmeoQRTXC8uueVu7vzDT+kbm0GKrYHc7Rupb9rF1ux6ti+ezZY1O8iuqafJ+ySwRI4tIJSwpiOU7l7Cp9uOkrvpI1YUmLG2HGZrViEbFrzGpMfu5eVXX+VfD7zExLWl3n2dNBWt4vVXXubVl+9m8tpyyuqjufynv+b3f/opo9oHEhEbR2D1dha++mcelP1feuph7pi8muLdS9lWZsURGEqg9zF6U2RPundrT9vKKizmbgwdJmKgzzBGh9dRV5bBwMHtiAuoZtOOcIZcOZyhnW3s2Vhh7KvRaDT/MUQNeJ5REEEgKy7DKYFwipMwyqmwx2m9/DXQIwzfEaq8LqYRhoBIE8Fp7Yjo/zt+26WGDR9+TJvH3+eBH43gyOpsosNiSU1XX4BppHDjKj6dfhRbrzHcODqJiNSB/OTnV5MekUiiOYvtZXHSKx8lPfh4QpVoqNpLTnEDJdZkMq35ZLk6kOnMwnbVs/zj1kjy8vzInfk2x5Iz6fHDWxk3ZiS9urSne2IQTeXV5O8tJKVLD/pn+EP6L7g01U3ba27m5pv6kZrcj36XXsVY1vLJ7BUEXvlnbr5yHD27JDMoKJ/qIY/w59/0p2eUZ2Y1NaNlQrga9FjFlooWGoJSGTKkD7YsERd5FRyoD6GP3yYmz1rMmv35bF+Zy9GSWEaNST35Q1wajUbzDXCmEYZ6NcJQvJGCKvXxKT/j9oQKd6pzuV3i3LSL6k6X1iMM52Bj9QiD5qvR4k9ToRj7yW8yd18Tse3C+Xz8v3ni5TfICwgjpI33fYey9Ux/7J+Mf2Umn1esY/b2KtJ79icooBu92wfR44ZHeHLCazx0Y0+SfLOfuptxNDfR6JCK7ZCefLOVFkc4If411FRXUF3XTFyngfTo2oOk9hl06p5Jn3TPy3iu+lrKDxRQnZpGu4RQrCYHNZWVVJaWUtZgpnbHQha8tYi15XH0GDCCzqkZdOjYntHd0wg0N1OuwrUaIGgo2MTajYdw9elOapsjbFx0gKxF09gZ0IWu/Y+Rv6uYLdO3YTHnkFNaSd3RPTS497O89SevNRqN5ttGDL56fspw0gMVbXBGp/A8w+BdOccOuRYMmq+GLYn48HCi8paypSaQzldegX3TImZN2U2b/p1Iy/B8e7mlshZ7B38CO5ay9K2ZfLKj9OyjX4FtiE1Mp0N8GMHxHenaJpDIth1JDvHHL6ANHVIiGXLTNbRxlLH81fG8+P4C1hV4XqMITIqm65BENr39Pq8vqSEq1E5qx44kRUcSEt6OtvZ6Gvcs51B4F3oN6sHR92X/V99k+pZKGiK60z05mPBWU1s2Ht3G6pkTeOWF91j+eQM9x6aQt34yb778Mq+8vIH4fhk4Egdx450vMHfuHOZ88jD/Oy6OY+XeCDQajeY/gTSsvgcdjwuHMzjPWxRnbYnPip646TtCld1/78RNGo1Gozkbyk6eaeKmkmOH+Wj7C6zJnUuQfxinn5MYnG4HLqeLyzJv5qY+d8gWZVxVuK9vZPUIg0aj0Wg0Fx1i9N1KVHheq/Q8s6B+T+OM8Eog+ETCufXItWDQaDQajeaiw+R5+8HdIs474+OXOaUczhMtGDQajUajucjwjCi4cYrzTNJ04hXK0zn1LMP5ogWDRqPRaDQXIa3fjlAzPp7ZecN69ztXtGDQaDQajeYiRAkAn2hoLR5OdcpPcW5PLpxAC4b/ehpocuwmvzTfu67RaL5XVO9lz5I3eWxxMY1O77avhQN2vsNTH29iU7F307lSuY0ti97myWXlxjC55txR2ecRA+oZhhMTNZ3Wef3PFz3T43eEKroLY6ZHVZGqaKycT075amotvYiwW7+gRCt2SaOzdSem9sk4Crcx7/GN0C9FwjrZNXcd5dYgYiICvaG/SfawYuMxXOYQIkNU/uRzIKeInIpoEiM9Ib55jrBj1gs8+sFmrB0G0U5978JH7nwW5gdjK99J9pFKigLiSPBNQPVNcHAei/L9cIeFE3W2qSMbdrJsj5Xw4EACWs0lcTINuKr3sOxAOGnRVpp3LODzpkjCwwM44y5nwpnNkvde4q1Zqzm4ZztTPl2KI3UYmRFe/y9QTM6hQg5WSVmdMYxQ9znvv/Qkkzc3EpfRkXi5FL4xnFms3eOgxRxK2LdRPb/AUQoP57PjSCwp0d5NZ6J8M7v2HWKXM4V0zzQm3xwtOew+WMrhmigSYtw4HWZMoUl0irN7A3wF3BXU7VnMwpI2RAeBy55Apv9+Zr3xFJO3tpDWqwPRX+VNcHc2Ow5UUlofSWyki2anH/bIFNpH+eaG/5oUzOXxZyay88Bh5s2exrJ8G2k90og4k81w7mL5ThuRYQHYL8LpWM/4LYmmGrYXbiCvYj82i11acskAMSxKF7R2aqZHt8tNRmx3eiUN8e59bmjB8B0h5XiBCAYLFnM4QbZ6KhqraWnaS1VtGUjjEGC1HRcOTYfWkrV9M/vbDiK1cCYzxm8gv+9QuoXtZ86n+YTFmyndMp/Xp85me4mbiLS2RCuL1FBLwbpZvPfRBKbMPIi5bRfaR1ay7r3JvDFjLlk1QaR2aEP99tlMnPA+S3fmEJDcnaiiRTzx9HNMe+s1phek0atHJ8knE0dWTuCpu59lwsZqkrp1pE3Nal556BneW7iauuRBpMX6eQ1hAWvefY2nJswgO7eYw0fFKL0/i827G4nMTCYwZz7PjJ/ItFW1JLU3k7NkFpM+mM0BRwNVuzfw8u/uZNLc/fh37Edq2xhC6/aI4Wki9OA0ZpW3J6ZyPQeqWti620Ss6wj+8S5qDmxjdVUqqWpKDZOUcMN+5r32Nu/OXUiBXyjVu0opK6shMqmWkoPSiJYH43dgOk++PoPlawqxpqSQWDiNaflJUFaC2V1Hs18z5QUF5BTUib2exVOTPmbd5+VYk/04NPk+7n/8Y9Y3p9GvcwAlK6bzyjsz2Xy4jtC0DGJFyDSXb+PTf/2Rv722nNzAziTlLmHO8slMnLaRspZkuoq1L9soef/aByzfdQhLSm/ahKihS0l/UzYLJ00WYbBA0m+iZOU8nvrjQ7y1aCnzFixj3cYC2gzuRcGMScxZsoqq6J50iC5j2cQXePGtD/jk48m8OXkGsz+vIiqzF51ilIFw4SrbxOR/PsOkmfMoiQnj8IcTufeeV/msKZMrfjKKDrZSDi2dwjNTl7K7NgF79g7cqZGEVG1iZV4gDWKQ9656kfHvLCVr50Gytszgg+X5BCZ1wPn5Gzz5/GRmzV1CVVw7qhY9z+MPT+aTogh69YylefM0Hn/yNRZlFUk964ll1yw+/Pg1pszYR2XRRqZPn8b22niS28YTarTNNeSvn87Tj01k6TbpXofVMP+Z55kyaz5lcf2IPZbPpoXP8/wbC8hzR+PfuJGp9zzIU58dJqJtBonFC3hi/JtM39xE23bNbJk6ifFvTmNXUyxp9kL2797NRttAhreRQzWJgT64mtV1aUSJOK5dvYTDLQVsnDeT1yZtoDhUyis5FHNzCblrpvH0m7NYu7kce3o6/rkbmP/JC0yYvJaKiERMObN4+a6neG1bE8mpaXSQa8fpF0HD52/z3AtvMeOThZRG9yHDLkb37WeY+O4eGmJCsBUuZfxjrzJ3ax7+CW0JzZ7O++V96R5VT2C0g+0Tn+TeByaxmViSQhpZ9f77rDpYTlhSJpa9H/HvZycwc84SVqxZw+oVe6mPiRI9+DbP3/sSb+8z007qeIc4B8WlDgqW78ScGUlY+XpW7StjxYcz+XT+XPaKoI1L8eV/A+W7l/LWS1NYsn0btUFmNj90F398ZSZzF33G8mXLKQuWjgsVLPvgQ9bm1RKTkYm9YCGvPPgs78yZxSfvvcmEdxexj3Q6ZyQR+U0K/P8AXyYYdohgOKQEg1UJQeOq/YJzeR+KzNSC4eJFFeSFIRgU0vuwpRNiLqa6ZDx7pBJWWESxByYR4K2g/uE1VLc0s2aNhT6uVRxKjiK7oSs9K5ZwMG4ACfWLmHzv//H09BUsWFuKvf+VXNpWrszKQ2yb8W8mbD1GfZHEH92bhKOTeOIP9/Hq3BXM3+1PTJKIjXd+x+/Gz2HpgjXsjR5C1+yJvLmxzKgXSCUf1b8jKWEmKg9Ig7p8D0fCO9G7QzjN6ybx4cZSKhvzyG/sycBOMYQFWCjdOJdFYtg2lLhIiPej9PN3efipqXy2rJC2V15Fx9w3ePjTYhr829LV8gkv3vMAr85awaf762iq8yfBYiN+6FX0C8yhMq0HKTXLmbrSTxrYPApDZd18lDr/RJrF8NNYIEIjhKa1H7M1eQwDpGdpdjdRMP8efnPb03y4YgWziqVhzD9CsBiCRr96jq5ZTUGKCKOtT/HjOyawYtlKTANvZmRkIdktGQTsW0Opoxmi4MiOLHYdlR7SwfHcet9bLF30OcEjx5F4ZC2b99Vi7zyMQf7LmHT3//Cv95eyaFkuzj5XMy4jEGfDYbI+m8PaI3YSeo6gt20bm7Pzyck+Sn1gByICcln/7K/5v5fnsXT+crLb3cIt/cKwimE/uuhv/PbWx5m6XNJ/1I69tJmEqAjCOnWlc0I8fX54PRnFz3PPI++xeMUy5rsGMaB5B3u3b2RLsYid+mqqappxhabRe9AgusfbcNaVsX/Oi7y7Ip8SRwH5DTE41+7E0qEzl/36dq7unUBo8WreH/8g962MZNyQrsTsmcHayAH4r5nKelMqttx5rFi1lNXbiyg9cphdJflUVxyj2tSeiB0v89bOehwq7vpU4st3cSC3kob0/gwMO8yexdOZm1dNdWO97BNB5P4XmbStiqqsXWytrBdxtpHc5gzSO3SkXbiZY7nb2PjphyzOqaWloQVnyXo57lGqmvPIqetGWt5HLNyxmQ17SmkOiMUq18ix7VvIknT27plO0qG3eHDBMQhqR2bTZyxds4d9VUcpqI0j3ewmSMRZaVgfBiXIReYoomLHJ7yT14l+CcWs/HgTzvo1PPOB1PlDUYwe25duSjCYitg38zF+dv/bLFu8jaCRP6Lt3leZvG4fhw4VUSf5HVxXxJHt+8gP78qgDNH/Bct5Nz+dyM3P886OGppU/tR1kfJawcfLxbgXJ9ApopSj2xexKLuKyvoqahvb0yfyMHutPehR8h4zioM4sHAnQR36MnZUFPlTH+Xfb83ls4V7qEnvQ//yD3hscTmW6s18+OZHUifmUpgylh7BlWSvl2s2thfD2tbjPryKSVsjCdy0iKo+A7AtmcDkZe/xxEOvME+ulTn7A8gYPIy+cVJfKjbx6RO386unP2bJwoWs8+9G4oFswvuPJDPSTEqv67lqEOx64xGefncBi1fmiVDsTYecGczdXUJ1fYP0WSopqzUT22Uog7unEv1NjmD9BziTYKgVwbBN2uqcyv34KcFwBpvpbhGRLqIhI7YHvZMGe7eeG1owfEdcWILBLY3hGvbn/pvDrt5EhYtCtyUTHpBCoM07bOgXQFlNI/um7SQqqhpH/57Ubm8kvGQv4SOGULfiLbZXRZA+8gqGDRxEly6Z9E0Jxl1dQFFhDgE3vM7jtwSya4+Nok9epDC+M5lDxzJYGobIo2soyz2AacCPufSSS4gNCyVUetWXvfo+9/88g7qjIcRExpESayWsjdSNtoPo/YPbuDlstzSYWxn8zoc89OMe7JqVS6fMZKKi7eycNB/rFTfx8J1/ZETvRCyHy7DHJ0kPIxB72mj6+h+i+dLnePS3vbDNeZLPatPpMuoHDOk1lmEZsVx2VX9Sxl5Jj2P7aeo5mm7SE9uWG05X/33st3cjWXp+5c4wEjpHST6V8O50N5FOK5dc38f41HVLYw2rX3uYnQnDGThyBP26j+DyPg4iU63MXyXn0RzAkBEpHMs+QlhYIhlpFvw6XstA+z72tbQlsOIIAW2SSM5MwK+ykn2HA0kNbiYosg0d21rx73Ibt1wajSPzdu64sQehq8YzI9tK6qhxjBw8hE6dOzIoPRSr1KuUDjHUZf6Vf16fIqJlJjvb3c19f76ENn4m1k2dS01VHraBNzB2+Cjad8rgks6xmJ0NrJvwd7bFDKL/iJH0734pl0reDfnROHqPGcd1PRIIGTgE6/zxlHb+CWOGDqFDl64ErtlKt3vu495f/5obJF2pqX3oNPRX3NrXMxbceDSfNdNmkfb0LP7987EUrakj07+Ofv/7G/pd0pdMdd3XH6PSHk5Uzx8wsksIXTsU89FaP3JXVTN8XG/aOtdREHcbt980nIzUKIIH/4b7Lg3j8y1OuicEMuDxF3ngxuHkLi1m5MBwAi75Az+7bhgdsz5ilYiIPz4/np8OjmD9m+vp0N5B0HWv8uioSnbG3Ma9P+tDuCkYq60NmW1sHF60mcPNkfzh6X9z06WZVM2ZTfsXZvDIraPJW3KQsJJVmK98iP/5w5Uk00STO4bhVw8guu8f+N2oJpzFuTRd/iJP/7IrdR++St11/+T5u/6XsJoS6jdvIrBdNEeCe3kEg9VNvaWGjWtqiMiaz77MKxnVIQm/NmkkDxnJqC7JJITaaCitoKiggpCoJDp1sGFpdyWdmjbgGvkYD/2+G45SK7ExEXT6waX0GHYjN/StoCSngKymznS31dP3kZd48OZLObLqIHHHdmC67C9cd+eNXHZ4JZuKw/j5Sy/zm0ti2DxlJ91TK9lu70d30272m0fRP8HMwJ/eTHjtfsr2HiR42HVcMmI47ZMDRORISyLX1J/6BpIUF0tSopWA9Ku4cnQm8T2HMnTMtVzVtZDc7BrKIvpzWcf9rK5K4tDCfExFs2joNoaBg0cxoE9f+nTNoGOsP1VbPmPh/MW4+t/EZcPHktlpsNQlO8m/eIgb29rp8qNbCS/aQHF+OdHDr2bUyOGE1TuIqHFy7UvP87sbfswNl4VSm/RH7ry+B+nhRjW8qDijYJA2ZlvhenIqvILhS0YYWlxuMrVguHhRBXlhCAYnLtdhKks/o8QZQ3Ti3+iadBnJYe1OiAUDK6bSfLLWr2RDfH+uH9GTluUzmVUdxqBRg0huyKMmIJ22I3/A6L49GNApnXB/E66qSor3HaQmsyfpzizWZEeQaqkivHM/2ksjOLJXF3pFSufKZSZ08I+4tE8XhndpKz2ibawvPczhzStYdTiR7l3bk6ZumDqK2bNmDRs+h5hEG+4jm1m3r4GCA/s46kpnYL9kwkKkUc1Zz6aDWewsrufI3HXsrnEQP6IHHS11lEWJ4HCvZ52jJx0TgrAWZVEd2Y2Owy9hVP/udPer4khxMTWx7YkqWs/yrYfJz9rA9roODAnbz25rV5Jdhyht9Kel+xBSaxazYsEarN1+ztV9PQ9WtDgd1Oftl57tCPoOGyyipRv9B8ZyZOssZiwtIWHADYwML2fn0jUcGz6MAUEVHI0cRR/LVrJc7Ymx1dBwZA8bd+1hT36N9KTtxNZl4xg+iJ42CRs3hj4xuWz+ZAOFrngiKMMd1oY2w69gdL8eDOrajogAqWDuJmqLP2fBjCwaQuMIKpKGPjaD1MgqDh5qpLYaESChBA+8jrF9uzFUyiM2WMrd4aIuby8NKUPoNXwoIyXOTEcuucec1OKHreQgR8MzSJKerF+Paxg5qDujB/YmuWILa3P2s6uwGmdTKQd37WPX1mMkdEojLtiM21lP1aHVrNtbyeGi3eTVSE8bqTtRsfglShn7SY2Ui8NUtp/c5VP5R24PfjImkcJ5L7LDPZwrRvUh/vA29olBjw+uoK7KSWNkOrFNh9heEEpb11rmZ1Vy5NAa9paliNCBA2u3sLc4nLiwakpyd7OxvIbcvSU0uuPJCK6htn030irXscvcn05hR9iX20JQdDqdkmw4yg9ycM9aVslxyrZnU1qVTVZOHUcPZ5Ffm0gHayWuth2Jj66jMLuaBv9wYuu38dnSahIS/Aks3cIK12B6xvthLlrJxj3F7C3fy4GjQXSIqMUtZZQf0o9hiVJp5Ppvch9l9aQF5OaEMuTn3TFV1mHdP5spq/MpCu/JZRnB1O7fS9aG7bSMHEwv/woKQ0eRWXOAxradSQsqZOc+CI32oyV3M6u3Si88romW8ny2urvRvmIhi3aVUJi3hj3FbegXc4QcawKmyLYixLLZv3cnG0vryNldhMMWQ/eoPNbTj57uTWxv6UR48W6pR2J13SYi/O1EDr2GMX27MyQzHGvZTpaUZxKyaT6VYvQHxtRSGdSHtml2jm1Yxoa9QaTG1NBUVMDB6GEMSdzPfBGP2dbRXJ5sJrLzcLqI2B3Rtxe92sUTLBqzoUKuw5oGggfcyA8GdGZot7bYVNmGdiL08OcU2ROwu5oIDZZ8HzaO0b27MzQtlPpDy1lQ4aQmp0gM5lHWzttFtSmapJRIgs7x0Ynvii8dYTi8ngMV+7BZpS3CfJJQ8DnjloTbLQKsO32Sz++WxHfVpdVcMDSLbaig2nwZvdo/QqcIufC9PidjIy46iI59WsixdCXRGsPgfk0cjWiLxRFE5tVXEl22myl/vYt7XviAzw55Pg5l9g8kJCGFWH8rFnsMqYnhDL71WoL3reT1++7ivolzOZwmDV9GBGsevYu7Hn6WGQebyRwYw6pXXuCxZ5dQLAIyzPcEYEB72rhKKFsyhZWuZHqJcMl+4QnGP7ONtDHdiU7wjDd2uKQDtftW8eIDjzIvr4hj1lImPvgKL6+oJikigKCYdFLCLPjL9Zd+3dVE5G5gkqT9b6/PZU1lGHGxCaSmJ5AgPcBDE5/l+Tc30BjkR2Cb9iRHBBESmUBsdDjh1kASRTgMaFdB6PB2xrEV5oBgel1/FS1Lp/LM3Xfx0JSV7HaKKPELZnhSI7H94/FLiaJDZzMf/ONpHvkgh0A/C+FxaSSGizEZ3kuM+zY+fH4yH60rp+fYdqSlNPL2g8/y+CdHiQr1Jzwlk5SceXy2ZCPNg66gvTSM0+6/i7uffpu5+xq9CQnDPyqRhD3TmL3mAMUBKaREhmC3hRERHMKgq0fRITGI5Y+ovH+GKZsrDYNttvvT40fjMK+ZzvP33MWD765iR3M8SfGxRIeFEhgRS0ZmKr3HDKTg1Yd48K57eWbuPhKGZlC67hNeeOBfvLepAYuzkpo105h7wJMee3QcfcZdQs1HE3j6gQUEds+QsupHZFAood7WqPmICJzJb/DhDri2X3cizV3oa80l7ZIUiBbhKsInLkLSEBhFeFQMcSF2AkNiaZvkT1P1XmY9+xhPPPwR1k7tiew3grQjq9i4cDGHM0bSs00Lc//+GNMX19D35oGEJacRI3XTGp4i5WonICCShNhIokI8DXNc7xSiQyt454GHeOmjjbj6DeXoOy/x7EMriBzQifRhvYgSsR9gCyUqMpK4du2IsjThXjeFWbuaMMn10TbchL8IoYzrryYoaxEvPfAGheZoulw9hFBJd7L3Q6/gj78zgb6JFjr97ZfSuJvY/9bz/GPiJkLiO3PjoHgjVEQnqZupUhcekrowu4hoEcgxKWnEBvljs0WQEC1l266j1MvDlK74kCUH7SIgUmkfY8ZVn83cFx/n8b+/h7udnHvvAcSHBRMuZR4ycDidUv1Z/M9/MXV2KT1/PJAgqe+p4Tb8IyV/IgOISkwkLDCQ3peNJC24mfl/l3rzxGvMzHJhC0+jW1ow/UYnsPa1F3jwta1UNJhIFCGTJMfNXzGD1XnBRMa2ISlWyi+sKwOks9Lzim70+80tmFbPYLzUtfvfXMwW79sYkT17071nOlufkOM8+BgTVpfiimor124AoTFtiJS87zvuUpJM5cx8UOr+M++wvjlYrisbMx96kL//awrLGxKIz1vI0tWfc7DGE+/3BdERxiuTnsmZ1GyOp3fGKIMKfJ7oj099R6hCvnA+PqUqkxnTWfNcvb7jFINiQ2ybrDpodlmwWszGaInLIeLD6aTFLA2wTXqhygBIOavZyFpMFlGnquJK2UpgV3OT7OuSc5a4/GxYWpw0NTXjklBWPzt+ZrexriYdsai4rJI+Iw0Spcshx3FjstmxmVw0N6r9LPgF+MlfH26czZ5wFqsVs6TF4XAaeaxGtCwmlRZJt6RFxetySHqcnvTYrBZP/ZOdTC2++E2SLj8pM5ULso86L3UYCZf76Sds3HeIdnffIX2x1rRIL7tJBJlbCttPjiuiSc7TJYVvsto8al3ys7HJIfljxqbiN0keyzmbJF0tkp9GmixqFE4Mpezb2CTnIHlphJX645Z8dIjEs/mJv7OZJjnHFpM3/49nhpyr5KVTnZsqKO85q2vQpDJG0tDcOu+PX3wnp98m5Sz/j5+/kT8Sd3NDk9FgmeSY/jYTjmY5lqgOs3E+0mBJGXj298XrxtHYhNMt5xxgl9Src/akxQjhdklZecpUnaezspRlTz6H4ze/YWi7dCLUNLcqDerBUvVfKq4ajHUW7mfbJ2+yYcBdXN8xlJgAf6O83FK2DjmW1S55LnWnqVnVAxt2u0hjiUvt76mbqh6r+ippkPJQWaUO4Fb7NEkNkN6dymeX5IlL4vOTtFtkP6O8JKzRpsl+qpycDhctFpXfsr+Ul+fUW6TeqzKVOimCTF1Dxutux4+lgqjjSfqM+iHh5VjNKvu814A3kOzXui5IfVbbvPmgvi2g6o9Uaqn/qq5JfZBdncV5ZH38Cqv6/omrO0WRECgCQ4IZUwZ706Curdb5YzKMjSd/VA9WHVsCG9eNJ6zDOD/1USSr2l/FIyXnu3ZVuq3GwVXHRKKVtKi88ISTc3VK3Ze6obY5mxuN61UueM816jtdqQ9NKs9lD6MtkDz15LPnnM3iVDzNDpUWuVYkP6xI/jSqa8Fb7uLvlFyyqmtQjnWxoOrUmT4+dbS6gLfWPcfi7E8JCQiTOtjqxDzFZOBwy7lLu3xd99v43eB7PBvPEV+RaP6rkYvvK11EqqHwigVjVZalMfA1dupi9g8IJMCuLmrPNhWxSYy0EUYuXiUWFBYxTAFGWGW8ZYOIDLusB0ojbxgsaYTs/tJzU+tyDO8hDEyqQbGLWFDHkHB+ASpca7Gg8Bi/ABGjRgMiDXCACidpM9KgGnH59cVrEfHhS48SQMeN1/H4pXFV21VDZ5yT/CpnaqRGRC/B0ts3YmqNNJhiGAKkRxYghsZ3nhafWFDIur+K318Mp5EuFa8nXWYjPwOkdyrhjWN6z0G6qx7bIeXh549d4jayQhpeI//F/4RYUEi+SzrsstEs52DEJU6lXx3HdGreH+fk9Bv50ur8PSGV4ZQ0ST77GwdVwkftE4BdCS9lNFVZnRSvhFFlGyjnbCTgRFoMpL7Y7BKfKisx4C5zJZWh0mO2BRFi+HvzSNJilINxPuq4YuSCI6WnH0649LY9eSTBpWztqp7Jsqo7Rp56Xx327X+8Phj5r7YZuwqSNouf5/yM9Mj5etNunJIR/kR+qv1UfqpzNuqtnMuJUxfx66uTnp29x/f4Gqh4jtcPCa/yX9U938kYqP1a1wVfPL70y68KZVwnqi54ys0m5eMXHEFURDiRwQEe8dgq3UbMp+SPROzJF3UNy68R1hvYE1bqjdRd4xi+eFpduz6hr+qmSovv2vKEk/ikjvvyx2rUG2+b0Pp05di++mmX+MxGe3LinI0gkmeetHjyQwkef8nnABF1Ngmn8l1dJydVw+8BIktFeIsTYaFGBo878Wu9rgS90oXnS+ti0Wg0Xxt/Og4dzpU3jybGu0XzTWLCPzSVK39/Hd0So85wu8xLVAodr/0tVyWJAPJu0rQiPJH21/yecSlilL2bNBcxIgDUKI5LFtUgoPtLXIs4Y9ThPNGCQaM5L8zSkwkkJCxAX0zfEmazndCIYOmxnzyG9AVUjzokghCb9Dy9mzStULe2VP74SY/bu0lz8aLsvxo1ULe3EeGgbkWp39M5JSyMcOepGvR1pdFoNBrNRYgSDOo5GGN6aHGer1ae3sn/80YLBo1Go9FoLkKUCFAjB+pbEuphanVr4nTOuC1xkmI4N/WgBYNGo9FoNBcZHrHgGVlovXxmp/YyGfueK1owaDQajUZzEeIWZ4wiiBgwXtF1u8/glFpQL92eH1owaDQajUZzsaGeZ5Qf4y0JcUo8nM2dL1owaDQajUZzsWGMKrRyar3F87bEqU4942BM1Obd9Vy5oASDUktq5OS/ycl/D94JSDQajUajUZw0e+MpKNuhRIAhBsS5RTSo5S84l+f35Icez40LSjCorFFTsyqnZnj7PjvfORrVQQkHdZ9JClQ77bTTTjvtlHN77cKZULcZPLM8nma2x9bOG/Z8uWC+JVFeWc22/Er2VJppdpvEoBre31vU6atpSjPDXHSJDyA8NMiYfvXLKodGo9Fo/ntQ9qC+vt4YaYiMjDzpWxKHKwt4btkzzN4zi3DjWxKn7/87XA6c4n7W9+fcfclfvVuVnfn6RvaCEAyBgYHU1dWJaKiS05CT+C8ZnjfOUhSkmjddfeZbo9FoNJrWOJ1O7HY7ERERJwuGisM8u+xpZu35WARD+JcKBpcSDP1+xj2X/M279SIVDCojgoODjXX1VcPv28dBzoZbskE5Izf06IJGo9FovKiRBWUbPR/9Uh8RO2EgCyoKeFoEw8dZIhgCzzzC0CxiQX1x9ef9fs5fx9zv3apszUUsGL7s4Q6NRqPRaDQnMATD0qeYaQgGNcJwehvquSXh5Jf9fsFfx/pGGM6NC+qhR41Go9FoNGdHdblP9wrlFxy+ZWMPY99zRQsGjUaj0WguQnzTPist8AWh0MoZr1wae/hGIc5NOGjBoNFoNBrNRYZIAREBrV+nbP165cnOmDpahMP5ogWDRqPRaDQXIWqc4IRYcOMUCXHSrziHWpaQJwuGcxMPWjBoNBqNRnORoW4x+JxL/rpEFLjUaELrX+Xcat0tIc7tNkRrtGDQaDQajeZiQ+y/ejbB85VK9auc6bROvbqvxMP5ogWDRqPRaDQXIS0+0aAeblTiwPuQ40nL3vVvAi0YNBqNRqO5yFDjBWrkwCmC4MR3I774wKPhvKMP54sWDBqNRqPRXISotx+aRRA0KScSwvg9dVlcs6yr5xrOFy0YNBqNRqO5CHEbzoRLfpUeUCMOp3PGQ5AmWThO6+WvjhYMGo1Go9FclCjD34LSAl8mAdTNiJNvSOjXKjUajUaj+S/j7KMF5zae8EW0YNBoNBqNRnNWtGDQaDQazbeMZ+j8e8Xx0/Gd2zfhvh6ePdTthbPt+8WbEueCFgwajUaj+eYxbNhpDGHr1VPt3Kl+Z1r3LZ/N30frZcWX+Z+63MoZLxr4luXnq+Lb7fhOrXY+7mcgS76DqF+fh3eTge9XMB1f8QgCnyxQSyeWPa51JJ4vV359tGDQaDQazbdAi9c8nWy2fD8GrZcVp/qdad23fDZ/H62XFV/mf+pyK2c6ddmg1cYzON+/4xG0iui4n8+1DqMWFd5NBt5fi8UsThbMzbjMTtzi1O8XnMXjpyaHPl+0YNBoNBrNN06Lz8AZnOjdXnxcmGkXvSCCwYrV5IfNbMPPbBWnfj3LxjaLcn64nNDUpF6+9BbKSWXz1TGVlZV9JznhGxKx2+0EBweLmDrHM9BoNBrNBYdq4VWrXtvYzKaDZeSV1RHgp7rEJ8yv8m9tgFqv+yzC6dZ9y4ov82/t51tWfJn/qWHVrQGPuZI/xn/1GqPa5nGGv/IwOvAtuNVHHYzFFsxqP28Y5VTcZhXeWFeBvJ+EUn/Udvmn4vZtNKlJFDxekjDPssJfhEBRTQlzdi9jc+EuAu0BRty+8/Jgwix2tbzmGP7+Fu694Rb+csVPDR/jOKeE/ipowaDRaDSab42C8lruf38HH286QnSY3bPRZ3VUs9/aArVe95mE0623Nhdf5t/az7es+DL/U/1kQX3gye0W4+52iXNj9v66XeLUxxzUsrHuwqmmUZJli+xjFn9aXB4RIMtqmwQSIaDiUOLCZXxJUsVvEn+13dTilH0knDq+xGf4GSLEK0QU4qdsphphsJg9NwpU8NYosVBb34TD6eAnV/fj7j9eTtvUOPHxnazvRL86+paERqPRaL5FTGLqLDhNNlzK4f09dfl0fmda9y2fzb+1n2/5bP6n+nmdW7adcFbDuQzn87eKWJBlw3n83SavazkR3m32OrXdF+4LzuL5VfG2qGWz59fnxL9F/brMoilMSlcoHdLKmampdVBf7+DqsX34y+1XiliIPyFEzkEsKPQIg0aj0Wi+NQ6X1/HAtCw+3lxEjBph+E4szvmgRhdaaHF5Rxikt+8bYXAZ2zwjDGokwCnbXS0eq211qVsS3hEG8VMjDGpUQU3krNZN4u9ucRojE8dHGCS8ydhf7SeHVn7e7bJipOar0Nzs5lhdPeMu7cYDf/4hXTsmezxUnIapPb7wtdAjDBqNRqPRnDNfQQH5gnyr/WLPQZxOF7V1dYwZkcm9/3PFCbGg/M9DLCi0YNBoNBqN5iugBsJ9pvaE2fXNhqBGD05GrbcO/3Ux9jk10jNgloBKLFTXNjJ0YHse+NPV9OyaZviphxxPRPQVIzwNWjBoNBqN5j+CMlsXo/PhvZP+FRCjfO52+Wujbuk3O93UiFjo3yOVv995Hf16tpUkiJhRtzi+IbRg0Gg0Gs1/BGVDL0Z3nJNWLgyUWHA4XNQcq6drxwQRC1czqE87w8/3+uRJX7Y+D7Rg0Gg0Gs23iDJaXxyuv1jw2FrD7IrhVWehtnjWW+M5Q+XX2jr71r3OeEvB606x4p7bBr5tEpdv0RjW8Kz4ljw5KqHEgiuxUCViIbN9LA/d8UNGDumkghoYaWx9H+U8sdxzzz3/8C5/J1itVvz8/M74loTr4ELeeek1ZueGkNEziRDv9q9PA807P+KeR19i6m4bXf3k5K0NHA0MJcJ3aEc9ziY3DpsVq3fTcQqPsD/rY1598znenl+KM6UnnaNNuOqacPj5wrvhUA55ERGEG+vnQVMe2+ZM5IHnZ7F9wzEik/xpjGoVb8kePpmymK1NkJoSh/ftZjkH2ZC7my0HPuXhf01g5hY3Hfp0JNYXoGoDyzbsZWt9Gp1iTs1zSX/uPP71r2eYtM5BWsQxDiyaxPjFRwmwBxLekM8OSzxt7I007JrJoy+9zUd7rHTqnE6E5CdNddS6JC+sp15KZ6E5j+2zJ/DvCQvZ6G7PyIwwr8fX5NAW3v5sH6bYCOKD/L0bNRrNd4Nh0qhpcLAsq5S9R+sIslsNI6ba+4vFHT8VMdyetdbiRzyUn2dJnOefWlK9cbP8qjkYfOHVNqUTDKc2evdV02KqcGbZpkSJ8vIcW+3vlnX5VeqgVbqsEtjhdFJV00D7tCj+fuc1/PDS3kZ0JyI2YvK68+fCf62ydDaP/N+7LDsczbhfpeB2pNB31C30DyvGL7KCPbnpxFfOY+qRBDpasqlvDBWD34K9ZDuF7gEM/9FY0iMt+NVXkj1zPK/taRALewW3J4htjbBQHVbO3jUbKDQP4dpLLiWxdAFLygsoPdaNHkHr2H6wnoh+f+ASdxFHWxYx8dOd1OyqxTzicob1uZQfR+xlaf4WDhXYyRz6W4ZWbmGtYz1bnf24dugoujWuYsZHyzgYMZSRfTMw7ZjCyvIoOo78GR0aDxLsyqYodRTpMSEnhItQXryf3dMfZfzUrSwo/CGTnuuDIzibwp3NJA28ndH1y0QMbKC42+3cHFdLwY5FbHW1Y1D/H9LlyDyWNeeyeEMFzmw73cbZcJY7CelwDSP8C9hVUUthfAa9Ds1nbU0U/a6U+NLloG4H+Z++yOub8qiL+QG/7rCbFx+4mwmNt/HMw/fxo7iD7O95FWP8j7L3uWvodN9Gom+fwaJfWlh3NJT2wW0YkLCHmdt2krWtFr+wtiT178eQhgUsy7ORMvTXDLMs572cSHokZTDAfzf7A1MIc2TxwT1/4G/bxnDv+D9yq3UVi7ba8Ut00JgwmtH+2zmwo0LKyIy55Rjm+CFc0rstzUc2sLgiiTH2LWyo7MaghoVMKLJIOdzOL/okE37u6lKj0Zw3qo03kVd6jD+/s41Z648QFhbg23zxILaqRb0C6VKvOro8rtVrlWqyJrVsrBvbneIvRt7dgkXWTcYkCXLSsk3N8qheyTQmaJJtbgmrXtNU8XsmU/C8Vqn8DAup4pPtJvk9SQMI6lXP5iYHHTvGGyMLN109yOOhAir7atjUbzajL3DBUMH+xe8y/rV8juQtpyhrC+uDfsD977zBsM33sqI+kaixt9N215sscnUhdfNDvL7KH2eog+DKbHKi7+Otp3/E0DF9iKo4wtxn72B/wkD6jb0By6HdHMnPw92YzY7509mTcj0Dbr2b3ivvZOqMd5hafS1X+3/M7N1mxr22mlvb+DO4/RGK/HtRtXQhu0qzORRzJT8ofYcPxk/k3cJ0fjd/CVfUbyV30vX8X83tYmx/y635T/DjP31C7nV/5S83prP1ttt4vboTv52+mKsOPMGmhkhChlzDLUM6kBAY5D1vKDq0g50zH+PTzaW8wQ08N7SGog/u5R9rYMiTK/izYxprCg9gGvMio3Mm8vydz7Ik/Qb+/dFEemyfS33VWg6G9iC83sLBxb/hyTnQ+S+f8lgfCIsSVRpwiKmj7+Qj/0t4ZN1n/DaxiOigQD4bfyebze3oevlv6Jr9BL//5VMs6/onHv37o4wL3Ulq/0FYjx1l5dv/ZM7+NEb/8RbCNk7gAxFsqXFpdK9fyZoV6/i8pJJDib1ItLel38p/8NShBH4+Yz4/LJ7G/Po+XNPOSX3ONg52volRsaVs/3gaR7r8jht7FfHeTy/n0W2d6By9h93d7uR/XG8we0cQdS0VNJQ2YrvkAZ556FKc6+aJSIogfOa9PFl5G//741SuG2xnu/9tjO6ZTLcYb2ZqNJrvANXGmyiqquPFhXtZllVGRPDFOA+DJFlpBTHmyoB7V4x1zxwK4pSo8K67jTBKGKh5GMTYq/CGYFAjDd4RAwmn1tUDiZ59ZbsRRuJS0zQZfurA8scQKJ5j+ASAMpf1jQ6CAuz85Jr+/OInI7w+Kryx4An0DXOBC4YCVjzxNBNXNRHWK5zwnN2Up93Grb/qQc2Uu3hn5yh+8cI4rIdhROcQCua9xNPLavDzd2COSMSSNJbbMxuJHTycsPoS1r7+a55ZcIwOv3qMPlEm/CvzaTAlM1wMS2A7O5/VheG/ag5Fuzax1NqRTg1Z7CseyE+evAJ7RQvd2Ed1WBvW7YtiWPsW4tq08Nm0TyhatYb11qv45VMjqN+2m8aFU5kVdCU/G2Qh6tNnuf2NRlIffYT7rrGw8v4JbAq5gp/edS0dst9gSkk3IuwJ/GREe2JiI7znLRRvZPbrT/Di5yEkjruR60MqcW2YzaycNgy751ek736XD6bsIvoXd3BFaj5Ln1rAsSE/46Y/96ZywRZMO5/mpQ0WIq+9k8tL5rF0jZ2ef72b0QFrKShpoDHQj10vTiUn7UZu/UtHSvZZ+EGfNuR9cgePTskh7Mbn+Un8ZtZ+OJt97X7MFddcS5/Aw7Rtl0F9QyOH8grp2lE9WFPBspVF9O4aRklZLmu2NDMyPpG0/i1s8bdR9dEOcpZ+wCrHWG57cjSug26Gd4mlavf7TN6dSPcR4xgaWUl1cQ5JyRFs3J3PzlnvsDJuJGNLl7MyfAA9Kz9nb2R30lyFVK8uwXztbVw6Lg2/fOiTfJgpTzzPLNNgBvQbzB9TK9kd14vYhBhSbZ6s1Gg03wUeA9fkdFFYUUtVXRM24/OKFx8ec6X+iDu+rH7USIBaVm8jKD/vdoUsK6um/Fs/rmA8fSB6QXkaYsHYX1aPPx9xIrznR/56132okE0OJ6EhgbRPiz8+PbQnrPgaEahQ3yx6psdvFRd7pz3Av94tIO7G+3nslk6oW/0nkFpTspBFeX3p2C6GlEjv5v8oZVRnr2dV9WWM6mYl6OQEfkuUsXRZLm0SU8jMjPVu02g0Gs2FjBYMmu+Eb0f/ajQajebbwjeOodH8R9FiQaPRaC4utGDQaDQajUZzVrRg0Gg0Go1Gc1a0YNBoNBqNRnNWtGDQaDQajUZzVrRg0Gg0Go1Gc1a0YNBoNBqNRnNWtGDQaDQajUZzVrRg0Gg0Go1Gc1a0YNBoNBqNRnNWtGDQaDQajUZzVrRg0Gg0Go1Gc1a0YNBoNBqNRnMW4P8B10sLf0fzaIsAAAAASUVORK5CYII=" style="width: 645px; height: 477px;" width="525"> </div><!-- Comment details --><a name="endocrinology8223attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8223_1_IMG%255f2069.JPG">IMG_2069.JPG</a>&nbsp;&nbsp;(1,1 MB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8223_2_IMG%255f2130.JPG">IMG_2130.JPG</a>&nbsp;&nbsp;(1,2 MB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8223_3_IMG%255f2131.JPG">IMG_2131.JPG</a>&nbsp;&nbsp;(1,2 MB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8223_4_IMG%255f2133.JPG">IMG_2133.JPG</a>&nbsp;&nbsp;(1,3 MB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8223_5_IMG%255f2079.JPG">IMG_2079.JPG</a>&nbsp;&nbsp;(997,1 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8223_6_IMG%255f2079.JPG">IMG_2079.JPG</a>&nbsp;&nbsp;(997,1 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8223_7_IMG%255f2079.JPG">IMG_2079.JPG</a>&nbsp;&nbsp;(997,1 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8223_8_IMG%255f2088.JPG">IMG_2088.JPG</a>&nbsp;&nbsp;(979,5 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8223_9_IMG%255f2092.JPG">IMG_2092.JPG</a>&nbsp;&nbsp;(1,1 MB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8223_10_IMG%255f2069.JPG">IMG_2069.JPG</a>&nbsp;&nbsp;(1,1 MB)<br>&nbsp;&nbsp;11.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8223_11_IMG%255f2130.JPG">IMG_2130.JPG</a>&nbsp;&nbsp;(1,2 MB)<br>&nbsp;&nbsp;12.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8223_12_IMG%255f2133.JPG">IMG_2133.JPG</a>&nbsp;&nbsp;(1,3 MB)<br>&nbsp;&nbsp;13.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8223_13_IMG%255f1954.JPG">IMG_1954.JPG</a>&nbsp;&nbsp;(1,3 MB)<br>&nbsp;&nbsp;14.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8223_14_IMG%255f2314.JPG">IMG_2314.JPG</a>&nbsp;&nbsp;(1,8 MB)<br>&nbsp;&nbsp;15.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8223_15_IMG%255f2312.JPG">IMG_2312.JPG</a>&nbsp;&nbsp;(2,1 MB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20151231&edate=20150901&rec=8223">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-09-30T18:28:19+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-09-30T18:28:19+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Phase 3 Study of Intravesical Apaziquone (EOquin®) as a Surgical Adjuvant in the Immediate Postoperative Period in Patients Undergoing TURBT</title>
	<pubDate>2015-09-30T16:57:14+02:00</pubDate>
	<wp:post_id>6860</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: clinicaltrials.<wbr>gov is listing a new Ph3 sponsored by Spectrum, which PE will measure time to recurrence.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Trial Details</STRONG> </div><div style="margin-bottom: 10px;">Ref: NCT02563561 </div><div style="margin-bottom: 10px;">Recruitment: 1869 </div><div style="margin-bottom: 10px;"><UL><LI class="color-bullet" style="margin-top: 0.7ex;">Patient must have a diagnosis with urothelial carcinoma of the bladder with clinically apparent tumor Ta, G1-G2.<wbr>
</LI>
<LI class="color-bullet" style="margin-top: 0.7ex;">Patient will have &le;4 tumors, none of which exceeds 3.<wbr>5 cm in diameter.<wbr>
</LI>
<LI class="color-bullet" style="margin-top: 0.7ex;">Patient must be willing to give written informed consent and must be able to adhere to dosing and visit schedules, and meet all study requirements.<wbr>
</LI>
<LI class="color-bullet" style="margin-top: 0.7ex;">Patient is at least 18 years of age at randomization.<wbr>
</LI>
<LI class="color-bullet" style="margin-top: 0.7ex;">Patient must be willing to practice two forms of contraception, one of which must be a barrier method, from study entry until at least 35 days after the last dose of the study drug.<wbr>
</LI>
<LI class="color-bullet" style="margin-top: 0.7ex;">Females of childbearing potential must have a negative pregnancy test within 30 days prior to randomization.<wbr> Females who are postmenopausal for at least 1 year (defined as more than 12 months since last menses) or are surgically sterilized do not require this test
</LI>
</UL> </div><div style="margin-bottom: 10px;">Timelines: from Sept 2015 to Nov 2020 : March 2021 </div><div>Location: </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20151231&edate=20150901&rec=10687">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-09-30T16:57:14+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-09-30T16:57:14+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Photocure and KARL STORZ to Start Comparative Trial in the U.S for Diagnosis of Bladder Cancer</title>
	<pubDate>2015-09-30T16:24:07+02:00</pubDate>
	<wp:post_id>6861</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: This is a prospective, open, comparative, within patient controlled multicenter trial of blue light cystoscopy with Cysview and white Light cystoscopy using KARL STORZ D-Light C PDD Flexible Videoscope System in detection of bladder cancer in patients with bladder cancer.<wbr> PE will measure the proportion of patients with histologically confirmed malignancy where malignancy is only detected with blue light cystoscopy with Cysview and not white light cystoscopy.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Trial Design</STRONG> </div><div style="margin-bottom: 10px;">Ref <a href="https://clinicaltrials.gov/ct2/show/NCT02560584?recr=Open&no_unk=Y&fund=2&rcv_s=08%2F30%2F2015&rank=6" class="defaultlink">NCT02560584</a> </div><div style="margin-bottom: 10px;">Recruitment: approx.<wbr> 360 </div><div style="margin-bottom: 10px;"><UL><LI class="color-bullet" style="margin-top: 0.7ex;">Patients with bladder cancer in follow-up for tumor recurrence (Note: Patients should be included at the first surveillance cystoscopy after Transurethral Resection of the Bladder (TURB))
</LI>
<LI class="color-bullet" style="margin-top: 0.7ex;">History of multiple or recurrent tumors
</LI>
<LI class="color-bullet" style="margin-top: 0.7ex;">Age 18 or older
</LI>
</UL> </div><div>Timelines: from Sept2015 to Nov/<wbr>Dec 2016 </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20151231&edate=20150901&rec=10686">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-09-30T16:24:07+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-09-30T16:24:07+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>NETTER-1 Data At ESMO - Key Takeaways</title>
	<pubDate>2015-09-30T14:26:52+02:00</pubDate>
	<wp:post_id>6862</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment:As anticipated, AAA released its phIII data from the NETTER-1 study at a Presidential Symposium at ESMO last Sunday.<wbr> The trial which prospectively evaluated the PRRT drug Lutathera demonstrated a signficant increase in PFS compared to octreotide in patients with progressive advanced midgut neuroendocrine tumours.<wbr> After a median of 30-months follow-up of 229 patients, treatment with Lutatha resulted in a 79.<wbr>1% risk reduction in disease progression (p&lt;0.<wbr>001) with the median PFS not reached with Lutathera versus 8.<wbr>4 months with octreotide (HR=0.<wbr>209).<wbr> AAA we believe will file before the year-end or early next year for approval in combination with SSA therapy for the treatment of mid-gut carcinoids.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>NETTER-1 Data</STRONG> </div><div style="margin-bottom: 10px;">The NETTER-1 study was undertaken in 51 centres in 10 countries across the world.<wbr> 75% of patients had ileal tumours and almost all had liver metastases with some being lymph node positive.<wbr> The strong performance of Lutathera (peptide radionuclide receptor therapy with Lu-177 Dotatate) in the study endorses data previously reported from a number of uncontrolled trials undertaken in greater than 1000 patients.<wbr> The slides below from Professor P Ruzniewski's (France) presentation and those included in the subsequent discussion by Professor E Grande (Spain) are highlighted below and illustrate both the study's key findings and some points of caution raised regarding the need for the further long-term safety assessment of Lutathera to trully characterise the product in particular the long-term incidience of pancytopenia.<wbr> </div><div style="margin-bottom: 10px;">Professor Ruzniewski in his presentation made reference to Lutathera as representing "a major advance in treatment for the progressive mid-gut carcnoid population" whilst Professor Grande suggested that "PRRT is here to stay with the NETTER-1 data the most impressive data seen so far in the NET field.<wbr>" </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8215_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8215_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8215_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8215_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8215_5_ScreenCapture5.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8215_6_ScreenCapture6.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8215_7_ScreenCapture7.jpg"> </div><div style="margin-bottom: 10px;"><STRONG>Professor E Grande's Discussion Of the Netter-1 Data</STRONG> </div><div style="margin-bottom: 10px;"><STRONG><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8215_9_ScreenCapture9.jpg"></STRONG> </div><div style="margin-bottom: 10px;"><STRONG><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8215_10_ScreenCapture10.jpg"></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Ipsen's Messaging Regarding Lutathera At The Global Somatuline Forum (GSF)</STRONG> </div><div style="margin-bottom: 10px;">Whilst not speculating on the magnitude of the Lutathera response most of the points mentioned at the GSF retain their relevance.<wbr> </div><div style="margin-bottom: 10px;">Intelligence does suggest that AAA will submit for and potentially gain label for use in combination with SSAs not specifically octreotide.<wbr> However, payers or national guidelines may still make reference to octreotide given the design of the NETTER-1 study.<wbr> From a timing perspective, Ipsen's PRELUDE study should provide data on PRRT usage with lanreotide broadly coinciding with the approval of Lutathera.<wbr> </div><div style="margin-bottom: 10px;">As mentioned, establishing a good long-term safety profile is something AAA will need to focus upon to gain full acceptance of its product.<wbr> There are also some practicalities and logistics that will not make the drug not so easily available for all patients e.<wbr>g number and access to centres, drug cost and the duration of hospital stay plus the cost of managing the patient's radioactive waste.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8215_11_ScreenCapture11.jpg"> </div><div style="margin-bottom: 10px;"><STRONG>Competitor's Positing Relative To AAA</STRONG> </div><div style="margin-bottom: 10px;">Finally, we need to anticipate what Novartis will do in terms of positioning its own NET portfolio relative to that of AAA.<wbr> Evidence to date suggests that together with the RADIANT-4 data it will look to try and push the usage of Lutathera therapy after everolimus usage.<wbr> </div><div style="margin-bottom: 10px;">Poster 2 229 focused on what should be the sequencing of these agents (see PFS outcome below) with some preliminary data suggesting a benefit of SSA/<wbr>Everolimus prior to PRRT therapy.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8215_8_ScreenCapture8.jpg"> </div><div>Much of the data reviewed above will be discussed in more detail during a specific ESMO TC/<wbr>Webex organised by the Franchise to be held on Tuesday 6th October.<wbr> </div><!-- Comment details --><a name="endocrinology8215attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8215_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(95,6 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8215_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(79,7 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8215_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(54,4 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8215_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(84,7 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8215_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(76,5 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8215_6_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(61 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8215_7_ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(62,1 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8215_8_ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(35,1 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8215_9_ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(58,5 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8215_10_ScreenCapture10.jpg">ScreenCapture10.jpg</a>&nbsp;&nbsp;(47,1 KB)<br>&nbsp;&nbsp;11.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8215_11_ScreenCapture11.jpg">ScreenCapture11.jpg</a>&nbsp;&nbsp;(135 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20151231&edate=20150901&rec=8215">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-09-30T14:26:52+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-09-30T14:26:52+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Bayer Defeats U.S. FTC in Probiotics/Dietary Supplement Case</title>
	<pubDate>2015-09-30T10:57:13+02:00</pubDate>
	<wp:post_id>6863</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Federal regulators have alleged that Bayer lacked reliable scientific evidence to support its claims re its Phillip's Colon Health (capsules containing Lactobacillus gasseri, KS-13, Bifidobacterium bifidum G9-1 and<BR>Bifidobacterium longum MM-2).<wbr> Bayer made the case that the substantiation that FTC sought went beyond Congress's intent for how dietary supplements should be regulated under Dietary Supplement Health and Education Act.<wbr> Under this law, Bayer presented evidence that its claims were properly substantiated.<wbr> According to a partner at the law firm representing the pharma group, "the government had been seeking to subject dietary supplements to the same gold standard for testing as prescription drugs".<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Historical Background</STRONG> </div><div style="margin-bottom: 10px;">Last year the US FTC brought a motion against Bayer for claims made in relation to Phillips' Coon Health (<A href="http://www.nutraingredients-usa.com/Manufacturers/Bayer-gratified-with-court-decision-vs-FTC">http:/<wbr>/<wbr>www.<wbr>nutraingredients-usa.<wbr>com/<wbr>Manufacturers/<wbr>Bayer-gratified-with-court-decision-vs-FTC</A>) </div><div style="margin-bottom: 10px;">The lawsuite filed by the U.<wbr>S FTC alleged that Bayer lacked reliable scientific evidence to support its claim that its Phillip's Colon Health could 'defend against' occasional constipation, diarrhea, and gas and bloating, and its implied claim that the product cure those conditions.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>About Phillips Colon Health</STRONG> </div><div style="margin-bottom: 10px;"><STRONG><a href="http://phillipspro.com/en/home/product-information/index.php" class="defaultlink">Phillips' products</a> offer probiotic chewables and capsules for digestive health, fiber supplements, laxatives (such as milk of magnesia), stool softener (liquid gel capsules containing docusate sodium).<wbr></STRONG> </div><div style="margin-bottom: 10px;"><SPAN style="text-decoration: underline;">Phillips' Colon Health</SPAN> is formulated with 3 types of probiotics that help defend against occasional symptoms such as constipation, diarrhea, gas and bloating (<A href="https://www.phillipsrelief.com/products/colon-health-probiotic-caps/">https:/<wbr>/<wbr>www.<wbr>phillipsrelief.<wbr>com/<wbr>products/<wbr>colon-health-probiotic-caps/<wbr></A>) </div><div><EM>Source; Bayer; ThomsonOne; U.<wbr>S.<wbr> v.<wbr> Bayer Corp, U.<wbr>S.<wbr> District Court, District of New Jersey, No.<wbr> 07-00001.<wbr></EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20151231&edate=20150901&rec=2559">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-09-30T10:57:13+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-09-30T10:57:13+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Revance's Injectable BTX-A Enters Phase 2 for Cervical Dystonia (CD)</title>
	<pubDate>2015-09-30T10:07:39+02:00</pubDate>
	<wp:post_id>6864</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: This news comes after two other strategic announcements in the month of September.<wbr> Revance has reported that the Ph2 study will evaluate safety, preliminary efficacy, and duration of effect of RT002 for injection in patients with moderate-to-severe isolated cervical dystonia symptoms of the neck.<wbr>Interim results are expected in 2016.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Phase 2 Details</STRONG> </div><div style="margin-bottom: 10px;">Design: open-label, sequential, dose-escalating study.<wbr> </div><div style="margin-bottom: 10px;">Objectives: to evaluate the safety, preliminary efficacy and duration of effect of a single treatment of RT002 (RTT150 (Botulinum Toxin Type A) for Injection) for isolated cervical dystonia.<wbr> </div><div style="margin-bottom: 10px;">Recruitment: Approximately 36 patients with at least moderate cervical dystonia.<wbr> </div><div style="margin-bottom: 10px;">Location: multiple sites in the United States.<wbr> </div><div style="margin-bottom: 10px;">Protocol/<wbr>Dosage: There will be three treatment groups of approximately 12 patients each who will be treated with one of three doses of RT002 for injection.<wbr> </div><div style="margin-bottom: 10px;">The primary efficacy endpoint of the study is an improvement in dystonia symptoms as measured by change (reduction) from baseline in TWSTRS (Toronto Western Spasmodic Torticollis Rating Scale) total score at four weeks.<wbr> TWSTRS is a composite scale that covers different features of the cervical dystonia condition.<wbr> The first part of the scale is based on the physical findings and severity of dystonia, the second part rates the patient&rsquo;s perceived level of disability, and the third part rates the pain.<wbr> </div><div style="margin-bottom: 10px;">Numerous secondary efficacy endpoints will be measured, including duration of effect and patient-rated quality of life as measured by change from baseline in CDIP (Cervical Dystonia Impact Profile).<wbr>All patients will be followed out to nine weeks post-injection.<wbr> Patients with sustained improvement after this initial period of nine weeks will continue to be assessed for duration of efficacy and other measures until they return to baseline or for up to a total of 24 weeks after treatment.<wbr> </div><div>Source: Revance </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20151231&edate=20150901&rec=8195">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-09-30T10:07:39+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-09-30T10:07:39+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Osmotica Pharm. Gains FDA Acceptance For Ontinua ER to Treat Spasticity in Multiple Sclerosis</title>
	<pubDate>2015-09-30T02:39:47+02:00</pubDate>
	<wp:post_id>6865</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Osmotica NDA for Ontinua<SUP>TM</SUP> extended-release tablets (arbaclofen), used in the treatment for spasticity in MS, has recently been accepted by the FDA.<wbr> In addition, another key product of Osmotica, Osmolex, has progressed to phase III </div><div style="margin-bottom: 10px;">Mark Stacy, MD, Vice Dean for Clinical Research, Duke University School of Medicine and head of the Osmotica&rsquo;s Scientific Advisory Board reported &ldquo;Using our proprietary OsmodexTM technology, we have developed OntinuaTM ER, a tablet that is intended to treat spasticity in patients with Multiple Sclerosis&rdquo; &ldquo;Ontinua<SUP>TM </SUP>ER given twice a day was shown to meet the co-primary endpoints of the Modified Ashworth Scale and the Clinical Global Impression of Change in the clinical study.<wbr> &ldquo;Ontinua<SUP>TM </SUP>ER represents a great treatment option for MS patients with spasticity, and we look forward to bringing this therapy to patients.<wbr>&rdquo; </div><div style="margin-bottom: 10px;">Praveen Tyle, PhD, President and CEO of Osmotica Pharmaceutical Corp highlighted &ldquo;Using our proprietary Osmodex<SUP>TM</SUP> technology, we have developed Ontinua<SUP>TM</SUP> ER, a tablet that is intended to treat spasticity in patients with Multiple Sclerosis.<wbr> We believe this product represents an innovative option for clinicians and physicians and we look forward to bringing this therapy to our patients upon regulatory approval.<wbr>&rdquo; </div><div style="margin-bottom: 10px;">Osmotica other key product, Osmolex<SUP>TM </SUP>ER, is a once-a-day, drug formulation of Amantadine HCI Extended Release Tablets also developed with Osmotica&rsquo;s patented Osmodex<SUP>TM</SUP> technology.<wbr> It is indicated for the treatment of levodopa induced dyskinesia for patients with Parkinson&rsquo;s disease.<wbr> Osmolex<SUP>TM</SUP> ER was granted orphan exclusivity in July 2015 and currently has a clinical trial program, including two phase 3 trials evaluating two doses (240mg and 320mg) in 324 aggregate patients.<wbr> Osmotica intends to file a NDA in 2016 </div><div style="margin-bottom: 10px;">Osmotica Pharmaceutical is focused on drug delivery technologies with a special focus in neurology-based therapies.<wbr> Osmotica is an international group of companies with principal operations located in the United States, Argentina and Hungary.<wbr> </div><div>Source : Osmotica&rsquo;s website at <A href="http://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.osmotica.com%2F&amp;esheet=51189964&amp;newsitemid=20150928006528&amp;lan=en-US&amp;anchor=www.osmotica.com&amp;index=1&amp;md5=8f51938c5ce15bcd6fa927b02cbd6486" target="_blank">www.<wbr>osmotica.<wbr>com</A>.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20151231&edate=20150901&rec=8194">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-09-30T02:39:47+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-09-30T02:39:47+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Key Messages from Meeting with Synergy Pharm. Senior Management and Investors</title>
	<pubDate>2015-09-29T14:18:04+02:00</pubDate>
	<wp:post_id>6866</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The report from BTIG outlines that plecanatide could become a meaningful new treatment with annual sales potential of approx $600M within 5 years post launch.<wbr> Synergy's management highlighted the drug's potential sources of differentiation, its unique MoA and a better tolerability profile vs.<wbr> Linzess and Amitiza.<wbr> With approx $160M of cash, the company is adequately funded to complete the clinical development through NDA submission (for CIC and IBS-C).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><U>Ph2b Results in IBS-C Show Promise</U> </div><div style="margin-bottom: 10px;">Synergy is currently evaluating once a day oral plecanatide at 3 mg and 6 mg doses vs.<wbr> placebo for IBS-C (constipation-predominant IBS) in two large patient Phase 3 trials (combined n ~2,100).<wbr> </div><div style="margin-bottom: 10px;">The primary study endpoints will be the aforementioned Overall Responder.<wbr> Interim data from the first study is expected by early 2016, with additional top-line data from the second study expected by mid-2016.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Pending favorable trial results, the company is targeting an NDA filing for IBS-C in 4Q16.<wbr></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2556_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><U>Top-Line Results from 2 Ph3 in CIC</U> </div><div style="margin-bottom: 10px;">Meaningful efficacy (20% patient response rate vs 10% with placebo) with a low incidence of diarrhea side effect (~3-5%).<wbr> <STRONG>Based on these positive Phase 3 results, Synergy is targeting a January 2016 NDA submission, with an FDA approval in 2017E</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2556_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><U>Side effect comparison</U> </div><div style="margin-bottom: 10px;"><STRONG>Compared with Amitiza and LINZESS, plecanatide demonstrates meaningfully lower rates of diarrhea</STRONG>.<wbr>  </div><div style="margin-bottom: 10px;"><UL><LI>In registrational trials for CIC and IBS-C, 16-20% of LINZESS patients experienced diarrhea, vs.<wbr> 3%-6% for plecanatide 3 mg and 6 mg.<wbr> 
</LI>
<LI>In addition to diarrhea, a significant number of patients taking Amitiza reported nausea (8%-29%) and headaches (11% at 24 mcg b.<wbr>id for CIC).<wbr>
</LI>
</UL> </div><div><EM>Source: BTIG September 29 Report</EM> </div><!-- Comment details --><a name="gastroenterology2556attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2556_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(70 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2556_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(76,4 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2556_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(49,6 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20151231&edate=20150901&rec=2556">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-09-29T14:18:04+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-09-29T14:18:04+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Takeda's 24-Week 22.5mg Leuplin® PRO Approved For Prostate And Premenopausal Breast Cancer In Japan</title>
	<pubDate>2015-09-29T12:22:52+02:00</pubDate>
	<wp:post_id>6867</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Takeda submitted New Drug Application for 6 month formulation of its leuprorelin on Sept 2014.<wbr> On 28th Sept 2015, Takeda announced that its Leuplin&reg; PRO for injection kit 22.<wbr>5mg (s.<wbr>c) is approved in Japan for prostate and premenopausal breast cancer.<wbr> This is its 6 month formulation of leuprorelin acetate.<wbr> This is the first approval of 24 week depot leuprorelin for the treatment of premenopausal breast cancer.<wbr> </div><div style="margin-bottom: 10px;">This approval is based on the results of two clinical ph3 comparative study.<wbr> </div><div style="margin-bottom: 10px;">Leuplin was initially launched as a once daily administration by injection and Takeda has applied multiple innovations to turn it into a sustained release microcapsule depot formulation, enabling to maintain stable blood concentration levels over a long period of time.<wbr> At present both 1 month and 3 month formulations have been approved and are marketed in Japan.<wbr> The 6 month depot have already been available in US, EU and some countries in Asia.<wbr> </div><div>Source: Takeda Press Release 28 Sept 2015 </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Oncology10827c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">Comment: Takeda announced that its Leuplin PRO for injection kit 22.<wbr>5mg is launched in Japan for Prostate and Premenopausal breast cancer with a price of &yen; 105,039.<wbr> </div><div style="margin-bottom: 10px;"><P style="white-space: normal; word-spacing: 0px; text-transform: none; color: #000000; font: 14px/21px Arial, 'Hiragino Kaku Gothic Pro', sans-serif, Helvetica, Geneva; margin: 0px 0px 15px; widows: 1; letter-spacing: normal; text-indent: 0px; -webkit-text-stroke-width: 0px; padding: 0px;"><STRONG style="font-size: 14px; font-weight: bold; line-height: 1.3;">Overview of the 24-week depot formulation </STRONG></P> </div><div style="margin-bottom: 10px;"><TABLE border="1" style="margin-bottom: 20px; border-top: #e6e6e6 1px solid; width: 693px; white-space: normal; word-spacing: 0px; text-transform: none; color: #000000; font: 14px/21px Arial, 'Hiragino Kaku Gothic Pro', sans-serif, Helvetica, Geneva; border-spacing: 0px; border-left: #e6e6e6 1px solid; widows: 1; letter-spacing: normal; text-indent: 0px; -webkit-text-stroke-width: 0px;"><TBODY><TR><TD style="border-right: #e6e6e6 1px solid; border-bottom: #e6e6e6 1px solid; margin: 0px; padding: 10px;">Brand name</TD>
<TD style="border-right: #e6e6e6 1px solid; border-bottom: #e6e6e6 1px solid; margin: 0px; padding: 10px;">Leuplin<SUP>&reg;</SUP><STRONG style="font-weight: bold;"> </STRONG>PRO for Injection Kit 22.<wbr>5 mg</TD>
</TR>
<TR><TD style="border-right: #e6e6e6 1px solid; border-bottom: #e6e6e6 1px solid; margin: 0px; padding: 10px;">Generic name</TD>
<TD style="border-right: #e6e6e6 1px solid; border-bottom: #e6e6e6 1px solid; margin: 0px; padding: 10px;">Leuprorelin acetate</TD>
</TR>
<TR><TD style="border-right: #e6e6e6 1px solid; border-bottom: #e6e6e6 1px solid; margin: 0px; padding: 10px;">Indications     </TD>
<TD style="border-right: #e6e6e6 1px solid; border-bottom: #e6e6e6 1px solid; margin: 0px; padding: 10px;">Prostate cancer<BR>Premenopausal breast cancer</TD>
</TR>
<TR><TD style="border-right: #e6e6e6 1px solid; border-bottom: #e6e6e6 1px solid; margin: 0px; padding: 10px;">Dosage and administration</TD>
<TD style="border-right: #e6e6e6 1px solid; border-bottom: #e6e6e6 1px solid; margin: 0px; padding: 10px;">Usually, for adults, 22.<wbr>5 mg of Leuprorelin Acetate is subcutaneously administered once every 24 weeks.<wbr><BR>When using Leuplin<SUP>&reg;</SUP> PRO, it should be used after suspending it completely by transferring the whole quantity of the vehicle into the powder part, by pressing the plunger rod, with the injection needle held upward, with caution against foaming.<wbr></TD>
</TR>
<TR><TD style="border-right: #e6e6e6 1px solid; border-bottom: #e6e6e6 1px solid; margin: 0px; padding: 10px;">Drug price</TD>
<TD style="border-right: #e6e6e6 1px solid; border-bottom: #e6e6e6 1px solid; margin: 0px; padding: 10px;">&yen; 105,039</TD>
</TR>
</TBODY>
</TABLE> </div><div>Source Takeda Press Release 15 Dec 2015 </div></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20151231&edate=20150901&rec=10683">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-09-29T12:22:52+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-09-29T12:22:52+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Generex Starts Buccal Leuprolide R&D Work for Endocrine Disorders</title>
	<pubDate>2015-09-29T11:34:47+02:00</pubDate>
	<wp:post_id>6868</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Generex recently announced a <A href="http://investor.generex.com/releasedetail.cfm?releaseid=914806">Memorandum of Understanding</A> with <ORG>NHTherapeutics, Inc.<wbr></ORG> pursuant to which they will co-develop a formulation for the delivery of Leuprolide via the buccal mucosa using the Generex proprietary RapidMist™ buccal drug delivery platform technologies.<wbr> The companies' initial goal is to develop the product in the 'field of endocrine disorders', such as hypogonadism.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Generex Technology</STRONG> </div><div style="margin-bottom: 10px;">The Generex proprietary RapidMist™ drug delivery platform technology administers active pharmaceutical ingredient via aerosolized metered dose spray into the mouth for rapid absorption by the buccal mucosa.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Generex has received from NHTherapeutics the first tranche of funding as well as the initial shipment of Leuprolide.<wbr> </div><div style="margin-bottom: 10px;">The Generex RapidMist™ R&amp;D protocols have been initiated, the goal of which is to achieve a formulation for the safe, simple, rapid, dose-specific, and effective administration of the active pharmaceutical ingredient into the human body via the buccal mucosa, after which local irritation and stability testing will be undertaken.<wbr> </div><div style="margin-bottom: 10px;">Upon successful completion of the R&amp;D work, Generex will grant to NHTherapeutics a license for the global commercial exploitation of the product in the field of endocrine disorders in exchange for royalties.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>About NHTherapeutics</STRONG> </div><div><UL><LI>incorporated in Toronto, Canada, with a subsidiary in the Netherlands.<wbr></LI>
<LI>clinical stage pharmaceutical company that focuses on conditions associated with decreased hormonal levels (hypogonadism) due to aging or disease.<wbr> Current treatment options for hypogonadism have abuse liability issues and other safety concerns, may be difficult to administer and have limited efficacy.<wbr></LI>
</UL> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20151231&edate=20150901&rec=8208">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-09-29T11:34:47+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-09-29T11:34:47+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: ReNeuron Completes The Largest Placing For A Cell Therapy Company & Moves Stroke Programme Into PhII</title>
	<pubDate>2015-09-29T11:15:05+02:00</pubDate>
	<wp:post_id>6869</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">ReNeuron Completes The Largest Placing For A Cell Therapy Company & Moves Stroke Programme Into PhII</span>&nbsp;<br><span style="font-size: 12px;">Comment ReNeuron, a leading UK based cell therapy company has raised a total 
of £68.<wbr>4m, before expenses, through a conditional placing that will enable the 
Company to build on the considerable recent progress it has achieved across its 
therapeutic programmes.<wbr> The placing will provide funding for the group's phII 
stroke disability and retinitis programmes through to market authorisation 
based on existing clinical development plans which anticipates PhII/<wbr>III data 
available for the stroke cell therapy in 2018.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20151231&edate=20150901&rec=8109">...</a><br></div><div style="margin-bottom: 10px;">&pound;68.<wbr>4mln raised in a share issue to support Clinical development is expected to fund the program until 2019.<wbr>  Hopefully long enough to see ReNeuron key product CTX (disability post-stroke) move into and complete pIII trials.<wbr> </div><div style="margin-bottom: 10px;">The clinical programmes include its CTX stem cell therapy candidate for disability caused by ischaemic stroke, currently in phase II clinical trials with data expected in the first half of 2016.<wbr> Olav Helleb&oslash;, CEO of ReNeuron reported &ldquo;Subject to an overall assessment of the collective data from the Phase I and Phase II studies, we are planning to submit an application to commence a controlled, pivotal Phase II/<wbr>III clinical trial in chronically disabled stroke patients,&rdquo; the company said.<wbr> </div><div style="margin-bottom: 10px;">At a recent company annual general meeting, Olav Helleb&oslash; reported that : &ldquo;Our business has made great strides over the past year and we are now funded to deliver key clinical milestones across all of our therapeutic programmes over the next three years.<wbr>&rdquo; </div><div>Source: ReNeuron </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20151231&edate=20150901&rec=8193">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology8109">View thread  Neurology8109: ReNeuron Completes The Largest Placing For A Cell Therapy Company & Moves Stroke Programme Into PhII</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-09-29T11:15:05+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-09-29T11:15:05+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Galderma Releases A New Range Of Facial Fillers</title>
	<pubDate>2015-09-29T11:07:58+02:00</pubDate>
	<wp:post_id>6870</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Galdema have recently released a new range of facial fillers called Emmervel.<wbr> </div><div style="margin-bottom: 10px;">Recently reviewed by Galderma Scientist, Dr Barry Lycka (costmetic Dermatologist) and Pelle Winlof, Emmervel a dermal filler (Hyaluronic Acid) was recently introduced into the North American market.<wbr> This new filler is thought to have a softer feel than others currently on the market providing a more natural look.<wbr> </div><div style="margin-bottom: 10px;">The product is positioned with a holistic view point; it’s backed by quality manufacturing, sound scientific research and dedicated customer service to both patients and physicians.<wbr> </div><div><DIV>
<P>Source Digital Journal</P></DIV> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20151231&edate=20150901&rec=8191">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-09-29T11:07:58+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-09-29T11:07:58+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Allergan Reports Continuing Operations Forecast</title>
	<pubDate>2015-09-29T11:07:48+02:00</pubDate>
	<wp:post_id>6871</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Management's objectives are to provide transparency ahaead of the Q3 financial results (November 3rd).<wbr> Following the sale of the generics business to Teva (transaction expected to close Q1:16), the reporting will be changing to 4 segments, namely: US Medical, US Brands, International Brands and Anda distribution.<wbr> Top-lines are provided below.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Key Messages</STRONG> </div><div style="margin-bottom: 10px;"><U>Morgan Stanley analysts</U> see that categorizing certain products into segments, such as Botox, remains unknown.<wbr> </div><div style="margin-bottom: 10px;"><U>For the second-half of 2015</U>, <ORG value="NYSE:AGN">Allergan</ORG> expects to report non-GAAP continuing operations as follows: </div><div style="margin-bottom: 10px;"><UL type="disc"><LI><STRONG>Revenue is expected to be greater than <MONEY>$8 billion</MONEY></STRONG> </LI>
<LI>Adjusted earnings before interest and taxes (EBIT) are expected to be between <MONEY>$3.<wbr>8 billion and $4.<wbr>0 billion</MONEY> </LI>
<LI>Non-GAAP earnings per share (EPS) are expected to be between <MONEY>$6.<wbr>25 and $6.<wbr>65</MONEY></LI>
</UL> </div><div style="margin-bottom: 10px;"><ORG value="NYSE:AGN">Allergan's</ORG> continuing operations forecast for the second half of 2015 includes all of the company's non-GAAP interest expense of approximately <MONEY>~$750 million</MONEY>.<wbr> </div><div style="margin-bottom: 10px;"><U>Following the close of the divestiture of the Generics business to Teva</U>, New Allergan expects to have a powerful financial profile to drive continued long-term growth: </div><div style="margin-bottom: 10px;"><UL type="disc"><LI>10% branded revenue growth </LI>
<LI>Non-GAAP gross margins of 77% to 79% with additional long-term expansion anticipated </LI>
<LI>Non-GAAP SG&amp;A as a percentage of revenue between 21-24%, declining within that range over time </LI>
<LI>Non-GAAP tax rate of ~15% </LI>
<LI>Interest expense for New Allergan will be largely dependent on capital deployment decisions following the close of the transaction </LI>
<LI>Commitment to investment grade ratings</LI>
</UL> </div><div>Source: Allergan; Morgan Stanley </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20151231&edate=20150901&rec=8190">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-09-29T11:07:48+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-09-29T11:07:48+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Revance Announces Initiation of Ph3 Study with RT001(Topical Gel) for LCL</title>
	<pubDate>2015-09-29T10:21:21+02:00</pubDate>
	<wp:post_id>6872</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Revance has announced the dosing of patients in the pivotal study to assess the safety and efficacy of the topical drug for lateral canthal lines (or crow's feet).<wbr> Information about the trial, including patient eligibility criteria, has not yet be published in clinicaltrials.<wbr>gov.<wbr> The company plans to release interim results in H1:16.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><U>Design</U>: randomized, double-blind, parallel-group, placebo-controlled study </div><div style="margin-bottom: 10px;"><U>Objectives</U>: to evaluate the safety and efficacy of RT001, also referred to as RTT150 (Botulinum Toxin Type A) Topical Gel, for the treatment of moderate to severe lateral canthal lines.<wbr> </div><div style="margin-bottom: 10px;"><U>Recruitment</U>: A total of up to 450 adult patients will be enrolled </div><div style="margin-bottom: 10px;"><U>Location</U>: multiple sites in the United States.<wbr> </div><div style="margin-bottom: 10px;"><U>Regimen/<wbr>Dosing</U>: randomized 1:1 to a single treatment of either RT001 topical gel or placebo.<wbr> </div><div style="margin-bottom: 10px;">The product will be applied to lateral canthal lines on both sides of the face using Revance's proprietary applicator.<wbr> </div><div style="margin-bottom: 10px;"><U>PE</U>: The primary efficacy endpoints are composites based upon the Investigator's Global Assessment of Lateral Canthal Lines (IGA-LCL) assessment and the Patient Severity Assessment (PSA) between baseline and 28 days after treatment.<wbr> </div><div style="margin-bottom: 10px;">One composite endpoint includes those patients with a 2-point or greater improvement as graded by the investigator's assessment and the patient's self-assessment.<wbr> </div><div style="margin-bottom: 10px;">The other composite endpoint includes those patients who experience a 1-point or greater improvement in the investigator's and patient's assessments.<wbr> Patients will also be assessed at Day 28 for muscle paralysis (or paralytic effect) using electromyography (EMG).<wbr> </div><div>Source: Revance </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20151231&edate=20150901&rec=8188">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-09-29T10:21:21+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-09-29T10:21:21+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Nestlé Health Science Licences Rights to Lipid Therapeutics' Novel UC Therapy</title>
	<pubDate>2015-09-28T15:05:23+02:00</pubDate>
	<wp:post_id>6873</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-size: 12px;">Thanks Brigitte, So if I understand well, this would not be a substitute to mesalazine, but would be ued in case mesalazine alone is not enough.<wbr> So it is still consistent with the "step-up approach" used in this disease management, and depending on results, this might delay the start of tnf-alpha inhibitors in the patient treatment pathway.<wbr> Definetely an interesting topic to follow for the long-term competitive environement of Etiasa in China.<wbr></span>&nbsp;<br></div><div>Ferring recently launched CORTIMENT MMX in EU; the company is the licensee in Asia (excluding Japan), Australia, Canada, Latin America and Africa).<wbr> The product is indicated &ldquo; &hellip; where 5-ASA treatment is not sufficient&rdquo;.<wbr> With Pentasa and Cortiment MMX Ferring is likely to be seen as a partner of choice for the treatment of UC products.<wbr> In terms of competition with Etiasa, interesting to monitor if the company plans to seek registration for the product in China, and look to market itself or with a partner ? </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20151231&edate=20150901&rec=2553">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2536">View thread  GastroEnterology2536: Nestlé Health Science Licences Rights to Lipid Therapeutics' Novel UC Therapy</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-09-28T15:05:23+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-09-28T15:05:23+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: First Analysis Demonstrates Synthetic's SYN-004's Ability to Protect the Microbiome from Damage Caused by IV Antibiotics</title>
	<pubDate>2015-09-28T13:45:01+02:00</pubDate>
	<wp:post_id>6874</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">First Analysis Demonstrates Synthetic's SYN-004's Ability to Protect the Microbiome from Damage Caused by IV Antibiotics</span>&nbsp;<br><span style="font-size: 12px;">Comment: The data of a pilot study of humanized pigs were presented in a late-breaker oral presentation at the 2015 Interscience Conference of Antimicrobial Agents and Chemotherapy and International Congress of Chemotherapy and Infection joint meeting (ICAAC/<wbr>ICC 2015) in San Diego, CA.<wbr> They show that SYN-004 protected the gut microbiome from damage often caused by the intravenous (IV) beta-lactam antibiotic, ceftriaxone.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20151231&edate=20150901&rec=2543">...</a><br></div><div style="margin-bottom: 10px;">Synthetic Biologis has reported the initiation of its SYN-004 Phase 2b proof-of-concept clinical trial, to evaluate the effectiveness of SYN-004the molecule to prevent <EM>C.<wbr> difficile</EM> infection (CDI), <EM>C.<wbr> difficile</EM> associated diarrhea (CDAD) and antibiotic-associated diarrhea (AAD) in patients hospitalized for a lower respiratory tract infection and receiving intravenous (IV) ceftriaxone.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Trial Design</STRONG> </div><div style="margin-bottom: 10px;">The Ph2b, parallel-group, double-blind, placebo-controlled study of SYN-004 is expected to enroll approximately 370 patients at up to 75 global clinical sites.<wbr> </div><div style="margin-bottom: 10px;">Patients age 50 years and older, hospitalized for a lower respiratory tract infection, are expected to be randomized 1:1 into two groups, and receive either SYN-004 or placebo during the standard of care regimen of ceftriaxone (with or without a macrolide).<wbr> </div><div style="margin-bottom: 10px;">The primary objectives of this clinical trial are to evaluate the effectiveness of SYN-004 to prevent CDIs and CDAD.<wbr> </div><div style="margin-bottom: 10px;">The secondary objective of this clinical trial is to evaluate the effectiveness of SYN-004 to prevent AAD.<wbr> </div><div>Source: Company's website </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20151231&edate=20150901&rec=2552">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2543">View thread  GastroEnterology2543: First Analysis Demonstrates Synthetic's SYN-004's Ability to Protect the Microbiome from Damage Caused by IV Antibiotics</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-09-28T13:45:01+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-09-28T13:45:01+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Chr Hansen Highlights Effect of its Probiotic Strain BB-12® in Constipation</title>
	<pubDate>2015-09-28T10:57:31+02:00</pubDate>
	<wp:post_id>6875</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Chr Hansen has released on its website the results from a study, published in <EM>British Journal of Nutrition</EM>, which show that the odds for having more regular bowel movements were significantly higher when consuming the <a href="http://www.chr-hansen.com/products/product-areas/probiotics-for-dietary-supplements/strains/bb-12r.html" class="defaultlink">BB-12®</a> probiotic strain for 4 weeks, compared to the placebo group.<wbr> It is reported that these findings show a clinically relevant effect of the probiotic strain on bowel regulariyt.<wbr> According to the company, this study which recruited 1248 subjects( varying in age from 18 to 70) has resulted in the largest dataset available on the effect of probiotics on bowel function.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>About the Results</STRONG> </div><div style="margin-bottom: 10px;"><P class="bodytext">Eskesen et al.<wbr> - <EM>Effect of the probiotic strain Bifidobacterium animalis subsp.<wbr> lactis, BB-12<SUP>&reg;</SUP> on defecation frequency in healthy subjects with low defecation frequency and abdominal discomfort: a randomized, double-blind, placebo-controlled, parallel-group trial</EM> - E-published ahead of print online September 21 of 2015 in British Journal of Nutrition</P> </div><div style="margin-bottom: 10px;"><P class="bodytext"><STRONG>Abstract</STRONG></P> </div><div style="margin-bottom: 10px;"><P class="bodytext">The aim of the present study was to investigate the effect of <EM>Bifidobacterium animalis</EM> subsp.<wbr> <EM>lactis</EM>, BB-12<SUP>&reg;</SUP>, on two primary end points &ndash; defecation frequency and gastrointestinal (GI) well-being &ndash; in healthy adults with low defecation frequency and abdominal discomfort.<wbr> A total of 1248 subjects were included in a randomised, double-blind, placebo-controlled trial.<wbr> After a 2-week run-in period, subjects were randomised to 1 or 10 billion colony-forming units/<wbr>d of the probiotic strain BB-12<SUP>&reg;</SUP> or a matching placebo capsule once daily for 4 weeks.<wbr> Subjects completed a diary on bowel habits, relief of abdominal discomfort and symptoms.<wbr> GI well-being, defined as global relief of abdominal discomfort, did not show significant differences.<wbr> The OR for having a defecation frequency above baseline for &ge;50 % of the time was 1&middot;31 (95 % CI 0&middot;98, 1&middot;75), <EM>P</EM>=0&middot;071, for probiotic treatment overall.<wbr> Tightening the criteria for being a responder to an increase of &ge;1 d/<wbr>week for &ge;50 % of the time resulted in an OR of 1&middot;55 (95 % CI 1&middot;22, 1&middot;96), <EM>P</EM>=0&middot;0003, for treatment overall.<wbr> A treatment effect on average defecation frequency was found (<EM>P</EM>=0&middot;0065), with the frequency being significantly higher compared with placebo at all weeks for probiotic treatment overall (all <EM>P</EM>&lt;0&middot;05).<wbr> Effects on defecation frequency were similar for the two doses tested, suggesting that a ceiling effect was reached with the one billion dose.<wbr> Overall, 4 weeks&rsquo; supplementation with the probiotic strain BB-12<SUP>&reg;</SUP> resulted in a clinically relevant benefit on defecation frequency.<wbr> <STRONG>The results suggest that consumption of BB-12<SUP>&reg;</SUP> improves the GI health of individuals whose symptoms are not sufficiently severe to consult a doctor (ISRCTN18128385).<wbr></STRONG> <A href="http://journals.cambridge.org/action/displayAbstract?fromPage=online&amp;aid=9963226">http:/<wbr>/<wbr>journals.<wbr>cambridge.<wbr>org/<wbr>action/<wbr>displayAbstract?fromPage=online&amp;aid=9963226</A>.<wbr></P> </div><div><P class="bodytext">Source: <A href="http://www.chr-hansen.com/news-media/singlenews/one-of-the-worlds-largest-clinical-studies-on-probiotics-reinforces-gastrointestinal-benefits-of-th.html">http:/<wbr>/<wbr>www.<wbr>chr-hansen.<wbr>com/<wbr>news-media/<wbr>singlenews/<wbr>one-of-the-worlds-largest-clinical-studies-on-probiotics-reinforces-gastrointestinal-benefits-of-th.<wbr>html</A></P> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20151231&edate=20150901&rec=2549">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-09-28T10:57:31+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-09-28T10:57:31+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Gotox Now Available on the Apple App Store</title>
	<pubDate>2015-09-25T15:48:48+02:00</pubDate>
	<wp:post_id>6876</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Gotox is a new mobile app that was developed in response to the needs of &gt;10 million people getting Botox® and dermal fillers in the US.<wbr> It is now available for 1.<wbr>99$ exclusively on the Apple App store.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Record</STRONG>: enter treatments and sepcify by product type, auqntities used and practitioner information </div><div style="margin-bottom: 10px;"><STRONG>Track</STRONG>: archive treatment summaries for future experience and automatically be reminded when your next treatment is due </div><div style="margin-bottom: 10px;"><STRONG>Visualize</STRONG>: set before and after selfies </div><div style="margin-bottom: 10px;"><A href="http://www.gotoxapp.com/">http:/<wbr>/<wbr>www.<wbr>gotoxapp.<wbr>com/<wbr></A> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_8186_2_ScreenCapture2.jpg"> </div><!-- Comment details --><a name="neurology8186attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_8186_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(25,7 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_8186_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(65,2 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20151231&edate=20150901&rec=8186">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-09-25T15:48:48+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-09-25T15:48:48+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Pfizer to be the Only Company with Two Targeted RCC Drugs in China</title>
	<pubDate>2015-09-25T14:49:48+02:00</pubDate>
	<wp:post_id>6877</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Pfizer has officially launched RCC treatment Inlyta (axitinib) during the Urological Association of Asian and Chinese Urological Association (UAA/<wbr>CUA) 2015 conference, convened in Shanghai last week.<wbr> Inlyta joins the company's already-approved Sutent (sunitinib).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Inlyta was approved by the CFDA in May, 2015, as a treatment for RCC in adult patients after failure of a prior therapy.<wbr> </div><div style="margin-bottom: 10px;"><UL><LI>The CFDA filing was based on the international Phase III study AXIS, and clinical data collected from a multi-center trial carried out in the Asia region, which demonstrated significant extension of progression-free survival (PFS) in comparison with Bayer's Nexavar (sorafenib).<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;">The drug is also being developed as a therapy for hepatocellular carcinoma, as an adjuvant treatment in combination with transarterial chemoembolization (TACE), with positive Phase II results reported at this year's American Society for Clinical Oncologists (ASCO).<wbr> </div><div>Source: GBI </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20151231&edate=20150901&rec=10682">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-09-25T14:49:48+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-09-25T14:49:48+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>BOTOX Assessed in the Treatment of Head Essential Tremor (HT)</title>
	<pubDate>2015-09-25T14:31:22+02:00</pubDate>
	<wp:post_id>6878</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: In collaboration with Allergan, the University Hospital, Clermon Ferrand will be conducting a trial in 13 centers in France to demonstrate the efficacy of BOTOX ® 200 U injections in essential HT.<wbr> The PE of the multi-center, randomized, double-blind, parallel-group, placebo-controlled study will measure clinical state improvement of patients evaluated by the Clinical Global Impression of Change (CGI).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">REF: <A href="https://clinicaltrials.gov/ct2/show/NCT02555982?recr=Open&amp;no_unk=Y&amp;fund=2&amp;rcv_s=08%2F25%2F2015&amp;rank=340">NCT02555982</A> </div><div style="margin-bottom: 10px;">Recruitment: approx.<wbr> 120 
 </div><div style="margin-bottom: 10px;">
<UL><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Patients suffering from a head tremor without (isolated) or with associated</LI>
</UL> </div><div style="margin-bottom: 10px;">
<UL><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">tremor in any other body parts.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;">
<UL><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">The HT must be troublesome for the patients (TRS 2 for the head tremor</LI>
</UL> </div><div style="margin-bottom: 10px;">
<UL><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">severity item).<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;">
<UL><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Patients never treated with botulinum toxin.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;">
<UL><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Men or women aged from 18 to 80 years old.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;">
<UL><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Social security coverage.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;">Timelines: from Sept 2015 to July /<wbr> Dec 2017 </div><div>Locations: Clermont-Ferrand, Paris (Fondation Rothschild et APHP), Toulouse, Lyon, Amiens, Bordeaux, Narbonne, Lille, Strasbourg, Nîmes, Marseille, Besançon.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20151231&edate=20150901&rec=8184">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-09-25T14:31:22+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-09-25T14:31:22+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Delayed Release (DR) Formulations of Linaclotide to Enter POC for IBS-C</title>
	<pubDate>2015-09-25T14:13:18+02:00</pubDate>
	<wp:post_id>6879</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Clinicaltrials.<wbr>gov is listing a new trial which purpose is to to evaluate the safety, efficacy, and dose response of two delayed release formulations of linaclotide to patients IBS-C.<wbr> Additional objectives include understanding how the two DR formulations compare with each other and with the FDA-approved 290 μg LINZESS® (the immediate release formulation of linaclotide).<wbr> PE will measure pain and CSBM.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">REF: <A href="https://clinicaltrials.gov/ct2/show/NCT02559206?recr=Open&amp;no_unk=Y&amp;fund=2&amp;rcv_s=08%2F25%2F2015&amp;rank=38">NCT02559206</A> </div><div style="margin-bottom: 10px;">Recruitment: approx.<wbr> 520 </div><div style="margin-bottom: 10px;"><UL><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Patient has completed a colonoscopy according to the AGA criteria, with no clinically significant findings</LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Patient has no clinically significant findings on a physical examination and clinical laboratory tests</LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Patient meets protocol criteria for diagnosis of IBS-C</LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Patient demonstrates continued IBS-C through Pretreatment Period</LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Patient maintains a minimum level of compliance with daily diary</LI>
</UL> </div><div style="margin-bottom: 10px;">Timelines: from October 2015 to November 2016 </div><div>Location: USA </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20151231&edate=20150901&rec=2548">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-09-25T14:13:18+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-09-25T14:13:18+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>POC of Linaclotide for IBS-C and Functional Constipation (FC) in Ped Setting to Start Next Month</title>
	<pubDate>2015-09-25T13:52:52+02:00</pubDate>
	<wp:post_id>6880</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: As reported during Ironwood Q2 results , the 2 studies will be starting next month.<wbr> The purpose of IBS-C study is to evaluate the safety and efficacy of linaclotide for IBS-C, in children age 7-17 years.<wbr> The objective of the constipation study is to evaluate the safety and efficacy of linaclotide for FC, in children age 6-17 years.<wbr> Both studies will have the same PE (change from baseline in 4-week overall spontaneous bowel movement (SBM) frequency rate (SBMs/<wbr>week) during the treatment period.<wbr> Those trial are part of Ironwood and Allergan continuous evaluation of the drug to strengthen the franchise.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">ID: <A href="https://clinicaltrials.gov/ct2/show/study/NCT02559817?recr=Open&amp;no_unk=Y&amp;fund=2&amp;rcv_s=08%2F25%2F2015&amp;rank=1&amp;show_locs=Y#locn">NCT02559817</A> </div><div style="margin-bottom: 10px;">REF: LIN-MD-63 </div><div style="margin-bottom: 10px;">Timelines: from October 2015 to April 2018 </div><div style="margin-bottom: 10px;">Recruitment: approx.<wbr> 260 </div><div style="margin-bottom: 10px;">Location: North America (38 sites) </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">ID: <A href="https://clinicaltrials.gov/ct2/show/NCT02559570?recr=Open&amp;no_unk=Y&amp;fund=2&amp;rcv_s=08%2F25%2F2015&amp;rank=2&amp;submit_fld_opt=">NCT02559570</A> </div><div style="margin-bottom: 10px;">REF: LIN-MD-62 </div><div style="margin-bottom: 10px;">Timelines: from October 2015 to June 2017 </div><div style="margin-bottom: 10px;">Recruitment: approx 160 </div><div style="margin-bottom: 10px;">Location: North America (48 sites) </div><div>Source: clinicaltrials.<wbr>gov </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20151231&edate=20150901&rec=2546">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-09-25T13:52:52+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-09-25T13:52:52+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Guerbet Partners with Chinese Group Kuyan to Market Contrast Medium for HCC</title>
	<pubDate>2015-09-25T10:06:30+02:00</pubDate>
	<wp:post_id>6881</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Lipiodol Ultra-Fluid (LUF), a contrast medium for the diagnosis and treatment of hepatocellular carcinoma (HCC), is used by hepatic intra-arterial infusion.<wbr> In China, first recorded therapy for HCC is TACE, followed by resection and percutaneous ethanol injection/<wbr>radiofrequency ablation.<wbr> TACE is recommended for Child-Pugh A/<wbr>B HCC patients by the Chinese Guidelines on the diagnosis and treatment of primary liver cancer.<wbr> To be noted, last year Sirtex and Guerbet initiated a collaboration in clinical studies of primary and secondary metastatic liver cancer to address the unmet clinical need in patients with HCC, metastatic CRC, metastic NET and different types of primary and secondary liver cancers.<wbr><WBR> The goal of the collaboration is to examine how the SIR-Spheres microspheres of Sirtex and Lipiodol Guerbet can be combined or sequenced optimally.<wbr></WBR> </div><div style="margin-bottom: 10px;"><EM>Guerbet /<wbr> Sirtex Agreement</EM>: See <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20151231&edate=20150901&rec=7634" class="defaultlink">Endocrinology7634: Sirtex & Guerbet To Co-Develop Their Interventional Radiology Products For Metastatic Liver Cancer</a>.<wbr><WBR></WBR> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">This agreement enables Guerbet flagship Interventional Radiology agent to benefit from Kyuan’s outstanding experience in distributing pharmaceuticals on the hospital market.<wbr>.<wbr> </div><div style="margin-bottom: 10px;"><H3>Beijing Kyuan Pharm Shortcut</H3> </div><div style="margin-bottom: 10px;">One of the leading importers and distributors of medicines in China.<wbr> </div><div style="margin-bottom: 10px;">It was created in 1995.<wbr> </div><div style="margin-bottom: 10px;">Since 2001, the group has been part of Group Shanghai Pharma, the second-largest pharmaceuticals distributor in China.<wbr> </div><div style="margin-bottom: 10px;"><H3><SPAN style="COLOR: #333333">Lipiodol Ultra-Fluid (LUF)</SPAN></H3> </div><div style="margin-bottom: 10px;"><P align="left"></P> </div><div style="margin-bottom: 10px;"><P align="left">diagnostic radiology in indications including liver lesion diagnosis, lymphography andhysterosalpingography, and then used in interventional radiology for conventional transarterial chemoembolization (cTACE) procedures of multinodular hepatocellular carcinoma, where Lipiodol was used as a procedure visualizer (contrast agent), a drug eluting vehicle (drug carrier), and a dual arterio-portal transient embolic.<wbr></P> </div><div style="margin-bottom: 10px;"><P align="left">Lipiodol has already been approved in China for iodine insufficiency and lymphography.<wbr></P> </div><div><P align="left">Source: Guerbet</P> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20151231&edate=20150901&rec=10679">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-09-25T10:06:30+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-09-25T10:06:30+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Exelixis Announces Three High-level Appointments</title>
	<pubDate>2015-09-25T09:42:40+02:00</pubDate>
	<wp:post_id>6882</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: As Exelixis prepares for the potential commercialization of cabozantinib ( for RCC), the company has announced three high-level appointments: William Berg, M.<wbr>D.<wbr> as Senior Vice President of Medical Affairs, Jonathan Berndt as Vice President of Sales, and Gregg Bernier as Vice President of Marketing.<wbr>The company prepares U.<wbr>S.<wbr> and EU regulatory filings for cabozantinib in advanced RCC, and awaits a U.<wbr>S.<wbr> regulatory decision on its partner Genentech's application for cobimetinib.<wbr> </div><div style="margin-bottom: 10px;"><SPAN style="text-decoration: underline;">Drug Status</SPAN> </div><div style="margin-bottom: 10px;">Planned U.<wbr>S.<wbr> and EU regulatory filings for cabozantinib in advanced renal cell carcinoma in late 2015 and early 2016.<wbr> </div><div style="margin-bottom: 10px;"><SPAN style="text-decoration: underline;"><STRONG>Mini Bio</STRONG></SPAN> </div><div style="margin-bottom: 10px;"><STRONG>William Berg</STRONG>, M.<wbr>D.<wbr> will oversee medical affairs in the United States.<wbr> He joins Exelixis after spending more than 12 years at Novartis, where he served in roles of increasing responsibility, including vice president and franchise head within Global Medical Affairs.<wbr> Notably, Dr.<wbr> Berg led the Afinitor<SUP>&reg;</SUP> Medical Affairs program which was instrumental in the development of Afinitor<SUP>&reg;</SUP> in advanced RCC.<wbr> Prior to Novartis, he was a director of U.<wbr>S.<wbr> medical affairs at Aventis Oncology.<wbr> Before entering the pharmaceutical industry.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Jonathan Berndt</STRONG> will lead all sales activities for cabozantinib and also direct U.<wbr>S.<wbr> co-promotion efforts for cobimetinib, including Exelixis&acirc;&euro;&trade; plans to field up to 25 percent of the cobimetinib U.<wbr>S.<wbr> sales force in the event of a potential regulatory approval later this year.<wbr> Mr.<wbr> Berndt joins Exelixis with two decades of commercial sales experience in the biopharmaceutical industry, including multiple oncology product and line extension launches.<wbr> Most recently, he served as senior director, oncology sales at Gilead Sciences, where he assembled and led the company&trade;s oncology sales team supporting Zydelig<SUP>&reg;</SUP>.<wbr> Prior to Gilead, Mr.<wbr> Berndt served at Genentech for 13 years.<wbr> While there, he served in a variety of roles, including directing national and regional sales for products including Rituxan<SUP>&reg;</SUP> and Avastin<SUP>&reg;</SUP>, and managing sales operations for Herceptin<SUP>&reg;</SUP> and Tarceva<SUP>&reg;.<wbr></SUP> </div><div><STRONG>Gregg Bernier</STRONG> will lead the marketing group in its commercialization of cabozantinib for RCC.<wbr> Mr.<wbr> Bernier has more than 20 years of experience in biotech and pharmaceutical sales and marketing, primarily in oncology.<wbr> Prior to joining Exelixis, he served as senior director of marketing at Medivation, where he led the launch of Xtandi<SUP>&reg;</SUP> for a new indication in metastatic castration-resistant prostate cancer.<wbr> Mr.<wbr> Bernier joined Medivation from Genentech, where he worked on a variety of product launches including Tarceva<SUP>&reg;</SUP>, Kadcyla<SUP>&reg;</SUP>, Erivedge<SUP>&reg;</SUP> and Avastin<SUP>&reg;</SUP>, among other products.<wbr> He has also held positions at Pharmacia and Sanofi.<wbr> Mr.<wbr> Bernier received his Bachelor of Arts in advertising at Michigan State University.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20151231&edate=20150901&rec=11254">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-09-25T09:42:40+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-09-25T09:42:40+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Merz Xeomin Is Now Registered In Australia For Multiple Therapeutic Indications Including Spasticity</title>
	<pubDate>2015-09-24T23:00:14+02:00</pubDate>
	<wp:post_id>6883</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Xeomin is now registered in Australia for Blepharospasm, Cervical Dystonia, Muscle hyerptonia and AUL.<wbr>  Initially expected to be for the private market, Merz have registered for both private and public settings.<wbr> </div><div style="margin-bottom: 10px;">Merz was accepted on the PBS in April of this year but is expected to launch in September.<wbr>  They have commercially positioned themselves with the key selling points of </div><div style="margin-bottom: 10px;">-          No fridge </div><div style="margin-bottom: 10px;">-          Pure protein </div><div style="margin-bottom: 10px;">-          Large doses with dosing flexibility </div><div style="margin-bottom: 10px;">Its thought to be priced the same as Dysport on the PBS but the private price remains unknown.<wbr> </div><div>Source : Thomson Reuters and Ipsen Internal source </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20151231&edate=20150901&rec=8183">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-09-24T23:00:14+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-09-24T23:00:14+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Allergan Presents The Vistion Of The ‘New Allergan’ At The Morgan Stanely Conference</title>
	<pubDate>2015-09-24T22:02:23+02:00</pubDate>
	<wp:post_id>6884</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment:  Brent Saunders and William Meury  represented Allergan at the recent Morgan Stanely  conference highlighting the two key visions for the &lsquo;new&rsquo; Allergan; development of an extensive portfolio in key therapeutic areas and maintaining a position of leadership </div><div style="margin-bottom: 10px;">Brent Saunders began his presentation by highlighting the continued strong performance of Allergan in its 3<SUP>rd</SUP> quarter.<wbr>  This includes the near completion (early October) of the acquisition of Kythera with its product Kybella.<wbr>  With the core generics business sold, the new Allergan with its branded pharmaceutical business is confirmed to be committed to producing top line double-digit growth , an improved and increased gross margin profile in the aim to become the most efficient pharmaceutical company with respect to SG&amp;A (as a percent of sales) while remaining to be committed to R&amp;D.<wbr> </div><div style="margin-bottom: 10px;">William J Meury the executive President of Branded Pharma highlighted the two key distinguishing components for the new Allergan; first a deep product line while showing category leadership.<wbr>  The new vision is to provide a portfolio of products for each key therapeutic area (eye care, CNS, gastroenterology, women's health, anti-infectives and urology).<wbr>  This is seen to be advantageous from both a strategic perspective but also promotional; greater access to providers and payers, and economic; providing a portfolio createsa  means of efficiency &ldquo;The incremental cost associated with the second, third, fourth, and fifth product is much smaller and a fraction of what the cost of the first one is&rdquo;.<wbr>  As such, across the major therapeutic areas it&rsquo;s thought that the new Allergan can give customers &ldquo;A more complete view of pharmacotherapy than other companies can&rdquo;.<wbr> </div><div style="margin-bottom: 10px;">The second key area is leadership.<wbr> The new Allergan is considered now to be &lsquo;more relevant in the market with its new offering &ldquo;We're number one or two in, I believe, five out of the seven product lines, which I think is a competitive advantage.<wbr> The growth rates on all of our major businesses are at or above expectations; the growth is being powered more by volume than by price, which is ultimately the true measure of the health of a business&rdquo; </div><div style="margin-bottom: 10px;">Contary to Actavis position on R&amp;D, the new Allergan has continued to finance R&amp;D and remains to support this part of the business with 10% of sales invested (consistent with industry norms).<wbr>  The investment is considered by William to be calculated &ldquo;We're not allergic to R&amp;D.<wbr> We're allergic to wasting money.<wbr> And so, we take a very practical view of it.<wbr> We'll invest heavily&rdquo; With over 70 products in mid to late stage programs the pipeline is strong.<wbr>  Further discussion about the future R&amp;D outlook will be discussed at the Allergan R&amp;D Day on November the 4<SUP>th</SUP>.<wbr> </div><div style="margin-bottom: 10px;">With this in mind, the new Allergan outlook will be about maintaining a strong leadership position across key therapeutic areas by providing payers, physicians and patients a portfolio of products thus being more efficient in their offering.<wbr>  The shift from just being about sales to now a volume&rsquo;s game and being a &lsquo;one stop shop&rsquo; provider, will allow Allergan to reach the goal of increasing margin.<wbr>  They will continue to support R&amp;D and also invest in M&amp;A so to expand this portfolio and maintain or gain a leadership position across all therapeutic areas </div><div>Source: Allergan </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20151231&edate=20150901&rec=8182">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-09-24T22:02:23+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-09-24T22:02:23+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>1st Prostpective Comparative Trial of Ga-68 PSMA PET Detects More Early Prostate Cancer Recurrence Than F18</title>
	<pubDate>2015-09-24T16:47:32+02:00</pubDate>
	<wp:post_id>6885</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The SNNMI in its latest press release has chosen to highlight the significantly better results obtained with Ga-68 PSMA imaging compared to F18 in detecting early recurrent prostate cancer.<wbr> Ga-68 PSMA in a 39 patient study changed treatment management in 44% more cases than F18.<wbr> </div><div style="margin-bottom: 10px;">Joshua James Morigi, MD, lead author of the study noted that the trial specifically addressed men with prostate cancer and low PSA levels, at which current imaging techniques struggle in detecting disease.<wbr> </div><div style="margin-bottom: 10px;">The researchers, of St.<wbr> Vincent’s Hospital, Sydney, Australia, evaluated 39 prostate cancer patients who had rising PSA following first-round treatment and were eligible for further targeted therapy.<wbr> Patients on systemic treatment were excluded.<wbr> Ga-68 PSMA PET/<wbr>CT, F-18 FMC PET/<wbr>CT and diagnostic CT were undertaken in all patients sequentially between January and April 2015 and assessed by masked, experienced nuclear medicine physicians.<wbr> Researchers then documented scan results and management impact changes, together with histological follow-up, if feasible.<wbr> Of the patients enrolled, 89 percent had only their prostate gland removed, while the other 11 percent were post-radiation treatment.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Commenting on the studies findings Morigi stated </STRONG> </div><div style="margin-bottom: 10px;">“Our main finding is that even at extremely low PSA levels (&lt;0.<wbr>5), PSMA was able to detect sites of possible recurrence in 50% of patients while FMC detected possible recurrence in only 12.<wbr>5%.<wbr> As a result of these high detection rates, PSMA also demonstrated a very high management impact in our patient cohort (63%), having an added value over FMC in 44%.<wbr>” </div><div style="margin-bottom: 10px;">He continued.<wbr> “These findings have important ramifications for the management of men with early biochemical failure and suggest that imaging-guided therapy even in low PSA range may be possible.<wbr>” </div><div>Source:- <A href="file:///C:/Users/jac89886/Documents/PRRT_Ga68PET%20Imaging/“,”http://www.snmmi.org/NewsPublications/NewsDetail.aspx?ItemNumber=14685“,”">http:/<wbr>/<wbr>www.<wbr>snmmi.<wbr>org/<wbr>NewsPublications/<wbr>NewsDetail.<wbr>aspx?ItemNumber=14685</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20151231&edate=20150901&rec=10678">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-09-24T16:47:32+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-09-24T16:47:32+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Nestlé New Push in the Health Arena</title>
	<pubDate>2015-09-24T15:02:52+02:00</pubDate>
	<wp:post_id>6886</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Nestl&eacute; reported today it is building a factory in Brazil to make skin healthcare products.<wbr> The company's Skin Health division has ramped up activity since its creation in February 2014 through the $3.<wbr>6 billion acquisition of Galderma.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>About the Plant</STRONG> </div><div style="margin-bottom: 10px;"><SPAN style="text-decoration: underline;">Objectives</SPAN>: 16,000-square-metre Brazilian skin health plant would help meet rising domestic and South American demand.<wbr> </div><div><SPAN style="text-decoration: underline;">Products</SPAN>: The planned Hortolandia, Sao Paolo-based factory will produce brands for Galderma ranging from over-the-counter soaps and creams to topical gels and anti-fungal lacquers.<wbr><BR><BR>Planned to open in 2018, the site will cost 200 million real (approx $48M), and is likely to employ 300 workers.<wbr><BR><BR>Source: Thomson </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20151231&edate=20150901&rec=8180">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-09-24T15:02:52+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-09-24T15:02:52+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Key Messages from an Orphan Drug Payor Survey in the U.S</title>
	<pubDate>2015-09-24T11:34:38+02:00</pubDate>
	<wp:post_id>6887</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Main outcomes from the Leerink MEDACorp Survey suggest that the reimbursement landscape remains highly favorable for commercially insured patients, and is able to absorb potential weakness caused by proposed changes to Medicare pricing.<wbr> Bottom line outlines that considerably uncertain events, such as the presidential election and congressional acquiescence, must play out for Medicare law and pricing to change drastically, although the market has reacted as if adverse change is inevitable.<wbr> The survey also includes highlights of the Clinton's plan.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>About the Survey</STRONG> </div><div style="margin-bottom: 10px;">MEDACorp surveyed 30 payors with over 165MM pharmacy and medical covered lives in the US on orphan drug spending and how it is managed at an organizational level.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Key Messages</STRONG> </div><div style="margin-bottom: 10px;">It is reported that the Center for Medicare/<wbr>Medicaid Services (CMS) estimates that prescription drugs comprise ~10% of the U.<wbr>S.<wbr> healthcare budget; this suggests that orphan drug spending still represents &lt;1% of U.<wbr>S healthcare spending.<wbr> </div><div style="margin-bottom: 10px;"><P align="left">For the payors who were able to estimate (just 63% within this enriched sample), orphan drugs remain a very small part of their budgets</P> </div><div style="margin-bottom: 10px;">Orphan Drug Spending Management is a Lower Priority than Many Other Drug Categories.<wbr> The increased cost per patient of orphan drugs appears to be trumped by the prevalence of many other chronic diseases with expensive, long-term management needs </div><div style="margin-bottom: 10px;">Clinical Efficacy Data Drives Reimbursement Decisions.<wbr> Payors&rsquo; recognition that efficacy tops all other characteristics in driving reimbursement decisions (even therapy cost and availability of alternatives) confirms that potent therapies will be reimbursed </div><div style="margin-bottom: 10px;"><P align="left">Among Orphan Therapeutic Categories, IVIG and Hemophilia Are Perceived As The Most Likely To Be Restricted In The Future</P> </div><div style="margin-bottom: 10px;"><P align="left"><STRONG>Clinton's Plan in a Nutshell</STRONG></P> </div><div style="margin-bottom: 10px;"><P align="left">- Require drug manufacturers to provide rebates for Medicare enrollees that are equivalent to rebates in the<BR>Medicaid program.<wbr><BR>- Require payors to place a monthly limit of $250 on covered out-of-pocket Rx drug costs for individuals.<wbr><BR>- Lower the biologic exclusivity period from 12 to 7 years (cited to save up to $5 billion for the federal<BR>government over 10 years).<wbr><BR>- Encourage the FDA to give prioritized, expedited review to biosimilar applications that only have one or<BR>two competitors in the marketplace (situations where such drugs are most likely to be excessively priced).<wbr><BR>- Allow Americans to import drugs from abroad &ndash; with careful protections for safety and quality.<wbr><BR>- Require pharmaceutical companies that benefit from federal support to invest &ldquo;a sufficient amount of their<BR>revenue in R&amp;D&rdquo; or pay penalties that support research.<wbr><BR>- Eliminate corporate write-offs for direct-to-consumer advertising and establish a mandatory FDA pre-clearance<BR>procedure for DTC advertisements.<wbr><BR>- Increase funding to the FDA&rsquo;s Office of Generic Drugs to expedite the generic drug approval process.<wbr></P> </div><div>Full report available on demand.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20151231&edate=20150901&rec=11252">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-09-24T11:34:38+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-09-24T11:34:38+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Novartis Files Afinitor For GI Or Lung NET In Japan</title>
	<pubDate>2015-09-24T11:24:47+02:00</pubDate>
	<wp:post_id>6888</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;"><P align="left" dir="ltr">Comment: Ahead of the Phase III RADIANT-4 data presentation at ECC this coming week-end, Novartis has filed an application seeking an additional indication for Afinitor (everolimus) for the treatment of NET of gastrointestinal (GI) or lung origin in Japan.<wbr></P> </div><div style="margin-bottom: 10px;"><P align="left" dir="ltr">Afinitor should be approved in 10-12 months + 2 months for pricing/<wbr>reimbursement: expected launch in 2H 2016.<wbr></P> </div><div><P align="left" dir="ltr">Source: Thank you to Hoel Goisbault (Project Manager, Japan) for the primary intelligence</P> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20151231&edate=20150901&rec=8206">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-09-24T11:24:47+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-09-24T11:24:47+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>'Novartis Access' Launches Portfolio of Affordable Medicines for Low-middle-income Countries</title>
	<pubDate>2015-09-24T08:36:30+02:00</pubDate>
	<wp:post_id>6889</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: This is the first-of-its kind portfolio approach in healthcare industry.<wbr> 'Novartis Access' will be launched first in Kenya, Ethiopia and Vietnam, with expansion to eventually include 30 countries.<wbr> Portfolio addresses 15 patented and generic medicines for cardiovascular diseases, diabetes, respiratory illnesses and breast cancer.<wbr> Treatments  will be offered to governments, NGOs and other public-sector healthcare providers for $1 per treatment, per month.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>'Novartis Access' Rationale</STRONG> </div><div style="margin-bottom: 10px;">The launch of 'Novartis Access' will coincide with the United Nations Sustainable Development Summit 2015, where the new Sustainable Development ProgrGoals will be adopted.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Figures</STRONG> </div><div style="margin-bottom: 10px;">Approx.<wbr> 28M people die from chronic diseases in those countries each year, representing about 75% of such deaths globally.<wbr>(source: World Health Organization, "Noncommunicable diseases fact sheet":<BR><A class="ext" href="http://www.who.int/mediacentre/factsheets/fs355/en/" target="_blank">http:/<wbr>/<wbr>www.<wbr>who.<wbr>int/<wbr>mediacentre/<wbr>factsheets/<wbr>fs355/<wbr>en/<wbr>(link is external)</A>, Accessed 14 September 2015  ).<wbr> </div><div>Source: from <A href="https://www.novartis.com/news/media-releases/novartis-launches-novartis-access-portfolio-affordable-medicines-treat-chronic">https:/<wbr>/<wbr>www.<wbr>novartis.<wbr>com/<wbr>news/<wbr>media-releases/<wbr>novartis-launches-novartis-access-portfolio-affordable-medicines-treat-chronic</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20151231&edate=20150901&rec=11251">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-09-24T08:36:30+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-09-24T08:36:30+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Mrs Clinton's Proposal on Cap Drug Costs Hits Lexicon Shares</title>
	<pubDate>2015-09-23T17:58:11+02:00</pubDate>
	<wp:post_id>6890</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Summary: While at a forum in Iowa, Hillary Clinton responded to the voter fury rising over the high-cost of prescriptions drugs with a proposal for capping out-of-pocket drug expenses at $250 a month.<wbr> The proposal also touched on establishing a set ratio between revenue and research spending, and eliminating the tax deductibility of drug marketing expenses.<wbr> The Pharmaceutical Research and Manufacturers of America, which represents the country&rsquo;s leading drug makers, said in a statement that Mrs Clinton&rsquo;s plan would &ldquo;turn back the clock on medical innovation, restrict patient's access to new medicines, resulting in fewer new treatments for patients, eroding the nation&rsquo;s standing as the world leader in biomedical innovation".<wbr> Her plans to reform hit the biotech stocks, Lexicon Pharmaceuticals being amongst those who have been impacted the most significantly (down 10.<wbr>1%).<wbr> </div><div style="margin-bottom: 10px;">The investors had reacted positively to the announcement of the positive Phase III results for Telotristat etiprate for carcinoid syndrome.<wbr> Telotristat etiprate has been awarded both fast-track and orphan drug status by the FDA.<wbr> Those designations could allow faster market entry for Lexicon's drug, and if so, telotristat etiprate could become an important treatment option for patients who don't respond to high-price SSA, such as sandostatin LAR (that costs $2,466 for a 30mg dose).<wbr> This proposal could have an impact on Lexicon&rsquo;s pricing strategy and revenue ambition in the US (i.<wbr>e.<wbr>Lexicon can't price telotristat etiprate similarly to sandostatin LAR), and possibly lead to readjustment of analysts&rsquo; forecast for Lexicon.<wbr> Hence its shares slumped yesterday.<wbr> </div><div>Source: FT, New York Times </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20151231&edate=20150901&rec=11248">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-09-23T17:58:11+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-09-23T17:58:11+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Oncogenex Reported Non Superiority Result For Its OGX-427 In 1L Metastatic Pancreatic Cancer</title>
	<pubDate>2015-09-23T17:31:25+02:00</pubDate>
	<wp:post_id>6891</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Oncogenex reported initial results from the Ph2 Rainier study that the addition of its apatorsen (OGX-427) to gemcitabine and Abraxane did not demonstrate a survival benefit compared to Abraxane + Gemcitabine alone in the first line setting.<wbr> While fewer patients taking apatorsen had discontinued treatment due to the disease progressing, more patients stopped the therapy due to adverse events such as anemia, fatigue and neutropenia, an abnormally low white blood cell count Further results will be presented by Sarah Cannon Research Institute at a future medical meeting (likely to be ASCO GI in 2016).<wbr> </div><div style="margin-bottom: 10px;">Pancreatic cancer has been one of the very difficult-to-treat cancers as over the last decade, very few treatments have been able to demonstrate a survival benefit.<wbr> Apatorsen (OGX-427) is a once-weekly intravenous (IV) experimental drug that is designed to inhibit production of heat shock protein 27 (Hsp27) to disable cancer cells' defenses and overcome treatment resistance.<wbr> Hsp27 in an intracellular protein that protects cancer cells by helping them survive, leading to resistance and more aggressive cancer phenotypes.<wbr> Both the potential single-agent activity and synergistic activity of apatorsen with cancer treatments may increase the overall benefit of existing therapies and augment the durability of treatment outcomes, which could lead to increased patient survival.<wbr> </div><div>Source: OncoGenex Press Release 23 Sept 2015 </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20151231&edate=20150901&rec=10676">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-09-23T17:31:25+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-09-23T17:31:25+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Nestlé Institute of Health (NIHS) Moves Forward in the Battle Against Alzheimer's Disease</title>
	<pubDate>2015-09-23T11:12:59+02:00</pubDate>
	<wp:post_id>6892</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: This further initiative into the medicine business has been signed with biotech firm AC Immune to develop a Tau diagnosis assay for Alzheimer's disease.<wbr> Link between nutrition and dementia has been very promising.<wbr> Since 2013, NIHS has applied its proprietary multiplexed ultrasensitive triplex antidody technology in Brain Health research, specifically in this condition, and last July, it established a new 'hub' in nutrition, metabolisms and dementia to feed innovation.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Financial terms: not disclosed </div><div style="margin-bottom: 10px;">Objective: to develop a sensitive, minimally invasive Tau diagnostic assay for early Alzheimer’s disease.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Two-day conference hosted by the New York Academy of Sciences and the Sackler Institute for Nutrition Science.<wbr> </div><div style="margin-bottom: 10px;">Sponsored by the Nestlé Nutrition Institute and Nestlé Health Science.<wbr> </div><div style="margin-bottom: 10px;">Focus: </div><div style="margin-bottom: 10px;"><UL><LI>Nutritional consequences of the aging demographic: epidemiological perspectives, 
</LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI>The role of nutrition in dementia prevention, and 
</LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI>The role of nutrition and distinct nutritional requirements in the management of dementia</LI>
</UL> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2545_1_ScreenCapture1.jpg"> </div><!-- Comment details --><a name="gastroenterology2545attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2545_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(30 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20151231&edate=20150901&rec=2545">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-09-23T11:12:59+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-09-23T11:12:59+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>HCC Continues to Pose China's Greatest Health Challenge</title>
	<pubDate>2015-09-23T09:28:57+02:00</pubDate>
	<wp:post_id>6893</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: As the world’s sixth most common cancer, and second most significant cause of cancer death, liver cancer can hardly be characterized as a disease exclusive to China.<wbr> The report outlines a significant unmet diagnosis and treatment needs in China.<wbr> Current development trends are seeing new signaling pathways (such as telomerase Wnt/<wbr>beta-catenin) or combinations of pathways being targeted while drugs that target single sites are being thoroughly investigated in combination treatments.<wbr> It is highlighted that the support of a local partner is a necessity as it allows access to accelerated CFDA review, and the potential for regulatory exclusivity upon approval.<wbr> A selection of molecules in development for HCC in Greater China is provided below, among which about ten are in Ph3.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10673_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;">Global Variations in Diagnosis and Treatment </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10673_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10673_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Sanofi's Eloxatin - chemo drug, marketed in 2013 for unresectable, advanced HCC.<wbr> </div><div style="margin-bottom: 10px;">The nationally reimbursed FOLFOX chemo-therapy regimen is included in the National Health and Family Planning Commission's treatment guideline.<wbr> </div><div style="margin-bottom: 10px;">The only targeted therapy for HCC to date is Bayer's Nexavar (sorafenib) approved in 2008.<wbr> However resource constraints limit its use in China.<wbr> </div><div style="margin-bottom: 10px;"><UL><LI>2014 Nexavar sales for both RCC and HCC were RMB 165M ($26.<wbr>7M), with growth at 12.<wbr>24% YOY.<wbr></LI>
</UL> </div><div><EM>Source: Liver Cancer - Meeting the treatment demand for China's silent killer.<wbr></EM> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Oncology10843c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">A new Ph2/<wbr>3 trial has been recently listed in clinicaltrials.<wbr>gov with the objective to assess efficacy and safety of donafenib in approx.<wbr> 600 patients with advanced hepatocellular carcinoma (HCC).<wbr> PE will measure OS.<wbr> Suzhou Zelgen Biopharmaceuticals Co.<wbr>,Ltd is the sponsor of the study, and the developper of donafenib, an oral multikinase inhibitor that targets Raf kinase and receptor tyrosine kinases.<wbr> </div><div style="margin-bottom: 10px;">Trial ID: NCT02645981 </div><div>Timelines: the trial is to start in February 2016 and complete Dec 2018 /<wbr> Aug 2019 </div></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20151231&edate=20150901&rec=10673">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-09-23T09:28:57+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-09-23T09:28:57+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Allergan Attempts To Re-enter The Generic Space Venturing into the Parkinson's Disease Market</title>
	<pubDate>2015-09-22T19:15:41+02:00</pubDate>
	<wp:post_id>6894</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Allergan confirmed yesterday a patent challenge to IMPAX's Rytary a carbidopa/<wbr>levadopa extended release formulation.<wbr> It has filed an ANDA with the U.<wbr>S.<wbr> FDA seeking approval to market  a generic version of Carbidopa and Levodopa Extended-release Capsules, 61.<wbr>25 mg/<wbr>245 mg, 23.<wbr>75 mg/<wbr>95 mg, 36.<wbr>25 mg/<wbr>145 mg and 48.<wbr>75 mg/<wbr>195 mg.<wbr> Rytary®, is currently indicated for the treatment of Parkinson's disease and post-encephalitic parkinsonism.<wbr> The questions is whether the rational is based around market seeding for a new undisclosed drug/<wbr> lifecycle indication or commercial adjacency to the botulinum toxin market.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>IMPAX's Response<BR></STRONG><BR>Impax Laboratories, Inc.<wbr> filed suit against Allergan on August 17, 2015 in the U.<wbr>S.<wbr> District Court for the District of New Jersey seeking to prevent Allergan from commercializing its ANDA product prior to the expiration of certain U.<wbr>S.<wbr> Patents.<wbr> </div><div style="margin-bottom: 10px;">The lawsuit was filed under the provisions of the Hatch-Waxman Act, resulting in a stay of final FDA approval of Allergan's ANDA for up to 30 months from the date the plaintiffs received notice of Allergan's ANDA filing or until final resolution of the matter before the court, whichever occurs sooner, subject to any other exclusivities.<wbr> </div><div style="margin-bottom: 10px;">Based on available information, Allergan believes it may be a "first applicant" to file an ANDA for the generic version of Rytary® and, should its ANDA be approved, may be entitled to 180 days of generic market exclusivity.<wbr> </div><div style="margin-bottom: 10px;">For the 12 months ending July 31, 2015, Rytary® had total U.<wbr>S.<wbr> sales of approximately $15 million, according to IMS Health data.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>The Rational For Allergan's Filing</STRONG> </div><div style="margin-bottom: 10px;">Having sold its generic business to Teva at the end of July this year, this development is somewhat surprising (see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20151231&edate=20150901&rec=8122" class="defaultlink">Neurology8122: Allergan Divests Generics Business To Merge With Teva As It Focuses On Becoming A Branded Pharma Leader</a>) especially as there no evidence on ClinicalTrials.<wbr>gov of any ongoing development activity in Parkinsons's disease.<wbr> However, maybe there are plans afoot as Allergan's 1st entry into the urology market with botulinum toxin was preceeded by the in-licensing of an anticholinergic drug Sanctura in 2007 which had only 3 yrs of patent exclusivity left and achieved peak sales of $62m before being impacted by generics and subsequently withdrawn from the market.<wbr> </div><div>Source: <A href="http://www.allergan.com">www.<wbr>allergan.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20151231&edate=20150901&rec=8179">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-09-22T19:15:41+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-09-22T19:15:41+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Two-Drug Combination Shows Very Early Promise in pNET</title>
	<pubDate>2015-09-22T17:36:39+02:00</pubDate>
	<wp:post_id>6895</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The University of Florida Health researchers have shown for the first time that the focal adhesion kinase (FAK) protein becomes overabundant in pNETs and have a key role in tumor development.<wbr> They looked at drug combinations that would increase efficacy and tested a small compound molecule, PF-04554787 in human pancreatic cancer cell lines.<wbr> They also paired the compound with everolimus, proving that the two-drug combination kills off one type of pancreatic cancer cells more effectively than everolimus alone.<wbr> While this is a very interesting approach it's still a very long way to any clinical trials and/<wbr>or every-day clinic, but offer new insights in the biology of pNETs.<wbr> </div><div style="margin-bottom: 10px;">FAK activates an enzyme called AKT, which helps islet cells in the pancreas to survive.<wbr> When islet cells begin turning into tumors, the FAK protein gets overexpresses, allowing the tumor to resist chemotherapy and evading the efforts to kill them off.<wbr> Once identified that FAK was important, the group tested a synthetic, small-molecule compound known as PF-04554787.<wbr> During lab testing, the compound &ldquo;markedly inhibited&rdquo; the growth of three human pancreatic cancer cell lines five days after treatment and induced the death of pancreatic cancer cells.<wbr> Researchers then tested its effectiveness on human pancreatic cells that had been implanted in mouse models.<wbr> Daily doses of the compound reduced tumor volume by about 50 percent after 25 days, they found.<wbr> </div><div style="margin-bottom: 10px;">Next, researchers paired the compound with everolimus.<wbr> While everolimus can extend some patients&rsquo; lives by holding tumors in check, it does little to make them regress and is not effective for many people.<wbr> Fran&ccedil;ois wondered if the synthetic compound would make everolimus more effective.<wbr> It did, with the two-drug combination killing off pancreatic cancer cells more effectively than everolimus alone.<wbr> In testing on two mouse cell lines, the drug combination reduced the viability of cancer cells by about 50 percent when compared with everolimus alone, according to the findings.<wbr> </div><div>Source: University of Florida Health </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20151231&edate=20150901&rec=8205">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-09-22T17:36:39+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-09-22T17:36:39+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>TRACON Pharm Reported To Target Two Orphan Tumours - Choriocarcinoma And Angiosarcoma</title>
	<pubDate>2015-09-22T17:21:56+02:00</pubDate>
	<wp:post_id>6896</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: TRACON pharm, formerly known as Lexington Pharm, announced that its leading candidate, TRC105 demonstrated complete response in two orphan tumour types that overexperess endoglin, choriocarcinoma, and angiosarcoma.<wbr>  A Ph2 multi-centre trial is expected to initiate in Q4 2015 and will file application for orphan drug status by end of 2015.<wbr> As a result, shares of Tracon Pharm soared 36% after the announcement.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>A single-patient compassionate use phase II study</STRONG> </div><div style="margin-bottom: 10px;">The patient was treated with TRC105 dosed 10 mg/<wbr>kg weekly in combination with Avastin&reg; (bevacizumab) dosed 10 mg/<wbr>kg every other week.<wbr> As of the time of the presentation, the patient had completed 7 cycles (28 weeks) of treatment.<wbr> Beta human chorionic gonadotropin (&beta;-hCG), a known, reliable marker of disease burden in choriocarcinoma, normalized during the fourth cycle of treatment, decreasing from greater than 3,000 IU/<wbr>L at treatment initiation to less than 1 IU/<wbr>L from cycles 4 through 7, indicating an ongoing complete response.<wbr> </div><div style="margin-bottom: 10px;">Choriocarcinoma represents the second tumor type known to express high levels of endoglin in which complete durable responses have been observed following treatment with a combination of TRC105 and a VEGF inhibitor.<wbr> In June 2015, Dr.<wbr> Steven Attia of the Mayo Clinic reported complete responses in two patients with angiosarcoma, treated with TRC105 and Votrient&reg; (pazopanib), at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>About Tracon</STRONG> </div><div style="margin-bottom: 10px;">Tracon expects to commercialize TRC105 on its own in the U.<wbr>S.<wbr> and to partner the agent elsewhere.<wbr> Theuer, who joined the company in 2006, was previously director of clinical oncology at Pfizer Inc.<wbr>, where he led the clinical development of Sutent (sunitinib), approved by the FDA in 2006 to treat gastrointestinal stromal tumours and advanced kidney cancer.<wbr> Before that, he served in senior management at Idec Pharmaceuticals Inc.<wbr>, which merged with Biogen Inc.<wbr> in 2003 to form the biotech powerhouse, and worked at the National Cancer Institute.<wbr> </div><div style="margin-bottom: 10px;">In 2014, Tracon inked a deal with Santen Pharmaceutical Co.<wbr> Ltd.<wbr>, of Osaka, Japan, for $10 million up front and undisclosed future milestones to develop and commercialize TRC105 in age-related macular degeneration.<wbr> Santen filed an investigational new drug application in that indication at the end of the second quarter.<wbr> In September 2014, Tracon raised $27 million in a series B before filing paperwork for its IPO, which brought in $36 million earlier this year.<wbr> Tracon reported cash and equivalents of $61.<wbr>2 million as of June 30, giving the company a runway of at least 18 months, according to Casey Logan, chief business officer.<wbr> </div><div>Source: TRACON Press Release </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20151231&edate=20150901&rec=10672">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-09-22T17:21:56+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-09-22T17:21:56+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>AstraZeneca To Harness The Scientific Prowess Of Crowds To Identify New Oncology Drug Combinations</title>
	<pubDate>2015-09-22T17:07:26+02:00</pubDate>
	<wp:post_id>6897</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: AstraZeneca has taken the unprecedented step of releasing preclinical data for 50 of its preclinical oncology drugs with the aim of utilising crowd sourcing to try and identify syntergistic tumour-fighting combinations.<wbr> </div><div style="margin-bottom: 10px;">The initiative is being run as part of the DREAM Challenge, an open inovation non-profit biology project in which scientists pool data and crunch data.<wbr> The data includes around 10,000 tested combinationns meansuring the ability of drugs to destroy cancer cell lines from different tumour types.<wbr> The data will be matched with genomic information from the Wellcome Trust Sanger Insititute.<wbr> </div><div style="margin-bottom: 10px;">Scientists with winning predictions will have their ideas submitted for publication in Nature.<wbr> </div><div>Source: <A href="http://www.astrazeneca.com">www.<wbr>astrazeneca.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20151231&edate=20150901&rec=10671">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-09-22T17:07:26+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-09-22T17:07:26+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>First Analysis Demonstrates Synthetic's SYN-004's Ability to Protect the Microbiome from Damage Caused by IV Antibiotics</title>
	<pubDate>2015-09-21T17:51:21+02:00</pubDate>
	<wp:post_id>6898</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The data of a pilot study of humanized pigs were presented in a late-breaker oral presentation at the 2015 Interscience Conference of Antimicrobial Agents and Chemotherapy and International Congress of Chemotherapy and Infection joint meeting (ICAAC/<wbr>ICC 2015) in San Diego, CA.<wbr> They show that SYN-004 protected the gut microbiome from damage often caused by the intravenous (IV) beta-lactam antibiotic, ceftriaxone.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Presented by Vice President, Research, Sheila Connelly, Ph.<wbr>D.<wbr>, </div><div style="margin-bottom: 10px;"><UL><LI>Of significant importance, in the cohort that was administered oral SYN-004 plus IV ceftriaxone, the natural balance of bacteria in the gut microbiome was maintained.<wbr> </LI>
<LI>In contrast, in the cohort administered IV ceftriaxone alone, damage occurred and the natural balance of the gut microbiome was altered.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2543_2_ScreenCapture2.jpg"></STRONG> </div><div style="margin-bottom: 10px;"><STRONG><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2543_1_ScreenCapture1.jpg"></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Timelines</STRONG>: SYN-004 Phase 2b proof-of-concept trial expected later this quarter </div><div>From <A href="http://www.syntheticbiologics/">http:/<wbr>/<wbr>www.<wbr>syntheticbiologics</A> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="GastroEnterology2552c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">Synthetic Biologis has reported the initiation of its SYN-004 Phase 2b proof-of-concept clinical trial, to evaluate the effectiveness of SYN-004the molecule to prevent <EM>C.<wbr> difficile</EM> infection (CDI), <EM>C.<wbr> difficile</EM> associated diarrhea (CDAD) and antibiotic-associated diarrhea (AAD) in patients hospitalized for a lower respiratory tract infection and receiving intravenous (IV) ceftriaxone.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Trial Design</STRONG> </div><div style="margin-bottom: 10px;">The Ph2b, parallel-group, double-blind, placebo-controlled study of SYN-004 is expected to enroll approximately 370 patients at up to 75 global clinical sites.<wbr> </div><div style="margin-bottom: 10px;">Patients age 50 years and older, hospitalized for a lower respiratory tract infection, are expected to be randomized 1:1 into two groups, and receive either SYN-004 or placebo during the standard of care regimen of ceftriaxone (with or without a macrolide).<wbr> </div><div style="margin-bottom: 10px;">The primary objectives of this clinical trial are to evaluate the effectiveness of SYN-004 to prevent CDIs and CDAD.<wbr> </div><div style="margin-bottom: 10px;">The secondary objective of this clinical trial is to evaluate the effectiveness of SYN-004 to prevent AAD.<wbr> </div><div>Source: Company's website </div></div><a name="gastroenterology2543attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2543_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(115,8 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2543_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(107,4 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20151231&edate=20150901&rec=2543">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-09-21T17:51:21+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-09-21T17:51:21+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Bayer Aligns Organization with Life Science Businesses</title>
	<pubDate>2015-09-21T12:55:36+02:00</pubDate>
	<wp:post_id>6899</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Announced two years ago, the new strategy is now in place to align the organization with Life Science businesses.<wbr> From January 1st 2016, the company's business will be managed by 3 divisions: Pharmaceuticals, Consumer Health and Crop Science.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The divisions are to focus on core competencies close to their businesses - research and development, production, and sales &amp; marketing.<wbr> </div><div style="margin-bottom: 10px;">They will be supported by integrated functions such as Human Resources and Procurement, and by global services.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Effective January 1, 2016, the Board of Management of Bayer AG will comprise eight members headed by Chairman Dr.<wbr> Marijn Dekkers.<wbr> Johannes Dietsch will be responsible for Finance; Werner Baumann will oversee Strategy and Portfolio Management; and Kemal Malik will have responsibility for Innovation.<wbr> Michael König will be leaving the company at his own request on expiration of his contract.<wbr> Dr.<wbr> Hartmut Klusik, currently responsible for Product Supply on the Board of Management of Bayer HealthCare AG, will be the new Labor Director and Board member responsible for Human Resources, Technology and Sustainability.<wbr> As part of the reorganization, the Board of Management areas for Innovation and Technology will be additionally strengthened.<wbr> The Board of Management will also be enlarged to include the three divisional heads: Dieter Weinand (headquartered in Berlin, Germany), Erica Mann (headquartered in the future in Basel, Switzerland) and Liam Condon (headquartered in Monheim, Germany).<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Background in Traction</STRONG> Please see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20151231&edate=20150901&rec=10957" class="defaultlink">PharmaWorld10957: Bayer To Transform Itself Into A Pure Life Science Company</a> </div><div>Source: <A href="http://www.press.bayer.com/baynews/baynews.nsf/id/Bayer-aligns-organization-with-Life-Science-businesses">http:/<wbr>/<wbr>www.<wbr>press.<wbr>bayer.<wbr>com/<wbr>baynews/<wbr>baynews.<wbr>nsf/<wbr>id/<wbr>Bayer-aligns-organization-with-Life-Science-businesses</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20151231&edate=20150901&rec=11247">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-09-21T12:55:36+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-09-21T12:55:36+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Pfizer Announces More Committment to Vaccines</title>
	<pubDate>2015-09-21T11:38:53+02:00</pubDate>
	<wp:post_id>6900</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Pfizer Announces More Committment to Vaccines</span>&nbsp;<br><span style="font-size: 12px;">Comment: Pfizer's strategy is definitely to expand beyond Prevnar.<wbr> Today management announced enrollment of its first patients in a Ph2b trial for its S<EM>taphylococcus aureus</EM> vaccine.<wbr> To be noted, in the company's pipeline is a Ph2 vaccine for the prevention <EM>Clostridium difficile</EM>.<wbr> In August 2014, the vaccine got a FDA fast-track designation, a competitive advantage over Sanofi Pasteur and Merck's investigational vaccines.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20151231&edate=20150901&rec=2463">...</a><br></div><div style="margin-bottom: 10px;">Merck anounced on Sept.<wbr>20th that the two pivotal Ph 3 clinical studies for bezlotoxumab, for prevention of <EM>Clostridium difficile</EM> (<EM>C.<wbr> difficile</EM>) infection recurrence, met their primary efficacy endpoint: the reduction in <EM>C.<wbr> difficile </EM>recurrence through week 12 compared to placebo, when used in conjunction with standard of care antibiotics for the treatment of <EM>C.<wbr> difficile</EM>.<wbr> The studies showed no benefit from a second experimental antibody, actoxumab, either alone or in combination with bezlotoxumab.<wbr> Merck said the actoxumab arm was stopped for efficacy and safety reasons after an interim analysis.<wbr> Based on these results, the company plans to submit new drug applications seeking regulatory approval of bezlotoxumab in the U.<wbr>S.<wbr>, EU and Canada in 2015.<wbr> </div><div style="margin-bottom: 10px;">Currently, there are no therapies approved for the prevention of recurrent disease caused by <EM>C.<wbr> difficile</EM>.<wbr> </div><div style="margin-bottom: 10px;">Results from the studies were presented for the first time at the Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC) and International Congress of Chemotherapy and Infection (ICC) joint meeting in San Diego, Sept.<wbr> 17-21.<wbr> </div><div style="margin-bottom: 10px;">Source: <A href="http://www.mercknewsroom.com/news-release/research-and-development-news/pivotal-phase-3-studies-bezlotoxumab-mercks-investigation">http:/<wbr>/<wbr>www.<wbr>mercknewsroom.<wbr>com/<wbr>news-release/<wbr>research-and-development-news/<wbr>pivotal-phase-3-studies-bezlotoxumab-mercks-investigation</A> </div><div style="margin-bottom: 10px;"><STRONG>About the pivotal Phase 3 studies</STRONG> </div><div style="margin-bottom: 10px;">Two global, Phase 3, double-blind studies were conducted to evaluate bezlotoxumab, either alone or in combination with actoxumab (a fully human monoclonal antibody against <EM>C.<wbr> difficile</EM> toxin A), compared to placebo for the prevention of recurrent <EM>C.<wbr> difficile </EM>infection in patients on standard of care antibiotics for a primary or recurrent <EM>C.<wbr> difficile </EM>infection.<wbr> </div><div>The MODIFY I study (MONOCOLONAL ANTIBODIES FOR <EM>C.<wbr> DIFFICILE</EM> THERAPY) enrolled 1452 patients (median age 65 years) in 19 countries and the MODIFY II study enrolled 1203 patients (median age 67 years) in 17 countries.<wbr> The studies were conducted in both hospital and outpatient settings, and the primary endpoint for each study was evaluated through 12 weeks following study drug administration </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20151231&edate=20150901&rec=2542">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2463">View thread  GastroEnterology2463: Pfizer Announces More Committment to Vaccines</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-09-21T11:38:53+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-09-21T11:38:53+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>18-Month Data of Versartis VRS-317 for PGHD</title>
	<pubDate>2015-09-21T09:56:28+02:00</pubDate>
	<wp:post_id>6901</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Versartis gained $2.<wbr>16 (20%) to $13.<wbr>14 after reporting 18-month data from a long-term extension study of somavaratan, a long-acting recombinant human growth hormone (rhGH), in pre-pubertal children with growth hormone deficiency (GHD).<wbr> Versartis said the data demonstrated a stabilization of mean height velocity, noting that patients commonly experience a decrease in height velocity during their second year on a daily rhGH treatment.<wbr> Furthermore, the number of adverse events (AEs) declined between 12 and 18 months, and no serious AEs were reported.<wbr> Detailed results will be presented at the European Society for Paediatric Endocrinology meeting in Barcelona on Oct.<wbr> 3.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The extension study included 56 patients who received either twice-monthly 2.<wbr>5 mg/<wbr>kg or once-monthly 5 mg/<wbr>kg doses of somavaratan for 12 months followed by twice-monthly 3.<wbr>5 mg/<wbr>kg doses for six months.<wbr> The 3.<wbr>5 mg/<wbr>kg dose is currently being evaluated in the Phase III VELOCITY trial.<wbr> </div><div style="margin-bottom: 10px;">Patients who switched from the twice-monthly 2.<wbr>5 mg/<wbr>kg dose to the twice-monthly 3.<wbr>5 mg/<wbr>kg dose experienced an increase in mean peak insulin-like growth factor-1 (IGF-1) standard deviation score (SDS) from -0.<wbr>30 to 0.<wbr>32 (p=0.<wbr>007).<wbr> </div><div style="margin-bottom: 10px;">During the first 12 months of treatment, patients in the 2.<wbr>5 mg/<wbr>kg dose group and 5 mg/<wbr>kg dose groups experienced a mean height velocity of 8.<wbr>5 cm/<wbr>year and 7.<wbr>9 cm/<wbr>year, respectively.<wbr> </div><div style="margin-bottom: 10px;">After switching to the twice-monthly 3.<wbr>5 mg/<wbr>kg dose for an additional six months, patients demonstrated a mean annualized height velocity of 8.<wbr>3 cm/<wbr>year and 8.<wbr>1 cm/<wbr>year, respectively.<wbr> </div><div style="margin-bottom: 10px;"><U>Background</U> </div><div>Versartis resumed the VELOCITY trial in July after FDA lifted a partial clinical hold on the study.<wbr> In May, FDA had suspended enrollment and requested additional bioanalytical data from the company.<wbr> See <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20151231&edate=20150901&rec=8044" class="defaultlink">Endocrinology8044: Versartis' Long-Acting PhIII Development Placed On Clinical Hold</a> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20151231&edate=20150901&rec=8203">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-09-21T09:56:28+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-09-21T09:56:28+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Novartis CEO Reports on the Slowdown in Emerging Markets</title>
	<pubDate>2015-09-21T09:43:19+02:00</pubDate>
	<wp:post_id>6902</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: In an interview with CNBC, Joe Jimenez has stated that business in China is "moving from mild-double-digit growth rates to now in the mid-single-digit growth rates".<wbr> Despite fears of an economic slowdown in the country, Novartis is "not pulling back from the country.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">According to Jimenez, <STRONG>Sandoz</STRONG> is expected to help drive growth in China.<wbr> </div><div style="margin-bottom: 10px;">He also has remarked on the Federal Reserve's recent decision to maintain current interest rates, saying that while the central bank will likely lift its rates at some point, the timing is not of great importance to Novartis.<wbr> </div><div>"The more interesting thing is that this is the first time that an event in China has led to global dislocation of financial markets," Jimenez explained, adding "that is a big marker that says China has arrived and it is going to have a big impact on global markets.<wbr>" </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20151231&edate=20150901&rec=8201">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-09-21T09:43:19+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-09-21T09:43:19+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>New Trial to Document Registry of Participants With Prostate Cancer in Asia</title>
	<pubDate>2015-09-18T18:03:28+02:00</pubDate>
	<wp:post_id>6903</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The purpose of this Ph4 study, sponsored by Janssen R&amp;D, is to document prostate cancer (PC) management including diagnosis, prognosis, treatment, and care in real-world practice.<wbr> PE will measure OS, prostate cancer-related mortality, MFS, PFS, TTPP.<wbr> Recruitment has been designed to enrol approx.<wbr> 3730 participants with documented diagnosis of PC with either: High-risk localized PC; Non-metastatic, biochemically recurrent PC; Metastatic PC.<wbr> The maximum observational period will be 5 years.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Trial Details</STRONG> </div><div style="margin-bottom: 10px;">REF: NCT02546908 </div><div style="margin-bottom: 10px;">ID: CR107351, NOPRODPCR4001 </div><div style="margin-bottom: 10px;">Timelines completion in Sept 2020 </div><div>Locations China; India; Korea; Malaysia;Singapore; Taiwan Thailand </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20151231&edate=20150901&rec=10669">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-09-18T18:03:28+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-09-18T18:03:28+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Drivers Behind AstraZeneca's Business In China</title>
	<pubDate>2015-09-18T15:45:55+02:00</pubDate>
	<wp:post_id>6904</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Deustche Bank analysts have just published a 69-page report on strong growth prospects for AstraZeneca based on its operational success in emerging markets and strength of the pipeline.<wbr> In March this year AZN set out its current strategy for a return-to-growth with the focus on driving investment behind its five current "growth platforms" i.<wbr>e.<wbr> Brilinta/<wbr>Brilique, diabetes, respiratory, Emerging Markets and Japan.<wbr> In doing this, management outlined plans to leverage its commercial infrastructure in primary care and its core specialty therapeutic areas, as well its strong position in China and emerging markets.<wbr> Both the Deutsche report and Pascal Soret's (CEO) comments during AZ's Q2 webcast (CEO) highlight the key factors behind AZ's success in the Chinese market and the group's significant expansion plans to maintain growth in this region.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Key Chinese Growth Drivers</STRONG> </div><div style="margin-bottom: 10px;">The main drugs generating strong growth in China are the group's respiratory drugs Pulmicort and Symbicort.<wbr> Although Pulmicort is now generic in the US, sales in emerging markets continue to grow strongly (+44% CER in 2Q).<wbr> This has been aided by AZN&rsquo;s collaboration with Omron to place nebulisers in hospitals in China, where access to asthma therapies is limited.<wbr> </div><div style="margin-bottom: 10px;">Duetsche analysts suggest that AZN is continuing to perform above its peers in emerging markets.<wbr> Its sales reached $5.<wbr>8bn in 2014 (+12% 22% of total sales) and it appears to be benefiting from GSK's continued woes in China with AZ's Symbicort taking sizeable market share from GSK's Advair in the respiratory category).<wbr> The company has also highlighted the statin Crestor and the GI drug Nexium as strong growth drivers in EMs.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>AZ's Risk Exposure to China</STRONG> </div><div style="margin-bottom: 10px;">With many pharmaceutical companies reporting a slowdown, Novartis as of today in a CNBC interview with CEO Joe Jimines the Deustche analysts make the following observation about AZ's risk profile:- </div><div style="margin-bottom: 10px;">"AZN now has the highest concentration of EM sales in China of any of our coverage companies.<wbr> In fact it is now second only to Pfizer among the multi-nationals in China, with &gt;10% of its sales coming from the country in 1H15.<wbr> However, more recently fears have been raised given several other healthcare companies suggesting that the China market appears to have shown a sharp deceleration in Q2.<wbr> Eli Lilly noted on their 2Q15 call that growth for international pharma companies was 2% in May in China, having been running at mid-teens in recent years.<wbr> Clearly this is a risk for AZN more than others companyies given its exposure and dependence on China for continued EM growth.<wbr> However, to date its growth has remained strong, with sales still growing at 10% CER in 2Q, despite reversal of a destock that drove exceptional growth in sales in 1Q15.<wbr> We note that AZN&rsquo;s Chinese sales are highly concentrated on several key franchises, with Pulmicort alone representing close to 20% of its sales in the region, reflecting its investment in supporting asthma and COPD treatment in the region.<wbr> Even with a slowdown in economic growth in the region, we expect improved access to healthcare to continue to represent a meaningful opportunity for the industry.<wbr>" </div><div style="margin-bottom: 10px;"><STRONG>CEO's Reference To China During Q2 Webcast</STRONG> </div><div style="margin-bottom: 10px;">During its Earnings Webcast on July 30th, Pascal Soret made the following comments about the growth outlook for its Chinese business and Emerging markets </div><div style="margin-bottom: 10px;"><P class="pwrapper">" There was a continued strong performance in the half.<wbr> After a very brisk Q1 with 18% growth overall and 28% in China, Q2 normalized to 9% growth in line with our long-term view.<wbr> China sales were slower in Q2 with a growth of 10%, equating to 19% over the half year.<wbr> Growth was spread across all main therapeutic areas.<wbr> Respiratory was up 30% in Emerging Markets to $556 million, Brilinta up 80% to $47 million, Diabetes up 88% to $117 million, and Oncology up 18% to $483 million.<wbr> Going to the second half of 2015 our expectation is to deliver continued double-digit growth in China.<wbr>"</P> </div><div style="margin-bottom: 10px;"><P class="pwrapper">"If we look at China I think it's fair to say that there is a structural slowing in the market, which I don't think is a surprise to anyone who's following the overall economy in China.<wbr> That being said where our focus is, I mean clearly we have a strong position in the large Eastern provinces.<wbr> But as we go to lower tier cities in the West, we have a concentrated expansion program there.<wbr> Also our mix of products right now, there is a lot of volume reflex.<wbr> If we look into the future again if we look at products such as Pearl and also the Oncology portfolio, again we're well placed if we look at the 5- to 10-year horizon And although this evolution in China is something that we have been expecting a long time, we have said many times, there will be price pressure.<wbr> And so we are expanding in the West.<wbr> And <STRONG>we have a very substantial expansion program to unlock growth potential in those areas that are economically developing,</STRONG> so we expect to maintain this.<wbr>"</P> </div><div>Source: <A href="http://www.astrazeneca.com/">www.<wbr>astrazeneca.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20151231&edate=20150901&rec=11243">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-09-18T15:45:55+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-09-18T15:45:55+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Chiasma Starts Planning The Phase III for Oral Octreotide In Europe</title>
	<pubDate>2015-09-18T14:41:02+02:00</pubDate>
	<wp:post_id>6905</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: We have gained some primary intelligence that confirms the Chiasma plans for conducting a Phase III study for oral octreotide in Europe for acromegaly.<wbr> The study is not yet in the public domain and the intended start date is January 2016, which potentially could meet the estimated MAA planning submission to the EMA in late 2017 or early 2018.<wbr> The details are listed below.<wbr> </div><div style="margin-bottom: 10px;">Eudract No 2015-002854-11 </div><div style="margin-bottom: 10px;">Sponsor Chiasma INC </div><div style="margin-bottom: 10px;">Protocol Title OOC-ACM-302 </div><div style="margin-bottom: 10px;">Countries- European Study </div><div style="margin-bottom: 10px;">Title: A phase 3, randomized, open-label, active controlled, multicenter study to evaluate maintenance of response, safety and patient reported outcomes in acromegaly patients treated with octreotide capsules, and in patients treated with standard of care parenteral somatostatin receptor ligands who previously tolerated and demonstrated a biochemical control on both treatments.<wbr> </div><div>Source: UK medical affairs - Thank you! </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Endocrinology8262c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">Further to the primary intelligence, Chiasma has released a preliminary design of the planned Phase III b trial to support EMA approval (see picture).<wbr> Chiasma is due to present the Q3 2015 results next week where we might learn more.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8262_1_Phase3%2dEU%2dChiasma.JPG"> </div><div>Source: Chiasma IR September 2015 </div></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20151231&edate=20150901&rec=8198">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-09-18T14:41:02+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-09-18T14:41:02+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Key Messages from Ironwood Management @ Morgan Stanley H/C Conference</title>
	<pubDate>2015-09-18T12:10:57+02:00</pubDate>
	<wp:post_id>6906</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Management sees LINZESS (linaclotide) as the market leader, with a "broad offering to a broad set of patients".<wbr> The drug has been approved and launched for IBS-C or CIC in adults since end of 2012.<wbr> Management reported it is too early to see Synergy Pharm.<wbr>'s plecanatide as a direct competitor, and reported that ".<wbr>.<wbr>.<wbr> they certainly have data in chronic constipation.<wbr> We'll have to wait and see what the IBS data looks like".<wbr> When questionned on M&amp;A, Mark Curie outlined they are looking at acquiring assets, and organizations if they bring value to the shareholders and the company.<wbr> Please see below additional information.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2540_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Completed enrollment in the Ph3 in adult patients with chronic idiopathic constipation (CIC).<wbr> Data from this trial are expected in the fourth quarter of 2015 and a supplemental new drug application is expected to be submitted to the <ORG>U.<wbr>S.<wbr> Food and Drug Administration</ORG> (<ORG>FDA</ORG>) in the first half of 2016.<wbr> </div><div style="margin-bottom: 10px;">If approved, the 72 mcg dose should accelerate the expansion of LINZESS use within adult CIC patients by providing physicians an additional dosing option for this large and diverse population.<wbr> According to management, the lower dose has been developed for patients with mild-to-moderate disease, or for patients who tend to be more sensitive to the drug.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Completed enrollment in the Ph2.<wbr> Data from this study are expected in the fourth quarter of 2015.<wbr> </div><div style="margin-bottom: 10px;">Management reported it is watching really closely 'how big the OIC market is', as Amitiza 'saw some modest growth" since its launch.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Indicatio/<wbr>status: gastroparesis Phase 2a group of concept study.<wbr> </div><div style="margin-bottom: 10px;">" .<wbr>.<wbr>.<wbr> We should have data in the first half of next year and it's a very exciting opportunity and that these patients essentially have no real therapy currently and there have been multiple attempts to try to fix the mechanics of improving gastric emptying in the gastroparesis patients that haven't been successful.<wbr> We're taking a very different approach, which is we are going after trying to reduce the visceral sensations that we've been so successful at previously with linaclotide in the lower GI.<wbr>" </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Finalizing preparations for the IW-3718 dose-ranging Ph2b study, which is expected to initiate in early 2016.<wbr> </div><div style="margin-bottom: 10px;">" .<wbr>.<wbr>.<wbr> we went into a broad population of patients that are suffering refractory GERD and we characterized broadly their symptom response and then we look for specifically now what are the phenotype of those patients that we can horn in on that where our drug would potentially work the best.<wbr> </div><div style="margin-bottom: 10px;">So with 3718, we are in that process and you'll see at the ACG".<wbr> </div><div style="margin-bottom: 10px;">When it comes to the positoinning of the drug: " .<wbr>.<wbr>.<wbr> So this is going to be used on top of PPIs.<wbr> So the base line treatment would be single or double dose PPI and if you're still suffering heart burn, this would be appropriate.<wbr> There's been a number of epidemiology studies done, probably the most notable is by Bill Chey, which is about 20% to 25% of the treated GERD population, which is roughly about 8 million Americans.<wbr> </div><div style="margin-bottom: 10px;">And the attractive thing commercially for us is, one, these patients are easily identified, they're actively seeking care and they're very problematic for the clinician.<wbr> So I think it's a great move for us.<wbr> It's right in the wheelhouse in GI for us.<wbr> So we're in those offices are ready.<wbr> So, commercially, it's a very attractive opportunity.<wbr> </div><div>As far as step edits, I think it's likely that early on there could be, but I think it could be fairly easy to walk through these -- the step edits of the prior authorization because they already got a history of treating and failing on PPIs.<wbr>" </div><!-- Comment details --><a name="gastroenterology2540attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2540_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(70,1 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20151231&edate=20150901&rec=2540">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-09-18T12:10:57+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-09-18T12:10:57+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Sandoz Inaugurates New Facility Dedicated to Manufacture Pre-Filled Syringes and Devices</title>
	<pubDate>2015-09-18T10:56:31+02:00</pubDate>
	<wp:post_id>6907</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The new BioInject facility in Austria will manufacture pre-filled syringes and devices for both Sandoz’s biosimilars and Novartis Pharma’s novel biologics.<wbr> BioInject will become a central part of Novartis’ biomanufacturing network which also includes facilities in Slovenia, Singapore and France.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11241_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;">Location: Schaftenau in the Tyrolean Alps in Austria </div><div style="margin-bottom: 10px;">Capacity: 18,000 syringes can be filled,and 100 packaged per minute </div><div style="margin-bottom: 10px;">Investment: &gt;€150M </div><div>Source: <A href="http://www.europeanpharmaceuticalreview.com/35075/news/industry-news/sandoz-opens-new-state-of-the-art-bioinject-facility-in-schaftenau/">http:/<wbr>/<wbr>www.<wbr>europeanpharmaceuticalreview.<wbr>com/<wbr>35075/<wbr>news/<wbr>industry-news/<wbr>sandoz-opens-new-state-of-the-art-bioinject-facility-in-schaftenau/<wbr></A> </div><!-- Comment details --><a name="pharmaworld11241attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11241_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(32,7 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20151231&edate=20150901&rec=11241">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-09-18T10:56:31+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-09-18T10:56:31+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Effect of Probiotics on Group B Streptococcus (GBS) Colonization During Pregnancy</title>
	<pubDate>2015-09-17T18:04:45+02:00</pubDate>
	<wp:post_id>6908</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Sponsored by Ryerson U.<wbr> and in collaboration with Chr Hansen A/<wbr>S, the randomized controlled trial will assess the use of Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14 (Lactobacillus fermentum RC-14) in the colonization status of GBS in pregnant people.<wbr> PE will measure the GBS colonization status.<wbr>
 </div><div style="margin-bottom: 10px;"><A href="http://www.chr-hansen.com/uploads/tx_tcdownloadables/Bacterial_Vaginosis_02.pdf">http:/<wbr>/<wbr>www.<wbr>chr-hansen.<wbr>com/<wbr>uploads/<wbr>tx_tcdownloadables/<wbr>Bacterial_Vaginosis_02.<wbr>pdf</A> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">ID <A href="https://clinicaltrials.gov/ct2/show/NCT02528981?fund=2&amp;rcv_s=08%2F17%2F2015&amp;rank=474">NCT02528981</A> </div><div style="margin-bottom: 10px;">Recruitment approx 200 </div><div style="margin-bottom: 10px;"><UL><LI>
Pregnant prior to 23 weeks' gestation</LI>
<LI>
Singleton pregnancy</LI>
<LI>
Greater than 18 years of age</LI>
<LI>
Lesser than 45 years of age</LI>
</UL> </div><div style="margin-bottom: 10px;"><P class="color-bullet" style="MARGIN-TOP: 0.7ex">PI: Mary Sharpe, PhD Ryerson U.<wbr></P> </div><div style="margin-bottom: 10px;"><P class="color-bullet" style="MARGIN-TOP: 0.7ex">Timelines completion June 2016 /<wbr> Aug 2016</P> </div><div><P class="color-bullet" style="MARGIN-TOP: 0.7ex">Location: Canada</P> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20151231&edate=20150901&rec=2539">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-09-17T18:04:45+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-09-17T18:04:45+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>AbbVie to Initiate Ph3 of Elagolix (GnRH Antagonist) for Uterine Fibroids (UF) in Q1:16</title>
	<pubDate>2015-09-17T11:15:58+02:00</pubDate>
	<wp:post_id>6909</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Preliminary results from 6-month, Ph2b safety and efficacy trial show elagolix met composite PE in UF.<wbr> Final results will be presented at a medical conference in the future.<wbr> Elagolix Uterine Fibroid Phase 2a data have been accepted for presentation at the 2015 Annual Meeting of the American Society of Reproductive Medicine in Baltimore, October 2015.<wbr> At the beginning of the year, management reported positive top-line results from the first of two ongoing Ph3 trials, designed to assess the efficacy and safety of the drug in premenopausal women with endometriosis </div><div style="margin-bottom: 10px;"><STRONG>Ph2b Results</STRONG> </div><div style="margin-bottom: 10px;">Preliminary results showed that all of the elagolix treatment arms, with and without add-back therapy, reduced heavy menstrual bleeding as compared to placebo (p&lt;0.<wbr>001).<wbr> </div><div style="margin-bottom: 10px;">The study's PE was a composite design where subjects had to achieve a menstrual blood loss (MBL) volume of less than 80 mL as well as a 50 percent or greater reduction in MBL volume from baseline at the final study month as measured by the alkaline hematin method.<wbr> </div><div style="margin-bottom: 10px;">Among the most common adverse events (AEs) were hot flush, headache, nausea, and vomiting.<wbr> Some AEs such as hot flush were more frequent in the elagolix only treatment arms as compared to the placebo and elagolix with add-back therapy treatment arms.<wbr> </div><div style="margin-bottom: 10px;">Reduction in bone mineral density associated with elagolix alone was attenuated when elagolix was co-administered with add-back therapy.<wbr> </div><div style="margin-bottom: 10px;">Discontinuations due to AEs were slightly greater for the elagolix 600 mg once-daily (QD) treatment arms with and without add-back therapy as compared to elagolix 300mg twice-daily (BID) treatment arms with and without add-back therapy.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>About the Ph3 Program</STRONG> </div><div style="margin-bottom: 10px;">Will include two replicate, pivotal, six-month efficacy and safety studies followed by a six-month safety and efficacy extension study.<wbr> </div><div>The primary endpoint in Phase 3 studies will be the same as that employed in the Phase 2b study; percent of subjects with reduction in uterine blood flow as measured by the alkaline hematin method.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20151231&edate=20150901&rec=10668">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-09-17T11:15:58+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-09-17T11:15:58+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Nestlé Health Science Licences Rights to Lipid Therapeutics' Novel UC Therapy</title>
	<pubDate>2015-09-17T03:08:34+02:00</pubDate>
	<wp:post_id>6910</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Nestlé Health Science Licences Rights to Lipid Therapeutics' Novel UC Therapy</span>&nbsp;<br><span style="font-size: 12px;">Comment: LT-02, phosphatidylcholine, is a novel barrier function therapy for patients with mild-to-moderate ulcerative colitis (UC).<wbr> Nestlé, which acquired WW rights except EU and Australia), plans to start Ph3 in the US in 2016.<wbr> EU development partner, Dr Falk Pharma GmbH started the Ph3 in 2014.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20151231&edate=20150901&rec=2536">...</a><br></div><div>Thanks Brigitte, So if I understand well, this would not be a substitute to mesalazine, but would be ued in case mesalazine alone is not enough.<wbr> So it is still consistent with the "step-up approach" used in this disease management, and depending on results, this might delay the start of tnf-alpha inhibitors in the patient treatment pathway.<wbr> Definetely an interesting topic to follow for the long-term competitive environement of Etiasa in China.<wbr> <a name="GastroEnterology2553c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div>Ferring recently launched CORTIMENT MMX in EU; the company is the licensee in Asia (excluding Japan), Australia, Canada, Latin America and Africa).<wbr> The product is indicated &ldquo; &hellip; where 5-ASA treatment is not sufficient&rdquo;.<wbr> With Pentasa and Cortiment MMX Ferring is likely to be seen as a partner of choice for the treatment of UC products.<wbr> In terms of competition with Etiasa, interesting to monitor if the company plans to seek registration for the product in China, and look to market itself or with a partner ? </div></div></div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20151231&edate=20150901&rec=2537">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2536">View thread  GastroEnterology2536: Nestlé Health Science Licences Rights to Lipid Therapeutics' Novel UC Therapy</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-09-17T03:08:34+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-09-17T03:08:34+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Nestlé Health Science Licences Rights to Lipid Therapeutics' Novel UC Therapy</title>
	<pubDate>2015-09-16T17:03:01+02:00</pubDate>
	<wp:post_id>6911</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: LT-02, phosphatidylcholine, is a novel barrier function therapy for patients with mild-to-moderate ulcerative colitis (UC).<wbr> Nestlé, which acquired WW rights except EU and Australia), plans to start Ph3 in the US in 2016.<wbr> EU development partner, Dr Falk Pharma GmbH started the Ph3 in 2014.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Financial terms: not disclosed </div><div style="margin-bottom: 10px;">Nestlé Health Science will further develop and commercialize LT-02 upon marketing approval by the relevant authorities in the licensed geographies </div><div style="margin-bottom: 10px;">As part of a strategic development approach, Nestlé Health Science, Dr Falk and Lipid Therapeutics will collaborate to generate the required clinical evidence in support of LT-02’s beneficial effects in the treatment of ulcerative colitis in order to obtain drug regulatory approvals.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">LT-02 restores the colonic barrier function in the gut mucosa or ‘wall’ and through anti-inflammatory signalling and represents a first-in-class therapy for those patients still suffering flares while being treated with mesalazine.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">biopharmaceutical company focused on the development and commercialization of phospholipids.<wbr> The company was set-up and financed in 2008 by the EMBL Technology Fund to commercialize the scientific work of Prof.<wbr> Wolfgang Stremmel, Krehl University Clinic in Heidelberg, Germany.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div>Please see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20151231&edate=20150901&rec=2121" class="defaultlink">GastroEnterology2121: Dr Falk's Second Registration Trial of Phosphatidylcholine for UC</a>.<wbr> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="GastroEnterology2537c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div>Thanks Brigitte, So if I understand well, this would not be a substitute to mesalazine, but would be ued in case mesalazine alone is not enough.<wbr> So it is still consistent with the "step-up approach" used in this disease management, and depending on results, this might delay the start of tnf-alpha inhibitors in the patient treatment pathway.<wbr> Definetely an interesting topic to follow for the long-term competitive environement of Etiasa in China.<wbr> <a name="GastroEnterology2553c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div>Ferring recently launched CORTIMENT MMX in EU; the company is the licensee in Asia (excluding Japan), Australia, Canada, Latin America and Africa).<wbr> The product is indicated &ldquo; &hellip; where 5-ASA treatment is not sufficient&rdquo;.<wbr> With Pentasa and Cortiment MMX Ferring is likely to be seen as a partner of choice for the treatment of UC products.<wbr> In terms of competition with Etiasa, interesting to monitor if the company plans to seek registration for the product in China, and look to market itself or with a partner ? </div></div></div></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20151231&edate=20150901&rec=2536">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-09-16T17:03:01+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-09-16T17:03:01+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Denmark's KRIS Recommends Eisai Lenvima for Thyroid Cancer</title>
	<pubDate>2015-09-16T16:43:45+02:00</pubDate>
	<wp:post_id>6912</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The drug received positive opinion from the EMA in March 2015.<wbr> Denmark's coordination council for the use of hospital medicine (KRIS) has issued a favourable recommendation supporting use of Eisai (Japan)'s Lenvima (lenvatinib) in patients with thyroid cancer.<wbr> It is recommended as 1st-line therapy option in Denmark.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The KRIS recommended Lenvima on the basis that the drug had demonstrated a longer rate of disease-free progression compared to a placebo (18.<wbr>3 months versus 3.<wbr>6 months).<wbr> </div><div style="margin-bottom: 10px;">The KRIS evaluation also concluded that Lenvima produced a statistically significant longer duration of disease-free progression when compared to the current standard of care therapy, namely Bayer (Germany)'s Nexavar (sorafenib) – at 10.<wbr>8 months versus 5.<wbr>8 months respectively.<wbr> </div><div>From IHS GlobalInsight </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20151231&edate=20150901&rec=10666">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-09-16T16:43:45+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-09-16T16:43:45+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>FDA Grants Priority Review to AAA Somakit-TATE Diagnostic For NET</title>
	<pubDate>2015-09-16T15:00:49+02:00</pubDate>
	<wp:post_id>6913</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: AAA announced today that the FDA has granted Priority Review to AAA&rsquo;s New Drug Application (NDA) for SomaKit-TATE, a patented Kit for the preparation of 68Ga-DOTATATE for injection, which is in development to help diagnose and manage somatostatin receptor-positive NET patients using Positron Emission Tomography (PET).<wbr> The Somakit NDA was submitted on July 1st, 2015 and it is the first NDA ever filed for a drug using Ga-68 as a positron emitter.<wbr> AAA also announced that the Pivotal Phase III study NETTER-1 met its primary endpoint, demonstrating a statistically significant and clinically meaningful increase in PFS for Lutathera versus double dose of Sandostatin LAR in patients with inoperable midgut NETs.<wbr> The full data are going to be released at ESMO on Sunday 27th September, Abstract 6LBA, presented by Prof.<wbr> P.<wbr> Ruszniewski.<wbr> </div><div style="margin-bottom: 10px;">The FDA and the EMA granted Orphan Drug Designation for  Ga-68 DOTATATE (Somakit) back in March 2014.<wbr> </div><div>Source: AAA Press Release </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20151231&edate=20150901&rec=8197">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-09-16T15:00:49+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-09-16T15:00:49+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Telesta Reported Prepartion To Establish US Sales Infrastructure For MCNA Launch In 2016</title>
	<pubDate>2015-09-16T12:05:57+02:00</pubDate>
	<wp:post_id>6914</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Telesta published its financial statements and associated Management's Discussion and Analysis for the fiscal year ended June 30 2015.<wbr> The company's key corporate updates include 1) significant strengthened balance sheet following US private placement and warrant exercise 2) execution of strategic business plan to prepare for the US commercial launch of MCNA in 2016 3) plan to add a US listing for its common shares 4) change in board of directors membership </div><div style="margin-bottom: 10px;"><SPAN style="text-decoration: underline;"><STRONG>Financial Statement - A Cash Position to Fund Ongoing Operations of ~$45M</STRONG></SPAN> </div><div style="margin-bottom: 10px;"><UL><LI>The company's cash and near term receivables at June 30 2015 was $6.<wbr>5 million with an addition of a US led private placement of US $28.<wbr>6 m and receipt of proceeds of $2.<wbr>7m from the exercise of $7.<wbr>4m common share warrants as of September 30 2015.<wbr>  
</LI>
<LI>
As of September 4, 2015, there were 12.<wbr>3 million of warrants due to expire before the end of September, 2015, with an exercise price of $0.<wbr>40 or less.<wbr> If all of these warrants were to be exercised prior to their maturity, the company would issue an additional 12.<wbr>3 million shares in return for proceeds of $4.<wbr>9 million.<wbr>

</LI>
</UL> </div><div style="margin-bottom: 10px;"><P align="LEFT">Assuming all of these warrants are exercised, Telesta would expect to have a cash position to fund ongoing operations of approximately $45 million, based on current cash resources on hand.<wbr></P> </div><div style="margin-bottom: 10px;"><SPAN style="text-decoration: underline;"><STRONG>US Launch Readiness For MCNA - To Establish a Lean But Efficient US Sales Infrastructure</STRONG></SPAN> </div><div style="margin-bottom: 10px;"><P align="LEFT">Telesta anticipates that its current burn rate will increase significantly, as the Company prepares for the commercial launch of MCNA in 2016.<wbr> These increased expenditures will include ongoing and new consulting mandates related to the regulatory advancement of MCNA, increased spending at Telesta's manufacturing site, in Montreal Canada, as the facility transitions to commercial production and expenditures related to the establishment of U.<wbr>S.<wbr>-based commercial infrastructure, as the Company prepares for commercial launch in 2016.<wbr></P> </div><div style="margin-bottom: 10px;"><P align="LEFT"><SPAN style="font: 12.8px/17.92px GillSansRegular, 'Gill Sans MT', helvetica, arial, sans-serif; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; float: none; display: inline !important; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; background-color: #ffffff; -webkit-text-stroke-width: 0px;"><SPAN style="text-decoration: underline;"><STRONG>Change In Board of Directors leadership - Driving Effort to Secure US Listing </STRONG></SPAN><BR></SPAN></P> </div><div style="margin-bottom: 10px;"><P align="LEFT"><SPAN style="font: 12.8px/17.92px GillSansRegular, 'Gill Sans MT', helvetica, arial, sans-serif; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; float: none; display: inline !important; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; background-color: #ffffff; -webkit-text-stroke-width: 0px;">Warren Whitehead is a Certified Management Accountant who has held several senior financial management positions with pharmaceutical and biotechnology firms.<wbr> He is the former CFO of Arius Research Inc.<wbr>, an anti-cancer antibody company (acquired by Roche in 2008), and former CFO of Labopharm Inc.<wbr> (2000 to 2006) where he led several rounds of financing, including a cross-border NASDAQ offering.<wbr> Prior positions include CFO of Resolution Pharmaceuticals Inc.<wbr> and finance and business development at Glaxo Canada (now GlaxoSmithKline).<wbr></SPAN></P> </div><div><P align="LEFT"><SPAN style="font: 12.8px/17.92px GillSansRegular, 'Gill Sans MT', helvetica, arial, sans-serif; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; float: none; display: inline !important; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; background-color: #ffffff; -webkit-text-stroke-width: 0px;">Source: <a href="http://www.telestatherapeutics.com/cms/phpE1vB3u.pdf" class="defaultlink">Telesta Press Release</a><BR></SPAN></P> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20151231&edate=20150901&rec=10665">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-09-16T12:05:57+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-09-16T12:05:57+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Outcomes from a New Report Call for Greater Focus on Adressing QoL of Patients with Prostate Cancer</title>
	<pubDate>2015-09-16T11:20:36+02:00</pubDate>
	<wp:post_id>6915</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The survey was developed by Janssen, in collaboration with patient associations.<wbr> Entitled <I>Prostate Cancer: Living, not Just Surviving</I>, the report details the findings from a large pan-European survey of 765 prostate cancer patients, 335 caregivers and 400 healthcare professionals (HCP).<wbr> Professor Louis Denis (Onco-Urologist and Strategic Consultant, Europa Uomo), Hugh Gunn (Patient and Tackle Prostate Cancer Trustee, UK), Calle Waller (Vice Chairman, Prostatacancerförbundet, Sweden)as well as Christian Arnold, Prostate Cancer Survivor and VP of ANAMACAP, France) are referenced in the report.<wbr> (please see attached).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Outcomes reveal that only 14% of HCP feel that they have sufficient resources to address quality of life issues, such as fatigue, pain and intimacy problems.<wbr> </div><div style="margin-bottom: 10px;">The survey reveals that for the patients who experience chronic physical effects from the disease, fatigue (66%) has the biggest negative impact compared to disability and pain (41% and 22% respectively), particularly in metastatic patients (93%) and patients on medication (83%).<wbr> Almost half of all men with prostate cancer surveyed (n=765) state that they are so tired, they no longer feel able to exercise and 74 per cent of this group say that this has had a negative effect on them emotionally.<wbr> </div><div style="margin-bottom: 10px;">It also suggests that men with prostate cancer worry more about quality of life issues associated with their disease, such as intimacy problems (54%) and feeling ill (41%), than dying (36%).<wbr> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10664_1_ScreenCapture1.jpg">
Please find attached the full report <a href="http://ci.beaufour-ipsen.com/traction?type=np&proj=*&sdate=20151231&edate=20150901&rs=/link%20Oncology10664%402" class="defaultlink">@2</a> </div><!-- Comment details --><a name="oncology10664attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10664_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(61,7 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10664_2_Prostate%20Cancer%20Living%20Not%20Surviving%20Report%20Design%2008.09.15%20%2d%20FINAL%20APPROVED.pdf">Prostate Cancer Living Not Surviving Report Design 08.09.15 - FINAL APPROVED.pdf</a>&nbsp;&nbsp;(4,8 MB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20151231&edate=20150901&rec=10664">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-09-16T11:20:36+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-09-16T11:20:36+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Key Messages from Versartis Investor Symposium</title>
	<pubDate>2015-09-15T16:19:26+02:00</pubDate>
	<wp:post_id>6916</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Ph Backeljauw started the event with a presentation on GH therapy for childhood GHD and current treatment issues in the US.<wbr> Followed by Jan-Maarten Wit who presented the diagnosis and treatment of GHD from a EU perspective.<wbr> GH treatment and treatment approaches in Japan were reported by Noriyuk Namba.<wbr> The event closed with Bradley Miller who spoke about somavaratan PGHD Ph2 experience.<wbr> On a separate press release issued today, management outlined a potential FDA approval by late 2018 for PGHD.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">- <STRONG>Ph Bakeljauw</STRONG>, MD-Professor of Pediatrics, U.<wbr> of Cincinnati College of Medicine, Cincinnati Children's Hospital Medical Center </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8196_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;">- <STRONG>Jan-Maarten Wit</STRONG>, MD-Professor Emeritus, Leiden U.<wbr> Medical Center, the Netherlands </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8196_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;">- <STRONG>Noriyuki Namba</STRONG>, MD-PhD Chiel fo Peditrics, Japan Community Health Care Organization (JCHO) Osaka Hospital </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8196_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;">- <STRONG>Bradley Miller</STRONG>, MD PhD Assistant Professor, Department of Pediatric Endocrinology, U.<wbr> of Minnesota </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8196_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8196_5_ScreenCapture5.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8196_6_ScreenCapture6.jpg"> </div><div style="margin-bottom: 10px;">Versartis eliminated planned company review of interim efficacy analysis that was to be conducted after all patients had reached 6 months on study </div><div style="margin-bottom: 10px;">Company reiterated expectation that it will have top line data on 12-month mean height velocity primary endpoint velocity trial by mid-2017 </div><div style="margin-bottom: 10px;">Company reiterated expectation of a potential biologics license application submission, followed by a potential FDA approval by late-2018 </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8196_7_ScreenCapture7.jpg"> </div><!-- Comment details --><a name="endocrinology8196attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8196_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(114,3 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8196_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(132,6 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8196_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(76,8 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8196_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(146,4 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8196_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(117,3 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8196_6_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(108,2 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8196_7_ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(117,6 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20151231&edate=20150901&rec=8196">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-09-15T16:19:26+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-09-15T16:19:26+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>PE Met in Ph3 Study of Amgen/UCB's Romosozumab for Osteoporosis</title>
	<pubDate>2015-09-15T14:59:06+02:00</pubDate>
	<wp:post_id>6917</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: UCB has announced that the Ph3 study (STRUCTURE - <A href="https://clinicaltrials.gov/ct2/show/NCT01796301?term=NCT01796301&amp;rank=1">NCT01796301</A>) met the primary endpoint, demonstrating a statistically significant difference in favor of romosozumab in the percent change of total hip bone mineral density (measured by DXA) through month 12.<wbr> Further analysis are ongoing and will be submitted to a future medical conference and for publication.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2534_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;">Romosozumab is being studied for its potential to reduce the risk of fractures in an extensive global Ph3 program.<wbr> </div><div style="margin-bottom: 10px;">This program includes two large fracture trials comparing romosozumab to either placebo or active comparator in more than 10,000 postmenopausal women with osteoporosis.<wbr> First results from the Phase 3 study<A href="https://clinicaltrials.gov/ct2/show/NCT01575834?term=Romosozumab+AND+FRAME&amp;rank=1"> FRAME </A>are expected in H1 2016.<wbr> </div><div style="margin-bottom: 10px;">A Ph3 (BRIDGE - <A href="https://clinicaltrials.gov/ct2/show/NCT02186171?term=Romosozumab&amp;phase=2&amp;rank=3">NCT02186171</A>) is currently ongoing to compare the efficacy nd safety of romosozumab vs placebo in approx 245 men with osteoporosis (timelines: June /<wbr> December 2016).<wbr> </div><div>Romosozumab is being co-developed by Amgen and UCB.<wbr> </div><!-- Comment details --><a name="gastroenterology2534attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2534_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(80 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20151231&edate=20150901&rec=2534">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-09-15T14:59:06+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-09-15T14:59:06+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Botox Observational GRACE Study For The Management Of Urinary Incontinence In Patients With iOAB Have Shifted The Completion Date To December 2016</title>
	<pubDate>2015-09-15T12:15:45+02:00</pubDate>
	<wp:post_id>6918</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The completion date for the Allegan study on iOAB has been made earlier while the primary completion date has been pushed by two months to both finish on December 2016 </div><div style="margin-bottom: 10px;">The study which began in June 2014 enrolled 500 patients from Germany, Spain, Sweden and the UK .<wbr>  The study is investigating Botox as a second line therapy to oral anticholinergic therapy.<wbr> </div><div>Source: clinicaltrials.<wbr>gov NCT02161159 </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20151231&edate=20150901&rec=8177">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-09-15T12:15:45+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-09-15T12:15:45+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>NCI Funds The First-Ever Specialized SPORE Grant To Study NETs</title>
	<pubDate>2015-09-15T11:50:19+02:00</pubDate>
	<wp:post_id>6919</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The first-ever Specialized Programs of Research Excellence (SPORE) grant to study neuroendocrine tumors, funded through the National Cancer Institute (NCI), was assigned to the University of Iowa (UI) Holden Comprehensive Cancer Centre researchers.<wbr> The five year, $10.<wbr>6 million grant is the only SPORE grant focusing research on neuroendocrine tumors and will fund four major projects to explore the NET genetics, molecular makeup, and how this information can be used to develop new approaches to diagnosis and treatment.<wbr> </div><div style="margin-bottom: 10px;">Researchers at Holden Comprehensive Cancer Center are playing significant roles in the new highly collaborative NET SPORE and come from the departments of pediatrics, internal medicine, surgery, radiology, pharmacology, pathology, radiation oncology, epidemiology, biostatistics, chemistry, and biomedical engineering.<wbr> </div><div style="margin-bottom: 10px;">Support provided by the Holden Family endowment and the UI Dance Marathon Pediatric Cancer and Blood Disorders Laboratories through the UI Foundation are also contributing to the neuroendocrine tumor research effort at the UI.<wbr> </div><div>Source: UI, NCI </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20151231&edate=20150901&rec=8195">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-09-15T11:50:19+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-09-15T11:50:19+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Raptor's RP103 Disappoints in NASH - Uncertainty on the HD Program</title>
	<pubDate>2015-09-15T10:04:13+02:00</pubDate>
	<wp:post_id>6920</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Raptor has reported that top-line Ph2b results of RP103 failed to meet the PE of improving nonalcoholic steatohepatitis (NASH) in children.<wbr> Near-term prioities remain on advancing the development of RP103 in Huntington's disease.<wbr> In 4Q15, the company will provide 36mo data from its Ph2/<wbr>3 study, along with regulatory clarity on the path to approval.<wbr> Investors' opinions differ subsequently when it comes to the drug's future.<wbr> Please see below.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Given that the study failed to meet the primary endpoint, analysts at Wedbush expect the FDA will require another study to be conducted for approval.<wbr> They are also unimpressed with the benefit observed in the subgroup of HD patients in the study not on concurrent tetrabenazine, since the decline observed with the early-stage HD patients administered RP103 appears to be comparable to the natural decline associated with the disease.<wbr> </div><div style="margin-bottom: 10px;">However, analysts at Leerink expect full 36-month data in 4Q15 to include a “delayed start” analysis, which may provide RPTP with a clean slate to make the a case for significantly derisked clinical development or potentially even accelerated approval </div><div>Analysts at JMP Securities believe that 36-month data have a chance to show consistent efficacy with the prior 18-month data, although it will likely be more directional than definitive given the absence of placebo in the second part of the study and small sample size.<wbr> Based on this assumption, we expect the program to advance into a Phase 3 program, which should give investors incremental comfort in the RP-103 potential in Huntington’s </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20151231&edate=20150901&rec=8176">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-09-15T10:04:13+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-09-15T10:04:13+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Latest Orphan Drug Designations Of Note</title>
	<pubDate>2015-09-11T19:21:31+02:00</pubDate>
	<wp:post_id>6921</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The meeting report issued today by the COMP following its recent meeting on the 3rd September notes two orphan designation approvals for RETT syndrome one for Glycyl-L-2-methylprolyl-L-glutamic acid (QCR Consultants) and the other for Sarizotan (Newron Pharmaceuticals) for control of respiratory dysfunction in RETT patients.<wbr> Additional designations of note are for lanreotide for the treatment of ADPKD (sponsor Prof.<wbr> Dr.<wbr> R.<wbr>T.<wbr>Gansevoort) and for Verucerfont (Neurocrine Biosciences) for the treatment of congenital adrenal hyperplasia.<wbr>
A link to new report is shown below:- </div><div><A href="http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/document_listing/document_listing_000201.jsp&amp;mid=WC0b01ac0580028e78#section3">http:/<wbr>/<wbr>www.<wbr>ema.<wbr>europa.<wbr>eu/<wbr>ema/<wbr>index.<wbr>jsp?curl=pages/<wbr>news_and_events/<wbr>document_listing/<wbr>document_listing_000201.<wbr>jsp&amp;mid=WC0b01ac0580028e78#section3</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20151231&edate=20150901&rec=11239">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-09-11T19:21:31+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-09-11T19:21:31+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Takeda to Position Lubiprostone in the IBS-M and IBS-U Subtypes</title>
	<pubDate>2015-09-11T15:57:27+02:00</pubDate>
	<wp:post_id>6922</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: IBS is subclassified according to the predominant bowel habits.<wbr> These subclassifications are IBS-D, IBS-C, IBS-M, and IBS-U.<wbr> The newly listed Ph2 in clinicaltrials.<wbr>gov is currently recruiting participants in the US to evaluate lubiprostone in adult subjects with mixed (M) or unsubtyped (U) IBS.<wbr> PE will measure overall abdominal pain response.<wbr> Takeda is looking to position the drug in segments with significant unmet needs, and where patients are the most challenging to manage.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Ref: <A href="https://clinicaltrials.gov/ct2/show/NCT02544152?recr=Open&amp;no_unk=Y&amp;phase=01234&amp;fund=2&amp;rcv_s=08%2F11%2F2015&amp;rank=6&amp;submit_fld_opt=">NCT02544152</A> </div><div style="margin-bottom: 10px;">Recruitment: Approx 150 </div><div style="margin-bottom: 10px;"><UL><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Subject meets the diagnosis of IBS-M or IBS-U as confirmed using the adapted ROME III Diagnostic Questionnaire for Adult Functional GI Disorders.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Subject Screening diary entries must show an average worst abdominal pain in the past 24 hours score of at least 4 on a 11-point scale.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Subject must be on a stable dose of selective serotonin re-uptake inhibitors (SSRIs), serotonin-specific reuptake inhibitor (SNRIs), or monoamine oxidase inhibitors (MAO) inhibitors if taking antidepressants.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;">Timelines: Completion October 2016 /<wbr> December 2016 </div><div>PI: Charles Barish, MD Wake Research Associates, LLC </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20151231&edate=20150901&rec=2532">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-09-11T15:57:27+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-09-11T15:57:27+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>BIND Therapeutics' BIND-014 Is Entering Ph2 For Cholangiocarcinoma, Cervical, Advanced Bladder, And H&N Cancer</title>
	<pubDate>2015-09-10T19:00:15+02:00</pubDate>
	<wp:post_id>6923</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: BIND Therapeutics announced patient dosing is underway in the iNSITE 2 trial for four tumour histologies.<wbr> BIND-014 is an improved docetaxel that utilises PSMA targeted nanoparticle technology.<wbr> PSMA is a clinically-validated target in prostate cancer and is the target of an FDA-approved imaging agent, ProstaScint, and ADCs currently in clinical development.<wbr> As part of the Ph2 trial, PSMA expression levels are also characterised as a potential basis for patient selection or a companion diagnostic Stage 1 data readout for the iNSITE 2 trial is expected in the 1H 2016.<wbr> .<wbr> </div><div style="margin-bottom: 10px;">The open-label, phase 2, multi-center two-stage iNSITE 2 clinical trial is designed to determine the activity, safety and tolerability of BIND-014 and will enroll up to 160 patients.<wbr> In addition, an imaging and biomarker program that can potentially inform the future clinical utility of BIND-014 is also planned.<wbr> </div><div style="margin-bottom: 10px;">ClinicalTrials.<wbr>gov Id: <a href="https://www.clinicaltrials.gov/ct2/show/NCT02479178?term=iNSITE+2&rank=1" class="defaultlink">NCT02479178</a> </div><div style="margin-bottom: 10px;"><TABLE border="0" cellpadding="0" cellspacing="0" class="layout_table" style="margin-bottom: 3ex;" summary="Layout table for enrollment information"><TBODY><TR valign="top"><TD headers="enrollmentInfoTitle" nowrap="nowrap">Study Start Date:</TD>
<TD headers="enrollmentInfoData" style="padding-left: 1em;">June 2015</TD>
</TR>
<TR valign="top"><TD headers="enrollmentInfoTitle" nowrap="nowrap">Estimated Study Completion Date:</TD>
<TD headers="enrollmentInfoData" style="padding-left: 1em;">January 2020</TD>
</TR>
</TBODY>
</TABLE> </div><div style="margin-bottom: 10px;"><STRONG>Clinical Evidence presented at the 26th EORTC-NCI-AACR Symposium:</STRONG> </div><div style="margin-bottom: 10px;">Six patients (5 confirmed, 1 unconfirmed per RECIST v1.<wbr>1) achieved a partial response (15%, N=40) with a median duration of response of 5.<wbr>2 months and median progression free survival (PFS) of 2.<wbr>7 months.<wbr> </div><div style="margin-bottom: 10px;"><UL><LI>Eight patients were enrolled with a confirmed KRAS mutation and two of those eight experienced an objective response (25%); median PFS in patients with KRAS mutant tumors was 2.<wbr>8 months.<wbr>
</LI>
<LI>In patients with squamous cell carcinoma (n=9) there were no confirmed objective responses; however, median PFS in patients with squamous cell carcinoma was 2.<wbr>8 months.<wbr> Prolonged (&gt;4 cycles) disease control was also noted in six of nine (66%) patients with squamous histology.<wbr>
</LI>
<LI>Preliminary median overall survival was 6.<wbr>2 months for all patients treated, 9.<wbr>6 months in patients with KRAS mutant tumors and 11.<wbr>1 months in patients with squamous cell carcinoma.<wbr>
</LI>
<LI>Twenty-one of 40 patients received four or more cycles of therapy, attesting to the tolerability of BIND-014.<wbr> Consistent with previous results, neutropenia, anemia, neuropathy, and alopecia, commonly observed with docetaxel, were significantly reduced with BIND-014.<wbr>
</LI>
</UL> </div><div>Source: BIND Therapeutics Press Release </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20151231&edate=20150901&rec=10663">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-09-10T19:00:15+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-09-10T19:00:15+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: CEO of Summit Pharm. Opened to Partner Drug for C.difficile</title>
	<pubDate>2015-09-10T17:50:36+02:00</pubDate>
	<wp:post_id>6924</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">CEO of Summit Pharm.<wbr> Opened to Partner Drug for C.<wbr>difficile</span>&nbsp;<br><span style="font-size: 12px;">Comment: Last week G.<wbr> Edwards reported that two Ph3 would take place during 2016, 2017 and possibly into 2018.<wbr> SMT19969 is an antibiotic selective against CDI that could enable a faster return to normal flora in affected patients.<wbr> The CDI program was granted Fast Track Designation by the US FDA last month.<wbr> It is currently in a Ph2 study with data expected in 4Q15, which could facilitate a partnership for Summit.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20151231&edate=20150901&rec=2515">...</a><br></div><div style="margin-bottom: 10px;">The company has announced the completion of patient enrolment into the CoDIFy Ph 2 proof of concept trial of SMT19969 for the treatment of CDI.<wbr> Patient dosing and follow-up is continuing and top-line results are expected in the fourth quarter of 2015.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>CoDIFy Phase 2 Clinical Trial</STRONG> - double-blind, randomized, active control Phase 2 trial evaluating the efficacy of SMT19969 against the current standard of care, vancomycin.<wbr> CoDIFy is being conducted in the United States and Canada.<wbr> The trial has enrolled a total of 100 patients, with half receiving ten days of dosing with SMT19969, and half receiving ten days of dosing with vancomycin.<wbr> The primary endpoint of the trial is sustained clinical response, a composite endpoint which is defined as clinical cure at the test of cure visit with no recurrence of CDI within 30 days after the end of treatment.<wbr> The trial is also examining a number of secondary endpoints, including the safety and tolerability of SMT19969 and its impact on patients' gut microbiome.<wbr> </div><div><STRONG>About SMT19969</STRONG> - novel, oral small molecule antibiotic that is being developed specifically for the treatment of CDI </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20151231&edate=20150901&rec=2531">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2515">View thread  GastroEnterology2515: CEO of Summit Pharm.<wbr> Opened to Partner Drug for C.<wbr>difficile</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-09-10T17:50:36+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-09-10T17:50:36+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>FDA Granted Fast Track To Biocancell's BC-819 For NMIBC</title>
	<pubDate>2015-09-10T16:48:43+02:00</pubDate>
	<wp:post_id>6925</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: BioCancell announced today that its BC-819 received FDA Fast Track designation for use in non muscle invasive bladdder cancer.<wbr> BC819 will enter two Ph3 confirmatory studies in 1H 2016.<wbr> The fast track is being granted for both BCG failure and BCG intolerant patients.<wbr> </div><div style="margin-bottom: 10px;">Company Profile<BR>BioCancell's R&amp;D activities build upon the research of Professor Abraham Hochberg of the Hebrew University of Jerusalem.<wbr> Professor Hochberg isolated the human H19 gene and determined that the gene is expressed in over forty different forms of cancer.<wbr> H19-based therapy combines a highly selective method of killing cancer cells with a strong safety profile.<wbr> Each of BioCancell's product candidates relies on a proprietary H19 technology platform, with the potential to provide benefits that are competitive with existing cancer treatment methods.<wbr> Bladder cancer is the primary focus for the company.<wbr><BR>BC-819 , is a double-stranded DNA plasmid construct that uses the H19 gene to activate the synthesis of diphtheria toxin after entering a cell in which H19 transcription factors exist, destroying only that cell.<wbr> The result of this mechanism is highly selective tumor cell destruction.<wbr>Two Ph3 trials planned: </div><div style="margin-bottom: 10px;"><UL><LI>BCG failure NMIBC: BC819 in combination with BCG in patients who had failed at least one course of BCG.<wbr> This will be performed under an FDA special protocol assessment
</LI>
<LI>BCG unresponsive/<wbr>intolerant: BC819 monotherapy
</LI>
</UL> </div><div style="margin-bottom: 10px;">In Sept 2014, Biocancell annouced positive results from its Ph2 trial that triggered The company's share price rose 9.<wbr>5% in afternoon trading on the TASE.<wbr> </div><div style="margin-bottom: 10px;">The clinical trials demonstrated for the first time the safety and effectiveness of the combined treatment including BCG on high-risk bladder cancer patients.<wbr> 17 patients were treated in the trial with three treatments regimens, following removal of all the malignant tumours in the bladder.<wbr> </div><div style="margin-bottom: 10px;">The results of the trial were that 11 of the 17 patients (65%) had no recurrence of the malignant tumor for three months from the beginning of the treatment.<wbr> No severe side effects related to the treatment were diagnosed during the trial.<wbr> </div><div>Source: marketwire press release </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20151231&edate=20150901&rec=10661">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-09-10T16:48:43+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-09-10T16:48:43+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Versartis Initiates POC With Monthly rhGH for AGHD</title>
	<pubDate>2015-09-10T15:43:49+02:00</pubDate>
	<wp:post_id>6926</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Today, Versartis announced the initiation of the <A href="https://views.thomsonone.com/gateway/PORTALSxDOCUMENTVIEWER.aspx?DocId=71595520&amp;mode=plain&amp;lang=en-US&amp;appName=T1_Web">VITAL</A> trial, an open-label, international, multicenter study with somavaratan treatment for 5 months.<wbr> Secondary endpoints is tracking the measurement and detection of neutralizing antibodies (not included in the VELOCITY trial).<wbr> Expected VITAL data in mid-2016, with potential for filing by 2019.<wbr> In parallel, the company reported the appointment of Lars Ekman as a consultant for its clinical development strategy.<wbr> Next week, management will hold an Investor Symposium.<wbr> The agenda features a panel of internationally renowned Ped endocrinologists, such as Ph Backeljauw, who will shares their perspectives, experiences and insights regarding pediatric GHD.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Ref <A href="https://views.thomsonone.com/gateway/PORTALSxDOCUMENTVIEWER.aspx?DocId=71595520&amp;mode=plain&amp;lang=en-US&amp;appName=T1_Web">NCT02526420</A> </div><div style="margin-bottom: 10px;">Recruitment: approx 40 (Subjects will be stratified into three cohorts based on age, gender and the use of oral estrogens) </div><div style="margin-bottom: 10px;">Timelines: June 2016 /<wbr> August 2016 </div><div style="margin-bottom: 10px;">This treatment period will include monthly dose titrations until a subject's mean IGF-I SDS value is within a target range for two consecutive months.<wbr> Subjects will be stratified into three cohorts based on age, gender and the use of oral estrogens.<wbr> </div><div style="margin-bottom: 10px;">Location: USA (4 active sites); EU and Australia (tbc) </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Dr.<wbr> Ekman is currently an Executive Partner at Sofinnova Ventures, and has more than 28 years in senior executive, scientific and clinical functions.<wbr> </div><div style="margin-bottom: 10px;">Most recently, he was appointed to the Board of Directors of Poseida Therapeutics.<wbr> He is Chairman of the Amarin Corporation, plc, The Prothena Corporation, plc, and Sophiris Bio, Inc.<wbr>, and he also serves on the Board of Directors of Spark Therapeutics, Inc.<wbr> </div><div style="margin-bottom: 10px;">Previously, Dr.<wbr> Ekman held the position of President of Research and Development at Elan Corporation, plc.<wbr> Dr.<wbr> Ekman joined Elan in January 2001, and he is credited with advancing Elan's pipeline during this period.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_8191_1_ScreenCapture1.jpg"> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20151231&edate=20150901&rec=8191">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-09-10T15:43:49+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-09-10T15:43:49+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Revance Has Commenced pII Study For RT001/RT1150 For Axillary Hyperhidrosis</title>
	<pubDate>2015-09-10T12:13:36+02:00</pubDate>
	<wp:post_id>6927</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The study investigating Revance RT001 (now referred to as RTT150) a BoNT A topical gel, has commenced.<wbr> The methodology will be a pII randomized double-blinded, placebo-controlled study designed to evaluate the safety and efficacy in the treatment of primary axillary hyperhidrosis </div><div style="margin-bottom: 10px;">The study will be conducted in the in the US with interim results expected end of 2015 </div><div style="margin-bottom: 10px;">Dan Browne President and CEO reported  "Hyperhidrosis, or excessive sweating, is a widespread condition in a highly underserved market, representing a significant therapeutic opportunity for topical RT001.<wbr>  Botulinum toxin injections have been validated as an effective treatment, but not widely embraced.<wbr> A big reason is the pain caused by the large number of required injections, up to fifteen per treated underarm.<wbr> We believe our needle-free approach may provide a targeted, painless, and long-lasting alternative, without daily application or the systemic side effects observed in many other hyperhidrosis treatments.<wbr> We also believe RT001 could dramatically expand the toxin market for excessive underarm sweating and bring new patients into the physician's office.<wbr>  Although this program's initial focus is on underarm hyperhidrosis, excessive sweating is often experienced in the palms, feet, and face.<wbr> These represent potential future indications for us to pursue with RT001 topical gel.<wbr>" </div><div>Source: Revance </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Neurology8280c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;"><SPAN style="font-size: small; font-family: arial,helvetica,sans-serif;">Revance today announced interim efficacy and safety results from its Phase II trial of RT001 topical botulinum toxin type A for the treatment of axilarry hyperhidrosis (excessive underarm sweating).<wbr> The trial was designed to evaluate two doses of RT001 applied on a single day of treatment.<wbr> </SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-size: small; font-family: arial,helvetica,sans-serif;">Revance announced that the data was positive using 'quantitative gravimetric measurements' (the trial sample size was not chosen to meet statistical significance), showing that a single treatment of RT001 topical gel achieved clinically meaningful efficacy at Week 4.<wbr> Using the qualitative Hyperhidrosis Disease Severity Scale (HDSS), RT-001 showed a positive efficacy trend for both 1-point and 2-point improvement.<wbr> Both doses appear to be safe and well tolerated.<wbr> </SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-size: small; font-family: arial,helvetica,sans-serif;">In the details below, however, its is interesting to note that at week 4, using the primary qualitative efficacy assessment of 2-point improvement, though the trend is positive in absolute, the RT001 improvement in relatively inferior to placebo (14.<wbr>3% to 13.<wbr>3% for RT001 vs 29.<wbr>4% for placebo)</SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-size: small; font-family: arial,helvetica,sans-serif;">Revance announced plans to advance RT001 to a larger hyperhidrosis Phase 2 study in 2016, to be designed to confirm a final dose.<wbr> Following the larger Phase 2 trial, Revance plans to meet the FDA to take RT001 into Phase 3 studies.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-size: small; font-family: arial,helvetica,sans-serif;">Key interim results are as below:</SPAN> </div><div><UL><LI><SPAN style="font-size: small; font-family: arial,helvetica,sans-serif;">On the primary quantitative assessment of average reduction from baseline in gravimetrically-measured sweat production, the results ranged from 214.<wbr>2 mg to 165.<wbr>7 mg (p=0.<wbr>003 for the higher dose) per five minutes for RT001, compared to 66.<wbr>3 mg per five minutes in patients who received placebo.<wbr> These ranges corresponded to 81.<wbr>1% to 79.<wbr>6% change for RT001, compared to 54.<wbr>6% for placebo.<wbr>  </SPAN>
</LI>
<LI><SPAN style="font-size: small; font-family: arial,helvetica,sans-serif;"> On the primary qualitative efficacy assessment of a 2-point or greater responders from baseline using the HDSS, at Weeks 1 and 2 the results ranged from a 23.<wbr>8% to 13.<wbr>3 % improvement for RT001 compared to a range of 17.<wbr>6% to 11.<wbr>8% improvement for placebo.<wbr>  By Week 4, there was a 14.<wbr>3% to 13.<wbr>3% improvement for RT001, compared to a 29.<wbr>4% improvement in patients who received placebo.<wbr></SPAN>
</LI>
<LI><SPAN style="font-size: small; font-family: arial,helvetica,sans-serif;">RT001 appears to be safe and well tolerated at both doses.<wbr>  Adverse events were generally mild, localized and transient.<wbr> There were no serious adverse events or evidence of any systemic exposure for either of the two doses evaluated.<wbr> The most common treatment-related adverse events reported were application site erythema (redness), folliculitis (razor bumps) and application site pain.<wbr></SPAN>
</LI>
</UL> </div></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20151231&edate=20150901&rec=8175">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-09-10T12:13:36+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-09-10T12:13:36+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Key Messages from Check Cap Presentation at Rodman & Renshaw Global Investment Conference</title>
	<pubDate>2015-09-10T09:15:47+02:00</pubDate>
	<wp:post_id>6928</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Chek Cap develops the world's first diagnostic system for cleanse-free examination of the colon to identify precancerous polyps and cancers.<wbr> Company claims that no prior bowel cleansing is needed because its x-rays create 360-degree angular scans that can "see through" intestinal content.<wbr> Clinical trials are ongoing in Israel (6 sites)/<wbr>EU (1 site).<wbr> Management reported it expects to initiate U.<wbr>S pivotal trial and launch the device in EU in H2:16.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Consists of ingestible X-ray scanning capsule, tracking system, processing software </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2529_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2529_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">18 granted, 1 allowed, and 29 pending from major juridictions including the U.<wbr>S PTO, European Patent Organisation, China, Japan and India covering the core technology.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Financial position: $19M cash as of June 30, 2015 </div><div style="margin-bottom: 10px;">Principal investigators: GE, Fosun Pharma, Pontifax, Counterpoint </div><div style="margin-bottom: 10px;">Founded: 2005 (US IPO in 2015) </div><div style="margin-bottom: 10px;">Location: Israel; Boston </div><div>Employees: roughly 50 </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="GastroEnterology2601c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">Check-Cap has reported that new data demonstrating safety and polyp detection from a clinical study evaluating the company's non-invasive system for preparation-free examination of the colon will be presented at the American College of Gastroenterology (ACG) Annual Scientific Meeting taking place October 16-21, 2015 and the United European Gastroenterology Week (UEGW) taking place October 24-28, 2015.<wbr> The company anticipates submitting data from this study for CE Mark inQ1:16, and initiating a U.<wbr>S.<wbr> pivotal trial in H2:16.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>About the Study</STRONG> </div><div style="margin-bottom: 10px;">The study evaluated data from 49 volunteers and tracked the entire passage of the capsule through the alimentary tract using radio frequency telemetry and Check-Cap's proprietary capsule position tracking system.<wbr> </div><div style="margin-bottom: 10px;">All capsules were swallowed naturally without adverse events, and there was a 100% capsule excretion rate after an average transit time of 68 +/<wbr>- 31 hours.<wbr> Enrolled subjects were exposed to ultra-low doses of radiation with an average total exposure of 0.<wbr>03 +/<wbr>- 0.<wbr>007 mSv (approximately equivalent to a single chest x-ray).<wbr> Quantitative ultra-low dose x-ray 3D imaging was achieved in the colon of human subjects, and the system successfully generated multiple reconstructions of colon segments with polyps.<wbr> </div><div style="margin-bottom: 10px;">While colonic polyps were clearly demonstrated by the system, in order to get statistically significant results, the efficacy of this colon screening modality will need to be validated in a larger multi-center study.<wbr> </div><div>These study results represent a preliminary analysis of the first patients evaluated in Check-Cap's ongoing multi-center clinical evaluation.<wbr> </div></div><a name="gastroenterology2529attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2529_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(68 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2529_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(49,9 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20151231&edate=20150901&rec=2529">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-09-10T09:15:47+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-09-10T09:15:47+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Highlights from the Next Third Microbiome R&D and Business Collaboration Forum</title>
	<pubDate>2015-09-09T11:57:27+02:00</pubDate>
	<wp:post_id>6929</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The forum will take place Sept.<wbr> 10-11 in San Diego, CA, USA and be attracting over 200 leading academics and industry experts.<wbr> Among the sponsors, 4D pharma (platinum), P&amp;G (silver), and Synthetic Biologics.<wbr> Speakers with big pharma companies such as J&amp;J, Novartis and Pfizer will be discussing, among other topics, the challenges of transforming bacteria into medicine, the promise and pitfalls of microbiome-modulating therapies for inflammatory and autoimmune diseases, and how to foster the growth of microbiome therapeutics.<wbr> Presentations of Enterome Biosciences, 4D Pharma, Seres and Synthetic Biologics are outlined below.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2527_1_ScreenCapture1.jpg"> Director of Inflammation and Immune Disorders, Seres Therapeutics </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2527_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2527_2_ScreenCapture2.jpg">, Senior Vice President, Clinical &amp; Regulatory Affairs, Synthetic Biologics will be presenting in the session 'Protecting the gut microbiome', SYN-004 which is designed to protect the gut microbiome from the effects of certain commonly used IV antibiotics for the prevention of C.<wbr> difficile infection and antibiotic-associated diarrhea (AAD), and SYN-010 which is intended to reduce the impact of methane producing organisms in the gut microbiome to treat the underlying cause of irritable bowel syndrome with constipation (IBS-C).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2527_7_ScreenCapture7.jpg"> </div><div><STRONG></STRONG><A href="http://www.globalengage.co.uk/microbiome/MicrobiomeUSAAgenda15.pdf">http:/<wbr>/<wbr>www.<wbr>globalengage.<wbr>co.<wbr>uk/<wbr>microbiome/<wbr>MicrobiomeUSAAgenda15.<wbr>pdf</A> </div><!-- Comment details --><a name="gastroenterology2527attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2527_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(3,8 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2527_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(2,8 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2527_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(62,9 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2527_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(12 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2527_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(22 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2527_6_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(3,4 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2527_7_ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(44,6 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20151231&edate=20150901&rec=2527">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-09-09T11:57:27+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-09-09T11:57:27+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Revance pII Clinical Trial To Treat Glabellar Lines With RT002 Has Completed Enrolment</title>
	<pubDate>2015-09-09T11:34:52+02:00</pubDate>
	<wp:post_id>6930</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Phase II Clinical trial by Revance to assess the efficacy and safety of RT002 product has now completed recruitment </div><div style="margin-bottom: 10px;">Estimated primary completion expected December 2015 with a completion date of March 2016.<wbr> The study comprises of 5 study arms with varying doses including a comparator to placebo.<wbr> </div><div style="margin-bottom: 10px;">RT002 is an injectable BoNT A that is thought to offer a more targeted delivery and a longer-lasting effect than current BoNT A on the market.<wbr> </div><div>Source: Clinicaltrial.<wbr>gov NCT02303002 </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20151231&edate=20150901&rec=8173">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-09-09T11:34:52+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-09-09T11:34:52+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>AstraZeneca Licences Starpharma Drug Delivery Platform To Co-Develop Cancer Compounds</title>
	<pubDate>2015-09-09T10:32:57+02:00</pubDate>
	<wp:post_id>6931</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: AZ has agreed to license Starpharma DEP drug delivery platform to co-develop and co-commercialize oncology compounds against an unspecified 'defined family' of targets.<wbr> AZ could pay up to $126 million for the first DEP product, and up to $94 million for each subsequent qualifying product plus royalties.<wbr> The DEP platform uses Starpharma&rsquo;s own dendrimers, with the aim of enhancing the dosing and efficacy characteristics of new drugs.<wbr> Starpharma cited preclinical studies of DEP conjugates with a number of different cancer drugs, which the company said have already established improved efficacy and reduced toxicities compared to marketed versions.<wbr> </div><div style="margin-bottom: 10px;">Starpharma&rsquo;s licensing agreement with AstraZeneca focuses on novel compounds, not on unmodified drugs in currently marketed formulations and is an expanding collaboration between the companies that first agreed to partner in September 2012, when the DEP drug delivery technology was applied to one important AstraZeneca oncology candidate.<wbr> </div><div style="margin-bottom: 10px;">Starpharma state that the licensing deal will not negatively impact other development programs, including its lead internal development candidate, a wholly-owned DEP docetaxel product.<wbr> According to Starpharma, DEP docetaxel continues to demonstrate excellent tolerability and improved pharmacokinetics in the clinic compared with the available data for its reference drug, Taxotere.<wbr> </div><div>Source: Starpharma PR </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20151231&edate=20150901&rec=11238">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-09-09T10:32:57+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-09-09T10:32:57+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: OTC Product for IBS-D to be Launched Next Month in the U.S</title>
	<pubDate>2015-09-09T10:03:44+02:00</pubDate>
	<wp:post_id>6932</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">OTC Product for IBS-D to be Launched Next Month in the U.<wbr>S</span>&nbsp;<br><span style="font-size: 12px;">Comment: IM HealthScience's IBgard is an encapsulated peppermint oil that reportedly works within 2 hours of administration to reduce symptoms of pain and urgency associated with IBS-D.<wbr> Company claims that IBgard is the only medical food with SST (Site Specific Targeting) technology for the dieatary management of IBS.<wbr> A poster with the results from the IBREST trial" was presented @ DDW 2015.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20151231&edate=20150901&rec=2362">...</a><br></div><div style="margin-bottom: 10px;">Results of the IBREST trial have been published in <EM>Digestive Disease &amp; Sciences</EM>.<wbr> The conclusion outlines that the novel Peppermint oil (PO) formulation, designed for sustained release in the small intestine, is a safe, effective treatment capable of providing rapid relief of IBS symptoms.<wbr> </div><div style="margin-bottom: 10px;"><H3 class="Heading">Results</H3> </div><div style="margin-bottom: 10px;"><P class="Para" id="Par4">Seventy-two patients (mean age 40.<wbr>7 years, 75 % female, 77.<wbr>8 % white) were randomized to PO (<EM class="EmphasisTypeItalic ">n</EM> = 35) or placebo (<EM class="EmphasisTypeItalic ">n</EM> = 37).<wbr> At 4 weeks, PO was associated with a 40 % reduction in the TISS from baseline (mean change &minus;1.<wbr>16, SD &plusmn; 0.<wbr>807), superior to the 24.<wbr>3 % decrease (mean change &minus;0.<wbr>70, SD &plusmn; 0.<wbr>737) observed with placebo (<EM class="EmphasisTypeItalic ">P</EM> = 0.<wbr>0246).<wbr> The decrease in the TISS of 19.<wbr>6 % (mean change &minus;0.<wbr>55, SD &plusmn; 0.<wbr>613) in the PO group at 24 h was also significantly larger than placebo (&minus;10.<wbr>3 %, mean change &minus;0.<wbr>27, SD &plusmn; 0.<wbr>342) (<EM class="EmphasisTypeItalic ">P</EM> = 0.<wbr>0092).<wbr> At trial completion, patients in the PO group experienced greater improvement in multiple individual gastrointestinal symptoms as well as in severe or unbearable symptoms, compared to placebo.<wbr> PO was well tolerated with few adverse events.<wbr></P> </div><div><P class="Para">Title: A Novel Delivery System of Peppermint Oil Is an Effective Therapy for Irritable Bowel Syndrome Symptoms</P> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20151231&edate=20150901&rec=2526">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2362">View thread  GastroEnterology2362: OTC Product for IBS-D to be Launched Next Month in the U.<wbr>S</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-09-09T10:03:44+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-09-09T10:03:44+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: POC Study to Assess Abiraterone and Degarelix 1M Together</title>
	<pubDate>2015-09-08T17:09:02+02:00</pubDate>
	<wp:post_id>6933</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">POC Study to Assess Abiraterone and Degarelix 1M Together</span>&nbsp;<br><span style="font-size: 12px;"><P dir="ltr" style="MARGIN-RIGHT: 0px">Comment: Sponsored by the Memorial Sloan-Kettering Cancer Center and ten collaborators among which J&amp;J, this randomized, 3-arm trial will assess both drugs in combinaison as possible treatment for PSA recurrent prostate cancer, following definitive radical prostatectomy, as compared to abiraterone and degarelix alone.<wbr> Primary endpoint will measure PFS.<wbr></P></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20151231&edate=20150901&rec=8682">...</a><br></div><div>Comment: Interestingly, the trial end date was initially postponed in March 2014 from Oct 2014 to Oct 2015.<wbr> Again, the trial completion has now been postponed to Oct 2016 mainly due to opening of additional clinical sites in the US.<wbr> This is still a proof of concept trial as the target patient remains quite small (n=120) for a 3 arm study.<wbr> At this stage, the primary focus for J&amp;J likely remains to ensure its ARN509 market entry.<wbr> (Source: clinicaltrial.<wbr>gov) </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20151231&edate=20150901&rec=10660">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8682">View thread  Oncology8682: POC Study to Assess Abiraterone and Degarelix 1M Together</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-09-08T17:09:02+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-09-08T17:09:02+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Incyte Inks An Acqusition of Anti-PD1 (SHR-1210) From Jiangsu Hengrui Medicine</title>
	<pubDate>2015-09-08T13:33:16+02:00</pubDate>
	<wp:post_id>6934</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Incyte Announces Global License Agreement with Jiangsu Hengrui Medicine for SHR-1210, an Investigational Anti-PD-1 Monoclonal Antibody.<wbr> Incyte to pay Hengrui $25 million upfront plus the potential for milestone and royalty payments .<wbr> Under the agreement, Incyte will have the exclusive development and commercialization rights to SHR-1210 worldwide, with the exception of Mainland China, Hong Kong, Macau, and Taiwan.<wbr> SHR-1210 is expected to enter proof-of-concept studies for the treatment of patients with advanced solid tumours in the coming months.<wbr> Jiangsu Hengrui has a strong research focus in drug discovery for oncology targeted small molecule.<wbr> It is one of the leading domestic manufactures for "China antineoplastic technological innovation and research alliance" that is one of the key Chinese government funded initiatives.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Company Profile</STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Jiangsu Hengrui Medicine Co.<wbr>, Ltd.<wbr>,</STRONG> established in 1970, is a fully integrated pharmaceutical company in China, with annual net sales of over U.<wbr>S.<wbr> $1.<wbr>2 billion.<wbr> Hengrui's products and innovative R&amp;D span multiple therapeutic areas, including oncology and haematology, anaesthesiology and pain management, cardiovascular and metabolic diseases, contrast media, and inflammation.<wbr> </div><div style="margin-bottom: 10px;">Its Key Subsidiaries include: </div><div style="margin-bottom: 10px;"><UL><LI>Hengrui USA LLC (New Jersey): funded in 2005.<wbr> R&amp;D site for drug development and discovery, and commercialisation for ANDA, API in the US
</LI>
<LI>Shanghai Hengrui Pharmaceuticals Co Ltd.<wbr>: funded in 2000.<wbr> Drug development site for IND drug discovery focusing on small molecule targeted therapy for oncology, CV, endocrinology
</LI>
<LI>Three preclinical research centres in Shanghai, Chengdu, and JiangSu
</LI>
</UL> </div><div style="margin-bottom: 10px;">Current Pipeline </div><div style="margin-bottom: 10px;">Its current pipeline includes a multi-target angiogenesis inhibitor (anti-cKIT, anti-VEGF, anti-PDGFR) is also being evaluated in various GI malignancies (including colorectal cancer in Ph3, GIST and NET in Ph2).<wbr> While Corporate Business Intelligence Team is aware of the initiation of the NET trial, however, the recruitment status for this trial still needs to be further validated.<wbr> </div><div style="margin-bottom: 10px;">* assets that are currently under evaluation in its Shanghai subsidiary </div><div style="margin-bottom: 10px;"><TABLE border="0" cellpadding="0" cellspacing="0" style="border: 0px solid #000000; width: 1175px; height: 720px;"><COLGROUP><COL width="221">
</COLGROUP>
<COLGROUP><COL width="431">
</COLGROUP>
<COLGROUP><COL width="215">
</COLGROUP>
<COLGROUP><COL width="290">
</COLGROUP>
<COLGROUP><COL width="180">
</COLGROUP>
<TBODY><TR height="36"><TD height="36" width="221"><SPAN style="font-size: x-small;"><STRONG></STRONG></SPAN></TD>
<TD width="431"><SPAN style="font-size: x-small;"><STRONG></STRONG></SPAN></TD>
<TD width="215"><SPAN style="font-size: x-small;"><STRONG></STRONG></SPAN></TD>
<TD width="290"><SPAN style="font-size: x-small;"><STRONG></STRONG></SPAN></TD>
<TD width="180"><SPAN style="font-size: x-small;"><STRONG></STRONG></SPAN></TD>
</TR>
<TR height="42"><TD height="103" rowspan="3"><SPAN style="font-size: x-small;"></SPAN></TD>
<TD width="431"><SPAN style="font-size: x-small;"></SPAN></TD>
<TD width="215"><SPAN style="font-size: x-small;"></SPAN></TD>
<TD width="290"><SPAN style="font-size: x-small;"></SPAN></TD>
<TD width="180"><SPAN style="font-size: x-small;"></SPAN></TD>
</TR>
<TR height="28"><TD height="28" width="431"><SPAN style="font-size: x-small;"></SPAN></TD>
<TD width="215"><SPAN style="font-size: x-small;"></SPAN></TD>
<TD width="290"><SPAN style="font-size: x-small;"></SPAN></TD>
<TD width="180"><SPAN style="font-size: x-small;"></SPAN></TD>
</TR>
<TR height="33"><TD height="33" width="431"><SPAN style="font-size: x-small;"></SPAN></TD>
<TD width="215"><SPAN style="font-size: x-small;"></SPAN></TD>
<TD width="290"><SPAN style="font-size: x-small;"></SPAN></TD>
<TD width="180"><SPAN style="font-size: x-small;"></SPAN></TD>
</TR>
<TR height="31"><TD height="31"><SPAN style="font-size: x-small;"></SPAN></TD>
<TD width="431"><SPAN style="font-size: x-small;"></SPAN></TD>
<TD width="215"><SPAN style="font-size: x-small;"></SPAN></TD>
<TD width="290"><SPAN style="font-size: x-small;"></SPAN></TD>
<TD width="180"><SPAN style="font-size: x-small;"></SPAN></TD>
</TR>
<TR height="27"><TD height="27"><SPAN style="font-size: x-small;"></SPAN></TD>
<TD width="431"><SPAN style="font-size: x-small;"></SPAN></TD>
<TD width="215"><SPAN style="font-size: x-small;"></SPAN></TD>
<TD width="290"><SPAN style="font-size: x-small;"></SPAN></TD>
<TD width="180"><SPAN style="font-size: x-small;"></SPAN></TD>
</TR>
<TR height="30"><TD height="69" rowspan="2"><SPAN style="font-size: x-small;"></SPAN></TD>
<TD width="431"><SPAN style="font-size: x-small;"></SPAN></TD>
<TD width="215"><SPAN style="font-size: x-small;"></SPAN></TD>
<TD width="290"><SPAN style="font-size: x-small;"></SPAN></TD>
<TD width="180"><SPAN style="font-size: x-small;"></SPAN></TD>
</TR>
<TR height="39"><TD height="39" width="431"><SPAN style="font-size: x-small;"></SPAN></TD>
<TD width="215"><SPAN style="font-size: x-small;"></SPAN></TD>
<TD width="290"><SPAN style="font-size: x-small;"></SPAN></TD>
<TD width="180"><SPAN style="font-size: x-small;"></SPAN></TD>
</TR>
<TR height="23"><TD height="93" rowspan="4" width="221"><SPAN style="font-size: x-small;"></SPAN></TD>
<TD width="431"><SPAN style="font-size: x-small;"></SPAN></TD>
<TD width="215"><SPAN style="font-size: x-small;"></SPAN></TD>
<TD width="290"><SPAN style="font-size: x-small;"></SPAN></TD>
<TD width="180"><SPAN style="font-size: x-small;"></SPAN></TD>
</TR>
<TR height="22"><TD height="22" width="431"><SPAN style="font-size: x-small;"></SPAN></TD>
<TD width="215"><SPAN style="font-size: x-small;"></SPAN></TD>
<TD width="290"><SPAN style="font-size: x-small;"></SPAN></TD>
<TD width="180"><SPAN style="font-size: x-small;"></SPAN></TD>
</TR>
<TR height="23"><TD height="23" width="431"><SPAN style="font-size: x-small;"></SPAN></TD>
<TD width="215"><SPAN style="font-size: x-small;"></SPAN></TD>
<TD width="290"><SPAN style="font-size: x-small;"></SPAN></TD>
<TD width="180"><SPAN style="font-size: x-small;"></SPAN></TD>
</TR>
<TR height="25"><TD height="25" width="431"><SPAN style="font-size: x-small;"></SPAN></TD>
<TD width="215"><SPAN style="font-size: x-small;"></SPAN></TD>
<TD width="290"><SPAN style="font-size: x-small;"></SPAN></TD>
<TD width="180"><SPAN style="font-size: x-small;"></SPAN></TD>
</TR>
<TR height="46"><TD height="322" rowspan="8" width="221"><SPAN style="font-size: x-small;"></SPAN></TD>
<TD rowspan="2" width="431"><SPAN style="font-size: x-small;"></SPAN></TD>
<TD width="215"><SPAN style="font-size: x-small;"></SPAN></TD>
<TD width="290"><SPAN style="font-size: x-small;"></SPAN></TD>
<TD width="180"><SPAN style="font-size: x-small;"></SPAN></TD>
</TR>
<TR height="39"><TD height="39" width="215"><SPAN style="font-size: x-small;"></SPAN></TD>
<TD width="290"><SPAN style="font-size: x-small;"></SPAN></TD>
<TD width="180"><SPAN style="font-size: x-small;"></SPAN></TD>
</TR>
<TR height="23"><TD height="123" rowspan="2" width="431"><SPAN style="font-size: x-small;"></SPAN></TD>
<TD width="215"><SPAN style="font-size: x-small;"></SPAN></TD>
<TD width="290"><SPAN style="font-size: x-small;"></SPAN></TD>
<TD width="180"><SPAN style="font-size: x-small;"></SPAN></TD>
</TR>
<TR height="100"><TD height="100" width="215"><SPAN style="font-size: x-small;"></SPAN></TD>
<TD width="290"><SPAN style="font-size: x-small;"></SPAN></TD>
<TD width="180"><SPAN style="font-size: x-small;"></SPAN></TD>
</TR>
<TR height="29"><TD height="57" rowspan="2" width="431"><SPAN style="font-size: x-small;"></SPAN></TD>
<TD width="215"><SPAN style="font-size: x-small;"></SPAN></TD>
<TD width="290"><SPAN style="font-size: x-small;"></SPAN></TD>
<TD width="180"><SPAN style="font-size: x-small;"></SPAN></TD>
</TR>
<TR height="28"><TD height="28" width="215"><SPAN style="font-size: x-small;"></SPAN></TD>
<TD width="290"><SPAN style="font-size: x-small;"></SPAN></TD>
<TD width="180"><SPAN style="font-size: x-small;"></SPAN></TD>
</TR>
<TR height="26"><TD height="26"><SPAN style="font-size: x-small;"></SPAN></TD>
<TD width="215"><SPAN style="font-size: x-small;"></SPAN></TD>
<TD width="290"><SPAN style="font-size: x-small;"></SPAN></TD>
<TD width="180"><SPAN style="font-size: x-small;"></SPAN></TD>
</TR>
<TR height="31"><TD height="31" width="431"><SPAN style="font-size: x-small;"></SPAN></TD>
<TD width="215"><SPAN style="font-size: x-small;"></SPAN></TD>
<TD width="290"><SPAN style="font-size: x-small;"></SPAN></TD>
<TD width="180"><SPAN style="font-size: x-small;"></SPAN></TD>
</TR>
<TR height="30"><TD height="30" width="221"><SPAN style="font-size: x-small;"></SPAN></TD>
<TD width="431"><SPAN style="font-size: x-small;"></SPAN></TD>
<TD width="215"><SPAN style="font-size: x-small;"></SPAN></TD>
<TD width="290"><SPAN style="font-size: x-small;"></SPAN></TD>
<TD width="180"><SPAN style="font-size: x-small;"></SPAN></TD>
</TR>
</TBODY>
</TABLE> </div><div style="margin-bottom: 10px;">source: pharmaetrack </div><div style="margin-bottom: 10px;">Incyte<BR>Interestingly in July 2014, Incyte Corporation announced that it has entered into a clinical trial agreement with Genentech to evaluate the safety, tolerability and preliminary efficacy of Incyte&rsquo;s oral indoleamine dioxygenase-1 (IDO1) inhibitor, INCB24360, in combination with Genentech&rsquo;s PD-L1 immune checkpoint inhibitor, atezolizumab, in patients with non-small cell lung cancer (NSCLC).<wbr> Under the terms of the collaboration, This is a non-exclusive collobaration to evaluate the combination.<wbr> Incyte will be responsible for conducting the study and the results will be used to determine whether further clinical development of this combination is warranted.<wbr> The acquisition of this anti-PD1 could allow Incyte to develop its co<img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10657_2_ScreenCapture2.jpg">mbination strategy solely.<wbr> </div><div>Source: GlobalData, Incyte Press Release, Jiangsu Hengrui Medicine Press Release </div><!-- Comment details --><a name="oncology10657attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10657_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(149 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10657_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(193,1 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20151231&edate=20150901&rec=10657">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-09-08T13:33:16+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-09-08T13:33:16+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>AstraZeneca to Support Clinical Bioinformatics Research</title>
	<pubDate>2015-09-08T09:41:33+02:00</pubDate>
	<wp:post_id>6935</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: AstraZeneca and the<A href="http://www.manchester.ac.uk/"> U.<wbr> of Manchester </A>have announced a £11.<wbr>5M collaboration harnessing clinical bioinformatics to deliver personalised healthcare for cancer patients.<wbr> The five-year agreement will see the organisations apply clinical trial bioinformatics to better identify the right cancer treatment for the right patient at the right time.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The research will be carried out in partnership with the state-of-the-art clinical trials unit of The Christie NHS Foundation Trust, which is at the forefront of experimental cancer medicine in the UK.<wbr> </div><div style="margin-bottom: 10px;">Projects will include the development of a new bioinformatics system to capture and integrate clinical trial safety, efficacy, biomarker and drug distribution data in real time.<wbr> </div><div style="margin-bottom: 10px;">The collaboration will also support new training programs in clinical research and pharmacokinetic and pharmacodynamic modelling for investigators to understand the distribution and clinical effects of medicines within the body.<wbr> </div><div>Source: AstraZeneca </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20151231&edate=20150901&rec=10656">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-09-08T09:41:33+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-09-08T09:41:33+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Novartis Has Launched the First Biosimilar in the U.S.</title>
	<pubDate>2015-09-07T17:26:55+02:00</pubDate>
	<wp:post_id>6936</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Novartis Has Launched the First Biosimilar in the U.<wbr>S.<wbr></span>&nbsp;<br><span style="font-size: 12px;">Comment: Sandoz has launched <A href="http://www.zarxio.com/assets/pdf/zarxio-full-pi.pdf">Zarxio</A> (filgrastim-sndz) in the five indications to Amgen's Neupogen, the reference product.<wbr> It is the first biosimilar approved by the FDA, and the first to launch in the U.<wbr>S.<wbr> With the product, the company offers Sandoz One Source<SUP>TM</SUP> a patient services center, providing support that connects the patient to the information and resources they need.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20151231&edate=20150901&rec=10652">...</a><br></div><div>Comment: Novartis-Sandoz kicked off a new era in U.<wbr>S.<wbr> medicine with the launch at a discount of 15% to the original Neupogen (Amgen), The arrival of biosimilars threatens companies heavily reliant on biotech drugs, such as Amgen, AbbVie and Roche, and Citigroup analysts have predicted a transfer of at least $110 billion of value from innovator companies to copycat producers in the next decade.<wbr> The 15 percent discount is the same price gap set when Zarxio was launched in Europe in 2009, although the discount in Europe has since widened to an average of around 20 to 30 percent.<wbr> The US Insurers hope biosimilars will eventually cost the public 40 percent to 50 percent less than the original brands.<wbr> (Source: Reuters) </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20151231&edate=20150901&rec=10655">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10652">View thread  Oncology10652: Novartis Has Launched the First Biosimilar in the U.<wbr>S.<wbr></a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-09-07T17:26:55+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-09-07T17:26:55+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>New Countries Listed in the Ph2 of Enzalutamide for HCC</title>
	<pubDate>2015-09-07T15:39:53+02:00</pubDate>
	<wp:post_id>6937</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Last May, Astellas outlined that enzalutamide is being evaluated in US and EU centers.<wbr> New countries such as Canada, Taiwan, Hong Kong and South Korea have been added.<wbr> In Europe, four countries have been listed such as UK, Italy, Spain, and France.<wbr> The POC trial is expected to start next month, and complete Q1:18.<wbr> PE will assess OS.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">ID: <A href="https://clinicaltrials.gov/ct2/show/NCT02528643?recr=Open&amp;no_unk=Y&amp;fund=2&amp;rcv_s=08%2F07%2F2015&amp;rank=16&amp;submit_fld_opt=">NCT02528643</A> </div><div style="margin-bottom: 10px;">Recruitment: approx 144 </div><div>Timelines: completion in January 2018 </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20151231&edate=20150901&rec=10654">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-09-07T15:39:53+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-09-07T15:39:53+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: BioGaia Aligns Strategy Behind L.reuteri DSM 17938 for Necrotizing Enterocolitis (NEC)</title>
	<pubDate>2015-09-07T15:13:01+02:00</pubDate>
	<wp:post_id>6938</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">BioGaia Aligns Strategy Behind L.<wbr>reuteri DSM 17938  for Necrotizing Enterocolitis (NEC)</span>&nbsp;<br><span style="font-size: 12px;">Comment: BioGaia is evaluating the possibility of a separate listing of its subsidiary Infant Bacterial Therapeutics AB (IBT), which develops a prophylactic drug against NEC.<wbr> To finance the first clinical trials (planned this year), IBT has an estimated capital need of approx.<wbr> SEK 130 million.<wbr> To enable BioGaia’s shareholders to invest directly in this project, the board of directors has instructed the management team to evaluate the possibility of a separate listing of IBT during the second half of 2015.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20151231&edate=20150901&rec=2409">...</a><br></div><div style="margin-bottom: 10px;">BioGaia&rsquo;s board of directors has resolved to invest a further SEK 35 million in the subsidiary Infant Bacterial Therapeutics AB (IBT), in addition to the approximately SEK 47 million previously decided.<wbr> BioGaia&rsquo;s total investment in IBT thus amounts to approx.<wbr> SEK 82 million and its holding to 94.<wbr>5%.<wbr> </div><div style="margin-bottom: 10px;">Efforts to evaluate the possibility for a separate listing of IBT are continuing.<wbr> </div><div style="margin-bottom: 10px;">IBT&rsquo;s work is aimed at developing a unique orphan drug to prevent the fatal disease necrotising enterocolitis (NEC).<wbr> </div><div style="margin-bottom: 10px;">The project has progressed more rapidly than previously scheduled and according to the updated development plan, IBT expects to conduct two clinical trials within the next three years.<wbr> </div><div>Source: BioGaia </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20151231&edate=20150901&rec=2525">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2409">View thread  GastroEnterology2409: BioGaia Aligns Strategy Behind L.<wbr>reuteri DSM 17938  for Necrotizing Enterocolitis (NEC)</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-09-07T15:13:01+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-09-07T15:13:01+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: NHS England Removes Drugs from Cancer Drugs Fund</title>
	<pubDate>2015-09-07T15:01:58+02:00</pubDate>
	<wp:post_id>6939</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">NHS England Removes Drugs from Cancer Drugs Fund</span>&nbsp;<br><span style="font-size: 12px;">Comment: 23 treatments (16 drugs) will be removed from the NHS England Cancer Drugs Fund from 4 November 2015, among which PRRT (for advanced NETs), Radium-223 Dichloride (for CRPC).<wbr> The NHS is to further examine the clinical criteria behind the inclusion of Cometriq (cabozantinib) and Caprelsa (vandetinib), both in the treatment of medullary thyroid cancer.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20151231&edate=20150901&rec=11236">...</a><br></div><div>Removing PRRT (Lutetium or Yttrium) from the Cancer Drugs Fund is the second NET treatment to be withdrawn this year, after the decision of delisting Everolimus back in April.<wbr> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20151231&edate=20150901&rec=11237">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld11236">View thread  PharmaWorld11236: NHS England Removes Drugs from Cancer Drugs Fund</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-09-07T15:01:58+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-09-07T15:01:58+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>NHS England Removes Drugs from Cancer Drugs Fund</title>
	<pubDate>2015-09-07T14:23:06+02:00</pubDate>
	<wp:post_id>6940</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: 23 treatments (16 drugs) will be removed from the NHS England Cancer Drugs Fund from 4 November 2015, among which PRRT (for advanced NETs), Radium-223 Dichloride (for CRPC).<wbr> The NHS is to further examine the clinical criteria behind the inclusion of Cometriq (cabozantinib) and Caprelsa (vandetinib), both in the treatment of medullary thyroid cancer.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11236_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;">The long-term future of the cancer fund remains unclear, especially whether it will be funded beyond its planned lifespan of 2016.<wbr> With demand for these types of treatment remaining strong, there seemingly remains a need for dialogue regarding how many of these drugs are funded.<wbr> For pharmaceutical companies there seems little scope for flexibility on pricing when the cost of development of biologics drugs (which the majority of these drugs are) is so high, and when the price of drugs in the UK remains a reference point for many other countries when conducting international reference price calculations.<wbr> It seems that the dialogue therefore needs to concentrate on priorities for NHS funding, perhaps considering if funding should be reduced elsewhere to pay for these kinds of treatments, if a new fund should be established, or whether patient expectations as to access to life-extending medicines should be moderated </div><div>Source: from IHS GlobalInsight </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="PharmaWorld11237c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div>Removing PRRT (Lutetium or Yttrium) from the Cancer Drugs Fund is the second NET treatment to be withdrawn this year, after the decision of delisting Everolimus back in April.<wbr> </div></div><a name="pharmaworld11236attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11236_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(248,3 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20151231&edate=20150901&rec=11236">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-09-07T14:23:06+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-09-07T14:23:06+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Cosmo's "Game Changer" Product Available for Licensing</title>
	<pubDate>2015-09-07T12:16:45+02:00</pubDate>
	<wp:post_id>6941</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Cosmo's "Game Changer" Product Available for Licensing</span>&nbsp;<br><span style="font-size: 12px;">Comment: Alongside its 1H financial results, management has highlighted that the licensing process of SIC 8000, a sub-mucosal injectable composition for the extraction of polyps in the colon, will commence in Q4 2014.<wbr> SIC 8000 is classified as a medical device with a very short regulatory approval path.<wbr> Cosmo expects therefore to be able to launch the product in North America and the EU in H1 2015.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20151231&edate=20150901&rec=2001">...</a><br></div><div>FDA has approved Cosmo's request for marketing authorization of SIC 8000.<wbr> According to the company, SIC 8000 will allow endoscopists to do their resection procedures safer and faster than before.<wbr> Management now intends to conduct two marketing trials in order to have the product ready for marketing by the beginning of 2016.<wbr> In the EU the request for marketing authorization filing was made on July 31<SUP>st</SUP> 2015 and with an approval expected in early 2016.<wbr> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20151231&edate=20150901&rec=2524">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2001">View thread  GastroEnterology2001: Cosmo's "Game Changer" Product Available for Licensing</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-09-07T12:16:45+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-09-07T12:16:45+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Cortendo's Strategy Disclosure While Planning For An IPO And Redomiciling The Parent Company to Ireland</title>
	<pubDate>2015-09-07T11:39:59+02:00</pubDate>
	<wp:post_id>6942</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Cortendo's Strategy Disclosure While Planning For An IPO And Redomiciling The Parent Company to Ireland</span>&nbsp;<br><span style="font-size: 12px;">Comment: On July 20<SUP>th</SUP> Cortendo announced the plans to conduct an IPO in the US, due to complete in September 2015.<wbr> More, on August 6<SUP>th</SUP>, Cortendo decided to redomicile the Cortendo Group&rsquo;s parent company from Sweden to Ireland by means of an Exchange Offer, and its name to be changed to Strongbridge Biopharma Plc upon receipt of consent from the Irish registrar of companies.<wbr> The Exchange Offer Prospectus discloses Cortendo&rsquo;s detailed strategy on how to focus on rare endocrine disorders and in particular the development plans for COR-003, COR-004 and COR-005, the commercialization plans for the US and EU and the intention to expand its franchise on rare therapeutic areas through disciplined in-licensing and acquisitions.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20151231&edate=20150901&rec=8172">...</a><br></div><div>Cortendo confirmed that the company name has changed to Strongbridge Biopharma plc.<wbr> and will become effective immediately with the new logo and corporate branding to be rolled out soon.<wbr> Under the new corporate name, Strongbridge Biopharma remains committed to building a biopharmaceutical company focused on the development, in-licensing, acquisition and eventual commercialization of complementary product candidates across multiple franchises that target rare endocrine disorders and other rare diseases.<wbr> </div><!-- Comment details --><br><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Endocrinology8241c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div>Strongbridge Biopharma plans for IPO did not go as originally planned: of the $86 million the biotech was hoping to raise when it filed the papers last month, it struggled to complete a $25 million listing on Nasdaq.<wbr> Strongbridge had planned to allocate $12 million to the Phase III trial of COR-003, for Cushing's syndrome, a sum that would have seen the study through to completion.<wbr> Now with just $5 million earmarked for the program, the company will only 'support' the continuation of the trial (currently recruiting).<wbr> COR-003 is one of two key Phase III clinical trials ongoing for Cushing's syndrome.<wbr> The other program in Phase III, LCI699 , is run by Novartis, and is also undergoing recruitment.<wbr> </div></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20151231&edate=20150901&rec=8190">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology8172">View thread  Endocrinology8172: Cortendo's Strategy Disclosure While Planning For An IPO And Redomiciling The Parent Company to Ireland</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-09-07T11:39:59+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-09-07T11:39:59+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Recent Updates on Acino's Strategy</title>
	<pubDate>2015-09-07T11:16:01+02:00</pubDate>
	<wp:post_id>6943</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Acino announed last Friday the US launch of its rivastigmine patch (for mild to moderate dementia associated with Alzheimer/<wbr>Parkinson) by its licensing partner Alvogen.<wbr> The patch is a generic version of Exelon fom Novartis.<wbr> Acino has extensive expertise in transdermal drug delivery technologies; it is currently the second largest fentanyl patch manufacturer in Europe as well as the only generic buprenorphine patch producer.<wbr> In addition, recent external intelligence has confirmed that the goserelin Ph3 trials have been terminated due to stability issues.<wbr> It is believed that the leuprorelin platform was in-licensed by AMW, and that <SPAN style="FONT-SIZE: 14pt; FONT-FAMILY: Arial; COLOR: #5a5a59; language: en-US; mso-ascii-font-family: Arial; mso-fareast-font-family: 'ＭＳ Ｐゴシック'; mso-bidi-font-family: Arial; mso-font-kerning: 12.0pt; mso-style-textfill-type: solid; mso-style-textfill-fill-color: #5A5A59; mso-style-textfill-fill-alpha: 100.0%"></SPAN>.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><U>Leuprorelin</U> is a priority for the company, who will require a partner for its commercialisation.<wbr> </div><div style="margin-bottom: 10px;">The <U>goserelin</U> 1M was delayed due to various issues, including recruitment, manufacturing and logistics.<wbr> Data are xpected by Q1:16, with an earliest filing in 2H2016.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><DIV class="O0" style="MARGIN-BOTTOM: 0pt; VERTICAL-ALIGN: baseline; unicode-bidi: embed; DIRECTION: ltr; TEXT-ALIGN: left; MARGIN-LEFT: 0.31in; MARGIN-TOP: 0pt; TEXT-INDENT: -0.31in; language: fr"><SPAN style="FONT-SIZE: 14pt">§</SPAN><SPAN style="FONT-SIZE: 14pt; FONT-FAMILY: Arial; COLOR: #5a5a59; language: en-US; mso-ascii-font-family: Arial; mso-fareast-font-family: 'ＭＳ Ｐゴシック'; mso-bidi-font-family: Arial; mso-font-kerning: 12.0pt; mso-style-textfill-type: solid; mso-style-textfill-fill-color: #5A5A59; mso-style-textfill-fill-alpha: 100.0%; mso-color-index: 3; mso-style-textfill-fill-themecolor: text2">AMW is funded by a mix of Dr</SPAN><SPAN style="FONT-SIZE: 14pt; FONT-FAMILY: Arial; COLOR: #5a5a59; language: en-US; mso-ascii-font-family: Arial; mso-fareast-font-family: 'ＭＳ Ｐゴシック'; mso-bidi-font-family: Arial; mso-font-kerning: 12.0pt; mso-style-textfill-type: solid; mso-style-textfill-fill-color: #5A5A59; mso-style-textfill-fill-alpha: 100.0%; mso-color-index: 3; mso-style-textfill-fill-themecolor: text2">.<wbr> </SPAN><SPAN style="FONT-SIZE: 14pt; FONT-FAMILY: Arial; COLOR: #5a5a59; language: en-GB; mso-ascii-font-family: Arial; mso-fareast-font-family: 'ＭＳ Ｐゴシック'; mso-bidi-font-family: Arial; mso-font-kerning: 12.0pt; mso-style-textfill-type: solid; mso-style-textfill-fill-color: #5A5A59; mso-style-textfill-fill-alpha: 100.0%; mso-color-index: 3; mso-style-textfill-fill-themecolor: text2">Wilfried</SPAN><SPAN style="FONT-SIZE: 14pt; FONT-FAMILY: Arial; COLOR: #5a5a59; language: en-GB; mso-ascii-font-family: Arial; mso-fareast-font-family: 'ＭＳ Ｐゴシック'; mso-bidi-font-family: Arial; mso-font-kerning: 12.0pt; mso-style-textfill-type: solid; mso-style-textfill-fill-color: #5A5A59; mso-style-textfill-fill-alpha: 100.0%; mso-color-index: 3; mso-style-textfill-fill-themecolor: text2"> Fischer’s own capital and VC investment</SPAN></DIV> </div><div style="margin-bottom: 10px;"><DIV class="O1" style="MARGIN-BOTTOM: 0pt; VERTICAL-ALIGN: baseline; unicode-bidi: embed; DIRECTION: ltr; TEXT-ALIGN: left; MARGIN-LEFT: 0.81in; MARGIN-TOP: 0pt; TEXT-INDENT: -0.31in; language: fr"><SPAN style="FONT-SIZE: 12pt">§</SPAN><SPAN style="FONT-SIZE: 12pt; FONT-FAMILY: Arial; COLOR: #5a5a59; language: en-US; mso-ascii-font-family: Arial; mso-fareast-font-family: 'ＭＳ Ｐゴシック'; mso-bidi-font-family: Arial; mso-font-kerning: 12.0pt; mso-style-textfill-type: solid; mso-style-textfill-fill-color: #5A5A59; mso-style-textfill-fill-alpha: 100.0%; mso-color-index: 3; mso-style-textfill-fill-themecolor: text2">Prior to the foundation of AMW GmbH, Dr.<wbr> Fischer founded, </SPAN><SPAN style="FONT-SIZE: 12pt; FONT-FAMILY: Arial; COLOR: #5a5a59; language: en-US; mso-ascii-font-family: Arial; mso-fareast-font-family: 'ＭＳ Ｐゴシック'; mso-bidi-font-family: Arial; mso-font-kerning: 12.0pt; mso-style-textfill-type: solid; mso-style-textfill-fill-color: #5A5A59; mso-style-textfill-fill-alpha: 100.0%; mso-color-index: 3; mso-style-textfill-fill-themecolor: text2">Novosis</SPAN><SPAN style="FONT-SIZE: 12pt; FONT-FAMILY: Arial; COLOR: #5a5a59; language: en-US; mso-ascii-font-family: Arial; mso-fareast-font-family: 'ＭＳ Ｐゴシック'; mso-bidi-font-family: Arial; mso-font-kerning: 12.0pt; mso-style-textfill-type: solid; mso-style-textfill-fill-color: #5A5A59; mso-style-textfill-fill-alpha: 100.0%; mso-color-index: 3; mso-style-textfill-fill-themecolor: text2"> AG (</SPAN><SPAN style="FONT-SIZE: 12pt; FONT-FAMILY: Arial; COLOR: #5a5a59; language: en-US; mso-ascii-font-family: Arial; mso-fareast-font-family: 'ＭＳ Ｐゴシック'; mso-bidi-font-family: Arial; mso-font-kerning: 12.0pt; mso-style-textfill-type: solid; mso-style-textfill-fill-color: #5A5A59; mso-style-textfill-fill-alpha: 100.0%; mso-color-index: 3; mso-style-textfill-fill-themecolor: text2">implant/<wbr>patch </SPAN><SPAN style="FONT-SIZE: 12pt; FONT-FAMILY: Arial; COLOR: #5a5a59; language: en-US; mso-ascii-font-family: Arial; mso-fareast-font-family: 'ＭＳ Ｐゴシック'; mso-bidi-font-family: Arial; mso-font-kerning: 12.0pt; mso-style-textfill-type: solid; mso-style-textfill-fill-color: #5A5A59; mso-style-textfill-fill-alpha: 100.0%; mso-color-index: 3; mso-style-textfill-fill-themecolor: text2">technology) in 1997 which he sold to the Swiss </SPAN><SPAN style="FONT-SIZE: 12pt; FONT-FAMILY: Arial; COLOR: #5a5a59; language: en-US; mso-ascii-font-family: Arial; mso-fareast-font-family: 'ＭＳ Ｐゴシック'; mso-bidi-font-family: Arial; mso-font-kerning: 12.0pt; mso-style-textfill-type: solid; mso-style-textfill-fill-color: #5A5A59; mso-style-textfill-fill-alpha: 100.0%; mso-color-index: 3; mso-style-textfill-fill-themecolor: text2">Schweizerhall</SPAN><SPAN style="FONT-SIZE: 12pt; FONT-FAMILY: Arial; COLOR: #5a5a59; language: en-US; mso-ascii-font-family: Arial; mso-fareast-font-family: 'ＭＳ Ｐゴシック'; mso-bidi-font-family: Arial; mso-font-kerning: 12.0pt; mso-style-textfill-type: solid; mso-style-textfill-fill-color: #5A5A59; mso-style-textfill-fill-alpha: 100.0%; mso-color-index: 3; mso-style-textfill-fill-themecolor: text2"> Group who changed their name to </SPAN><SPAN style="FONT-SIZE: 12pt; FONT-FAMILY: Arial; COLOR: #5a5a59; language: en-US; mso-ascii-font-family: Arial; mso-fareast-font-family: 'ＭＳ Ｐゴシック'; mso-bidi-font-family: Arial; mso-font-kerning: 12.0pt; mso-style-textfill-type: solid; mso-style-textfill-fill-color: #5A5A59; mso-style-textfill-fill-alpha: 100.0%; mso-color-index: 3; mso-style-textfill-fill-themecolor: text2">Acino</SPAN><SPAN style="FONT-SIZE: 12pt; FONT-FAMILY: Arial; COLOR: #5a5a59; language: en-US; mso-ascii-font-family: Arial; mso-fareast-font-family: 'ＭＳ Ｐゴシック'; mso-bidi-font-family: Arial; mso-font-kerning: 12.0pt; mso-style-textfill-type: solid; mso-style-textfill-fill-color: #5A5A59; mso-style-textfill-fill-alpha: 100.0%; mso-color-index: 3; mso-style-textfill-fill-themecolor: text2"> in 2008.<wbr> It is understood Dr.<wbr> Fischer still works </SPAN><SPAN style="FONT-SIZE: 12pt; FONT-FAMILY: Arial; COLOR: #5a5a59; language: en-US; mso-ascii-font-family: Arial; mso-fareast-font-family: 'ＭＳ Ｐゴシック'; mso-bidi-font-family: Arial; mso-font-kerning: 12.0pt; mso-style-textfill-type: solid; mso-style-textfill-fill-color: #5A5A59; mso-style-textfill-fill-alpha: 100.0%; mso-color-index: 3; mso-style-textfill-fill-themecolor: text2">in </SPAN><SPAN style="FONT-SIZE: 12pt; FONT-FAMILY: Arial; COLOR: #5a5a59; language: en-US; mso-ascii-font-family: Arial; mso-fareast-font-family: 'ＭＳ Ｐゴシック'; mso-bidi-font-family: Arial; mso-font-kerning: 12.0pt; mso-style-textfill-type: solid; mso-style-textfill-fill-color: #5A5A59; mso-style-textfill-fill-alpha: 100.0%; mso-color-index: 3; mso-style-textfill-fill-themecolor: text2">an advisory capacity </SPAN><SPAN style="FONT-SIZE: 12pt; FONT-FAMILY: Arial; COLOR: #5a5a59; language: en-US; mso-ascii-font-family: Arial; mso-fareast-font-family: 'ＭＳ Ｐゴシック'; mso-bidi-font-family: Arial; mso-font-kerning: 12.0pt; mso-style-textfill-type: solid; mso-style-textfill-fill-color: #5A5A59; mso-style-textfill-fill-alpha: 100.0%; mso-color-index: 3; mso-style-textfill-fill-themecolor: text2">to </SPAN><SPAN style="FONT-SIZE: 12pt; FONT-FAMILY: Arial; COLOR: #5a5a59; language: en-US; mso-ascii-font-family: Arial; mso-fareast-font-family: 'ＭＳ Ｐゴシック'; mso-bidi-font-family: Arial; mso-font-kerning: 12.0pt; mso-style-textfill-type: solid; mso-style-textfill-fill-color: #5A5A59; mso-style-textfill-fill-alpha: 100.0%; mso-color-index: 3; mso-style-textfill-fill-themecolor: text2">Acino</SPAN></DIV> </div><div style="margin-bottom: 10px;"><DIV class="O0" style="MARGIN-BOTTOM: 0pt; VERTICAL-ALIGN: baseline; unicode-bidi: embed; DIRECTION: ltr; TEXT-ALIGN: left; MARGIN-LEFT: 0.31in; MARGIN-TOP: 0pt; TEXT-INDENT: -0.31in; language: fr"><SPAN style="FONT-SIZE: 14pt">§</SPAN><SPAN style="FONT-SIZE: 14pt; FONT-FAMILY: Arial; COLOR: #5a5a59; language: en-US; mso-ascii-font-family: Arial; mso-fareast-font-family: 'ＭＳ Ｐゴシック'; mso-bidi-font-family: Arial; mso-font-kerning: 12.0pt; mso-style-textfill-type: solid; mso-style-textfill-fill-color: #5A5A59; mso-style-textfill-fill-alpha: 100.0%; mso-color-index: 3; mso-style-textfill-fill-themecolor: text2">Recently received a total of 5 million Euros of new financing </SPAN></DIV> </div><div style="margin-bottom: 10px;"><DIV class="O1" style="MARGIN-BOTTOM: 0pt; VERTICAL-ALIGN: baseline; unicode-bidi: embed; DIRECTION: ltr; TEXT-ALIGN: left; MARGIN-LEFT: 0.81in; MARGIN-TOP: 0pt; TEXT-INDENT: -0.31in; language: fr"><SPAN style="FONT-SIZE: 12pt">§</SPAN><SPAN style="FONT-SIZE: 12pt; FONT-FAMILY: Arial; COLOR: #5a5a59; language: en-US; mso-ascii-font-family: Arial; mso-fareast-font-family: 'ＭＳ Ｐゴシック'; mso-bidi-font-family: Arial; mso-font-kerning: 12.0pt; mso-style-textfill-type: solid; mso-style-textfill-fill-color: #5A5A59; mso-style-textfill-fill-alpha: 100.0%; mso-color-index: 3; mso-style-textfill-fill-themecolor: text2">Hoping to see profit in 2016</SPAN></DIV> </div><div><DIV class="O0" style="MARGIN-BOTTOM: 0pt; VERTICAL-ALIGN: baseline; unicode-bidi: embed; DIRECTION: ltr; TEXT-ALIGN: left; MARGIN-LEFT: 0.31in; MARGIN-TOP: 0pt; TEXT-INDENT: -0.31in; language: fr"><SPAN style="FONT-SIZE: 14pt">§</SPAN><SPAN style="FONT-SIZE: 14pt; FONT-FAMILY: Arial; COLOR: #5a5a59; language: en-US; mso-ascii-font-family: Arial; mso-fareast-font-family: 'ＭＳ Ｐゴシック'; mso-bidi-font-family: Arial; mso-font-kerning: 12.0pt; mso-style-textfill-type: solid; mso-style-textfill-fill-color: #5A5A59; mso-style-textfill-fill-alpha: 100.0%; mso-color-index: 3; mso-style-textfill-fill-themecolor: text2">Currently employees 26 people with the aim to increase by an additional 30 (by end of 2017</SPAN><SPAN style="FONT-SIZE: 14pt; FONT-FAMILY: Arial; COLOR: #5a5a59; language: en-US; mso-ascii-font-family: Arial; mso-fareast-font-family: 'ＭＳ Ｐゴシック'; mso-bidi-font-family: Arial; mso-font-kerning: 12.0pt; mso-style-textfill-type: solid; mso-style-textfill-fill-color: #5A5A59; mso-style-textfill-fill-alpha: 100.0%; mso-color-index: 3; mso-style-textfill-fill-themecolor: text2">)</SPAN></DIV> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=DKPHybrids&sdate=20151231&edate=20150901&rec=264">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-09-07T11:16:01+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-09-07T11:16:01+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category dkphybrids > <![CDATA[dkphybrids]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Amgen And Novartis Enter Into A Global Partnership in Neuroscience Treatments</title>
	<pubDate>2015-09-03T18:22:23+02:00</pubDate>
	<wp:post_id>6944</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Amgen and Novartis have announced a global partnership to co-develop treatments for Alzheimer&rsquo;s disease and migraine.<wbr> </div><div style="margin-bottom: 10px;">This global partnership includes the combination of each companies BACE programs, including Novartis&rsquo; inhibitor CNP520.<wbr> </div><div style="margin-bottom: 10px;">Amgen will make upfront and milestone payments to Novartis in addition to 50/<wbr>50 cost and profit share arrangement.<wbr> Novartis will acquire global co-development rights and commercial rights outside of the US, Canada and Japan to Amgen&rsquo;s migraine portfolio.<wbr> </div><div style="margin-bottom: 10px;">Vas Narasimhan Novartis' global head of development reported that this collaboration &ldquo;"Allows us to share risk on the Alzheimer's programme.<wbr> While there's a tremendous unmet need clinical trials are long, endpoints are still unknown and mechanisms underlying the disease are still something we're all trying to work out.<wbr>" </div><div style="margin-bottom: 10px;">Sean Harper, executive vice president of R&amp;D at Amgen reported that "We are very pleased to be joining forces with Novartis on two important neuroscience programmes where there remains high unmet medical need.<wbr> Our collaboration on BACE inhibition reflects Amgen's strategic focus on genetically validated drug candidates while our collaboration in migraine creates an opportunity to more rapidly advance AMG 334 on a global scale.<wbr>" </div><div>Source: Firstword </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20151231&edate=20150901&rec=8171">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-09-03T18:22:23+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-09-03T18:22:23+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Novartis Has Launched the First Biosimilar in the U.S.</title>
	<pubDate>2015-09-03T08:59:40+02:00</pubDate>
	<wp:post_id>6945</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Sandoz has launched <A href="http://www.zarxio.com/assets/pdf/zarxio-full-pi.pdf">Zarxio</A> (filgrastim-sndz) in the five indications to Amgen's Neupogen, the reference product.<wbr> It is the first biosimilar approved by the FDA, and the first to launch in the U.<wbr>S.<wbr> With the product, the company offers Sandoz One Source<SUP>TM</SUP> a patient services center, providing support that connects the patient to the information and resources they need.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10652_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10652_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Sandoz currently markets three biosimilars outside the US: Omnitrope®, Binocrit® and Zarzio® </div><div style="margin-bottom: 10px;"><U>Pipeline</U> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10652_1_ScreenCapture1.jpg"> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Oncology10655c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div>Comment: Novartis-Sandoz kicked off a new era in U.<wbr>S.<wbr> medicine with the launch at a discount of 15% to the original Neupogen (Amgen), The arrival of biosimilars threatens companies heavily reliant on biotech drugs, such as Amgen, AbbVie and Roche, and Citigroup analysts have predicted a transfer of at least $110 billion of value from innovator companies to copycat producers in the next decade.<wbr> The 15 percent discount is the same price gap set when Zarxio was launched in Europe in 2009, although the discount in Europe has since widened to an average of around 20 to 30 percent.<wbr> The US Insurers hope biosimilars will eventually cost the public 40 percent to 50 percent less than the original brands.<wbr> (Source: Reuters) </div></div><a name="oncology10652attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10652_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(128,8 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10652_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(12,4 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10652_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(22,4 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20151231&edate=20150901&rec=10652">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-09-03T08:59:40+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-09-03T08:59:40+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>A Publication In BJUI Showed Hexvix® Has No Budget Impact On The Lifetime Costs</title>
	<pubDate>2015-09-02T17:00:14+02:00</pubDate>
	<wp:post_id>6946</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Photocure has made an annoucement that a newly published article in BJUI showing that Hexvix has not budget impact on the liftetime costs in Sweden.<wbr> The analysis shows that, even with conservative estimates of clinical effectiveness, a single Hexvix instillation for each patient is likely to be cost neutral or cost negative over 5 years, compared with white-light cystoscopy.<wbr> </div><div style="margin-bottom: 10px;">The objective of the study is to explore the cost impact on Swedish healthcare of incorporating one instillation of HEXVIX into the transurethral resection of bladder tumours in patients with suspected new or recurrent non muscle invasive bladder.<wbr> This is a Photocure funded publication.<wbr> </div><div>Source: Photocure Press Release, Rose James et al.<wbr> BJU Internation (2015 Aug Full text link available in <A href="http://cis12103:8080/qesipsen/servlet/QESServlet_prepare?Format_document=1&amp;Mouvement=966369&amp;Urlorigine=&amp;Premier=0&amp;Dernier=0&amp;Doc1=3223471">PERAL</A>) </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20151231&edate=20150901&rec=10649">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-09-02T17:00:14+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-09-02T17:00:14+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Astellas to Develop Mirabegron in Ped Setting for NDO or OAB</title>
	<pubDate>2015-09-02T16:32:16+02:00</pubDate>
	<wp:post_id>6947</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The new Ph1 will evaluate PK (primary endpoint), safety and tolerability of mirabegron oral suspension.<wbr> The study will be starting Q4:15 when the other Ph1 testing mirabegron Oral Controlled Absorption System is complete.<wbr> On top of the ped indications, Astellas aims at developing combo trial with Vesicare.<wbr> </div><div style="margin-bottom: 10px;"><U>Study reference </U><A href="https://clinicaltrials.gov/ct2/show/NCT02526979?recr=Open&amp;no_unk=Y&amp;fund=2&amp;rcv_s=08%2F02%2F2015&amp;rank=136">NCT02526979</A> </div><div style="margin-bottom: 10px;">Timelines: from Nov 2015 to June 2016 (primary completion date) </div><div>Location: EU; US </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20151231&edate=20150901&rec=10648">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-09-02T16:32:16+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-09-02T16:32:16+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Recruitment has completed for phase IIII Xeomin study, SIAXI, in Sialorrhoea</title>
	<pubDate>2015-09-02T15:13:39+02:00</pubDate>
	<wp:post_id>6948</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Merz phase III study investigating Xeomin in various neurological conditions for the treatment of chronic troublesome sialorrhea has now completed recruitment, with a primary completion expected in December 2015 </div><div style="margin-bottom: 10px;">The study <EM>Clinical Study to Investigate the Efficacy and Safety of Two Dose Levels of NT 201 Versus Placebo in Treating Chronic Troublesome Sialorrhea in Various Neurological Conditions (SIAXI)</EM> has completed recruitment.<wbr>  The neurological conditions investigated include Parkinson's Disease, Post-stroke and Traumatic Brain Injury.<wbr>  The primary completion date is expected in December 2015 and the completion date, November 2016.<wbr> </div><div style="margin-bottom: 10px;">The treatment arms are 100 units and 75 units with study locations in Germany and Poland.<wbr> </div><div>Source: Clinicaltrials.<wbr>gov NCT02091739 </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20151231&edate=20150901&rec=8170">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-09-02T15:13:39+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-09-02T15:13:39+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Allergan To Purchase Naurex As They Continue To Strengthen Their Neurology Portfolio</title>
	<pubDate>2015-09-02T15:02:41+02:00</pubDate>
	<wp:post_id>6949</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Allergan To Purchase Naurex As They Continue To Strengthen Their Neurology Portfolio</span>&nbsp;<br><span style="font-size: 12px;">Comment: Allergan has entered into an agreement to purchase Naurex for $560 million which will continue to strengthen Allergan’s long-term growth profile.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20151231&edate=20150901&rec=8121">...</a><br></div><div style="margin-bottom: 10px;">Allergan has now completed the acquisition of Naurex with the payment of $460 million with a further $100 million payable by January of 2016, as well as potential R&amp;D success-based and sales-threshold milestone payments.<wbr> </div><div style="margin-bottom: 10px;">Brent Saunders CEO discussed "The acquisition of Naurex enhances our ability to be among the leaders in the development of novel, game-changing therapies in mental health.<wbr> This is an area of medicine that requires new ways to tackle some of society's most challenging diseases and disorders.<wbr>  Naurex's unique pipeline includes GLYX-13 and NRX-1074, two compounds that utilize NMDA modulation as a potential new approach to the treatment of Major Depressive Disorder (MDD).<wbr>  We have geared up to advance the development of these compounds into the next phase of clinical trials.<wbr>" </div><div style="margin-bottom: 10px;">This acquisition further strengthens Allergan&rsquo;s late stage program in mental health </div><div>Source: Allergan </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20151231&edate=20150901&rec=8169">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology8121">View thread  Neurology8121: Allergan To Purchase Naurex As They Continue To Strengthen Their Neurology Portfolio</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-09-02T15:02:41+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-09-02T15:02:41+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	

</channel>
</rss>
